

SPECIALIST PERIODICAL REPORTS

**Amino - acids
Peptides
and Proteins
VOLUME 4**

THE CHEMICAL SOCIETY

A Specialist Periodical Report

Amino-acids, Peptides, and Proteins

Volume 4

A Review of the Literature Published
during 1971

Senior Reporter

G. T. Young, *The Dyson Perrins Laboratory, University
of Oxford*

ISBN: 0 85186 034 6

Library of Congress Catalog Card No. 72-92548

© Copyright 1972

The Chemical Society
Burlington House, London, W1V 0BN

Reporters

P. M. Bayley, *National Institute of Medical Research, Mill Hill, London*

T. L. Blundell, *University of Oxford*

J. R. Brocklehurst, *University of Pennsylvania, U.S.A.*

B. W. Bycroft, *University of Nottingham*

J. S. Davies, *University College of Swansea, University of Wales*

C. S. Johnson, *University of Liverpool*

J. H. Jones, *University of Oxford*

G. L. Kellett, *University of York*

R. H. Pain, *University of Newcastle upon Tyne*

R. N. Perham, *Cambridge University*

N. C. Price, *University of Pennsylvania, U.S.A.*

H. W. E. Rattle, *Portsmouth Polytechnic*

B. Ridge, *University of Exeter*

B. Robson, *University of Newcastle upon Tyne*

R. M. Stephens, *Portsmouth Polytechnic*

J. O. Thomas, *Cambridge University*

Organic formulae composed by Wright's Symbolset method

Preface

This fourth Report reviews papers relevant to the chemistry of amino-acids, peptides, and proteins, appearing in the main journals during 1971; the literature continues to increase, and this volume contains nearly 3,000 references. Metal derivatives are reviewed biennially in this series and are not covered this year; volume 5 will survey papers in this field appearing in 1971 and 1972. As in Volume 3, work on the structure and synthesis of cyclic peptides will be found in Chapter 4 (Peptides with Structural Features Not Typical of Proteins). In Chapter 5 we reprint for the convenience of readers the 1971 revision of the recommendations of the I.U.P.A.C.-I.U.B. Commission on Biochemical Nomenclature, 'Symbols for Amino-acid Derivatives and Peptides', together with their recommendations 'Abbreviations and Symbols for the Description of the Conformation of Polypeptide Chains'.

For the new reader, we would note that in place of a subject index (the preparation of which would delay publication unduly) there is an extended list of contents from which the sections relevant to a search can be ascertained. Some overlap between sections will be found, and within limits is no doubt desirable.

Finally, I express my gratitude here to the contributors who in these first four volumes have established this series as a service to their colleagues in research.

G. T. YOUNG

Contents

Chapter 1 Amino-acids

By B. W. Bycroft

1 Naturally Occurring Amino-acids	1
A Occurrence of Known Amino-acids	1
B New Natural Free Amino-acids	3
C New Amino-acids from Hydrolysates	5
2 Chemical Synthesis and Resolution of Amino-acids	5
A Introduction and General Methods	5
B Synthesis under Simulated Prebiotic Conditions	7
C Protein and Other Naturally Occurring Amino-acids	7
D C-Alkyl- and Substituted C-Alkyl- α -amino-acids	8
E α -Amino-acids with Aliphatic Hydroxy-groups in the Side-chain	9
F Aromatic and Heterocyclic α -Amino-acids	10
G N-Substituted α -Amino-acids	11
H α -Amino-acids containing Sulphur	12
I A List of α -Amino-acids which have been Synthesized for the First Time	12
J Labelled Amino-acids	14
K Resolution of α -Amino-acids	16
3 Physical and Stereochemical Studies of α-Amino-acids	17
A Crystal Structures of Amino-acids	17
B Nuclear Magnetic Resonance Spectra	18
C Optical Rotatory Dispersion and Circular Dichroism	19
D Mass Spectrometry	21
E Other Physical and Stereochemical Studies	21
4 Chemical Studies of Amino-acids	22
A Introduction	22
B General Reactions	22
C Specific Reactions	24
D Non-enzymic Models of Biochemical Processes involving Amino-acids	26
E Effects of Electromagnetic Radiation on Amino-acids	27

5 Analytical Methods	29
A Gas-Liquid Chromatography	29
B Ion-exchange Chromatography	30
C Thin-layer Chromatography	30
D Other Methods	31
E Determination of Specific Amino-acids	31

Chapter 2 Structural Investigation of Peptides and Proteins

1: Primary Structure and Chemical Modification

By R. N. Perham and J. O. Thomas

1 Introduction	32
2 Methods	32
A Amino-acid Analysis	33
Ion-exchange Chromatography	34
High-voltage Electrophoresis and Thin-layer Chromatography	35
Gas-Liquid Chromatography	36
B End-group Analysis and Sequential Degradation	36
C Mass Spectrometry	39
D Cleavage of Protein Chains	44
Enzymic Cleavage	44
Restriction of Enzymic Cleavage	45
Insolubilized Enzymes	45
E Fractionation Methods	47
Peptide Separation, Detection, and Identification	47
Chromatography	49
Electrophoresis	50
Isoelectric Focusing	55
Affinity Chromatography	56
3 Structural Proteins	61
A The Proteins of Motility	61
B Collagen	62
Primary Structure	63
Cross-links	64
Hydroxylated Residues	65
C Elastin	66
D Fibrinogen	66
E Chromosomal Proteins	67
F Ribosomal Proteins	69
G Serum and Egg Proteins	70

H Miscellaneous	72
Crystallins	72
Keratins and Wool Proteins	73
Casein	75
Other Proteins	75
4 Peptides and Hormones	77
A Pancreatic Hormones	77
B Pituitary Hormones	78
C Other Hormones and Peptides	82
D Toxins	83
E Proteins of the Nervous System	86
5 Enzymes	88
A Proteolytic Enzymes	88
Carboxypeptidases	88
Serine Proteases and Their Inhibitors	90
Neutral Proteases, Acid Proteases, and Thiol Proteases	102
B Lysozyme and α -Lactalbumin	106
C Dehydrogenases	109
D Aldolases	114
E Nucleases	116
F Pyridoxal Phosphate Enzymes	118
G Other Enzymes	121
H Quaternary Structure	128
6 Electron-transport and Oxygen-transport Proteins	128
A Electron-transport Proteins	128
Cytochromes	128
Other Electron-transport Proteins	136
B Oxygen-transport and -storage Proteins	140
Haemoglobin and Myoglobin	140
Haemerythrin	147
7 Immunoglobulins	148
A Light Chains	149
B Heavy Chains	151
C Disulphide Bridges	153
D Antibody Binding Sites	154
E Some Problems of Biosynthesis	156
8 Membrane Proteins	157
A Solubilization and Fractionation	157
B Red Blood Cell Membranes	158
C Mitochondrial and Other Membranes	160

9 Chemical Modification	164
A Amino-groups	164
B Carboxy-groups	166
C Thiol Groups and Disulphide Bridges	167
D Tyrosine	168
E Tryptophan, Arginine, and Histidine	171
F Photo-oxidation	172
G Affinity Labelling	173
10 Conclusion	176

II: X-Ray Studies

By T. L. Blundell

1 Introduction	176
2 Amino-acids and Peptides	178
3 Methods of Protein Structure Analysis	181
4 Globular Proteins	182
A General Structural Principles	182
B Proteases	184
C Nucleases	191
D Glycoside Hydrolases	193
E Carbonic Anhydrase	194
F Enzymes of the Glycolytic Pathway	195
G Dehydrogenases	198
H Regulatory Enzymes	201
I Redox Proteins	203
J Haemoglobins	207
K Concanavalin A	214
L Toxins	215
M Hormones	215
N Plasma Proteins	218
O Immunoglobulins	218
P Muscle Proteins	220
Q Viruses	221
5 Fibrous Proteins	223
A Keratins	223
B Silks	223
C Collagen	224
D Flagella	224

*III: Conformation and Interaction of Peptides and Proteins
in Solution*

Edited by R. H. Pain

1 Theoretical Aspects of Protein Structure	224
<i>Contributed by B. Robson</i>	
A The General Approach using Energy Functions	224
B Solvent Effects	226
C Studies on the Conformation of Single Residues using Energy Functions	226
D Predictions of Local Conformations in Polypeptides	227
E Predictions of the Stability of Globular Proteins	229
2 Spin Labels	230
<i>Contributed by N. C. Price</i>	
A Haemoglobin	230
B Enzyme Binding Sites	232
Creatine Kinase	232
Glyceraldehyde 3-Phosphate Dehydrogenase	232
Glycogen Phosphorylase <i>b</i>	233
Monomeric Enzymes	233
C New Spin Labels	235
3 Fluorescence	236
<i>Contributed by J. R. Brocklehurst</i>	
A Interpretation of Fluorescence	236
B Fluorescent Probes	237
Non-covalently bound	237
Covalently bound	238
C Protein Fluorescence	239
Binding of Small Molecules	240
Protein-Protein Interaction	241
Protein Structure	241
4 Mössbauer Spectroscopy	243
<i>Contributed by C. E. Johnson</i>	
A Haem Proteins	244
B Iron-Sulphur Proteins	244
C Other Proteins	245
5 Nuclear Magnetic Resonance	246
<i>Contributed by H. W. E. Rattle</i>	
A Peptides and Polypeptides	246
B Proteins	247

6 Infrared Spectroscopy	250
<i>Contributed by R. M. Stephens</i>	
A Model Compounds, Amino-acids, and Oligopeptides	250
B Synthetic Polypeptides	251
C Solvation and Structure	252
 7 Circular Dichroism and Optical Rotatory Dispersion	 253
<i>Contributed by P. M. Bayley</i>	
A General	254
Reviews	254
Theory	254
Analysis	256
Instrumental	257
B Small Molecules, Model Compounds, and Synthetic	
Polymers	258
Amino-acids and Derivatives	258
Dipeptides and Oligopeptides	260
Polypeptides	261
C Denaturation	263
Detergents and Neutral Salts	263
Unfolding and Refolding	265
D Proteins	265
Aromatic and Disulphide Chromophores	265
Non-chromophoric Proteins	269
Chromophoric Proteins	271
NAD(P)-dehydrogenases	271
Flavoproteins	271
Pyridoxal enzymes	272
Haem-proteins	273
Metalloproteins	276
Visual pigments	277
Added Extrinsic Chromophores	277
Naphthalenesulphonate derivatives	277
Purine and pyrimidine nucleotides	278
Metals	279
Other extrinsic effects	279
Chemical Modification and Peptide Cleavage	280
E Nucleic Acid-Protein Complexes	281
Model Systems	281
Natural Systems	282
F Immunological Systems	283
Immunoglobulins	283
Antibody-Hapten Interactions	284
G Antibiotics and Hormones	284

H Membrane Systems	285
Artefacts	285
Membrane Proteins	286
Phospholipid Micelles	286
8 Dissociation and Association of Proteins	287
<i>Contributed by G. L. Kellett</i>	
A Analytical Ultracentrifugation Techniques	287
Difference Sedimentation	288
Terminology for Sedimentation and Gel-filtration	
Experiments	289
Active-enzyme Sedimentation	291
B Gel Chromatography	292
Difference Chromatography	293
C Light Scattering	294
D Transport Studies	294
E Kinetic Studies	295
Ligand-induced Association–Dissociation	296
F Subunit Structure of Proteins	297
SDS Gel Electrophoresis	299
Measurements in Guanidine Hydrochloride	300
Hybridization Techniques	301
Isozymes	301
Haemoglobins	302
Bacterial luciferase	302
Cold Inactivation	303
G Protein–Small Molecule Equilibria	303
H Examples of Association–Dissociation Equilibria	304
Enzymes	304
Haemoglobin	305
Cyclic-AMP-dependent Protein Kinases	307
I Comment	308

Chapter 3 Peptide Synthesis

By J. H. Jones and B. Ridge

1 Introduction	309
2 Methods	310
A Protective Groups	310
Established Methods of Amino-group Protection	310
New Methods of Amino-group Protection	317
Protection of Carboxy-groups	324
Protection of Hydroxy-groups	328

Protection of Thiol Groups and Synthesis of Cystine Peptides	328
Protection of Histidine Side-chains	334
Final Deprotection	338
Miscellaneous Matters relating to Protective Groups	339
B Formation of the Peptide Bond	340
Activated Esters	341
Coupling Methods involving Acyloxyposphonium Salts	343
<i>N</i> -Carboxy-anhydrides and <i>N</i> -Thiocarboxy-anhydrides	349
Other Methods	353
C Racemization	354
D Repetitive Methods of Peptide Synthesis	355
E Synthesis of Polymeric Models for Studies in Protein Chemistry	359
Polyamino-acids	359
Sequential Polypeptides	360
F Synthetic Operations with Peptides of Biological Origin	361
With Naked Natural Peptides	361
With Partially Blocked Peptides	362
3 Syntheses Achieved and Structure-Activity Correlations	363
A Calcitonin	365
B Hypothalamic Releasing Factors	366
Growth-hormone Releasing Factor	366
Luteinizing-hormone Releasing Factor and Follicle-stimulating Hormone Releasing Factor	367
Melanocyte-stimulating Hormone Release	370
Thyroid-stimulating Hormone Releasing Factor	371
C Oxytocin	372
D Ribonuclease T₁	373
E Solid-phase Synthesis of High Molecular Weight Polypeptides	375
Acyl Carrier Protein	376
Basic Pancreatic Trypsin Inhibitor	377
Human Growth Hormone	377
Lysozyme	378
Parathyroid Hormone	379
Ribonuclease A	379
Staphylococcal Nuclease	381
F Scotophobin	382
G Substance P	383

<i>Contents</i>	xiii
4 Appendix A. A List of Syntheses Reported during 1971	383
A Naturally Occurring Peptides, Proteins, Analogues, and Partial Sequences	383
B Sequential Polypeptides	390
C Miscellaneous Peptides	391
5 Appendix B. A List of Some Useful New Synthetic Inter- mediates Described during 1971	393

Chapter 4 Peptides with Structural Features Not Typical of Proteins

By J. S. Davies

1 Introduction	399
2 Cyclic Peptides	400
A 2,5-Dioxopiperazines	403
B Gramicidins	407
C Tyrocidins	410
D Alamethicin	410
E Peptides from <i>Amanita phalloides</i>	410
F Viomycin, Capreomycin, and Tuberactinomycin	412
G Nisin	413
H Other Cyclic Peptides	414
I Synthesis of Homodetic Cyclic Peptides	415
3 Depsipeptides (Heterodetic Peptides)	418
A Actinomycins	418
B Valinomycin	421
C Other Naturally Occurring Depsipeptides	422
D Miscellaneous	424
4 Peptide-Carbohydrate Linkages	425
A Glycopeptides from Bacterial Cell Walls	425
B Glycopeptides from Miscellaneous Sources	426
C Studies on Model Glycopeptide Linkages	428
D Other Carbohydrate-linked Compounds	428
5 Peptides and Amino-acids Linked to Nucleosides and Nucleotides	429
6 Peptide Alkaloids	431
7 Hydrazino Peptides	432
8 Penicillins and Cephalosporins	432
9 Miscellaneous	438

Chapter 5 Further Extracts from the Rules and Tentative Rules of
the I.U.P.A.C.—I.U.B. Commission on Biochemical
Nomenclature

<i>I Symbols for Amino-Acid Derivatives and Peptides — Recommendations (1971)</i>	441
1 General Considerations	442
2 Symbols for Amino-Acids	443
3 Amino-Acid Residues	445
4 Substituted Amino-Acids	448
5 Symbols for Substituents	450
6 Polypeptides	452
 <i>II Abbreviations and Symbols for the Description of the Conformation of Polypeptide Chains</i>	455
Preamble	455
Rule 1. General Principles of Notation	455
Rule 2. The Sequence Rule, and Choice of Torsion Angle	458
Rule 3. The Main Chain (or Polypeptide Backbone)	461
Rule 4. Side Chains	465
Rule 5. Hydrogen Bonds	469
Rule 6. Helical Segments	469
 <i>Appendix</i>	470
Recommendation A. Conformation and Configuration	470
Recommendation B. Definitions of Primary, Secondary, Tertiary, and Quaternary Structure	470
 Author Index	472

Abbreviations

Abbreviations for amino-acids and their use in the formulation of derivatives follow with some exceptions the revised (1971) Recommendations of the I.U.P.A.C.-I.U.B. Commission on Biochemical Nomenclature, which are reprinted in Chapter 5 of this volume.

Other abbreviations which have been used without definition are:

Adoc	adamantylloxycarbonyl
Aoc	t-amyloxycarbonyl
Asu	α -aminosuberic acid
Asx	aspartic acid or asparagine (not yet determined)
ATP	adenosine 5'-triphosphate
Bpoc	2-(4-biphenyl)-isopropoxycarbonyl
BSA	bovine serum albumin
c.d.	circular dichroism
Cha	cyclohexylamine
Cm	carboxymethyl
Cmc	<i>S</i> -carboxymethylcysteine
Dce	2,2-diethoxycarbonyl
Dcha	dicyclohexylamine
DMF	<i>NN</i> -dimethylformamide
DMSO	dimethyl sulphoxide
DNA	deoxyribonucleic acid
Dnp	2,4-dinitrophenyl
Dns	1-dimethylaminonaphthalene-5-sulphonyl (dansyl)
Dopa	3,4-dihydroxyphenylalanine
DP	degree of polymerization
Ec	ethylcarbamoyl
edta	ethylenediamine tetra-acetate
e.p.r.	electron paramagnetic resonance
e.s.r.	electron spin resonance
Gal	galactose
g.l.c.	gas-liquid chromatography
Glc	glucose
Glp or Pca	pyrrolid-2-one-5-carboxylic acid
Glx	glutamic acid or glutamine (not yet determined)
GTP	guanosine 5'-triphosphate
i.r.	infrared

Man	mannose
NAD	nicotinamide-adenine dinucleotide (NAD ⁺ , oxidized; NADH, reduced)
n.m.r.	nuclear magnetic resonance
ONSu	succinimido-oxy
OPcp	pentachlorophenoxy
OPic	4-picolyloxy
o.r.d.	optical rotatory dispersion
OTcp	2,4,5-trichlorophenoxy
Pca	<i>see</i> Glp
Pipoc	piperidino-oxycarbonyl
Pth-Gly	the phenylthiohydantoin derived from glycine, <i>etc.</i>
RNA	ribonucleic acid
SDS	sodium dodecyl sulphate
Ser(P)	<i>O</i> -phosphorylserine
t.l.c.	thin-layer chromatography
u.v.	ultraviolet
Ztf	1-benzoyloxycarbonylamino-2,2,2-trifluoro-ethyl

The past twelve months have witnessed interesting developments in amino-acid chemistry, but pride of place must be taken by the isolation, characterization, and synthesis of the amino-acid derivative from phenylalanine t-RNA. This work also reflects the growing sophistication in the application of physical methods in general. The interesting advances reported last year on asymmetric synthesis have been extended, and a staggering number of new amino-acids continues to be synthesized for a variety of reasons. The established pattern of coverage for this chapter is maintained, attention being focused on a broad selection of topics with the significant developments highlighted where necessary.

1 Naturally Occurring Amino-acids

A. Occurrence of Known Amino-acids.—A large number of papers which are concerned with the free amino-acid content of a wide variety of living organisms is published annually. Since the emphasis for the majority of this work is on biological aspects, it is not considered appropriate to cover them in this section and only those amino-acids which are rarely encountered or are interesting from the chemical viewpoint have been included.

The presence of amino-acids in extra-terrestrial material as well as their synthesis under simulated prebiotic conditions (see Section 2B) has attracted a considerable amount of attention. Examination of samples from the Apollo 11 and Apollo 12 missions has revealed extremely low concentrations of amino-acids (*ca.* 20—70 p.p.b.);¹⁻³ ultra-sensitive analytical techniques were employed for these investigations and, because of the presence of a considerable number of non-protein amino-acids, the investigators maintain that they are not due to terrestrial contamination. Similar conclusions have been made concerning the presence of amino-acids in the Murray⁴ and

¹ B. Nagy, J. E. Modzeleski, V. E. Modzeleski, M. A. J. Mohammad, L. A. Nagy, W. M. Scott, C. M. Drew, J. E. Thomas, R. Ward, P. B. Hamilton, and H. C. Urey, *Nature*, 1971, 232, 94.

² K. Harada, P. E. Hara, C. R. Windsor, and S. W. Fox, *Science*, 1971, 173, 433.

³ C. W. Gehrke, R. W. Zumwalt, D. L. Stalling, D. Roach, W. A. Aue, C. Ponnampuruma, and K. A. Kvenvolden, *J. Chromatog.*, 1971, 59, 305.

⁴ J. G. Lawless, K. A. Kvenvolden, E. Peterson, C. Ponnampuruma, and C. Moore, *Science*, 1971, 173, 626.

Murchinson⁵ meteorites. In the case of the Murray meteorite, seventeen amino-acids were identified of which seven were conclusively shown to be racemic and eleven to be non-protein in origin. An earlier report⁶ that the amino-acid content of the Orgueil meteorite was due solely to terrestrial contamination has been questioned, and it is now suggested that there are amino-acids indigenous to the meteorite in addition to those present as contaminants.⁷

The presence of amino-acids in the North Atlantic ocean has been the subject of a detailed examination and the distribution appears to be non-uniform and varies qualitatively with depth.⁸ In marine sediments the degree of racemization of free amino-acids shows a progressive increase with the age of the sediment,^{9, 10} and the ratio of *allo*-isoleucine to leucine is a reliable indicator of age for samples less than 400 000 years old. In samples older than about 15×10^6 years the amino-acids are completely racemic.

The stereochemistry of the α -hydroxy-analogue of cysteine present in the urine of certain mentally retarded patients has been established by comparison with synthetic material.¹¹ The work reported initially last year on the isolation of the methylated derivatives of arginine and lysine has been extended and it has been noted that, in patients with malignant tumours, the relative urinary level of *guanidino*-*NN*-dimethylarginine to that of arginine is markedly increased.¹² Bovine and rat brain tissue has been shown to contain appreciable amounts of *N*^G-monomethylarginine as well as *N*^G*N*^G-dimethylarginine.¹³

Further spectral evidence on the aldol condensation product isolated on alkaline hydrolysis of elastin provides strong support¹⁴ for the previously assigned structure (1).

Interest in plants containing L-Dopa continues, and a widespread investigation has shown that several *Mucuna* species contain up to 5% of this important amino-acid.¹⁵ The neurotoxin α -amino- β -oxalylaminopropionic acid has been isolated from *Lathyrus sativus*¹⁶ and the major alkaloid of *Aotus subglauca* has been identified as *S*-(+)-*N* ^{α} -methyltryptophan methyl ester.¹⁷ The previously unidentified amino-acid from *Peganum harmala* is

⁵ J. R. Cronin and C. B. Moore, *Science*, 1971, **172**, 1327.

⁶ J. Oro, S. Nakaparksin, H. Lichenstein, and E. Gil-Av, *Nature*, 1971, **230**, 107.

⁷ J. G. Lawless, K. A. Kvenvolden, E. Peterson, and C. Ponnampereuma, *Nature*, 1972, **234**, 66.

⁸ R. Pocklington, *Nature*, 1971, **230**, 374.

⁹ R. O. Brinkhurst, K. E. Chua, and E. Batoosingh, *Limnol. Oceanogr.*, 1971, **16**, 555.

¹⁰ J. Wehmiller and P. E. Hare, *Science*, 1971, **173**, 907.

¹¹ M. Wälti and D. B. Hope, *J. Chem. Soc. (C)*, 1971, 2326.

¹² S. Akazawa, *Osaka Daigaku Igaku Zasshi*, 1970, **22**, 461.

¹³ T. Nakajima, Y. Matsuoka, and Y. Kakimoto, *Biochim. Biophys. Acta*, 1971, **230**, 212.


¹⁴ G. Crombie, B. Faris, P. M. Gallop, and C. Franzblau, *Biochemistry*, 1971, **10**, 4145.

¹⁵ E. A. Bell, J. R. Nulu, and C. Cone, *Phytochemistry*, 1971, **10**, 2191.


¹⁶ K. Bahadar and S. P. Billa, *Indian J. Appl. Chem.*, 1970, **33**, 168.

¹⁷ S. R. Johns, J. A. Lambertson, and A. A. Sioumis, *Austral. J. Chem.*, 1971, **24**, 439.

established as L-4-hydroxypipelicolic acid.¹⁸ D-Pipelicolic acid, as well as L-threo- and D-erythro- $\alpha\beta$ -diaminobutyric acid, has been isolated on acid hydrolysis of the antibiotic amphotycin,¹⁹ and griselimycin afforded, *inter alia*, 4-trans-4-methyl-L-proline and N-methyl-D-leucine on hydrolysis.²⁰




(1)




(2)

B. New Natural Free Amino-acids.—The novel azirine amino-acid (2) isolated from a strain of *Streptomyces aureus*, and appropriately named azirinomycin, exhibits broad-spectrum activity *in vitro* against both Gram positive and negative bacteria.²¹ It is unstable especially in concentrated form and was identified by spectral analysis and by conversion on catalytic hydrogenation into L- α -aminobutyric acid.²² L-2,5-Dihydrophenylalanine (3), which had previously been synthesized by a Birch reduction of L-phenylalanine,²³ is an antimetabolite of L-phenylalanine produced by an unidentified *streptomyces*.²⁴ A related compound, anticapsin (4), is produced by a strain of *Streptomyces griseoplanus*²⁵ and is presumably derived from L-tyrosine by a similar reduction with subsequent epoxidation.



(3)



(4)

The increasing application of mass spectrometry as a valuable tool for characterization is apparent and has been employed for many of the amino-acids described in this section. Trimethylsilylation is still the most commonly employed procedure for enhancing the volatility of amino-acids containing a number of polar substituents and has been successfully applied in characterizing L-threo- α -amino- $\beta\gamma$ -dihydroxybutyric acid.²⁶ The new compound (5), which has been isolated from the common mushroom, affords on oxidation an unstable quinone, also present in the organism.²⁷

¹⁸ V. U. Ahmad and M. A. Khan, *Phytochemistry*, 1971, 10, 3339.

¹⁹ M. Bodanszky, N. C. Chaturvedi, J. A. Scozzie, R. K. Griffith, and A. Bodanszky, *Antimicrobial Agents and Chemotherapy*, 1969, 135.

²⁰ B. Terlain and J. P. Thomas, *Bull. Soc. chim. France*, 1971, 2349.

²¹ E. O. Stapley, D. Hendlin, M. Jackson, and A. K. Miller, *J. Antibiotics*, 1971, 24, 42.

²² T. W. Miller, E. W. Tristram, and F. J. Wolf, *J. Antibiotics*, 1971, 24, 48.



²³ M. L. Snow, C. Lawinger, and C. Ressler, *J. Org. Chem.*, 1968, 33, 1774.

²⁴ J. P. Scannell, D. L. Pruess, T. C. Demny, T. Williams, and A. Stempel, *J. Antibiotics*, 1970, 23, 618.





²⁵ R. Shah, N. Neuss, M. Gorman, and L. D. Boeck, *J. Antibiotics*, 1970, 23, 613.

²⁶ J. W. Westley, D. L. Pruess, L. A. Volpe, T. C. Demny, and A. Stempel, *J. Antibiotics*, 1971, 24, 330.

²⁷ R. F. Weaver, K. V. Rajagopalan, P. Handler, D. Rosenthal, and P. W. Jeffs, *J. Biol. Chem.*, 1971, 246, 2010.



Glutamic acid derivatives have also been isolated from a number of plant sources. Pinnatanine (6), a new amino-acid isolated from the European bladder nut²⁸ (*Staphylea pinnata*), affords on acid hydrolysis *L-allo-γ*-hydroxyglutamic acid, ammonia, and compound (7), the structure of which has been confirmed by synthesis. It is suggested that (7) arises *via* a Diels-Alder dimerization of the transient 2-methylenebut-3-enal initially formed in the hydrolysis. In the course of an investigation on nitrogen metabolism in tobacco plants a new amino-acid, nicotianamine, was isolated and the structure (8) was assigned on the basis of extensive chemical degradation and spectral analysis.²⁹ Azetidine-2-carboxylic acid had previously been obtained from a considerable number of plant species.³⁰



The isoquinoline derivative (9) has been isolated from the plant *Mucuna mutisiana*¹⁵ which also contains appreciable amounts of *L-Dopa*, and it

²⁸ M. D. Grove, M. E. Daxenbichler, D. Weisleder, and C. H. VanEtten, *Tetrahedron Letters*, 1971, 4477.

²⁹ M. Noma, M. Noguchi, and E. Tamaki, *Tetrahedron Letters*, 1971, 2017.

³⁰ L. Fowden, *Adv. Enzymol.*, 1967, 29, 89.

appears likely that (9) is derived from L-Dopa by condensation with formaldehyde. The corresponding derivative (10), formed from L-Dopa and acetaldehyde, had previously been isolated.³¹

The urine of homocystinuric patients has been shown to contain *S*-(3-hydroxy-3-carboxy-*n*-propylthio)- and *S*-(2-hydroxy-2-carboxyethylthio)-homocystine³² in addition to the α -hydroxy-analogue of cystine. Further work on the phaeomelanin pigments has been reported, and an isomer of trichosiderin C has been isolated and characterized.³³

C. New Amino-acids from Hydrolysates.—The most notable achievement in this field is undoubtedly the characterization and subsequent synthesis (see Section 2C) of the fluorescent Y base present in phenylalanine t-RNA derived from yeast, wheat germ, and rat liver. It represents a significant triumph for the application of physical methods; the structure (11) was established on 300 μ g of material mainly on the interpretation of the results obtained from high-resolution mass spectrometry and n.m.r. spectroscopy.³⁴

Full details on the structures of the novel piperazic acid derivatives from the antibiotic monamycin³⁵ and the guanidine amino-acid viomycin from viomycin³⁶ have been reported. β -Hydroxyhistidine has been isolated on the acid hydrolysis of the antibiotic bleomycin.³⁷

2 Chemical Synthesis and Resolution of Amino-acids

A. Introduction and General Methods.—The interest in asymmetric syntheses of amino-acids continues unabated and a valuable article covering the literature up to 1969 has been published.³⁸ In addition those syntheses which involve enantioselective catalytic hydrogenation have also been reviewed.³⁹ In this respect it is of considerable interest to note that this year has seen the first significant application of homogeneous asymmetric catalysis to amino-acid synthesis.⁴⁰ The rhodium complex of the chiral diphosphine (12) readily reduces *N*-acyldehydroamino-acids (13) to the corresponding (*R*)-*N*-acylamino-acids in high yield and with an optical efficiency of about 70%. The relatively high stereoselectivity is ascribed to the conformational rigidity of the diphosphine chelating the rhodium, together with the participation of the acid function of the substrate.

³¹ P. Müller and H. R. Schütte, *Z. Naturforsch.*, 1968, **236**, 491.

³² H. Kodama, S. Ohmori, M. Suzuki, S. Mizuhara, T. Oura, G. Isshiki, and I. Uemura, *Physiol. Chem. Phys.*, 1971, **3**, 81.

³³ G. Protá, A. Suarato, and R. A. Nicolaus, *Experientia*, 1971, **27**, 1145.

³⁴ K. Nakanishi, N. Furutachi, M. Funamizu, D. Grunberger, and I. B. Weinstein, *J. Amer. Chem. Soc.*, 1970, **92**, 7617.

³⁵ C. H. Hassall, Y. Ogihara, and W. A. Thomas, *J. Chem. Soc. (C)*, 1971, 522.



³⁶ G. Büchi and J. A. Raleigh, *J. Org. Chem.*, 1971, **36**, 871.

³⁷ T. Takita, T. Yoshioka, Y. Muraoka, K. Maeda, and H. Umezawa, *J. Antibiotics*, 1971, **24**, 795.


³⁸ J. D. Morrison and H. S. Mosher, 'Asymmetric Organic Reactions', Prentice-Hall, New Jersey, 1971.

³⁹ Y. Izumi, *Angew. Chem., Internat. Edn.*, 1971, **12**, 871.

⁴⁰ T. P. Dang and H. B. Kagan, *Chem. Comm.*, 1971, 481.




The inherent problem of conformational mobility of the substrate in all asymmetric syntheses which was referred to in last year's Report is probably the cause of the relatively low optical efficiency of the new synthesis ⁴¹ outlined in Scheme 1 and of the asymmetric reduction of dehydroamino-acid



Reagents: i, R^1MgX ; ii, H^+


Scheme 1

peptides.⁴² Unfortunately, the ingenious synthesis of amino-acids by the insertion of a carbene into an N—H bond of an optically active amine ⁴³ (Scheme 2) also gives low optical efficiency, presumably for the same reason.



Scheme 2

A general synthesis has been reported ⁴⁴ which employs a carbonylation reaction and is essentially a variation of the hydroformylation reaction and the Oxo process (Scheme 3). Although the products are completely racemic



Scheme 3

⁴¹ J. Fiaud and H. B. Kagan, *Tetrahedron Letters*, 1971, 1019.

⁴² M. Nakayama, G. Maeda, T. Kaneko, and H. Katsura, *Bull. Chem. Soc. Japan*, 1971, **44**, 1150.

⁴³ J. F. Nicoud and H. B. Kagan, *Tetrahedron Letters*, 1971, 2065.

⁴⁴ H. Wakamatsu, J. Uda, and N. Yamakami, *Chem. Comm.*, 1971, 1540.

the yields are reasonable and it is claimed that the reaction has a wide application to amino-acid synthesis. The starting materials are readily available and the synthesis reflects the growing commercial interest in the large-scale chemical production of amino-acids.

B. Synthesis under Simulated Prebiotic Conditions.—It is now well established that amino-acids are formed when a simulated primitive atmosphere is subjected to high temperature, u.v. irradiation, or high-frequency discharge, or any combination of these conditions. Recent work has centred on more rigorous analysis of the reaction mixtures and identification of amino-acids with functional groups in the side-chain.^{45, 46} Irradiation of mixtures of methane, ammonia, hydrogen sulphide, and water produces mixtures which contain either cysteine or cystine depending on the reaction conditions⁴⁷ and similar experiments using high-frequency discharge produce mixtures in which histidine has been conclusively identified.^{48, 49} The preferential adsorption of the L-isomer of racemic amino-acids on Kaolinite templates has been demonstrated⁵⁰ and is of particular interest in connection with the natural predominance of L-amino-acids.

C. Protein and Other Naturally Occurring Amino-acids.—Many of the syntheses described in this section have been achieved by standard procedures, and therefore only the salient features of the more important will be presented.

The various methods for the synthesis of glycine have been reviewed⁵¹ and a large-scale preparation of ornithine from glutamic acid has been reported.⁵² A new synthesis of threonine from the glycine copper complex and acetaldehyde has been described⁵³ together with a detailed investigation of the course of this reaction. Interest in the synthesis of L-Dopa and related compounds (Section 2F) continues, and two further syntheses^{54, 55} are now available.

The full details of the syntheses of capreomycin,⁵⁶ indospicine,⁵⁷ and the piperazic acid derivatives⁵⁸ from the antibiotic monamycin, initially reported in preliminary form, have now been published.

⁴⁵ D. Yoshino, R. Hayatsu, and E. Anders, *Geochim. Cosmochim. Acta*, 1971, **35**, 927, 939.

⁴⁶ V. Marshall and A. Bennett, *Proc. Indian Acad. Sci.*, 1970, **80**, 369.

⁴⁷ B. N. Khare and C. Sagan, *Nature*, 1971, **232**, 577.

⁴⁸ S. Yuasa, M. Ishigami, Y. Honda, and K. Imahori, *Sci. Rep. Osaka Univ.*, 1970, **19**, 33.

⁴⁹ S. Yuasa, M. Yamamoto, Y. Honda, M. Ishigami, and K. Imahori, *Sci. Rep. Osaka Univ.*, 1970, **19**, 7.

⁵⁰ T. A. Jackson, *Experientia*, 1971, **27**, 242.

⁵¹ B. P. Thacker, *Indian J. Chem.*, 1971, **5**, 42.

⁵² V. Gut and K. Poduška, *Coll. Czech. Chem. Comm.*, 1971, **36**, 3470.

⁵³ B. Maldonado, C. Richaud, J. P. Aune, and J. Metzger, *Bull. Soc. chim. France*, 1971, 2933.

⁵⁴ K. Ogura and G. Tsuchihashi, *Tetrahedron Letters*, 1971, 3151.


⁵⁵ H. Nakamoto, M. Aburatuni, and M. Inagaki, *J. Medicin. Chem.*, 1971, **14**, 1021.

⁵⁶ B. W. Bycroft, D. Cameron, and A. W. Johnson, *J. Chem. Soc. (C)*, 1971, 3040.

⁵⁷ C. C. J. Culvenor, M. C. Foster, and M. P. Hegarty, *Austral. J. Chem.*, 1971, **24**, 371.

⁵⁸ K. Bevan, J. S. Davies, C. H. Hassall, R. B. Morton, and D. A. S. Phillips, *J. Chem. Soc. (C)*, 1971, 514.


The structure of the Y base from phenylalanine t-RNA, as well as the stereochemistry at the single asymmetric centre, has been conclusively established⁵⁹ by the synthesis outlined in Scheme 4. The novel cyclopropyl




Reagents: i, H_2 -Pd/C; ii, Br_2-CHCl_3 ; iii, H_2O

Scheme 4

amino-acid (14) from horse chestnuts has been synthesized by carbene addition to 3,4-dehydropioline.⁶⁰ The reaction gives rise to a mixture of the *cis*- and *trans*-isomers (14) and (15) in the ratio 1 : 3.5. The stereochemistry of the natural amino-acid (14) was established by X-ray crystallographic analysis.



D. C-Alkyl- and Substituted C-Alkyl- α -amino-acids.—An improved method is claimed for the preparation of unsaturated α -amino-acids by reduction with aluminium amalgam of the unsaturated α -hydroxyimino intermediate (16) derived by the normal malonate route.⁶¹ A convenient method for



direct conversion of *N*-acyl- α -amino-acids into the *N*-acyl- $\alpha\beta$ -dehydro-amino-acids has been reported.⁶² (*S*)- α -Methyl- α -amino-acids have been obtained in high yield by a modified Strecker synthesis⁶³ and new syntheses of α -aminosuberic and α -aminosebacic acids have been described.⁶⁴

Considerable interest exists in cyanoamino-acids because of the strong neurotoxic properties of the naturally occurring β -cyano-L-alanine.

⁵⁹ M. Funamizu, A. Terahara, A. M. Feinberg, and K. Nakanishi, *J. Amer. Chem. Soc.*, 1971, **93**, 6708.

⁶⁰ Y. Fujimoto, F. Irreverre, J. M. Karle, I. L. Karle, and B. Witkop, *J. Amer. Chem. Soc.*, 1971, **93**, 3471.

⁶¹ D. J. Drinkwater and P. W. G. Smith, *J. Chem. Soc. (C)*, 1971, 1305.


⁶² J. M. Riordan and C. H. Stammer, *Tetrahedron Letters*, 1971, 4969.

⁶³ K. Weinges, G. Graab, D. Nagel, and B. Stemmler, *Chem. Ber.*, 1971, **104**, 3594.

⁶⁴ G. M. Shakhnazaryan, L. A. Voskanyan, and M. T. Dangyan, *Armenian. khim. Zhur.*, 1970, **23**, 709.

Dehydration of *N*-*o*-nitrophenylsulphenyl (Nps) asparagine and glutamine with dicyclohexylcarbodi-imide affords the corresponding protected ω -cyanoamino-acid.⁶⁵ The free amino-acids were obtained by removing the Nps group under mild conditions which did not effect the cyano-group. α -Cyanoglycine has been prepared by enzymic deacetylation of the readily available acetamidocyanoacetic acid.⁶⁵ Attempts to prepare it by chemical hydrolysis were unsuccessful because it undergoes rapid decarboxylation in hot aqueous solution.

N-Trifluoroacetylphenylglycine (17) has been converted by an interesting and unusual series of thermal rearrangements into trifluoroalanine (18).⁶⁶ The proposed reaction sequence is outlined in Scheme 5. The overall yield is acceptable and it is probable that this novel synthesis could be extended to other fluorinated amino-acids.



Reagents: i, $\text{ClCO}_2\text{Me-NEt}_3$; ii, 4-dimethylaminopyridine; iii, HBr-HOAc

Scheme 5

E. α -Amino-acids with Aliphatic Hydroxy-groups in the Side-chain.—The considerable interest in β -hydroxyvaline in relation to penicillin chemistry is reflected in the large number of syntheses already available for this compound. A further synthesis involves the addition of ethoxycarbonylnitrene to ethyl $\beta\beta$ -dimethylacrylate to give the aziridine intermediate (19). Ring opening of (19) with acetic acid and subsequent base hydrolysis affords (20) in good yield.⁶⁷

Both *erythro*- and *threo*- β -hydroxyleucine have been synthesized from β -isopropylglycidic acid,⁶⁸ and a detailed account of a number of unsuccessful routes to α -hydroxyamino-acids has appeared.⁶⁹


⁶⁵ A. Chimiak and J. J. Pastuszak, *Chem. Ind. Internat.*, 1971, 427.

⁶⁶ G. Hofle and W. Steglich, *Chem. Ber.*, 1971, 104, 1408.


⁶⁷ C. Berse and P. Bessette, *Canad. J. Chem.*, 1971, 49, 2610.

⁶⁸ S. Futagawa, M. Nakahara, T. Inui, H. Katsura, and T. Kaneko, *Nippon Kagaku Zasshi*, 1971, 92, 374.

⁶⁹ Y. Liwischitz, A. Singerman, Y. Wiesel, M. Michman, P. Braun, S. Kassel, and D. Perera, *Israel J. Chem.*, 1971, 9, 89.



F. Aromatic and Heterocyclic α -Amino-acids.—Aromatic amino-acids continue to be synthesized as potential enzyme inhibitors. A series of 6-alkyl-Dopa derivatives ⁷⁰ and 3-(2,5-dimethoxy-4-methyl)phenylalanine ⁷¹ have been prepared by standard routes, and an improved synthesis of 6-hydroxy-Dopa is claimed. ⁷² A variety of tyrosine derivatives ^{73, 74} and 2-aminoindan-2-carboxylic acids ⁷⁵ have been prepared as possible inhibitors of tyrosine hydroxylase. A novel method for the synthesis of α -hydrazino-acids related to L-Dopa ⁷⁶ has been reported. The key intermediate was the hydantoic acid (21) (prepared from the amino-acid and potassium cyanate) which on treatment with sodium hypochlorite afforded the hydrazino-acid (22) in good yield. The stereochemistry at the α -centre was retained, but in all the cases so far investigated the α -centre was fully substituted. It is possible that this method may have a broader application to the synthesis of α -hydrazino-acids.



⁷⁰ A. P. Morgenstern, C. Schuijt, and W. Th. Nauta, *J. Chem. Soc. (C)*, 1971, 3706.

⁷¹ K. Brewster and R. M. Pinder, *J. Medicin. Chem.*, 1971, **14**, 650.

⁷² F. Lee, G. H. Dickson, E. Donald, and A. A. Manian, *J. Medicin. Chem.*, 1971, **14**, 266.

⁷³ Y. H. Caplan, N. Zenker, D. A. Blake, and E. M. Johnson, *J. Medicin. Chem.*, 1971, **14**, 405.

⁷⁴ R. E. Counsell, P. Desai, A. Ide, P. G. Kulkarni, P. A. Weinhold, and V. B. Rethy, *J. Medicin. Chem.*, 1971, **14**, 789.


⁷⁵ R. M. Pinder, B. H. Butcher, D. A. Buxton, and D. J. Howells, *J. Medicin. Chem.*, 1971, **14**, 892.

⁷⁶ S. Karady, M. G. Ly, S. H. Pines, and M. Sletzing, *J. Org. Chem.*, 1971, **36**, 1946, 1949.

A number of fluoro-^{77, 78} and amino-phenylalanines,⁷⁹ as well as *p*-azidophenylalanine,⁸⁰ designed as a photoaffinity probe in synthetic peptides, has been reported. Interest continues in structural analogues of thyroxine; the stilbene derivative (23) has been synthesized by means of a Wittig reaction.⁸¹

A wide range of pyridyl,^{82, 83} pyrimidyl,⁸⁴⁻⁸⁶ and purinyl^{87, 88} amino-acids have been synthesized mainly by well-established routes for a variety of specific reasons too diverse to enumerate. The first example of a ring-fluorinated histidine derivative has been obtained⁸⁹ by a new route involving the photochemical decomposition of diazonium fluoroborates, and the method promises to offer a general route to aromatic and heterocyclic fluorination.

G. N-Substituted α -Amino-acids.—A further method for the preparation of *N*-methylamino-acids, which is also claimed to give high yields and optical purity, has been reported.⁹⁰ The reaction of the L-bromo-acid (24) with *anti*-benzaloxime afforded the *N*-oxide (25) which, on hydrogenation and hydrolysis, gave D-phenylalanine,⁹¹ thus demonstrating that the reaction



⁷⁷ A. T. Prudchenko, *Izvest. sibirsk. Otdel. Akad. Nauk, Ser. khim. Nauk*, 1970, 95.

⁷⁸ J. L. Fauchere and R. Schwyzer, *Helv. Chim. Acta*, 1971, **54**, 2078.

⁷⁹ I. Straukas, N. Dirvianskyte, and J. Degutis, *Zhur. org. Khim.*, 1971, **7**, 1390.

⁸⁰ R. Schwyzer and M. Caviezel, *Helv. Chim. Acta*, 1971, **54**, 1395.

⁸¹ G. Jones and S. Wright, *J. Chem. Soc. (C)*, 1971, 141.

⁸² S. J. Scotty, P. T. Sullivan, and C. B. Sullivan, *J. Medicin. Chem.*, 1971, **14**, 211.

⁸³ P. T. Sullivan and S. J. Norton, *J. Medicin. Chem.*, 1971, **14**, 557.

⁸⁴ M. Y. Lidak, R. A. Paegle, M. G. Plata, and Y. P. Shvachkin, *Khim. geterotsikl. Soedinenii*, 1971, 530.

⁸⁵ R. A. Paegle, M. G. Plata, M. Y. Lidak, and Y. Y. Popel, *Khim. geterotsikl. Soedinenii*, 1971, 258.

⁸⁶ I. Y. Ulane and M. Y. Lidak, *Khim. geterotsikl. Soedinenii*, 1971, 527.

⁸⁷ D. S. Letham and H. Young, *Phytochemistry*, 1971, **10**, 23.

⁸⁸ M. Y. Lidak, Y. Y. Shluke, S. E. Poritere, and Y. P. Shvachkin, *Khim. geterotsikl. Soedinenii*, 1971, 427.

⁸⁹ K. L. Kirk and L. A. Cohen, *J. Amer. Chem. Soc.*, 1971, **93**, 3060.


⁹⁰ J. R. Coggins and N. L. Benoiton, *Canad. J. Chem.*, 1971, **49**, 1968.

⁹¹ B. Liberek and Z. Palacz, *Roczniki Chem.*, 1971, **45**, 1173.

had proceeded with inversion of configuration at the α -centre. A novel route to α -hydrazino-acids from the corresponding amino-acid has been described in the foregoing section.⁷⁶

An interesting variation of the Favorski reaction has been employed to synthesize a series of ring homologues of proline.⁹² α -Halogenation of the readily available ω -aminolactams (26) afforded the α -halogeno-compounds (27) which underwent ring contraction on treatment with base to give the α -imino-acids (28). The already extensive programme on the synthesis of *N*-bis-2-halogenoethyl derivatives of amino-acids as potential antimetabolites has been extended.⁹³⁻⁹⁵

H. α -Amino-acids containing Sulphur.—Thioamides react smoothly with α -bromo- $\alpha\beta$ -unsaturated acids to form the thiazolinium derivatives (29) which on hydrolysis yield *N*-substituted cysteines. The rate of thiazolinium



formation decreases with increasing number of substituents owing to unfavourable steric interactions; nevertheless the reaction offers an interesting and versatile route to substituted cysteine derivatives.⁹⁶ The syntheses of a series of *S*-alkyl-2-methyl cysteine⁹⁷ and *S*-alkylhomocysteine derivatives⁹⁸ employing standard procedures have been reported.

I. α -Amino-acids which have been Synthesized for the First Time

Compound	Ref.
L-3-Carboxy-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline	15
' γ -L-Glutaminyl-4-hydroxybenzene' (<i>N</i> - γ -L-glutamyl- <i>p</i> -aminophenol)	27
<i>S</i> -(3-Hydroxy-3-carboxyethylthio)homocysteine	32
<i>S</i> -(2-Hydroxy-2-carboxyethylthio)homocysteine	32
<i>cis</i> - and <i>trans</i> -3,4-methylene-L-proline	60
3-(2-Methyl-4,5-dihydroxyphenyl)-DL-alanine	70
3-(2-Ethyl-4,5-dihydroxyphenyl)-DL-alanine	70
3-(2-Isopropyl-4,5-dihydroxyphenyl)-DL-alanine	70
3-(2- <i>t</i> -Butyl-4,5-dihydroxyphenyl)-DL-alanine	70
3-(2,5-Dimethoxy-4-methylphenyl)-DL-alanine	71
3-Ethyl- α -methyl-DL-tyrosine	74

⁹² H. T. Nagasawa, J. A. Elberling, P. S. Fraser, and N. S. Mizumo, *J. Medicin. Chem.*, 1971, 14, 501.

⁹³ G. G. Blinova and E. G. Sochilin, *Zhur. obshchei Khim.*, 1970, 40, 2748.

⁹⁴ L. V. Alekseeva, N. L. Burde, and Z. V. Pushkareva, *Zhur. org. Khim.*, 1971, 7, 647.

⁹⁵ G. A. Davydova, B. M. Karmanskaya, I. A. Redkin, and A. I. Tochilkin, *Khim. Farm. Zhur.*, 1971, 5, 11.

⁹⁶ A. Eidem, K. Undheim, and K. R. Reistad, *Acta Chem. Scand.*, 1971, 25, 1.

⁹⁷ S. Tahara and Y. Obata, *Agric. and Biol. Chem. (Japan)*, 1971, 35, 53.

⁹⁸ A. Rinaldi and C. De Marco, *Ital. J. Biochem.*, 1971, 20, 1.

Compound	Ref.
3-Isopropyl- α -methyl-DL-tyrosine	74
3- <i>t</i> -Butyl- α -methyl-DL-tyrosine	74
DL-2-Amino-5-hydroxy-indan-2-carboxylic acid	75
DL-2-Amino-5-methoxy-indan-2-carboxylic acid	75
DL-2-Amino-5-carboxy-indan-2-carboxylic acid	75
DL-2-Amino-5-chloro-indan-2-carboxylic acid	75
DL-2-Amino-5-bromo-indan-2-carboxylic acid	75
DL-2-Amino-5-iodo-indan-2-carboxylic acid	75
L- α -(3,4-Dihydroxybenzyl)- α -hydrazinopropionic acid	76
L- α -(3,4-Dimethoxybenzyl)- α -hydrazinopropionic acid	76
L- α -(3,4-Dihydroxybenzyl)- α -hydrazinobutyric acid	76
L- α -(3,4-Dimethoxybenzyl)- α -hydrazinobutyric acid	76
3-(2,4-Difluorophenyl)-DL-alanine	77
3-(3,4-Difluorophenyl)-DL-alanine	77
3-(3,5-Difluorophenyl)-DL-alanine	77
3-(2,5-Difluorophenyl)-DL-alanine	77
3-(2,6-Difluorophenyl)-DL-alanine	77
3-(2,3,5,6-Tetrafluorophenyl)-DL-alanine	77
3-(3,5-Dichloro-2,4,6-trifluorophenyl)-DL-alanine	77
3-(2,3,4,5,6-Pentafluorophenyl)-DL-alanine	78
3-(<i>m</i> -Bis-2-chloroethylaminophenyl)-DL-serine (<i>threo</i> and <i>erythro</i>)	79
3-(<i>p</i> -Bis-2-chloroethylaminophenyl)-DL-serine (<i>threo</i> and <i>erythro</i>)	79
<i>p</i> -Azido-L-phenylalanine	80
<i>trans</i> - β -4- <i>p</i> -hydroxystyryl-DL-phenylalanine	81
β -(1,2-Dihydro-2-oxo-3-pyridyl)-DL-alanine	82
β -(1,2-Dihydro-2-oxo-4-pyridyl)-DL-alanine	82
β -(1,2-Dihydro-2-oxo-5-pyridyl)-DL-alanine	82
β -(1,2-Dihydro-2-oxo-6-pyridyl)-DL-alanine	82
β -(2-Fluoro-3-pyridyl)-DL-alanine	82
β -(2-Fluoro-5-pyridyl)-DL-alanine	82
β -(2-Fluoro-6-pyridyl)-DL-alanine	82
β -(2-Bromo-3-pyridyl)-DL-alanine	83
β -(2-Bromo-4-pyridyl)-DL-alanine	83
β -(2-Bromo-5-pyridyl)-DL-alanine	83
β -(2-Bromo-6-pyridyl)-DL-alanine	83
β -(2-Chloro-3-pyridyl)-DL-alanine	83
β -(2-Chloro-4-pyridyl)-DL-alanine	83
β -(2-Chloro-5-pyridyl)-DL-alanine	83
β -(2-Chloro-6-pyridyl)-DL-alanine	83
β -(Thymin-1-yl)-DL-alanine	84
β -(5-Fluorouracil-1-yl)-DL-alanine	84
β -(5-Bromouracil-1-yl)-DL-alanine	84
β -(5-Chlorouracil-1-yl)-DL-alanine	84
β -(Cytosin-1-yl)-DL-alanine	84
<i>N</i> -(2-Chloro-5-fluoro-4-pyrimidyl)glycine	85
<i>N</i> -(2-Chloro-5-fluoro-4-pyrimidyl)-DL-phenylalanine	85
<i>N</i> -(2-Chloro-5-fluoro-4-pyrimidyl)-DL-leucine	85
<i>N</i> -(2-Chloro-5-fluoro-4-pyrimidyl)-DL-valine	85
<i>N</i> -(2-Chloro-5-fluoro-4-pyrimidyl)-DL-tryptophan	85
<i>N</i> -(2-Ethylthio-5-fluoro-4-pyrimidyl)glycine	85
<i>N</i> -(2-Ethylthio-5-fluoro-4-pyrimidyl)-DL-phenylalanine	85
<i>N</i> -(2-Ethylthio-5-fluoro-4-pyrimidyl)-DL-leucine	85
<i>N</i> -(2-Ethylthio-5-fluoro-4-pyrimidyl)-DL-valine	85
<i>N</i> -(2-Ethylthio-5-fluoro-4-pyrimidyl)-DL-tryptophan	85

Compound	Ref.
<i>N</i> -(2-Chloro-5-bromo-4-pyrimidyl)-DL-alanine	86
<i>N</i> -(2-Chloro-5-bromo-4-pyrimidyl)-DL- and L-leucine	86
<i>N</i> -(2-Chloro-5-bromo-4-pyrimidyl)-DL- and L-valine	86
<i>N</i> -(2-Chloro-5-bromo-4-pyrimidyl)-DL-tryptophan	86
<i>N</i> -(2-Chloro-5-bromo-4-pyrimidyl)-L-isoleucine	86
<i>N</i> -(2-Chloro-5-iodo-4-pyrimidyl)-DL-leucine	86
<i>N</i> -(2-Chloro-5-iodo-4-pyrimidyl)-DL-valine	86
<i>N</i> -(2-Chloro-5-iodo-4-pyrimidyl)-DL-alanine	86
<i>N</i> -(Purin-6-yl)-DL- α -phenylglycine	87
<i>N</i> -(Purin-6-yl)-L-leucine	87
<i>N</i> -(Purin-6-yl)-L-valine	87
DL-2-(Purin-6-yl-amino)-5-methylhex-4-enoic acid	87
<i>N</i> ⁶ -(5-Amino-6-chloro-4-pyrimidyl)lysine	88
α -Amino- ϵ -(6-chloro-9-puriny)caproic acid	88
4-Fluoro-DL-histidine	89
DL-Hexahydro-1 <i>H</i> -azepine-2-carboxylic acid	92
DL-Octahydro-2-azocine carboxylic acid	92
DL-Octahydro-2-azonine-2-carboxylic acid	92
DL-Decahydro-2-azecine carboxylic acid	92
DL-Azacycloundecane-2-carboxylic acid	92
<i>S</i> -Methyl-2-methyl-DL-cysteine	97
<i>S</i> -Ethyl-2-methyl-DL-cysteine	97
<i>S</i> -Propyl-2-methyl-DL-cysteine	97
<i>S</i> -Isopropyl-2-methyl-DL-cysteine	97
<i>S</i> -Butyl-2-methyl-DL-cysteine	97
<i>S</i> -Isobutyl-2-methyl-DL-cysteine	97
<i>S</i> - <i>t</i> -Butyl-2-methyl-DL-cysteine	97
<i>S</i> -Amyl-2-methyl-DL-cysteine	97
<i>S</i> -Isoamyl-2-methyl-DL-cysteine	97
<i>S</i> -Allyl-2-methyl-DL-cysteine	97
<i>S</i> -(β -Aminoethyl)homocysteine	98

J. Labelled Amino-acids.—The commercial availability of a wide range of ¹⁴C-labelled amino-acids is reflected in the noticeable drop in the publications relating to their syntheses, and those described have been performed by standard procedures such as the Strecker synthesis.⁹⁹ The chemical emphasis appears to have shifted to stereospecific syntheses of tritiated and deuteriated amino-acids and this has led to detailed examinations of the mechanisms of some of the general amino-acid syntheses.


In last year's Report it was pointed out that the synthesis of labelled aldehydes of the type (30) had considerable potential for specific labelling of amino-acids at the prochiral β -centre. This potential has now been realized by two groups working independently.^{100, 101} Condensation of (30) with an *N*-acylglycine derivative gave an oxazolone which opened with alkali to yield the acylaminocinnamic acid (31) of established *trans*-configuration. Catalytic hydrogenation of (31) was expected, and observed,

⁹⁹ L. Pichat, P. N. Liem, and J. P. Guermont, *Bull. Soc. chim. France*, 1971, 837.


¹⁰⁰ K. R. Hanson, R. H. Wightman, J. Staunton, and A. R. Battersby, *Chem. Comm.*, 1971, 185.

¹⁰¹ G. W. Kirby and J. Michael, *Chem. Comm.*, 1971, 415.

to proceed in a *syn*-stereospecific fashion. Resolution of the resulting acylamino-acid by enzymic deacylation afforded the (3*R*)-L- and (3*S*)-D-amino-acids (32) and (33) respectively. So far this method has only been applied to derivatives of phenylalanine and tyrosine but it undoubtedly has wider potential.



An alternative route^{101,102} to some of the deuteriated derivatives described above, which has also confirmed the stereochemical assignments, employs (1*S*)-[1-²H]benzyl alcohol (34). Enzymic reduction of benzaldehyde under established conditions afforded (34) and reaction of the corresponding tosylate (35) with diethyl malonate or with diethyl *N*-acetamidomalonate gave (36) and (37) respectively, which were converted by standard methods into (3*R*)-DL-[3-²H]phenylalanine (38). The reaction proceeds with inver-



sion of configuration at the β -centre and the high degree of stereoselectivity has been established by physical methods and by comparison with the corresponding products from the azlactone route described above.

¹⁰² R. Ife and E. Haslam, *J. Chem. Soc. (C)*, 1971, 2818.

A convenient and specific general method for the preparation of α -deuteriated and α -tritiated amino-acids involves incorporation of solvent isotopic hydrogen concomitant with decarboxylation of synthetic substituted aminomalonate precursors.¹⁰³ Reaction of substituted pyruvic acids with ^{15}N -labelled ammonia and sodium cyanohydridoborate affords a facile route to ^{15}N -labelled amino-acids. The use of the deuteriated or tritiated cyanohydridoborate and ^{15}N -labelled ammonia allows the synthesis of doubly labelled amino-acids.¹⁰⁴

K. Resolution of α -Amino-acids.—A general review which analyses the problems associated with enzymic, chemical, and chromatographic methods for resolving optical isomers has appeared.¹⁰⁵ The separation of racemates on asymmetric sorbents continues to attract attention. A co-polymer of a chloromethylated styrene-*p*-divinylbenzene and L-proline is claimed to resolve quantitatively DL-amino-acids when used as sorbent in the presence of transition-metal ions.^{106, 107} The basis of the technique is stated to be the preferential transition-metal complex formation between the L-amino-acid bound in the resin and the D-isomer in solution.

It has been known for some time that optically active stationary phases, usually dipeptides, are effective in resolving amino-acid derivatives by gas-liquid chromatography, but so far this method has been limited to analytical applications rather than preparative use; further investigations in this area have been reported.¹⁰⁸

The use of carrier-bound enzymes, *i.e.* water-insoluble enzyme systems, for the resolution of amino-acids is now well established. A continuous process using carrier-bound hog acylase has been developed which is claimed to be more efficient than the normal process, since the inhibition of the enzyme is reduced by the continual removal of the reaction products.¹⁰⁹ The papain-catalysed reaction between racemic *N*-acylamino-acids and phenylhydrazines has been shown to proceed preferentially with the L-isomer to give the corresponding optically active hydrazide.¹¹⁰ Practically 100% optical efficiency was achieved with *o*-fluorophenylhydrazine, and the method represents a novel application of the reverse of the normal proteolytic action of papain. Chymotrypsin-catalysed reactions have been employed to resolve a series of ring-substituted phenylalanine esters.¹¹¹

Chemical methods of resolution of synthetic racemates are still commonly

¹⁰³ J. W. Thanassi, *J. Org. Chem.*, 1971, **36**, 3019.

¹⁰⁴ R. F. Borch, M. D. Bernstein, and H. D. Durst, *J. Amer. Chem. Soc.*, 1971, **93**, 2897.

¹⁰⁵ S. V. Rogozhin, *Vestnik Akad. Nauk S.S.S.R.*, 1971, **40**, 56.

¹⁰⁶ S. V. Rogozhin, V. A. Davankov, V. V. Korshak, V. Vesa, and A. L. Belchich, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1971, 502.

¹⁰⁷ S. V. Rogozhin and V. A. Davankov, *Chem. Comm.*, 1971, 490.


¹⁰⁸ W. Parr, J. Pleterski, C. Yang, and E. Bayer, *J. Chromatog. Sci.*, 1971, **9**, 141.

¹⁰⁹ T. Barth and H. Mašková, *Coll. Czech. Chem. Comm.*, 1971, **36**, 2398.

¹¹⁰ J. L. Abernethy, E. Albano, and J. Comyns, *J. Org. Chem.*, 1971, **36**, 1580.

¹¹¹ J. H. Tong, C. Petitclerc, A. Diorio, and N. L. Benoiton, *Canad. J. Biochem.*, 1971, **49**, 877.

employed for routine work and details on the use of ephedrine¹¹² and menthol¹¹³ have been described. An obvious limitation to the normal methods of resolution is that, if a specific enantiometer is required, then the maximum yield is only 50%. An interesting preliminary report on a possible method of converting racemates completely into either the D- or the L-enantiomer has been outlined.¹¹⁴ The reaction of a racemic amino-acid with trifluoroacetic anhydride leads to the oxazolinone (39) which with dimethyl L-glutamate affords the LL-dipeptide derivative (40). Hydrolysis of the dipeptide, in the case of L-leucine, the only example so far reported, gave *ca.* 80% chemical and optical yields of the L-isomer. Whether or not this method has a wider application must await further evaluation.



3 Physical and Stereochemical Studies of α -Amino-acids (See also Chapter 2, Part II, Section 2, and Part III)

A. Crystal Structures of Amino-acids.—The crystal structures of L-isoleucine,¹¹⁵ L-tyrosine,¹¹⁶ L-arginine,¹¹⁷ L-cysteine,¹¹⁷ DL-lysine,¹¹⁷ DL-phenylalanine,¹¹⁷ L- α -diaminobutyric acid¹¹⁸ and the hydrochloride,¹¹⁹ L-Dopa hydrochloride,¹²⁰ and DL-tryptophan formate,¹²¹ have been described, and also those of the amides, N-acetyl-L-prolyl methylamide,¹²² N-acetyl-L-methionyl dimethylamide,¹²³ and 3,5-di-iodo-L-thyroninyl-methylamide.¹²⁴ The structure, configuration, and conformation in the crystal state of the novel amino-acid (14) have been established by an X-ray crystallographic analysis.⁶⁰ An analysis of the addition compound derived from bromomalic anhydride and 6-methylpyrid-2-thione has confirmed the structure (41) proposed on the basis of chemical and physical data.¹²⁵

¹¹² H. Kinoshita, M. Shintani, T. Saito, and H. Kotake, *Bull. Chem. Soc. Japan*, 1971, **44**, 286.

¹¹³ V. M. Belikov, T. F. Saveleva, and E. N. Safonova, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1971, 1461.

¹¹⁴ W. Steglich, E. Frauendorfer, and F. Weygand, *Chem. Ber.*, 1971, **104**, 687.

¹¹⁵ K. Torii and Y. Iitaka, *Acta Cryst.*, 1971, **B27**, 2237.

¹¹⁶ A. Mostad, H. M. Nissen, and C. Rømming, *Tetrahedron Letters*, 1971, 2131.

¹¹⁷ B. Khawas, *Acta Cryst.*, 1971, **B27**, 1517.

¹¹⁸ P. S. Naganathan and K. Venkatesan, *Acta Cryst.*, 1971, **B27**, 2159.

¹¹⁹ H. Hinazumi and T. Mitsui, *Acta Cryst.*, 1971, **B27**, 2152.

¹²⁰ R. J. Jandacek and K. M. Earle, *Acta Cryst.*, 1971, **B27**, 841.


¹²¹ E. Bye, A. Mostad, and C. Rømming, *Acta Chem. Scand.*, 1971, **25**, 364.

¹²² T. Matsuzaki and Y. Iitaka, *Acta Cryst.*, 1971, **B27**, 507.

¹²³ A. Aubry, M. Marraud, J. Protas, and J. Neel, *Compt. rend.*, 1971, **273**, C, 959.

¹²⁴ V. Cody, W. L. Duax, and D. A. Norton, *Chem. Comm.*, 1971, 683.

¹²⁵ P. Groth, *Acta Chem. Scand.*, 1971, **25**, 118.



B. Nuclear Magnetic Resonance Spectra.—N.m.r. spectroscopy is now an indispensable tool for structural elucidation and has played a decisive role in the characterization of many of the new amino-acids described in Section 1 (see, for example, refs. 22, 25, 28, 29, and 34). A detailed n.m.r. study on the conformation of valine and phenylalanine derivatives in different solvents, using the variation of the vicinal coupling constants to calculate changes in the population of side-chain rotamers, suggests that intramolecular interactions are more important than the dielectric constant of the medium in determining the relative energies of the rotamers.¹²⁶

Carbamate formation in solutions of α -amino-acids and carbonate-bicarbonate, as well as the conformation of the products, has been studied by n.m.r. techniques.¹²⁷ Also conformational studies have been reported on *N*-nitroso-derivatives of sarcosine and proline,¹²⁸ and *N*-acylproline derivatives.¹²⁹

The use of lanthanide complexes to produce large differential shifts in the ^1H and ^{13}C n.m.r. spectra of a wide range of organic compounds has greatly simplified the interpretation of the spectra of complex molecules. Unfortunately the use of these shift reagents has, until now, been limited to solutions of non-co-ordinating organic solvents, thus excluding the majority of amino-acids. It has now been reported that the hydrated perchlorates of europium or praseodymium afford considerable differential shifts on the spectra of compounds in deuterium oxide.¹³⁰ So far this technique has had limited application but developments in this area could be of considerable interest.

Interest continues in the ^{13}C n.m.r. spectra of amino-acids,¹³¹ but the most significant development in this area is the application of pulsed Fourier transform techniques to make use of the natural abundance of this isotope.¹³² The spectra were determined with the amino-acids bound to cationic resins, and deuterium-decoupled spectra of deuteriated amino-acids showed ^{13}C linewidths which were significantly narrower than those

¹²⁶ R. A. Newmark and M. A. Miller, *J. Phys. Chem.*, 1971, **75**, 505.

¹²⁷ R. U. Lemieux and M. A. Barton, *Canad. J. Chem.*, 1971, **49**, 767.

¹²⁸ F. H. C. Stewart, *Austral. J. Chem.*, 1971, **24**, 1949.

¹²⁹ H. L. Maia, K. G. Orrell, and H. N. Rydon, *Chem. Comm.*, 1971, 1209.

¹³⁰ F. A. Hart, G. P. Moss, and M. L. Staniforth, *Tetrahedron Letters*, 1971, 3389.

¹³¹ W. Voelter, G. Jung, E. Breitmaier, and E. Bayer, *Z. Naturforsch.*, 1971, **26**, 213.

¹³² H. Sternlicht, G. L. Kenyon, E. L. Packer, and J. Sinclair, *J. Amer. Chem. Soc.*, 1971, **93**, 199.

from proton-decoupled, protonated amino-acids. The resin method has the advantage of shortening the spin-lattice relaxation time for quaternary carbons and other carbons that do not have hydrogens bonded to them, thus enabling these to be distinguished from carbons which are bonded to hydrogens.

The recent advances in pulsed Fourier transform techniques have allowed n.m.r. studies of ^{15}N in natural abundance to be undertaken, and the ^{15}N chemical shifts of some amino-acid methyl ester hydrochlorides have been reported.¹³³ There are as yet insufficient data to give more than broad generalizations, but it appears that a γ -alkyl substituent effect operates similar to that observed in ^{13}C spectra, and the method could have considerable potential. The abundant ^{14}N isotope is less useful since it possesses an electric quadrupole moment which results in considerable line-broadening, but studies on amino-acids in the solid state have established the ^{14}N nuclear coupling constants.¹³⁴ A further study in the solid state has determined the proton spin-lattice relaxation times as a function of temperature and has related the results to the activation energies for reorientation of the various $^+\text{NH}_3$ groups.¹³⁵ The first routine measurements on amino-acids of tritium magnetic resonance spectra have been reported.¹³⁶ The problems, including self-radiolysis, were discussed in detail but it is difficult, at present, to envisage any significant advantages of this technique to amino-acid chemistry.

C. Optical Rotatory Dispersion and Circular Dichroism.—Surveys of the o.r.d. and c.d. curves of protein amino-acids and the c.d. curves of less-common amino-acids¹³⁷ have revealed that all compounds with the L-configuration at the α -centre give positive Cotton effects, provided that there is no other chromophoric system present. A general sector rule for α -amino-acids has now been proposed¹³⁸ which relates the sign and amplitude of the Cotton effect with the conformation and the absolute configuration at the α -centre. The rule is based on the octant rule and derives from the sector principle originally proposed for lactones. It depends on the basic assumption, for which there is considerable evidence, that in solution the $\text{N}-\text{C}^\alpha-\text{COO}$ atoms are co-planar. For the purpose of analysis the two $\text{C}-\text{O}$ bonds in the carboxylate ion are considered as two equivalent ketone groups and the plane bisecting the carboxylate ion is taken as a symmetry plane (Figure 1, plane A). By assigning two additional planes P_1 and P_2 through the carboxylate carbon atom, each perpendicular to a $\text{C}-\text{O}$ bond, the octant rule can be applied to each separately. The

¹³³ P. S. Pregosin, E. W. Randall, and A. I. White, *Chem. Comm.*, 1971, 1602.

¹³⁴ D. T. Edmonds and P. A. Speight, *Phys. Letters (A)*, 1971, 34, 325.

¹³⁵ R. G. C. McElroy, R. Y. Dong, M. M. Pintar, and W. F. Forbes, *J. Magn. Resonance*, 1971, 5, 262.

¹³⁶ J. Bloxside, J. A. Elvidge, J. R. Jones, and E. A. Evans, *Org. Magn. Resonance*, 1971, 3, 127.

¹³⁷ L. Fowden, P. M. Scopes, and R. N. Thomas, *J. Chem. Soc. (C)*, 1971, 833.

¹³⁸ E. G. Jorgensen, *Tetrahedron Letters*, 1971, 863.

summation of the two effects leads to the cancellation of contributions in some 30° sectors and reinforcement in others, as illustrated in Figure 1. Since the carboxylate ion has a true plane of symmetry the corresponding sectors below the plane are of opposite sign.




Figure 1




Figure 2

It can be seen from Figure 2 that, assuming the above-mentioned conditions apply, only the side-chain group and the α -hydrogen atom make significant contributions to the rotatory effect and that for L- α -amino-acids a greater amount of the positive sector is occupied. The rule appears to be generally applicable and rationalizes the low rotation of L-proline and the increase in rotation with increasing bulk of the side-chain, and it can be modified to account for the greater positive amplitude of L- α -amino-acids in acidic solution.

The c.d. curves for a range of α -aryl- α -amino-acids and their derivatives have been recorded. Those with the *S*-configuration all give strong positive Cotton effects and the conformations of these compounds have been discussed in relation to other α -amino-acids.¹³⁹ The o.r.d. and c.d. have also been reported for L-tyrosine,¹⁴⁰ L-tryptophan,¹⁴¹ mono- and oligonucleotides¹⁴² of L- α -amino-acids, and dithioethoxycarbonyl-L- α -amino-acids.¹⁴³

¹³⁹ W. Klyne, P. M. Scopes, R. N. Thomas, and H. Dahn, *Helv. Chim. Acta*, 1971, **54**, 2420.

¹⁴⁰ E. H. Strickland, M. Wilchek, J. Horwitz, and C. Billups, *J. Biol. Chem.*, 1971, **247**, 572.

¹⁴¹ H. Umeyama, T. Nagai, and H. Nogami, *Chem. and Pharm. Bull. (Japan)*, 1971, **19**, 441.

¹⁴² E. S. Gromova, B. V. Tyaglov, and Z. A. Shabarova, *Biochim. Biophys. Acta*, 1971, **240**, 1.

¹⁴³ K. Ishikawa, K. Achiwa, and I. S. Yamada, *Chem. and Pharm. Bull. (Japan)*, 1971, **19**, 912.

D. Mass Spectrometry.—The continuing interest in the application of mass spectrometry to peptide sequence determination has led to further investigations on the mass spectra of amino-acid derivatives, and the spectra of methyl-,¹⁴⁴ phenyl-,¹⁴⁴ and phenylthio-hydantoins¹⁴⁵ as well as 2-anilino-5-thiazoline¹⁴⁶ derivatives have been reported. For the same reason, chemical ionization mass spectrometry has been extended to phenylthio-hydantoins. The technique leads to enhanced stability of the molecular ion and markedly reduces fragmentation, thus increasing the analytical potential of the method.¹⁴⁷

Trimethylsilylation is still commonly employed to increase the volatility of amino-acids (see ref. 26) and the mass spectra of a series of trimethylsilyl derivatives of deuteriated and ¹³C-enriched amino-acids have been determined,¹⁴⁸ in relation to their possible application to biosynthetic studies. Details of the fragmentation patterns of simple amino-acids have also been recorded.^{149, 150}

E. Other Physical and Stereochemical Studies.—A considerable amount of detail on the conformation of free amino-acids^{151, 152} and their derivatives,^{153–155} both in solution and the solid state, has been deduced from i.r. and Raman spectroscopy. The heats of ionization of all the commonly occurring amino-acids have been calculated from calorimetric data¹⁵⁶ and the heats of solution of a number determined both in light and heavy water.¹⁵⁷

The determination of the relative and absolute stereochemistry is an integral part of structure elucidation of amino-acids, and physical methods have played a predominant role in establishing the chirality of a considerable number of synthetic and naturally occurring amino-acids. The separation and characterization of the diastereoisomers of threonine,¹⁵⁸ γ -fluoroglutamic acid,¹⁵⁹ and β -methyltryptophan¹⁶⁰ have been reported.

¹⁴⁴ T. Sun and R. E. Lovins, *Analyt. Biochem.*, 1971, **45**, 176.

¹⁴⁵ F. Weygand and R. Obermeier, *European J. Biochem.*, 1971, **20**, 72.

¹⁴⁶ T. Fairwell and R. E. Lovins, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 1280.

¹⁴⁷ H. M. Fales, Y. Nagai, G. W. A. Milne, H. B. Brewer, J. T. Bronzert, and J. J. Pisano, *Analyt. Biochem.*, 1971, **43**, 288.

¹⁴⁸ W. J. A. Van den Heuvel, J. L. Smith, and J. S. Cohen, *Proceedings of the Sixth International Symposium on Advances in Chromatography*, 1970, p. 293.

¹⁴⁹ J. G. Lawless and M. S. Chadha, *Analyt. Biochem.*, 1971, **44**, 473.

¹⁵⁰ E. Stenhagen and B. A. Andersson, *Arch. Mass Spectral Data*, 1971, **2**, 146.

¹⁵¹ P. K. Ponnuswamy and V. Sasisekharan, *Internat. J. Protein Res.*, 1971, **3**, 1, 9.

¹⁵² T. Akimoto, M. Tsuboi, M. Kainosho, F. Tamura, A. Nakamura, S. Muraishi, and T. Kajiuira, *Bull. Chem. Soc. Japan*, 1971, **44**, 2577.

¹⁵³ Y. Koyama, T. Shimanouchi, M. Sato, and T. Tatsumo, *Biopolymers*, 1971, **10**, 1059.

¹⁵⁴ J. Smolliková, A. Vitek, and K. Bláha, *Coll. Czech. Chem. Comm.*, 1971, **36**, 2474.

¹⁵⁵ S. Boehm and B. Ruestow, *Studies Biophys.*, 1969, **13**, 169.

¹⁵⁶ M. A. Marini, R. L. Berger, D. P. Lam, and C. J. Martin, *Analyt. Biochem.*, 1971, **43**, 188.

¹⁵⁷ A. I. Klimov and V. I. Deshcherevskii, *Biofizika*, 1971, **16**, 556.

¹⁵⁸ Y. Ariyoshi and N. Sato, *Bull. Chem. Soc. Japan*, 1971, **44**, 2787.

¹⁵⁹ J. C. Unkeless and P. Goldman, *Mol. Pharmacol.*, 1971, **7**, 293.

¹⁶⁰ K. F. Turchin, M. N. Preobrazhenskaya, Yu. N. Sheinker, and N. N. Suvorov, *Zhur. org. Khim.*, 1971, **7**, 1290.

An additional chemical correlation between viomycin and capreomycin has provided further confirmation for the relative and absolute stereochemistry of these guanidine amino-acids.¹⁶¹

4 Chemical Studies of Amino-acids

A. Introduction.—The first volume of what is intended as a continuous series of reviews on the general chemistry and biochemistry of amino-acids, peptides, and proteins has been published.¹⁶² Although the first issue contained only a limited amount on amino-acids (assignment of configuration), the series offers a further source of information on amino-acid chemistry. Each year a great deal of research is published on the chemistry of amino-acids and their derivatives, much of it in relation to peptide synthesis, and this is presented elsewhere in this Report; the remainder is undertaken for a wide variety of reasons and it is therefore inevitable that this section is something of a miscellany.

B. General Reactions.—When amino-acids are heated at 1000 °C the predominant pyrolysis product is hydrogen cyanide;¹⁶³ in some cases the amino-nitrogen is almost quantitatively converted into hydrogen cyanide. At lower temperatures phenylalanine and tryptophan afford a mixture of polynuclear hydrocarbons and heterocyclic compounds.¹⁶⁴ A detailed investigation on the thermal decomposition employing differential scanning calorimetry has allowed thermolysis pathways to be proposed for a number of amino-acids in terms of the resolved thermograms.¹⁶⁵

The stereochemistry and product distribution on nitrous acid deamination of L-phenylalanine, and of *p*-substituted phenylalanine ethyl esters in trifluoroacetic acid, suggests¹⁶⁶ that the reaction proceeds predominantly through the phenonium ion (42) as outlined in Scheme 6.

The deamination of a series of aminocycloalkane carboxylic acids has been reported;¹⁶⁷ the results were discussed in relation to the possible conformation of the ring systems. Strecker degradation of amino-acids with benzil afforded the expected aldehydes and tetraphenylpyrazine, which is claimed to arise by self-condensation of the intermediate 2-amino-2-phenylacetophenone.¹⁶⁸ Isatogen derivatives of the type (43) react with α -amino-acids in a similar manner to ninhydrin and isatin, causing oxidative deamination and decarboxylation to the aldehydes and isatogen reduction products.¹⁶⁹

¹⁶¹ C. Gallina, C. Marta, C. Colombo, and A. Romeo, *Tetrahedron*, 1971, **27**, 4681.

¹⁶² 'Chemistry and Biochemistry of Amino-acids, Peptides, and Proteins', ed. B. Weinstein, Marcel Dekker, New York, 1971.

¹⁶³ W. R. Johnson and J. C. Kang, *J. Org. Chem.*, 1971, **36**, 189.

¹⁶⁴ J. M. Patterson, W. Y. Chen, and W. J. Smith, *Tobacco Sci.*, 1971, **15**, 41.


¹⁶⁵ P. G. Olafsson and A. M. Bryan, *Geochim. Cosmochim. Acta*, 1971, **35**, 327.

¹⁶⁶ K. Koga, C. C. Wu, and S. Yamada, *Tetrahedron Letters*, 1971, 2283.


¹⁶⁷ R. J. W. Cremling, R. M. Ellam, and T. K. Mitra, *J. Chem. Soc. (C)*, 1971, 1647.

¹⁶⁸ A. F. Al-Sagayab, A. T. Atto, and F. Y. Sarah, *J. Chem. Soc. (C)*, 1971, 3260.

¹⁶⁹ M. Hooper and J. W. Robertson, *Tetrahedron Letters*, 1971, 2139.



Scheme 6



The generally accepted mechanism for the photo-decarboxylation of 2,4-dinitrophenyl- α -amino-acids,¹⁷⁰ which involves decarboxylation with intramolecular oxygen transfer from the nitro-group, has been questioned.¹⁷¹ It is pointed out that such a mechanism cannot explain the photo-decarboxylation in the solid state when the nitro-group is unaffected. Furthermore, it has been demonstrated that *N*-*p*-nitrophenylvaline is rapidly photo-decarboxylated to give isobutyraldehyde and *p*-nitro-aniline,¹⁷¹ which suggests that the initial process is decarboxylation without oxygen transfer.

A generally efficient azeotropic method for the esterification of amino-acids has been reported.¹⁷² The reduction of amino-acid esters proceeds more readily with lithium dimethoxyaluminium hydride than with lithium aluminium hydride itself,¹⁷³ and the esters also react with borane, trichloroborane, and trifluoroborane to form adducts which can be converted into the corresponding *N*-substituted borazines.¹⁷⁴ A kinetic investigation extending further the programme on the Dakin-West reaction has provided evidence for the proposed pathway for the rearrangement of *N*-acyl-*s*-amino-acids.¹⁷⁵

¹⁷⁰ O. Meth-Cohn, *Tetrahedron Letters*, 1970, 1235.

¹⁷¹ P. H. MacFarlane and D. W. Russell, *Tetrahedron Letters*, 1971, 725.

¹⁷² A. K. Saund and N. K. Mathur, *Indian J. Chem.*, 1971, 9, 936.

¹⁷³ E. F. Rothgery and L. F. Hohnstedt, *Inorg. Chem.*, 1971, 10, 181.


¹⁷⁴ M. Dymicky, E. F. Mellon, and J. Naghski, *Analyt. Biochem.*, 1971, 41, 487.

¹⁷⁵ R. Knorr and G. K. Staudinger, *Chem. Ber.*, 1971, 104, 3621, 3633.

Amino-acids continue to be used as convenient chiral reagents both in synthesis and chromatography. The asymmetric synthesis of the alkaloid (+)-mesembrine has been achieved *via* an intermediate L-proline derivative.¹⁷⁶ Enantioselective Raney nickel catalysts have been prepared with amino-acids^{39, 177} and amino-acid derivatives have been employed as stationary phases in ion-exchange^{106, 107} and gas-liquid chromatography.¹⁰⁸

C. Specific Reactions.—A systematic investigation of the desulphurization of sulphur-containing amino-acids with Raney nickel has established that cysteine and cystine can be completely desulphurized under relatively mild conditions, whereas methionine is essentially unchanged.¹⁷⁸ Similar results have been obtained using phosphorous acid, which has been used successfully with glutathione and oxytocin.¹⁷⁹

The alkynyl cysteine-S-oxide (44) and the corresponding dioxide, in the presence of base, undergo an internal addition of the amino-function to the triple bond to give a cyclic sulphoxide (45) and a cyclic sulphone respectively.¹⁸⁰ Bisulphite has been shown to catalyse the aerial oxidation of methionine to the S-oxide¹⁸¹ and a detailed investigation of thiazolidine formation from L-cysteine and formaldehyde has been reported.¹⁸² S-Acetamido-methylcysteine can be directly oxidized to cystine derivatives with iodine,¹⁸³ and the method has been applied to the synthesis of the previously unknown cyclo-L-cystine (46).



1-Acetyltryptophan has been synthesized from tryptophan *via* the N-phthaloyl derivative (47); surprisingly this compound had not previously been reported in the literature.¹⁸⁴ Oxidation of (47) with chromium trioxide afforded the kynurenine derivative (48) and the unusual dioxindole lactone (49).

¹⁷⁶ S. Yamada and G. Otani, *Tetrahedron Letters*, 1971, 1133.

¹⁷⁷ F. Higashi, T. Ninomiya, and Y. Izumi, *Bull. Chem. Soc. Japan*, 1971, **44**, 1333.

¹⁷⁸ M. T. Perlstein, M. Z. Atassi, and S. H. Cheng, *Biochem. Biophys. Acta*, 1971, **236**, 174.

¹⁷⁹ C. Ivanov and C. O. Ivanov, *Doklady Bolg. Akad. Nauk*, 1971, **23**, 1365.


¹⁸⁰ J. F. Carson and L. E. Boggs, *J. Org. Chem.*, 1971, **36**, 611.

¹⁸¹ M. Inoue and H. Hikoya, *Chem. and Pharm. Bull. (Japan)*, 1971, **19**, 1286.


¹⁸² R. G. Kallen, *J. Amer. Chem. Soc.*, 1971, **93**, 6227, 6236.

¹⁸³ B. Kamber, *Helv. Chim. Acta*, 1971, **54**, 927.

¹⁸⁴ S. Ohki and T. Nagasaka, *Chem. and Pharm. Bull. (Japan)*, 1971, **19**, 545, 603.



Tryptophan methyl ester reacts smoothly with 3-pyrrolin-2-one to yield (50); the stereochemical course of the reaction is not defined but it is suggested that the reaction could be employed for modifying peptide structures.¹⁸⁵



A new mild reductive cleavage of acyl-guanidines to amines has been demonstrated by the conversion of arginine into ornithine.¹⁸⁶ The reaction of nitromalondialdehyde with arginine in aqueous alkaline media results in the quantitative formation of δ -(5-nitro-2-pyrimidyl)ornithine.¹⁸⁷ The reaction may have potential in peptide sequence work and in mass spectrometry for increasing the volatility of guanidine-containing amino-acids.

The *N*-oxides of *NN*-alkylamino-acids readily decarboxylate when heated with toluene-*p*-sulphonyl chloride in pyridine to yield the secondary amine and formaldehyde,¹⁸⁸ presumably by the mechanism outlined in Scheme 7.

The α , β -dehydrovaline ester (51), prepared by reduction of the corresponding α -nitro-ester, dimerizes on heating¹⁸⁹ to give the diketopiperazine (52), whereas the α -imino-ester (53), prepared from the α -keto-ester by the

¹⁸⁵ V. Bocchi, G. Casnati, and G. P. Gardini, *Tetrahedron Letters*, 1971, 683.


¹⁸⁶ J. S. Bland and J. F. W. Keana, *Chem. Comm.*, 1971, 1024.

¹⁸⁷ A. Signor, G. M. Bonora, L. Biondi, D. Nisato, A. Marzotto, and E. Scoffone, *Biochemistry*, 1971, 10, 2748.


¹⁸⁸ Y. Ikutani, *Bull. Chem. Soc. Japan*, 1971, 44, 271.

¹⁸⁹ C. Shin, M. Masaki, and M. Ohta, *Bull. Chem. Soc. Japan*, 1971, 44, 1657.

addition of *N*-phenyltriphenylphosphinimine, cyclizes at room temperature to the imidazolidone (54). It is suggested that under the conditions of the two reactions there is no interconversion between (51) and (53).



Scheme 7



A novel synthesis of D-ribose has been reported which employs as the starting material L-glutamic acid, the asymmetric α -centre of which is subsequently converted into C-4 of D-ribose.¹⁹⁰

D. Non-enzymic Models of Biochemical Processes Involving Amino-acids.—


The chemical oxidation of tyrosine with potassium nitrosodisulphonate (Fremy's salt) has been found to follow the proposed enzymic pathways. Tyrosine methyl ester (55) is oxidized to 2-carboxy-5,6-dihydroxyindole (57) through the intermediacy of (56), which possesses the characteristic spectral properties of the enzyme-catalysed intermediate for amino-terminal tyrosine peptides. Carboxy-terminal peptides are oxidized by Fremy's salt to the *o*-quinone intermediate (58) which on reduction affords 3,4-dihydroxyphenylalanine derivatives, again paralleling the enzymic pathway.¹⁹¹

The stability of organically bound nitrogen in soil humic acids has been attributed to combination of amino-acids, peptides, and proteins with quinones. In order to investigate the chemical ability of this type of compound the synthesis of a number of benzoquinones containing α -amino-acid esters has been described.¹⁹² Model reactions involving the

¹⁹⁰ K. Koga, M. Taniguchi, and S. Yamada, *Tetrahedron Letters*, 1971, 266.

¹⁹¹ S. Dukler, M. Wilchek, and D. Lavie, *Tetrahedron*, 1971, 27, 607.

¹⁹² P. A. Cranwell and R. D. Haworth, *Tetrahedron*, 1971, 27, 1831.



direct cleavage of diphenyl ether linkages, in studies related to the metabolism of thyroxine, have been documented.¹⁹³ The non-enzymic reaction of L-serine with indole and hydrogen sulphide, in the presence of pyridoxal, to give DL-tryptophan and DL-cystine respectively, is reported to proceed through an intermediate pyridoxylidene amino-acrylic acid derived by β -elimination of the Schiff base.¹⁹⁴

A synthetic chiral biphenyl derivative is stated to act as a stereospecific catalyst for the racemization of amino-acids.¹⁹⁵ Tropic acid with the *S*-configuration, *i.e.* naturally occurring tropic acid, has been obtained from L-phenylalanine by nitrous acid deamination, and the reaction is claimed to proceed by a route similar to the biochemical process.¹⁹⁶

E. Effects of Electromagnetic Radiation on Amino-acids.—The radicals produced from amino-acids continue to be studied under various conditions. Both radiolysis and chemical techniques have been employed for the formation of radicals which were subsequently studied by e.s.r. spectroscopy, and it is important to note that in cases in which a comparison of the results from both methods is possible the e.s.r. spectra obtained are essentially identical. E.s.r. studies on radicals produced by radiolysis support the generally established pathways for the reaction of amino-acids with $\cdot\text{OH}$ radicals and hydrated electrons,^{197–200} and in the aqueous alkaline solution of all the amino-acids investigated, radicals of the type (59) were observed.¹⁹⁷ Similar observations were made on the radicals produced with $\text{Ti}^{3+}-\text{H}_2\text{O}_2$ at pH 9–12, and in this case the temperature-dependent proton hyperfine splitting from the amino-hydrogens was noted and interpreted in terms of

¹⁹³ T. Matsuura, T. Nagamachi, and A. Nishinaga, *J. Org. Chem.*, 1971, **36**, 2016.

¹⁹⁴ K. Korte and U. Schmidt, *Monatsh.*, 1971, **102**, 207.

¹⁹⁵ K. Hirota and Y. Izumi, *Bull. Chem. Soc. Japan*, 1971, **44**, 2287.

¹⁹⁶ K. Koga, C. C. Wu, and S. Yamada, *Tetrahedron Letters*, 1971, 2287.

¹⁹⁷ R. W. Fessenden and P. Neta, *J. Phys. Chem.*, 1971, **75**, 738.


¹⁹⁸ H. C. Box and E. E. Budzinski, *J. Chem. phys.*, 1971, **55**, 2446.

¹⁹⁹ G. Lassman and W. Damerau, *Studies Biophys.*, 1969, **17**, 195.

²⁰⁰ V. T. Srinivasan and A. Van de Vorst, *Internat. J. Radiation Biol.*, 1971, **19**, 133.

the non-coplanarity of the amino-group with the nodal plane of the π -system.²⁰¹

The radicals (60) and (61), which have different e.s.r. spectra, are formed from the $\cdot\text{OH}$ radical and glycine in aqueous solution; exchange between the two radicals can be induced by addition of phosphoric acid.²⁰²



Radiolysis of oxygenated cysteine²⁰³ and cysteine formate²⁰⁴ solutions has provided further evidence for the radiolytic pathways involving sulphur radicals. The major volatile products formed by radiolysis of *S*-n-propyl-L-cysteine sulfoxide and *S*-allyl-L-cysteine sulfoxide have been identified by a combination of g.l.c. and mass spectrometry.²⁰⁵

Flash spectrophotometry has been employed to follow the reactions of the hydrated electron with aromatic amino-acids and the results accord well with those obtained from pulse radiolysis.²⁰⁶

The photo-luminescence of aromatic amino-acids is still being extensively investigated,²⁰⁷⁻²¹⁰ usually with the object of applying the results to the elucidation of protein structure. The photolysis of tryptophan and tryptophan derivatives has attracted considerable attention; evidence has been presented which suggests that the primary photochemical reaction is N—H bond fission.²¹¹ Photo-oxidation of tryptophan in aqueous solution at pH 6—9 affords *N*-formyl-kynurenine,^{212, 213} but in dilute ammonia the main product is 4-(2-amino-2-carboxyethyl)quinazoline, which is not formed *via* formyl-kynurenine.²¹³ The rates of the flavin-sensitized photo-oxidation of tryptophan and of tyrosine have been determined,²¹⁴ and the role of the triplet state in their photo-ionization has been discussed.²¹⁵

The general photochemically induced deamination of amino-acids has been investigated in detail.²¹⁶

²⁰¹ R. Poupko, A. Loewenstein, and B. L. Silver, *J. Amer. Chem. Soc.*, 1971, **93**, 580.

²⁰² H. Paul and H. Fischer, *Helv. Chim. Acta*, 1971, **54**, 485.

²⁰³ J. P. Barton and E. J. Packer, *Internat. J. Radiation Phys. Chem.*, 1970, **2**, 159.

²⁰⁴ M. Morita, K. Sasai, M. Tajima, and M. Fujimaki, *Bull. Chem. Soc. Japan*, 1971, **44**, 2257.

²⁰⁵ H. Nishimura, J. Mizutani, Y. Obata, and M. Namiki, *Tetrahedron*, 1971, **27**, 307.

²⁰⁶ B. Finnstrom, *Photochem. and Photobiol.*, 1971, **13**, 375.

²⁰⁷ E. Leroy, H. Lami, and G. Laustriat, *Photochem. and Photobiol.*, 1971, **13**, 411.

²⁰⁸ P. G. Bogach, V. L. Zima, and A. M. Filenko, *Biofizika*, 1971, **16**, 340.

²⁰⁹ I. P. Vinogradov and N. Ya. Dodonova, *Biofizika*, 1971, **16**, 343.

²¹⁰ J. Tournon and M. A. El-Bayoumi, *J. Amer. Chem. Soc.*, 1971, **93**, 6396.

²¹¹ M. T. Pailthorpe and C. H. Nicholls, *Photochem. and Photobiol.*, 1971, **14**, 135.

²¹² R. S. Asquith and D. E. Rivett, *Biochim. Biophys. Acta*, 1971, **252**, 111.

²¹³ W. E. Savage, *Austral. J. Chem.*, 1971, **24**, 1285.

²¹⁴ F. Y. H. Wu and D. B. McCormick, *Biochim. Biophys. Acta*, 1971, **236**, 479.

²¹⁵ E. E. Fesenko, *Studies Biophys.*, 1968, **9**, 155.

²¹⁶ A. Riva and R. Cultrera, *Ann. Chim. (Italy)*, 1971, **61**, 624.

5 Analytical Methods (See also Chapter 2, Part I, Section 2A)

The pattern established in previous Reports for this section is maintained; the majority of references are cited under the appropriate heading without discussion and only the pertinent advances are presented in more detail. The improvements and developments of technique for amino-acid analysis in relation to structural studies on proteins and peptides are also covered. A book describing recent developments in analytical methods has been published.²¹⁷

A. Gas-Liquid Chromatography.—The wealth of literature relating to g.l.c. of derivatized amino-acids emphasizes the developing potential of this truly quantitative method. The great advantages of the technique are speed and sensitivity. The instrumentation is simple and the resolution is such that even optical isomers can be separated on an asymmetric support.^{218–220} The problems encountered with derivatization have now been largely overcome and more convenient methods for sample handling and quantitative preparation with a minimum of manipulation are being developed.²²¹ It is perhaps significant that the methods employed to investigate the amino-acid content of extra-terrestrial material were predominantly g.l.c. methods (see Section 1A), and arising out of this work a g.l.c. technique for nanogramme amounts of amino-acids is now available.²²² Several papers report that the effective resolution of all twenty protein amino-acids has been documented,^{223–225} establishing that the problems encountered with resolving histidine, arginine, tryptophan, and cysteine have now been largely overcome. A number of other papers relating to g.l.c. of amino-acids in general have been published^{226–230} and the increasing application of the method for biological materials is evident.^{231–234} Chromatography of phenyl- and methyl-hydantoin derivatives also would appear to be promising²³⁵ and the

²¹⁷ A. Niederwieser and G. Pataki, 'New Techniques in Amino-acid, Peptide, and Protein Analysis', Ann Arbor-Humphrey Sci. Publishers, Ann Arbor, Michigan, 1971.

²¹⁸ B. Feibush, *Chem. Comm.*, 1971, 544.

²¹⁹ W. Parr and P. Howard, *Chromatographia*, 1971, **4**, 162.

²²⁰ J. C. Dabiowiak and D. W. Cooke, *Analyt. Chem.*, 1971, **43**, 791.

²²¹ J. M. L. Mee and C. C. Brooks, *J. Chromatog.*, 1971, **62**, 138.

²²² R. W. Zumwalt, K. Kuo, and C. W. Gehrke, *J. Chromatog.*, 1971, **55**, 267; **57**, 193.

²²³ C. W. Gehrke, K. Kuo, and R. W. Zumwalt, *J. Chromatog.*, 1971, **57**, 209.

²²⁴ C. W. Gehrke, R. W. Zumwalt, and K. Kuo, *J. Agric. Food Chem.*, 1971, **19**, 605.

²²⁵ C. W. Moss, M. A. Lambert, and F. J. Diaz, *J. Chromatog.*, 1971, **60**, 134.

²²⁶ B. C. Pettit and J. E. Stouffer, ref. 148, p. 273.

²²⁷ E. Gil-Av, W. Parr, C. Yang, and E. Bayer, ref. 148, p. 287.

²²⁸ J. Metz, W. Ebert, and H. Weicker, *Chromatographia*, 1971, **4**, 259.

²²⁹ D. A. Shearer and R. M. Warner, *Internat. J. Environ. Analyt. Chem.*, 1971, **1**, 11.

²³⁰ K. Bergstrom and J. Gurtler, *Acta Chem. Scand.*, 1971, **25**, 175.

²³¹ F. J. Diaz, C. W. Moss, and M. A. Lambert, *Rev. Asoc. bioquim. argentina*, 1971, **36**, 67.

²³² J. L. Laseter, J. D. Weete, A. Albert, and C. H. Walkinshaw, *Analyt. Letters*, 1971, **4**, 671.

²³³ J. E. R. Schultz, *Column*, 1971, **13**, 5.

²³⁴ E. D. Pellizzari, C. Rising, J. H. Brown, R. W. Farmer, and L. F. Fabre, *Analyt. Biochem.*, 1971, **44**, 312.

²³⁵ J. J. Pisano, T. J. Bronzert, and H. B. Brewer, *Analyt. Biochem.*, 1972, **45**, 43.

radiochromatographic assay of the optical purity of ^{14}C -labelled amino-acids has been described.²³⁶

B. Ion-exchange Chromatography.—Two review articles on ion-exchange techniques have been published^{237, 238} and various aspects of quantification of automatic analyser data reported.^{239–242} The effect of conditions of preparation of resins on their resolution efficiency,²⁴³ the use of Chelex-100,²⁴⁴ and the separation of acidic amino-acids have also been investigated.²⁴⁵ A modified pyridine-formic acid solvent system is recommended for use with radioactive compounds; no initial desalting is necessary but the resolution is not as good as with citrate buffers.²⁴⁶ The hydrolysis of proteins and peptides in the presence of tritiated hydrochloric acid affords a simple and novel means of estimating the degree of racemization.²⁴⁷

It has been suggested that in order to avoid errors in quantitative work it is necessary to determine the colour constants with hydrindatin-ninhydrin for every amino-acid of interest.²⁴⁸ The use of titanous chloride with ninhydrin instead of stannous chloride is claimed to give better colorimetric analysis²⁴⁹ and further details on the detection of amino-acids with ninhydrin have been reported.^{250, 251} Further work on the use of 2,4,6-trinitrobenzenesulphonic acid for the quantitative determination of amino-acids has been described.²⁵²

C. Thin-layer Chromatography.—Amino-acid derivatives which do not react readily with ninhydrin can be detected on t.l.c. by exposing the chromatogram to bleaching powder and hydrochloric acid and subsequently spraying with starch-potassium iodide solution.²⁵³ Further improved techniques for the t.l.c. of free amino-acids have been

²³⁶ A. V. Barooshian, M. J. Lautenschleger, and W. G. Harris, *Analyt. Biochem.*, 1971, **44**, 543.

²³⁷ Y. Watanabe and N. Hamada, *Kagaku Tokogyo*, 1971, **45**, 17.

²³⁸ A. N. Kosharov and M. A. Marina, *Nov. Metody Modif. Biokhim. Issed. Zhivotnovod*, 1970, 36.

²³⁹ W. F. Kwolek and J. F. Cavins, *J. Assoc. Offic. Analyt. Chemists*, 1971, **54**, 1283.

²⁴⁰ L. S. Bates, *Analyt. Biochem.*, 1971, **41**, 158.

²⁴¹ E. Welte, E. Przemeck, and M. C. Nuh, *Z. Pflanzennernaehr. Bodenk.*, 1971, **128**, 243.

²⁴² J. P. Ellis and J. M. Prescott, *J. Chromatog.*, 1971, **61**, 152.

²⁴³ J. Rahm, H. Weinova, and Z. Prochazka, *J. Chromatog.*, 1971, **60**, 256.

²⁴⁴ J. Boisseau and P. Jouan, *J. Chromatog.*, 1971, **54**, 231.

²⁴⁵ A. Smith, P. J. Peterson, and L. Fowden, *J. Chromatog.*, 1971, **62**, 144.

²⁴⁶ M. Reford-Ellis and M. N. Kelson, *J. Chromatog.*, 1971, **59**, 434.

²⁴⁷ J. M. Manning, *J. Amer. Chem. Soc.*, 1970, **92**, 7449.

²⁴⁸ M. Yamamoto and J. L. Lowell, *J. Chromatog.*, 1971, **57**, 152.

²⁴⁹ L. B. James, *J. Chromatog.*, 1971, **59**, 178.

²⁵⁰ K. Samejima, W. Dairman, and S. Udenfriend, *Analyt. Biochem.*, 1971, **42**, 222.

²⁵¹ K. Samejima, W. Dairman, J. Stone, and S. Udenfriend, *Analyt. Biochem.*, 1971, **42**, 237.

²⁵² K. T. Kossmann, *Aerzt. Lab.*, 1971, **17**, 375.

²⁵³ Y. Ariyoshi, N. Sato, H. Zenda, and K. Adachi, *Bull. Chem. Soc. Japan*, 1971, **44**, 2558.

described.^{254, 255} The chromatography of dinitrophenylamino-acids on thin layers of proteins is claimed to give good results.²⁵⁶ Conditions for the effective separation of the dinitrophenyl derivatives of arginine and lysine,^{257, 258} and for the rapid separation of phenylthiohydantoins,²⁵⁹ have been reported.

D. Other Methods.—A theoretical study of the paper electrophoretic separation of amino-acids gives results in good agreement with experimental observations.²⁶⁰ Further details of instrumentation²⁶¹ and of the applications of paper electrophoresis to amino-acids²⁶² have been reported. Many other topics in the analytical chemistry of amino-acids have been discussed, including polarographic determinations in water²⁶³ and in DMSO,²⁶⁴ partition chromatography,^{265, 266} fluorometric measurements,²⁶⁷ enzyme electrode probes for D-amino-acids,²⁶⁸ and the detection of sulphur-containing amino-acids.²⁶⁹

E. Determination of Specific Amino-acids.—Papers on the determination of the following amino-acids have appeared: glutamic and aspartic acids,²⁷⁰ tryptophan,^{271–273} proline,²⁷⁴ hydroxyproline,²⁷⁵ cystine,²⁷⁶ methionine,^{277, 278} lysine,^{278, 279} ornithine,²⁸⁰ histidine,²⁸¹ and thyroxine.²⁸²

²⁵⁴ J. G. Heathcote, D. M. Davies, C. Haworth, and R. W. A. Oliver, *J. Chromatog.*, 1971, **55**, 377.

²⁵⁵ A. F. Krivis, *Microchem. J.*, 1971, **16**, 391.

²⁵⁶ P. R. Brady and R. M. Hoskinson, *J. Chromatog.*, 1971, **54**, 65.

²⁵⁷ H. M. Jacoby and L. Spero, *Analyt. Biochem.*, 1971, **44**, 299.

²⁵⁸ T. Skrabka-Blotnicka, *Chem. Analit. (Warsaw)*, 1971, **16**, 631.

²⁵⁹ K. D. Kuble and H. Konschewski, *Analyt. Biochem.*, 1971, **44**, 548.

²⁶⁰ Y. Kiso and E. Falk, *J. Chromatog.*, 1971, **59**, 401.

²⁶¹ O. Sova and A. Sullova, *Chem. Listy*, 1971, **65**, 1102.

²⁶² T. Fukuda and K. Mikami, *Shokuhin Eiseigaku Zasshi*, 1970, **11**, 292.

²⁶³ S. Fujiwara, Y. Umezawa, and H. Ishizuka, *Bull. Chem. Soc. Japan*, 1971, **44**, 1984.

²⁶⁴ R. T. Koch and W. C. Purdy, *Analyt. Chim. Acta*, 1971, **54**, 271.

²⁶⁵ Y. Tanimura, *Farumashia*, 1971, **7**, 628.

²⁶⁶ B. A. Persson, *Acta Pharm. Suecica*, 1971, **8**, 193.

²⁶⁷ S. R. Nahorski, *Analyt. Biochem.*, 1971, **42**, 136.

²⁶⁸ G. G. Guilbault and E. Hrabanova, *Analyt. Chim. Acta*, 1971, **56**, 285.

²⁶⁹ P. E. Belliveau and R. W. Frei, *Chromatographia*, 1971, **4**, 189.

²⁷⁰ M. E. Balis, *Methods Biochem. Analysis*, 1971, **20**, 103.

²⁷¹ M. Friedman and J. W. Finley, *J. Agric. Food Chem.*, 1971, **19**, 626.

²⁷² M. A. Marina and Yu. E. Shut, *Nov. Metody Modif. Boikhim. Issed. Zhivotnovod*, 1970, **50**.

²⁷³ T. Devenyi, J. Bati, and F. Fabian, *Acta Biochim. Biophys. Acad. Sci. Hung.*, 1971, **6**, 133.

²⁷⁴ V. Koppel, *Tartu Riikliku Ulikooli Torin*, 1971, **270**, 41.

²⁷⁵ D. Dabev and H. Struck, *Biochem. Med.*, 1971, **5**, 17.

²⁷⁶ J. W. Purdie and D. E. Hanafi, *J. Chromatogr.*, 1971, **59**, 181.

²⁷⁷ G. M. Ellinger and R. H. Smith, *Biochem. J.*, 1971, **124**, 151.

²⁷⁸ S. Ferenczi, J. Bati, and T. Devenyi, *Acta Biochim. Biophys. Acad. Sci. Hung.*, 1971, **6**, 123.

²⁷⁹ B. Wheeler, *Israel J. Agric. Res.*, 1971, **10**, 49.

²⁸⁰ C. W. Moss, F. J. Diaz, and M. A. Lambert, *Analyt. Biochem.*, 1971, **44**, 458.

²⁸¹ D. A. Newton and G. K. Summer, *Clinical Chem.*, 1971, **17**, 386.

²⁸² N. N. Nihei, M. C. Gershengorn, T. Mitsuma, L. R. Stringham, A. Cordy, B. Kuchmy, and C. S. Hollander, *Analyt. Biochem.*, 1971, **43**, 433.

2

Structural Investigations of Peptides and Proteins

BY R. N. PERHAM, J. O. THOMAS, T. L. BLUNDELL, AND R. H. PAIN

PART I: Primary Structure and Chemical Modification *by J. O. Thomas and R. N. Perham*

1 Introduction

Another year, another Report, another attempt to compress the proverbial quart into the pint pot. Gibbon boasted that his English text was chaste, and that all licentious passages were left in the decent obscurity of a learned language.¹ Our readers will also find nothing licentious in these pages: our sins are (we earnestly hope) ones of omission not commission, and we beg the forgiveness of those whose work is inadvertently neglected. Since the amount of material published in this field increases annually and the rate of increase shows no sign of diminishing, such inadvertence regrettably cannot be avoided. Indeed, when confronted with the reference list for this article, your Reporters limply recalled the siren voice of Wordsworth.² But sterner counsel prevailed and we, at least, are the wiser for it.

The form of this Report follows that of previous years, with a somewhat arbitrary distinction drawn between methods and results.

2 Methods

The determination of the primary structure and the evolution of proteins has been reviewed³ and a new method for the comparison of amino-acid sequences has been described.⁴ This uses a measure of similarity between every pair of amino-acids based on observed substitutions in homologous proteins, and suggests that the gene duplication predicted for the origin of bacterial ferredoxins has not occurred in plant ferredoxins. Moreover, the sequence repetitions in cytochrome *c* were held not to be significant.

¹ Edward Gibbon, 'Memoirs of my Life and Writings'.

² Up! Up! my friend and quit your books
Or surely you'll grow double
Up! Up! my friend and clear your looks
Why all this toil and trouble?

William Wordsworth, 'The Tables Turned'.

³ P. Jollès and J. Jollès, *Prog. Biophys. Mol. Biol.*, 1971, **22**, 97.

⁴ A. D. McLachlan, *J. Mol. Biol.*, 1971, **61**, 409.

The proceedings of a conference devoted to recent developments in the chemical study of proteins have also been published ⁵ and should provide a useful source book for ideas and references on many aspects of the art.

A. Amino-acid Analysis. (See also Chapter 1, Section 5.)—The amino-acid analyses of 120 proteins drawn from the recent literature have been collated ⁶ and a statistical method of comparing analyses has been given.⁷ It has been shown that if nitroarginine is present in a peptide, tyrosine and phenylalanine suffer chlorination during acid hydrolysis and that methionine, tryptophan, and serine are lost as unidentified products.⁸ Presumably the inclusion of a little phenol in the hydrolysis mixture would cure much of this.

It has been reported ⁹ that the tryptophan fluorescence of eleven reduced proteins in the presence of sodium dodecyl sulphate (SDS) is directly proportional to the tryptophan content of the proteins, thereby making this the basis of an analytical method for tryptophan. Another study ¹⁰ has shown that if a protein is hydrolysed in 3N-toluene-*p*-sulphonic acid containing 0.2% 3-(2-aminoethyl)indole in evacuated tubes at 110 °C for up to 72 h, tryptophan is recovered quantitatively, together with the other amino-acids. Since the hydrolysate may be placed directly on to the ion-exchange columns of an amino-acid analyser, without the prior removal of acid that is required when 6N-HCl is used for the hydrolysis, this would seem to represent a neat step forward in technique. The complete hydrolysis of peptides by a mixture of Sepharose-bound peptidases has been described,¹¹ which also avoids the destruction of tryptophan and, additionally, retains the amide groups of asparagine and glutamine.

Improvements have been reported ¹² in the determination of amino-groups with trinitrobenzenesulphonic acid, and a micro-method has been described ¹³ for detecting reactive carbonyl groups in proteins and peptides, using 2,4-dinitrophenylhydrazine. The colorimetric determination of proline in protein hydrolysates and biological fluids with isatin has also been improved ¹⁴ and a colorimetric assay for hydroxylysine has been reported.¹⁵ Proline interferes with this assay and the hydroxylysine and proline must first be separated.

⁵ 'Recent Developments in the Chemical Study of Protein Structures', Proceedings of Inserm Meeting, Montpellier, 1971, Institut National de la Santé de la Recherche Médicale, Paris, 1971.

⁶ D. M. Kirschenbaum, *Analyt. Biochem.*, 1971, **44**, 159.

⁷ H. M. Shapiro, *Biochim. Biophys. Acta*, 1971, **236**, 725.

⁸ P. Moritz and R. Wade, *Analyt. Biochem.*, 1971, **41**, 446.

⁹ K. R. Shelton and K. S. Rogers, *Analyt. Biochem.*, 1971, **44**, 134.

¹⁰ T.-Y. Lui and Y. H. Chang, *J. Biol. Chem.*, 1971, **246**, 2842.

¹¹ H. P. J. Bennett, D. F. Elliott, P. J. Lowry, and C. McMarker, *Biochem. J.*, 1971, **125**, 80P.

¹² (a) R. Fields, *Biochem. J.*, 1971, **124**, 581; (b) B. V. Plapp, S. Moore, and W. H. Stein, *J. Biol. Chem.*, 1971, **246**, 939.

¹³ R. Fields and H. B. F. Dixon, *Biochem. J.*, 1971, **121**, 587.

¹⁴ F. N. Bocktor, *Analyt. Biochem.*, 1971, **43**, 66.

¹⁵ N. Blumenkrantz and D. J. Prockop, *Analyt. Biochem.*, 1971, **39**, 59.

Many papers on the determination of thiol groups continue to appear. For example, a sensitive polarographic estimation of thiol groups using *N*-ethylmaleimide has been described¹⁶ and 2-vinylquinoline has been suggested¹⁷ as a reagent for the spectrophotometric determination of cysteine residues in proteins. A novel membrane filter assay for protein thiol groups has also been reported;¹⁸ the adduct formed between ¹⁴C-labelled mercuribenzoate and a protein that contains thiol groups is retained on a nitrocellulose filter whereas the superfluous label passes through. The minimum size of protein retained by the filter remains to be determined. The disulphide bridges of proteins can be reduced with dithiothreitol in liquid ammonia.¹⁹ After reduction and alkylation the ammonia is removed by evaporation and the excess reagent and the by-products are removed by washing with methanol. The best alkyl halides to use are the chlorides, since iodides and bromides react with ammonia. A strange series of side-reactions between DTNB [5,5'-dithio-bis-(2-nitrobenzoate)] and the disulphide bridges of proteins has also been reported.²⁰ This involves reduction of the disulphide bridge by the nitrothiophenoxide anion. However, since the nitrothiophenoxide anion is stabilized by resonance, this reaction can best be described as unlikely, and the whole concept has now been refuted by other workers.²¹

Ion-exchange Chromatography. Titanous chloride has been recommended²² as a substitute for stannous chloride in the reduction of the ninhydrin reagent for analysers since it causes no precipitation in the apparatus, and a simple device for cleaning the Teflon reaction coil in analysers has also been described.²³ It has been reported²⁴ that the condensation of ninhydrin with aldehydes and primary amines to yield highly fluorescent ternary products can be put to good use in automatic analysis, in which it is 10–100 times as sensitive as the conventional colorimetric procedure.

A detailed study has been made of accelerated amino-acid analysis using lithium citrate buffers on Aminex A5 resin.²⁵ Particular attention was paid to the effect of resin cross-linking and the avoidance of microbial contamination of the analyser columns. Aminex A5 resin has additionally been used for improving the separation of basic amino-acids and related compounds.²⁶ The column chromatographic analysis of tryptophan with the basic amino-acids, particularly useful for physiological fluids, has also been described.²⁷

¹⁶ P. D. J. Weitzman and H. J. Tyler, *Analyt. Biochem.*, 1971, **43**, 321.

¹⁷ L. H. Krull, D. E. Gibbs, and M. Friedman, *Analyt. Biochem.*, 1971, **40**, 80.

¹⁸ J. S. Krakow and S. P. Goolsby, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 453.

¹⁹ J. Meizenhofer, J. Czombos, and H. Maeda, *J. Amer. Chem. Soc.*, 1971, **93**, 3080.

²⁰ J. F. Robyt, R. J. Ackerman, and C. G. Chittenden, *Arch. Biochem. Biophys.*, 1971, **147**, 262.

²¹ K. Brocklehurst, M. Kierstan, and G. Little, *Biochem. J.*, 1972, **128**, 811.

²² L. B. James, *J. Chromatog.*, 1971, **59**, 178.

²³ K. D. Hapner, *Analyt. Biochem.*, 1971, **43**, 613.

²⁴ K. Samejima, W. Dairman, J. Stone, and S. Udenfriend, *Analyt. Biochem.*, 1971, **42**, 237.

²⁵ G. E. Atkin and W. Ferdinand, *J. Chromatog.*, 1971, **62**, 373.

²⁶ A. Mondino, G. Bongiovanni, V. Nol, and I. Raffalle, *J. Chromatog.*, 1971, **63**, 411.

²⁷ B. J. Berridge, W. R. Chao, and J. H. Peters, *Analyt. Biochem.*, 1971, **41**, 256.

Single-column chromatography systems continue to attract attention. Using three lithium citrate buffers and an ammonia filtration system, it has been possible to design a single-column system that will adequately resolve most amino-acids.²⁸ A modified gradient elution procedure that resolves all the amino-acids from connective tissue proteins has also been described.²⁹

Another modification to the analyser involves reading the absorbance of the effluent at 405 nm instead of the more normal 570 nm.³⁰ This enables proline and hydroxyproline to be quantitated in the same colorimeter channel as the other amino-acids and, moreover, the three colorimeters in conventional analysers can then be used to run three samples simultaneously. It is claimed that there is no loss in sensitivity. Volatile pyridine-formic acid buffers can replace the citrate buffers commonly used, which is particularly useful when one wishes to recover amino-acids from the analyser effluent.³¹

The quantitation of imino-acids can be improved by omitting hydrindantin from the ninhydrin reagent so as to favour the reaction with imino-acids,³² and new conditions have been given for the rapid analysis of collagen hydrolysates,³³ for the determination of homocitrulline,^{12b} and for the estimation of various methylated histidine compounds in muscle extracts.³⁴ Further studies on the chromatographic determination of D- and L-amino-acids in pneumococcal C-polysaccharide after their coupling with an L-amino-acid N-carboxy-anhydride have been reported³⁵ (see Volume 2 of these Reports) and a detailed analysis of the separation of oligopeptides and amino-acids on Chelex X-100 has been made.³⁶ The exchanger was used in the Cu²⁺ form and the amino-acids were eluted, free of Cu²⁺, with ammonia.

High-voltage Electrophoresis and Thin-layer Chromatography. Because of their cheapness and simplicity, these methods continue to be very popular for separating amino-acids. It has been suggested²⁴ that the fluorescent ninhydrin technique referred to above for automatic analysers might find use in detecting amino-acids on paper and thin-layer chromatograms. A new empirical relation between the chromatographic mobility of a peptide on t.l.c. and its amino-acid composition has been derived³⁷ that is comparable with the original equation of Pardee.

A series of papers³⁸ has dealt with the analysis of amino-acids in the form of their dansyl derivatives and with the preparation of Dns-peptide maps.

²⁸ S. B. Melançon and J. Tayco, *J. Chromatog.*, 1971, **63**, 404.

²⁹ B. C. Starcher, L. Y. Wenger, and L. D. Johnson, *J. Chromatog.*, 1971, **54**, 425.

³⁰ J. P. Ellis, jun. and J. B. Garcia, jun., *J. Chromatog.*, 1971, **59**, 321.

³¹ M. Redford-Ellis and M. N. Kelson, *J. Chromatog.*, 1971, **59**, 437.

³² J. P. Ellis, jun. and J. M. Prescott, *J. Chromatog.*, 1971, **61**, 152.

³³ R. M. Osborne, R. W. Longton, and B. L. Lamberts, *Analyt. Biochem.*, 1971, **44**, 317.

³⁴ A. A. Christman, *Analyt. Biochem.*, 1971, **39**, 181.

³⁵ J. M. Manning, *J. Biol. Chem.*, 1971, **246**, 2926.

³⁶ J. Boisseau and P. Jouan, *J. Chromatog.*, 1971, **54**, 231.

³⁷ C. Haworth and R. W. A. Oliver, *Biochem. J.*, 1971, **124**, 255.

³⁸ V. A. Spivak, V. V. Shcherbukhin, V. M. Orlov, and J. M. Varshavsky, *Analyt. Biochem.*, 1971, **39**, 271; V. A. Spivak, V. A. Fedoseev, V. A. Orlov, and J. M. Varshavsky, *ibid.*, 1971, **44**, 12; V. A. Spivak, M. I. Levjant, S. P. Katrukha, and J. M. Varshavsky, *ibid.*, p. 503.

Gas-Liquid Chromatography. Further applications of a system for separating nanogram amounts of amino-acids as the *N*-trifluoroacetyl derivatives of their *n*-butyl esters have been described.³⁹ The same authors⁴⁰ have given details of the conversion of the amino-acids into their derivatives and have looked at the suitability of heptafluorobutyryl as an *N*-blocking group for higher sensitivity. They have also described the complete separation of the 20 amino-acids found in proteins, using two columns.⁴¹ Other workers have now achieved the same complete separation on a single column.⁴² The amino-acids are separated as their *N*-heptafluorobutyryl *n*-propyl ester derivatives in 43 min.

The conversion of amino-acids into their trimethylsilyl derivatives and their separation in this form have been described,⁴³ and it has been reported⁴⁴ that methionine can readily be determined by estimating the methyl thiocyanate released by treatment with cyanogen bromide. Since methionine sulfoxide does not react with cyanogen bromide, one can determine the proportion of oxidized methionine in any sample.

B. End-group Analysis and Sequential Degradation.—The methods for identification of *N*-terminal amino-acids in peptides and proteins have been reviewed.⁴⁵

It has been shown⁴⁶ that despite some previous reports to the contrary *Im*-Dnp-histidine does not decompose under conditions of acid hydrolysis. Fluorodinitrobenzene reacts preferentially with the 3'-nitrogen of *N*^α-acetylhistidine. Dnp-arginine and *ε*-Dnp-lysine have been separated using high-voltage paper electrophoresis at pH 11.2, and it is claimed that the same technique is applicable to the Dns-derivatives.⁴⁷ A technique for the determination of dinitrophenylamino-acids using chromatography on columns of nylon powder has also been described.⁴⁸ Two-dimensional separation of Dns-amino-acids has been effected by high-voltage paper electrophoresis and chromatography⁴⁹ and the identification of Dns-amino-acids in the mass spectrometer has been discussed.^{50a} Pivaloyl chloride has been suggested as a reagent for *N*-terminal analysis of peptides and proteins and the characterization of *N*^α-pivaloyl amino-acid derivatives by mass spectrometry has been described.^{50b}

The *N*-terminal stepwise degradation due to Edman continues to be subject to various attempts to improve it. Thus for small peptides it has

³⁹ R. W. Zumwalt, K. Kuo, and C. W. Gehrke, *J. Chromatog.*, 1971, **55**, 267.

⁴⁰ R. W. Zumwalt, K. Kuo, and C. W. Gehrke, *J. Chromatog.*, 1971, **57**, 193.

⁴¹ C. W. Gehrke, K. Kuo, and R. W. Zumwalt, *J. Chromatog.*, 1971, **57**, 209.

⁴² C. W. Moss, M. A. Lambert, and F. J. Diaz, *J. Chromatog.*, 1971, **60**, 137.

⁴³ C. W. Gehrke and K. Leriner, *J. Chromatog.*, 1971, **57**, 219.

⁴⁴ G. M. Ellinger and R. H. Smith, *Biochem. J.*, 1971, **124**, 15P.

⁴⁵ J. Rosmus and Z. Deyl, *Chromatog. Rev.*, 1971, **13**, 163.

⁴⁶ P. Henkart, *J. Biol. Chem.*, 1971, **246**, 2711.

⁴⁷ H. M. Jacoby and L. Spero, *Analyt. Biochem.*, 1971, **44**, 299.

⁴⁸ H. Beyer and U. Schenk, *J. Chromatog.*, 1971, **61**, 263.

⁴⁹ G. L. Moore and R. S. Antonoff, *Analyt. Biochem.*, 1971, **39**, 260.

⁵⁰ (a) N. Seiler, H. H. Schneider, and K.-D. Sonnenberg, *Analyt. Biochem.*, 1971, **44**, 451;

(b) G. Protá, F. Chioccare, and A. Previero, *Biochimie*, 1971, **53**, 51.

been proposed⁵¹ that methyl isothiocyanate be substituted for phenyl isothiocyanate and that after the first step of degradation the methylthiohydantoin be identified in a sample of the reaction mixture by g.l.c. After the second step, analysis by g.l.c. of another sample of the reaction mixture reveals two methylthiohydantoins, that derived from the second residue in the peptide together with that previously identified as N-terminal. This process can be repeated, but obviously quantitative g.l.c. is required if the peptide contains two or more residues of the same amino-acid. An automatic method for the quantitation of methylthiohydantoins of acidic and neutral amino-acids following their separation on sulphopolystyrene resins has also been described.⁵² Conditions have been found for the rapid separation of Pth-amino-acids using t.l.c. on polyamide-coated glass plates,⁵³ and the use of chemical ionization mass spectrometry for the analysis of Pth-amino-acids has also been described⁵⁴ (see also Section 2C). An aberration in the Edman degradation of peptides with N-terminal arginine or histidine residues has been reported³⁴⁸ (see p. 72).

However, as in previous years, it is the automated Edman degradation procedure that shows the biggest growth in application. Examples of its use will be found throughout this Report, and comment here will be restricted to some reflections on the method. Several useful reviews will be found in an earlier reference.⁵ A good typical application of the sequenator is to the determination of the N-terminal sequence of some myeloma light chains⁵⁵ (see also Section 7). It was observed that two methods of hydrolysis, with hydriodic acid and with sodium hydroxide-sodium sulphate, allowed direct conversion of the extracted thiazolinones into the corresponding amino-acids without the need for intermediate conversion into other derivatives. One of the problems associated with the use of the sequenator for the analysis of tryptic peptides containing lysine is the high repetitive loss of peptide in the various extractions during the last few steps, which explains why tryptic peptides with C-terminal arginine are favoured.⁵ To circumvent this difficulty, it has been proposed that the first step of the degradation should be carried out with a sulphonated phenyl isothiocyanate.⁵⁶ With the ϵ -amino-group of the lysine residue safely modified by this hydrophilic reagent, the extraction losses are much diminished. Of the various reagents (1)–(4) that have been tested, (3) and (4) were reported to be the most effective.^{5, 56} It is inevitable, but none the less a pity, that the commercial sequenators are so expensive. Few university laboratories can ever expect to possess one (see last year's Report).

⁵¹ D. E. Vance and D. A. Feingold, *Nature*, 1971, **229**, 121.





⁵² V. M. Stepanov, S. P. Katrukha, L. A. Baratova, L. P. Belyanova, and V. P. Korzhenko, *Analyt. Biochem.*, 1971, **43**, 209.

⁵³ K. D. Kulbe, *Analyt. Biochem.*, 1971, **44**, 548.


⁵⁴ H. M. Fales, Y. Nagai, G. W. A. Milne, H. B. Brewer, jun., T. J. Bronzert, and J. J. Pisano, *Analyt. Biochem.*, 1971, **43**, 288.

⁵⁵ O. Smithies, D. Gibson, E. M. Fanning, R. M. Goodflesh, J. G. Gilman, and D. L. Ballantyne, *Biochemistry*, 1971, **10**, 4912.

⁵⁶ G. Braunitzer, B. Schrank, A. Ruhfus, S. Petersen, and U. Petersen, *Z. physiol. Chem.*, 1971, **352**, 1730.



In a wholly different approach to the same problem, complete details of a solid-phase Edman degradation have now been given.^{5, 57} The peptide is attached by means of its α -carboxy-group to a solid support (Scheme 1) and



Scheme 1

the usual Edman degradation is then carried out using methyl isothiocyanate. The addition of ring amino-groups to the polystyrene resin greatly increases its polarity, thereby enabling it to swell readily in trifluoroacetic acid, which in turn facilitates the cleavage step in the degradation. There are several obvious disadvantages to the method as it stands. For example, side-chain carboxy-groups should also become attached to the resin, which means that the corresponding amino-acid residue remains bound to the support, causing a gap to appear in the sequence. In fact, this does happen with glutamic acid but with aspartic acid residues the degradation actually stops altogether, presumably because a cyclic imide is formed after the activation of the β -carboxy-group in the coupling procedure. Several possible improvements remain to be tested,⁵⁷ for example the attachment of lysine-containing peptides through the ϵ -amino-group to resins containing isothiocyanate groups.⁵⁸ Even with the present technique, approximately 20

⁵⁷ R. A. Laursen, *European J. Biochem.*, 1971, **20**, 89.

⁵⁸ L. M. Dowling and G. Stark, *Biochemistry*, 1969, **8**, 4728.

cycles of degradation have successfully been carried out⁵⁷ on the A- and B-chains of insulin, with average yields per step of *ca.* 90%, and the method clearly bears watching.

Further work has been reported⁵⁸ on sequential degradation from the C-terminus (see Volume 2 of these Reports). The peptidyl-thiohydantoin is formed in a non-aqueous medium (a mixture of acetic anhydride, acetic acid, and sodium thiocyanate), is cleaved using the acidic form of a cation-exchange resin, and the thiohydantoin is then identified. Four steps of degradation were achieved with ribonuclease A. The C-terminal residue of rat liver lactate dehydrogenase has been identified as phenylalanine by the selective tritiation method⁶⁰ (reviewed in Volume 1 of these Reports), the labelled amino-acid being released by treatment with carboxypeptidase, and a stream-splitting device that enables the tritiated amino-acid to be counted in the effluent of the amino-acid analyser has been described.⁶¹

C. Mass Spectrometry.—Perhaps the main hindrance to the establishment of mass spectrometry as a standard tool for the determination of the sequence of purified peptides lies in the relatively large amounts that the technique demands for convenient operation. Whereas these pages last year conveyed the hope that 10–20 nmol would serve to give considerable sequence information, the literature suggests that much larger amounts are routinely being used. The main concrete advance, and one which gives mass spectrometry the edge over ‘wet’ methods in this respect at least, has been in the direct analysis of peptide mixtures by low-resolution mass spectrometry. This also goes a long way to solving the supply problem, since 100 nmol of pure peptide is much harder to produce than mixtures containing comparable amounts. Two laboratories have reported the analysis of peptide mixtures^{62, 63} and both have taken advantage of the differential volatility of the permethylated *N*-acetyl-peptide methyl esters. A steady temperature gradient is generated by fractional insertion of the probe into the ion source; when volatilization of a component begins (as indicated on an oscilloscope screen) the temperature gradient is rapidly increased and the spectrum recorded.⁶³ Mixtures of two or three synthetic peptides up to heptapeptides have been successfully resolved in this way, as well as a mixture of three tryptic peptides from pepsin.⁶³ Although a knowledge of the amino-acid composition is apparently not essential,⁶³ it has been suggested⁶² that this is highly desirable for unambiguous identification; this would require a further 20 nmol or so. As an indication of growing confidence in mixture analysis, a general strategy has been formulated for investigating oligopeptides and proteins.⁶³ Briefly, an enzymic

⁵⁹ S. Yamashita, *Biochim. Biophys. Acta*, 1971, **229**, 301.

⁶⁰ W. T. Hsieh, L. E. Gundersen, and C. S. Vestling, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 69.

⁶¹ G. Cappugi, P. Nassi, C. Treves, and G. Ramponi, *Experientia*, 1971, **27**, 237.

⁶² P. Roepstorff, R. K. Spear, and K. Brunfeldt, *F.E.B.S. Letters*, 1971, **15**, 237.

⁶³ H. R. Morris, D. H. Williams, and R. P. Ambler, *Biochem. J.*, 1971, **125**, 189.

digest of the protein is subjected to gel filtration to obtain a mixture of peptides with molecular weight less than 1000 (*i.e. ca.* ten residues, the limit of the technique at present). The mixture would then be derivatized in the usual way and subjected to direct mass spectral analysis, using differential volatility as above. Larger fragments from the gel column would be digested with a different enzyme and treated similarly. Since peptide purification is the main stumbling block in conventional 'wet' methods of sequence determination, mixture analysis has the enormous advantage of saving labour and time, as well as being a partial solution to the problem of supply.

The other problem, that of 'difficult' amino-acids, is still real but continues to diminish. The hope that permethylation with strictly controlled amounts of methyl iodide might be successful for methionine peptides, as it was for cysteine peptides (see last year's Report), appears to have been borne out; the peptides Met-Met-Gly-Met and Thr-Met gave good electron-impact spectra⁶⁴ after permethylation on a microgram scale, using⁶⁵ a carbanion (methylsulphinylmethide): MeI : peptide ratio of 10 : 10 : 1. Good spectra, containing *N*-terminal sequence peaks, have been obtained⁶⁶ for small arginine peptides, and for the relatively large bradykinin (a nonapeptide containing two arginines) after derivatization at the 100 nmol level with acetylacetone. This converts arginyl into *N*-2-(4,6-dimethyl)pyrimidyl-ornithine residues; the peptide is then *N*-acetylated and permethylated in the usual way. Desulphurization of sulphur-containing amino-acids is still being explored;⁶⁷ however, mass spectra of a series of *S*-carboxymethylated and *S*-carboxamidomethylated cysteine- and (reduced) cystine-peptides have also been described.⁶⁸ No further details have been published since last year⁶⁹ on the use of diethyl pyrocarbonate to avoid problems of quaternization during the permethylation of histidine-containing peptides. Under the conditions of treatment with diethyl pyrocarbonate (pH 8), the α -amino-group and the side-chains of tyrosine, cysteine, and histidine (but not arginine) are modified. Since the substituted imidazole ring will still quaternize on permethylation, exhaustive treatment with diethyl pyrocarbonate is carried out. This cleaves the ring, eliminating C-2 as formate and converting the remainder into a 1,2-bis(ethoxycarbonamido)ethylene derivative (Scheme 2). This does not form quaternary salts and is extracted satisfactorily into chloroform after permethylation. The method worked successfully on a series of histidine peptides up to a pentapeptide;⁶⁹ this contained arginine, which was converted into ornithine by hydrazinolysis

⁶⁴ P. A. Leclercq and D. M. Desiderio, jun., *Biochem. Biophys. Res. Comm.*, 1971, **45**, 308.


⁶⁵ P. A. Leclercq and D. M. Desiderio, jun., *Analyt. Letters*, 1971, **4**, 305.

⁶⁶ P. A. Leclercq, L. C. Smith, and D. M. Desiderio, jun., *Biochem. Biophys. Res. Comm.*, 1971, **45**, 937.

⁶⁷ Yu. A. Ovchinnikov, A. A. Kiryushkin, V. A. Gorlenko, and B. V. Rozynov, *Zhur. obshchei Khim.*, 1971, **41**, 660.

⁶⁸ Yu. A. Ovchinnikov, A. A. Kiryushkin, V. A. Gorlenko, Ts. E. Agadzhanian, and B. V. Rozynov, *Zhur. obshchei Khim.*, 1971, **41**, 385 (*Chem. Abs.*, 1971, **75**, 20 992b).

⁶⁹ J. F. G. Vliengenthart and L. Dorland, *Biochem. J.*, 1970, **117**, 31P.



Scheme 2

before mass spectrometry. It is possible, however, that derivatization of histidine may be unnecessary if permethylation is carried out with controlled amounts⁶⁸ of carbanion and methyl iodide; Glp-Pro-Tyr-His-NH₂ gave a good spectrum.⁷⁰ So it appears that the presence of arginine, histidine, methionine, and cysteine residues in peptides does not preclude determination of their sequences by mass spectrometry, but one must, of course, be aware of their presence. Does, then, a routine application of mass spectrometry to the analysis of mixtures, for example, call for a succession of derivatization treatments? A better suggestion,⁶⁸ perhaps, is that a preliminary paper-electrophoretic step be included so that cysteine, arginine, histidine, *etc.* could be detected by staining and the sample treated accordingly. In dealing with mixtures (as above) sufficient material would probably be available and the electrophoretic mobilities would also be useful; even dealing with more precious pure peptides, the advantage of being able to circumvent trouble at a later stage would make an amino-acid analysis of the sample highly desirable. Application of the Edman degradation to remove troublesome amino-acids from peptides for mass spectrometry⁷¹ is useful in principle, but with the reservation that it calls for some prior knowledge of the sequence. If this is used on C-terminal lysine peptides a hydrazinolysis step must be included before the mass spectrum is run, so that the ϵ -PTH derivative (involatile) is liberated as the free amine.⁷¹ Mass spectra of the chromophoric *N*-(azulen-4-yl)acetyl derivatives of amino-acid and peptide methyl esters have been described.⁷² These showed strong molecular ions, low fragmentation in the high-mass region, and good sequence peaks for the series of N-terminal proline peptide derivatives studied.

While efforts to deal successfully with mixtures and 'difficult' amino-acids continue, mass spectrometry is being used in peptide chemistry where suitably straightforward problems arise. Thus it was used⁷³ in the identification of small tryptic peptides from soluble tropoelastin (considered to be the precursor of insoluble elastin). The peptides Ala-Ala-Ala-Lys and Ala-Ala-Lys, identified after permethylation of samples N-acetylated with a mixture of acetic anhydride and its perdeuterio-analogue, apparently occur

⁷⁰ P. A. White and D. M. Desiderio, jun., *Analyt. Letters*, 1971, 4, 141.

⁷¹ N. A. Aldanova, E. I. Vinogradova, S. A. Kazaryan, B. V. Rozynov, and M. M. Shemyakin, *Biochemistry (U.S.S.R.)*, 1970, 35, 742.

⁷² E. Wünsch and E. Jaeger, *Z. physiol. Chem.*, 1971, 352, 1584.

⁷³ L. B. Sandberg, N. Weissman, and W. R. Gray, *Biochemistry*, 1971, 10, 52.

six times in the tropoelastin polypeptide chain, and are thought to be the areas involved in the formation of the desmosine and isodesmosine cross-links of insoluble elastin (see the section on Structural Proteins in this, and earlier, Reports). Mass spectrometry played an important part ⁷⁴ in defining the sequence of the hypothalamic thyroid-stimulating-hormone releasing factor as Glp-His-Pro-NH₂ which, with both ends blocked, would present something of a problem for conventional methods of sequence analysis. In another study of this peptide a normal ('peptide') fragmentation was not observed;⁷⁵ however, the sample had not been derivatized, and the high temperature used gave some thermal degradation. Whether or not one believes that scotophobin really is a 'specific behaviour-inducing brain peptide', its structure was revealed ⁷⁶ by mass spectrometry as Ser-Asp-Asn-Asn-Gln-Gln-Gly-Lys-Ser-Ala-Gln-Gln-Gly-Gly-Tyr-NH₂. Spectra of the whole molecule and of the two tryptic peptides arising from cleavage at the conveniently placed lysine residue were obtained after diazomethane treatment, the only derivatization. The advantages of permethylation again become apparent when we read ⁷⁶ that the sequence was reconstructed from the spectra of di- and tri-peptides resulting from extensive pyrolysis! That (presumably) also made certain amide assignments impossible, whereas this is now recognized as one of the benefits of sequence analysis by mass spectrometry.

In last year's Report, some of the advantages of chemical ionization mass spectrometry over the electron-impact method were outlined, with reference to the spectra of very simple peptides. Chemical ionization spectra of a series of blocked, permethylated peptides up to pentapeptides, and containing most of the amino-acids or suitable derivatives, have now been examined.⁷⁷ Two series of ions were recognized and their presence in the spectra was lucidly discussed.⁷⁷ When C—N cleavage occurs, retention of the positive charge on the carbon atom gives acyl carbonium ions, *i.e.* the N-terminal sequence-determining ions familiar from electron-impact spectra. Chemical ionization spectra show also the complementary ammonium ions (*i.e.* peaks that determine the C-terminal sequence), and from these data additional sequence information can be deduced and ambiguities can be minimized. In addition, the spectra are cleaner, with less evidence of C—C bond cleavage, and good results were obtained on 20 µg (*ca.* 30 nmol of a hexapeptide). It is suggested ⁷⁷ that chemical ionization mass spectrometry will complement rather than supersede the electron-impact method for sequence analysis of peptides, despite the attractive bonus of ions determining the C-terminal sequence, because N-terminal sequence ions are often more intense in the electron-impact spectra.

⁷⁴ D. M. Desiderio, jun., R. Burgus, T. F. Dunn, W. Vale, R. Guillemin, and D. N. Ward *Org. Mass Spectrometry*, 1971, 5, 221.

⁷⁵ J.-K. Chang, H. Sievertsson, C. Bogentoft, B. Currie, K. Folkers, and G. D. Daves, *J. Medicin. Chem.*, 1971, 14, 481.

⁷⁶ D. M. Desiderio, jun., G. Ungar, and P. A. White, *Chem. Comm.*, 1971, 432.

⁷⁷ A. A. Kiryushkin, H. M. Fales, T. Axenrod, E. J. Gilbert, and G. W. A. Milne, *Org. Mass Spectrometry*, 1971, 5, 19.

Mass spectrometry continues to be recommended for the identification of thiohydantoin derivatives of amino-acids from the Edman degradation of proteins. Chemical ionization spectra of phenylthiohydantoin derivatives⁵⁴ gave a clearly defined ($M + 1$) ion for all amino-acids except arginine, lysine, and *S*-carboxymethylcysteine, but since electron-impact spectra of Pth derivatives also show good parent peaks the main advantage of the chemical ionization method here lies in the basic similarity of the spectra, and in much greater sensitivity. Isotope dilution, with labelled Pth-amino-acids, was used in the identification of the Pth derivative released (*cf.* last year's Report, and the identification of methylthiohydantoins). The method was demonstrated on sperm whale myoglobin and compared with the identification of the thiohydantoins by g.l.c. Automation will truly have arrived when thiazolinones from the sequenator are fed direct into the mass spectrometer!⁷⁸ The electron-impact spectra of thiazolinones are very similar to those of the corresponding thiohydantoins, presumably as a result of thermal rearrangement in the mass spectrometer; the first five residues of ribonuclease were successfully identified. Direct analysis of thiazolinones holds the advantage of minimal decomposition of those amino-acids (*e.g.* serine) which are sensitive to the acid conditions used for conversion of thiazolinone into thiohydantoin.⁷⁸ In another study⁷⁹ *p*-bromophenyl isothiocyanate was reported to lead to easier recognition of thiohydantoin peaks within the spectrum using the strong doublets arising from the natural isotope abundance of bromine. The method was illustrated on an uncomplicated octapeptide and the N-terminal sequence of glucagon.

It will be apparent that computer analysis of high-resolution spectra has not featured to any great extent in the determination of peptide sequences during the past twelve months. Those who work at low resolution, and without computers, have outlined⁶³ what they consider to be unnecessary disadvantages inherent in the former approach, namely decreased sensitivity, increased cost, and the complication of additional black boxes. It does seem that more answers are coming from the low-resolution approach at the moment, but one should perhaps bear in mind certain advantages of computer-aided high-resolution mass spectrometry, *e.g.* objective identification of the sequence ions when these are not the strongest in the spectrum (even for permethylated samples), and a vast amount of information which might be useful in minimizing ambiguities. The differential volatility approach could, of course, be applied to mixtures, as described earlier for low-resolution work. Whether or not one feels that the requirements of sequence analysis have already been met by low-resolution mass spectrometry seems at the moment to be as much a subjective judgement as an objective one. A new computer analysis of high-resolution mass spectra applicable to peptides has been described;⁸⁰ termed 'submolecular group

⁷⁸ T. Fairwell and R. E. Lovins, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 1280.

⁷⁹ F. Weygand and R. Obermeier, *European J. Biochem.*, 1971, **20**, 72.

⁸⁰ A. Kunderd, R. B. Spencer, and W. L. Budde, *Analyt. Chem.*, 1971, **43**, 1086.

analysis', it permits identification of ions other than sequence ions. It is likely that aspects of the application of mass spectrometry to peptides will feature in a companion series of Reports, the first of which has already appeared ⁸¹ and the second of which is currently being prepared.

D. Cleavage of Protein Chains.—Enzymic Cleavage. For many years protein chemists have been bothered by the chymotrypsin-like activity of pure, crystalline trypsin, which cannot be removed even by treatment with active-site-directed inhibitors of chymotrypsin. Several recent papers bear on this problem. It has been reported ⁸² that gel filtration on Sephadex-G50 can remove the chymotryptic activity. Other experiments ⁸³ have shown α - and β -trypsin purified by chromatography on SE-Sephadex to possess only 'pure' tryptic action. β -Trypsin is the single polypeptide chain form of the enzyme, whereas α -trypsin has a single peptide bond split at position Lys(131)–Ser(132). Moreover, it appears ⁸⁴ that ψ -trypsin, which differs from α -trypsin in having an additional bond split at Lys(176)–Asp(177), is what confers the chymotrypsin-like activity on unfractionated preparations of crystalline trypsin, although ψ -trypsin clearly differs from chymotrypsin in that it will not cleave some peptides rapidly hydrolysed by chymotrypsin. It is especially interesting that the residue Asp-177 is believed to be of prime importance in defining the specificity of trypsin.

The action of thrombin on fibrinogen is, of course, that of a very restricted trypsin. Various peptides related to fibrinopeptides have been synthesized and tested as substrates for thrombin and trypsin.⁸⁵ None is as good as fibrinogen, suggesting that factors other than the primary structure in the immediate vicinity of the susceptible bond contribute to the interaction between fibrinogen and enzyme. Comparable experiments in another laboratory ⁸⁶ show that denaturation of fibrinogen reduces the susceptibility to thrombin but enhances the susceptibility to trypsin.

Thermolysin continues to arouse interest. A study of the effect of pH on its activity with synthetic substrates indicates that groups of pK 5.15 and 8 are implicated in its action,⁸⁷ and Ca^{2+} ions have been shown ⁸⁸ to affect the kinetic parameters of the enzyme and limit the autodigestion. Since a number of dipeptides containing S-alkylcysteine residues have been observed to be substrates for thermolysin, it is possible that useful additional cleavages for sequence work on proteins might occur at such residues.⁸⁹

⁸¹ 'Mass Spectrometry', ed. D. H. Williams (Specialist Periodical Reports), The Chemical Society, London, 1971, Vol. 1.

⁸² J. Jentsch, *J. Chromatog.*, 1971, **57**, 450.

⁸³ V. Keil-Dlouhá, N. Zylber, N.-T. Tong, and B. Keil, *F.E.B.S. Letters*, 1971, **16**, 287.

⁸⁴ V. Keil-Dlouhá, N. Zylber, J. M. Imhoff, N.-T. Tong, and B. Keil, *F.E.B.S. Letters*, 1971, **16**, 291.

⁸⁵ R. K. H. Lieu, R. H. Andreatta, and H. A. Scheraga, *Arch. Biochem. Biophys.*, 1971, **147**, 201.

⁸⁶ Y. Inada, M. Bando, I. Kotoku, A. Matsushima, and J. Hirano, *Biochim. Biophys. Acta*, 1971, **251**, 94.

⁸⁷ C. E. Stauffer, *Arch. Biochem. Biophys.*, 1971, **147**, 568.

⁸⁸ H. Drucker and S. L. Borchers, *Arch. Biochem. Biophys.*, 1971, **147**, 242.

⁸⁹ A. P. Damoglou, H. Lindley, and I. W. Stapleton, *Biochem. J.*, 1971, **123**, 379.

A number of new enzymes have been reported. An aminopeptidase has been isolated from *Aeromonas proteolytica*⁹⁰ and a carboxypeptidase C from orange leaves.⁹¹ The carboxypeptidase shows the combined action of carboxypeptidases A and B. A dipeptidase (a metalloenzyme) that will cleave only L- α -dipeptides with free amino- and carboxy-groups has been purified from mouse ascites tumour cells.⁹² Two new proteases have also been described. One, a protease from *E. coli*, has a molecular weight of 43 000 and is inhibited by DFP;⁹³ the other, from *Acremonium kiliense*,⁹⁴ has a molecular weight of ca. 28 000 and a pH optimum of 10.5. Moreover, it is fully active even after prolonged exposure to 8M-urea. Other enzymes of interest are the peptidoglutaminases from *B. circulans*.⁹⁵ These enzymes show no peptidase activity but will selectively hydrolyse the γ -amide of peptide-bound glutamine.

Several studies of neutral proteases from micro-organisms have also been described. The specificity of such enzymes seems to be affected by the sequence of at least five or six residues near the bond actually split in the substrate,⁹⁶ a property shared by various serine proteinases of micro-organisms.⁹⁷ Peptide bonds involving the N-terminal groups of phenylalanine, leucine, or alanine are rapidly split by the neutral protease of *Micrococcus caseolyticus*, similar to that of *Pseudomonas aeruginosa* and *Streptomyces griseus*,⁹⁸ whereas the endopeptidase from the marine bacterium *Vibrio B-30* shows specificity for the N-terminal side of aromatic amino-acids.⁹⁹

Restriction of Enzymic Cleavage. This has been discussed extensively in previous Reports. Some recent developments in the reversible blocking of protein amino-groups to restrict tryptic cleavage have been reviewed¹⁰⁰ and a comparative study has been made of several reversible reagents for that purpose.¹⁰¹ 2-Methylmaleic (citraconic) anhydride was held to be the most suitable for most purposes.

Insolubilized Enzymes. A comprehensive review¹⁰² discusses many aspects of insolubilization of enzymes and its effect on enzymic parameters, and

⁹⁰ J. M. Prescott, S. H. Wilkes, F. W. Wagner, and K. J. Wilson, *J. Biol. Chem.*, 1971, **246**, 1756.

⁹¹ B. Sprössler, H.-D. Heilmann, E. Grampp, and H. Uhlig, *Z. physiol. Chem.*, 1971, **352**, 1524.

⁹² S. Hayman and E. K. Patterson, *J. Biol. Chem.*, 1971, **246**, 660.

⁹³ M. Pacaud and J. Uriel, *European J. Biochem.*, 1971, **23**, 435.

⁹⁴ S. van Heyningen and D. Secher, *Biochem. J.*, 1971, **125**, 1159.

⁹⁵ M. Kikuchi, H. Hayashida, E. Nakano, and K. Sakaguchi, *Biochemistry*, 1971, **10**, 1222.

⁹⁶ K. Morihara and H. Tseuki, *Arch. Biochem. Biophys.*, 1971, **146**, 291.

⁹⁷ K. Morihara, T. Oka, and H. Tsuzuki, *Arch. Biochem. Biophys.*, 1971, **146**, 297.

⁹⁸ M. J. Desmazeaud and J. H. Hermier, *European J. Biochem.*, 1971, **19**, 51.


⁹⁹ T. Sipos and J. R. Merkel, *Arch. Biochem. Biophys.*, 1971, **145**, 137.

¹⁰⁰ R. N. Perham in Ref. 5, p. 57.


¹⁰¹ (a) A. F. S. A. Habeeb and M. Z. Atassi, *Biochemistry*, 1970, **9**, 4939; (b) R. P. Singhal and M. Z. Atassi, *ibid.*, 1971, **10**, 1757.

¹⁰² E. Katchalski, I. Silman, and R. Goldman, *Adv. Enzymology*, 1971, **34**, 445.

another volume¹⁰³ contains several articles of interest. A theoretical model describing steady-state catalysis by enzymes immobilized in gel particles was verified by experiment.¹⁰⁴ Many enzymes have previously been attached to cross-linked dextrans activated by treatment with cyanogen bromide; as a further example, tRNA nucleotidyl transferase was insolubilized in this way and shown to be active in the repair of the $pCpCpA$ sequence of tRNA.¹⁰⁵ The chemistry of the attachment has now been described in some detail.¹⁰⁶ The activation of the dextran and the attachment of the protein are thought to take place as shown in Schemes 3 and 4 respectively. A new



Scheme 3



Scheme 4

method¹⁰⁷ for the attachment of enzymes to polymers bearing various functional groups uses isocyanides for the coupling step. The chemistry of the process is described¹⁰⁷ and it is worth noting that it permits coupling through a variety of alternative side-chains on the enzyme (ligand) (*cf.* the use of variously modified agaroses, described in last year's Report, to introduce flexibility in the choice of groups used for the coupling). The isocyanide method was used successfully¹⁰⁸ for the attachment of pepsin to

¹⁰³ (a) L. Goldstein, *Methods Enzymology*, 1970, **19**, 935; (b) E. M. Crook, K. Brocklehurst, and C. W. Wharton, *ibid.*, p. 963; (c) B. Alexander and A. M. Engel, *ibid.*, p. 978.

¹⁰⁴ V. Kasche, H. Lundqvist, R. Bergman, and R. Axén, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 615.

¹⁰⁵ S. Litvak, L. Tarrago-Litvak, D. S. Carre, and F. Chapeville, *European J. Biochem.*, 1971, **24**, 249.

¹⁰⁶ R. Axén and S. Ernback, *European J. Biochem.*, 1971, **18**, 351.

¹⁰⁷ R. Axén, P. Vretblad, and J. Porath, *Acta Chem. Scand.*, 1971, **25**, 1129.

¹⁰⁸ P. Vretblad and R. Axén, *F.E.B.S. Letters*, 1971, **18**, 254.

modified agarose. Hyaluronidase attached to agarose by the triazine method¹⁰⁹ could prove useful in structural work on proteoglycans.

Other supports and other methods of insolubilization have also been investigated. Thus, Pronase has been immobilized on porous glass¹¹⁰ and shown to be useful in the total hydrolysis of proteins when used in conjunction with immobilized leucine aminopeptidase. Acid phosphatase, trypsin, chymotrypsin, and glucose oxidase have been attached to polyacrylamide beads using glutaraldehyde¹¹¹ and trypsin, chymotrypsin, and papain have been linked to cross-linked poly(methacrylic acid anhydride),¹¹² with substantial retention of activity (towards small substrates) in all cases. Papain has also been converted into a giant polymer by cross-linking it with glutaraldehyde;¹¹³ in such a form it will attack only the surface of ox-casein micelles. When chymotrypsin was insolubilized similarly, retention of activity was greater if the glutaraldehyde treatment was carried out in the presence of an inhibitor of the enzyme.¹¹⁴ Co-insolubilized α -chymotrypsin-papain had both enzymatic activities.¹¹⁴ In another study¹¹⁵ glutaraldehyde-insolubilized trypsin and chymotrypsin were used for selective adsorption of the naturally occurring protein inhibitors and *vice versa*; insolubilized concanavalin A was used to isolate glycoproteins and insoluble glycoproteins to purify agglutinins.

The kinetic behaviour of glucose oxidase attached to porous glass has been discussed¹¹⁶ and the attachment of invertase to bentonite¹¹⁷ and of amino-acylase to halogenoacetyl-celluloses¹¹⁸ has been reported.

E. Fractionation Methods.—Discussion is restricted here to fractionation of peptides and proteins; procedures for amino-acids have already been dealt with in Section 2A. Chromatographic and electrophoretic methods are treated in some detail below. It is also worth noting a study of the fractionation of proteins and viruses with poly(ethylene glycol).¹¹⁹ The effect acts quantitatively like 'salting out', and there is a linear relationship between log solubility and % poly(ethylene glycol). The selectivity of the method is greater for larger proteins and viruses. A useful volume¹²⁰ devoted to enzyme purification carries many useful accounts of specialized techniques.

Peptide Separation, Detection, and Identification. Adsorption on to a neutral polystyrene resin (Porapak Q) has been recommended¹²¹ as a

¹⁰⁹ W. H. Stimson and A. Serafini-Fracassini, *F.E.B.S. Letters*, 1971, **17**, 318.

¹¹⁰ G. P. Royer and G. M. Green, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 426.

¹¹¹ P. D. Weston and S. Avrameas, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1574.

¹¹² A. Conte and K. Lehmann, *Z. physiol. Chem.*, 1971, **352**, 533.

¹¹³ S. H. Ashoor, R. A. Sair, N. F. Olson, and T. Richardson, *Biochim. Biophys. Acta*, 1971, **229**, 423.

¹¹⁴ E. F. Jansen, V. Tomimatsu, and A. C. Olson, *Arch. Biochem. Biophys.*, 1971, **144**, 394.

¹¹⁵ S. Avrameas and B. Guilbert, *Biochimie*, 1971, **53**, 603.

¹¹⁶ M. K. Weibel and H. J. Bright, *Biochem. J.*, 1971, **124**, 801.

¹¹⁷ P. Monsan and G. Durand, *F.E.B.S. Letters*, 1971, **16**, 39.

¹¹⁸ T. Sato, T. Mori, T. Tosa, and I. Chibata, *Arch. Biochem. Biophys.*, 1971, **147**, 788.

¹¹⁹ I. R. M. Jackes, *Biochim. Biophys. Acta*, 1971, **229**, 535.

¹²⁰ *Methods Enzymology*, 1971, Vol. 22.

¹²¹ A. Niederwieser, *J. Chromatog.*, 1971, **61**, 81.

method for rapid desalting and fractionation of non-polar amino-acids and peptides. Adsorption increased with increasing ionic strength, demonstrating the hydrophobic nature of the interaction, and elution was performed with water or aqueous-organic mixtures. Such adsorption of amino-acids on to polystyrene is presumably superimposed upon the ion-exchange effect in the separation of amino-acids on sulphonated polystyrene resin in the standard Moore and Stein method, and probably explains why the chromatographic behaviour of several neutral amino-acids does not correlate with their pK or pI ; hydrophilic and basic amino-acids chromatograph normally. Preliminary work on peptides gave every indication that the effect would be useful for desalting peptides containing non-polar residues.

A theoretical study¹²² of the behaviour of amino-acids and peptides during paper electrophoresis suggests that with a knowledge of pK values and molecular weights the optimum conditions for separation can be read off from standard graphs. One supposes that visual dye markers are routinely used by the exponents of paper electrophoresis; the mobilities of several dyes at commonly used pH values have been documented¹²³ and the dyes of choice at each pH indicated. Conditions conducive to the deamidation of side-chains, a recognized hazard in peptide and protein purification, have been reported¹²⁴ for two asparaginyl peptides; borate rather than phosphate buffer, low ionic strengths, a pH near 5, and temperatures less than 4 °C should all minimize deamidation.

This year's candidate for the 'diagonal' spot (see Vol. 1, p. 61) is a method for the selective isolation of histidine-containing peptides.¹²⁵ Briefly, the procedure is to dinitrophenylate histidine side-chains after the reaction of the amino-groups with citraconic anhydride; the modified protein is then digested with pepsin in 10% formic acid, with concomitant regeneration of the amino-groups. The first electrophoretic step is then carried out at pH 3.5 or 6.5, and the second at right angles after thiolysis of the Dnp residues on the paper by exposure to 2-mercaptoethanol. Histidine peptides will lie off the diagonal in the direction of the cathode. Disulphide bonds must be modified (*e.g.* by performic acid oxidation) at some point before the thiolytic step, preferably at the very beginning. A pH of 3.5 was preferred for the electrophoretic steps since this gave a better resolution of *Im*-Dnp-histidyl peptides in the first dimension and hence purer off-diagonal peptides. Disulphide exchange with cystamine has again been suggested¹²⁶ as the basis of a method for the selective isolation of cystinyl peptides; it is also noted that the *S*-(2-aminoethylthio)cysteinyl bond, although similar to the *S*-aminoethylcysteinyl bond, may or may not be cleaved by trypsin.

¹²² Y. Kiso and E. Falk, *J. Chromatog.*, 1971, **59**, 401.

¹²³ K. J. Stevenson, *Analyt. Biochem.*, 1971, **40**, 29.

¹²⁴ J. H. McKerrow and A. B. Robinson, *Analyt. Biochem.*, 1971, **42**, 565.

¹²⁵ W. H. Cruickshank, T. M. Radhakrishnan, and H. Kaplan, *Canad. J. Biochem.*, 1971, **49**, 1225.

¹²⁶ D. J. Cox and J. R. Brown, *Analyt. Biochem.*, 1971, **41**, 139.

A useful trick has been applied to the separation of cysteine and glutathione derivatives;¹²⁷ cysteic acid and glutathione, which had the same elution time on Dowex-1, were well resolved on a Dowex-1-Sephadex G-10 mixed-bed column. This is worth bearing in mind in other cases where molecules have similar chromatographic properties but different molecular weights. Satisfactory fingerprints of large polypeptide chains (in this case of m. wt. 80 000—90 000) were obtained by two-dimensional separation of the dansylated digest on silica-gel plates.¹²⁸ Even better results were obtained, however, by passing the dansylated mixture through Sephadex G-25 and running a series of plates in parallel on successive cuts from the column. In this way 64—68 of the expected 77 tryptic peptides were resolved, and very little material was required.

It appears that an improvement on the usual starch-iodide method for detecting imino-group-containing compounds on t.l.c. can be achieved by including starch in the silica-gel plates from the beginning;¹²⁹ after chromatography only potassium iodide spraying is necessary, and this is done more evenly from 75 % aqueous acetone. N-terminal tryptophyl dipeptides (and Trp itself) give intense fluorescence on silica-gel t.l.c. after exposure to gaseous formaldehyde; as little as 0.3—0.1 μ g can be detected.¹³⁰

Chromatography. A unified theory proposed earlier for molecular-sieve chromatography and electrophoresis in polyacrylamide gels is borne out in practice.¹³¹ Chromatography on Sephadex ion-exchangers has been discussed¹³² and illustrated with fractionation of a tryptic digest of immunoglobulin κ -chains on SE-Sephadex C-25. A simple rule allows the calculation of the optimum column volume and gradient in any particular case. It is noted that resolution is improved by using a shallower gradient only if proteins are eluted from the ion-exchange column at high concentration, and that often a steeper gradient may be better. A word of warning is issued¹³³ to those who use ribonuclease A to calibrate Sephadex columns for molecular weight determinations; elution of the expected peak from G-100 was followed by further ribonuclease activity several void volumes later, and loading with other proteins displaced still more activity from the gel. This may be ribonuclease itself or an active fragment, and buffers of high ionic strength are recommended for use with commercial calibration kits to minimize interactions between protein and gel. A word of warning of a different sort concerns the degradation of Sephadex (in this case G-150) by 50 % formic and acetic acids.¹³⁴

As little as 100 μ g of a protein is sufficient for determination of its Stokes'

¹²⁷ J. W. Purdie and D. E. Hanagi, *J. Chromatog.*, 1971, **59**, 181.

¹²⁸ B. Kremer and J. Ullrich, *Z. physiol. Chem.*, 1971, **352**, 189.

¹²⁹ S. D. Killilea and P. O'Carra, *J. Chromatog.*, 1971, **54**, 284.

¹³⁰ R. Håkanson and F. Sundler, *J. Chromatog.*, 1971, **59**, 209.

¹³¹ C. J. O. R. Morris and P. Morris, *Biochem. J.*, 1971, **124**, 517.

¹³² J. Novotný, *F.E.B.S. Letters*, 1971, **14**, 7.

¹³³ W. E. Mitch and C. C. Levy, *Biochim. Biophys. Acta*, 1971, **251**, 388.

¹³⁴ R. Fairweather and J. H. Jones, *J. Chromatog.*, 1971, **58**, 285.

radius (in only 8 h) if thin-layer gel-filtration is used.¹³⁵ For staining, the protein is transferred to a sheet of moist filter paper pressed gently on to the gel layer. The subunit molecular weight also can be determined rapidly by t.l.c. if Sephadex swollen in 6M-guanidine hydrochloride (but not urea) is used.¹³⁶ The method requires 10–30 μ g of protein and takes about 3 h; cytochrome *c* is run as an internal marker and the usual relationship between mobility and log m. wt. holds. It is difficult to see this method replacing SDS-gels for the determination of subunit molecular weight, but it could well be a more attractive method for determining the chain molecular weight in guanidine hydrochloride than the running of columns in this solvent. The column method is being used successfully for proteins and was recently shown to be applicable also to peptides. Agarose columns run in 6M-guanidine hydrochloride gave¹³⁷ the molecular weights of the three cyanogen bromide fragments of apoferritin (in the range 1400–8000) with an accuracy better than 10%. It is worth noting that for molecular weights less than 9000 Sepharose gave much better resolution than the BioGel equivalent, whereas there was very little difference in the range 16 000–80 000. With the increasing use of guanidine hydrochloride as a denaturant in protein chemistry, a statement of the criteria of purity, by Tanford and co-workers, is most welcome.¹³⁸ The purity of urea solutions has also received attention,^{139a} and the kinetics of cyanate formation were used to plot graphs of the concentration of cyanate in urea solutions as a function of time at different pH values, for periods up to two months, and at 0 and 25 °C. The effect of cyanate on the lens protein α -crystallin in concentrated urea was clearly illustrated by the appearance of additional bands on polyacrylamide gels.^{139b} Cyanate formation in urea solutions is, however, slow at low temperatures and therefore not a real problem over short periods; it occurs rapidly at a pH higher than 4. The interaction of urea with proteins has now been studied¹⁴⁰ by means of ultrafiltration; one urea molecule binds per three amino-acid residues, suggesting that the peptide bond is again the major site of interaction (*cf.* the binding of SDS to proteins; see last year's Report).

Electrophoresis. This year again this section deals very largely with electrophoresis in polyacrylamide gels, with or without denaturants. Some consideration is also given to the increasingly used technique of isoelectric focusing.

¹³⁵ Z. Wasył, E. Luchter, and W. Bielański, jun., *Biochim. Biophys. Acta*, 1971, **243**, 11.

¹³⁶ F. Heinz and W. Prosch, *Analyt. Biochem.*, 1971, **40**, 327.

¹³⁷ C. F. A. Bryce and R. R. Crichton, *J. Chromatog.*, 1971, **63**, 267.

¹³⁸ K.-P. Wong, R. Roxby, and C. Tanford, *Analyt. Biochem.*, 1971, **40**, 459.

¹³⁹ (a) P. Hagel, J. J. T. Gerding, W. Fieggen, and H. Bloemendal, *Biochim. Biophys. Acta*, 1971, **243**, 366; (b) J. J. T. Gerding, A. Koppers, P. Hagel, and H. Bloemendal, *ibid.*, p. 374.

¹⁴⁰ J. R. Warren and J. A. Gordon, *Biochim. Biophys. Acta*, 1971, **229**, 216.

A useful survey of the theory and practice of polyacrylamide gel electrophoresis, both analytical and preparative, has appeared¹⁴¹ with particular attention to the quantitative physical-chemical aspects. A theoretical treatment of chromatography and electrophoresis in polyacrylamide gels has already been mentioned.¹³¹ A further series of papers¹⁴² deals quantitatively with the behaviour of proteins in polyacrylamide gels. The practical aspects of preparative acrylamide gel electrophoresis (both continuous and disc techniques),^{143a} and of analytical gel electrophoresis^{143b} (the latter with emphasis on problems related to the separation of enzymes) have recently been treated lucidly. A two-dimensional technique has been used to determine the isoelectric points of the proteins of *E. coli* ribosomes without preliminary fractionation.¹⁴⁴ Tryptophan-containing proteins can be located in polyacrylamide gels by fluorimetry;¹⁴⁵ tyrosine and phenylalanine fluorescence alone is not sufficient. The location of dansylated proteins in gels by fluorimetry is mentioned below. The only comments on starch gels are new methods suggested for visualizing proteins. First comes a procedure¹⁴⁶ for the rapid staining (about 5 min) of peptides and proteins by chlorination; thin slices of gel are treated for 1 min with hypochlorite, and the excess is then removed with a hydrazinium sulphate wash for 2–3 min, before staining with aqueous potassium iodide. Other methods that have been suggested¹⁴⁷ involve the immersion of gel slices in copper sulphate solution (photographs should be taken soon afterwards); the inclusion of fluorescein in the gel so that protein-containing regions will quench fluorescence when observed under u.v. light; and finally, dansylation of the gel in acetone to give fluorescent protein bands.

A discontinuous (sulphate–borate) buffer system for SDS-gel electrophoresis has been thoroughly investigated,¹⁴⁸ and the relationship between relative mobility and molecular weight of protein–SDS complexes has been explored by calculating retardation coefficients and free mobilities from gels of different concentrations. It is becoming clear that the intrinsic charge on a protein does determine the amount of SDS it binds, so that migration in SDS-gels may not be determined entirely by size. Maleylation of protein amino-groups caused a disproportionate increase in the apparent molecular weight, an effect that was attributed to decreased binding of SDS,¹⁴⁹ and the abnormal mobilities of two acidic proteins were shown to be normalized by esterification.¹⁵⁰ The effect of charge was also noted in another study;

¹⁴¹ A. Chrambach and D. Rodbard, *Science*, 1971, **172**, 440.

¹⁴² (a) D. Rodbard and A. Chrambach, *Analyt. Biochem.*, 1971, **40**, 95; (b) D. Rodbard G. Kapadia, and A. Chrambach, *ibid.*, p. 135; (c) J. Lunney, A. Chrambach, and D., Rodbard, *ibid.*, p. 158.

¹⁴³ (a) L. Shuster in ref. 120, p. 124; (b) O. Gabriel in ref. 120, p. 565.

¹⁴⁴ E. Kaltschmidt, *Analyt. Biochem.*, 1971, **43**, 25.

¹⁴⁵ D. M. Easton, H. Lipner, J. Hines, and R. C. Leif, *Analyt. Biochem.*, 1971, **39**, 478.

¹⁴⁶ R. L. Darskus, *J. Chromatog.*, 1971, **55**, 425.

¹⁴⁷ S. J. Tata, *Analyt. Biochem.*, 1971, **42**, 470.

¹⁴⁸ D. M. Neville, jun., *J. Biol. Chem.*, 1971, **246**, 6328.

¹⁴⁹ J.-S. Tung and C. A. Knight, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 1117.

¹⁵⁰ J. G. Williams and W. B. Gratzer, *J. Chromatog.*, 1971, **57**, 121.

glucose oxidase, papain, and pepsin were found to be much more resistant to binding of SDS, and to loss of activity, than were other proteins.¹⁵¹ It was also found that the maximum amount of SDS bound by proteins could be increased to 2 g (g protein)⁻¹ [cf. 1.4 g (g protein)⁻¹ reported last year] by increasing both the ionic strength (so confirming the hydrophobic nature of the interaction) and the SDS concentration. The effect of protein charge is acknowledged in the determination of the molecular weights of histones by SDS-gel electrophoresis;¹⁵² the standard curve was drawn up using histones of known molecular weight. Histones have a lower mobility than expected in SDS gels, and this is attributed to the reduced net negative charge on the protein-SDS complex. The cationic detergent cetyltrimethylammonium bromide has been suggested¹⁵⁰ as a possible replacement for SDS in an attempt to circumvent the anomalous binding of the anionic detergent to (negatively) charged proteins. A linear log m. wt. *versus* mobility relationship is demonstrated, except for rather steep curvature in the region of high molecular weight. One can presumably expect anomalous binding of this detergent to basic proteins, and the answer might be to run gels in the presence of both anionic and cationic detergents. In the same survey¹⁵⁰ of the limitations of molecular weight determination in detergent-polyacrylamide gels, the point was made that the relation between molecular weight and mobility in SDS gels breaks down for proteins with molecular weight less than *ca.* 15 000, and that below *ca.* 6000 all molecules migrate with the same mobility. The effect is independent of acrylamide concentration, and is interpreted as a loss of asymmetry of the protein-SDS complexes, as expected (*i.e.* assuming a prolate ellipsoid, the major and minor semi-axes become equal, so that the frictional coefficient becomes essentially independent of molecular weight). Despite this, molecular weights of polypeptides in the range 1225—10 000 have been determined in SDS gels;¹⁵³ the accuracy claimed was $\pm 18\%$ in most cases, and intrinsic charge had more effect than for proteins. Better resolution was achieved by including 8M-urea in the gels. When the molecular weights of the cyanogen bromide fragments of collagen (m. wt. *ca.* 5000—67 000) were studied in SDS gels it was found¹⁵⁴ that peptides from the α_1 - and α_2 -chains lay on two distinct straight lines, the mobilities in each case being lower than for globular proteins of similar molecular weights and being unchanged by various chemical treatments, including succinylation. This behaviour is attributed to a certain rigidity inherent in the structure of collagen (high Pro and Hypo content) which persists even after denaturation. In any event, for peptides from each chain there exists a good linear log m. wt. *versus* mobility relationship.¹⁵⁴ Complications aside, gel electrophoresis continues to make available information that

¹⁵¹ C. A. Nelson, *J. Biol. Chem.*, 1971, **246**, 3895.

¹⁵² S. Panyim and R. Chalkley, *J. Biol. Chem.*, 1971, **246**, 7557.

¹⁵³ R. T. Swank and K. D. Munkres, *Analyt. Biochem.*, 1971, **39**, 462.

¹⁵⁴ H. Furthmayr and R. Timpl, *Analyt. Biochem.*, 1971, **41**, 510.

would be difficult to obtain in other ways. For instance, micro-scale disc-electrophoresis makes possible a study of protein synthesis in single, identified neurons,¹⁵⁵ and a comparison of the sizes and number of copies of proteins in 70S and 80S ribosomes.¹⁵⁶ In a study of the ribosomal proteins of rabbit reticulocytes,¹⁵⁷ electrophoresis in the first dimension was carried out in urea gels in tubes, and in the second dimension in the presence of SDS in polyacrylamide slabs into which the gels were embedded after dialysis to remove urea. Molecular weights of all 63 resolved proteins could be estimated from the second-dimension run. SDS-gel electrophoresis has also given the molecular weights of all the major myofibrillar and sarcoplasmic muscle proteins.¹⁵⁸ There have been many instances in which the proposed quaternary structure of a protein has been checked by studying the SDS-gel pattern after intramolecular cross-linking with dimethyl suberimide (see last year's Report). The method confirmed that 17 β -hydroxysteroid dehydrogenase from human placenta was a dimer,¹⁵⁹ that inosine-5'-phosphate dehydrogenase¹⁶⁰ and glycerol kinase¹⁶¹ were tetramers, and that carbamyl phosphate synthetase contained one catalytic and one regulatory subunit.¹⁶² In a particularly interesting application¹⁶³ the effect of a feedback inhibitor on isopropylmalate synthase, an associating-dissociating system, could be observed directly on SDS gels; when cross-linking was carried out in the presence of the inhibitor, tetramers were shown to have been converted into dimers and monomers.

Electrophoresis in SDS gels is potentially even more powerful now that two reports have appeared of renaturation of proteins from SDS solutions. In a careful study¹⁶⁴ Weber and Kruter describe removal of the detergent with Dowex 1-X2; addition of urea avoids precipitation and irreversible adsorption on to the column. Then follows reactivation as usual from urea, either by dilution into buffer or by dialysis, with good recovery of enzymic activity. The procedure was applied successfully to several oligomeric proteins, even those as demanding as aspartate transcarbamylase, which also regained its allosteric properties, and RNA polymerase, which has the quaternary structure $\beta\beta'\alpha_2\omega_2$. Details are also given for recovering proteins in a fairly active form from (unstained) SDS gels, but it was found necessary to pre-run the gels in order to regain any activity at all. In addition, a procedure adapted for fingerprinting eluted proteins is described.¹⁶⁴ For this purpose the Dowex 1-X2 eluate (6 mol l⁻¹ urea) is diluted to a urea

¹⁵⁵ H. Gainer, *Analyt. Biochem.*, 1971, **44**, 589.

¹⁵⁶ T. A. Bickle and R. R. Traut, *J. Biol. Chem.*, 1971, **246**, 6828.

¹⁵⁷ O. H. W. Martini and H. J. Gould, *J. Mol. Biol.*, 1971, **62**, 403.

¹⁵⁸ R. K. Scopes and I. F. Penny, *Biochim. Biophys. Acta*, 1971, **236**, 409.

¹⁵⁹ J. Jarabak and M. A. Street, *Biochemistry*, 1971, **10**, 3831.

¹⁶⁰ T.-W. Wu and K. G. Scrimgeour, *Canad. J. Biochem.*, 1971, **49**, 473.

¹⁶¹ J. W. Thorner and H. Paulus, *J. Biol. Chem.*, 1971, **246**, 3885.

¹⁶² P. P. Trotter, M. E. Burt, R. H. Haschemeyer, and A. Meister, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2599.

¹⁶³ G. Kohlhaw and G. Boatman, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 741.

¹⁶⁴ K. Weber and D. J. Kuter, *J. Biol. Chem.*, 1971, **246**, 4504.

concentration of 2 mol l⁻¹, digested with trypsin, and the tryptic peptides are then retained on Dowex 50-X2 to remove urea, and subsequently stripped with ammonia solution and freeze-dried for fingerprinting. A radioactively labelled membrane protein has recently¹⁶⁵ been eluted from SDS gels and successfully fingerprinted after an ion-exchange step to remove SDS. Another study¹⁶⁶ of the removal of SDS from proteins on an ion-exchange resin gave 100% recovery of activity from ribonuclease. [³⁵S]SDS was used to show that in general 99% of the detergent was removed, and it was noted that the remaining 1% might hinder the refolding of some proteins. It is likely that this method will be widely used, not only to recover small amounts of enzymes from analytical gels run in SDS, but also for membrane preparations solubilized in SDS and fractionated by preparative electrophoresis (see Section 8).

A technique that might find favour is dansylation of proteins as a means of making them visible in SDS gels.^{167, 168} The advantages are increased sensitivity (10–50 ng detectable), and direct visualization of the gel through glass in u.v. light. For large samples, electrophoresis of a dansylated portion in parallel with the bulk could prove useful in locating regions of the gel from which proteins are to be eluted.¹⁶⁸ The mobility of proteins is apparently affected negligibly by dansylation.¹⁶⁸ A study¹⁶⁹ of radioactively labelled envelope proteins of *E. coli* used dansylated marker proteins for molecular weight estimations. Dansylation of proteins which have been fixed in polyacrylamide gels is described¹⁷⁰ as a means of identifying their N-terminal residues. Dansylation is carried out in the presence of acrylamide, and dansylated amino-acids are separated and identified on polyamide layers as usual, after hydrolysis and precipitation of the acrylamide. The method was demonstrated successfully on *S*-sulphotrypsinogen. Amino-acid analysis of stained (Amido Schwarz) bands from polyacrylamide gels has been described,¹⁷¹ a good recovery of amino-acids being achieved by including 2-mercaptoethanol in the hydrolysis mixture. Again, the hydrolysis step was carried out in the presence of the gel. This is perhaps safer than attempted elution of the protein since, for example, dansylated immunoglobulin heavy chains (m. wt. 50 000) were eluted with great difficulty under conditions in which the light chains (m. wt. 25 000) were readily extractable.¹⁶⁸ A membrane protein (m. wt. 105 000) appears, however, to have been eluted successfully from gels.¹⁶⁵

There have been numerous reports of improved procedures for counting radioactive proteins in polyacrylamide gels. The effectiveness of various commercially available solubilizers has been compared¹⁷² and a procedure

¹⁶⁵ M. S. Bretscher, *J. Mol. Biol.*, 1971, **59**, 351.

¹⁶⁶ J. Lenard, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 662.

¹⁶⁷ D. N. Talbot and D. A. Yphantis, *Analyt. Biochem.*, 1971, **44**, 246.

¹⁶⁸ K. R. Shelton, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 367.

¹⁶⁹ M. Inouye, *J. Biol. Chem.*, 1971, **246**, 4834.

¹⁷⁰ R. Schyne, S. Bricteux-Grégoire, and M. Florin, *J. Chromatog.*, 1971, **62**, 115.

¹⁷¹ L. L. Houston, *Analyt. Biochem.*, 1971, **44**, 81.

¹⁷² P. N. Paus, *Analyt. Biochem.*, 1971, **42**, 372.

in which the gel slice is put directly into the scintillation cocktail has been described.¹⁷³ A danger in the conventional hydrogen peroxide method of solubilizing gels is the loss of ^{14}C and ^3H (as carbon dioxide and water), and conditions have now been described¹⁷⁴ which avoid this. Specific radioactivities of brain proteins in stained gels have been measured:¹⁷⁵ slices of the gel (cross-linked with ethylene diacrylate) were solubilized in alkali and the radioactivity and the stain intensity (related to the amount of protein present) were determined. In a new method of counting,¹⁷⁶ proteins are eluted from the gel slice on to a glass-fibre disc and this is then counted while immersed in scintillation fluid; quenching is said to need no correction. It is possible, however, that there may be difficulties in eluting high-molecular-weight proteins (see above). Another procedure for mechanical fractionation of gels has been described¹⁷⁷ and faster diffusion destaining may be possible if activated charcoal is used for continuous removal of the eluted dye.¹⁷⁸ '... and the crooked shall be made straight ...'¹⁷⁹ if those who photograph their gels in glass tubes adopt a suggestion made recently.¹⁸⁰

Isoelectric Focusing. This method of using a pH gradient to separate proteins according to their isoelectric points has achieved wide currency both as a preparative method and as a criterion of homogeneity. Of the numerous instances in which it has proved useful only a few representative examples are cited here. The technique has been reviewed^{181a} and details of the practical aspects have been clearly presented.^{181b} Separation of lipoproteins from serum¹⁸² is a typical example of its use; it is worth noting that a very narrow pH range was achieved in this case by pre-running the column and then collecting the ampholyte in the pH range desired. The tendency for proteins to precipitate at their pI can apparently be overcome by inclusion of 0.5 % of a non-ionic detergent (Brij 35) in the pH gradient.¹⁸³ Isoelectric focusing in polyacrylamide gels (gel electrofocusing) is also becoming widely used, both preparatively and analytically, and details of the technique have been documented.^{184, 185} Its use is illustrated by the preparative separation¹⁸⁶ of six rat haemoglobins, the largest difference in pI being 0.26 and the smallest only 0.04 pH units. A method for the rapid staining of protein bands after gel electrofocusing does not require removal

¹⁷³ S. A. Leon and A. T. Bohrer, *Analyt. Biochem.*, 1971, **42**, 54.

¹⁷⁴ D. Goodman and H. Matzura, *Analyt. Biochem.*, 1971, **42**, 481.

¹⁷⁵ K. Hemminki, *Acta Chem. Scand.*, 1971, **25**, 3887.

¹⁷⁶ C. W. Helleiner and W. H. Wunner, *Analyt. Biochem.*, 1971, **39**, 333.

¹⁷⁷ B. Bakay, *Analyt. Biochem.*, 1971, **40**, 429.

¹⁷⁸ L. J. Gathercol and L. Klein, *Analyt. Biochem.*, 1971, **44**, 232.

¹⁷⁹ Isaiah, Chap. 40, vs. 4.

¹⁸⁰ D. Oliver and R. Chalkley, *Analyt. Biochem.*, 1971, **44**, 540.

¹⁸¹ (a) N. Catsimpoilas, *Separation Sci.*, 1970, **5**, 523; (b) O. Vesterberg in ref. 120, p. 389.

¹⁸² J. J. Albers and A. M. Scanu, *Biochim. Biophys. Acta*, 1971, **236**, 29.

¹⁸³ A. D. Friesen, J. C. Jamieson, and F. E. Ashton, *Analyt. Biochem.*, 1971, **41**, 149.

¹⁸⁴ C. W. Wrigley, in Ref. 120, p. 559.

¹⁸⁵ P. Righette and J. W. Drysdale, *Biochim. Biophys. Acta*, 1971, **236**, 17.

¹⁸⁶ S. Stein, M. G. Cherian, and A. Mazur, *J. Biol. Chem.*, 1971, **246**, 5287.

of the ampholyte from the gel.¹⁸⁷ Isoelectric focusing in the absence and presence of urea (whether¹⁸⁸ or not¹⁸⁹ in gels) can yield information about the conformation of a protein, and about the nature of any micro-heterogeneity. In one study¹⁸⁸ it was found that whereas the pI values of several proteins were not affected by the presence of urea in the gel, that of plasma albumin was increased by *ca.* one pH unit. This was interpreted as the normalization of buried ionizable groups (in this case lysine); compensation of buried acidic and basic groups could account for cases of an unaltered isoelectric point in the presence of urea. In a related case (but no urea) an increase in the pI of TPCK-treated α -chymotrypsin relative to the native enzyme was held¹⁹⁰ to be consistent with the exposure of Ile-16. If multiple bands persist in a purified protein on isoelectric focusing in the presence of urea, this may be taken as evidence of differences in primary structure; it was observed for bovine plasma albumin¹⁸⁸ and it showed that fumarase isoenzymes contained six distinct types of subunit.¹⁹¹ A procedure for the two-dimensional separation of proteins by a combination of thin-layer gel-filtration and thin-layer isoelectric focusing has been described.¹⁹²

Affinity Chromatography. The power of this elegant method of purifying proteins is reflected in the countless cases in which it is being used to good effect; a selection of these is included in Table 1. The principles, limitations, and execution of the technique have been the subject of several excellent reviews¹⁹³⁻¹⁹⁵ and little will be added here. Agarose activated with cyanogen bromide continues to be the support of choice in almost every instance; some exceptions are noted in Table 1. A report¹⁰⁶ of the chemistry of the activation step has already been mentioned; so has a method for coupling biologically active substances to polymers using isocyanides¹⁰⁷ (see Section 2D). Although flexible 'arms' for attachment of ligands to the support were found to be essential in some cases (*cf.* refs. 206, 207, 213, 217) to minimize interactions with the matrix, inspection of Table 1 shows that this is not always so; it is possible, of course, that in many instances 'arms' would have improved the chromatography. It is interesting that in one case at least a flexible 'arm' was found to be undesirable:²¹⁹ thymidine kinase was adsorbed better on to a column of Sepharose-5'-amino-5'-deoxythymidine than on to a column of the *N*-(6-aminohexyl) derivative. Affinity chromatography of β -galactosidase²⁰⁶ did, however, require that the inhibitor ligand be attached *ca.* 21 Å from the matrix (10 Å was much worse). Other observations made in this work²⁰⁶ may turn out to be generally applicable: 'interacting systems of low affinity' can lead to very effective adsorption,

¹⁸⁷ O. Vesterberg, *Biochim. Biophys. Acta*, 1971, **243**, 345.

¹⁸⁸ M. R. Salaman and A. R. Williamson, *Biochem. J.*, 1971, **122**, 93.

¹⁸⁹ N. Ui, *Biochim. Biophys. Acta*, 1971, **229**, 567.

¹⁹⁰ N. Ui, *Biochim. Biophys. Acta*, 1971, **229**, 582.

¹⁹¹ P. E. Penner and L. H. Cohen, *J. Biol. Chem.*, 1971, **246**, 4261.




¹⁹² F. Drawert and W. Müller, *Chromatographia*, 1971, **4**, 23.

¹⁹³ P. Cuatrecasas and C. B. Anfinsen, *Ann. Rev. Biochem.*, 1971, **40**, 259.

¹⁹⁴ P. Cuatrecasas and C. B. Anfinsen in ref. 120, p. 345.

¹⁹⁵ G. Feinstein, *Naturwiss.*, 1971, **58**, 389.

Table 1 Some recent applications of affinity chromatography of proteins

Substance purified	Ligand (* indicates attachment through side-arm)	Elution	Ref.
Acetylcholinesterase: electric eel		'Tensilon' ($K_i = 10^{-6}$ mol l ⁻¹)	196
		'Tensilon' ($K_i = 10^{-6}$ mol l ⁻¹)	196
erythrocyte		'Tensilon' ($K_i = 10^{-6}$ mol l ⁻¹)	196
<i>ara</i> C Protein (<i>E. coli</i>)	* 4-Aminophenyl- β -D-6-deoxygalactopyranoside	Borate buffer, pH 10	197
Brain-specific antibodies (human)	Brain proteins	Acetic acid	198
Cobalamin-binding proteins	Cobalamin-albumin conjugate ^b	Hydroxycobalamin	199
DNA Polymerase (HeLa cells)	HeLa DNA (with single-stranded end)	0.1M-Phosphate buffer	200
Deoxyribonuclease I inhibitor (calf thymus)	Deoxyribonuclease I (pancreatic)	3M-Guanidine hydrochloride, 1M-acetate, 30% glycerol	201
3-Deoxy-D- <i>arabino</i> -heptulosonate-7-phosphate synthetase (tyrosine-sensitive isoenzyme)	Tyrosine ^c	—	202

¹⁹⁶ I. D. Berman and M. Young, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 395.¹⁹⁷ G. Wilcox, K. J. Clemetson, D. V. Santi, and E. Englesberg, *Proc. Nat. Acad. Sci., U.S.A.*, 1971, **68**, 2145.¹⁹⁸ I. Tripatzis, K. Warecka, and M.-C. Wong, *Nature New Biology*, 1971, **230**, 250.¹⁹⁹ H. Olesen, E. Hippe, and E. Haber, *Biochim. Biophys. Acta*, 1971, **243**, 66.²⁰⁰ M. S. Poonian, A. J. Schlabach, and A. Weissbach, *Biochemistry*, 1971, **10**, 424.²⁰¹ U. Lindberg and S. Eriksson, *European J. Biochem.*, 1971, **18**, 474.²⁰² M. Takahashi and W. W.-C. Chan, *Canad. J. Biochem.*, 1971, **49**, 1015.

Table 1 (cont.)

Substance purified

Substance purified	Ligand (* indicates attachment through side-arm)	Elution	Ref.
Dihydrofolate reductase: <i>Lactobacillus casei</i> chicken liver T ₄ phage	* Methotrexate ($K_1 = 10^{-8}$ mol l ⁻¹)	Dihydrofolate ($K_m = 5 \times 10^{-6}$ mol l ⁻¹) and NADPH	203
	* Methotrexate	Dihydrofolate	204
	* N ¹⁰ -Formylaminopterin ^a	Dihydrofolate	205
β -Galactosidase (<i>E. coli</i>)	* <i>p</i> -Aminophenyl- β -D-thiogalactopyranoside	0.1M-Borate	206
Glutamic-oxaloacetic transaminase apoenzyme (pig heart)	* Pyridoxamine 5'-phosphate	Glutamic acid, phosphate	207
Glycogen synthetase	UDP hexitolamine	Glycogen	208
Growth hormone (monkey)	Anti-human-placental lactogen	Not done (contaminant of prolactin)	209
Lactose synthase A protein (bovine)	β -Lactalbumin	Omission of glucose from buffer	210
	UDP hexitolamine	Cacodylate buffer + edta	208
Lipoprotein lipase (bovine milk)	Heparin	NaCl gradient	211
Neuraminidases: micro-organisms	* <i>N</i> -(<i>p</i> -Aminophenyl)oxamic acid	0.1M-NaHCO ₃	212
Protein kinase (rat parotid, rabbit muscle)	* <i>N</i> -(<i>p</i> -Aminophenyl)oxamic acid	0.1M-NaHCO ₃	212
Pyridine-nucleotide-dependent dehydrogenases	* Cyclic AMP	see text	213
	* NAD ⁺ or NADP ⁺ ^b	KCl gradient	214
	* NAD ⁺	NAD ⁺	215
	* AMP	NAD ⁺	215
Receptors: acetylcholine (electroplax)	Cobra toxin	—	216
Retinol binding protein (liver)	* Glucagon	—	217
Retinol binding protein (human)	Prealbumin	Dec. ionic strength	218
Thymidine kinase (<i>E. coli</i>)	5'-Amino-5'-deoxythymidine	0.5M-NaCl	219
Tyrosine hydroxylase (brain)	3-Iodotyrosine	1mM-KOH	220
<i>Proteolytic Enzymes, Zymogens, and Inhibitors</i>			
Carboxypeptidase A	Gly-D-Phe ^b	0.25M-NaCl (pH 7.5)	221
	Gly-D-Phe ^d	Acetic acid	222
Carboxypeptidase B	D-Ala-L-Arg	NaCl gradient	223
Chymotrypsin	4-Phenylbutylamine	pH 3	224
Pepsin	Polylysine (inhibitor)	NaCl gradient	225

Trypsin (bovine) (α - and β -forms separated)	Chicken ovomucoid	Dec. pH gradient	
Thrombin (bovine)	<i>p</i> -(<i>p</i> '-Aminophenoxypropoxy)benzamidine	pH 4	227
Plasminogen (human)	* <i>p</i> -Chlorobenzylamine	Benzamidine (1.0 mol l ⁻¹)	228
Ovoinhibitor (chicken)	Lysine (inhibitor analogue)	Lysine (0.1 mol. l ⁻¹)	229
Trypsin inhibitor (peanuts)	Lysine ^a	ϵ -Aminocaproic acid	230
	Chymotrypsin (bovine)	0.2M-KCl, pH 2	231
	Trypsinogen (bovine)	0.01M-HCl	232
^a Polyacrylamide; ^b Cellulose; ^c Sephadex; ^d Glass.			
203 P. C. H. Newbold and N. G. L. Harding, <i>Biochem. J.</i> , 1971, 124 , 1.			
204 B. T. Kaufman and J. V. Pierce, <i>Biochem. Biophys. Res. Comm.</i> , 1971, 44 , 608.			
205 J. S. Erickson and C. K. Mathews, <i>Biochem. Biophys. Res. Comm.</i> , 1971, 43 , 1164.			
206 E. Steers, jun., P. Cuatrecasas, and H. B. Pollard, <i>J. Biol. Chem.</i> , 1971, 246 , 196.			
207 R. Collier and G. Kohlaw, <i>Analyt. Biochem.</i> , 1971, 42 , 48.			
208 J. Shaper, R. L. Hill, and R. Barker, <i>Fed. Proc.</i> , 1971, 30 , 1265.			
209 H. J. Guyda and H. G. Friesen, <i>Biochem. Biophys. Res. Comm.</i> , 1971, 42 , 1068.			
210 I. P. Trayer and R. L. Hill, <i>J. Biol. Chem.</i> , 1971, 246 , 6666.			
211 T. Olivecrona, T. Egelrud, P.-H. Ivertius, and U. Lindahl, <i>Biochem. Biophys. Res. Comm.</i> , 1971, 44 , 178.			
212 P. Cuatrecasas and G. Illiano, <i>Biochem. Biophys. Res. Comm.</i> , 1971, 45 , 1177.			
213 M. Wilchek, Y. Salomon, M. Lowe, and Z. Selinger, <i>Biochem. Biophys. Res. Comm.</i> , 1971, 43 , 524.			
214 C. R. Lowe, and P. D. G. Dean, <i>F.E.B.S. Letters</i> , 1971, 14 , 313.			
215 K. Mosbach, H. Guilford, P.-O. Larsson, R. Ohlsson, and M. Scott, <i>Biochem. J.</i> , 1971, 125 , 20P.			
216 J. P. Changeux, J. C. Meunier, and M. Huchet, <i>Mol. Pharmacol.</i> , 1971, 7 , 538.			
217 F. Krug, B. Desbuquois, and P. Cuatrecasas, <i>Nature New Biology</i> , 1971, 234 , 268.			
218 (a) L. Rask, A. Vahlquist, and P. A. Peterson, <i>J. Biol. Chem.</i> , 1971, 246 , 6638; (b) A. Vahlquist, S. F. Nilsson, and P. A. Peterson, <i>European J. Biochem.</i> , 1971, 20 , 160.			
219 W. Rohde and A. G. Lezius, <i>Z. physiol. Chem.</i> , 1971, 352 , 1507.			
220 W. N. Poillon, <i>Biochem. Biophys. Res. Comm.</i> , 1971, 44 , 64.			
221 J. R. Uren, <i>Biochim. Biophys. Acta</i> , 1971, 236 , 67.			
222 P. J. Robinson, P. Dunnill, and M. D. Lilly, <i>Biochim. Biophys. Acta</i> , 1971, 242 , 659.			
223 M. Sokolovsky and N. Zisapel, <i>Biochim. Biophys. Acta</i> , 1971, 250 , 203.			
224 K. J. Stevenson and A. Landman, <i>Canad. J. Biochem.</i> , 1971, 49 , 119.			
225 B. Nevaldine and B. Kassell, <i>Biochim. Biophys. Acta</i> , 1971, 250 , 207.			
226 G. W. Jameson and D. T. Elmore, <i>Biochem. J.</i> , 1971, 124 , 66P.			
227 N. C. Robinson, R. W. Tye, H. Neurath, and K. A. Walsh, <i>Biochemistry</i> , 1971, 10 , 2743.			
228 A. R. Thompson and E. W. Davie, <i>Biochim. Biophys. Acta</i> , 1971, 250 , 210.			
229 T. H. Liu and E. T. Mertz, <i>Canad. J. Biochem.</i> , 1971, 49 , 1055.			
230 E. E. Rickli and P. A. Cuendet, <i>Biochim. Biophys. Acta</i> , 1971, 250 , 447.			
231 G. Feinstein, <i>Biochim. Biophys. Acta</i> , 1971, 236 , 74.			
232 K. K. Stewart and R. F. Doherty, <i>F.E.B.S. Letters</i> , 1971, 16 , 226.			

provided that the insolubilized ligand is present in high concentration, is separated substantially from the matrix backbone, and is readily accessible to the protein in solution. In the particular case of β -galactosidase, agarose beads were good, but polyacrylamide was not porous enough to allow the large enzyme to reach the ligand inside the beads. Inactive monomers of β -galactosidase also bound to the affinity column, suggesting that the method might be applicable to inactive mutant proteins if these can still bind substrate analogues.²⁰⁶

Noteworthy are the preliminary reports of isolation of cell receptors; the membrane receptor of the neurotransmitter acetylcholine was separated from acetylcholinesterase,²¹⁶ and the cell receptor for glucagon (dissociation constant 10^{-9} – 10^{-10}) was isolated.²¹⁷ (The glucagon receptor in liver cells has also been studied extensively by other workers.²³³) Of interest too is the use of insolubilized cofactors to resolve groups of enzymes.^{214, 215} It seems that the distance of the bound cofactor from the matrix is of less significance in the binding of enzyme than is the conformation of the cofactor.²¹⁴ Cofactors insolubilized in Sephadexes of various pore sizes form the basis of a method suggested for determining the molecular weight of dehydrogenases,²³⁴ and NAD^+ bound to porous glass will function in dehydrogenase reactions.²³⁵ Insolubilized UDP could prove useful for purification of a variety of enzymes (*e.g.* glycosyl transferases) which use UDP or its derivatives as substrate.²⁰⁹ Protein kinases are activated by cyclic AMP, which binds tightly to them. It is perhaps not too surprising, then, that affinity chromatography of a protein kinase preparation on insolubilized AMP gave²¹³ a fully activated enzyme. This is attributed to the retention by the column of a regulatory unit that binds cAMP (although this has not yet been recovered), and the method is suggested as a good one for isolating the free catalytic unit.²¹³

Last year saw an elegant approach to the purification of affinity-labelled active-site peptides by affinity chromatography with the native protein itself as ligand. The same workers describe²³⁶ a method which is generally applicable to the isolation of any modified peptides. This uses a column of an antibody directed against the particular modifying group, so that all modified peptide(s) will be retained; a mixture of adsorbed peptides then calls for separation by conventional methods. In the examples described (for Dnp- and arsanilazo-²³⁶ and nitro-²³⁷ groups) the method is used to identify labelled peptides in a selectively modified protein, but it is worth bearing in mind the suggestion²³⁷ that it might prove useful in sequence work for isolation of all peptides containing a particular modifiable residue (*e.g.* tyrosine, tryptophan, lysine).

²³³ M. Rodbell, H. M. J. Krans, S. L. Pohl, and L. Birnbaumer, *J. Biol. Chem.*, 1971, **246**, 1861, and several accompanying papers.

²³⁴ C. R. Lowe and P. D. G. Dean, *F.E.B.S. Letters*, 1971, **18**, 31.

²³⁵ M. K. Weibel, H. H. Weetall, and H. J. Bright, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 347.

²³⁶ M. Wilchek, V. Bocchini, M. Becker, and D. Givol, *Biochemistry*, 1971, **10**, 2828.

²³⁷ M. Helman and D. Givol, *Biochem. J.*, 1971, **125**, 971.

3 Structural Proteins

The term 'structural proteins' is taken here to include the fibrous proteins, proteins connected with motility, and certain other globular proteins that have no identified enzymic activity. Immunoglobulins and membrane proteins are dealt with separately in Sections 7 and 8 respectively. Methylated amino-acids occur in many 'structural' proteins and a useful review of their occurrence, biosynthesis, and biological significance has been published.²³⁸

A. The Proteins of Motility.—A study has been made of the enzymic methylation of skeletal-muscle contractile proteins²³⁹ which shows that methionine can act as the methyl donor for the methylation of histidine and lysine residues *in vitro*. Actin has been isolated from the soil amoeba *Acanthamoeba*;²⁴⁰ it resembles muscle actin in many ways but, unlike muscle actin, it also contains *N*^ε-dimethyl-lysine.

Amino-acid sequences around four of the five cysteine residues of trout actin have been reported.²⁴¹ The trout and rabbit muscle actins are clearly highly homologous. The amino-acid sequence around the single residue of 3-methylhistidine in rabbit skeletal muscle actin has also been determined;²⁴²

-Gly-Gln-Lys-Asp-Ser-Tyr-Val-Gly-Asp-Glu-Ala-Gln-Ser-Lys-Arg-Gly-Ile-Leu-Thr-Leu-Lys-Tyr-Pro-Ile-Glu-3MeHis-Trp-Gly-Ile-Ile-Thr-Asn-Asp-Asp-Met-

During the preparation of myosin, low concentrations of chains intermediate in size between heavy and light chains have been detected using SDS-gel electrophoresis.²⁴³ It is suggested that these proteins may be new proteins of the thick filament assembly. The *S*-β-(4-pyridylethyl)-L-cysteine derivatives of myosin have also been used for isoelectric focusing in polyacrylamide gels.²⁴⁴ A detailed study of the light chains of myosin has now been published.²⁴⁵ Three types of light chain were detected, of which two are related (although they differ in molecular weight by up to 9000 daltons) in that they each contain the sequence -Met-Ala-Gly-Gln-Glu-Asp-Ser-Asn-Gly-Cmc-Ile-Asn-Tyr-. Myosin and heavy meromyosin contain two moles of these related light chains, removal of which (at pH 11) causes total loss of ATPase activity. The third type of light chain is chemically different from the other two and can be released from myosin by treatment with DTNB [5,5'-dithiobis-(2-nitrobenzoate)] without loss of ATPase activity, but again there appear to be two moles of this light chain.

²³⁸ W. K. Paik and S. Kim, *Science*, 1971, **174**, 114.

²³⁹ B. Krzysik, J. P. Vergnes, and I. R. McManus, *Arch. Biochem. Biophys.*, 1971, **146**, 34.

²⁴⁰ R. R. Weihing and E. D. Korn, *Biochemistry*, 1971, **10**, 590.

²⁴¹ J. Bridgen, *Biochem. J.*, 1971, **123**, 541.

²⁴² M. Elzinga, *Biochemistry*, 1971, **10**, 224.

²⁴³ R. Starr and G. Offer, *F.E.B.S. Letters*, 1971, **15**, 40.

²⁴⁴ P. J. Bechtel, A. M. Pearson, and C. E. Bodwell, *Analyt. Biochem.*, 1971, **43**, 509.

²⁴⁵ A. G. Weeds and S. Lowey, *J. Mol. Biol.*, 1971, **61**, 701.

The amino-acid sequence around the single residue of 3-methylhistidine in rabbit skeletal muscle myosin has also been established:²⁴⁶

-Leu-Leu-Gly-Ser-Ile-Asp-Val-Asp-3MeHis-Gln-Thr-Tyr-Lys-

It is quite unlike the corresponding sequence in actin (see above). Although located uniquely in myosin subfragment-1, its function is obscure, but there is some correlation between the content of 3-methylhistidine and ATP-ase activity. N^{GN^G} -Dimethylarginine has been detected in the myosin from the developing leg muscle of various animals but not in the actin nor in adult myosin.²⁴⁷ There was no evidence for the existence of NN' -dimethylarginine or N^G -monomethylarginine.

Tropomyosins from a number of invertebrates (crayfish, oyster, abalone, and blowfly) have been shown to have a subunit molecular weight of 34 000, indistinguishable from that of vertebrate tropomyosins.²⁴⁸ The preparation of parvalbumins, the occurrence of which is restricted to the muscles of animals from the lower phyla of vertebrates, has been described.²⁴⁹ The major parvalbumin from hake muscle has a molecular weight of 11 500 and glycine as its C-terminal residue.²⁵⁰

The tubulin from microtubules of sea urchin sperm flagellae and pig brain²⁵¹ and from other mammals²⁵² has been reported to contain two non-identical but homologous subunits. Similar heterogeneity has been found for the cytoplasmic microtubules of chick embryo brain, the microtubules appearing as heteropolymers.²⁵³ Two distinct proteins have been observed in the microtubules from brain and neuroblastoma cells, and at least five different proteins were recognized in the outer doublet microtubules of flagellae from *Chlamydomonas*.²⁵⁴ There is also a very interesting report²⁵⁵ that ATP will induce sliding of tubules in the flagellae of sea-urchin sperm after trypsin treatment.

The partial amino-acid sequence of flagellin from *Salmonella adelaide* has been described.²⁵⁶ Difficulty was experienced in cleaving a Met-Ser bond with cyanogen bromide, comparable with that reported for Met-hydroxyamino-acid bonds in other proteins (see last year's Report).

B. Collagen.—The chemistry and structure of collagen have been well reviewed in detail.²⁵⁷ It now appears that collagen is actually synthesized

²⁴⁶ G. Huszar and M. Elzinga, *Biochemistry*, 1971, **10**, 229.

²⁴⁷ M. Reporter and J. L. Corbin, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 644.

²⁴⁸ E. F. Woods and M. J. Pont, *Biochemistry*, 1971, **10**, 270.

²⁴⁹ J.-F. Pechère, J. Demaille, and J.-P. Capony, *Biochim. Biophys. Acta*, 1971, **236**, 391.

²⁵⁰ J.-F. Pechère, J.-P. Capony, and L. Ryden, *European J. Biochem.*, 1971, **23**, 421.

²⁵¹ H. Feit, L. Slusarek, and M. L. Shelanski, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2028.

²⁵² R. E. Fine, *Nature New Biology*, 1971, **233**, 283.

²⁵³ J. Bryan and L. Wilson, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1762.

²⁵⁴ J. B. Olmsted, G.-B. Witman, K. Carlson, and J. L. Rosenbaum, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2273.

²⁵⁵ K. E. Summers and I. R. Gibbons, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 3092.

²⁵⁶ B. E. Davidson, *European J. Biochem.*, 1971, **18**, 524.

²⁵⁷ W. Traub and K. A. Piez, *Adv. Protein Chem.*, 1971, **25**, 243.

as a larger procollagen molecule from which much non-collagen peptide material is subsequently removed enzymically.²⁵⁸ The presence in normal tissues of an enzyme that trims off such peptide from the N-terminus of procollagen during or after the formation of the typical triple helix has been demonstrated.²⁵⁹ It is absent in dermatosparaxia animals.

Primary Structure. The enzymic hydrolysis of collagen has been improved by constructing a 'cocktail' of aminopeptidase, prolidase, prolinase, carboxypeptidase, and X-prolyl-aminopeptidase:²⁶⁰ sequential addition of collagenase, papain, and the 'cocktail' causes 90% hydrolysis of collagen. The zymogen of tadpole collagenase has been isolated.²⁶¹

An unusual collagen, containing three identical α -chains, has been isolated from chick cartilage.²⁶² The component α -chains are designated $\alpha 1(\text{II})$ -chains, since they differ in primary structure from the normal $\alpha 1(\text{I})$ -chains. The $\alpha 1(\text{II})$ -chain contains much more hydroxylysine than the $\alpha 1(\text{I})$ -chain and is apparently restricted to cartilage. Other experiments²⁶³ have shown that the $\alpha 1$ - and $\alpha 2$ -chains of both rat and bovine collagen differ in molecular weight by 6000 daltons, as estimated by SDS-gel electrophoresis. The significance is unclear as yet but it would have a bearing on collagen cross-linking if substantiated.²⁶³ Differences in the glycosylation of lysine residues in collagens from human skin and bone have also been reported.²⁶⁴

Further work has been described on the peptic digestion of collagen from rat-tail tendon.²⁶⁵ Several fragments were recovered from the digest of denatured collagen and located in tropocollagen by electron microscopy after renaturation. However, for a molecule as large as collagen, cleavage with cyanogen bromide is clearly the method of choice. Thus, studies are in progress on the cyanogen bromide peptides from the $\alpha 1$ - and $\alpha 2$ -chains of acid-soluble ox collagen,²⁶⁶ pig-skin collagen,²⁶⁷ soluble human- and baboon-skin collagens,²⁶⁸ and the $\alpha 1$ -chain of acid-soluble calf-skin collagen.²⁶⁹ Electron microscopy is again proving useful in establishing the order of the fragments.^{267, 269} The amino-acid sequence of peptide CB4 (third from the

²⁵⁸ G. Bellamy and P. Bornstein, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1138; R. L. Church, S. E. Pfeiffer, and M. L. Tanzer, *ibid.*, p. 2638.

²⁵⁹ C. M. Lapière, A. Lenaers, and L. D. Kohn, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 3054.

²⁶⁰ H. B. Bensusan, S. N. Dixit, and S. D. McKnight, *Biochim. Biophys. Acta*, 1971, **251**, 100.

²⁶¹ E. Harper, K. J. Bloch, and J. Gross, *Biochemistry*, 1971, **10**, 3035.

²⁶² E. J. Miller, *Biochemistry*, 1971, **10**, 1652.

²⁶³ B. C. Sykes and A. J. Bailey, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 340.

²⁶⁴ S. R. Pinnell, R. Fox, and S. M. Krane, *Biochim. Biophys. Acta*, 1971, **229**, 119.

²⁶⁵ J. Pikkariainen, K. Lampaiho, and K. Kulonea, *Biochim. Biophys. Acta*, 1971, **251**, 141.

²⁶⁶ D. Volpin and A. Veis, *Biochemistry*, 1971, **10**, 1751.

²⁶⁷ W. Heinrich, P. M. Lange, T. Stirtz, C. Iancu, and E. Heidemann, *F.E.B.S. Letters*, 1971, **16**, 63.

²⁶⁸ E. H. Epstein, R. D. Scott, E. J. Miller, and K. A. Piez, *J. Biol. Chem.*, 1971, **246**, 1718.

²⁶⁹ J. Rauterberg and K. Kühn, *European J. Biochem.*, 1971, **19**, 398.


Gly-Pro-Arg-Gly-Pro-Hyp-Gly-Pro-Hyp-Gly-Lys-Asn-Gly-Asp-Asp-
 1 10
 Gly-Glu-Ala-Gly-Lys-Pro-Gly-Arg-Hyp-Gly-Gln-Arg-Gly-Pro-Hyp-
 20 30
 Gly-Pro-Gln-Gly-Ala-Arg-Gly-Leu-Hyp-Gly-Thr-Ala-Gly-Leu-Hyp-
 40
 Gly-Met

Chick skin	Gly-Pro-Ala -Gly-Asn-Arg-Gly-Ala-Ser-Gly-Pro-Ala-Gly-Val-Lys-
Rat sin	Gly-Pro-Hyp-Gly-Asn-Arg-Gly-Thr-Ser-Gly-Pro-Ala-Gly-Val-Arg-
	1 10
Chick skin	Gly -Pro -Asn -Gly -Asp -Ala -Gly -Arg -Hyp -Gly -Glu -Hyp -Gly-
Rat skin	(Gly, Pro, Asx, Gly, Asx, Ala, Gly, Arg, Hyp, Gly, Glx, Hyp, Gly,
	20
Chick skin	Leu -Met
Rat skin	Leu, Met)
	30

The cyanogen bromide peptides from the $\alpha 1(\text{II})$ -chain of chick cartilage collagen (see above) have also been isolated and the C-terminal sequence of the chain has been shown to be -Met-Tyr.²⁷² A non-helical region of *ca.* 20 residues has been detected at the C-terminus of calf-skin collagen.²⁷³ It is rich in aromatic amino-acids and contains a lysine-derived aldehyde, suggestive of cross-links.

Cross-links. The cross-links in collagen from invertebrates, cyclostomes, and elasmobranchs have been compared.²⁷⁴ Detailed evidence has been presented²⁷⁵ for the existence of two aldimine bonds as cross-links in the intact collagen from soft tissues: dehydro-hydroxylysino-norleucine (5) occurs as a major component whereas dehydro-lysino-norleucine is only found in traces. In highly insoluble collagens, the proportion of dehydro-lysino-norleucine rises and that of dehydro-hydroxylysino-norleucine falls. Neither aldimine appears to become reduced *in vivo* in collagen, which suggests that factors other than reduction stabilize the cross-links. This is in contrast with elastin, where dehydro-lysino-norleucine does become reduced to give a more stable link.

²⁷⁵ A. J. Bailey and C. M. Peach, *Biochem. J.*, 1971, **121**, 257.



Other experiments²⁷⁶ have shown that selective removal of the non-helical regions from the N-terminus of rat-skin collagen using cyanogen bromide leaves *ca.* 70% of the protein aldehydes still covalently attached to the helical region. These aldehydes participate in cross-links of the Schiff-base type with lysine or hydroxylysine residues of neighbouring molecules, the aldol-type cross-link being largely restricted to the N-terminal region. On the other hand, it has been reported²⁷⁷ that the long-term gain in tensile strength of scar-tissue collagen in man and guinea-pig does not correlate well with the extent of cross-linking.

Hydroxylated Residues. Collagen contains hydroxylated proline and lysine residues. 2,2'-Bipyridyl blocks the hydroxylation in chick calvaria and permits the isolation of an $\alpha 1$ -chain that appears to be non-hydroxylated (a protocollagen).²⁷⁸ The inhibition of hydroxylation appears also to inhibit the normal extrusion of collagen by fibroblasts in culture.²⁷⁹ The enzymes involved in the hydroxylation of lysine and proline in protocollagen can be separated chromatographically²⁸⁰ and the proline hydroxylase from chick embryo has been examined in some detail.²⁸¹ An investigation of its specificity²⁸² shows that the minimum sequence for hydroxylation is an intact -X-Pro-Gly- triplet. The neighbouring amino-acids determine the rate of proline hydroxylation. On the other hand, studies *in vitro* of the $\alpha 1$ -CB2 fragments of rat skin and tendon collagen indicate that intracellular factors other than primary structure govern the degree of hydroxylation of susceptible proline residues.²⁸³

The degree of hydroxylation of lysine residues in the N-terminal telopeptide region of the $\alpha 1$ - and $\alpha 2$ -chains of various collagens has been investigated.²⁸⁴ The extent varies with the collagen, skin collagen having no hydroxylysine in these positions except in the chick embryo and newly born rat, the level falling with age.²⁸⁵

²⁷⁶ K. Deshmukh and M. E. Nimmi, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 416.

²⁷⁷ L. Forrest and D. S. Jackson, *Biochim. Biophys. Acta*, 1971, **229**, 681.

²⁷⁸ P. K. Müller, E. McGoodwin, and G. R. Martin, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 110.

²⁷⁹ P. B. Ramaley and J. Rosenbloom, *F.E.B.S. Letters*, 1971, **15**, 59.

²⁸⁰ R. L. Miller, *Arch. Biochem. Biophys.*, 1971, **147**, 339.

²⁸¹ M. Pankalainen and I. K. Kivirikko, *Biochem. Biophys. Acta*, 1971, **229**, 504.

²⁸² J. O'D. McGee, R. E. Rhoads, and S. Udenfriend, *Arch. Biochem. Biophys.*, 1971, **144**, 343.

²⁸³ R. E. Rhoads, S. Udenfriend, and P. Bornstein, *J. Biol. Chem.*, 1971, **246**, 4138.

²⁸⁴ M. J. Barnes, B. J. Constable, L. F. Morton, and E. Kodicek, *Biochem. J.*, 1971, **125**, 433.

²⁸⁵ M. J. Barnes, B. J. Constable, L. F. Morton, and E. Kodicek, *Biochem. J.*, 1971, **125**, 925.

C. Elastin.—Elastin has been the subject of a substantial review.²⁸⁶ Tropoelastin, the putative precursor of elastin, can now be purified easily from the aorta of copper-deficient pigs.²⁸⁷ It contains virtually no carbohydrate.²⁸⁸ Structural studies suggest that the sequences -Ala-Ala-Ala-Lys- and -Ala-Ala-Lys- may each be repeated six times in the peptide chain and may be implicated in the formation of the desmosine and isodesmosine cross-links.⁷³

There is mass-spectral evidence²⁸⁹ for the existence in elastin of cyclic dehydrosomopiperidines, precursors of desmosine and isodesmosine. The presence of dehydromerodesmosine in ox ligamentum elastin has also been reported.²⁹⁰ Elastin therefore contains at least two types of Schiff-base cross-links, since the occurrence of dehydro-lysino-norleucine is well established, and both occur naturally in elastin as their reduced derivatives merodesmosine and lysino-norleucine, respectively (*cf.* collagen above).

D. Fibrinogen.—The *S*-carboxymethylated chains of human fibrinogen have been separated by chromatography on CM-cellulose in 8M-urea²⁹¹ and a comparative study of human, cow, pig, and sheep fibrinogens has been reported.²⁹² Peptide maps reveal the close similarity. The C-terminal residues of various mammalian fibrinogens and fibrin have also been established:²⁹³

Source	Chain		
	α -	β -	γ -
Ox, Sheep	Pro	Val	Val
Human, Horse	Val	Val	Val
Pig, Dog	Pro	Val	Ile

The conversion of fibrinogen into fibrin in the lobster has been shown²⁹⁴ to involve the formation of *N* ^{ϵ} -(γ -glutamyl)lysine cross-links but, unlike vertebrate fibrinogen, lobster fibrinogen apparently undergoes no prior proteolysis. The existence of cross-links between α -chains in human fibrin has now been reported²⁹⁵ but no β - β links could be detected, although α - γ and γ - γ links are, of course, already known. At least five or six α -chains

²⁸⁶ 'Chemistry and Molecular Biology of the Intercellular Matrix', ed. E. A. Balazs, Academic Press, London, 1970, Vol. 1.

²⁸⁷ L. B. Sandberg, R. D. Zeikus, and I. M. Coltrain, *Biochim. Biophys. Acta*, 1971, **236**, 542.

²⁸⁸ M. E. Grant, F. S. Steven, D. S. Jackson, and L. B. Sandberg, *Biochem. J.*, 1971, **121**, 197.

²⁸⁹ M. A. Paz, P. M. Gallop, O. O. Blumenfeld, E. Henson, and S. Seifter, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 289.

²⁹⁰ M. A. Paz, E. Henson, O. O. Blumenfeld, S. Seifter, and P. M. Gallop, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 1518.

²⁹¹ G. Murano, B. Wiman, M. Blombäck, and B. Blombäck, *F.E.B.S. Letters*, 1971, **14**, 37.

²⁹² T. Cartwright and R. G. O. Kekwick, *Biochim. Biophys. Acta*, 1971, **236**, 550.

²⁹³ M. Okude and S. Iwanaga, *Biochim. Biophys. Acta*, 1971, **251**, 185.

²⁹⁴ G. M. Fuller and R. F. Doolittle, *Biochemistry*, 1971, **10**, 1311.

²⁹⁵ R. P. McDonagh, J. McDonagh, M. Blombäck, and B. Blombäck, *F.E.B.S. Letters*, 1971, **14**, 33.

³⁰⁵ S. C. Rall and R. D. Cole, *J. Biol. Chem.*, 1971, **246**, 7175.

fraction 4 is readily phosphorylated: this can be explained by the observation that fraction 3 has alanine and fraction 4 has serine at position 37 in the sequence.³⁰⁶

Ac-Ser-Glu-Ala-Pro-Ala-Glu-Thr-Ala-Ala-Pro-Ala-Pro-Ala-Glu-Lys-Ser-Pro-
 1 10
 Ala-Lys-Lys-Lys-Lys-Ala-Ala-Lys-Lys-Pro-Gly-Ala-Gly-Ala-Ala-Lys-Arg-Lys-
 20 30
 Ala-Ala-Gly-Pro-Pro-Val-Ser-Glu-Leu-Ile-Thr-Lys-Ala-Val-Ala-Ala-Ser-Lys-Glu-
 40 50
 Arg-Asn-Gly-Leu-Ser-Leu-Ala-Ala-Leu-Lys-Lys-Ala-Leu-Ala-Ala-Gly-Gly-Tyr-
 60 70

Figure 1 The N-terminal amino-acid sequence of lysine-rich histone from rabbit thymus

The histones of chicken erythrocytes and calf thymus are very similar apart from the existence of histone F2c, peculiar to erythrocytes.³⁰⁷ On the other hand, the histones of sea urchin sperm and calf thymus are readily distinguished.³⁰⁷ Structural studies are in progress on the cysteine-containing histone F₃ from chicken erythrocytes,³⁰⁸ and the N-terminal sequence of histone V (F2c) from the same source has been established:^{309, 310}

Thr-Glu-Ser-Leu-Val-Leu-Ser-Pro-Ala-Pro-Ala-Lys-Pro-Lys-Gln-
 1 10 Arg-
 Val-Lys-Ala-Ser-Arg-Arg-Ser-Ala-Ser-His-Pro-Thr-Tyr-Ser-Glu-
 20 30
 Met-Ile-Ala-Ala-Ala-Ile-Arg-

There is what appears to be an allelic interchange Gln/Arg at position 15.³⁰⁹ Nonetheless, the relative lack of heterogeneity observed in all these studies of the primary structure of histones reinforces the suspicion that histones have little or no control function in chromatin.

The lysine residues of histones can be converted into homocitrulline in a non-enzymic reaction with carbamyl phosphate³¹¹ but the biological significance remains obscure. A single tyrosine residue is nitrated in histone F1 from calf thymus on treatment with tetranitromethane and the extent of reaction is reduced when the protein is complexed with DNA.³¹² Studies with synchronized mammalian cells³¹³ show that differential methylation of the various histone fractions occurs and that the methylation does not coincide with periods of histone and DNA biosynthesis.

³⁰⁶ T. A. Langan, S. C. Rall, and R. D. Cole, *J. Biol. Chem.*, 1971, **246**, 1942.

³⁰⁷ T. Senshu, *Biochim. Biophys. Acta*, 1971, **243**, 323.

³⁰⁸ W. F. Brandt and C. von Holt, *F.E.B.S. Letters*, 1971, **14**, 338.

³⁰⁹ P. J. Greenaway and K. Murray, *Nature New Biology*, 1971, **229**, 233.

³¹⁰ P. J. Greenaway, *Biochem. J.*, 1971, **124**, 319.

³¹¹ G. Ramponi, J. L. Leaver, and S. Grisolia, *F.E.B.S. Letters*, 1971, **16**, 311.

³¹² M. Bustin, *Biochim. Biophys. Acta*, 1971, **251**, 172.

³¹³ G. R. Shepherd, J. M. Hardin, and B. J. Noland, *Arch. Biochem. Biophys.*, 1971, **143**, 1.

A new histone has been isolated from rainbow trout:³¹⁴ it contains no aromatic or sulphur-containing amino-acids and proline is the *N*-terminal residue. During trout spermatogenesis, extensive acetylation of histone occurs and, in histone IV, the acylation is limited to lysine residues at positions 5, 8, 12, and 16.³¹⁵ Transformation occurs by replacement of the histones with protamine, and proteolysis appears to play an important role in the removal of histone from the chromatin in the transformation process.³¹⁶ Thynnin, the protamine of tuna fish, has been separated into four fractions: all have *N*-terminal proline and the C-terminal sequence -Arg-Arg-Arg-Arg.³¹⁷

Various papers have been concerned with non-histone proteins of the nucleus. The separation of such proteins from rat liver nuclei by isoelectric focusing in polyacrylamide gels³¹⁸ and from mouse chromatin by SDS-gel electrophoresis³¹⁹ has been described, and it has been suggested³²⁰ that there may be a single species of chromosomal RNA-binding protein in rat ascites tumour. It is likely that chromosomal RNA is bound to protein through its dihydropyrimidine groups.³²⁰

F. Ribosomal Proteins.—It is a measure of the growing technical resource of the subject that protein chemists (well, some of them) are prepared to tackle structures as complex as the ribosome. Clearly this problem will not be solved overnight but a growing list of papers documents the early progress. Little strokes fell great oaks.³²¹

Polyacrylamide gel electrophoresis in two dimensions has been used to effect an almost complete separation of the proteins from rabbit reticulocyte ribosomes.^{157, 322} If SDS is included in the buffer for the second dimension, an estimate of the molecular weight of the protein is also obtainable (see also last year's Report). Differences in the size and number of proteins in 70s and 80s ribosomes have also been demonstrated using SDS-gel electrophoresis.¹⁵⁸ the 80s ribosome contains a greater number of proteins and a greater proportion of these proteins are of high molecular weight.

The proteins from the ribosomes of *E. coli* are receiving the most systematic investigation. Thirty-three pure proteins have been obtained from 50 g of ribosomes using a new method of fractionation that involves treatment with lithium chloride in the presence and absence of urea rather than zonal centrifugation.³²³ Details have been given of the purification of all

³¹⁴ D. T. Wible and G. H. Dixon, *J. Biol. Chem.*, 1971, **246**, 5636.

³¹⁵ E. P. M. Candido and G. H. Dixon, *J. Biol. Chem.*, 1971, **246**, 3182.

³¹⁶ K. Marushige and G. H. Dixon, *J. Biol. Chem.*, 1971, **246**, 5799.

³¹⁷ G. Bretzel, *Z. physiol. Chem.*, 1971, **352**, 1025.

³¹⁸ M. Gronow and G. Griffiths, *F.E.B.S. Letters*, 1971, **15**, 340.

³¹⁹ A. J. MacGillivray, D. Carroll, and J. Paul, *F.E.B.S. Letters*, 1971, **13**, 204.

³²⁰ R. A. Jacobson and J. Bonner, *Arch. Biochem. Biophys.*, 1971, **146**, 557.

³²¹ Benjamin Franklin, 'Poor Richard's Almanac'.

³²² H. Welfle, J. Stahl, and H. Bielka, *Biochim. Biophys. Acta*, 1971, **243**, 416.

³²³ E. Kaltschmidt, V. Rudloff, H. G. Janda, M. Cech, K. Nierhaus, and H. G. Wittmann, *Z. physiol. Chem.*, 1971, **352**, 1545.

twenty-one proteins from the 30s subunit³²⁴ but the mixture of proteins from the 50s subunit is more complex and more difficult to fractionate.³²⁵ Immunological studies show³²⁶ that the twenty-one proteins from the 30s subunit and twenty-four proteins from the 50s subunit are all different in amino-acid sequence but that two have some structural homology. A preliminary study³²⁷ of the tryptic peptides of three proteins from the 30s subunit is in accord with this observation.

Few of the protein thiol groups are reactive in the intact *E. coli* ribosome³²⁸ and a study of the digestibility of the ribosome with trypsin suggests that the 30s subunit may be a less compact structure than the 50s subunit.³²⁹ Digestion of the 30s subunit with ribonuclease T₁ can be used to produce a specific ribonucleoprotein fragment and it was reported that the mild anionic detergent Sarkosyl-L (*N*-laurylsarcosine) is preferable to SDS for gel electrophoresis of the proteins in the fragment.³³⁰ The curious enzyme leucyl,phenylalanyl-tRNA protein transferase of *E. coli* catalyses the transfer of these amino-acids from the corresponding tRNA to the N-terminal arginine residue of a specific protein in the 30s subunit.³³¹ Photo-oxidation of ribosomes in the presence of Rose Bengal affects the binding sites for tRNA and poly-U, perhaps by modification of histidine in a single protein.³³² The 16s RNA is also modified.

The initiation factor F₁ from *E. coli* ribosomes has been isolated and crystallized:³³³ it has a molecular weight of 9400, N-terminal alanine, and C-terminal lysine.

G. Serum and Egg Proteins.—The amino-acid sequence around the pyridoxal-phosphate-binding lysine (*) of bovine serum albumin has been reported and then amended slightly.³³⁴

The sequence is:

-Ser-Leu-Gln-Phe-Lys-Pro-Lys-Lys-*

Ten defined fragments, one of which is probably derived from the C-terminus of the protein, have been obtained from peptic digests of bovine serum albumin.³³⁵ Not surprisingly, the protein is more readily digested

³²⁴ I. Hindennach, G. Stöffler, and H. G. Wittmann, *European J. Biochem.*, 1971, **23**, 7.

³²⁵ I. Hindennach, E. Kaltschmidt, and H. G. Wittmann, *European J. Biochem.*, 1971, **23**, 12.

³²⁶ G. Stöffler and H. G. Wittmann, *J. Mol. Biol.*, 1971, **62**, 407; *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2283.

³²⁷ B. Wittmann-Liebold, *Z. physiol. Chem.*, 1971, **352**, 1705.

³²⁸ L. I. Slobin, *J. Mol. Biol.*, 1971, **61**, 281.

³²⁹ F. N. Chang and J. G. Flaks, *J. Mol. Biol.*, 1971, **61**, 387.

³³⁰ R. Brimacombe, J. Morgan, D. G. Oakley, and R. A. Cox, *Nature New Biol.*, 1971, **231**, 209.

³³¹ M. J. Leibowitz and R. L. Soffer, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1866.

³³² H. F. Noller, C. Chang, G. Thomas, and J. Aldridge, *J. Mol. Biol.*, 1971, **61**, 669.

³³³ S. Lee-Huang, M. A. G. Sillero, and S. Ochoa, *European J. Biochem.*, 1971, **18**, 536.


³³⁴ J. A. Anderson, H. W. Chang, and C. J. Grandjean, *Biochemistry*, 1971, **10**, 2408, 3810.

³³⁵ W. G. M. Braam, B. J. M. Harmsen, J. A. L. I. Walters, and G. A. J. van Os, *Internat. J. Protein Res.*, 1971, **3**, 271.

if it is unfolded.³³⁶ In a separate study, seven cyanogen bromide fragments that together account for the whole molecule have been isolated from human serum albumin.³³⁷


An interchange Arg/Gln has been reported³³⁸ to distinguish the two major genetically transmitted variants of human α -acid glycoprotein (orosomucoid). There is some evidence for duplication in the evolution of the structural genes for transferrin from a variety of vertebrates³³⁹ and for the participation of histidine residues in the binding of iron.³⁴⁰ It has also been reported³⁴¹ that apoferritin (from horse spleen) is in general digested more rapidly and to a greater extent by various proteolytic enzymes than is ferritin, indicating that conformational changes take place when iron is bound.

A study of the cyanogen bromide fragments of ovotransferrin³⁴² suggests that the molecule (m. wt. 80 000) may contain a duplicated amino-acid sequence, which is not easy to reconcile with earlier work on the thiol sequences.³⁴³ Of the two types of hen egg phosphvitin only one contains methionine (1 residue per chain of m. wt. 34 000), and cyanogen bromide has been used to cleave the molecule into two fragments.³⁴⁴ A partial structure of the carbohydrate moiety of phosphvitin has been published³⁴⁵ and the carbohydrate has been shown to be attached to the protein in the sequence:³⁴⁶



The occurrence of eight serine phosphate residues in a row is worth remarking.

The primary structure of the 33-residue peptide from plakalbumin has now been established, which enables the sequence of 49 residues at the C-terminus of ovalbumin to be formulated:³⁴⁷



³³⁶ W. G. M. Braam, B. J. M. Harmsen, and G. A. J. van Os, *Biochim. Biophys. Acta*, 1971, **236**, 99.

³³⁷ R. H. McMenamy, H. M. Dintzis, and F. Watson, *J. Biol. Chem.*, 1971, **246**, 4744.

³³⁸ R. Nimberg, T. Motoyama, and K. Schmid, *J. Biol. Chem.*, 1971, **246**, 5817.

³³⁹ R. M. Palmour and H. E. Sutton, *Biochemistry*, 1971, **10**, 4026.

³⁴⁰ A. Bezkorovainy and D. Grohlich, *Biochem. J.*, 1971, **123**, 125.

³⁴¹ R. R. Crichton, *Biochim. Biophys. Acta*, 1971, **229**, 75.

³⁴² J. L. Phillips and P. Azari, *Biochemistry*, 1971, **10**, 1160.

³⁴³ T. C. Elleman and J. Williams, *Biochem. J.*, 1970, **116**, 515.

³⁴⁴ R. C. Clark and F. J. Joubert, *F.E.B.S. Letters*, 1971, **13**, 225.

³⁴⁵ R. Shainkin and G. E. Perlmann, *Arch. Biochem. Biophys.*, 1971, **145**, 693.

³⁴⁶ R. Shainkin and G. E. Perlmann, *J. Biol. Chem.*, 1971, **246**, 2278.

³⁴⁷ E. O. P. Thompson, R. W. Sleight, and M. B. Smith, *Austral. J. Biol. Sci.*, 1971, **24**, 525.

The complete amino-acid sequence of the protein subunit of the tetrameric avidin from egg-white has been determined (Figure 2).³⁴⁸ Carbohydrate is attached at position 17 and half the molecules have isoleucine at position 34 whereas the other half have threonine. There is no obvious similarity to




Figure 2 The amino-acid sequence of avidin from hen egg-white

lysozyme or α -lactalbumin, making it extremely unlikely that these three proteins had a common genetic ancestor. Two points of technique in the sequence analysis are noteworthy. First, trouble was again found with the cyanogen bromide cleavage of Met-Ser and Met-Thr bonds despite quantitative conversion of the methionine into a homoserine residue (see ref. 256 above and last year's Report). Secondly, with several peptides containing N-terminal arginine or histidine it was noted that a substantial amount of the penultimate (*i.e.* second) residue is released (presumably as the thiazolinone) in the first step of the Edman degradation, which can lead to erroneous assignment of amino-acid sequence. (Problems such as this lead one to doubt that the automatic sequenator can ever entirely take over as the sole method of sequence analysis in proteins – which is not to deny its usefulness in other circumstances.)

Structural work has also been reported on the eggshell of the oriental garden cricket *Gryllus mitratus*.³⁴⁹ One major protein was isolated (m. wt. 57 500), rich in serine and O-phosphoserine.

H. Miscellaneous.—*Crystallins*. A simple chromatographic method for preparing the polypeptide chains of α -crystallin has been described³⁵⁰ and the N-terminal amino-acid sequence of both acidic (A1 and A2) peptide

³⁴⁸ R. J. DeLange and T.-S. Huang, *J. Biol. Chem.*, 1971, **246**, 698.

³⁴⁹ H. Kawasaki, H. Sato, and M. Suzuke, *Biochem. J.*, 1971, **125**, 495.

³⁵⁰ G. J. van Kamp, H. J. Hoenders, and H. Bloemendal, *Biochim. Biophys. Acta*, 1971, **243**, 149.

chains of ox α -crystallin has been established;³⁵¹

Ac-Met-Asp-Ile-Ala-Ile-Gln-His-Pro-Trp-Phe-Lys-Arg-

The amino-acid analyses of these chains appear to fit a molecular weight of 12 000 but this value cannot be confirmed by SDS-gel electrophoresis.³⁵¹ The subunits from calf lens α -crystallin all have molecular weights of 19 500 or 22 500 and again there is no evidence for smaller chains although three distinct populations of macromolecules were observed, apparently not in equilibrium with one another.³⁵² One of these subunits has been obtained sufficiently pure for structural studies and its N-terminal sequence has been shown to be:³⁵³

Ac-Met-Asp-Ile-Ala-Ile-Ser-His-Pro-Trp-Ile-Arg-Pro-Ser-Phe-Phe-Glu-Phe-His-

The molecule was cleaved at the only other methionine residue with cyanogen bromide, and the N-terminal sequence of the second fragment was shown to be:³⁵³

Ser-Leu-Thr-Lys-Asp-Phe-Asp-Glu-Val-Asn-Ile-Asp-Val-Ser-His-Phe-

Both sequence analyses were carried out in a sequenator. It was also suggested³⁵³ that the acidic and basic polypeptide chains that make up α -crystallin have evolved from a common ancestral form. Other experiments³⁵⁴ have been concerned with the thiol groups in the acidic chains of calf lens α -crystallin. It is likely that the chains (m. wt. estimated at *ca.* 20 000) contain two methionine residues and a single cysteine residue; the cysteine residue is in the sequence:³⁵⁴

-Tyr-Arg-Leu-Pro-Ser-Asn-Val-Asp-Glu-Ser-Ala-Leu-Ser-Cys-Ser-Leu-Ser-Ala-Asp-Gly-Met-Leu-Thr-Phe-Ser-Gly-Pro-Lys-

On the other hand, eight thiol groups can be distinguished in ox γ -crystallin on the basis of the analysis of cysteic-acid-containing peptides after performic acid oxidation,³⁵⁵ and the C-terminal sequence of the protein has been shown to be -Val-Met-Asp-Phe-Tyr.³⁵⁶ The results indicate that the γ -crystallin is homogeneous and has a molecular weight of 19 200. In general, therefore, the weight of evidence is now decidedly against the existence of crystallins with molecular weights of only *ca.* 10 000.

Keratins and Wool Proteins. The amino-acid sequence of component C from the high-sulphur proteins of α -keratin (Lincoln wool) has been established

³⁵¹ A. E. Leon, J. J. T. Gerding, K. de Groot, H. J. Hoenders, and H. Bloemendal, *Internat. J. Protein Res.*, 1971, **3**, 19.

³⁵² A. Spector, L.-K. Li, R. C. Augusteyn, A. Schneider, and T. Freund, *Biochem. J.*, 1971, **125**, 337.

³⁵³ R. C. Augusteyn and A. Spector, *Biochem. J.*, 1971, **124**, 345.

³⁵⁴ P. H. Corran and S. G. Waley, *Biochem. J.*, 1971, **124**, 61.

³⁵⁵ L. R. Croft and S. G. Waley, *Biochem. J.*, 1971, **121**, 453.

³⁵⁶ L. R. Croft, *Biochem. J.*, 1971, **121**, 557.

(Figure 3).³⁵⁷ The protein contains many repetitions of the 'same' sequence of about ten residues, and it was suggested that it may be the product of many gene duplication events. Further, it was pointed out that other structural proteins such as silk fibroin and collagen contain repetitive sequences and

1	Acetyl-Ala-Cmc-Cmc-Ser -Thr-Ser -Phe-Cmc-Gly -Phe-
11	Pro-Ile -Cmc-Ser -Thr-Ala -Gly-Thr -Cmc-Gly-
21	<u>Ser</u> - <u>Ser</u> - <u>Cmc-Cmc</u> -Arg-Ser -Thr-Cmc-Ser - <u>Gln</u> -
31	<u>Thr-Ser</u> - <u>Cmc-Cmc</u> -Gln-Pro -Thr-Ser - <u>Ile</u> - <u>Gln</u> -
41	<u>Thr-Ser</u> - <u>Cmc-Cmc</u> -Gln-Pro -Thr-Cmc- <u>Leu</u> - <u>Gln</u> -
51	<u>Thr-Ser</u> -Gly - <u>Cmc</u> -Glu-Thr -Gly-Cmc-Gly -Ile-
61	Gly-Gly -Ser -Ile -Gly-Tyr -Gly-Gln -Val -Gly-
71	Ser-Ser -Gly -Ala -Val-Ser -Ser -Arg -Thr -Arg-
81	Trp-Cmc-Arg -Pro -Asp-Cmc-Arg-Val -Glu -Gly-
91	Thr-Ser -Leu-
94	Pro-Pro - <u>Cmc-Cmc</u> -Val -Val - <u>Ser</u> - <u>Cmc</u> -Thr -Ser-
104	Pro- <u>Ser</u> - <u>Cmc-Cmc</u> -Gln-Leu -Tyr - <u>Tyr</u> -Ala - <u>Gln</u> -
114	Ala- <u>Ser</u> - <u>Cmc-Cmc</u> -Arg-Pro - <u>Ser</u> - <u>Tyr</u> -Cmc-Gly-
124	Gln- <u>Ser</u> - <u>Cmc-Cmc</u> -Arg-Pro -Ala-Cmc-
132	<u>Cmc-Cmc</u> -Gln-Pro -Thr-Cmc-Thr -Glu-
140	Pro -Val - <u>Cmc</u> -Glu-Pro -Thr-Cmc-Ser - <u>Gln</u> -
149	Pro-Ile -Cmc

Figure 3 The complete amino-acid sequence of component C of the high-sulphur fraction of Lincoln wool. Homologous residues are underlined, and the sequence has been arranged to show maximum homology
(Reproduced by permission from *Nature New Biol.*, 1971, **234**, 148)

that this feature may therefore be structurally significant for the wool proteins. The amino-acid sequences of two high-sulphur proteins (98 residues) from reduced Merino wool have also been compared and shown to differ in only four positions.³⁵⁸

The presence of N^{ϵ} -(γ -glutamyl)-lysine cross-links has been demonstrated in the citrulline-containing proteins of hair,³⁵⁹ and N^{ϵ} -(β -aspartyl)-lysine cross-links have been reported in native and heated keratin.³⁶⁰ Dityrosine has been detected in silk fibroin and, in smaller amounts, in keratin, where it is located in the crystalline regions of the fibre rather than the amorphous matrix.³⁶¹ The content of aspartic acid, asparagine, glutamic acid, and

³⁵⁷ T. C. Elleman, *Nature New Biology*, 1971, **234**, 148.

³⁵⁸ T. Haylett, L. S. Swart, and D. Parris, *Biochem. J.*, 1971, **123**, 191; L. S. Swart and T. Haylett, *ibid.*, 1971, **123**, 201.

³⁵⁹ H. W. J. Harding and G. E. Rogers, *Biochemistry*, 1971, **10**, 624.

³⁶⁰ R. S. Asquith, M. S. Otterburn, and K. L. Gardner, *Experientia*, 1971, **27**, 1388.

³⁶¹ D. J. Raven, C. Earland, and M. Little, *Biochim. Biophys. Acta*, 1971, **251**, 96.

glutamine in wool proteins has been determined by digesting the *S*-carboxy-methylated protein successively with Pronase, Prolidase, and leucine aminopeptidase.³⁶² The accuracy of the technique was confirmed by carrying out the same estimation for ribonuclease and insulin.

Breed and species differences have been reported for the high-sulphur proteins of wools from various domestic, feral, and wild sheep,³⁶³ and the proteins of normal human hair have been shown to be significantly different from those of mentally retarded siblings.³⁶⁴ However, since similar differences were found for hair from some individuals not mentally retarded, it is probable that there is only a fortuitous connection between the hair defect and mental retardation in the case described.³⁶⁴ A blocked N-terminal peptide, Ac-Ser-Cmc-Tyr, has been isolated from chymotryptic digests of keratin from goose feather calamus.³⁶⁵ It is thought likely that it is the only N-terminal peptide.

Casein. The complete amino-acid sequence of the B variant of ox α_{S1} -casein has now been established and the distinguishing features of the A, C, and D variants have been determined (Figure 4).³⁶⁶ It has also been reported that the N-terminal sequence of ox β -casein A₂ is:³⁶⁷

Arg-Glu-Leu-Glu-Glu-Leu-Asn-Val-Pro-Gly-Glu-Ile-Val-Glu-Ser(P)-
Leu-Ser(P)-Ser(P)-Ser(P)-Glu-Glu-Ser-Ile-Thr-Arg-Ile-Asn-Lys-Lys-Ile-
Glu-Lys-

and that the C-terminal sequence is:³⁶⁸

-His-Gln-Pro-His-Gln-Pro-Leu-Pro-Pro-Thr-Val-Met-Phe-Pro-Pro-
Gln-Ser-Val-Leu-Ser-Leu-Ser-Gln-Ser-Lys-Val-Leu-Pro-Val-Pro-
Glu-Lys-Ala-Val-Pro-Tyr-Pro-Gln-Arg-Asp-Met-Pro-Ile-Gln-Ala-
Phe-Leu-Leu-Tyr-Gln-Gln-Pro-Val-Leu-Gly-Pro-Val-Arg-Gly-Pro-
Phe-Pro-Ile-Ile-Val

Further work is in progress on the structure ³⁶⁹ of β -casein A₂, and the same N-terminal sequence of 25 residues has been reported for ox β -casein A₁.³⁷⁰

Other Proteins. The molecular weight of the coat protein of alfalfa mosaic virus has been redetermined and shown to be 24 500.³⁷¹ The primary structure of the coat protein of the RNA bacteriophage Q β has been

³⁶² L. A. Holt, B. Milligan, and C. M. Roxburgh, *Austral. J. Biol. Sci.*, 1971, **24**, 509.

³⁶³ R. L. Darskus and J. M. Gillespie, *Austral. J. Biol. Sci.*, 1971, **24**, 515.

³⁶⁴ R. J. Pollitt and P. D. Stonier, *Biochem. J.*, 1971, **122**, 433.

³⁶⁵ I. J. O'Donnell, *Austral. J. Biol. Sci.*, 1971, **24**, 179.

³⁶⁶ J.-C. Mercier, F. Grosclaude, and B. Ribadeau-Dumas, *European J. Biochem.*, 1971, **23**, 41.

³⁶⁷ B. Ribadeau-Dumas, G. Brignon, F. Grosclaude, and J.-C. Mercier, *European J. Biochem.*, 1971, **20**, 264.

³⁶⁸ B. Ribadeau-Dumas, G. Brignon, F. Grosclaude, and J.-C. Mercier, *European J. Biochem.*, 1971, **20**, 258.

³⁶⁹ G. Brignon, B. Ribadeau-Dumas, F. Grosclaude, and J.-C. Mercier, *European J. Biochem.*, 1971, **22**, 179.

³⁷⁰ W. Manson and W. D. Annan, *Arch. Biochem. Biophys.*, 1971, **145**, 16.

³⁷¹ J. Kruseman, B. Kraal, E. M. J. Jaspars, J. F. Bol, F. Th. Brederode, and H. Veldstra, *Biochemistry*, 1971, **10**, 447.

established and compared with that of bacteriophage f2,³⁷² as explained in last year's Report. It has also been reported³⁷³ that another Q β -specific protein, viz. A₁, of m. wt. 36 000, has an N-terminal sequence which is identical (for eight residues) with that of the Q β coat protein.³⁷³




Figure 4 The amino-acid sequence of bovine α_{S1} -casein. The differences found for the genetic variants A, C, and D are marked in boxes

Further work has been described³⁷⁴ on the freezing-point-depressing glycoproteins of the antarctic fish *Trematomus borchgrevengi*. They are shown to contain the tripeptide -Ala-Ala-Thr- in a repeating sequence, the threonine being in glycosidic linkage with the disaccharide galactosyl-*N*-acetylgalactosamine. Even more unusual perhaps are the polymers of arginine and aspartic acid (m. wt. 25 000—100 000) which occur in granules in the blue-green alga *Anabaena cylindrica* and are thought to be storage proteins.³⁷⁵

³⁷² T. Maita and W. Konigsberg, *J. Biol. Chem.*, 1971, **246**, 5003.

³⁷³ A. M. Weiner and K. Weber, *Nature*, 1971, **234**, 206.

³⁷⁴ A. L. DeVries, J. Vandenheede, and R. E. Feeney, *J. Biol. Chem.*, 1971, **246**, 305.

³⁷⁵ R. D. Simon, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 265.

4 Peptides and Hormones

A. Pancreatic Hormones.—The isolation of an enzyme that converts proinsulin into insulin has been reported.³⁷⁶ Details of the structural analysis of ox proinsulin have been given and some forms of the hormone intermediate between proinsulin and insulin were isolated from commercial crystalline insulin.³⁷⁷ The C-peptide of ox proinsulin has also been purified from pancreas and shown to be identical with that obtained from intact proinsulin.³⁷⁸ The primary structure of the C-peptide reported in all these papers is slightly different (an inversion of two residues) from that formulated in the first investigation of ox proinsulin. A comparative study³⁷⁹ of the C-peptides of proinsulin from man, pig, and ox reveals that they show interesting variations in length:

Man	Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-
Pig	Glu-Ala-Glu-Asn-Pro-Gln-Ala-Gly-Ala-Val-Glu-Leu-Gly-Gly-Gly-
Ox	Glu-Val-Glu-Gly-Pro-Gln-Val-Gly-Ala-Leu-Glu-Leu-Ala-Gly-Gly-

Man	Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln
Pig	Leu-Gly-Gly - - Leu-Gln-Ala-Leu-Ala-Leu-Glu-Gly-Pro-Pro-Gln
Ox	Pro-Gly-Ala-Gly - - - - Gly-Leu-Glu-Gly-Pro-Pro-Gln

This in turn implies some degree of freedom in the structural requirements of the C-peptide region despite its function in the folding of the proinsulin molecule.³⁷⁹

The mouse, like the rat, has been reported to have two different insulins:³⁸⁰ the molecules are distinguished by a Pro/Ser interchange at position B-9 and a Lys/Met interchange at position B-29. Chemical modification of insulin with phenylglyoxal³⁸¹ and a study of semisynthetic insulins³⁸² both indicate the functional importance of arginine at position B-22. On the other hand, a detailed analysis of the acetylation of insulin³⁸³ showed that acetylation of any of the hormone amino-groups did not affect the biological activity despite changes in the immunological specificity.

The amino-acid sequence of ox glucagon has been shown³⁸⁴ to be identical with that of pig, first established in 1957.

³⁷⁶ C. C. Yip, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1312.

³⁷⁷ C. Nolan, E. Margoliash, J. D. Peterson, and D. F. Steiner, *J. Biol. Chem.*, 1971, **246**, 2780.

³⁷⁸ (a) A. Salokangas, D. G. Smyth, J. Markussen, and F. Sundby, *European J. Biochem.*, 1971, **20**, 183; (b) D. F. Steiner, S. Cho, P. E. Oyer, S. Terris, J. D. Peterson, and A. H. Ruben, *J. Biol. Chem.*, 1971, **246**, 1365.

³⁷⁹ A. S. C. Ko, D. G. Smyth, J. Markussen, and F. Sundby, *European J. Biochem.*, 1971, **20**, 190.

³⁸⁰ J. Markussen, *Internat. J. Protein Res.*, 1971, **3**, 149.

³⁸¹ H. F. Bünzli and H. R. Bosshard, *Z. physiol. Chem.*, 1971, **352**, 1180.

³⁸² G. Weitzel, U. Weber, J. Martin, and K. Eisele, *Z. physiol. Chem.*, 1971, **352**, 1005.

³⁸³ D. G. Lindsay and S. Shall, *Biochem. J.*, 1971, **121**, 737.

³⁸⁴ W. W. Bromer, M. E. Boucher, and J. E. Koffenberger, jun., *J. Biol. Chem.*, 1971, **246**, 2822.

B. Pituitary Hormones.—The pituitary hormones have been the subject of furious activity in the past year or so, and many remarkable structural interrelations are coming to light. The purification of human chorionic gonadotropin (CG), has been described³⁸⁵ and the resolution of the two subunits of luteinizing hormone (LH) from human,³⁸⁶ pig,³⁸⁷ and rat³⁸⁸ pituitaries and of follicle-stimulating hormone (FSH) from human pituitaries³⁸⁹ has




Figure 5 The amino-acid sequence of the α -subunit of ox TSH

been reported. Hybridization experiments with CG, LH, FSH, and thyroid-stimulating hormone (TSH) suggest that each molecule contains a hormone-specific β -chain and an α -chain that is similar if not identical in all the hormones.^{386, 389, 390} For example, the β -chain of ox TSH together with the α -chain of human CG forms a hormone that is almost as good in thyroid-stimulating activity as TSH itself.³⁹⁰

Compelling evidence in support of this idea comes from studies of the primary structure of the hormones. Thus, the amino-acid sequences of the α - and β -chains of ox TSH have been determined (Figures 5 and 6)³⁹¹ and it is likely that the α -chains of ox TSH and LH are identical apart from differences in carbohydrate content.³⁹² The TSH β -chain is found to lack the C-terminal methionine residue in some molecules, and the α -chain is also heterogeneous in that it can lack the Phe-Pro- sequence at the N-terminus.³⁹¹ The arrangement of the disulphide bridges remains to be

³⁸⁵ R. Brossmer, M. Dörner, U. Hilgenfeldt, F. Leindenberger, and E. Trude, *European J. Biochem.*, 1971, **15**, 33.

³⁸⁶ P. Rathnam and B. B. Saxena, *J. Biol. Chem.*, 1971, **246**, 7087.

³⁸⁷ G. Hennen, Z. Prusik, and G. C. Maghuin-Rogister, *European J. Biochem.*, 1971, **18**, 376.

³⁸⁸ D. N. Ward, L. E. Reichart, B. A. Fitzak, H. S. Nahm, C. M. Sweeney, and J. D. Neill, *Biochemistry*, 1971, **10**, 1796.

³⁸⁹ B. B. Saxena and P. Rathnam, *J. Biol. Chem.*, 1971, **246**, 3549.

³⁹⁰ J. G. Pierce, O. P. Bahl, J. S. Cornell, and N. Swaminathan, *J. Biol. Chem.*, 1971, **246**, 2321.

³⁹¹ T.-H. Liao and J. G. Pierce, *J. Biol. Chem.*, 1971, **246**, 850.

³⁹² J. G. Pierce, T.-H. Liao, R. B. Carlsen, and T. Reimo, *J. Biol. Chem.*, 1971, **246**, 866.




Figure 6 The amino-acid sequence of the β -subunit of ox TSH




Figure 7 The amino-acid sequence of the β -subunit of ox LH. R is probably acetyl

determined. These conclusions are further borne out by the analysis of the amino-acid sequence of the α - and β -subunits of sheep LH.³⁹³ The α -subunits of ox TSH³⁹¹ and sheep LH³⁹³ are identical apart from an inversion of residues 88 and 89, which is possibly simply the result of an error in one of the two investigations. Unfortunately, the results of independent determinations of the amino-acid sequences of the β -subunit of LH from ox (Figure 7)³⁹⁴ and sheep³⁹³ do not agree so well, since the differences between the versions are almost certainly more than can be accounted for by the difference in species of origin. The discrepancies are

³⁹³ H. Papkoff, M. R. Sairam, and C. H. Li, *J. Amer. Chem. Soc.*, 1971, **93**, 1531.

³⁹⁴ G. C. Maghuin-Rogister and A. Dockier, *F.E.B.S. Letters*, 1971, **19**, 209.

³⁹⁵ G. C. Maghuin-Rogister, J. Closset, and G. P. Hennen, *F.E.B.S. Letters*, 1971, **13**, 301.

³⁹⁶ G. P. Hennen, I. Klüh, and G. C. Maghuin-Rogister, *F.E.B.S. Letters*, 1971, **19**, 207.

³⁹⁷ G. C. Maghuin-Rogister and G. P. Hennen, *European J. Biochem.*, 1971, **21**, 489.

yet to be resolved. It has also been reported that the α -subunits of LH from ox and pig are very similar³⁹⁵ and that there is heterogeneity in the N-terminal³⁹⁶ and C-terminal³⁹⁷ sequences of the ox chain. The N-terminal sequence was determined in a sequenator.

Revisions to the previously published amino-acid sequence of human growth hormone (HGH) have now been agreed^{398, 399} (see last year's Report) and the sequence of ox growth hormone has been established.⁴⁰⁰ It contains 188 residues, 61% of which are identical with those of HGH, and there is heterogeneity at position 124, 30% of the molecules having valine and 70% having leucine at this position.^{400, 401a} Allelic genes appear to be responsible.^{401b} The primary structure of human placental lactogen (HPL) has also been established^{398, 402, 403} and compared^{398, 402-404} with HGH and sheep prolactin (SP). HPL and HGH (each 190 residues) are identical for 85% of their amino-acid sequence and the homology with SP is unmistakable (see last year's Report). It is interesting that growth hormone and prolactin (secreted by the pituitary) and placental lactogen (secreted by trophoblasts during pregnancy) are all potent lactogenic hormones but that, despite the exceedingly close homology, placental lactogen does not promote growth. Further evidence that human pituitary prolactin and HGH are not the same molecule has been presented.⁴⁰⁵ In other experiments⁴⁰⁶ it has been shown that six out of eight tyrosine residues in HGH can react with tetranitromethane at pH 8. The modified hormone retains full lactogenic activity but only 60% activity in promoting growth. On the other hand, if the modification is carried out in 5M-guanidine hydrochloride, all eight tyrosine residues react, with complete loss of both hormonal activities.

The amino-acid sequences of two neurophysins (pituitary proteins that bind the hormones oxytocin and vasopressin) have been established. That of ox neurophysin-II⁴⁰⁷ is shown in Figure 8. The primary structure of pig neurophysin-I⁴⁰⁸ is somewhat different: it is found in two forms, one of

³⁹⁸ H. D. Niall, *Nature New Biol.*, 1971, **230**, 90.

³⁹⁹ C. H. Li and J. S. Dixon, *Arch. Biochem. Biophys.*, 1971, **146**, 233.

⁴⁰⁰ J. A. Santomé, J. M. Dellacha, A. C. Paladini, C. E. M. Wolfenstein, C. Peña, E. Poskus, S. T. Daurat, M. J. Biscoglio, Z. M. M. de Sesé, and A. V. F. de Sangüesa, *F.E.B.S. Letters*, 1971, **16**, 198.

⁴⁰¹ (a) H. N. Fernandez, S. T. Daurat, C. Peña, J.-M. Dellacha, J. A. Santomé, and A. C. Paladini, *F.E.B.S. Letters*, 1971, **18**, 53; (b) B. K. Seavey, R. N. P. Singh, U. J. Lewis, and I. I. Geschwind, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 189.

⁴⁰² C. H. Li, J. S. Dixon, and D. Chung, *Science*, 1971, **173**, 56.

⁴⁰³ L. M. Sherwood, S. Handwerger, W. D. McLaurin, and M. Lanner, *Nature New Biol.*, 1971, **233**, 59.

⁴⁰⁴ T. A. Bewley and C. H. Li, *Experientia*, 1971, **27**, 1368.

⁴⁰⁵ U. J. Lewis, R. N. P. Singh, and B. K. Seavey, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 1169.

⁴⁰⁶ L. Ma, J. Brovetto-Cruz, and C. H. Li, *Biochim. Biophys. Acta*, 1971, **229**, 444.

⁴⁰⁷ (a) R. Walter, D. H. Schlesinger, I. L. Schwartz, and J. D. Capra, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 293; (b) D. H. Schlesinger, J. D. Capra, I. L. Schwartz, and R. Walter, *Experientia*, 1971, **27**, 213.

⁴⁰⁸ T. C. Wu, S. Crumm, and M. Saffran, *J. Biol. Chem.*, 1971, **246**, 6043.

which has 91 residues whereas the other carries an additional leucine residue at the C-terminus. The disulphide bridges remain to be determined but the ox and pig proteins are clearly homologous. Unlike the ox and the pig, which appear to contain two principal neurophysins (I and II), the rat probably has only one major and one minor component,⁴⁰⁹ but the presence of a third form of pig neurophysin has been reported.⁴¹⁰ Since it is likely that oxytocin and vasopressin have separate neurophysins, it has been suggested⁴¹¹ that there may even be a pro-oxytocin and a provasopressin that are cleaved to yield oxytocin-neurophysin and vasopressin-neurophysin respectively, comparable with the liberation of insulin from proinsulin.

Ala-Met-Ser-Asp-Leu-Glu-Leu-Arg-Gln-Cys-Leu-Pro-Cys-Gly-Pro-Gly-Gly-Lys-
 1 10
 Gly-Arg-Cys-Phe-Gly-Pro-Ser-Ile-Cys-Cys-Gly-Asn-Glu-Leu-Gly-Gln-Phe-Val-
 20 30
 Gly-Thr-Ala-Glu-Ala-Leu-Arg-Cys-Gln-Glu-Glu-Asn-Tyr-Leu-Pro-Ser-Pro-Cys-
 40 50
 Gln-Ser-Gly-Gln-Arg-Pro-Cys-Gly-Ser-Gly-Gly-Arg-Cys-Ala-Ala-Ala-Thr-Ile-
 60 70
 Cys-Cys-Ser-Asp-Glu-Glu-Cys-Val-Pro-Asp-Glu-Gln-Val-Lys-Pro-Gly-Gly-
 80
 Arg-Gly-Gly-Cys-Phe-Cys-Arg-Val
 90

Figure 8 The amino-acid sequence of ox neurophysin II

Various papers have dealt with the characterization of a peptide from the hypothalamus that stimulates secretion of LH and FSH from the pituitary. It has been described in pig,^{412, 413} sheep,⁴¹⁴ and ox⁴¹³ and, following the recognition that the hormone contains tryptophan,^{412b, 413} the amino-acid sequence of the pig peptide has been established:⁴¹⁵

Glp-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂

Various chemical modification experiments show⁴¹⁶ that tyrosine, histidine, tryptophan, and arginine are important for the biological activity, and the

⁴⁰⁹ A. Norström, J. Sjöstrand, B. G. Livett, L. O. Uttenthal, and D. B. Hope, *Biochem. J.* 1971, **122**, 671.

⁴¹⁰ K. W. Cheng and H. G. Friesen, *J. Biol. Chem.*, 1971, **246**, 7656.

⁴¹¹ G. D. Burford, C. W. Jones, and B. T. Pickering, *Biochem. J.*, 1971, **124**, 809.

⁴¹² (a) A. V. Schally, A. Arimura, Y. Baba, R. M. G. Nair, H. Matsuo, T. W. Redding, L. Debeljuk, and W. F. White, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 393; (b) A. V. Schally, R. M. G. Nair, T. W. Redding, and A. Arimura, *J. Biol. Chem.*, 1971, **246**, 7230.

⁴¹³ C. Bogentoft, B. L. Currie, H. Sievertsson, J.-K. Chang, K. Folkers, and C. Y. Bowers, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 403.

⁴¹⁴ M. Amoss, R. Burgus, R. Blackwell, W. Vale, R. Fellows, and R. Guillemin, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 205.

⁴¹⁵ Y. Baba, H. Matsuo, and A. V. Schally, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 459.

⁴¹⁶ Y. Baba, A. Arimura, and A. V. Schally, *J. Biol. Chem.*, 1971, **246**, 7581.

synthetic peptide Glp-Tyr-Arg-Trp-NH₂ has been found to possess the power of LH-release.⁴¹⁷ It is interesting that the peptide Glp-Trp-Tyr-Arg-NH₂ is inactive despite the fact that the sequence of residues is the same as that in the native hormone.⁴¹⁷

It has been observed that, during incubation with human plasma, TSH-releasing hormone, Glp-His-Pro-NH₂, is inactivated as a result of loss of the amide group at the C-terminus.⁴¹⁸ A peptide from pig hypothalamus that shows growth-hormone-releasing activity has also been isolated, and shown to have the amino-acid sequence:⁴¹⁹



C. Other Hormones and Peptides.—The preparation of thyroglobulin that contains no sialic acid has been described⁴²⁰ and heterogeneity in the binding of sialic acid has been demonstrated.⁴²¹ A study of the tryptic peptides of non-iodinated pig thyroglobulin suggests⁴²² that the molecule contains $2n$ peptide chains, where n is an integer awaiting determination. Ox thyroglobulin has been shown⁴²³ to be capable of accepting arginine from Arg-tRNA in an enzymic reaction catalysed by a transferase (see also ref. 331) to give the new N-terminal sequence Arg-Asp-Ile-Phe-. It is suggested⁴²³ that ox thyroglobulin is composed of two chains each with the N-terminal sequence Asp-Ile-Phe-. Further work on the transferase indicates⁴²⁴ that for acceptor activity a protein needs to have aspartic or glutamic acid as N-terminal residue.

The isolation of three ox parathyroid hormones has been described.⁴²⁵ All contain 84 residues and the amino-acid sequence of the major form was given in last year's Report. The isolation of pig parathyroid hormone has also been reported⁴²⁶ and the amino-acid sequence of pig β -lipotropic hormone has been shown to be closely related to that of the sheep hormone determined some years ago.⁴²⁷

The curious peptide from ox hypothalamus, substance P, which was first described by von Euler as long ago as 1931, has been resurrected and examined. Its amino-acid sequence turns out to be not unlike that of physalaemin (from the skin of a South American amphibian) and eledoisin

⁴¹⁷ J.-K. Chang, H. Sievertsson, C. Bogentoft, B. L. Currie, K. Folkers, and C. Y. Bowers, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 409.

⁴¹⁸ R. M. G. Nair, T. W. Redding, and A. V. Schally, *Biochemistry*, 1971, **10**, 3621.

⁴¹⁹ A. V. Schally, Y. Baba, R. M. G. Nair, and C. O. Bennett, *J. Biol. Chem.*, 1971, **246**, 6647.

⁴²⁰ O. Tarutani and S. Shulman, *Biochim. Biophys. Acta*, 1971, **229**, 642.

⁴²¹ O. Tarutani and S. Shulman, *Biochim. Biophys. Acta*, 1971, **236**, 384.

⁴²² T. Hayashi, K. Iwai, and N. Ui, *Biochem. Biophys. Acta*, 1971, **251**, 208.

⁴²³ R. L. Soffer, *J. Biol. Chem.*, 1971, **246**, 1481.

⁴²⁴ R. L. Soffer, *J. Biol. Chem.*, 1971, **246**, 1602.

⁴²⁵ H. T. Keutmann, G. D. Aurbach, B. F. Dawson, H. D. Niall, L. J. Deftos, and J. T. Potts, jun., *Biochemistry*, 1971, **10**, 2779.

⁴²⁶ J. S. Woodhead, J. L. H. O'Riordan, H. T. Keutmann, M. L. Stoltz, B. F. Dawson, H. D. Niall, C. J. Robinson, and J. T. Potts, jun., *Biochemistry*, 1971, **10**, 2787.

⁴²⁷ L. Graf, E. Barat, G. Cseh, and M. Sajgo, *Biochim. Biophys. Acta*, 1971, **229**, 276.

(from the salivary glands of a cephalopod):⁴²⁸

Substance P	Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH ₂
Physalaemin	Glp-Ala-Asp-Pro-Asn-Lys-Phe-Try-Gly-Leu-Met-NH ₂
Eledoisin	Glp-Pro-Ser-Lys-Asp-Ala-Phe-Ile-Gly-Leu-Met-NH ₂

Two other peptides, bombesin and alytesin, from the skin of European amphibians, have also been characterized:⁴²⁹

Bombesin	Glp-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH ₂
Alytesin	Glp-Gly-Arg-Leu-Gly-Thr-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH ₂

Both are hypertensives and uterine stimulants.




Figure 9 The amino-acid sequence of viscotoxin B from European mistletoe

Six peptides from the venom of *Bothrops jararaca* that act as inhibitors of angiotensin-converting enzymes have been shown to have the following amino-acid sequences:⁴³⁰

Glp-Gly-Gly-Trp-Pro-Arg-Pro-Gly-Pro-Glu-Ile-Pro-Pro
Glp - - Trp-Pro-Arg-Pro-Thr-Pro-Gln-Ile-Pro-Pro
Glp - - Trp-Pro-Arg - - Pro-Gln-Ile-Pro-Pro
Glp - Asn-Trp-Pro-Arg - - Pro-Gln-Ile-Pro-Pro
Glp - Asn-Trp-Pro-His - - Pro-Gln-Ile-Pro-Pro
Glp - Ser-Trp-Pro-Gly - - Pro-Asn-Ile-Pro-Pro

They are probably the same as the bradykinin-potentiating peptides of the same venom (see last year's Report).

D. Toxins.—The diphtheria toxin from *Corynebacterium diphtheriae* is biosynthesized as a single polypeptide chain of m. wt. 62 000, but most preparations contain a 'nicked' species consisting of two fragments, A (m. wt. 24 000) and B (m. wt. 38 000), linked by a disulphide bridge.⁴³¹ The amino-acid sequence of viscotoxin B from the European mistletoe has been determined⁴³² (Figure 9).

However, most research has been concerned with snake toxins. Thus, the isolation of several neurotoxins with almost identical amino-acid

⁴²⁸ M. C. Chang, S. E. Leeman, and H. D. Niall, *Nature New Biol.*, 1971, **232**, 86.

⁴²⁹ A. Anastasi, V. Erspamer, and M. Bucci, *Experientia*, 1971, **27**, 166.

⁴³⁰ M. A. Ondetti, N. J. Williams, E. F. Sabo, J. Plušec, E. R. Weaver, and O. Kocy, *Biochemistry*, 1971, **10**, 4033.

⁴³¹ D. M. Gill and L. L. Dinius, *J. Biol. Chem.*, 1971, **246**, 1485; D. M. Gill and A. M. Pappenheimer, jun., *ibid.*, p. 1492; R. Drazin, J. Kandel, and R. J. Collier, *ibid.*, p. 1504.

⁴³² G. Samuelsson and B. M. Pettersson, *European J. Biochem.*, 1971, **21**, 86.

sequences of 71 residues from the Thailand cobra (*Naja naja Siamensis*) and the spectacled Indian cobra (*Naja naja naja*) has been described.⁴³³ The amino-acid sequence of the toxin A from *Naja naja*⁴³⁴ is shown in Figure 10. On the other hand, the principal neurotoxins of African cobras contain

```

Ile-Arg-Cys-Phe-Ile-Thr-Pro-Asp-Ile-Thr-Ser-Lys-Asp-Cys-Pro-Asn-Gly-His-
 1                               10
Val-Cys-Tyr-Thr-Lys-Thr-Trp-Cys-Asp-Gly-Phe-Cys-Ser-Ile-Arg-Gly-Lys-
 20                               30
Arg-Val-Asp-Leu-Gly-Cys-Ala-Ala-Thr-Cys-Pro-Thr-Val-Arg-Thr-Gly-Val-
 40                               50
Asp-Ile-Gln-Cys-Cys-Ser-Thr-Asp-Asp-Cys-Asp-Pro-Phe-Pro-Thr-Arg-Lys-
                               60
Arg-Pro
70

```

Figure 10 Amino-acid sequence of toxin A isolated from the venom of the Indian cobra *Naja naja*

61 residues, and two such toxins (β and δ) have been isolated from the South African Cape cobra, *Naja nivea*.⁴³⁵ Toxin δ has the same amino-acid sequence as toxin α of the cobra *Naja haje haje* and toxin β is closely similar. Toxin α from *Naja nivea*, however, has 71 residues^{435, 436} and the toxins α and β , though distinct, are homologous.⁴³⁶ Two further related toxins of 61 residues from the South African Ringhals cobra, *Haemachatus haemachatus*, have also been characterized.⁴³⁷ The amino-acid sequence of α -bungarotoxin from *Bungarus multicinctus* (Elapidæ snake), which contains 74 residues, is very similar to that of toxin α from *Naja nivea*.⁴³⁸ Crotoxin, a neurotoxin from the Brazilian rattlesnake, has been reported to contain two components.⁴³⁹

Toxins have also been isolated from the sea-snake, *Laticauda semifasciata*.^{440, 441a} The amino-acid sequences of two forms (62 residues) have been established and compared with those of cobra neurotoxins⁴⁴¹ (Figure 11). The proteins are obviously closely related and have the same arrangement of disulphide bridges (residues 3—24, 17—41, 43—54, and 55—60).^{441b} Another toxin (61 residues) has been isolated from Hardwick's sea-snake, *Lapernis hardwickii*.⁴⁴²

⁴³³ E. Karlsson, H. Arnberg, and D. Eaker, *European J. Biochem.*, 1971, **21**, 1.

⁴³⁴ K. Nakai, T. Sasaki, and K. Hayashi, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 893.

⁴³⁵ D. P. Botes, D. J. Strydom, C. G. Anderson, and P. A. Christensen, *J. Biol. Chem.*, 1971, **246**, 3132.

⁴³⁶ D. P. Botes, *J. Biol. Chem.*, 1971, **246**, 7383.

⁴³⁷ A. J. C. Strydom and D. P. Botes, *J. Biol. Chem.*, 1971, **246**, 1341.

⁴³⁸ D. Mebs, K. Narita, S. Iwanaga, Y. Samejima, and C. Y. Lee, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 711.

⁴³⁹ R. A. Hendon and H. Fraenkel-Conrat, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1560.

⁴⁴⁰ A.-T. Tu, B.-S. Hong, and T. N. Solie, *Biochemistry*, 1971, **10**, 1295.

⁴⁴¹ (a) S. Sato and N. Tamiya, *Biochem. J.*, 1971, **122**, 453; (b) Y. Endo, S. Sato, S. Ishii, and N. Tamiya, *ibid.*, p. 463.

⁴⁴² A.-T. Tu and B.-S. Hong, *J. Biol. Chem.*, 1971, **246**, 2772.

1. <i>Laticauda semifasciata</i>	Erabutoxin a	Arg-Ile	-Cys-Phe-Asn-Gln-His-Ser-Ser-Gln-Pro-Gln-Thr-	-Lys-Thr-Cys-Pro-Ser-Gly-
2. <i>Naja nigricollis</i>	Erabutoxin b	Arg-Ile	-Cys-Phe-Asn-Gln-His-Ser-Ser-Gln-Pro-Gln-Thr-	-Lys-Thr-Cys-Pro-Ser-Gly-
3. <i>Naja naja atra</i>	Toxin α	Leu-Glu-Cys-His-Asn-Gln-Gln-Ser-Ser-Gln-Pro-Thr-Thr-	-Lys-Thr-Cys-Pro-Gly-	
4. <i>Naja naja atra</i>	Cobrotoxin	Leu-Glu-Cys-His-Asn-Gln-Gln-Ser-Ser-Gln-Thr-Pro-Thr-	-Thr-Gly-Cys-Ser-Gly-Gly-	
5. <i>Naja haje haje</i>	Toxin α	Leu-Gln-Cys-His-Asn-Gln-Gln-Ser-Ser-Gln-Pro-Pro-Thr-	-Lys-Thr-Cys-Pro-Gly-	
		1	10	20
1. Ser	-Glu-Ser	-Cys-Tyr-Asn-Lys-Gln-Trp-Ser	-Asp-Phe-Arg-Gly-Thr-Ile	-Ile -Glu-Arg-Gly-Cys-Gly-Cys-Pro-Thr-Val-Lys-Pro-
2. Ser	-Glu-Ser	-Cys-Tyr-His-Lys-Gln-Trp-Ser	-Asp-Phe-Arg-Gly-Thr-Ile	-Ile -Glu-Arg-Gly-Cys-Gly-Cys-Pro-Thr-Val-Lys-Pro-
3. Glu	-Thr-Asn-Cys-Tyr-Lys-Lys-Val	-Trp-Arg-Asp-His-Arg-Gly-Thr-Ile	-Ile -Glu-Arg-Gly-Cys-Gly-Cys-Pro-Thr-Val-Lys-Pro-	
4. Glu	-Thr-Asn-Cys-Tyr-Lys-Lys-Arg	-Trp-Arg-Asp-His-Arg-Gly-Tyr-Arg-Thr	-Glu-Arg-Gly-Cys-Gly-Cys-Pro-Ser-Val-Lys-Asn-	
5. Glu	-Thr-Asn-Cys-Tyr-Lys-Lys-Arg	-Trp-Arg-Asp-His-Arg-Gly-Ser	-Ile -Thr-Glu-Arg-Gly-Cys-Gly-Cys-Pro-Ser-Val-Lys-Lys-	
		30	40	
1. Gly-Ile-Lys-Leu-Ser	-Cys-Cys-Glu-Ser	-Glu-Val	-Cys-Asn-Asn	
2. Gly-Ile-Lys-Leu-Ser	-Cys-Cys-Glu-Ser	-Glu-Val	-Cys-Asn-Asn	
3. Gly-Ile-Lys-Leu-Asn	-Cys-Cys-Thr-Thr-Asp-Lys	-Cys-Asn-Asn		
4. Gly-Ile-Glu-Ile	-Asn-Cys-Cys-Thr-Thr-Asp-Arg	-Cys-Asn-Asn		
5. Gly-Ile-Glu-Ile	-Asn-Cys-Cys-Thr-Thr-Asp-Lys	-Cys-Asn-Asn		
		50	60	

Figure 11 Comparison of the amino-acid sequences of sea-snake and cobra neurotoxins

Guanidination and nitroguanidination of the amino-groups of staphylococcal enterotoxin B have been reported to have little or no effect on the biological activity.⁴⁴³ Similarly, modification of the lysine or arginine residues of the toxins from *Laticauda semifasciata* causes no loss of toxicity⁴⁴⁰ but Lys-47 appears to be essential for the activity of cobrotoxin.⁴⁴⁴ On the other hand, six of the seven free carboxy-groups of cobrotoxin can be modified using a water-soluble carbodi-imide without effect on the biological activity, but modification of the seventh (that of Glu-21) causes a total loss of toxicity.^{444, 445} The toxicity of sea-snake venoms is also lost when the single tryptophan residue in each molecule is modified.^{440, 442} A study of the reaction of cobrotoxin with tetranitromethane indicates that Tyr-25 is normally 'buried' and essential for activity, whereas Tyr-35 is 'exposed' and inessential.⁴⁴⁶ This result is borne out by the fact that Tyr-25 has been conserved in all neurotoxins so far examined⁴⁴⁶ (see Figure 11).

E. Proteins of the Nervous System.—The eponymous review⁴⁴⁷ gives a good account of the proteins of myelin, in particular encephalitogenic basic protein. The amino-acid sequences of the proteins (170 residues) from ox⁴⁴⁸ and human⁴⁴⁹ myelin have now been published in detail but there are some discrepancies still between the results. It is worth noting that this is the first structural protein of membranes for which the sequence is known and that trypsin was reported to hydrolyse Lys-Pro and Arg-Pro bonds in the ox protein.⁴⁴⁸ As isolated, the protein contains no carbohydrate, but it can be glycosylated enzymically at the threonine residue in position 98.⁴⁴⁸ On the other hand, Arg-107 is present in methylated forms, both ω -*N*-monomethyl- and ω -*NN'*-dimethyl-arginine being detected,^{448, 450} and an enzyme from guinea-pig brain has been reported⁴⁵¹ to transfer methyl groups from *S*-adenosylmethionine specifically to Arg-107 in the basic protein. The biological significance remains uncertain. Other experiments⁴⁵² have also dealt with the enzymic methylation of arginine and lysine residues in brain (and liver) proteins, and the presence of citrulline in a protein fraction from normal human myelin has been reported.⁴⁵³ Presumably it also arises by modification of arginine *in situ*. A comparison

⁴⁴³ L. Spero, H. M. Jacoby, J. E. Daldidowicz, and S. J. Silverman, *Biochim. Biophys. Acta*, 1971, **251**, 345.

⁴⁴⁴ C. C. Chang, C. C. Yang, K. Nakai, and K. Hayashi, *Biochim. Biophys. Acta*, 1971, **251**, 334.

⁴⁴⁵ C. C. Chang, C. C. Yang, M. Kurobe, K. Nakai, and K. Hayashi, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 429.

⁴⁴⁶ C. C. Chang, C. C. Yang, K. Hamaguchi, K. Nakai, and K. Hayashi, *Biochim. Biophys. Acta*, 1971, **236**, 164.

⁴⁴⁷ E. M. Shooter and E. Roboz Einstein, *Ann. Rev. Biochem.*, 1971, **40**, 635.

⁴⁴⁸ E. H. Eylar, S. Brostoff, G. Hashim, J. Caccam, and P. Burnett, *J. Biol. Chem.*, 1971, **246**, 5770.

⁴⁴⁹ P. R. Carnegie, *Nature*, 1971, **229**, 25; P. R. Carnegie, *Biochem. J.*, 1971, **123**, 57.

⁴⁵⁰ G. S. Baldwin and P. R. Carnegie, *Biochem. J.*, 1971, **123**, 69.

⁴⁵¹ G. S. Baldwin and P. R. Carnegie, *Science*, 1971, **171**, 579.

⁴⁵² Y. Kakimoto, *Biochim. Biophys. Acta*, 1971, **243**, 31.

⁴⁵³ P. R. Finch, D. D. Wood, and M. A. Moscarello, *F.E.B.S. Letters*, 1971, **15**, 145.

with the published amino-acid sequence of ox myelin basic protein suggests⁴⁵⁴ that a protein isolated some time ago from pig hypothalamus⁴⁵⁵ is in fact the pig myelin basic protein.




Figure 12 Schematic representation of the amino-acid sequence of the primary subunit of nerve growth factor from mouse submaxillary glands (Reproduced by permission from *Proc. Nat. Sci. U.S.A.*, 1971, **68**, 2417)

Peptic digestion can be used to produce a 46-residue fragment (residues 44—89) from the ox myelin basic protein that retains the ability to induce experimental allergic encephalomyelitis in rabbits.^{456, 457} The amino-acid sequences of the corresponding fragments from the guinea-pig, rabbit, monkey, and human proteins are very similar.⁴⁵⁷ The single tryptophan residue of the ox and human proteins can be oxidized to the oxindole derivative by treatment with a bromine adduct of 2-(2-nitrophenylsulfenyl)-3-methylindole.⁴⁵⁸ No loss of biological activity accompanies the modification. Under stronger conditions, the tryptophyl peptide bond is

⁴⁵⁴ R. E. Martenson, G. E. Deibler, and M. W. Kies, *Nature New Biol.*, 1971, **234**, 87.

⁴⁵⁵ B. Shome and M. Saffran, *J. Neurochem.*, 1966, **13**, 433.

⁴⁵⁶ E. H. Eylar, F. C. Westall, and S. Brostoff, *J. Biol. Chem.*, 1971, **246**, 3418.

⁴⁵⁷ R. Shapira, S. S. McKneally, F. Chou, and R. F. Kibler, *J. Biol. Chem.*, 1971, **246**, 4630.

cleaved, and only the N-terminal fragment (116 residues) of the protein retains antigenic determinants.⁴⁵⁸

The amino-acid sequence of nerve growth factor from mouse submaxillary gland has been determined⁴⁵⁹ (Figure 12).

5 Enzymes

The Proceedings of the 1971 Cold Spring Harbor Symposium on 'Structure and Function of Proteins at the Three-dimensional Level',⁴⁶⁰ is an excellent collection of articles dealing with proteins whose structure is being, or has been, studied by X-ray crystallography. A readable review⁴⁶¹ surveys structure and function in several well-characterized proteins and another⁴⁶² is concerned with the function of amino-acid side-chains in proteins, particularly the serine side-chain in its various manifestations, e.g. as a carrier for phosphate or for phosphopantetheine, or as a reactive nucleophile in the serine proteases, etc.

A. Proteolytic Enzymes.—An excellent volume⁴⁶³ deals with structure, mechanism, formation by activation, and inhibition of all the proteases. Another,⁴⁶⁴ equally comprehensive and equally warmly recommended, has a different emphasis and is concerned with preparation, methods of assay, etc. of proteases and their naturally occurring inhibitors. A sensitive radioisotopic assay has been suggested⁴⁶⁵ as an improvement over the usual haemoglobin and casein methods of assaying proteases; the substrate is haemoglobin completely labelled at carboxy-groups by coupling with radioactive methyl glycinate, and the release of radioactivity is measured.

Carboxypeptidases. A complete picture of carboxypeptidase A as 'a protein and an enzyme' has been presented in a recent review⁴⁶⁶ and full details have been published⁴⁶⁷ of the determination of the primary structure reported last year. Residue 151, shown as tryptophan in the X-ray structure,⁴⁶⁸ is confirmed as phenylalanine, and a correction is noted:⁴⁶⁹ the amidated glutamic acid residue is Glu-31 not Glu-28. Details have also been given⁴⁷⁰ of the stoichiometric inactivation of carboxypeptidase A

⁴⁵⁸ P. R. Burnett and E. H. Eylar, *J. Biol. Chem.*, 1971, **246**, 3425.

⁴⁵⁹ R. H. Angeletti and R. A. Bradshaw, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2417.

⁴⁶⁰ Cold Spring Harbor Symposium on Quantitative Biology, 1972, vol. 36.

⁴⁶¹ G. P. Hess and J. A. Rupley, *Ann. Rev. Biochem.*, 1971, **40**, 1013.

⁴⁶² J. Matheja and E. T. Degens, *Adv. Enzymol.*, 1971, **34**, 1.

⁴⁶³ 'The Enzymes', ed. P. D. Boyer, Academic Press, N.Y. and London, 3rd edition, 1971, vol. 3.

⁴⁶⁴ *Methods Enzymology*, 1970, vol. 19.

⁴⁶⁵ H. R. Williams and T.-Y. Lin, *Biochim. Biophys. Acta*, 1971, **250**, 603.

⁴⁶⁶ F. A. Quiocho and W. N. Lipscomb, *Adv. Protein Chem.*, 1971, **25**, 1.

⁴⁶⁷ R. A. Bradshaw, K. A. Walsh, and H. Neurath, *Biochemistry*, 1971, **10**, 938, 951, 961.


⁴⁶⁸ W. N. Lipscomb, J. A. Hartsuck, F. A. Quiocho, and G. N. Reeke, jun., *Proc. Nat. Acad. Sci. U.S.A.*, 1969, **64**, 28.

⁴⁶⁹ P. H. Pétra, M. A. Hermodson, K. A. Walsh, and H. Neurath, *Biochemistry*, 1971, **10**, 4023.

⁴⁷⁰ (a) P. H. Pétra, *Biochemistry*, 1971, **10**, 3163; (b) P. H. Pétra and H. Neurath, *ibid.*, p. 3171.

with *N*-ethyl-5-phenylisoxazolium 3'-sulphonate (Woodward's Reagent K) by reaction with Glu-270 at the active site, and carboxy-groups are also implicated⁴⁷¹ at the active site of carboxypeptidase B. Thus affinity labelling with *N*-bromoacetyl-D-[5-¹⁴C]arginine at pH 7 was consistent with reaction at a carboxy-group, but not one involved directly in catalysis since treatment of the labelled inactive enzyme with hydroxylamine gave partial reactivation with incorporation of one equivalent of hydroxamate.

Bovine carboxypeptidase A prepared in different ways contains different proportions of three equally active forms (α , β , and γ), and it is pointed out⁴⁶⁹ that this may be an important variable in structural and functional studies. Differences in the N-terminal regions of the three forms were conveniently demonstrated using the sequenator:



Not all laboratories prepare their enzyme in the same way, and it is a little distressing that the amount of β -form in different preparations can vary from 25% to 70%. An improved preparation of the β -form has been described.⁴⁷² Although the three forms are equally active, differences clearly exist since, for instance, affinity-labelling of carboxypeptidase A_γ with *N*-bromoacetyl-*N*-methyl-L-phenylalanine caused alkylation of Asn-8 (the N-terminal residue) and His-13 (without loss of activity) in addition to the reaction at Glu-270 which resulted in inactivation.⁴⁷³ The reaction of 2-hydroxy-5-nitrobenzyl bromide with the amino-terminus of carboxypeptidase A_γ (rather than with tryptophan⁴⁷⁴) may be recalled (see last year's Report). However, other workers, using carboxypeptidase similarly prepared, have reported⁴⁷⁵ that tryptophan is modified with a related but water-soluble reagent, dimethyl-(2-hydroxy-5-nitrobenzyl)sulphonium chloride, without reaction at the amino-terminus; they attribute the earlier results to unfolding caused by addition of the reagent in solution in acetone.

Activation of bovine procarboxypeptidase has been studied⁴⁷⁶ using the arsanilazo chromophore as a probe of environmental changes, and differences between the conformation of arsanilazotyrosine-248 in the crystalline state and in solution have led to the suggestion⁴⁷⁷ that 'speculations on the catalytic mechanism based on crystal structure studies alone may require some re-examination', since Tyr-248 has been ascribed the role of proton donor in the catalytic mechanism. The same chromophore has revealed conformational and activity changes when carboxypeptidase is cleaved with

⁴⁷¹ T. H. Plummer, jun., *J. Biol. Chem.*, 1971, **246**, 2930.

⁴⁷² G. R. Reeck, K. A. Walsh, and H. Neurath, *Biochemistry*, 1971, **10**, 4690.

⁴⁷³ G. M. Hass and H. Neurath, *Biochemistry*, 1971, **10**, 3535, 3541.

⁴⁷⁴ T. M. Radhakrishnan, R. A. Bradshaw, D. A. Deranleu, and H. Neurath, *F.E.B.S. Letters*, 1970, **7**, 72.

⁴⁷⁵ V. R. Naik and H. R. Horton, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 44.

⁴⁷⁶ W. D. Behnke and B. L. Vallee, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 760.

⁴⁷⁷ J. T. Johansen and B. L. Vallee, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2532.

subtilisin.⁴⁷⁸ Substrate binding has been studied⁴⁷⁹ by quenching of fluorescence.

The three forms of carboxypeptidase B from activated pancreatic juice have been characterized:⁴⁷² the minor form (10%) is a single chain and probably the initial activation product; the two main forms are two-chain proteins which have undergone further splits at the His-95–Met-96 and Arg-92–Glu-93 bonds respectively. Taking advantage of these additional specific cleavages and the availability of a sequenator, comparison of the sequence of carboxypeptidase B with that of carboxypeptidase A was extended by an additional 51 residues,⁴⁸⁰ supporting further the hypothesis that they are homologous proteins. Isoleucine at position 255 in carboxypeptidase A is replaced by aspartic acid in the B form, but this may not be the anomaly it seems at first sight since the aspartic acid residue is suitably located in the three-dimensional structure (based on carboxypeptidase A) to provide the negative charge in the binding site of carboxypeptidase B.⁴⁸⁰ Purification of bovine carboxypeptidase B by affinity chromatography (Section 2E) with D-Ala-L-Arg as ligand gave a product that was free of carboxypeptidase A but still hydrolysed synthetic substrates of the A form,²²⁴ and an enzyme from orange leaves with the combined specificities of carboxypeptidase A and B has already been mentioned.⁹¹ Four forms of human pancreatic procarboxypeptidase A have recently been demonstrated⁴⁸¹ by isoelectric focusing. The first naturally occurring inhibitor of carboxypeptidase A to be described is the carboxypeptidase B inhibitor (m. wt. ca. 3500) from potatoes; combination with the A and B enzymes is mutually exclusive.⁴⁸²

Serine Proteases and Their Inhibitors. Two useful source books^{483, 484} dealing with all aspects of serine proteases have already been mentioned. Sensitive fluorimetric assays for chymotrypsin using *N*-benzyloxycarbonyl-L-phenylalanine β -naphthyl ester⁴⁸³ and 4-methylumbelliferyl *p*-trimethylammoniumcinnamate chloride,⁴⁸⁴ and a spectrophotometric assay using 4-phenylazobenzoyloxycarbonyl-L-Pro-L-Phe-Gly-D-Arg⁴⁸⁵ have been described. Trypsin and thrombin can be assayed spectrofluorimetrically with 4-methylumbelliferyl *p*-guanidinobenzoate hydrochloride,⁴⁸⁴ an analogue of the *p*-nitrophenyl ester commonly used for spectrophotometric assay of the enzymes.

Certain aspects of the mechanism of action of chymotrypsin and trypsin are being questioned. A kinetic study of the catalytic activity of trypsin

⁴⁷⁸ J. F. Riordan and D. M. Livingston, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 695.

⁴⁷⁹ N. Lasser and J. Feitelson, *Biochemistry*, 1971, **10**, 307.

⁴⁸⁰ G. R. Reeck, K. A. Walsh, M. A. Hermodson, and H. Neurath, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1226.

⁴⁸¹ W. J. Kim and T. T. White, *Biochim. Biophys. Acta*, 1971, **242**, 441.

⁴⁸² C. A. Ryan, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 1265.

⁴⁸³ E. Haas, Y. Elkana, and R. G. Kulka, *Analyt. Biochem.*, 1971, **40**, 218.

⁴⁸⁴ D. V. Roberts, R. W. Adams, D. T. Elmore, G. W. Jameson, and W. S. A. Kyle, *Biochem. J.*, 1971, **123**, 41P.

acylated at the active serine with a variety of different carboxy- and dialkyl-phosphoryl radicals led to the suggestion⁴⁸⁶ that the acyl enzyme pathway is not the only one for the hydrolysis of amide and peptide bonds. This, however, is refuted⁴⁸⁷ by others who block the active serine of chymotrypsin by carbamylation (*i.e.* with a small polar group, stable to deacylation) and interpret the exactly parallel loss of esterase and amidase activity as evidence that all substrates of serine proteases are hydrolysed *via* an acyl enzyme intermediate. The question of the role of Ile-16 in the catalytic mechanism of α -chymotrypsin is not being settled quite as easily. It will be recalled that the X-ray crystallographic work showed that the N-terminal residue Ile-16 forms a salt bridge with Asp-194, thereby maintaining the conformation of the active site, and that the commonly accepted mechanism of α -chymotrypsin action identifies the kinetically important group of pK 9 as Ile-16.⁴⁸⁸ A study⁴⁸⁹ of the reactivity of Ile-16 by the method of competitive labelling with very small amounts of radioactive acetic anhydride (see Section 9) shows that the N-terminus is freely accessible only above pH 9.8, and supports the role of Ile-16 in controlling activity and conformation. On the other hand, retention both of activity and the normal bell-shaped pH-dependence curve when Ile-16 in α -chymotrypsin is hydroxymethylated with formaldehyde,^{490a} or when the δ -form is amidinated with either ethyl acetimidate or methyl picolinimide,⁴⁹¹ as well as retention of activity even after succinylation of the α -amino-group of Ile-16 in δ -chymotrypsin⁴⁹² have been taken as evidence that Ile-16 is neither essential for activity nor is it the group of pK 9.3 that gives rise to the alkaline limb of the bell-shaped pH-dependence curve. A comparison of α -, α_1 -, and δ -chymotrypsins has led to the suggestion⁴⁹³ that the ionizable group determining the behaviour of α -chymotrypsins at high pH (*i.e.* whose deprotonation leads to disruption of the binding site) is in fact Ala-149, which is the N-terminus of the C-chain in α -chymotrypsin. Ala-149 is bound in peptide linkage in δ -chymotrypsin, in which the C-chain is not cleaved, and in α_1 -chymotrypsin the N-terminus of the C-chain is Thr-147. Some support for this comes from the competitive labelling studies⁴⁸⁹ which suggest that after deprotonation of Ile-16 (*i.e.* above pH 9.8) a further structural change is dependent on Ala-149. These observations would explain why the pH dependence of the N-terminal group in δ -chymotrypsin does not follow the alkaline

⁴⁸⁵ E. Wünsch, A. Högel-Betz, and E. Jaeger, *Z. physiol. Chem.*, 1971, **352**, 1553.

⁴⁸⁶ S. E. Bresler, V. M. Krutyakov, and G. P. Vlasov, *European J. Biochem.*, 1971, **18**, 131.

⁴⁸⁷ C. E. Stauffer, *F.E.B.S. Letters*, 1971, **16**, 45.

⁴⁸⁸ H. L. Oppenheimer, B. Labouesse, and G. P. Hess, *J. Biol. Chem.*, 1966, **241**, 2720.

⁴⁸⁹ H. Kaplan, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 1042.

⁴⁹⁰ (a) M. A. Marini and C. J. Martin, *European J. Biochem.*, 1971, **19**, 162; (b) M. A. Marini and C. J. Martin, *ibid.*, p. 153.

⁴⁹¹ S. P. Agarwal, C. J. Martin, T. T. Blair, and M. A. Marini, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 510.

⁴⁹² T. T. Blair, M. A. Marini, S. P. Agarwal, and C. J. Martin, *F.E.B.S. Letters*, 1971, **14**, 86.

⁴⁹³ P. Valenzuela and M. L. Bender, *J. Amer. Chem. Soc.*, 1971, **93**, 3783.

activity curve, and support the idea that the internal split in α -chymotrypsin, releasing Ala-149 as the N-terminal residue of the C-chain, increases the disruptive effect of the deprotonation of Ile-16. Chemical modification of Ile-16 in δ -chymotrypsin⁴⁸⁴ is consistent with an appreciable conformational change on binding to the substrate and with the existence of a salt bridge between Ile-16 and Asp-194 in solution, and other studies⁴⁹⁵ on α -chymotrypsin demonstrate an ionic-strength-dependent equilibrium between exposed (at low ionic strength) and buried states of Ile-16 at pH 4. A detailed kinetic study⁴⁹⁶ of α -chymotrypsin demonstrates two conformational states at neutral pH – the normal active form and as much as 15–20% of an inactive form which is the major form above pH 9. There is a slow interconversion of the two forms, and the authors call for caution in interpreting kinetic results. They give the pK of Ile-16 in the inactive form as 7.94, an indication that the N-terminus is exposed.

The role of His-57 in the catalytic mechanism has also been explored further. α -Chymotrypsin methylated selectively at His-57 with methyl *p*-nitrobenzenesulphonate (see last year's Report) showed⁴⁹⁷ unimpaired substrate binding, but the rate of acylation and of deacylation were much slower, although still dependent on a group of pK_a 7. It is thus suggested that 3-MeHis-57 acts as a general base on the hydroxy-group of Ser-195 in the acylation, and that deacylation occurs by a similar mechanism; the poor hydrogen-bond between N-1 of 3-MeHis-57 and the serine side-chain presumably accounts for the decreased rate. If this is correct then there can be no hydrogen-bond between Asp-102 and 3-MeHis-57 during catalysis, and on this basis the contribution of Asp-102 to the rate enhancement in the native enzyme is estimated⁴⁹⁷ as, at most, 5×10^3 . A similar explanation might account for the retention of (impaired) activity when the histidine residues are hydroxymethylated with formaldehyde.^{498b, 498}

While the details of the actual catalytic mechanism are being sorted out, work continues on elucidation of the nature of the substrate-binding site. Crystallographic studies⁴⁹⁹ of bovine chymotrypsin A_z inhibited with a series of specific active-site-directed peptide chloromethyl ketones confirmed the nature of the specific aromatic binding site (subsite S_1) and identified subsites S_2 and S_3 ; it was held to be unlikely that any more than three residues on the N-terminal side of the bond cleaved in the substrate would be recognized. Two investigations have compared the dimensions of the binding sites of elastase and chymotrypsin in solution, using in one case⁵⁰⁰

⁴⁸⁴ P. Valenzuela and M. L. Bender, *Biochim. Biophys. Acta*, 1971, **235**, 411.

⁴⁸⁵ A. Kurosky, J. E. S. Graham, J. W. Dixon, and T. Hofmann, *Canad. J. Biochem.*, 1971, **49**, 529.

⁴⁸⁶ A. R. Fersht and Y. Requena, *J. Mol. Biol.*, 1971, **60**, 279.

⁴⁸⁷ R. Henderson, *Biochem. J.*, 1971, **124**, 13.



⁴⁸⁸ P. Dunlop, M. A. Marini, and C. J. Martin, *Biochim. Biophys. Acta*, 1971, **243**, 320; C. J. Martin, N. B. Oza, and M. A. Marini, *European J. Biochem.*, 1971, **20**, 276.

⁴⁸⁹ D. M. Segal, J. C. Powers, G. H. Cohen, D. R. Davies, and P. E. Wilcox, *Biochemistry*, 1971, **10**, 3728.

⁵⁰⁰ T. H. Marshall and A. Akgün, *J. Biol. Chem.*, 1971, **246**, 6019.

fatty acid nitrophenyl esters of different chain length, and in the other ⁵⁰¹ a series of homologous alkyl isocyanates. The results, which indicate a small binding cavity in elastase, and a larger one in chymotrypsin capable of accommodating bulky side-chains, are in accord with the picture given by X-ray crystallography.

Cetyldimethylbenzylammonium chloride (6) inhibition appears to be another test for a serine protease.⁵⁰² At acid pH it inhibits chymotrypsin, trypsin, and elastase as well as aspergillopeptidase B and subtilisin, but does not inhibit non-serine proteases. Binding to trypsin is reversible but binding cannot be reversed in the case of chymotrypsin, presumably because the benzene ring binds tightly in the substrate-binding pocket. Inhibition of serine proteinases that differ widely in amino-acid sequence suggests a common element in the environment of the active site; the common charge-relay catalytic mechanism is already accepted as one such feature. A new inhibitor of elastase has been described;⁵⁰³ the site of the inhibition by 1-bromo-4-(2,4-dinitrophenyl)butan-2-one (7) has been tentatively



identified as Glu-6. The inhibitor is not a substrate analogue and there is no glutamic acid either at, or near, the active site as shown by the X-ray model. The dinitrophenyl group was found to be essential for inhibition, leading to the speculation that the inhibitor binds to the enzyme at a site involved in binding desmosine or isodesmosine residues of elastin *in vivo*.⁵⁰³ The reaction between chymotrypsin and phenylalanine chloro(or bromo)methyl ketones, or N-substituted derivatives of these, resulted in alkylation of His-57 in each case indicating that the inhibitors were similarly positioned.⁵⁰⁴ Photoaffinity labelling is a powerful method of mapping the active sites of enzymes. Its advantages are specificity in the placement of the label and almost complete non-specificity in the side-chains which the reactive radical generated on activation can attack. A product of photolysis of diazo[¹⁴C]acetylchymotrypsin, identified ⁵⁰⁵ after hydrolysis as O-carboxymethyl-Tyr-146 (the C-terminal residue of the B chain), is thought to result from intermolecular reaction within a chymotrypsin dimer, by reaction of the carbene generated at diazoacetyl-Ser-195 in one molecule with Tyr-146 in the other. Photolysis of ethyl diazomalonyltrypsin and chymotrypsin,

⁵⁰¹ W. E. Brown and F. Wold, *Science*, 1971, 174, 608.

⁵⁰² E. Feldbau and C. Schwabe, *Biochemistry*, 1971, 11, 2131.

⁵⁰³ L. Visser, D. S. Sigman, and E. R. Blout, *Biochemistry*, 1971, 10, 735.

⁵⁰⁴ E. Shaw and J. Ruscica, *Arch. Biochem. Biophys.*, 1971, 145, 484.

⁵⁰⁵ C. S. Hexter and F. H. Westheimer, *J. Biol. Chem.*, 1971, 246, 3928.

however, gave *S*-carboxymethylcysteine as the main product after hydrolysis, indicating⁵⁰⁶ that the carbene had cleaved a disulphide bond, tentatively identified as the disulphide that maintains the 'histidine loop'.

A new species of chymotrypsin, K-chymotrypsin, has been isolated from activation of bovine chymotrypsinogen A and introduced into the generally accepted activation scheme between δ - and γ -chymotrypsin on the fast activation pathway.⁵⁰⁷ Chymotrypsin C from autolysed pig pancreas was shown⁵⁰⁸ to differ from the π -form only by loss of the four C-terminal residues of the A chain; unlike the initial cleavage products of chymotrypsinogens A and B it shows no susceptibility to further proteolytic attack. Chymotrypsin-P, generated by papain activation of chymotrypsinogen A, is identical with α -chymotrypsin except that it is three residues shorter at the C-terminus of the A-chain.⁵⁰⁹ The second major chymotrypsin (chymotrypsin II), isolated from human pancreas,⁵¹⁰ has only two chains, like bovine δ -chymotrypsin; it is not clear whether chymotrypsins I and II arise from the same or different zymogens. With zymogen granules, rather than the usual pancreatic juice as starting material, chymotrypsinogens, trypsinogens, and procarboxypeptidases have been isolated from chick pancreas.⁵¹¹

Lungfish and dogfish, cows and camels, deer and goats . . . not Noah's guest list but some of the species for whose trypsinogens amino-acid sequence information has recently become available. The sequenator has yielded the first 20 amino-acid residues of bovine, lungfish, and dogfish trypsinogens⁵¹² and shown them to be highly homologous (residues in brackets are tentative assignments):

	1	5	↓	10	
Bovine	Val	Asp	Asp	Asp	Asp-Lys-Ile-Val-Gly-Gly-Tyr-Thr-Cys -Gly-
Dogfish	Ala	Pro	Asp	Asp	Asp-Lys-Ile-Val-Gly-Gly-Tyr-Glu-Cys -Pro-
Lungfish	Phe	Pro	Ile	-Glu-Glu-Asp-Lys-Ile-Val-Gly-Gly-Try	Glu-(Cys)-Pro-
	15	20			
Bovine	Ala	Asn-Thr	-Val	Pro	Tyr-
Dogfish	Lys	His	-Ala	Pro	Trp-
Lungfish	Lys	His	-(Thr)-Val	Pro	Trp-

The activation point is the Lys-6-Ile-7 bond: the five N-terminal residues of the resulting trypsin are identical. It is interesting that the usual activation sequence X-(Asp)₄-Lys-Ile- is replaced in lungfish trypsinogen by X-Ile-Glu-Glu-Asp-Lys-Ile-; presumably conservation of three negative charges is crucial for the activation. Dromedary⁵¹³ and goat⁵¹⁴ trypsinogens have

⁵⁰⁶ C. S. Hexter and F. H. Westheimer, *J. Biol. Chem.*, 1971, **246**, 3934.

⁵⁰⁷ D. D. Miller, T. A. Horbett, and D. C. Teller, *Biochemistry*, 1971, **10**, 4641.

⁵⁰⁸ D. Gratecos and P. Desnuelle, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 857.

⁵⁰⁹ M. C. Shaw and T. Viswanatha, *Canad. J. Biochem.*, 1971, **49**, 999.

⁵¹⁰ M. H. Coan, R. C. Roberts, and J. Travis, *Biochemistry*, 1971, **10**, 2711.

⁵¹¹ R. Zelikson, G. Eilam-Rubin, and R. G. Kulka, *J. Biol. Chem.*, 1971, **246**, 6115.

⁵¹² M. A. Hermodson, R. W. Tye, G. R. Reeck, H. Neurath, and K. A. Walsh, *F.E.B.S. Letters*, 1971, **14**, 222.

⁵¹³ S. Bricteux-Grégoire, R. Schyns, and M. Florkin, *Biochim. Biophys. Acta*, 1971, **251**, 79.

⁵¹⁴ S. Bricteux-Grégoire, R. Schyns, and M. Florkin, *Biochim. Biophys. Acta*, 1971, **229**, 123.

the normal activation sequence and the activation peptides (apparently two in the case of the goat zymogen) have the sequences:

<i>Camelus dromedarius</i>	Val-Pro-Ile -Asp-Asp-Asp-Asp-Lys-
Goat	Phe-Pro-Val-Asp-Asp-Asp-Asp-Lys-
and	Val-Asp-Asp-Asp-Asp-Lys-

The action of enterokinase on trypsinogen is that of a very restricted trypsin (*cf.* the action of thrombin on fibrinogen, Section 2D). Enterokinase, which has recently been purified⁵¹⁵ and which is specific for native trypsinogen, shows subsite specificity and recognizes the whole of the $-(\text{Asp})_4\text{-Lys-}$ structure. It is found in the duodenum; although its K_m for trypsinogen is six times larger than that of trypsin, its V_{\max} is 2000 times larger, and it may thus be the trigger for activation, producing the initial molecules of trypsin for autocatalysis to take over, conveniently away from the pancreas. Another study⁵¹⁶ of the autoactivation of trypsinogen suggests that the zymogen has an inherent proteolytic activity which allows it to activate itself; since it cannot have an active site maintained by Ile-16, it is suggested⁵¹⁶ that the active site is formed in a dimer using Ser-183 of one molecule and His-46 of the other. The familiar trypsinogen is cationic. Anionic trypsinogens recently purified from pig⁵¹⁷ and bovine⁵¹⁸ pancreas give rise to trypsins with catalytic and inhibition properties similar to those of normal cationic trypsin, and an anionic trypsin-like enzyme has also been purified from *Streptomyces erythreus*.⁵¹⁹ The zymogen of the trypsin-like enzyme cocoonase, from the silk moth, has been characterized;⁵²⁰ it has a molecular weight of *ca.* 30 000, and *ca.* 20% of the molecule is removed in the activation process, whereas only six residues are lost when trypsinogen is activated. The immunochemical cross-reactivity that exists between trypsin and cocoonase is not present in the zymogens, suggesting perhaps that activation peptides are not subject to the stringent selection pressures that operate on catalytic chains.⁵²⁰ It will thus be interesting to see whether the $-(\text{Asp})_4\text{-Lys-}$ sequence is conserved in the acidic fragment removed on activation of prococoonase.

There are many ways of probing the conformational changes that accompany zymogen activation. Two disulphide bonds are readily reduced in trypsinogen but are buried in trypsin,⁵²¹ and the tetracarboxymethylated zymogen can be activated to give the expected yield of active sites, showing that the reducible disulphides are not essential structural elements.⁵²¹ Selective reduction of only one disulphide (179—203) and carboxymethylation gave on activation carboxymethyltrypsin of impaired catalytic efficiency, probably a consequence of a slightly distorted conformation in the

⁵¹⁵ S. Maroux, J. Baratti, and P. Desnuelle, *J. Biol. Chem.*, 1971, **246**, 5031.

⁵¹⁶ J. Kay and B. Kassell, *J. Biol. Chem.*, 1971, **246**, 6661.

⁵¹⁷ P. Voytek and E. C. Gjessing, *J. Biol. Chem.*, 1971, **246**, 508.

⁵¹⁸ A. Puigserver and P. Desnuelle, *Biochim. Biophys. Acta*, 1971, **236**, 499.





⁵¹⁹ N. Yoshida, A. Sasaki, and H. Inoue, *F.E.B.S. Letters*, 1971, **15**, 129.

⁵²⁰ E. Berger, F. C. Kafatos, R. L. Felsted, and J. H. Law, *J. Biol. Chem.*, 1971, **246**, 4131.

⁵²¹ D. L. Sondack and A. Light, *J. Biol. Chem.*, 1971, **246**, 1630.

modified trypsin, since the (carboxymethylated) disulphide bond can no longer become buried in the usual way.⁵²² The fate of tyrosine and tryptophan residues on activation of trypsinogen has been studied by solvent perturbation methods,⁵²³ and fluorescent probes have also been exploited. Conformational changes on activation have been revealed using non-covalently bound 7-(*p*-methoxybenzylamino)-4-nitrobenzoxadiazole,⁵²⁴ and the dansyl group has been covalently bound⁵²⁵ (by reaction at pH 5) to a ring amino-group which had been introduced by specific nitration and reduction of Tyr-137. Trypsin dansylated under normal conditions⁵²⁶ shows increased activity towards *N*-benzoyl-L-arginine *p*-nitroanilide but not the ethyl ester, suggesting more efficient binding rather than enhanced catalysis.

Several investigations have been concerned with the active centre of trypsin. Full details have now been given⁵²⁷ of the modification of Asp-177 in the active centre using a water-soluble carbodi-imide to couple it to glycinamide. The active-site-directed phenacyl halides *p*-amidinophenacyl bromide (8) and *p*-guanidinophenacyl bromide (9) inactivate trypsin irreversibly,⁵²⁸ and in the case of (9) this is attributed to formation of an ether link with the active serine, Ser-183. It will be recalled that the active-site-directed tosyl-lysine chloromethyl ketone (TLCK) alkylated His-46 at the active centre, indicating (not surprisingly) small differences in the geometry of binding of the two reagents. From the same laboratory comes the elegant approach⁵²⁹ of acylating the active site with a group which is only very slowly deacylated and which also carries a functional group potentially able to cross-link to some reactive group in the vicinity. The compound chosen was the isothiuronium derivative (10) of a compound related to the active-site titrant *p*-nitrophenyl *p*'-guanidinobenzoate (11; R = *p*-nitro-



⁵²² L. M. Hatfield, S. K. Banerjee, and A. Light, *J. Biol. Chem.*, 1971, **246**, 6303.

⁵²³ G. B. Villanueva and T. T. Herskovits, *Biochemistry*, 1971, **10**, 3358.

⁵²⁴ R. A. Kenner and A. A. Aboderin, *Biochemistry*, 1971, **10**, 4433.

⁵²⁵ R. A. Kenner and H. Neurath, *Biochemistry*, 1971, **10**, 551.

⁵²⁶ J. G. Franklin and J. Leslie, *Canad. J. Biochem.*, 1971, **49**, 516.


⁵²⁷ A. W. Eyl, jun., and T. Inagami, *J. Biol. Chem.*, 1971, **246**, 738.

⁵²⁸ D. D. Schroeder and E. Shaw, *Arch. Biochem. Biophys.*, 1971, **142**, 340.

⁵²⁹ P. Bodlaender and E. Shaw, *Arch. Biochem. Biophys.*, 1971, **147**, 810.

phenyl) (see last year's Report), and it was hoped that the positively charged isothiuronium group would modify a carboxy-group, particularly Asp-177 at the specificity site. Unfortunately this did not occur; covalent bonds were, however, formed when methyl mercaptide was eliminated with mercuric chloride, but the positions of these have not been identified. In another approach⁵³⁰ to mapping the environment of the active centre it was found that the *trans*-isomer of a photochromic substrate for trypsin, *p*-phenylazobenzoyl-L-Arg-OMe, could be accommodated more easily at the active site than the bulky *cis*-analogue.

The stages involved in the formation of bovine thrombin from prothrombin have been closely examined.⁵³¹ The picture which has emerged is as follows:



The chains in all three forms (a, b, and c) are disulphide-linked. All three forms have the same activity towards small substrates but the clotting activities differ ($a > b > c$). It thus appears fairly certain that the forms having molecular weight 28 000, found in commercial thrombin, are not artefacts but normal prothrombin activation products. The site of the final cleavage to give the three-chain form has been identified⁵³² as either Arg-73 or Arg-76. Traces of thrombin are apparently required for prothrombin activation in a step that follows a structural change in the zymogen.⁵³³ Inhibition of thrombin by phenylmethylsulphonyl fluoride occurs at, or near, the active site,⁵³⁴ and resembles inhibition with di-isopropyl fluorophosphate, suggesting once again that thrombin shares the catalytic mechanism of the serine proteases. It is also inhibited by TLCK and by *p*-nitrobenzyloxycarbonylarginine chloromethyl ketone, and the site of alkylation has now been identified⁵³² as His-43 in the B-chain, which the partial sequence for thrombin⁵³⁵ shows to be homologous with His-57 of chymotrypsin. The purification of human thrombin has been reported⁵³⁶ and several active species of the human enzyme with different molecular

⁵³⁰ M. A. Wainberg and B. F. Erlanger, *Biochemistry*, 1971, **10**, 3816.

⁵³¹ K. G. Mann, C. M. Heldebrandt, and D. N. Fass, *J. Biol. Chem.*, 1971, **246**, 5994, 6106.

⁵³² G. Glover and E. Shaw, *J. Biol. Chem.*, 1971, **246**, 4594.

⁵³³ I. P. Baskova, S. M. Strukova, and A. Uriarte, *Biochemistry (U.S.S.R.)*, 1970, **35**, 670.

⁵³⁴ R. L. Lundblad, *Biochemistry*, 1971, **10**, 2501.

⁵³⁵ S. Magnusson, 'Structural Aspects of Thrombin and Prothrombin: Structure-Function Relationships of Proteolytic Enzymes', ed. P. Desnuelle, H. Neurath, and M. Otteson, Munksgaard, Copenhagen, 1970, p. 138.

⁵³⁶ J. W. Fenton, W. P. Campbell, J. C. Harrington, and K. D. Miller, *Biochim. Biophys. Acta*, 1971, **229**, 26.

weights have been found;⁵³⁷ how this fits in with the report of glutamic acid as the (sole) C-terminal residue of human thrombin⁵³⁸ remains to be seen. A thrombin-like enzyme which acts on fibrinogen and which is inhibited by DFP and TLCK has been purified⁵³⁹ from the venom of the Eastern Diamond rattlesnake *Crotalus adamanteus*; it has a single chain and molecular weight 32 000. The specificity of thrombin action on fibrinogen has already been mentioned in the context of chain cleavage (Section 2D). Thrombin brings about the formation of blood clots and plasmin their solubilization; human plasminogen free from plasmin has been prepared by affinity chromatography²³¹ and has N-terminal glutamic acid. The S-carboxymethylated heavy chains of human plasmin have been characterized⁵⁴⁰ (m. wt. 48 000) and have C-terminal arginine. Preliminary work⁵⁴¹ on pig pancreatic kallikrein suggests that it may resemble the other pancreatic serine proteinases in having an -Asp-Ser-Gly- sequence at its active site.

The proceedings⁵⁴² of an international meeting on inhibitors of proteolytic enzymes, recently published, are evidence of considerable activity in this field. The other standard works of reference^{463, 464} have already been noted. The small size and the single-chain nature of the naturally occurring inhibitors would seem to make them suitable systems on which to study many aspects of protein structure and synthesis.

Bovine pancreatic tissue contains two inhibitors of trypsin: the basic (Kunitz) inhibitor, of known primary and tertiary⁵⁴³ structure and which has recently been synthesized (58 residues) by the solid-phase method,⁵⁴⁴ and the Kazal inhibitor (56 residues), also of known amino-acid sequence. The sequence of the trypsin inhibitor from cow colostrum has recently been determined.⁵⁴⁵ It shows considerable homology with the sequence of the bovine basic pancreatic inhibitor (Figure 13) and has -*Lys-Ala- at the active site. The active site appears to be similar in the inhibitors from pig colostrum.⁵⁴⁶ When the basic inhibitor combines with trypsin a single easily reducible disulphide bond in both the inhibitor and the enzyme becomes buried,⁵⁴⁷ suggesting that 'the mutual binding regions are located near these disulphides'. Conformational changes would also seem to be a possible

⁵³⁷ T. M. Chulkova and V. N. Orekhovich, *Biochemistry (U.S.S.R.)*, 1971, **36**, 550.

⁵³⁸ K.-I. Kasai, Y. Takai, T. Watanabe, and S.-I. Ishi, *Internat. J. Protein Res.*, 1971, **3**, 117.

⁵³⁹ F. S. Markland and P. S. Damus, *European J. Biochem.*, 1971, **246**, 6460.

⁵⁴⁰ L. Summaria, K. C. Robbins, and G. H. Barlow, *J. Biol. Chem.*, 1971, **246**, 2143.

⁵⁴¹ F. Fielder, B. Müller, and E. Werle, *Z. physiol. Chem.*, 1971, **352**, 1463.

⁵⁴² 'First Conference on Proteinase Inhibitors', ed. H. Fritz, H. Tschesche, and E. Werle, Walter de Gruyter and Co., Berlin, 1971.

⁵⁴³ R. Huber, D. Kukla, A. Rühlmann, O. Epp, and H. Formanek, *Naturwiss.*, 1970, **57**, 389.

⁵⁴⁴ K. Noda, S. Terada, N. Mitsuyasu, M. Waki, T. Kato, and N. Izumiya, *Naturwiss.*, 1971, **58**, 147.

⁵⁴⁵ D. Čechová, V. Jonáková, and F. Šorm in Ref. 542, p. 105.

⁵⁴⁶ L. F. Kress, S. R. Martin, and M. Laskowski, *Biochim. Biophys. Acta*, 1971, **229**, 836.

⁵⁴⁷ W. Liu, H. Trzeciak, H. Schüssler, and J. Meienhofer, *Biochemistry*, 1971, **10**, 2849.

explanation but another study⁵⁴⁸ suggests that these do not occur, and it is estimated, from tritium exchange studies, that between 10 and 25 residues of trypsin are in contact with the inhibitor, a fairly large 'active centre'. Basic inhibitor, in which the easily reducible disulphide bond (14—38) had been reduced and carboxamidomethylated, still inhibited trypsin, but the inhibition was 'temporary' and trypsin activity was gradually released.⁵⁴⁹




Figure 13 Comparison of amino-acid sequences of cow colostrum trypsin inhibitor (CTI) and basic pancreatic trypsin inhibitor (BPTI)

This was accompanied by the sequential cleavage of three bonds in the inhibitor identified as Lys-15-Ala-16 (the active site), Arg-39-Ala-40, and Arg-17-Ile-18. The X-ray model suggests that reduction of the disulphide bond increases the flexibility of the chain segment ending in Lys-15 such that the interaction required at this point for formation of the usual permanent inhibition cannot occur.⁵⁴⁹ The basic pancreatic inhibitor can exist in three pH-dependent conformational states;⁵⁵⁰ the acid isomerization is dependent on the ionization of a buried carboxylate group which may be the side-chain of Glu-7, and the alkali isomerization on the unmasking of the α -amino-group of the N-terminal arginine (apparent pK 9.4), reminiscent of the situation in chymotrypsin. It is well established that the basic pancreatic inhibitor belongs to the class in which a lysyl bond is cleaved in the trypsin-inhibitor complex; a recent investigation⁵⁵¹ of the reaction of the arginine residues with phenylglyoxal showed that five of the six could be modified

⁵⁴⁸ M. A. Chepyzheva, G. Ya. Kolomiitseva, and A. G. Tarasenko, *Biochemistry (U.S.S.R.)*, 1971, **36**, 306.

⁵⁴⁹ K. A. Wilson and M. Laskowski, *J. Biol. Chem.*, 1971, **246**, 3555.

⁵⁵⁰ J.-P. Vincent, R. Chicheportiche, and M. Lazdunski, *European J. Biochem.*, 1971, **23**, 401.

⁵⁵¹ B. Keil, *F.E.B.S. Letters*, 1971, **14**, 181.

without loss of inhibitory activity; the lack of reactivity of the remaining arginine (Arg-53) was difficult to explain in the X-ray model, but the fact that it was distinctly removed from the active-site lysine suggested that it was unlikely to be involved in complex formation.⁵⁵¹ A study of the susceptibility of the four lysyl bonds in the Kunitz inhibitor to tryptic digestion

Pig I	Thr-Ser-Pro-Gln-Arg-Glu-Ala-Thr-Cys-Thr-Ser -Glu-Val-Ser -Gly-Cys-	
Sheep	Asn-Ile -Leu-Gly-Arg-Glu-Ala-Lys-Cys-Thr-Asn-Glu-Val-Asn-Gly-Cys-	
	5 10 15	
Pig I	Pro- [*] Lys-Ile-Tyr-Asn-Pro-Val-Cys-Gly-Thr-Asp-Gly-Ile -Thr-Tyr-Ser-Asn-	
Sheep	Pro- [*] Arg-Ile-Tyr-Asn-Pro-Val-Cys-Gly-Thr-Asp-Gly-Val-Thr-Tyr-Ala-Asn-	
	20 25 30	
Pig I	Glu-Cys-Val-Leu-Cys-Ser-Glu-Asn-Lys-Lys-Arg-Gln-Thr-Pro-Val-Leu-	
Sheep	Glu-Cys-Leu-Leu-Cys-Met-Glu-Asn-Lys-Glu-Arg-Gln-Thr-Pro-Val-Leu-	
	35 40 45	
Pig I	Ile-Gln-Lys-Ser-Gly-Pro-Cys	
Sheep	Ile-Gln-Lys-Ser-Gly-Pro-Cys	
	50 55	

Figure 14 Comparison of the amino-acid sequences of pancreatic secretory trypsin inhibitor from pig (inhibitor I) and sheep

after guanidination led to the conclusion⁵⁵² that homoarginyl bonds are substrates for trypsin although in the sequences -Harg-X-Arg- and -Harg-Arg- they are very poorly split. Care must therefore be taken when retention of inhibitory activity after guanidination is interpreted as evidence against a lysine active site.

The amino-acid sequence of pig pancreatic secretory trypsin inhibitor (Kazal type inhibitor), reported last year, has now been confirmed in another laboratory.⁵⁵³ This has 56 residues, with 12 differences relative to the bovine sequence determined earlier; the primary structure of the inhibitor from sheep⁵⁵⁴ has also been presented and this differs from the inhibitor from pig in 13 positions (Figure 14). The accumulation of substitutions at the N-terminus suggests that this region is not critical for inhibitor activity. All three have identical sequences around the bond cleaved, although this itself may be an arginyl (cow, sheep) or lysyl (pig) bond; the pancreatic secretory inhibitor from the cat also has a lysine residue at the active site.⁵⁵⁵ The three disulphide bonds of the bovine inhibitor have recently been identified⁵⁵⁶ and probably occur in homologous positions in the inhibitors of cow and pig, which also have three disulphide bonds.

⁵⁵² J. Chauvet and R. Acher, *F.E.B.S. Letters*, 1971, **18**, 265.


⁵⁵³ D. C. Bartelt and L. J. Greene, *J. Biol. Chem.*, 1971, **246**, 2218.

⁵⁵⁴ H. Tschesche, E. Wachter, S. Kupfer, R. Obermeier, G. Reidel, G. Haenisch, and M. Schneider, in Ref. 542, p. 207.


⁵⁵⁵ H. Tschesche and S. Kupfer, *Z. physiol. Chem.*, 1971, **352**, 764.

⁵⁵⁶ O. Guy, R. Shapanka, and L. J. Greene, *J. Biol. Chem.*, 1971, **246**, 7740.

Protease inhibitors from plants are also being extensively investigated, the lima-bean inhibitor, the Bowman-Birk soybean, and the Kunitz soybean inhibitors being the best characterized. The complete sequence of the lima-bean inhibitor (84 residues) is now known⁵⁵⁷ but shows no obvious resemblance to the pancreatic inhibitors described above. It is possible that certain regions of the lima-bean sequence may have arisen by gene duplication. For example, (but bearing in mind the Yiddish proverb⁵⁵⁸) the sequence 15—34 is homologous with 43—61, assuming one deletion:



The anti-chymotryptic site is now identified as the Leu-55-Ser-56 bond, and it is very tempting to speculate that the apparently homologous Lys-28-Ser-29 bond is the anti-tryptic site, and that the double-headed inhibitor has arisen by gene-duplication.^{557b} The Lys-28-Ser-29 bond does appear to be readily cleaved by chymotrypsin, or by trypsin after guanidination.^{557b} The existence of two functionally independent sites for trypsin and chymotrypsin in lima-bean inhibitor has been confirmed.⁵⁵⁹ The Bowman-Birk soybean inhibitor (71 residues) is also double-headed and the amino-acid sequence around the anti-tryptic (lysyl) site is similar to that of the lima-bean inhibitor:



There is no homology with the active sites of the basic and secretory pancreatic inhibitors or with the Kunitz soybean inhibitor. Guanidination did not abolish the anti-tryptic activity⁵⁶⁰ and again the homoarginyl bond was cleaved by trypsin.⁵⁶¹ In a strange report,⁵⁶² 'accidental' chemical modification (when tap-water was used for dialysis) seemed to indicate that certain tyrosine, methionine, and tryptophan residues were not essential for

⁵⁵⁷ (a) C. G. L. Tan and F. C. Stevens, *European J. Biochem.*, 1971, **18**, 503; (b) C. G. L. Tan and F. C. Stevens, *ibid.*, p. 515.

⁵⁵⁸ " 'For example' is not proof."

⁵⁵⁹ J. Krahn and F. C. Stevens, *F.E.B.S. Letters*, 1971, **13**, 339.

⁵⁶⁰ D. S. Seidl and I. E. Liener, *Biochim. Biophys. Acta*, 1971, **251**, 83.

⁵⁶¹ D. S. Seidl and I. E. Liener, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 1101.

⁵⁶² S. Odani, T. Koide, and T. Ikenaka, *J. Biochem. (Japan)*, 1971, **70**, 925.

inhibitory activity in the Kunitz soybean inhibitor. A tetrameric chymotrypsin inhibitor from potatoes ⁵⁶³ appears to dissociate in the presence of chymotrypsin to form complexes of the type I₂E and IE.

Egg-white contains two well-characterized protease inhibitors: ovomucoid and ovomucoid (which is about twice as large); the inhibitory properties of ovomucoid from different species differ greatly. In contrast with other inhibitors of chymotrypsin and trypsin, turkey ovomucoid and chicken ovomucoid will inhibit elastase;⁵⁶⁴ ovomucoid appears to have a common anti-elastase/anti-chymotrypsin site different from the trypsin site, whereas there are three distinct sites in the ovomucoid. A study of several avian ovomucoids ⁵⁶⁵ suggests two anti-tryptic and two anti-chymotryptic sites (the latter absent in penguin ovomucoid) with an arginyl bond at the anti-tryptic site; in contrast most avian ovomucoids have lysyl active sites. The purification of chicken ovomucoid free from ovomucoid by affinity chromatography on a column of agarose-chymotrypsin ²³² (see Section 2E) rests on the fact that chicken ovomucoid inhibits only trypsin whereas ovomucoid inhibits both trypsin and chymotrypsin, and is therefore selectively retained by the column. Although chicken ovomucoid does not inhibit human trypsin (whereas it does inhibit the bovine enzyme) the two proteins do form a complex, and several bond cleavages occur, one of which is at the active site of the inhibitor;⁵⁶⁶ the modified inhibitor will still inhibit bovine trypsin.

Protease inhibitors from human nasal secretion,⁵⁶⁷ human sperm plasma,⁵⁶⁸ and human tears ⁵⁶⁹ are being studied, although in some cases the small amounts available are somewhat restrictive.

Neutral Proteases, Acid Proteases, and Thiol Proteases. Some reference to neutral proteases has already been made in the section on chain cleavage (Section 2D). The heterogeneity of commercial Pronase from *S. griseus* has been shown by gel electrophoresis to extend to fourteen bands with various enzymatic activities,⁵⁷⁰ and an improved fractionation on carboxymethyl-Sephadex has been described ⁵⁷¹ which resolves the major endo- and exopeptidase activities (three of each). The endopeptidases, it will be recalled, have -Asp-Ser-Gly- at their active centres like the mammalian serine proteases. Sequence work on *S. griseus* trypsin was reported last year and

⁵⁶³ H.-D. Belitz, K.-P. Kaiser, and K. Santarius, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 420.

⁵⁶⁴ A. Gertler and G. Feinstein, *European J. Biochem.*, 1971, **20**, 547.

⁵⁶⁵ W.-H. Liu, G. E. Means, and R. E. Feeney, *Biochim. Biophys. Acta*, 1971, **229**, 176.

⁵⁶⁶ J. Travis, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 793.

⁵⁶⁷ K. Hochstrasser, H. Haendle, R. Reichert, E. Werle, and S. Schwarz, *Z. physiol. Chem.*, 1971, **352**, 954.

⁵⁶⁸ E. Fink, E. Jaumann, H. Fritz, H. Ingrisch, and E. Werle, *Z. physiol. Chem.*, 1971, **352**, 1591.

⁵⁶⁹ F. Kueppers, *Biochim. Biophys. Acta*, 1971, **229**, 845.

⁵⁷⁰ B. Löfqvist and L.-B. Sjöberg, *Acta Chem. Scand.*, 1971, **25**, 1663.

⁵⁷¹ L. Jurašek, P. Johnson, R. W. Olafson, and L. B. Smillie, *Canad. J. Biochem.*, 1971, **49**, 1195.

the sequences of the peptic peptides of *S. griseus* protease A, which has wide specificity, have recently been determined.⁵⁷² The high homology with other serine proteases, both from mammalian sources and from micro-organisms, can be clearly seen in the N-terminal sequences:^{572a}

<i>S. griseus</i> protease A	Ile -Ala-Gly-Gly-Glu-Ala-
Bovine trypsin	Ile -Val-Gly-Gly-Try-Thr-
Bovine chymotrypsin A	Ile -Val-Asn-Gly-Glu-Glu-
Porcine elastase	Val-Val-Gly-Gly-Thr-Glu-
<i>Myxobacter</i> α -lytic protease	Ala-Asn-Ile -Val-Gly-Gly-Ile -Glu-

and in the sequences around the disulphide bridges,^{572b} where the homology with *Myxobacter* α -lytic protease and *S. griseus* trypsin is particularly striking. These are important regions of the sequence since one of the bridge peptides contains the active-site serine, and the other the active-site histidine.

Elastase	-Thr-Ala-Ala-His-Cys-,	-Gly-Asp-Ser-Gly-Gly-Pro-Leu-
Chymotrypsin	-Thr-Ala-Ala-His-Cys-,	-Gly-Asp-Ser-Gly-Gly-Pro-Leu-
<i>S. griseus</i> trypsin	-Thr-Ala-Ala-His-Cys-,	-Gly-Asp-Ser-Gly-Gly-Pro-Met-
α -Lytic protease	-Thr-Ala-Gly-His-Cys-,	-Gly-Asp-Ser-Gly-Gly-Ser-Trp-
<i>S. griseus</i> protease A	-Thr-Ala-Gly-His-Cys-,	-Gly-Asp-Ser-Gly-Gly-Ser-Leu-

A comparison⁵⁷³ of the amino-acid sequences of α -lytic protease and elastase was included in last year's Report (p. 81); based on this homology, and the known three-dimensional structure for elastase, a model was built for α -lytic protease⁵⁷³ (see last year's Report). Elastase-like enzymes from Pronase which hydrolyse acetyl-L-Ala-L-Ala-L-Ala-OMe are also being investigated.⁵⁷⁴ A rapid method for removing metal ions from metallo-neutral-proteases uses gel filtration in columns equilibrated with chelator⁵⁷⁵ and has been employed to prepare the apoenzymes of thermolysin and the neutral proteases from *B. subtilis* and *B. cereus*.

The acid proteases constitute another 'family' of enzymes. The best characterized is pepsin, and the extensive studies of its specificity and mechanism of action have been well reviewed,⁵⁷⁶ particularly in relation to subsite specificity, *i.e.* the influence on the enzymic cleavage of interactions at sites somewhat removed from the actual catalytic site. Different subsites presumably accounted for the significant differences in the rate of hydrolysis of the Phe-Phe bond by different acid proteases,⁵⁷⁷ and penicillopepsin⁵⁷⁸ showed the same specificity, with a requirement for

⁵⁷² (a) P. Johnson and L. B. Smillie, *Canad. J. Biochem.*, 1971, **49**, 1083; (b) P. Johnson and L. B. Smillie, *ibid.*, p. 548.

⁵⁷³ A. D. McLachlan and D. M. Shotton, *Nature New Biol.*, 1971, **229**, 202.

⁵⁷⁴ A. Gertler and M. Trop, *European J. Biochem.*, 1971, **19**, 90.


⁵⁷⁵ J. Feder and L. R. Garrett, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 943.

⁵⁷⁶ J. S. Fruton, *Adv. Enzymol.*, 1970, **33**, 401.


⁵⁷⁷ I. M. Voynick and J. S. Fruton, *Proc. Nat. Acad. Sci. U.S.A.* 1971, **68**, 257.

⁵⁷⁸ G. Mains, M. Takahashi, J. Šodek, and T. Hofmann, *Canad. J. Biochem.*, 1971, **49**, 1134.


an extended binding site. The X-ray studies in progress on pepsin, rennin, and penicillopepsin will show whether an extended binding site is indeed conserved. Preliminary crystallographic studies of the acid protease from *Rhizopus chinensis* have also been reported.⁵⁷⁹ The homology between pig pepsin and calf rennin (chymosin) at the N-terminus (reported last year) has now been extended⁵⁸⁰ by other workers with sequenator determination of the first 16 residues of leucyl-pepsin (the additional N-terminal leucine residue resulting from activation of pepsinogen with thermolysin, rather than the usual pepsin):



The greatest differences are near the activation points (shown with arrows); the residue preceding Ile-1 in pepsin is now given as Leu and not Glu (see last year's Report), making it easier to explain the different bond cleavages to give pepsin and rennin. Comparison of tryptic peptides obtained after maleylation of prorennin (prochymosin) and pepsinogen showed that the activation peptides were, however, homologous:⁵⁸¹



In last year's Report (p. 84) the C-terminal sequences of pig pepsin, human pepsin, and human gastricsin were compared. The 19 C-terminal residues of bovine pepsin have now been determined⁵⁸² and appear (not surprisingly) to resemble the C-terminal region of human and pig pepsins more than that of calf rennin:



Stoichiometric labelling of the active site of bovine pepsin with *N*-diazoacetyl[¹⁴C]norleucine methyl ester (an inhibitor)⁵⁸⁴ led to identification of the sequence around a reactive aspartyl residue as -Ile-Val-Asp-Thr-Gly-Thr-Ser-, identical with the sequence reported earlier for porcine pepsin,

⁵⁷⁹ I.D.A. Swan, *J. Mol. Biol.*, 1971, **60**, 405.

⁵⁸⁰ V. M. Stepanov, E. A. Timokhina, L. A. Baratova, L. P. Belyanova, V. P. Korzhenko, and I. G. Zhukova, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1482.



⁵⁸¹ B. Foltmann and B. Andersen, *F.E.B.S. Letters*, 1971, **17**, 87.

⁵⁸² K. T. Rasmussen and B. Foltmann, *Acta Chem. Scand.*, 1971, **25**, 3873.

⁵⁸³ B. Foltmann, *Phil. Trans. Roy. Soc.*, 1970, **B257**, 147.

⁵⁸⁴ P. A. Meitner, *Biochem. J.*, 1971, **124**, 673.

and homologous with the sequence -Ile-Ala-Asp-Thr-Gly-Thr-Thr- reported for penicillopepsin from *Penicillium janthinellum*;⁵⁸⁵ the active site of the minor pepsin from pig (pepsin C) also had -Ile-Val-Asp-Thr- at the active centre.⁵⁸⁶ The sequence around the phosphoserine residue in pig pepsin has now been extended to 11 residues,⁵⁸⁷ the tryptophan-containing peptides have been re-examined,⁵⁸⁸ and the sequences of some chymotryptic peptides from the N-terminal region have been determined in the same laboratory.⁵⁸⁹ Two of the three disulphide bonds in pepsin and pepsinogen can be reversibly reduced without loss of activity and have now been identified.⁵⁹⁰ The bisdiazoketone (12), designed as a bifunctional inhibitor of pepsin and related acid proteases, reacted stoichiometrically (1 : 1) and intramolecularly with pepsin;⁵⁹¹ 50% of the label was bound in alkali-stable linkage but the site of reaction was not identified. The bromodiazoketone (13) was also studied⁵⁹¹ and a spectrophotometric assay for pepsin using phenyl sulphate as a specific substrate has been reported.⁵⁹²



The bovine pepsinogens and pepsins can be separated chromatographically⁵⁹³ by virtue of their different organic phosphate content, while their amino-acid compositions are very similar. Three bovine pepsinogens have N-terminal Ser-Val- and C-terminal -Val-Ala- and contain carbohydrate; the corresponding pepsins all have N-terminal Val, have C-terminal Ala, and are carbohydrate-free.^{593a} Bovine pepsinogens and pepsin are also under study in other laboratories.^{594, 595} A canine pepsinogen,⁵⁹⁶ with one mole of organic phosphate and N-terminal Ala-Ile-, resembles other mammalian

⁵⁸⁵ J. Sodek and T. Hofmann, *Canad. J. Biochem.*, 1970, **48**, 1014.

⁵⁸⁶ J. Kay and A. P. Ryle, *Biochem. J.*, 1971, **123**, 75.

⁵⁸⁷ E. A. Vakhitova, M. M. Amirkhanyan, and V. M. Stepanov, *Biochemistry (U.S.S.R.)*, 1970, **35**, 1009.

⁵⁸⁸ V. I. Vasenev, Yu. S. Kuznetsov, and V. M. Stepanov, *Biochemistry (U.S.S.R.)*, 1970, **35**, 690.

⁵⁸⁹ R. A. Balyulis and V. M. Stepanov, *Biochemistry (U.S.S.R.)*, 1971, **36**, 297.

⁵⁹⁰ Y. Nakagawa and G. E. Perlmann, *Arch. Biochem. Biophys.*, 1971, **144**, 59.

⁵⁹¹ S. S. Husain, J. B. Ferguson, and J. S. Fruton, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2765.

⁵⁹² T. P. Stein, T. W. Reid, and D. Fahrney, *Analyt. Biochem.*, 1971, **41**, 360.

⁵⁹³ (a) P. A. Meitner and B. Kassell, *Biochem. J.*, 1971, **121**, 249; (b) H. M. Lang and B. Kassell, *Biochemistry*, 1971, **10**, 2296.

⁵⁹⁴ J. Antonini and B. Ribadeau Dumas, *Biochimie*, 1971, **53**, 321.

⁵⁹⁵ A. Z. Vafin, *Biochemistry (U.S.S.R.)*, 1971, **36**, 35.

⁵⁹⁶ J. P. Marcinišzyn, jun., and B. Kassell, *J. Biol. Chem.*, 1971, **246**, 6560.

pepsinogens in its content of all amino-acids except methionine, which is high, reminiscent of dogfish and chicken pepsinogens. It has been proposed that the conversion of pepsinogen into pepsin at acid pH involves an intramolecular reaction in which the zymogen cleaves itself.⁵⁹⁷

The structure of papain, the best characterized of the thiol proteases, has recently been reviewed.⁵⁹⁸ Clostripain, like trypsin, shows specificity for arginyl and lysyl bonds, but particularly arginyl because of the high affinity of clostripain for the guanidino-group, demonstrated on specific substrate.⁵⁹⁹ It will hydrolyse the Arg-Pro bond and *p*-nitrophenyl *p*'-guanidinobenzoate which with trypsin gives a stable acyl enzyme and is therefore useful as a specific active-site titrant. Clostripain is inhibited by TLCK, and the site of alkylation has been tentatively identified as a thiol residue;⁶⁰⁰ this might be a useful way of inhibiting clostripain contamination of collagenase.⁶⁰⁰

B. Lysozyme and α -Lactalbumin.—A 6 Å *X*-ray analysis of human urine leukaemic lysozyme⁶⁰¹ confirms the high structural homology with hen egg-white lysozyme predicted from the similarities in primary structure.⁶⁰² As expected, the homology of the 'internal' residues (74%) is higher than that of the 'external' residues (52%) although significantly lower than the internal homology in chymotrypsin and elastase, where the overall homology is, in fact, lower. The active site is highly conserved but four of the five residues in the extended binding site are different. The two lysozymes are identical in 77 of the 129 positions (with a deletion and an insertion in the human enzyme) (Figure 15). An almost complete sequence of the lysozyme from human milk has also been presented,⁶⁰³ and appears to be identical with the human leukaemic lysozyme except for a slight difference in the position of the deletion and an amide assignment.⁶⁰⁴ Primary structural studies confirm that multiple duck lysozymes are due to multiple alleles at one locus,⁶⁰⁵ unlike the case of the Black Swan which has two non-allelic genes for lysozyme (see Vol. 3 of these Reports). It is curious that the first 30 residues determined (using a sequenator) for goose lysozyme⁶⁰²

Arg-Thr-Asp-Cys-Tyr-Gly-Asn-Val-Asn-Arg-Ile-Asp-Thr-Thr-Gly-Ala-Ser-Cys-Lys-Thr-Ala-Lys-Pro-Glu-Gly-Ile-Ser-Tyr-Cys-Gly-

reveal no similarity with other avian lysozymes, suggesting that a different non-allelic gene is being expressed, possibly one of the two expressed in the

⁵⁹⁷ M. Bustin and A. Conway-Jacobs, *J. Biol. Chem.*, 1971, **246**, 615.

⁵⁹⁸ J. Drenth, J. N. Jansonius, R. Koekoek, and B. G. Wolthers, *Adv. Protein Chem.*, 1971, **25**, 79.

⁵⁹⁹ P. W. Cole, K. Murakami, and T. Inagami, *Biochemistry*, 1971, **10**, 4246.

⁶⁰⁰ W. H. Porter, L. W. Cunningham, and W. M. Mitchell, *J. Biol. Chem.*, 1971, **246**, 7675.

⁶⁰¹ C. C. F. Blake and I. D. A. Swan, *Nature New Biol.*, 1971, **232**, 12.

⁶⁰² R. E. Canfield, S. Kammerman, J. H. Sobel, and F. J. Morgan, *Nature New Biol.*, 1971, **232**, 16.

⁶⁰³ P. Jollès, *Chimia (Switz.)*, 1971, **25**, 1.

⁶⁰⁴ J. Hermann, J. Jollès, and P. Jollès, *European J. Biochem.*, 1971, **24**, 12.

⁶⁰⁵ E. M. Prager and A. C. Wilson, *J. Biol. Chem.*, 1971, **246**, 523.

	1	10	20	
HLL	Lys-Val -Phe-Glu-Arg-Cys-Glu-Leu-Ala-Arg-Thr-Leu-Lys-Arg-Leu-Gly-Met-Asp-Gly-Tyr-Arg-Gly-Ile-Ser-Leu-Ala-Asn-			
HEL	Lys-Val -Phe-Gly-Arg-Cys-Glu-Leu-Ala-Ala-Met-Lys-Arg-His-Gly-Leu-Asp-Asn-Tyr-Arg-Gly-Tyr-Ser-Leu-Gly-Asn-			
BAL	Glu-Gln-Leu-Thr-Lys-Cys-Glu-Val-Phe-Arg-Glu-Leu-Lys-Asp-Leu-Lys-Gly-Tyr-Gly-Gly-Val-Ser-Leu-Pro-Glu-	30	50	
HLL	Trp-Met-Cys-Leu-Ala-Lys-Trp-Glu-Ser-Gly-Tyr-Asn-Thr-Arg-Ala-Thr-Asn-Tyr-Asn-Ala-Gly-Asp-Arg-Ser-Thr-Asp-			
HEL	Trp-Val -Cys-Ala-Ala-Lys-Phe-Glu-Ser-Asn-Phe-Asn-Thr-Gln-Ala-Thr-Asn-Arg-Asn-Thr-Asp-Gly-Ser-Thr-Asp-	40		
BAL	Trp-Val -Cys-Thr-Thr-Phe-His-Thr-Ser-Sly-Tyr-Asp-Thr-Glu-Ala-Ile-Val-Glu-Asn-Asn-Gln-Ser-Thr-Asp-	60	70	80
HLL	Tyr-Gly-Ile -Phe-Gln-Ile-Asn-Ser -Arg-Tyr-Trp-Cys-Asn-Asp-Gly-Lys-Thr-Pro-Gly-Ala-Val-Asn-Ala-Cys-His-Leu-Ser-			
HEL	Tyr-Gly-Ile -Leu-Gln-Ile-Asn-Ser -Arg-Trp-Trp-Cys-Asn-Asp-Gly-Arg-Thr-Pro-Gly-Ser-Arg-Asn-Leu-Cys-Asn-Ile -Pro-			
BAL	Tyr-Gly-Leu-Phe-Gln-Ile-Asn-Lys-Ile -Trp-Cys-Lys-Asn-Asp-Gly-Asp-Pro-His-Ser-Ser -Asn-Ile -Cys-Asn-Ile -Ser-	90	100	
HLL	Cys-Ser -Ala-Leu-Leu-Gln-Asp-Asn-Ile -Ala-Asp-Ala-Val-Ala -Cys-Ala-Lys-Arg-Val-Arg-Asp-Pro-Gln-Gly-Ile -Arg-			
HEL	Cys-Ser -Ala-Leu-Leu-Ser -Ser -Asp-Ile -Thr-Ala-Ser -Val-Asn-Cys-Ala-Lys-Lys-Ile -Val-Ser-Asp-Gly-Asp-Gly-Met-Asn-			
BAL	Cys-Asp-Lys-Phe-Leu-Asn-Asp-Leu-Thr-Asn-Asn-Ile -Met-Cys-Val-Lys-Lys-Ile -Leu-Asp-Lys-Val -Gly-Ile -Asn-	110	120	
HLL	Ala-Trp-Val -Ala-Trp-Arg-Asn-Arg-Cys-Gln-Asn-Arg-Asp-Val -Arg-Gln-Tyr-Val -Gln-Gly-Cys-Gly-Val			
HEL	Ala-Trp-Val -Ala-Trp-Arg-Asn-Arg-Cys-Lys-Gly-Thr-Asp-Val -Gln-Ala-Trp-Ile -Arg-Gly-Cys-Arg-Val			
BAL	Trp-Trp-Leu-Ala-His-Lys-Ala-Leu-Cys-Ser -Glu-Lys-Leu-Asp-Gln-Trp-Leu-Cys-Lys-Glu-Leu			

Figure 15 Amino-acid sequence of human leukaemia lysozyme (HLL), hen egg-white lysozyme (HEL), and bovine α -lactalbumin (BAL). The numbers correspond to the sequence of HLL.

Black Swan (unfortunately not the most readily available source of lysozyme for sequence studies, except perhaps to Australians!).

Immunological cross-reactivity is certainly a useful method for investigating similarities between proteins, particularly for comparing different species. However, since antigenic determinants will lie on the surface of a protein, which is also well established as the location of most of the amino-acid changes in different species, immunological cross-reaction can only give information about the most dissimilar regions of the protein. Lack of immunological cross-reactivity, therefore, does not necessarily indicate major differences in tertiary structure (although an antigenic determinant may have several elements brought into proximity by folding) (see also last year's Report). These points are borne out in several studies of lysozyme and α -lactalbumin. Thus in a series of clearly homologous avian lysozymes, sequences which showed less than 40% homology did not cross-react,⁶⁰⁶ in keeping with the fact that most evolutionary changes occur at the surfaces of proteins. A better measure of similarity in protein sequences, therefore, is the immunological cross-reactivity of the unfolded molecules; for example, after reduction and carboxymethylation, hen egg-white lysozyme and bovine α -lactalbumin cross-reacted⁶⁰⁷ whereas the native molecules did not. Human leukaemia lysozyme and hen egg-white lysozyme similarly cross-reacted only after reduction and carboxymethylation,⁶⁰⁸ confirming that immunological cross-reactivity is not a necessary consequence of high sequence homology. The unique antigenic determinant in lysozyme, formed from the loop peptide (residues 60—83), has been further studied; antibodies to the loop peptide have been partially purified⁶⁰⁹ and the peptide containing residues 64—82 has been synthesized by the solid-phase method.⁶¹⁰ Nitration of hen lysozyme suggested that Tyr-20 and Tyr-23 belong to the same antigenic determinant,⁶¹¹ and the selective nitration and acetylation of human lysozyme did not occur at the active site.⁶¹²

The isolation and properties of α -lactalbumin from various sources have been described.^{613, 614} The homology between the amino-acid sequences of bovine α -lactalbumin and hen egg-white lysozyme (Figure 15) makes it almost certain that the three-dimensional structures will be basically the same; and it has, of course, already been shown that the α -lactalbumin sequence can be fitted to the lysozyme model. Energy calculations based on this model for the α -lactalbumin structure have, however, been taken as

⁶⁰⁶ E. M. Prager and A. C. Wilson, *J. Biol. Chem.*, 1971, **246**, 5978.

⁶⁰⁷ R. Arnon and E. Maron, *J. Mol. Biol.*, 1971, **61**, 225.

⁶⁰⁸ N. Arnheim, J. Sobel, and R. Canfield, *J. Mol. Biol.*, 1971, **61**, 237.

⁶⁰⁹ E. Maron, C. Shiozawa, R. Arnon, and M. Sela, *Biochemistry*, 1971, **10**, 763.

⁶¹⁰ R. Arnon, E. Maron, M. Sela, and C. B. Anfinsen, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1450.

⁶¹¹ A. D. Strosberg, B. van Hoeck, and L. Kanarek, *European J. Biochem.*, 1971, **19**, 36.

⁶¹² R. L. Fawcett, T. J. Limbird, S. L. Oliver, and C. L. Borders, jun., *Canad. J. Biochem.*, 1971, **49**, 816.

⁶¹³ D. V. Schmidt and K. E. Ebner, *Biochim. Biophys. Acta*, 1971, **243**, 273.

⁶¹⁴ N. I. Phillips and R. Jenness, *Biochim. Biophys. Acta*, 1971, **229**, 407.

support⁶¹⁵ for results of an earlier small-angle X-ray study in solution⁶¹⁶ which suggested that the gross shapes of lysozyme and α -lactalbumin differed considerably, but these results⁶¹⁶ have now been shown to be invalid⁶¹⁷ and explicable in terms of α -lactalbumin dimer in the solution. A theoretical treatment,⁶¹⁸ which predicted correctly all the helices in lysozyme, predicted helices for the same regions of α -lactalbumin (with a greater helix content in the C-terminal region). On the other hand, marked differences in the susceptibility of the disulphide bonds in the two proteins to reduction and in behaviour in denaturing media⁶¹⁹ were taken as a warning of the dangers of assuming similar conformations from sequence homology. However, slight differences in reactivity can almost certainly be explained in terms of differences in side-chain orientation, and it is likely that the main conformational element, the polypeptide backbone, is indeed very similar in lysozyme and α -lactalbumin. Full details have now been published of the purification of the A protein of lactose synthetase on an agarose- α -lactalbumin affinity column,⁶²⁰ clear indication that a complex does indeed form between the two proteins. The molecular weight of the A protein, at 112 000, is higher than the generally accepted value.

The almost complete amino-acid sequence (157 residues) of λ -phage endolysin has been published.⁶²¹ There is no structural similarity between λ -endolysin and T₄ phage or egg-white lysozyme, and it is likely that the enzyme is not a neuraminidase like the other two.⁶²¹ Preliminary structural work is under way on the *NO*-diacetylmuramidase (m. wt. 23 400) of a fungus (*Chalaropsis* species)⁶²² and the characterization of turnip lysozyme (m. wt. 25 000) has been described.⁶²³ This resembles papaya latex lysozyme in having chitinase activity as well as normal lysozyme activity. The papaya enzyme (m. wt. 28 000), with four disulphide bridges, can be reversibly reduced and denatured.⁶²⁴

C. Dehydrogenases.—Preliminary sequence studies⁶²⁵ show that glyceraldehyde 3-phosphate dehydrogenase (GPDH) from the red kangaroo (*Megaleia rufa*) is very similar to the enzyme from the pig and that the sequence of 17 residues around the active-site cysteine is conserved in this species, as in others. An improved preparation has been reported⁶²⁶ for GPDH apoenzyme from *B. stearothermophilus*, which is much more stable

⁶¹⁵ W. R. Krigbaum and B. H. Rubin, *Biochim. Biophys. Acta*, 1971, **229**, 368.

⁶¹⁶ W. R. Krigbaum and F. R. Kügler, *Biochemistry*, 1970, **9**, 1216.

⁶¹⁷ E. K. Achter and I. D. A. Swan, *Biochemistry*, 1971, **10**, 2976.

⁶¹⁸ P. N. Lewis and H. A. Scheraga, *Arch. Biochem. Biophys.*, 1971, **144**, 584.

⁶¹⁹ A. F. S. A. Habeeb and M. Z. Atassi, *Biochim. Biophys. Acta*, 1971, **236**, 131.

⁶²⁰ I. P. Trayer and R. L. Hill, *J. Biol. Chem.*, 1971, **246**, 6666.

⁶²¹ M. Imada and A. Tsugita, *Nature New Biol.*, 1971, **233**, 230.

⁶²² J. W.-K. Shih and J. H. Hash, *J. Biol. Chem.*, 1971, **246**, 994.

⁶²³ I. Bernier, E. Van Leemputten, M. Horisberger, D. A. Bush, and P. Jollès, *F.E.B.S. Letters*, 1971, **14**, 100.


⁶²⁴ A. O. Barel, M. Dolmans, and J. Léonis, *European J. Biochem.*, 1971, **19**, 488.

⁶²⁵ R. J. Simpson and B. E. Davidson, *Austral. J. Biol. Sci.*, 1971, **24**, 263.

⁶²⁶ K. Suzuki and J. I. Harris, *F.E.B.S. Letters*, 1971, **13**, 217.

than the apoenzyme from other species, and crystallizes in a form suitable for crystallographic studies. The enzyme from *E. coli* as prepared contains very little NAD⁺ but (unlike the yeast enzyme) will crystallize only with bound coenzyme.⁶²⁷ The amino-acid compositions and peptide maps of GPDH from various insects have been compared,⁶²⁸ some properties of the enzyme from Ehrlich ascites tumour cells have been recorded,⁶²⁹ and the isolation of GPDH strongly retained by human erythrocyte ghosts has been described.⁶³⁰ Cariogenic streptococci possess both an NAD⁺-linked and an NADP⁺-linked GPDH which can be separated;⁶³¹ the NADP-specific enzyme is assigned a role in generation of NADPH since the organism lacks alternative pathways of production of the reduced coenzyme, namely the oxidative portion of the pentose-phosphate-shunt pathway and trans-hydrogenase activity.

The lysine residues of rabbit muscle GPDH that reacted most readily with pyridoxal phosphate⁶³² were residues 191 and 212, while there was no reaction at the 'active' lysine, Lys-183; the sequence around Lys-212, it will be recalled, is homologous with the region containing Lys-97 (the essential pyridoxal-binding lysine) in glutamate dehydrogenase (see last year's Report). For the first time the active-site cysteine, Cys-149, has been cross-linked⁶³³ to the active lysine, Lys-183. Thus the peptide:



was one of four isolated when rabbit muscle apoenzyme was treated with four moles of 1,5-difluoro-2,4-dinitrobenzene per mole of tetramer. The cysteine and the lysine must, therefore, be within 5—6 Å of each other,⁶³³ but it is not possible to distinguish between intra- and inter-monomer reaction (*i.e.* between an active site contributed entirely by one monomer and one situated between monomers). This is of particular interest in view of the apparent pairing of subunits ($\alpha_2\alpha'_2$) suggested by crystallographic studies and, more recently, by chemical studies (see below). Three elegantly conceived active-site-directed spin-labels for GPDH based, respectively, on iodoacetate, *p*-nitrophenyl acetate, and glyceraldehyde 3-phosphate have been described.⁶³⁴

⁶²⁷ G. D'Alessio and J. Josse, *J. Biol. Chem.*, 1971, **246**, 4326.

⁶²⁸ C. W. Carlson and R. W. Brosemer, *Biochemistry*, 1971, **10**, 2113.

⁶²⁹ F. P. Mamaril and S. Green, *Arch. Biochem. Biophys.*, 1971, **147**, 583.

⁶³⁰ M. J. A. Tanner and W. R. Gray, *Biochem. J.*, 1971, **125**, 1109.

⁶³¹ A. T. Brown and C. L. Wittenberger, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 217.

⁶³² B. G. Forcina, G. Ferri, M. C. Zapponi, and S. Ronchi, *European J. Biochem.*, 1971, **20**, 535.

⁶³³ S. Shaltiel and M. Tauber-Finkelstein, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 484.

⁶³⁴ W. Balthasar, *European J. Biochem.*, 1971, **22**, 158.

Differences in the binding of NAD^+ to GPDH from rabbit muscle and yeast continue to be of considerable interest. Equilibrium, temperature-jump, and stopped-flow kinetic studies,⁶³⁵ and X-ray small-angle scattering⁶³⁶ all support the concerted mechanism of binding for the yeast enzyme. Temperature-jump studies on the binding of NAD^+ to rabbit muscle GPDH under conditions that permitted direct comparison with the yeast enzyme still supported the sequential mechanism of conformational changes accompanying binding,⁶³⁷ so the anomaly of substantial differences in coenzyme binding in enzymes that are highly homologous remains. Apparently it cannot be accounted for in terms of differences in the coenzyme binding-sites⁶³⁸ and must arise from differences elsewhere in the enzyme molecules.

Further evidence in support of the non-equivalence of the four active sites in GPDH, despite the chemical identity of the four subunits, is based on acylation of only two active sites in rabbit muscle⁶³⁹ by either furyl-acryloyl phosphate or glyceraldehyde 3-phosphate. However, in another study⁶⁴⁰ it was shown that all four sites of the lobster enzyme are acylated by 1,3-diphosphoglycerate, and that NAD^+ dissociates from these sites before acylation. Since hydrolysis of the sturgeon acyl-enzyme occurred fairly rapidly even in the absence of NAD^+ , it was suggested⁶⁴⁰ that the stability of the rabbit acyl-enzyme should be checked before taking for granted the non-equivalence of the four active sites. However, support for the functional non-identity of subunits and, further, for the existence of enzymically active dimers, comes also from another laboratory.⁶⁴¹

A series of papers⁶⁴² gives full details of the determination of the amino-acid sequence of bovine liver glutamate dehydrogenase (GDH). The complete sequence (506 residues) was reproduced in last year's Report (p. 96); residue 341, shown there as Ile, is now given^{642f} as Asn, the difference being attributed to true allelic variation and different starting material. Apart from the variety of lines of attack used for a sequence of this length, and the authors' valid plea for better methods of separating large peptides, it is also worth noting limited tryptic cleavage at many arginyl bonds; this was attributed to neighbouring acidic residues, either in the sequence itself or arising from maleylation of hydroxy-groups.^{642e} The reaction of ox-liver

⁶³⁵ (a) K. Kirschner, E. Gallego, I. Schuster, and D. Goodall, *J. Mol. Biol.*, 1971, **58**, 29; (b) K. Kirschner, *ibid.*, p. 51.

⁶³⁶ H. Durchschlag, G. Puchwein, O. Kratky, I. Schuster, and K. Kirschner, *European J. Biochem.*, 1971, **19**, 9.

⁶³⁷ G. G. Hammes, P. J. Lillford, and J. Simplicio, *Biochemistry*, 1971, **10**, 3686.

⁶³⁸ D. Eby and M. E. Kirtley, *Biochemistry*, 1971, **10**, 2677.

⁶³⁹ R. A. MacQuarrie and S. A. Bernhard, *J. Mol. Biol.*, 1971, **55**, 181.

⁶⁴⁰ P. J. Harrigan and D. R. Trentham, *Biochem. J.*, 1971, **124**, 573.

⁶⁴¹ J. Ovadi, M. Telegedi, J. Batke, and T. Keleti, *European J. Biochem.*, 1971, **22**, 430.

⁶⁴² (a) M. Landon, M. D. Melamed, and E. L. Smith, *J. Biol. Chem.*, 1971, **246**, 2360; (b) M. Landon, D. Piskiewicz, and E. L. Smith, *ibid.*, p. 2374; (c) W. J. Brattin, jun., and E. L. Smith, *ibid.*, p. 2400; (d) T. J. Langley and E. L. Smith, *ibid.*, p. 3789; (e) M. Landon, T. J. Langley, and E. L. Smith, *ibid.*, p. 3802; (f) M. Landon, T. J. Langley and E. L. Smith, *ibid.*, p. 3807.

GDH with trinitrobenzenesulphonic acid (TNBS) has received further attention,^{643, 644} the availability of the sequence making possible the identification of residues involved in previous chemical modification studies. It has been shown⁶⁴⁴ that rapid reaction with Lys-428 in three of the chains is followed by slower reaction at Lys-425 in the other three chains; no chain has both lysine residues modified. Despite the chemical identity of the subunits it is as though Lys-425 is unavailable until Lys-428 has reacted; neither residue appears to be involved in catalysis. One practical point of interest in this study⁶⁴⁴ is that the use of sulphoethyl-Sephadex at elevated temperatures was found to improve recoveries of peptides modified with hydrophobic groups. An accompanying paper describes the complete characterization of the kinetic and molecular properties of the enzyme after modification.⁶⁴⁵ Nitration of GDH, like trinitrophenylation, causes desensitization to allosteric inhibition by GTP, and details have now appeared⁶⁴⁶ of the identification of the single tyrosine residue involved as Tyr-412. A kinetic study of the inactivation of GDH by pyridoxal⁶⁴⁷ confirms the involvement of the ϵ -amino-group of Lys-97 in this reaction. The involvement of tyrosine and lysine residues in the reactivity of catalytic and regulatory sites in ox-liver GDH has also been studied by dinitrophenylation,⁶⁴⁸ and the subunit structure has been examined using the electron microscope.⁶⁴⁹ Preliminary work on GDH from pea roots⁶⁵⁰ suggests that it is slightly smaller than the bovine enzyme, with m. wt. 208 000.

An X-ray crystallographic study at 5 Å of an abortive ternary complex of lactate dehydrogenase (dogfish M₄) has been published⁶⁵¹ and compared with previous results for the apoenzyme (see this chapter, Part II, Section 4G), and other experiments⁶⁵² indicate a covalent bond between the 3-position of the pyridine ring of NAD⁺ and pyruvate in the ternary complex with chicken-heart LDH. It is of interest that substituents in this position of the ring in coenzymes influence the rate and equilibrium of hydride transfer.⁶⁵³ A modifiable arginine residue which becomes inaccessible in the abortive ternary complex is implicated in substrate binding of pig-heart lactate dehydrogenase⁶⁵³ and a histidine residue may also be involved;⁶⁵⁴ other studies suggest a single tyrosine residue to be essential for activity.⁶⁵⁵

⁶⁴³ C. E. Clark and K. L. Yielding, *Arch. Biochem. Biophys.*, 1971, **143**, 158.

⁶⁴⁴ C. J. Coffee, R. A. Bradshaw, B. R. Goldin, and C. Frieden, *Biochemistry*, 1971, **10**, 3516.

⁶⁴⁵ B. R. Goldin and C. Frieden, *Biochemistry*, 1971, **10**, 3527.

⁶⁴⁶ D. Piszkiwicz, M. Landon, and E. L. Smith, *J. Biol. Chem.*, 1971, **246**, 1324.

⁶⁴⁷ D. Piszkiwicz and E. L. Smith, *Biochemistry*, 1971, **10**, 4538.

⁶⁴⁸ G. di Prisco, *Biochemistry*, 1971, **10**, 585.

⁶⁴⁹ (a) R. Josephs, *J. Mol. Biol.*, 1971, **55**, 147; (b) A. M. Fiskin, E. F. J. van Bruggen, and H. F. Fisher, *Biochemistry*, 1971, **10**, 2396.

⁶⁵⁰ E. Pahlisch and K. W. Joy, *Canad. J. Biochem.*, 1971, **49**, 127.

⁶⁵¹ I. E. Smiley, R. Koekoek, M. J. Adams, and M. G. Rossmann, *J. Mol. Biol.*, 1971, **55**, 467.

⁶⁵² G. Di Sabato, *Biochemistry*, 1971, **10**, 395.

⁶⁵³ J. Berghäuser and I. Falderbaum, *Z. physiol. Chem.*, 1971, **352**, 1189.

⁶⁵⁴ J. Berghäuser, I. Falderbaum, and Ch. Woenckhaus, *Z. physiol. Chem.*, 1971, **352**, 52.

⁶⁵⁵ D. Jeckel, R. Anders, and G. Pfeleiderer, *Z. physiol. Chem.*, 1971, **352**, 769.

Beef-heart⁶⁵⁶ and chicken-heart⁶⁵⁷ LDH have *N*-acetyl-Ala-Thr- at the N-terminus and Leu at the C-terminus, in common with all other H₄ isoenzymes examined;⁶⁵⁶ M₄ isoenzymes end with Phe and begin with *N*-acetyl-Ala-Ala- (rat liver and rabbit muscle), although dogfish M₄ has *N*-acetyl-Thr-Ala-Leu-.

Carboxamidomethylation of an essential histidine residue in pig mitochondrial malate dehydrogenase (see last year's Report) has been confirmed from another laboratory;⁶⁵⁸ there was no reaction at methionine although some confusion had arisen because of the similar chromatographic and electrophoretic properties of *N*-3-carboxamidomethyl-His-Gly-Gly and *S*-carboxamidomethylmethionine.⁶⁵⁸ Selective modification of the enzyme with *N*-ethylmaleimide at pH 5 suggested an essential cysteine residue in the enzyme⁶⁵⁹ and it will be interesting to see whether this turns out to occur in the cysteine-containing sequence that is conserved in several species.⁶⁶⁰ Another study,⁶⁶¹ however, concluded that the involvement of a thiol group in the catalytic mechanism was unlikely, and that tyrosine is implicated in the substrate or coenzyme binding-site. The amino-acid sequences of several tryptic peptides from the supernatant malic dehydrogenase pig heart have been reported.⁶⁶²

The covalently linked flavin in beef-liver monoamine oxidase is bound through the 8 α -carbon atom of the riboflavin ring to a cysteine residue in the sequence -Ser-Gly-Gly-Cys-Tyr-.⁶⁶³ Beef-heart succinic dehydrogenase, which has flavin covalently attached to histidine (see last year's Report), has been shown in two laboratories^{664, 665} to consist of one large subunit (m. wt. 68 000 or 70 000) and one small (30 000 or 27 000) subunit, both of which contain iron and labile sulphide whereas only the larger subunit contains flavin. Determination of the amino-acid sequence around the active-centre disulphide of the two thioredoxins from yeast (*Saccharomyces cerevisiae*)⁶⁶⁶ permits comparison with the sequence from *E. coli* thioredoxin reported last year. The corrected sequence⁶⁶⁷ for the same region

⁶⁵⁶ L. D. Stegink, B. M. Sanborn, M. C. Brummel, and C. S. Vestling, *Biochim. Biophys. Acta*, 1971, **251**, 31.

⁶⁵⁷ M. C. Brummel, B. M. Sanborn, and L. D. Stegink, *Arch. Biochem. Biophys.*, 1971, **143**, 330.

⁶⁵⁸ E. M. Gregory, M. S. Rohrbach, and J. H. Harrison, *Biochim. Biophys. Acta*, 1971, **243**, 489.

⁶⁵⁹ E. M. Gregory, F. J. Yost, jun., M. S. Rohrbach, and J. H. Harrison, *J. Biol. Chem.*, 1971, **246**, 5491.

⁶⁶⁰ T. P. Fondy, G. B. Kitto, and G. A. Driscoll, *Biochemistry*, 1970, **9**, 1001.

⁶⁶¹ L. Siegel and J. S. Ellison, *Biochemistry*, 1971, **10**, 2856.

⁶⁶² L. M. Allen, J. Vanecek, and R. G. Wolfe, *Arch. Biochem. Biophys.*, 1971, **143**, 166.

⁶⁶³ E. B. Kearney, J. I. Salach, W. H. Walker, R. L. Seng, W. Kenney, E. Zeszotek, and T. P. Singer, *European J. Biochem.*, 1971, **24**, 321; W. H. Walker, E. B. Kearney, R. L. Seng, and T. P. Singer, *ibid.*, p. 328.


⁶⁶⁴ P. Righetti and P. Cerletti, *F.E.B.S. Letters*, 1971, **13**, 181.

⁶⁶⁵ K. A. Davis and Y. Hatefi, *Biochemistry*, 1971, **10**, 2509.

⁶⁶⁶ D. E. Hall, A. Baldesten, A. Holmgren, and P. Reichard, *European J. Biochem.*, 1971, **23**, 328.

⁶⁶⁷ O. Berglund and A. Holmgren, *J. Biol. Chem.*, 1971, **246**, 5544.

of the thioredoxin induced by phage T₄ is also shown, with a Tyr/Val inversion ⁶⁶⁷ of the previous ⁶⁶⁸ sequence:



Apart from the conserved disulphide loop there is no obvious homology between the yeast thioredoxins and the others, and whatever the reason for the two yeast thioredoxins they are clearly the products of different genes.

D. Aldolases.—Preliminary crystallographic studies on a new crystalline form of rabbit-muscle fructose 1,6-diphosphate (FDP) aldolase have been reported,⁶⁶⁹ and the catalytic and immunochemical properties of various hybrids of aldolase have been described.⁶⁷⁰ The amino-acid sequence around the active-site lysine in rabbit-muscle aldolase has been extended substantially by work in two laboratories^{671, 672} but unfortunately the sequences are at variance in many positions. Close homology with aldolase from rabbit muscle is observed in the 28 residues around the active-site lysine of codfish-muscle enzyme,⁶⁷³ and 12 residues around the lysine in the enzyme from lobster muscle⁶⁷⁴ are identical with those in other muscle aldolases:



Aldolases from different species contain different amounts of methionine; the single methionine in the frog-muscle enzyme⁶⁷⁵ is near the active-site lysine in the sequence -Lys-Pro-Asn-Met-. This lysine occurs in the sequence -Leu-Leu-Lys-Pro-Ser- in the FDP aldolase from spinach leaf.⁶⁷⁶ The unique C-terminal sequence of sturgeon-muscle aldolase,⁶⁷⁷ like the rabbit enzyme, is -His-Ala-Tyr, again evidence of homology. Aldolases from liver are also receiving attention. The amino-acid sequence at the

⁶⁶⁸ O. Berglund and A. Holmgren, *J. Biol. Chem.*, 1970, **245**, 6036.

⁶⁶⁹ E. G. Heidner, B. H. Weber, and D. Eisenberg, *Science*, 1971, **171**, 677.

⁶⁷⁰ E. E. Penhoet and W. J. Rutter, *J. Biol. Chem.*, 1971, **246**, 318.

⁶⁷¹ C. Y. Lai and T. Oshima, *Arch. Biochem. Biophys.*, 1971, **144**, 363.

⁶⁷² M. Sajgó, *F.E.B.S. Letters*, 1971, **12**, 349.

⁶⁷³ C. Y. Lai and C. Chen, *Arch. Biochem. Biophys.*, 1971, **144**, 467.

⁶⁷⁴ A. Guha, C. Y. Lai, and B. L. Horecker, *Arch. Biochem. Biophys.*, 1971, **147**, 692.

⁶⁷⁵ S.-M. Ting, C. L. Sia, C. Y. Lai, and B. L. Horecker, *Arch. Biochem. Biophys.*, 1971, **144**, 485.

⁶⁷⁶ G. Ribereau-Gayon, T. Ramasarma, and B. L. Horecker, *Arch. Biochem. Biophys.*, 1971, **147**, 343.

⁶⁷⁷ P. J. Anderson, *Canad. J. Biochem.*, 1971, **49**, 372.

active centre of the enzyme from rabbit liver has been extended ⁶⁷⁸ and the corresponding 36 residues have been established for the enzyme from ox liver ⁶⁷⁸ (see below); a 27-residue sequence included in this region of the enzyme from ox liver was determined independently.⁶⁷⁹ It is worth noting that in a correction ⁶⁷⁹ of a previous sequence, a proposed serine insertion in the enzyme from liver vanishes, so this is clearly not the reason for the kinetic differences between the muscle and liver enzymes. The active-centre sequences (36 residues) of the enzymes from rabbit and ox liver are identical, but even more remarkable perhaps is the high homology between liver and muscle enzymes (see also last year's Report):⁶⁷⁸

Rabbit liver	-Ala-Leu-Asn-Asp-His-His-Val-Tyr-Leu-Glu-Gly-Thr-Leu-Leu-
Ox liver	-Ala-Leu-Asn-Asp-His-His-Val-Tyr-Leu-Glu-Gly-Thr-Leu-Leu-
Rabbit muscle	-Ala-Leu-Ser -Asp-His-His-Ile -Tyr-Leu-Glu-Gly-Thr-Leu-Leu-
Rabbit liver	Lys-Pro-Asn-Met-Val-Thr-Ala-Gly-His-Ala-Cys-Thr-Lys-Lys-
Ox liver	Lys-Pro-Asn-Met-Val-Thr-Ala-Gly-His-Ala-Cys-Thr-Lys-Lys-
Rabbit muscle	Lys-Pro-Asn-Met-Val-Thr-Pro-Gly-His-Ala-Cys-Thr-Gln-Lys-
Rabbit liver	Tyr-Thr-Pro-Gln-Glu-Val-Ala-Met-
Ox liver	Tyr-Thr-Pro-Gln-Glu-Val-Ala-Met-
Rabbit muscle	Tyr-Ser -His-Glu-Glu-Ile -Ala-Met-

A further study of the thiol groups of rabbit-muscle aldolase has confirmed the presence of an eighth, which is assigned to the N-terminal cyanogen bromide fragment.⁶⁸⁰

Aldolases from various other sources have been described. The enzyme from the muscle of the shark ⁶⁸¹ (*Mustelus canis*) is similar to rabbit-muscle aldolase, and the enzyme from the liver of the domestic fowl is also unexceptional in its properties.^{682a} Statistical treatment of amino-acid compositions, and immunochemical studies, support the idea that divergences between enzymes from different species are smaller than between the same enzyme from different tissues within a species.^{682b} It is interesting that the green alga *Chlamydomonas reinhardtii* contains two aldolases whose properties suggest that one is a Class I enzyme whereas the other belongs to Class II.⁶⁸³

Unfashionable though trimers may be, sedimentation and chemical evidence in support of a three-subunit structure for 2-keto-3-deoxy-6-phosphogluconate aldolase from *Pseudomonas putida* has been presented,⁶⁸⁴

⁶⁷⁸ B. G. Forcina and R. N. Perham, *F.E.B.S. Letters*, 1971, **18**, 59.

⁶⁷⁹ S.-M. Ting, C. Y. Lai, and B. L. Horecker, *Arch. Biochem. Biophys.*, 1971, **144**, 476.

⁶⁸⁰ C. Y. Lai, C. Chen, J. D. Smith, and B. L. Horecker, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1497.


⁶⁸¹ C. E. Caban and L. F. Hass, *J. Biol. Chem.*, 1971, **246**, 6807.

⁶⁸² (a) R. R. Marquardt, *Canad. J. Biochem.*, 1971, **49**, 647; (b) R. R. Marquardt, *ibid.*, p. 658.

⁶⁸³ A. M. Guerrini, T. Cremona, and E. C. Preddie, *Arch. Biochem. Biophys.*, 1971, **146**, 249.

⁶⁸⁴ R. H. Hammerstedt, H. Möhler, K. A. Decker, and W. A. Wood, *J. Biol. Chem.*, 1971, **246**, 2069.

the strongest evidence perhaps being the generation of four hybrid species from native and maleylated enzyme. It is a Class I aldolase and the sequence around the substrate-binding lysine has been shown ⁶⁸⁵ to be:



There is clearly no similarity between this and the active site of the Class I fructose 1,6-diphosphate aldolases from muscle (see above). Inactivation of the enzyme with fluorodinitrobenzene has been re-examined ⁶⁸⁶ and the reaction of chlorodinitrobenzene with the isoenzymes of transaldolase from *Candida utilis* now appears ⁶⁸⁷ to be with cysteine, and not lysine as reported earlier. The 2-keto-4-hydroxyglutarate aldolase ⁶⁸⁸ and the 2-keto-4-hydroxybutyrate aldolase ⁶⁸⁹ from bovine liver are the same enzyme ⁶⁸⁹ and function *via* a Schiff-base mechanism, *i.e.* they are Class I aldolases.

E. Nucleases.—Staphylococcal nuclease, ribonucleases, and deoxyribonucleases are excellently reviewed in a single volume.⁶⁹⁰ A high-resolution (2 Å) structure of an inhibitor complex of the staphylococcal nuclease has now been published,⁶⁹¹ and, with the primary structure of the enzyme from the same strain of *S. aureus* (Foggi) also available,⁶⁹² publication of a detailed mechanism of the catalytic action will doubtless soon follow. The enzyme from the Foggi strain has the same sequence as that of the V-8 strain published some years ago, with a change of Leu to His at position 124.

The elegant reconstitution experiments in which inactive fragments from limited tryptic cleavage of the enzyme regain activity are now well known, and further experiments continue to contribute to a general picture of protein folding. Two types of active complementing structures were formed simultaneously and in approximately equal amount when the fragments 1—126 and 49—149 were mixed.⁶⁹³ In one case binding was between residues 1—126 and 111—149 and in the other between 1—48 and 49—149. The redundant portions (49—110 and 49—126 respectively) appeared to be flexible, external to the folded structure, and readily digested with trypsin. Residues 1—126 also bind to the cyanogen bromide fragment 99—149 to give an enzymically active complex from which residues 99—110 could be removed with trypsin. These experiments show that peptide bonds either between residues 48 and 50 (in an exposed loop in the X-ray structure) or

⁶⁸⁵ D. C. Robertson, W. W. Altekari, and W. A. Wood, *J. Biol. Chem.*, 1971, **246**, 2084.

⁶⁸⁶ L. R. Barran and W. A. Wood, *J. Biol. Chem.*, 1971, **246**, 4028.

⁶⁸⁷ O. Tsolas, J. de Castro, and B. L. Horecker, *Arch. Biochem. Biophys.*, 1971, **143**, 516.

⁶⁸⁸ R. D. Kobes and E. E. Dekker, *Biochemistry*, 1971, **10**, 388.

⁶⁸⁹ R. S. Lane, A. Shapley, and E. E. Dekker, *Biochemistry*, 1971, **10**, 1353.

⁶⁹⁰ 'The Enzymes', ed. P. D. Boyer, Academic Press, New York, and London, 3rd edn., 1971, vol. 4.

⁶⁹¹ A. Arnone, C. J. Bier, F. A. Cotton, V. W. Day, E. E. Hazen, jun., D. C. Richardson, J. S. Richardson, and A. Yonath, *J. Biol. Chem.*, 1971, **246**, 2302.

⁶⁹² J. L. Cone, C. L. Cusumano, H. Taniuchi, and C. B. Anfinsen, *J. Biol. Chem.*, 1971, **246**, 3103.

⁶⁹³ H. Taniuchi and C. B. Anfinsen, *J. Biol. Chem.*, 1971, **246**, 2291.

somewhere between residues 113 and 124 can be cleaved without destroying the information required for formation of a functional structure, and that stable structures resembling the native enzyme can be formed in a number of ways when the minimum information requirement (the entire amino-acid sequence) is fulfilled. Breaks at both sites simultaneously are even permissible and the three fragments will recombine to generate (albeit low) enzymic activity.⁶⁹⁴ Solid-phase synthetic studies confirmed (see above) that in the recombination system (1—126) + (99—149), the sequence (99—126) present in both fragments is contributed in the active functional complex by (1—126), since fragment (99—149) may be shortened by several residues without affecting productive complementation with fragment (1—126).⁶⁹⁵ Trp-140 may also be replaced by Phe without ill effect.⁶⁹⁶ This single tryptophan residue is probably important in stabilizing the structure rather than in catalysis, since modification of tryptophan in the native enzyme with nitrophenylsulphenyl halides disrupted the helical content substantially, with loss of only half the enzymic activity.⁶⁹⁶ This is in agreement with the position of the tryptophan residue between two stretches of α -helix in the X-ray structure.⁶⁹¹ The importance of Asp-21, Arg-35, Asp-40, and Glu-43 (thought to be involved in binding the inhibitor and Ca^{2+} ions in the X-ray structure) has been demonstrated, using analogues of the peptide 6—47 made by solid-phase synthesis,⁶⁹⁷ and testing for formation of active complex with 49—149. When charge was preserved (Asp \rightarrow Glu, Arg \rightarrow Lys, Glu \rightarrow Asp) the fragments associated but the complex was inactive; if charge was not preserved there was no binding. The only exception was the substitution of Asp-40 by Asn, which gave rise to active complex. (It is worth noting that this information made available by solid-phase synthesis would not be easily available in any other way.)

Full details have now been published⁶⁹⁸ of the solid-phase synthesis of bovine pancreatic ribonuclease A. As a bonus of the solid-phase method, the des-(21—25)-S-protein and S-protein itself were obtained by removing samples from the machine after the appropriate number of couplings; both combined equally well with S-peptide when mixtures were denatured and renatured, showing that the first five residues of S-protein are not required for the folding process.⁶⁹⁸ ^{19}F N.m.r. has been used to observe changes in conformation when ribonuclease S, trifluoroacetylated at Lys-1 and Lys-7, associates with S-peptide,⁶⁹⁹ and the crystallization of 41-Dnp-S-protein has been reported.⁷⁰⁰ Elongation of all four disulphide bonds in ribonuclease A by *ca.* 3 Å by conversion into -S-Hg-S- (see these Reports for

⁶⁹⁴ G. Andria, H. Taniuchi, and J. L. Cone, *J. Biol. Chem.*, 1971, **246**, 7421.

⁶⁹⁵ I. Parikh, L. Corley, and C. B. Anfinsen, *J. Biol. Chem.*, 1971, **246**, 7392.

⁶⁹⁶ I. Parikh and G. S. Omenn, *Biochemistry*, 1971, **10**, 1173.

⁶⁹⁷ I. M. Chaiken and C. B. Anfinsen, *J. Biol. Chem.*, 1971, **246**, 2285.

⁶⁹⁸ B. Gutte and R. B. Merrifield, *J. Biol. Chem.*, 1971, **246**, 1922.

⁶⁹⁹ W. H. Huestis and M. A. Raftery, *Biochemistry*, 1971, **10**, 1181.

⁷⁰⁰ D. S. Fung and M. S. Doscher, *Biochemistry*, 1971, **10**, 4099.

1969, 1970) caused conformational changes, but some activity was retained.⁷⁰¹ A further study⁷⁰² of the carboxymethylation of histidine residues in the enzyme (see last year's Report) shows that both His-12 and His-119 can be carboxymethylated in the same active site, even though it has generally been assumed that the carboxymethylations are mutually exclusive. The reaction can go to completion in time, but 17% of the species containing 3-Cm His-12 and 1-Cm His-119 is present even after 24 h. His-48 (which the X-ray structure shows to be buried) does not react but methionine and lysine do, and the sequence of events has been determined.⁷⁰³

Several ribonucleases from micro-organisms are also being studied. A much improved purification of ribonuclease T₁ from *Takadiastase* (an extract of the mould *Aspergillus oryzae*) has been published,⁷⁰³ and a series of papers⁷⁰⁴ gives full details of the determination of the amino-acid sequence of the enzyme reported in 1965. There are two disulphide bridges [(2—10) and (6—103)] and the sequence is quite unrelated to that of bovine ribonuclease A. Ribonuclease U₁ (from *Ustilago sphaeroides*) has been purified in two laboratories^{705, 706} and ribonuclease N₁ (from *Neurospora crassa*) also described.⁷⁰⁶ All three nucleases (T₁, U₁, and N₁) have two disulphide bridges (involving in U₁ the N-terminus⁷⁰⁵ and in T₁ the 2-position^{704a}) and molecular weights of ca. 11 000. A much larger ribonuclease (m. wt. 34 000) which cleaves after purine bases (particularly adenine) has been purified from *Octopus vulgaris*.⁷⁰⁷

Of the two tryptophan residues in bovine pancreatic deoxyribonuclease that can be modified chemically, one is essential for catalysis.⁷⁰⁸ Unpublished work from another laboratory quoted in this paper⁷⁰⁸ claims that the enzyme has a total of three tryptophan residues, not four.

F. Pyridoxal Phosphate Enzymes.—Studies of the primary structure of aspartate aminotransferase from pig heart⁷⁰⁹ place 383 residues in sequence, out of a total of 400—430. Two additional thiol groups per dimer of 90 000 daltons become exposed when the aldimine form (PLP-enzyme)

⁷⁰¹ R. Sperling and I. Z. Steinberg, *J. Biol. Chem.*, 1971, **246**, 715.

⁷⁰² J. Bello and E. F. Nowoswiat, *European J. Biochem.*, 1971, **22**, 225.

⁷⁰³ R. Fields, H. B. F. Dixon, and G. R. Law, *Biochem. J.*, 1971, **121**, 591.

⁷⁰⁴ (a) K. Takahashi, *J. Biochem. (Japan)*, 1971, **70**, 477, 603, 617, 803; (b) K. Takahashi, *ibid.*, p. 945.

⁷⁰⁵ W. C. Kenney and C. A. Dekker, *Biochemistry*, 1971, **10**, 4962.

⁷⁰⁶ J. Hashimoto, T. Uchida, and F. Egami, *J. Biochem. (Japan)*, 1971, **70**, 903.

⁷⁰⁷ F. De Lorenzo, G. Molea, and M. Molinaro, *Arch. Biochem. Biophys.*, 1971, **146**, 327.

⁷⁰⁸ T. L. Poulos and P. A. Price, *J. Biol. Chem.*, 1971, **246**, 4041.

⁷⁰⁹ (a) Yu. A. Ovchinnikov, A. A. Kiryushkin, Ts. A. Egorov, N. G. Abdulaev, A. P. Kiselev, N. N. Modyanov, E. V. Grishin, E. I. Vinogradova, M. Yu. Feigina, N. A. Aldanova, and V. M. Lipkin, *F.E.B.S. Letters*, 1971, **12**, 194; (b) Yu. A. Ovchinnikov, A. A. Kiryushkin, Ts. A. Egorov, N. G. Abdulaev, A. P. Kiselev, N. N. Modyanov, E. V. Grishin, A. P. Sukhikh, E. I. Vinogradova, M. Yu. Feigina, N. A. Aldanova, V. M. Lipkin, A. E. Braunstein, O. L. Polyanovsky, and V. V. Nosikov, *F.E.B.S. Letters*, 1971, **17**, 133.

is converted into the amine form (PMP + enzyme),⁷¹⁰ and inactivation of the apoenzyme with tetranitromethane can be correlated with nitration of a single tyrosine residue at the coenzyme binding site.⁷¹¹ Some conclusions about steric relationships at the active site of aspartate aminotransferase can be drawn from a spectral study of the free and bound forms of the apoenzyme inhibitors *N*-(5'-phosphopyridoxyl)glutamic acid and its pyrrolidonecarboxylic acid analogue.⁷¹² These resemble the holoenzyme-glutamate complex. The relation between the quite distinct soluble and mitochondrial forms of glutamic-oxaloacetic transaminase from pig-heart muscle is being investigated at the level of primary structure.⁷¹³ A cyanogen bromide fragment from each shows clear homology:^{713a}

soluble	-Ala-Asp-Arg-Ile-Leu-Ser-Met-
mitochondrial	-Ala-Asp-Arg-Ile-Ile -Ser-Met-

but the amino-terminal sequences are not obviously related:^{713b}

soluble	Ala-Pro-Pro-Ser -Val-Phe-Ala-Glu-Val-
mitochondrial	Ser-Ser-Trp-Trp-Ala-His-Val-Glu-Met-

and it will be interesting to see what further studies of the sequences hold in store.

Chemical evidence suggests⁷¹⁴ that the histidine decarboxylase from *Micrococcus* sp.n. has six chains, three with *N*-terminal Met and three with *N*-terminal X-Phe, where X awaits identification. It is worth recalling that the enzyme from *Lactobacillus* 30a (last year's Report, p. 103) had ten chains, five of which have *N*-terminal pyruvoylphenylalanyl residues, and perhaps speculating that a similar situation might obtain for the micrococcal enzyme. There has been some uncertainty about the subunit structure of glutamate decarboxylase; electron microscopy now reveals a hexamer for the enzyme from *E. coli* B.⁷¹⁵ The amino-acid sequence around the pyridoxal-binding lysine residue in glutamate decarboxylase reported last year (these Reports) can now be compared with the sequence determined for the pyridoxal site in arginine decarboxylase:⁷¹⁶

Arg decarboxylase:

-Ala-Thr-His-Ser-Thr-^{*}His-Lys-Leu-Leu-Asn-Ala-Leu-Ser-Gln-Ala-Ser-Tyr-

⁷¹⁰ I. Cournil and M. Arrio-Dupont, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 40.

⁷¹¹ C. Turano, D. Barra, F. Bossa, A. Ferraro, and A. Giartosio, *European J. Biochem.*, 1971, **23**, 349.

⁷¹² R. M. Khomutov, H. B. F. Dixon, L. V. Vdovina, M. P. Kirpichnikov, Y. V. Morozov, E. S. Severin, and E. N. Khurs, *Biochem. J.*, 1971, **124**, 99.

⁷¹³ (a) T. Watanabe and H. Wada, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 1310; (b) H. Wada, T. Watanabe, and A. Miyatake, *ibid.*, p. 1318.

⁷¹⁴ V. N. Prozorovskii, S. R. Mardashev, and A. M. Sokhina, *Biochemistry (U.S.S.R.)*, 1970, **35**, 788.

⁷¹⁵ C. M. To, *J. Mol. Biol.*, 1971, **59**, 215.

⁷¹⁶ E. A. Boeker, E. H. Fischer, and E. E. Snell, *J. Biol. Chem.*, 1971, **246**, 6776.

Glu decarboxylase:

-Ser-Ile -Ser -Ala-Ser-Gly-His-Lys-Phe-^{*}

It remains to be seen whether the -His-Lys-^{*} sequence will be a common feature in pyridoxal-phosphate-dependent decarboxylases.

It is interesting that the same peptide also occurs in the β_2 -subunits of tryptophan synthetase from *E. coli*⁷¹⁷ and *Pseudomonas putida*⁷¹⁸ which are clearly homologous in the region containing the pyridoxal-phosphate-binding site:

<i>E. coli</i>	-Arg-Glu-Asp-Leu-Leu-His-Gly-Gly-Ala-His-Lys-Thr-Asn-Gln-
<i>Pseudomonas putida</i>	-Arg-Glu-Glu-Leu-Asn-His-Thr-Gly-Ala-His-Lys-Val-Asn-Asn-
<i>E. coli</i>	Val-Leu-Gly-Gln-Ala-Leu-Leu-Ala-Lys-
<i>Pseudomonas putida</i>	Cys-Ile -Gly-Gln-Val-Leu-Leu-Ala-Lys-

This is the first information on the primary structure of the β_2 -subunit of the $\alpha_2\beta_2$ complex, whereas the structure of the α -subunit has been known for some time. It has thus been possible⁷¹⁹ to identify the cross-link introduced into the α -subunit by the bifunctional reagent bis(maleimidomethyl) ether (*cf.* modification of haemoglobins, p. 146) as Cys-80/Cys-117, with no reaction at the remaining cysteine, Cys-153; this appears to be 'buried' in native enzyme, but will, however, react with *N*-ethylmaleimide, as a result of a conformational change, in the presence of indole.⁷²⁰ The cross-linked product from reaction with bis(maleimidomethyl) ether is functionally heterogeneous, with 70% of the modified α -subunit being devoid of independent indole glycerol phosphate activity and unable to form a functional complex with the β_2 subunit.⁷¹⁹ Similar loss of enzymic activity was observed when Cys-80 and Lys-108 were cross-linked with 1,5-difluoro-2,4-dinitrobenzene⁷²¹ but not when intramolecular methylene cross-links were introduced into the α -subunit with formaldehyde.⁷²² The sites of reaction in the latter case⁷²² were tentatively assigned as Asn-156/Ser-214 and Gln-218/Ser-232. It is worth remarking that studies such as these with cross-linking reagents of different span lengths are a nice and effective way of charting the surface of the protein molecule, with X-ray analysis being the final test of their validity. The many mutant forms of tryptophan synthetase which have been well characterized in Yanofsky's laboratory not only illuminate elegantly the effect of defined amino-acid substitution on

⁷¹⁷ R. Fluri, L. E. Jackson, W. E. Lee, and I. P. Crawford, *J. Biol. Chem.*, 1971, **246**, 6620.

⁷¹⁸ R. Maurer and I. P. Crawford, *J. Biol. Chem.*, 1971, **246**, 6625.

⁷¹⁹ W. B. Freedberg and J. K. Hardman, *J. Biol. Chem.*, 1971, **246**, 1439.

⁷²⁰ W. B. Freedberg and J. K. Hardman, *J. Biol. Chem.*, 1971, **246**, 1449.

⁷²¹ J. K. Hardman and D. F. Hardman, *J. Biol. Chem.*, 1971, **246**, 6489.

⁷²² J. S. Myers and J. K. Hardman, *J. Biol. Chem.*, 1971, **246**, 3863.

protein function but also make this a particularly attractive protein for chemical modification studies.

A sequence of 42 residues containing the pyridoxal-phosphate-binding site of rabbit-muscle phosphorylase is as shown:⁷²³

-Arg-Val-Ser-Leu-Ala-Glx-Lys-Val-Ile-Pro-Ala-Ala-Asp-Leu-Ser-Glx-Glx-Ile-

Ser-Thr-Ala-Gly-Thr-Gln-Ala-Ser-Gly-Thr-Gly-Asp-Met-Lys-Phe-Met-Gly-Arg-
Thr-Leu(Glx,Asx,Thr)-Met-

Worth noting, perhaps, is the ^{*}-Lys-Phe- sequence, also found in the pyridoxal-phosphate-binding site of glutamate decarboxylase (see above). Fluorescence studies⁷²⁴ support an earlier suggestion that pyridoxal phosphate is bound in a hydrophobic environment in the phosphorylase b dimer, and the particles seen in an electron-microscopic study⁷²⁵ were taken to be phosphorylase b tetramers. Phosphorylases a and b from yeast have also been described.⁷²⁶

G. Other Enzymes.—The composition and C-terminal sequences of erythrocyte carbonic anhydrase from various mammalian species have been determined⁷²⁷ (asterisked) and compared with existing sequences:

Human	B	-Val-Arg-Ala-Ser-Phe
	C	-Ile -Lys-Ala-Ser-Phe-Lys
Pig	B	-Lys-Ala-Ser-Phe
	C*	-Arg-Ser-Phe -Lys
Horse	B*	-Val-Arg-Ala-Phe-Phe
	C*	-Ile -Arg-Ala-Ser -Phe-Lys
Ox	B(C)	-Val-Arg-Gly-Phe-Pro-Lys
Sheep	C*	-Val-Arg-Val-Phe-Pro-Lys
Deer	C*	-Pro-Arg

They clearly fall into two groups: those containing C-terminal -Pro-^{Arg}Lys, and those that have Phe as the last or penultimate residue. It is suggested that there is a relationship between evolutionary grouping and the predominant carbonic anhydrase, and a scheme for the evolution of B- and C-type carbonic anhydrases by gene duplication from a primordial carbonic anhydrase C is proposed.⁷²⁷ The enzyme from two species of shark appears to have properties similar to those of the mammalian enzymes.⁷²⁸ Dinitrophenylation of human carbonic anhydrase B occurred⁷²⁹ at the 3-position of His-204, also the site of reaction of iodo-

⁷²³ A. W. Forrey, C. L. Sevilla, J. C. Saari, and E. H. Fischer, *Biochemistry*, 1971, **10**, 3132.

⁷²⁴ D. C. Jones and R. W. Cowgill, *Biochemistry*, 1971, **10**, 4276.

⁷²⁵ N. A. Kiselev and F. Ya Lerner, *J. Mol. Biol.*, 1971, **62**, 537.

⁷²⁶ M. Fosset, L. W. Muir, L. D. Nielsen, and E. H. Fischer, *Biochemistry*, 1971, **10**, 4105.

⁷²⁷ R. B. Ashworth, J. M. Brewer, and R. L. Stanford, jun., *Biochem. Biophys. Res. Comm.*, 1971, **44**, 667.

⁷²⁸ J. R. Maynard and J. E. Colman, *J. Biol. Chem.*, 1971, **246**, 4455.

⁷²⁹ P. Henkart and F. Dorner, *J. Biol. Chem.*, 1971, **246**, 2714.

acetate. The residue is not ascribed a role in catalysis although it does appear to be near the active site. Its reactivity towards FDNB is attributed to its high nucleophilicity, thought to be a consequence of a fairly hydrophobic environment.⁷²⁹

Additional evidence has been presented⁷³⁰ that the three main isoenzymes (97%) of triose phosphate isomerase from rabbit muscle are of the form AA, BB, and AB; the nature of the difference between the chains has not yet been revealed in what is known of the amino-acid sequence. Happily the slight uncertainty about the sequence around the glutamic acid residue labelled by halogenoacetol phosphates (see last year's Report) has now disappeared with publication of full details from the two laboratories concerned^{731, 732} and some correction in one case.⁷³² So the sequence is now:

-Trp-Val-Leu-Ala-Tyr-Glu-Pro-Val-Trp-Ala-Ile-Gly-Thr-Gly-Lys-

Amino-acid sequences around the five cysteine residues⁷³³ give an additional 75 residues of the primary structure. Preliminary work on purified triose phosphate isomerase from human erythrocytes⁷³⁴ shows three main bands on isoelectric focusing.

In the accepted model of the α -keto-acid dehydrogenase multienzyme complexes, a basic structural unit composed of transacylase chains binds the decarboxylase and dihydrolipoyl dehydrogenase enzymes. The subunit molecular weights of the component enzymes of the complexes from *E. coli* (Crookes' strain) have been redetermined⁷³⁵ and some revision of accepted molecular weights was found necessary. The N-terminus of the pyruvate decarboxylase component (subunit m. wt. 90 000) from the pyruvate dehydrogenase complex of *E. coli* K 12 is Ser-^{736, 737} and the C-terminal sequence is -Arg-Leu-Ala.⁷³⁷ The transacylase component (subunit m. wt. 80 000) of the same complex has the C-terminal sequence -Arg-Arg-(Val,Leu)-Met and no detectable N-terminus.⁷³⁸ It has not yet been crystallized but a preliminary X-ray analysis of the corresponding enzyme, dihydrolipoyl trans-succinylase, from the α -ketoglutarate dehydrogenase complex has been reported.⁷³⁹ The organization of the transacylase and trans-succinylase units as seen in the electron microscope is very similar,

⁷³⁰ W. K. G. Kietsch, P. G. Pentchev, and H. Klingenburg, *European J. Biochem.*, 1971, **23**, 77.

⁷³¹ J. C. Miller and S. G. Waley, *Biochem. J.*, 1971, **123**, 163.

⁷³² F. C. Hartman, *Biochemistry*, 1971, **10**, 146.

⁷³³ J. C. Miller and S. G. Waley, *Biochem. J.*, 1971, **122**, 209.

⁷³⁴ E. E. Rozacky, T. H. Sawyer, R. A. Barton, and R. W. Gracy, *Arch. Biochem. Biophys.*, 1971, **146**, 312.

⁷³⁵ R. N. Perham and J. O. Thomas, *F.E.B.S. Letters*, 1971, **15**, 8.

⁷³⁶ G. Dennert and D. Eaker, *F.E.B.S. Letters*, 1970, **6**, 257.

⁷³⁷ O. Vogel and U. Henning, *European J. Biochem.*, 1971, **18**, 103.

⁷³⁸ O. Vogel, H. Beikirch, H. Müller, and U. Henning, *European J. Biochem.*, 1971, **20**, 169.

⁷³⁹ D. J. Derosier, R. M. Oliver, and L. J. Reed, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1135.

and the presence of 24 chains in cubic array seems confirmed by the *X*-ray results.⁷³⁹ The reaction of the decarboxylase components of the pyruvate dehydrogenase complexes of *E. coli*⁷⁴⁰ and pigeon breast muscle⁷⁴¹ with mercurials suggests that thiol groups may be involved in binding the cofactor thiamine pyrophosphate.

Ile-Ile-Tyr-Pro-Gly-Thr-Leu-Trp-Cys-Gly-His-Gly-Asn-Lys-Ser-Ser-Gly-Pro-
 1 10
 Asn-Glu-Leu-Gly-Arg-Phe-Lys-His-Thr-Asp-Ala-Cys-Cys-Arg-Thr-His-Asp-
 20 30
 Met-Cys-Pro-Asn-Val-Met-Ser-Ala-Gly-Glu-Ser-Lys-His-Gly-Leu-Thr-Asp-
 40 50
 Thr-Ala-Ser-Arg-Leu-Ser-Cys-Asn-Asp-Asn-Asp-Leu-Phe-Tyr-Lys-Asp-Ser-
 60
 Ala-Asp-Thr-Ile-Ser-Ser-Tyr-Phe-Val-Gly-Lys-Met-Tyr-Phe-Asn-Leu-Ile-Asn-
 70 80
 Thr-Lys-Cys-Tyr-Lys-Leu-Glu-His-Pro-Val-Thr-Gly-Cys-Gly-Glu-Arg-
 90 100
 Thr-Glu-Gly-Arg-Cys-Leu-His-Tyr-Thr-Val-Asp-Lys-Ser-Lys-Pro-Lys-Val-
 110 120
 Tyr-Gln-Trp-Phe-Asp-Leu-Arg-Lys-Tyr
 129

Figure 16 Amino-acid sequence of phospholipase-A from bee venom

Pancreatic lipase has been reviewed⁷⁴² and the preliminary characterization of the colipase as a small protein (m. wt. 10 000) reported.⁷⁴³ *Tout c'est la même chose*: histidine may be involved in the active site of pig pancreatic lipase.⁷⁴⁴ Phospholipases from bee and snake venoms are being actively studied. The complete amino-acid sequence (129 residues) of phospholipase A₂ from the common European honey bee *Apis mellifica* has been determined (Figure 16);⁷⁴⁵ the enzyme is a dimer of molecular weight 40 000 (about 30% of which is carbohydrate)⁷⁴⁶ with four disulphide bridges; the pancreatic enzyme (123 residues), whose zymogen sequence was reported last year (p. 102), had six. There is no obvious homology between the two enzymes but it may be worth noting the C-terminal sequence -Lys-Lys-Tyr-Cys of the pancreatic enzyme and the C-terminal sequence -Arg-Lys-Tyr in bee-venom phospholipase. It is now clear that the phospholipases A₂ of the venoms of the snakes *Crotalus adamanteus*⁷⁴⁷ and *C. atrox*⁷⁴⁸ are also dimers (m. wt. ca. 30 000) with a high cystine

⁷⁴⁰ E. R. Schwartz and L. J. Reed, *J. Biol. Chem.*, 1970, **245**, 183.

⁷⁴¹ L. S. Khailova, *Biochemistry (U.S.S.R.)*, 1971, **36**, 120.

⁷⁴² P. Desnuelle, *Biochimie*, 1971, **53**, 841.

⁷⁴³ M. F. Maylié, M. Charles, C. Gache, and P. Desnuelle, *Biochim. Biophys. Acta*, 1971, **229**, 286.

⁷⁴⁴ M. Sémériva, C. Dufour, and P. Desnuelle, *Biochemistry*, 1971, **10**, 2143.

⁷⁴⁵ R. A. Shipolini, G. L. Callewaert, R. C. Cottrell, and C. A. Vernon, *F.E.B.S. Letters*, 1971, **17**, 39.

⁷⁴⁶ R. A. Shipolini, G. L. Callewaert, R. C. Cottrell, S. Doonan, C. A. Vernon, and B. E. C. Banks, *European J. Biochem.*, 1971, **20**, 459.

⁷⁴⁷ M. A. Wells, *Biochemistry*, 1971, **10**, 4074.


⁷⁴⁸ Y. Hachimori, M. A. Wells, and D. J. Hanahan, *Biochemistry*, 1971, **10**, 4084.

content, but the C-terminal sequence (*C. adamanteus*) is -Ser-Gly-Cys-Leu. A phospholipase A inhibitor from *Bothrops neuwiedii* venom⁷⁴⁹ appears to require thiol groups for its inhibitory activity. A new membrane-bound phospholipase, phospholipase A₁, has been isolated from *E. coli*.⁷⁵⁰ It has a different substrate specificity from phospholipase A₂ and appears to have a subunit molecular weight of *ca.* 29 000. The enzyme is stable in 3% SDS and tends to aggregate in its absence, all implying, perhaps, a hydrophobic exterior that may be related to its location at the membrane.


A peptide isolated from the luciferin-binding site of firefly luciferase had the sequence:⁷⁵¹



where X may be tyrosine and attachment is through a thioether linkage. Specific labelling was achieved with the active-site-directed inhibitor 2-cyano-6-chlorobenzothiazole (14), an analogue of firefly luciferin (15). No



(14)



(15)

reaction occurred at the two reactive thiol groups per dimer (m. wt. 100 000) and the importance of precise design of reagent is apparent here because earlier work had shown that these thiol groups are close to the site that binds the carboxy-group of luciferin, *i.e.* removed from the 6-position which reacts in the present instance. A self-associating low molecular weight luciferase with one thiol group per subunit of 12 000 daltons has been isolated⁷⁵² from the sea pansy *Renilla reniformis*. The roles of the two non-identical subunits of luciferase (from *Photobacterium fischeri*) in the bioluminescent reaction are clearly different, as shown⁷⁵³ by the properties of hybrids in which one or other (or both or neither) of the subunits is succinylated. The $\alpha\beta_s$ species had at least 50% of native activity while the $\alpha_s\beta$ enzyme was virtually inactive. The α -subunit appears to participate directly in the catalytic step of the reaction, the function of the β -subunit being unclear.⁷⁵⁴ Perhaps some remarks about the 'genetic' approach to the study of quaternary structure are not amiss here. Briefly, in one sort of experiment⁷⁵⁵ a bacterium (either wild-type or mutant) carries an episome of another bacterium and produces two types of a given enzyme, one characteristic of each organism. From the number of *in vivo* hybrid

⁷⁴⁹ J. C. Vidal and A. O. M. Stoppani, *Arch. Biochem. Biophys.*, 1971, **147**, 66.

⁷⁵⁰ C. J. Scandella and A. Kornberg, *Biochemistry*, 1971, **10**, 4447.

⁷⁵¹ R. T. Lee and W. O. McElroy, *Arch. Biochem. Biophys.*, 1971, **146**, 551.

⁷⁵² Y. D. Karkhanis and M. J. Cormier, *Biochemistry*, 1971, **10**, 317.

⁷⁵³ E. A. Meighen, M. Ziegler Nicoli, and J. W. Hastings, *Biochemistry*, 1971, **10**, 4062.

⁷⁵⁴ E. A. Meighen, M. Ziegler Nicoli, and J. W. Hastings, *Biochemistry*, 1971, **10**, 4069.

⁷⁵⁵ K. K. Lew and J. R. Roth, *Biochemistry*, 1971, **10**, 204.

species shown by electrophoresis the number of subunits in the enzymes can be calculated. The pros and cons of the genetic approach have been considered.^{755, 753} Using genetic variants in a rather different, more clearly defined way, hybrids have been constructed from subunits of wild-type and defective β -galactosidase⁷⁵⁶ and it could be shown, for example, that a single wild-type subunit in a hybrid tetramer could be active independent of the other subunits. This approach is, of course, limited by the availability of mutants but should nonetheless be a powerful tool in the study of subunit interactions.

The subunit structure of aspartate transcarbamylase from *E. coli* has been thoroughly re-investigated⁷⁵⁷ and the structure favoured contains two catalytic trimers intercalated by six regulatory subunits as dimers (Figure 17). There is much evidence for the existence of the catalytic subunit as a trimer, including titration with the transition-state analogue *N*-(phosphonacetyl)-L-aspartate,⁷⁵⁸ which combines most of the structural features of the two natural substrates, carbamyl phosphate and L-aspartate, and binds 1000 times more strongly than carbamyl phosphate.

Hybridization of native dimers of creatine kinase with dimers modified with iodoacetamide at the one essential thiol group per subunit gives a stable tetrameric structure, but with only 50% of the native activity.⁷⁵⁹ Lombricine kinase, ATP:guanidine phosphotransferase, from *Lumbricus terrestris* (earthworm) muscle, is a dimer (m. wt. ca. 80 000) with only one essential thiol group per dimer (perhaps because only one of the subunits is catalytic). Comparison of the sequence around the thiol group⁷⁶⁰ with known sequences around the essential thiol (2 per dimer) in creatine kinase and arginine kinase shows that they are clearly homologous:

Lombricine kinase (earthworm)	-Leu-Gly-Tyr-Ile - - Thr-Cys-Pro-Gly-Ser-Asn-*
Creatine kinase (rabbit muscle)	-Asn-His-Leu-Gly-Tyr-Val-Leu-Thr-Cys-Pro- - -Ser-Asn-
(ox brain)	-Asn-His-Leu-Gly-Tyr-Ile -Leu-Thr-Cys-Pro- - -Ser-Asn-
Arginine kinase (lobster)	-Gln-Thr-Cys-Pro-Thr-Ser-Asn-
Lombricine kinase (earthworm)	Leu-Gly-Thr- - -Leu-Arg-
Creatine kinase (rabbit muscle)	Leu-Gly-Thr-Gly-Leu-Arg-
(ox brain)	Leu-Gly-Thr-Gly-Leu-Arg-
Arginine kinase (lobster)	Leu-Gly-Thr- - -Val-Arg-

The sequence around a single lysine residue in chicken creatine kinase that

⁷⁵⁵ F. Melchers and W. Messer, *J. Mol. Biol.*, 1971, **61**, 401.

⁷⁵⁷ J. P. Rosenbusch and K. Weber, *J. Biol. Chem.*, 1971, **246**, 1644.

⁷⁵⁸ K. O. Collins and G. R. Stark, *J. Biol. Chem.*, 1971, **246**, 6599.

⁷⁵⁹ D. Allard and J. C. Dreyfus, *Biochimie*, 1971, **53**, 311.

⁷⁶⁰ E. der Terrossian, G. Desvages, L.-A. Pradel, R. Kassab, and N. van Thoai, *European J. Biochem.*, 1971, **22**, 585.

can be labelled with dansyl chloride (after blocking the thiol group with tetrathionate) is:⁷⁶¹




Figure 17 Proposal for the arrangement of the polypeptide chains in aspartate transcarbamylase. The larger units (light shading) represent the six catalytic chains grouped in two trimers around a 3-fold symmetry axis (vertical line). The two trimers are arranged around three 2-fold symmetry axes (one of which is indicated by a horizontal line). The six regulatory chains (dark shading) are intercalated as dimers between the two catalytic trimers. Placing the subunits in register along the 3-fold axis is used for the purpose of better visualization only (Reproduced by permission from *J. Biol. Chem.*, 1971, 246, 1644)

Numerous other observations on a number of enzymes ought to be mentioned. Phenylalanine ammonia-lyase from yeast has been shown to have dehydroalanine at its active site⁷⁶² like histidine ammonia-lyase. The dimeric model (m. wt. 88 000) for yeast enolase has been confirmed⁷⁶³ and the enzyme shown to be very resistant to exopeptidase digestion, contrary

⁷⁶¹ S. Bose and F. Friedberg, *Biochem. Biophys. Res. Comm.*, 1971, 45, 271.

⁷⁶² D. S. Hodgins, *J. Biol. Chem.*, 1971, 246, 2977.

⁷⁶³ P. A. Hargrave and F. Wold, *J. Biol. Chem.*, 1971, 246, 2904.

to previous reports. Active monomers of enolase have apparently been obtained by frontal elution⁷⁶⁴ and the technique is advocated as a possible general method for such purposes.⁷⁶⁴ Allosteric inhibition of glutamine synthetase by AMP results from binding of AMP in phosphodiester linkage to a tyrosyl side-chain in each of the chains. The sequence of amino-acid residues around this tyrosine residue, reported last year, has now been extended⁷⁶⁵ and a correction of Asp to Asn has been incorporated:

-Ile-His-Pro-Gly-Glu-Ala-Met-Lys-Asp-Asn-Leu-Tyr-Asp-Leu-Pro-Pro-Glu-Gly-Glu-Ala-Lys-

The complete amino-acid sequence (125 residues) has been determined⁷⁶⁶ for the Δ^5 -3-keto-steroid isomerase of *Pseudomonas testosteroni*, an enzyme with a very high turnover number, a putative trimeric structure, and clusters of hydrophobic residues throughout the sequence, any significance of which is unknown.

When Met tRNA synthetase from *E. coli* is incubated with trypsin at 37 °C the tetramer of $4 \times 43\,000$ molecular weight is converted into an enzymically active dimer of molecular weight $2 \times 32\,000$.⁷⁶⁷ Thus proteolysis is obviously the explanation for the dimeric form isolated when an autolytic step is included in the preparation of the enzyme. It is remarkable that loss of 20% of the structure by chain cleavage reduces the activity relative to the tetrameric form by only 20%, and this leads to speculation on the existence of two distinct regions in the subunit, produced by gene fusion. The two regions could be connected by a flexible piece of chain, whose presence intact promotes the formation of tetramers, thereby somehow conferring some selective advantage.⁷⁶⁷ In another study, deliberate genetic manipulation gave a fused protein in which histidinol dehydrogenase and imidazolylacetol phosphate:L-glutamate aminotransferase, folded in their usual conformations, were linked, presumably by a length of flexible chain.⁷⁶⁸ Mild proteolysis released histidinol dehydrogenase carrying an extra length of polypeptide but the aminotransferase activity was destroyed.⁷⁶⁹ In the case of DNA polymerase proteolysis released an active polymerase fragment and an active exonuclease fragment,⁷⁷⁰ suggesting again that the two proteins are linked (through a flexible chain) as a result of a gene fusion event.

Two new active-site titrants for acetylcholinesterase have been reported: one is an inhibitor and the other a poor substrate. The inhibitor⁷⁷¹ is

⁷⁶⁴ S. Keresztes-Nagy and R. Orman, *Biochemistry*, 1971, **10**, 2506.

⁷⁶⁵ R. L. Heinrikson and H. S. Kingdon, *J. Biol. Chem.*, 1971, **246**, 1099.

⁷⁶⁶ A. M. Benson, R. Jarabak, and P. Talalay, *J. Biol. Chem.*, 1971, **246**, 7514.

⁷⁶⁷ D. Cassio and J.-P. Waller, *European J. Biochem.*, 1971, **20**, 283.


⁷⁶⁸ M. M. Rechler and C. B. Bruni, *J. Biol. Chem.*, 1971, **246**, 1806.

⁷⁶⁹ T. Kohno and J. Yourno, *J. Biol. Chem.*, 1971, **246**, 2203.


⁷⁷⁰ H. Klenow, K. Overgaard-Hansen, and S. A. Patkar, *European J. Biochem.*, 1971, **22**, 371.

⁷⁷¹ J. B. Suszkiw, *Analyt. Biochem.*, 1971, **44**, 321.

OO'-diethyl *S*-(2-diethylaminoethyl)phosphorothiolate (16). Liberation of 2-diethylaminoethyl thiolate (Scheme 5) is measured spectrophotometrically after reaction with Ellman's reagent [5,5'-dithiobis-(2-nitrobenzoate)]. The poor substrate is the *N*-methyl-7-hydroxyquinolinium iodide ester of dimethylcarbamic acid (17);⁷⁷² decarbamylation is slow and the zwitter-



Scheme 5



ionic form of the leaving group is fluorescent. There seems to be some disagreement on the subunit structure of acetylcholinesterase from *Electrophorus electricus* (m. wt. 260 000). In one case⁷⁷³ an $\alpha_2\beta_2$ tetrameric structure with two active sites is suggested, and in the other⁷⁷⁴ a hexamer of subunit molecular weight 42 000.

H. Quaternary Structure.—Some of the newer quaternary structures have already been mentioned in the Report; many others are listed in Table 2.

6 Electron-transport and Oxygen-transport Proteins

A. Electron-transport Proteins.—*Cytochromes.* *X*-Ray crystallography has given the structure of horse-heart ferricytochrome *c* to 2.8 Å resolution;⁷⁷⁵ the phases were also used to calculate the structure of the isomorphous ferricytochrome *c* from bonito. A 4 Å resolution study of the reduced form reported from another laboratory⁷⁷⁶ indicates some difference in side-chain conformation at the surface in the ferri- and ferro-forms. The primary

⁷⁷² T. L. Rosenberry and S. A. Bernhard, *Biochemistry*, 1971, **10**, 4114.

⁷⁷³ W. Leuzinger, *Biochem. J.*, 1971, **123**, 139.

⁷⁷⁴ D. B. Millar and M. A. Grafius, *F.E.B.S. Letters*, 1970, **12**, 61.

⁷⁷⁵ R. E. Dickerson, T. Takano, D. Eisenberg, O. B. Kallai, L. Samson, A. Cooper, and E. Margoliash, *J. Biol. Chem.*, 1971, **246**, 1511.

⁷⁷⁶ T. Ashida, T. Ueki, T. Tsukihara, A. Sugihara, T. Takano, and M. Kakudo, *J. Biochem. (Japan)*, 1971, **70**, 913.

Table 2 *Quaternary structure of some individual enzymes*

<i>Enzyme</i>	<i>Source</i>	<i>Molecular weight</i>	<i>No. of subunits</i>
Acetolactate-forming enzyme (pH 6) ^a	<i>Aerobacter aerogenes</i>	220 000	4
Adenosine triphosphatase ^b	Pig brain	280 000	12
Aldolase ^{c, d, e, f}	Codfish muscle	160 000	4
	Frog muscle	164 000	4
	Lobster muscle	160 000	4
	Shark muscle	160 000	4
δ -Aminolaevulinatase ^{g, h}	Mouse liver	250 000	6
	<i>Rhodopseudomonas spheroides</i>	240 000	6
δ -Aminolaevulinatase synthase ⁱ	<i>Rhodopseudomonas spheroides</i>	57 000	1
α -Amylase ^j	Pig pancreas	50 000	2
Anthranilate synthetase ^k	<i>Serratia marcescens</i>	141 000	4 ($\alpha_3\beta_3$)
Anthranilate synthetase-anthranilate-5-phospho- ribosylpyrophosphate phosphoribosyltransferase ^l	<i>Salmonella typhimurium</i>	280 000	4 ($\alpha_3\beta_3$)
Apoferitin ^{m, n}	Horse spleen	450 000	24
Arylamidase ^o	Human liver	235 000	6
L-Asparaginase ^p	<i>E. coli</i>	142 000	4
Aspartase ^q	<i>E. coli</i> B	170 000	4
Aspartate transcarbamylase ^r	<i>E. coli</i>	300 000	12 ($\alpha_6\beta_6$)
Azoferredoxin ^s	<i>Clostridium pasteurianum</i> W5	55 000	2
Butyryl-CoA dehydrogenase ^t	<i>Peptostreptococcus elsdenii</i>	150 000	4
Catabolite gene activator protein (<i>lac</i>) ^u	<i>E. coli</i> K12	44 000	2
Chorismate mutase-prephenate dehydrogenase ^v	<i>E. coli</i>	80 000	2
Citrate oxaloacetate lyase ^w	<i>Klebsiella aerogenes</i>	560 000	16
Citrate synthase ^x	Rat heart, liver	100 000	2
Concanavalin A ^y	Jack bean	70 000	4
	Jack bean	54 000	2
Cytochrome <i>b</i> ₂ (L-lactate) cytochrome <i>c</i> oxidoreductase ^z	Baker's yeast	220 000	8 ($\alpha_4\beta_4$)

[References for Table on pages 132 and 133]

Table 2 (cont.)

Enzyme	Source	Molecular weight	No. of subunits
Diacetyl (acetoin) reductase ^{aa}	<i>Aerobacter aerogenes</i>	100 000	4
Dihydrofolate reductase ^{bb}	<i>Diplococcus pneumoniae</i>	20 000	1
DNA-dependent RNA polymerase ^{cc}	<i>Anacystis nidulans</i>	436 000	5 ($\alpha_2\beta\beta'\sigma$)
DNA polymerase ^{dd}	Phage T7	100 000	1
Enolase ^{ee}	<i>E. coli</i>	90 000	2
F ₁ -initiation factor ^{ff}	<i>E. coli</i> ribosomes	9 400	1
Follicle-stimulating hormone ^{gg}	Human	35 000	2
Formyl tetrahydrofolate ^{hh} synthetase	<i>Clostridium cylindrosporium</i>	240 000	4
Galactokinase ⁱⁱ	Human red blood cells	55 000	2
β -Glucuronidase ^{jj}	Rat liver lysosomes	280 000	4
Glutathioneperoxidase I ^{kk}	Ox blood	84 000	4
Glyceraldehyde 3-phosphate dehydrogenase ^{ll}	<i>E. coli</i>	144 000	4
Glycerate dehydrogenase ^{mm}	Ox liver	68 000	2
Glycerol kinase ⁿⁿ	<i>E. coli</i>	215 000	4
Glycerol 3-phosphate dehydrogenase ^{oo}	Rat liver	63 000	2
Haemoglobin ^{pp}	<i>Arenicola cristata</i>	2.85×10^6	192 ($\alpha_9\beta_9$)
Hydrogenase ^{qq}	<i>Clostridium pasteurianum</i> W5	60 000	2
Hypoxanthine-guanine phosphoribosyltransferase ^{rr}	Human erythrocytes	68 000	2
Invertase ^{ss}	<i>Neurospora crassa</i>	210 000	4
2-Keto-3-deoxy-6-phosphogluconate aldolase ^{tt}	<i>Pseudomonas putida</i>	72 000	3
Lactoferrin ^{uu}	Human	76 000	1
Leucine aminopeptidase ^{vv}	Ox lens	327 000	6
Malonyl-CoA-acyl-carrier-protein transacylase ^{ww}	<i>E. coli</i>	35 000	1
N-Methylglutamate synthetase ^{xx}	<i>Pseudomonas MA</i>	350 000	12
Molybdoferredoxin ^{yy}	<i>Clostridium pasteurianum</i> W5	170 000	3 ($\alpha_3\beta$)
Nerve growth factor ^{zz}	Mouse submaxillary gland	29 000	2
Nucleoside diphosphate kinase ^{aaa}	Pea seed	70 000	4
17 β -Oestradiol dehydrogenase ^{bbb}	Human placenta	68 000	2
Paramyosin ^{ccc}	<i>Venus mercenaria</i>	200 000	2
Phosphoenolpyruvate carboxylase ^{ddd}	<i>E. coli</i>	402 000	4
Phosphoglucose isomerase ^{eee}	Human erythrocytes	125 000	2

Table 2 (cont.)

Enzyme	Source	Molecular weight	No. of subunits
3-Phosphoglycerate kinase ^{fff}	Yeast	50 000	1
Phosphofructokinase ^{ggg, hhh}	Yeast	600 000	6
	Human erythrocytes	(104 000) _n	<i>n</i> = 2, 4, 6, 8, or 10
Phospholipase A ⁱⁱⁱ	<i>Apis mellifica</i>	40 000	2
Prealbumin ^{fff}	Human?	56 000	4
Pyruvate decarboxylase ^{kkk}	<i>E. coli</i> K12	200 000	2
Pyruvate kinase ^{lll, mmm}	Yeast (<i>Saccharomyces cerevisiae</i>)	160 000	8
	<i>Saccharomyces carlsbergensis</i>	191 000	4
	<i>Neurospora crassa</i> mitochondria	64 000	1
RNA polymerase ⁿⁿⁿ	Ox brain	21 000	3 ($\alpha_2\beta$)
S-100 protein ^{ooo}	Ox heart	98 000	2 ($\alpha\beta$)
Succinate dehydrogenase ^{ppp}	Ox heart	35 000	2
Superoxide dismutase ^{qqq}	<i>Rhodospirillum rubrum</i>	180 000	4
Threonine deaminase ^{rrr}	<i>E. coli</i> K12	68 000	1
Thymidine phosphorylase ^{sss}	Ehrlich ascites carcinoma	70 000	1
Thymidylate synthetase ^{ttt, uuu}	<i>Lactobacillus casei</i>	70 000	2
	Human	64 000	4
Thyroxine-binding prealbumin ^{vvv}	Yeast	140 000	2
Transketolase ^{www}	Houseflies	120 000	4
1,1,1-Trichloro-2,2-bis-(<i>p</i> -chlorophenyl)ethane dehydrochlorinase ^{xxx}	(<i>Musca domestica</i> L.)		
[DDT-dehydrochlorinase]			
tRNA synthetase:			
Glutaminyl ^{yyy}	<i>E. coli</i>	69 000	1
Seryl ^{zzz}	Yeast	120 000	2
Tryptophanyl ^{aaaa}	<i>E. coli</i>	74 000	2
Tryptophan synthetase ^{bbbb} B component	<i>Pseudomonas putida</i>	86 000	2
Vitamin-D-binding protein ^{cccc}	Human plasma	53 000	1

[References for Table on pages 132 and 133]

References for Table 2

- ^a N. E. Huseby, T. B. Christensen, B. R. Olsen, and F. C. Størmer, *European J. Biochem.*, 1971, **20**, 209; ^b A. Atkinson, A. D. Gatenby, and A. G. Lowe, *Nature New Biol.*, 1971, **233**, 145; ^c C. Y. Lai and C. Chen, *Arch. Biochem. Biophys.*, 1971, **144**, 467; ^d S.-M. Ting, C. L. Sia, C. Y. Lai, and B. L. Horecker, *Arch. Biochem. Biophys.*, 1971, **144**, 485; ^e A. Guha, C. Y. Lai, and B. L. Horecker, *Arch. Biochem. Biophys.*, 1971, **147**, 692; ^f C. E. Caban and L. F. Hass, *J. Biol. Chem.*, 1971, **246**, 6807; ^g D. Doyle, *J. Biol. Chem.*, 1971, **246**, 4965; ^h S. van Heyningen and D. Shemin, *Biochemistry*, 1971, **10**, 4676; ⁱ G. R. Warnick and B. F. Burnham, *J. Biol. Chem.*, 1971, **246**, 6880; ^j J. F. Robyt, C. G. Chittenden, and C. T. Lee, *Arch. Biochem. Biophys.*, 1971, **144**, 160; ^k H. Zalkin and L. H. Hwang, *J. Biol. Chem.*, 1971, **246**, 6899; ^l E. J. Henderson and H. Zalkin, *J. Biol. Chem.*, 1971, **246**, 6891; ^m I. Bjork and W. W. Fish, *Biochemistry*, 1971, **10**, 2844; ⁿ C. F. A. Bryce and R. R. Crichton, *J. Biol. Chem.*, 1971, **246**, 4198; ^o G. H. Little and F. J. Behal, *Biochim. Biophys. Acta*, 1971, **243**, 312; ^p H. Glossmann and W. Bode, *Z. physiol. Chem.*, 1971, **352**, 132; ^q F. B. Rudolph and H. J. Fromm, *Arch. Biochem. Biophys.*, 1971, **147**, 92; ^r J. P. Rosenbusch and K. Weber, *J. Biol. Chem.*, 1971, **246**, 1644; ^s G. Nakos and L. Mortenson, *Biochemistry*, 1971, **10**, 455; ^t P. C. Engel and V. Massey, *Biochem. J.*, 1971, **125**, 879; ^u A. D. Riggs, G. Reiness, and G. Zubay, *Proc. Nat. Acad. Sci., U.S.A.*, 1971, **68**, 1222; ^v G. L. E. Koch, D. C. Shaw, and F. Gibson, *Biochim. Biophys. Acta*, 1971, **229**, 805; ^w T. J. Bowen and M. G. Mortimer, *European J. Biochem.*, 1971, **23**, 262; ^x T. Moriyama and P. A. Srere, *J. Biol. Chem.*, 1971, **246**, 3217; ^y W. D. McCubbin and C. M. Kay, *Biochim. Biophys. Res. Comm.*, 1971, **44**, 101; ^z C. Wang, B. A. Cunningham, and G. M. Edelman, *Proc. Nat. Acad. Sci., U.S.A.*, 1971, **68**, 1130; ^{aa} F. Lederer and A. M. Simon, *European J. Biochem.*, 1971, **20**, 469; ^{ab} F. Lederer and C. Jacq, *ibid.*, p. 475; ^{ac} Ø. Hetland, B. R. Olsen, T. B. Christensen, and F. C. Størmer, *European J. Biochem.*, 1971, **20**, 200; ^{ad} F. M. Sirotnak and J. S. Salser, *Arch. Biochem. Biophys.*, 1971, **145**, 286; ^{ae} F. Herzfeld and W. Zillig, *European J. Biochem.*, 1971, **24**, 242; ^{af} J. L. Oey, W. Strätling, and R. Knippers, *European J. Biochem.*, 1971, **23**, 497; ^{ag} T. G. Spring and F. Wold, *J. Biol. Chem.*, 1971, **246**, 6797; ^{ah} S. Lee-Huang, M. A. G. Sillero, and S. Ochoa, *European J. Biochem.*, 1971, **18**, 536; ^{ai} R. J. Ryan, N.-S. Jiang, and S. Hanlon, *Biochemistry*, 1971, **10**, 1321; ^{aj} W. H. Welch, D. H. Buttlair, R. T. Hersh, and R. H. Himes, *Biochim. Biophys. Acta*, 1971, **236**, 599; ^{ak} K. G. Blume and E. Beutler, *J. Biol. Chem.*, 1971, **246**, 6507; ^{al} P. D. Stahl and O. Touster, *J. Biol. Chem.*, 1971, **246**, 5398; ^{am} L. Flohé, B. Eisele, and A. Wendel, *Z. physiol. Chem.*, 1971, **352**, 151; ^{an} G. d'Alessio and J. Josse, *J. Biol. Chem.*, 1971, **246**, 4326; ^{ao} I. Y. Rosenblum, D. H. Autkowiak, H. J. Sallach, L. E. Flanders, and L. A. Fahien, *Arch. Biochem. Biophys.*, 1971, **144**, 375; ^{ap} J. W. Thorner and H. Paulus, *J. Biol. Chem.*, 1971, **246**, 3885; ^{aq} T. P. Fondy, K. J. Herwig, S. J. Sollohr, and D. B. Rutherford, *Arch. Biochem. Biophys.*, 1971, **145**, 583; ^{ar} L. Waxman, *J. Biol. Chem.*, 1971, **246**, 7318; ^{as} G. Nakos and L. E. Mortenson, *Biochemistry*, 1971, **10**, 2442; ^{at} W. J. Arnold and W. N. Kelley, *J. Biol. Chem.*, 1971, **246**, 7398; ^{au} Z. D. Meadum, jun., H. J. Colvin, jun., and H. D. Braymer, *Biochemistry*, 1971, **10**, 326; ^{av} R. H. Hammerstedt, H. Möhler, K. A. Dekker, and W. A. Wood, *J. Biol. Chem.*, 1971, **246**, 2069; ^{aw} P. Querinjean, P. L. Masson, and J. F. Heremans, *European J. Biochem.*, 1971, **20**, 420; ^{ax} S. W. Melbye and F. H. Carpenter, *J. Biol. Chem.*, 1971, **246**, 2459; ^{ay} V. C. Joshi and S. J. Wakil, *Arch. Biochem. Biophys.*, 1971, **143**, 493; ^{az} R. J. Pollock and L. B. Hersh, *J. Biol. Chem.*, 1971, **246**, 4737; ^{ba} G. Nakos and L. Mortenson, *Biochim. Biophys. Acta*, 1971, **229**, 431; ^{bb} R. H. Angeletti, R. A. Bradshaw, and R. D. Wade, *Biochemistry*, 1971, **10**, 463; ^{bc} B. Edlund, *F.E.B.S. Letters*, 1971, **13**, 56; ^{bd} D. J. W. Burns, L. L. Engel, and J. L. Bethune, *Biochim. Biophys. Res. Comm.*, 1971, **44**, 786; ^{be} J. Olander, *Biochemistry*, 1971, **10**, 601; ^{bf} T. E. Smith, *J. Biol. Chem.*, 1971, **246**, 4234; ^{bg} K. K. Tsuboi, K. Fukunaga, and C. H. Chervenka, *J. Biol. Chem.*, 1971, **246**, 7586; ^{bh} R. K. Scopes, *Biochem. J.*, 1971, **122**, 89; ^{bi} H. Wilgus, J. R. Pringle, and E. Stellwagen, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 89; ^{bj} K. W. Wenzel, G. Zimmerman, J. Gauer, W. Diezel, S. Liebe, and E. Hofmann, *F.E.B.S. Letters*, 1971, **19**, 285; ^{bk} R. A. Shipolini, G. L. Callewaert, R. C. Cottrell, S. Doonan, C. A. Vernon, and B. E. C. Banks, *European J. Biochem.*, 1971, **20**, 459; ^{bl} G. Gonzalez and R. E. Offord, *Biochem. J.*, 1971, **125**, 309; ^{bm} O. Vogel and U. Henning, *European J. Biochem.*, 1971, **18**, 103; ^{bn} K. Ashton and A. R. Peacocke, *F.E.B.S. Letters*, 1971, **16**, 25; ^{bo} H. Bischofberger, B. Hess, and P. Röschlau, *Z. physiol. Chem.*, 1971, **352**, 1139; ^{bp} H. Kuntzel and K. P. Schäfer, *Nature New Biol.*, 1971, **231**, 265; ^{bq} P. S. Dannies and L. Levine, *J. Biol. Chem.*, 1971, **246**, 6276; ^{br} K. A. Davis and Y. Hatefi, *Biochemistry*, 1971, **10**, 2509; ^{bs} P. Righetti and P. Cerletti, *F.E.B.S. Letters*, 1971, **13**, 181;

^{aaa} B. B. Keele, jun., J. M. McCord, and I. Fridovich, *J. Biol. Chem.*, 1971, **246**, 2875; ^{rr} R. S. Feldberg and P. Datta, *European J. Biochem.*, 1971, **21**, 438; ^{aaa} M. Schwartz, *European J. Biochem.*, 1971, **21**, 191; ^{uu} A. Fridland, R. J. Langenbach, and C. Heidelberger, *J. Biol. Chem.*, 1971, **246**, 7110; ^{uuu} R. B. Dunlap, N. G. L. Harding, and F. M. Huennekens, *Biochemistry*, 1971, **10**, 88; ^{vvv} L. Rask, P. A. Peterson, and S. F. Nilsson, *J. Biol. Chem.*, 1971, **246**, 6087; ^{www} C. P. Heinrich and O. Wiss, *F.E.B.S. Letters*, 1971, **14**, 251; ^{zzz} M. L. Dinamarea, L. Levenbook, and E. Valdés, *Arch. Biochem. Biophys.*, 1971, **147**, 374; ^{vvv} W. R. Folk, *Biochemistry*, 1971, **10**, 1728; ^{zzz} H. Heider, E. Gottschalk, and F. Cramer, *European J. Biochem.*, 1971, **20**, 144; ^{aaaa} D. R. Joseph and K. H. Muench, *J. Biol. Chem.*, 1971, **246**, 7610; ^{bbbb} R. Maurer and I. P. Crawford, *Arch. Biochem. Biophys.*, 1971, **144**, 193; ^{ccc} P. A. Peterson, *J. Biol. Chem.*, 1971, **246**, 7748.

structure of bonito cytochrome *c* has also been determined;⁷⁷⁷ it differs from the tuna cytochrome only in the change Asp → Glu at position 61. A three-dimensional structure has been proposed⁷⁷⁸ for cytochrome *c*₅₅₁ from *Pseudomonas aeruginosa* based on the structures of horse and bonito cytochrome *c* and a comparison of amino-acid sequences. Most of the differences could be accounted for by deletion of a single 16-residue loop in the cytochrome from horse heart, and the structure showed how the sequences should be aligned to maximize homology; this was also predicted using a new method for comparing amino-acid sequences.⁴ There was no evidence from either the *X*-ray study⁷⁷⁵ or the theoretical treatment⁴ for repeating polypeptide sequences in cytochrome *c*. Bacterial cytochrome *c*₅₅₁ and horse-heart cytochrome *c* turn out to be clearly homologous at the level of both primary and tertiary structure. In other cases where homology in primary structures needs some imagination this might turn out not to be so, and a warning of the dangers of detecting otherwise invisible homologies from minimization of minimum mutational distances⁷⁷⁸ would be well heeded. Helix probability profiles calculated for 27 cytochrome *c* sequences,⁷⁷⁹ again based on the *X*-ray structure of the horse-heart protein, were similar in all but three cases. In these cases (screw-worm fly, fruit fly, and yeast) it appears that either there are errors in the amino-acid sequences, or there are true differences in three-dimensional structure.⁷⁷⁹ The former is, perhaps, more likely.

The two fragments obtained by specific cyanogen bromide cleavage at Met-65 in horse-heart cytochrome *c* will reassociate with regeneration of the spectral properties of the parent protein.⁷⁸⁰ A method for removing haem⁷⁸¹ is based on selective oxidation of the thioether bridge to the sulfoxide with limited amounts of iodine, followed by cyanogen bromide treatment to remove the haem; the cleavage at Met-65 apparently occurs more slowly and can be avoided. Reversible formylation of Trp-59 in horse-heart cytochrome *c* has also been reported.⁷⁸²

⁷⁷⁷ T. Nakayama, K. Titani, and K. Narita, *J. Biochem. (Japan)*, 1971, **70**, 311.

⁷⁷⁸ R. E. Dickerson, *J. Mol. Biol.*, 1971, **57**, 1.

⁷⁷⁹ P. N. Lewis and H. A. Scheraga, *Arch. Biochem. Biophys.*, 1971, **144**, 576.

⁷⁸⁰ G. Corradin and H. A. Harbury, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 3036.

⁷⁸¹ F. Lederer and J. Tarin, *European J. Biochem.*, 1971, **20**, 482.

⁷⁸² I. Aviram and A. Schejter, *Biochim. Biophys. Acta*, 1971, **229**, 113.

bean sequence determined earlier and now amended slightly in the region of residues 5 to 9. Cauliflower⁷⁸⁶ and rape⁷⁸⁷ (both members of the Brassicaceae) cytochromes *c* are identical, and very similar to that of pumpkin;⁷⁸⁸ both pumpkin and rape show some evidence of polymorphism. The proteins from *Abutilon* and *Gossypium* (cotton), from the Malvaceae, are also very similar.⁷⁸⁹ In addition to these angiosperms, the complete sequence of cytochrome *c* from a gymnosperm (*Ginkgo biloba* L.) has been determined;⁷⁸⁴ it has the usual common features of plant cytochromes *c* and appears to be two residues longer at the C-terminus. The sequence of cytochrome *c* from the yeast *Debaryomyces hansenii* (109 residues)⁷⁹⁰ showed that it was very similar (ca. 80% homology) to cytochromes from *Candida* and *Saccharomyces*. Again there is a 'tail' (5 or 6 residues) at the N-terminus and they all have one residue of trimethyllysine at position 72. A *c*-type cytochrome from *Micrococcus denitificans*⁷⁹¹ has only one histidine, and with about 135 residues is larger than mammalian cytochrome *c*. A protozoan cytochrome⁷⁹² has only one cysteine, in the sequence -Ala-Ala-Gln-Cys-His-(Thr,Gly,Ala)-Lys-, and two histidines.

Other cytochromes have several cysteine-histidine clusters and several haem groups per chain. For instance there are four such clusters per chain of 103 residues in cytochrome *c*₃ from *Desulfovibrio desulfuricans*;⁷⁹³ three of these have the standard separation of the two cysteines (-Cys-X-Y-Cys-His-) while the separation is greater in the fourth. Assuming some deletions, this cytochrome is clearly homologous with other *Desulfovibrio* cytochromes. It is also homologous (more so than the other *Desulfovibrio* cytochromes) with cytochrome *c*_{551.5} (cytochrome *c*₇) from the green photosynthetic bacterium *Chloropseudomonas ethylica*,⁷⁹⁴ thus establishing a connection between these anaerobic bacteria and sulphate-reducing bacteria. The *c*₇ cytochrome has 68 amino-acid residues and three cysteine-histidine clusters, all with the normal sequence (above) and each presumably carrying one haem. The N-terminal sequence of the haem peptide of cytochrome *c*₅₅₂ from chloroplasts of *Euglena gracilis*⁷⁹⁵ is Ala-Asp-Asp-, and the peptide clearly contains histidine.

Cytochrome *b*₂ from baker's yeast is found to be an octamer of the type ($\alpha\beta$)₄ where the α -chains have a molecular weight of 36 000 daltons and the

⁷⁸⁶ E. W. Thompson, M. Richardson, and D. Boulter, *Biochem. J.*, 1971, **124**, 783.

⁷⁸⁷ M. Richardson, J. A. M. Ramshaw, and D. Boulter, *Biochim. Biophys. Acta*, 1971, **251**, 331.

⁷⁸⁸ E. W. Thompson, M. Richardson, and D. Boulter, *Biochem. J.*, 1971, **124**, 779.

⁷⁸⁹ E. W. Thompson, B. A. Notton, M. Richardson, and D. Boulter, *Biochem. J.*, 1971, **124**, 787.

⁷⁹⁰ K. Sugeno, K. Narita, and K. Titani, *J. Biochem. (Japan)*, 1971, **70**, 659.

⁷⁹¹ P. B. Scholes, G. McLain, and L. Smith, *Biochemistry*, 1971, **10**, 2072.

⁷⁹² G. Pettigrew, *Biochem. J.*, 1971, **125**, 46P.

⁷⁹³ R. P. Ambler, M. Bruschi, and J. Le Gall, *F.E.B.S. Letters*, 1971, **18**, 347.

⁷⁹⁴ R. P. Ambler, *F.E.B.S. Letters*, 1971, **18**, 351.

⁷⁹⁵ M. A. Cusanovich, T. Meyer, S. M. Tedro, and M. D. Kamen, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 629.

β -chains of 21 000 daltons.⁷⁹⁶ The 'cytochrome b_2 core' obtained by tryptic digestion derives from the heavy chain and contains the haem-binding site. Spectral evidence suggests that the environment of the haem in the native protein is preserved in the core, and apo-core was thus used for photo-oxidation studies⁷⁹⁷ to investigate residues involved in ligand binding. This was lost on destruction of two histidine residues; cysteine was thought not to be involved in ligand bonding, nor was methionine, since this was absent from cytochrome b_2 from another strain. Cytochrome b_5 is found in the endoplasmic reticulum and is strongly bound to the membrane. The molecular weight of cytochrome b_5 isolated from rabbit liver,⁷⁹⁸ avoiding proteolysis and lipolysis steps and using only detergent, was higher than usual (16 700 rather than 11 000) and the additional hydrophobic sequence of 40 amino-acid residues may be the clue to its strong association with the membrane. Complete sequences for liver microsomal cytochromes b_5 from man, monkey, pig, and chicken have been proposed⁷⁹⁹ from an analysis of the tryptic peptides and homology with the known sequence of rabbit liver cytochrome b_5 (97 residues). Residues 42–72 were totally invariant in all five sequences, and the two histidine residues (positions 43 and 67) make this region a strong candidate for haem binding. The molecules contain no cysteine and, in fact, haem structure and ligand binding in microsomal cytochromes b_5 resemble those of haemoglobin although the spectral and enzymic properties are those of cytochromes. Cytochrome f , a c -type (c_{555}) from chloroplasts, is also firmly membrane-bound. The protein from spinach grana membranes⁸⁰⁰ appears to have one haem-containing polypeptide chain and one non-haem chain, each reported to have molecular weight *ca.* 31 000, somewhat different from existing values for cytochrome f from other plant chloroplasts. A re-investigation⁸⁰¹ of the subunit structure of cytochrome oxidase [cytochrome ($a + a_3$)] by SDS-gel electrophoresis suggests the quaternary structure $\alpha\beta\gamma_2\delta_4$ ($\alpha = 37\ 000$, $\beta = 19\ 000$, $\gamma = 14\ 000$, $\delta = 10\ 000$).

Other Electron-transport Proteins. The structure of ferredoxins (non-haem iron proteins) and their function in photosynthesis, nitrogen fixation, and fermentative metabolism have been reviewed.⁸⁰² The primary structures of two more bacterial ferredoxins have been established.^{803, 804} That of ferredoxin from the thermophile *Clostridium tartarivorum*⁸⁰³ is compared in Figure 19 with other known bacterial ferredoxin sequences (from

⁷⁹⁶ F. Lederer and A.-M. Simon, *European J. Biochem.*, 1971, **20**, 469.

⁷⁹⁷ O. Groudinsky, *European J. Biochem.*, 1971, **18**, 480.

⁷⁹⁸ L. Spatz and P. Strittmatter, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1042.

⁷⁹⁹ F. G. Nóbrega and J. Ozols, *J. Biol. Chem.*, 1971, **246**, 1706.

⁸⁰⁰ J. Singh and A. R. Wasserman, *J. Biol. Chem.*, 1971, **246**, 3532.

⁸⁰¹ J. J. Keirns, C. S. Yang, and M. V. Gilmour, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 835.

⁸⁰² B. B. Buchanan and D. I. Arnon, *Adv. Enzymol.*, 1970, **33**, 119.

⁸⁰³ M. Tanaka, M. Haniu, G. Matsueda, K. T. Yasunobu, R. H. Himes, J. M. Akagi, E. M. Barnes, and T. Devanathan, *J. Biol. Chem.*, 1971, **246**, 3953.

⁸⁰⁴ J. Travis, D. J. Newman, J. Le Gall, and H. D. Peck, jun., *Biochem. Biophys. Res. Comm.*, 1971, **45**, 452.

M. a. Ala-Tyr-Val-Ile-Asn-Asp-Ser -Cys-Ile -Ala-Cys-Gly-Ala-Cys-Lys-Pro-
C. b. Ala-Phe-Val-Ile-Asn-Asp-Ser -Cys-Val-Ser -Cys-Gly-Ala-Cys-Ala-Gly-
C. p. Ala-Tyr-Lys-Ile-Ala -Asp-Ser -Cys-Val-Ser -Cys-Gly-Ala-Cys-Ala-Ser-
C. a. Ala-Tyr-Val-Ile-Asn-Glu-Ala -Cys-Ile -Ser -Cys-Gly-Ala-Cys-Asp-Pro-
C. t. Ala-His-Ile -Ile-Thr -Asp-Glu-Cys-Ile -Ser -Cys-Gly-Ala-Cys-Ala-Ala-
1 10
M. a. Glu-Cys-Pro-Val-Asn- -Ile-Gln-Gln-Gly- -Ser-Ile -Tyr-Ala-Ile -
C. b. Glu-Cys-Pro-Val-Ser -Ala-Ile-Thr-Gln-Gly-Asp-Thr-Gln-Phe-Val-Ile -
C. p. Glu-Cys-Pro-Val-Asn-Ala-Ile-Ser -Gln-Gly-Asp-Ser-Ile -Phe-Val-Ile -
C. a. Glu-Cys-Pro-Val-Asp-Ala-Ile-Ser -Gln-Gly-Asp-Ser -Arg-Tyr-Val-Ile -
C. t. Glu-Cys-Pro-Val-Glu-Ala-Ile-His -Glu-Gly-Thr-Gly-Lys-Tyr-Gln-Val-
20 30
M. a. Asp-Ala-Asp-Ser -Cys-Ile-Asp-Cys-Gly-Ser- Cys-Ala-Ser -Val-Cys-Pro-
C. b. Asp-Ala-Asp-Thr-Cys-Ile-Asp-Cys-Gly-Asn-Cys-Ala -Asn-Val-Cys-Pro-
C. p. Asp-Ala-Asp-Thr-Cys-Ile-Asp-Cys-Gly-Asn-Cys-Ala -Asn-Val-Cys-Pro-
C. a. Asp-Ala-Asp-Thr-Cys-Ile-Asp-Cys-Gly-Ala -Cys-Ala-Gly-Val-Cys-Pro-
C. t. Asp-Ala-Asp-Thr-Cys-Ile-Asp-Cys-Gly-Ala -Cys-Gln-Ala -Val-Cys-Pro-
40
M. a. Val-Gly-Ala-Pro-Asn-Pro-Glu-Asp
C. b. Val-Gly-Ala-Pro-Asn-Gln-Glu
C. p. Val-Gly-Ala-Pro-Val-Gln-Glu
C. a. Val-Asp-Ala-Pro-Val-Gln-Ala
C. t. Thr-Gly-Ala-Val-Lys-Ala-Glu
50

sequence is that from the sulphate-reducing bacterium *Desulfovibrio gigas*,⁸⁰⁴ which is unique among bacterial ferredoxins in having only four cysteines. Two are in the first half of the molecule, which is highly homologous with the first half (residues 1—28) of the ferredoxins from other bacteria (see above), and two in the second half, which, in this case, is less homologous either with its own first half or with other ferredoxins. Ferredoxin from *C. pasteurianum* can exist in a dimeric form in which the number of atoms of iron and labile sulphide is reduced by half,⁸⁰⁵ and it is suggested that four cysteinyl residues per subunit participate in disulphide bridges in the dimer. This observation will probably call for re-examination of many physicochemical studies on this protein.⁸⁰⁵ The role of ferredoxin in reductive nitrogen fixation in *Clostridia* is to accept electrons from hydrogenase and transfer them to nitrogenase; hydrogenase is a non-haem iron protein with four atoms each of iron and labile sulphide, whose distribution within the dimer of molecular weight 60 000 is as yet unknown.⁸⁰⁶ The gene

⁸⁰⁶ G. Nakos and L. Mortenson, *Biochim. Biophys. Acta*, 1971, **227**, 576.

duplication recognized in bacterial ferredoxins has not occurred in plant ferredoxins,⁴ which are also much larger (ca. 110 residues) and contain five or six cysteine residues, only four of which are probably essential.⁸⁰⁷ The ferredoxin of *E. coli* (m. wt. 12 600) has two atoms of iron and labile sulphide and resembles plant-type ferredoxins rather than those of anaerobic bacteria (e.g. *Desulfovibrio*).⁸⁰⁸ The role of ferredoxins in the origin of life and in evolution has been discussed.⁸⁰⁹

When certain anaerobic bacteria are grown on an iron-deficient medium, flavodoxins are produced instead of ferredoxins, and can replace ferredoxins in electron transport. Using a sequenator, the first 41 residues of *Peptostreptococcus elsdenii* flavodoxin and the first 51 of that of *C. pasteurianum* were determined;⁸¹⁰ the sequence of the former (137 residues) was almost completed⁸¹¹ and the latter was extended. In the regions that can be compared the homology is 45% (Figure 20). If a cysteine is involved in FMN binding this is probably Cys-128 in *P. elsdenii* since the second cysteine at position 55 is replaced by serine in *C. pasteurianum* flavodoxin. The flavodoxin from *E. coli* (m. wt. 14 000) also contains one mole of FMN but appears to resemble the phytoflavins of blue-green algae more than the flavodoxins of anaerobic bacteria.⁸⁰⁸

The rubredoxins are non-haem iron proteins that function as electron carriers in hydroxylations. The sequence of the rubredoxin from the aerobic microbe *Pseudomonas oleovorans* has been almost completely determined (174 residues)⁸¹² and the homology between the regions 1—54 and the C-terminal 119—174 in the sequence is clear evidence of gene duplication. These regions also show homology with the sequences of rubredoxins from anaerobic bacteria, evidence of a common ancestor (Figure 21). The *P. oleovorans* rubredoxin can bind one or two iron atoms (cf. transferrin; see last year's Report, p. 67), the iron-binding sites being a group of four cysteine residues near the C-terminus and another group of four near the N-terminus.⁸¹³ In the one-Fe form the iron is bound near the C-terminus and the iron-containing peptide from the C-terminus can, in fact, serve as an electron carrier in hydroxylation.⁸¹³

The phycobiliproteins are photosynthetic pigments containing the phycobilin prosthetic group, a linear tetrapyrrole. Several investigations have been concerned with the subunit molecular weights of these proteins. One of the previously accepted molecular weights of 30 000 for the monomer of phycocyanin has been re-offered,⁸¹⁴ but appears to be at variance with

⁸⁰⁷ S. J. Aggarwal, K. K. Rao, and H. Matsubara, *J. Biochem. (Japan)*, 1971, **69**, 601.

⁸⁰⁸ H. Vetter, jun., and J. Knappe, *Z. physiol. Chem.*, 1971, **352**, 433.

⁸⁰⁹ D. O. Hall, R. Cammack, and K. K. Rao, *Nature*, 1971, **233**, 136.

⁸¹⁰ M. Tanaka, M. Haniu, G. Matsueda, K. T. Yasunobu, S. Mayhew, and V. Massey, *Biochemistry*, 1971, **10**, 3041.

⁸¹¹ M. Tanaka, M. Haniu, K. T. Yasunobu, S. Mayhew, and V. Massey, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 886.

⁸¹² A. Benson, K. Tomoda, J. Chang, G. Matsueda, E. T. Lode, M. J. Coon, and K. T. Yasunobu, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 640.

⁸¹³ E. T. Lode and M. J. Coon, *J. Biol. Chem.*, 1971, **246**, 791.

⁸¹⁴ O. Kao, D. S. Berns, and R. MacColl, *European J. Biochem.*, 1971, **19**, 595.

several other studies,^{815, 817} which make extensive use of SDS-gel electrophoresis. These suggest that (blue) phycocyanin and (red) phycoerythrin from several strains of blue-green algae all contain two non-identical subunits, each of which is associated with a chromophore; an association

	1	10
P. e.	Met-	Val-Glu-Ile-Val-Tyr-Trp-Ser-Gly-Thr-Gly-Asn-Thr-Glu-Ala-
C. p.	Met-Lys-Val-Asn-Ile-Ile	-Tyr-Trp-Ser-Gly-Thr-Gly-Asn-Thr-Glu-Ala-
	20	30
P. e.	Met-Ala-Asn-Glu-Ile-Glu-Ala-Ala-Val-Lys-Ala-Ala-Gly-Ala-Asp-Val-	
C. p.	Met-Ala-Lys-Leu-Ile-Ala-Glu-Gly-Ala-Gln-Glu-Lys-Gly-Ala-Glu-Val-	
	40	
P. e.	Glu-Ser-Val-Arg-Phe-Glu-Asp-Thr-Asn-Val-Asp-Asn-Val-Ala-Ser-Lys-	
C. p.	Lys-Leu-Leu-Asn-Val-Ser-(Asp,Ala)Lys-Glu-Asp-Asp-Val-Lys-Glu-Ala-	
	50	60
P. e.	Asp-Val-Ile-Leu-Leu-Gly-Cys-Pro-Ala-Met-Gly-Ser-Glu-Glu-Leu-Glu-	
C. p.	Asp-Val-Val-Ala-Phe-Gly-Ser-Pro-Ser-Met-Gly-Ser-Glu-Val(Ser,Gln,	
	70	80
P. e.	Asp-Ser-Val-Val-Glu-Pro-Phe-Phe-Thr-Asp-Leu-Ala-Pro-Lys-Gly-Lys-	
C. p.	Glu,Glu,Pro,Met)Phe-Leu-Asp-Val-Val-Ser-Ser-Ile-Val-Thr-Gly-Lys-	
	90	
P. e.	Lys-Leu-Lys-Val-Gly-Leu-Phe-Gly-Ser-Tyr-Gly-Trp-Ser-Trp(Gly,Gly,	
C. p.	Lys-	
	100	110
P. e.	Glu)Met-Asp-Ala-Trp-Lys-Gln-Arg-Thr-Glu-Asp-Thr-Gly-Ala-Thr-Val-	
	120	
P. e.	Ile-Gly-Thr-Ala-Ile-Val-Asn-Glu-Met-Pro-Asp-Asn-Ala-Pro-Glu-Cys-	
	130	138
P. e.	Lys-Glu-Leu-Gly-Glu-Ala-Ala-Ala-Lys-Ala	

Figure 20 Amino-acid sequences of the *P. elsdennii* and *C. pasteurianum* flavodoxins

of two different chains had also been suggested earlier. The subunit molecular weights⁸¹⁵ of phycoerythrin are 22 000 and 20 000, and of phycocyanin 20 000 and 16 000 (other values^{816, 817} are not substantially different). Allophycocyanin has either one subunit⁸¹⁶ of 16 000 daltons or two⁸¹⁵ of 17 500 and 15 000 daltons. An 11-residue peptide from phytochrome of oat seedlings (another chromoprotein with a covalently bound linear tetrapyrrole) has the partial sequence -Leu-Arg-Ala-Pro-His-X-Y-His-Leu-Gln-Tyr-.⁸¹⁸

⁸¹⁵ A. N. Glazer and G. Cohen-Bazire, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1398.

⁸¹⁶ A. Bennett and L. Bogorad, *Biochemistry*, 1971, **10**, 3625.

⁸¹⁷ P. O'Carra and S. D. Killilea, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1192.

⁸¹⁸ K. T. Fry and F. E. Mumford, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1466.

B. Oxygen-transport and -storage Proteins.—*Haemoglobin and Myoglobin.* With true chauvinism, work on marsupial globins progresses in leaps and bounds. The complete amino-acid sequence of the α -chain of haemoglobin from the grey kangaroo has been determined,⁸¹⁹ the sequence of the β -chain

P. e.	¹ f-Met-Asp-Lys-Tyr-Glu-Cys-Ser-Ile -Cys-Gly-Tyr-Ile -Tyr-
M. a.	¹ f-Met-Gln-Lys-Phe-Glu-Cys-Thr-Leu-Cys-Gly-Tyr-Ile -Tyr-
P. o. (N-term)	Ala-Ser-Tyr-Lys-Cys-Pro-Asp-Cys-Asn-Tyr-Val-Tyr-
P. o. (C-term)	¹¹⁹ Leu-Lys-Trp-Ile -Cys-Ile -Thr-Cys-Gly-His-Ile -Tyr-
P. e.	^{25 26} Asp-Glu-Ala-Glu-Gly-Asp-Asp-Gly-Asn-Val-Ala-Ala-Gly-Thr-
M. a.	^{25 26} Asp-Pro-Ala-Leu-Val-Gly-Pro-Asp-Thr-Pro-Asp-Gln-Asp-Gly-
P. o. (N-term)	^{24 25} Asp-Glu-Ser-Ala-Gly-Asn-Val-His-Glu-Gly-Phe-Ser-Pro-Gly-
P. o. (C-term)	^{143 144} Asp-Glu-Ala-Leu-Gly-Asp-Glu-Ala-Glu-Gly-Phe-Thr-Pro-Gly-Trp
P. e.	Lys-Phe-Ala-Asp-Leu-Pro-Ala-Asp-Trp-Val -Cys-Pro-Thr-Cys-
M. a.	Ala-Phe-Glu-Asp-Val-Ser-Glu-Asn-Trp-Val -Cys-Pro-Leu-Cys-
P. o. (N-term)	Thr-Pro-Trp-His-Leu-Pro-Glu-Asp-Trp-Asp-Cys-Pro-Cys-Cys-
P. o. (C-term)	^{Ile} Thr-Phe-Glu-Asn-Ile -Pro- -Asp-Trp-Asp-Cys-Cys-Trp-Cys-Arg
P. e.	^{49 53} Gly-Ala-Asp-Lys-Asp-Ala-Phe- -Val-Lys-Met-Asp
M. a.	^{49 53} Gly-Ala-Gly-Lys-Glu-Asp-Phe-Glu-Val-Tyr-Glu-Ala
P. o. (N-term)	^{49 53} -Ala-Val-Arg-Asp-Lys-Leu-Asp-Phe-Met-Leu-Ile-
P. o. (C-term)	¹⁶⁷ Asx,Pro-Gly-Ala-Thr-Lys-Glu-Asn-Tyr-Val-Leu-Tyr-Glu-
P. o. (C-term)	Glu-Lys

Figure 21 Homologous sequences in *P. elsdennii*, *M. aerogenes*, and *P. oleovorans rubredoxins*

having been reported earlier. As expected, the contact residues between the subunits are largely conserved and any replacements are conservative. The complete primary structure of myoglobin from the red kangaroo,⁸²⁰ shows again that amino-acid replacements compared with sperm-whale myoglobin are conservative, the most striking being the change Val \rightarrow Glu at position 21. The β -chain of red-kangaroo haemoglobin is identical with that of the

⁸¹⁹ J. M. Beard and E. O. P. Thompson, *Austral. J. Biol. Sci.*, 1971, **24**, 765.

⁸²⁰ G. M. Air and E. O. P. Thompson, *Austral. J. Biol. Sci.*, 1971, **24**, 75.

grey kangaroo except that residue 56 is glycine not alanine.⁸²¹ This position was found to be variable in 11 species of the marsupial subfamily Macropodinae, where 55—56 are -Met-X- and X is Ala, Gly, Ser, or Thr. In the potoroo, *Potorous tridactylus*, residue 55 was leucine.⁸²¹ The divergence of the Macropodinae and Potoroinae, estimated from comparison of the complete sequence of the potoroo β -chain with that of the grey kangaroo, appears to have started *ca.* 50 million years ago.⁸²¹ A wider comparison of globin sequences gave an estimate of the time in evolution when marsupials and eutherians diverged.⁸²²

	55	60	65
Leghaemoglobin α	-Val-Asn-Pro-Lys-Leu-Thr-Gly-His-Ala-Glu-Lys-Leu-Phe-		
Human γ -chain	-Gly-Asn-Pro-Lys-Val-Lys-Ala-His-Gly-Lys-Lys-Val-Leu-		
	70	75	
Leghaemoglobin α	Ala-Leu-Val-Arg-Asp-Ser-Ala-Gly-Gln-Leu-Lys-Ala-Ser-		
Human γ -chain	Thr-Ser-Leu-Gly-Asp-Ala-Ile-Lys-His-Leu-Asp-Asp-Leu-		
	80	85	90
Leghaemoglobin α	Gly-Thr-Val-Val-Ala-Asp-Ala-Ala-Leu-Gly-Ser-Val-His-		
Human γ -chain	Lys-Gly-Thr-Phe-Ala-Gln-Leu-Ser-Gly-Leu-His-		
		100	
Leghaemoglobin α	Ala-Gln-Lys-Ala-Val-Thr-Asn-Pro-Glu-		
Human γ -chain	Cys-Asp-Lys-Leu-His-Val-Asp-Pro-Glu-		

Figure 22 Amino-acid sequences surrounding the haem-linked histidines in soybean leghaemoglobin α and in human γ -chain

The complete sequence of soybean leghaemoglobin α (142 residues) is now available.⁸²³ There is 12% identity with human globin in the sequence of 48 residues surrounding the two haem-binding histidines (Figure 22), strong support for evolution from a common ancestor that existed before plants and animals diverged. The histidine residues in leghaemoglobin are 30 residues apart rather than the usual 28, and the -Lys-Lys- sequence usually found near one of the haem-linked histidines is also absent.⁸²³ Haemoglobin II from the edible frog (*Rana esculenta*) has the terminal sequences:⁸²⁴

β -chain:	N-terminus	Gly-Ser-Asp-Leu-
	C-terminus	-Lys-Ala-Tyr-His
α -chain:	N-terminus	Acetyl-Ala-Leu-
	C-terminus	-Lys-Tyr

The α -chain of haemoglobin from the viper *Vipera aspis* has N-terminal valine, like mammalian α -chains, rather than the acetylated N-terminus characteristic of amphibians,⁸²⁵ and the α -chain of haemoglobin from White Leghorn chickens resembles that of man (35 differences) more than that of

⁸²¹ E. O. P. Thompson and G. M. Air, *Austral. J. Biol. Sci.*, 1971, **24**, 1199.


⁸²² G. M. Air, E. O. P. Thompson, B. J. Richardson, and G. B. Sharman, *Nature*, 1971, **229**, 391.

⁸²³ N. Ellfolk and G. Sievers, *Acta Chem. Scand.*, 1971, **25**, 3532.

⁸²⁴ J.-P. Chauvet and R. Acher, *Internat. J. Protein Res.*, 1971, **3**, 261.

⁸²⁵ M. Dugué, J.-P. Chauvet, and R. Acher, *F.E.B.S. Letters*, 1971, **18**, 185.

horse (40 differences).⁸²⁶ The β -chain of haemoglobin from the Japanese monkey (*Macaca fuscata fuscata*) is identical with that known for the β -chain of the rhesus monkey (*M. mulatta*) apart from the change Leu-33 \rightarrow Met.⁸²⁷ The chains of the minor adult haemoglobin, $\alpha_2\delta_2$, differ in man and the chimpanzee only at position $\delta 126$, which is methionine in man and valine in the chimpanzee.⁸²⁸ The two species are thus similar in all their globin chains, and even in the mechanism whereby the relative amounts of the two γ -chains (the products of allelic genes) change a few months after birth.⁸²⁹ The two foetal haemoglobins F and F₁ can be separated by polyacrylamide gel electrophoresis⁸³⁰ and it now appears⁸³¹ that in F₁ both γ -chains are acetylated at the N-terminus. This fractionation method does not require prior removal of haem and will resolve all globin chains. Two allelic genes have been demonstrated for rabbit β -chains⁸³² and the existence of two α -chain genes has been confirmed.⁸³³ X-Ray crystallography of the (monomeric) haemoglobin of the lamprey⁸³⁴ shows that the haem pocket is roughly the same as that in other globin chains, although the additional 11 residues at the N-terminus cause significant differences elsewhere in the tertiary structure. The results also suggest⁸³⁴ that two residues should be inserted into the known sequence so that the correct sequences should read:



The large haemoglobins that constitute the respiratory pigments of invertebrates continue to be studied, and an improved X-ray analysis of *Chironomus thummi* erythrocrucorin at 2.5 Å resolution has been presented.⁸³⁵ Particularly noteworthy is the presence of seven phenylalanine residues in the haem pocket (in contrast to the three of vertebrates) and the replacement of the distal histidine at E7, invariant in all known vertebrates, by a glutamic acid residue which makes no contact with the haem and protrudes into solution.⁸³⁵ The structural basis of the pH-induced structural change in the crystalline state has been discussed⁸³⁶ and the ligands occupying the sixth co-ordination position of the haem in components I and III of erythrocrucorin have been identified.⁸³⁷ The N-terminal 45 residues of haemoglobin

⁸²⁶ G. Matsuda, H. Takei, K. C. Wu, and T. Schiozawa, *Internat. J. Protein Res.*, 1971, **3**, 173.

⁸²⁷ G. Matsuda, T. Maita, H. Ota, I. Tachikawa, Y. Yanaka, A. Araya, and Y. Nakashima, *Internat. J. Protein Res.*, 1971, **3**, 53.

⁸²⁸ W. W. W. De Jong, *Nature New Biol.*, 1971, **234**, 176.

⁸²⁹ W. W. W. De Jong, *Biochim. Biophys. Acta*, 1971, **251**, 217.

⁸³⁰ L. D. Stegink, P. D. Meyer, and R. Chalkley, *Analyt. Biochem.*, 1971, **41**, 351.

⁸³¹ L. D. Stegink, P. D. Meyer, and M. C. Brummel, *J. Biol. Chem.*, 1971, **246**, 3001.

⁸³² J. Delaunay, N. Maleknia, and G. Schapira, *Biochim. Biophys. Acta*, 1971, **229**, 712.

⁸³³ U. Flamm, J. S. Best, and G. Braunitzer, *Z. physiol. Chem.*, 1971, **352**, 885.

⁸³⁴ W. A. Hendrickson and W. E. Love, *Nature New Biol.*, 1971, **232**, 197.

⁸³⁵ R. Huber, O. Epp, W. Steigemann, and H. Formanek, *European J. Biochem.*, 1971, **19**, 42.

⁸³⁶ R. Huber, O. Epp, and H. Formanek, *J. Mol. Biol.*, 1971, **57**, 377.

⁸³⁷ G. Braunitzer, H. Neuwirth, and F. Reinhard, *Z. physiol. Chem.*, 1971, **352**, 757.

from the marine worm *Glycera dibranchiata* (determined in a sequenator)⁸³⁸ show high homology with sperm-whale myoglobin, a similar tertiary structure having been suggested some years ago. The highly co-operative haemoglobin of *Arenicola cristata* (a polychaete annelid) has two types of chain with m. wt. 13 000 and 14 000 daltons,⁸³⁹ and it is suggested that one haem is bound by two chains, giving about 96 haems per molecule. The two types of chain in chlorocruorin from the marine worm *Spirographis spallanzani* (both of m. wt. ca. 35 000) have N-termini Glu- and Ala-, and C-termini -Arg and -Tyr-His, respectively.⁸⁴⁰

The complete primary structure of human myoglobin has been determined⁸⁴¹ and subsequently amended slightly⁸⁴² so that residue 83 is Glu not Gln, and the sequence 19—22 is -Ala-Asp-Ile-Pro-. It agrees with an earlier partial structure⁸⁴³ in all but a few points. Not unexpectedly perhaps, it resembles other mammalian myoglobins more than it does human haemoglobin, and the 26 differences compared with sperm-whale myoglobin either occur on the surface of the molecule or are highly conservative. Of particular interest is the replacement of valine at B2 by proline, so far found only in the globin of *Chironomus*, a feature which should impart extra stability to the corner.⁸⁴¹ Myoglobin from the gibbon (*Hylobates agilis*) is identical with that of man but for the replacement of Gly at position 23 by Ser.⁸⁴² A partial sequence for sheep-heart myoglobin,⁸⁴⁴ and the N-terminal sequence of dolphin myoglobin determined on a home-built sequenator,⁸⁴⁵ have been reported. This almost completes the determination of the dolphin sequence, with two corrections⁸⁴⁵ of earlier results: residue 26 is Glu and residue 15 is Gly. All the sequences are highly homologous with that of sperm-whale myoglobin. Myoglobin from *Aplysia limacina* is unusual in having an acetylated N-terminus and a single histidine; the sequence of 63 residues at the C-terminus is reported.⁸⁴⁶ Immunochemical cross-reactivity between peptides from sperm whale and fin-back whale has been used to detect similarities between the proteins⁸⁴⁷ (cf. immunochemical studies on lysozyme and α -lactalbumin, this volume, p. 10,8 and last year's Report), and a warning has been sounded⁸⁴⁸ on proteolytic activity in commercial myoglobin preparations. The activity was purified on an affinity column and resembled trypsin and chymotrypsin.

⁸³⁸ S. L. Li and A. F. Riggs, *Biochim. Biophys. Acta*, 1971, **236**, 208.

⁸³⁹ L. Waxman, *J. Biol. Chem.*, 1971, **246**, 7318.

⁸⁴⁰ D. Guerritore and R. Zito, *Biochim. Biophys. Acta*, 1971, **229**, 720.

⁸⁴¹ A. E. Romero Herrera and H. Lehmann, *Nature New Biol.* 1971, **232**, 149.

⁸⁴² A. E. Romero Herrera and H. Lehmann, *Biochim. Biophys. Acta*, 1971, **251**, 482.

⁸⁴³ R. L. Hill, C. M. Harris, J. F. Naylor, and W. M. Sams, *J. Biol. Chem.*, 1969, **244**, 2182.

⁸⁴⁴ K. Han, D. Tetaert, M. Dautrevaux, V. Moschetto, and G. Biserte, *F.E.B.S. Letters*, 1971, **15**, 116.

⁸⁴⁵ I. Kluh and A. Bakardjieva, *F.E.B.S. Letters*, 1971, **17**, 31.

⁸⁴⁶ L. Teutori, G. Vivaldi, S. Carta, M. Marinucci, A. Massa, E. Antonini, and M. Brunori, *F.E.B.S. Letters*, 1971, **12**, 181.

⁸⁴⁷ M. Z. Atassi and B. J. Saplin, *Biochemistry*, 1971, **10**, 4740.

⁸⁴⁸ D. F. Goldspink, D. Holmes, and R. J. Pennington, *Biochem. J.*, 1971, **125**, 865.

Abnormal haemoglobins whose oxygen affinities are atypical have been divided into those in which the amino-acid substitution affects the oxygen-binding site direct and those in which the substitution affects the balance between the tertiary structures of the oxy- and deoxy-forms.⁸⁴⁹ Up to the present, abnormal haemoglobins have been identified solely on the basis of abnormal electrophoretic mobility, which means that most of those that have been characterized show a replacement of an amino-acid by one of dissimilar charge. In a new method⁸⁵⁰ which permits identification of neutral mutations, the abnormality is revealed by a slight change in chromatographic mobility of the abnormal peptide in a digest. To avoid the uncertainties of comparison with a standard map, the abnormal peptide is identified as the only non-radioactive one when the abnormal haemoglobin and [¹⁴C]haemoglobin are co-digested. Thus in Hb-*Christchurch*, which results in haemolytic anaemia, the mutation was shown to be $\beta 71$ Phe \rightarrow Ser, important because $\beta 71$ forms a hydrophobic haem contact. Various other new abnormal haemoglobins have been reported, three of them α -chain variants: Hb-*Fort Worth* ($\alpha 27$ Glu \rightarrow Gly),⁸⁵¹ Hb-*Atago* ($\alpha 85$ Asp \rightarrow Tyr),⁸⁵² and Hb-*Rampa* ($\alpha 95$ Pro \rightarrow Ser).⁸⁵³ Among the β -chain variants characterized are Hb-*Rainier* ($\beta 145$ Tyr \rightarrow Cys),⁸⁵⁴ Hb-*Bethesda* ($\beta 145$ Tyr \rightarrow His),⁸⁵⁴ Hb-*Toulouse* ($\beta 66$ Lys \rightarrow Glu),⁸⁵⁵ Hb-*Bucuresti* ($\beta 42$ Phe \rightarrow Leu),⁸⁵⁶ Hb-*Ta-Li* ($\beta 83$ Gly \rightarrow Cys),⁸⁵⁷ and Hb-*J Kaolisiung* ($\beta 59$ Lys \rightarrow Thr).⁸⁵⁸ A re-examination⁸⁵⁹ of Hb-*Hiroshima* shows that it has the substitution $\beta 146$ His \rightarrow Asp and not $\beta 143$ His \rightarrow Asp as reported earlier, consistent with the proposed role of His-143 in 2,3-diphosphoglycerate (DPG) binding and the apparently normal response of the oxygen affinity of Hb-*Hiroshima* to DPG.⁸⁵⁹ Hb-*Toulouse*⁸⁵⁵ is noteworthy for the rupture of an ionic bond in the haem pocket, and Hb-*Ta-Li*⁸⁵⁷ and -*Rainier*⁸⁵⁴ for a substitution by cysteine, resulting in the former case in a tendency to polymerize (*in vitro*) and in the latter case in the formation of an intramolecular disulphide bond, as shown by X-ray crystallography (see below). Hb *A₂-Indonesia*⁸⁶⁰ has the change $\delta 69$ Gly \rightarrow Arg, and in Hb-*Myiada*⁸⁶¹

⁸⁴⁹ H. Morimoto, H. Lehmann, and M. F. Perutz, *Nature*, 1971, **232**, 408.

⁸⁵⁰ R. W. Carrell and M. C. Owen, *Biochim. Biophys. Acta*, 1971, **236**, 507.

⁸⁵¹ R. G. Schneider, B. Brimhall, R. T. Jones, R. Bryant, C. B. Mitchell, and A. I. Goldberg, *Biochim. Biophys. Acta*, 1971, **243**, 164.

⁸⁵² N. Fujiwara, T. Maekawa, and G. Matsuda, *Internat. J. Protein Res.*, 1971, **3**, 35.

⁸⁵³ W. W. W. De Jong, L. F. Bernini, and P. M. Khan, *Biochim. Biophys. Acta*, 1971, **236**, 197.

⁸⁵⁴ A. Hayashi, G. Stamatoyannopoulos, H. Yoshida, and J. Adamson, *Nature New Biol.*, 1971, **230**, 264.

⁸⁵⁵ D. Labie, J. Rosa, O. Belkhdja, and R. Bierme, *Biochim. Biophys. Acta*, 1971, **236**, 201.

⁸⁵⁶ V. Bratu, P. A. Lorkin, H. Lehmann, and C. Predescu, *Biochim. Biophys. Acta*, 1971, **251**, 1.

⁸⁵⁷ R. Q. Blackwell, C.-S. Liu, and C.-L. Wang, *Biochim. Biophys. Acta*, 1971, **243**, 467.

⁸⁵⁸ R. Q. Blackwell, C.-S. Liu, and T.-B. Shih, *Biochim. Biophys. Acta*, 1971, **229**, 343.

⁸⁵⁹ M. F. Perutz, P. Del Pulsinelli, L. Ten Eyck, J. V. Kilmartin, S. Shibata, I. Iuchi, T. Miyaji, and H. B. Hamilton, *Nature New Biol.*, 1971, **232**, 147.

⁸⁶⁰ L. I. L. Eng, W. Pribadi, F. W. Boerma, G. D. Efremov, J. B. Wilson, C. A. Reynolds, and T. H. J. Huisman, *Biochim. Biophys. Acta*, 1971, **229**, 335.

⁸⁶¹ Y. Ohta, K. Yamaoka, I. Sumida, and T. Yanase, *Nature New Biol.*, 1971, **234**, 218.

normal β -chains are replaced by chains which are the result of non-homologous cross-over of δ and β genes. It differs from Hb-*Lepore* in that the N-terminus in Hb-*Myiada* derives from the β -chain gene and the C-terminus from the δ gene, rather than *vice versa*. Two other unusual abnormal haemoglobins have elongated α - (Hb-*Constant Spring*)⁸⁶² or β - (Hb-*Tak*) chains,⁸⁶³ and it appears that the explanation is not as simple as a mutation in the normal chain-termination codon.⁸⁶² Three further variants of human myoglobin have also been reported,⁸⁶⁴ two of them with substitutions at the same position: Arg-139 \rightarrow Gln,^{864a} Arg-139 \rightarrow Trp,^{864b} and Lys-133 \rightarrow Asn^{864c} (numbering of residues as in ref. 841). The contribution of structural studies of abnormal haemoglobins to a precise understanding of the functional consequences of mutation are discussed below. Isoelectric focusing in polyacrylamide gels is likely to be a useful method for characterizing haemoglobin variants,⁸⁶⁵ and human Hb A₂ is easily separated from Hb C by chromatography on phosphocellulose,⁸⁶⁶ although the variability between different batches of adsorbent is likely to be a nuisance in this method.

The X-ray analysis⁸⁶⁷ of deoxy Hb-*Rainier* (β 145 Tyr \rightarrow Cys) shows that the cysteine introduced by the mutation forms a disulphide bridge with Cys-93 of the same β -chain, and the abnormal physico-chemical properties of the molecule can be explained.⁸⁶⁷ An elegant approach to structure-function relationships is possible through a combination of X-ray studies and the availability of more than one variant haemoglobin involving a single position in the chain. Thus crystallographic studies of Hb-*Kansas* (β 102 Asn \rightarrow Thr) and Hb-*Richmond* (β 102 Asn \rightarrow Lys) showed⁸⁶⁸ that the highly abnormal properties of the former arose from the distortion caused by the additional methyl group while the properties of the latter were virtually normal; Asn-102 is known to be important since it forms the only hydrogen-bond across the $\alpha_1\beta_1$ interface in oxy-haemoglobin. Further crystallographic studies⁸⁶⁹ show that when tyrosine replaces a haem-linked histidine (α 87 in Hb M-*Iwate*, or β 92 in Hb M-*Hyde Park*) the mutant chains are stabilized in the ferric form and will not combine reversibly with oxygen; the detailed structural changes are described.⁸⁶⁹ Arg-92 α of normal haemoglobin is replaced by glutamine in Hb J-*Capetown* and by leucine in Hb-*Chesapeake*. The properties of the molecules, resulting from different

⁸⁶² J. B. Clegg, D. J. Weatherall, and P. F. Milner, *Nature*, 1971, **234**, 337.

⁸⁶³ G. Flatz, J. L. Kinderlerer, J. V. Kilmartin, and H. Lehmann, *Lancet*, 1971, 732.

⁸⁶⁴ (a) F. E. Boulton, R. G. Huntsman, G. I. Yawson, A. E. Romero Herrera, P. A. Lorkin, and H. Lehmann, *Brit. J. Haematol.*, 1971, **20**, 69; (b) F. E. Boulton, R. G. Huntsman, A. E. Romero Herrera, P. A. Lorkin, and H. Lehmann, *Biochim. Biophys. Acta*, 1971, **229**, 716; (c) F. E. Boulton, R. G. Huntsman, A. E. Romero Herrera, P. A. Lorkin, and H. Lehmann, *ibid.*, p. 871.

⁸⁶⁵ J. W. Drysdale, P. Righetti, and H. F. Bunn, *Biochim. Biophys. Acta*, 1971, **229**, 42.

⁸⁶⁶ B. F. Horton and A. I. Chernoff, *J. Chromatog.*, 1971, **63**, 414.


⁸⁶⁷ J. Greer and M. F. Perutz, *Nature New Biol.*, 1971, **230**, 261.

⁸⁶⁸ J. Greer, *J. Mol. Biol.*, 1971, **59**, 99.


⁸⁶⁹ J. Greer, *J. Mol. Biol.*, 1971, **59**, 107.

types of perturbations in each case, have been the subject of a detailed kinetic investigation.⁸⁷⁰

Correlation of specific chemical modification of proteins with an alteration in properties is another way of studying the same problem of structure-function relationships; when this is combined with X-ray analysis of the modified molecule the approach becomes doubly powerful. The functional properties of haemoglobin substituted at Cys-93 with a variety of N-substituted maleimides depended not only on the nature of the modifying reagent but also on the ligand state of the protein.^{871, 872} In general it was found that reaction with the oxy-form gave a derivative in which co-operativity was eliminated, while it was only impaired if the deoxy-form was used. Two bifunctional reagents reacted at a second site in horse oxy-haemoglobin after initial reaction at Cys-93; bis(maleimidomethyl) ether⁸⁷¹ (18) reacted at His-97 β , and N- α -(bromoacetoxymethyl)maleimide⁸⁷³ (19)



(18)



(19)

at Val-1 β , although the ester bond in this cross-link was then hydrolysed rapidly. Reaction with the deoxy-form was confined to Cys-93, also the site of reaction of monofunctional N-substituted maleimides with both the oxy- and deoxy-forms.⁸⁷¹ X-Ray studies⁸⁷⁴ showed that the loss of co-operativity in derivatives alkylated at Cys-93 arose from structural changes that stabilized the oxy-configuration even in the absence of ligands; in particular, displacement of the hydrogen-bonded position of Tyr-145 β distorted the region of the β -chain involved in the $\alpha_1\beta_2$ contact. Hence co-operativity, which involves a change of conformation on binding or release of ligands, disappears. The functional consequences of structural alterations have been discussed in detail.⁸⁷⁵ The absence of any effect of 2,3-DPG on haemoglobin treated with bis(maleimidomethyl) ether is thus taken to imply that an essential conformational change is involved in DPG function.⁸⁷⁶ On the other hand, when Cys-93 β reacts with DTNB there is no

⁸⁷⁰ R. L. Nagel, Q. H. Gibson, and T. Jenkins, *J. Mol. Biol.*, 1971, **58**, 643.

⁸⁷¹ D. J. Arndt, S. R. Simon, T. Maita, and W. Konigsberg, *J. Biol. Chem.*, 1971, **246**, 2602.

⁸⁷² S. R. Simon, D. J. Arndt, and W. Konigsberg, *J. Mol. Biol.*, 1971, **58**, 69.

⁸⁷³ D. J. Arndt and W. Konigsberg, *J. Biol. Chem.*, 1971, **246**, 2594.

⁸⁷⁴ J. K. Moffat, *J. Mol. Biol.*, 1971, **58**, 79.

⁸⁷⁵ J. K. Moffat, S. R. Simon, and W. Konigsberg, *J. Mol. Biol.*, 1971, **58**, 89.

⁸⁷⁶ J. M. Salhany, *F.E.B.S. Letters*, 1971, **14**, 11.

loss of co-operativity,⁸⁷⁷ although the Bohr effect and the oxygen affinity are altered, and if loss of co-operativity is indeed associated with the structural changes revealed by the *X*-ray work⁸⁷⁴ then it appears that the large thiolate residue at β -93 does not expel Tyr-145 β . Similar retention of co-operativity was observed when Cys-93 β reacted with mercurials.⁸⁷⁸ A study⁸⁷⁹ of the binding of CO₂ by haemoglobin in which either the α -chains or the β -chains, or both, had been modified with cyanate, with retention of co-operativity, confirmed the view that under physiological conditions haemoglobin binds CO₂ through the four terminal amino-groups, and that the amino-termini of the α -chains are those involved in the Bohr effect. The pK_a of the α -amino-group of the free α -chain, determined by reaction with fluorodinitrobenzene,⁸⁸⁰ is 7.4. Support for the role of the amino-termini of the β -chains in the control of oxygen binding comes from a study of the two major haemoglobins of the cat;⁸⁸¹ one has the N-terminal sequence Gly-Phe- and is sensitive to 2,3-DPG whereas the other has the blocked N-terminal sequence Acetyl-Ser-Phe- (uncharacteristic of mammalian haemoglobins) and is not sensitive. Further, it has now been suggested⁸⁸² that DPG does, in fact, affect the Bohr effect. Thus differences in the Bohr effect of the haemoglobins of mouse, man, and elephant in the presence of physiological concentrations of DPG are attributed to differences in the sensitivity of the oxygen equilibria to DPG arising from small differences in the environment of the DPG-binding site as a result of mutation, reflecting adaptation to the metabolic needs of the animal (greatest in the mouse).⁸⁸²

Haemerythrin. The primary structure of the non-haem respiratory pigment, haemerythrin, of the sipunculid worm *Dendrostomum pyroides* has been determined⁸⁸³ using the sequenator for the first 35 residues, and comparison of tryptic peptides to establish the remainder by homology with the sequence of haemerythrin from *Golfingia gouldii*. The sequences appear to differ in only four positions, and an error in the *G. gouldii* sequence is corrected;⁸⁸⁴ residues 10 and 11 are Trp and Asp respectively. From two reports concerned with identification of the tyrosine residues implicated in iron binding in haemerythrin^{885, 886} Tyr-8 and Tyr-109 are the most likely candidates. It is interesting that side-reactions in the use of tetranitromethane were observed in one case⁸⁸⁵ but not the other.⁸⁸⁶

⁸⁷⁷ G. Amiconi, E. Antonini, M. Brunori, A. Nason, and J. Wyman, *European J. Biochem.*, 1971, **22**, 321.

⁸⁷⁸ B. Giardina, I. Binotti, G. Amiconi, E. Antonini, M. Brunori, and C. H. McMurray, *European J. Biochem.*, 1971, **22**, 327.

⁸⁷⁹ J. V. Kilmartin and L. Rossi-Bernardi, *Biochem. J.*, 1971, **124**, 31.

⁸⁸⁰ S. H. De Bruin and E. Bucci, *J. Biol. Chem.*, 1971, **246**, 5228.

⁸⁸¹ F. Taketa, A. G. Mauk, and J. L. Lessard, *J. Biol. Chem.*, 1971, **246**, 4471.

⁸⁸² S. Tomita and A. Riggs, *J. Biol. Chem.*, 1971, **246**, 547.

⁸⁸³ R. E. Ferrell and G. B. Kitto, *Biochemistry*, 1971, **10**, 2923.

⁸⁸⁴ R. E. Ferrell and G. B. Kitto, *F.E.B.S. Letters*, 1971, **12**, 322.

⁸⁸⁵ R. L. Hill and I. M. Klotz, *Arch. Biochem. Biophys.*, 1971, **147**, 226.

⁸⁸⁶ J. L. York and C. C. Fan, *Biochemistry*, 1971, **10**, 1659.

7 Immunoglobulins

The interested reader need fear no shortage of reviews in this fast-moving field. Among the good ones this year,⁸⁸⁷ that by Williamson can be particularly recommended as a brief introduction to some of the recent developments in the study of cell-cell interactions involved in antibody biosynthesis. A report⁸⁸⁸ of the relevant colloquium at the 7th F.E.B.S. Meeting in Varna, Bulgaria, in September 1971 serves to remind one of the strong divergence of opinion about the problem of the genetics of antibody formation, which is also evident in the reviews cited.

The use of an immunoabsorbent (an antibody against myeloma IgE trapped in polyacrylamide gel) for the isolation of IgE has been described⁸⁸⁹ and 7s subunits of IgM have been obtained from the lemon shark.⁸⁹⁰ Natural 7s IgM has been isolated from human sera and some preliminary structural work has been carried out on its disulphide bridges.⁸⁹¹ Immunoglobulin-like molecules that contain no light chains but only heavy chains of IgM have been reported in the serum of bursectomized, irradiated chicks.⁸⁹²

The immune macroglobulin from the gar, *Lepisosteus osseus*,⁸⁹³ and the paddlefish, *Polyodon spatula*,⁸⁹⁴ has a molecular weight of ca. 650 000 and appears to have a tetrameric $(H_2L_2)_4$ structure. The same is probably true of the IgM from the giant grouper, *Epinephelus itaira*.⁸⁹⁵ No free N-terminal residue could be detected in the light chains of paddlefish IgM, but the heavy chain was shown to have the N-terminal sequence Asp-Val-Val-Leu-Thr.⁸⁹⁴ The duck contains curious 5.7s and 7.8s immunoglobulins and it has been reported⁸⁹⁶ that the heavy chains in these proteins have molecular weights of 35 000 and 59 000 respectively. Since a study of the evolution of the amino-acid sequence of normal γ -chains shows that the constant region is three times the length of the variable region and suggests that the molecule arose by a series of gene duplication events,⁸⁸⁷ it is proposed⁸⁹⁶ that the constant region of the heavy chain of duck 5.7s immunoglobulin is only twice as long as the variable region, whereas that

⁸⁸⁷ R. R. Porter, 'Harvey Lectures 1969—70' Academic Press, New York, p. 157; C. Milstein and A. J. Munro, *Ann. Rev. Microbiol.*, 1970, **24**, 335; J. R. L. Pink, A. C. Wang, and H. H. Fudenberg, *Ann. Rev. Med.*, 1971, **22**, 145; G. P. Smith, L. Hood, and W. M. Fitch, *Ann. Rev. Biochem.*, 1971, **41**, 969; A. R. Williamson, *Nature*, 1971, **231**, 359.

⁸⁸⁸ M. Sela, *F.E.B.S. Letters*, 1971, **19**, 181.

⁸⁸⁹ S. Carrel, L. Theilkäs, A. Morell, F. Skvaril, and S. Barandum, *Biochem. J.*, 1971, **122**, 405.

⁸⁹⁰ D. G. Klapper, L. W. Clem, and P. A. Small, jun., *Biochemistry*, 1971, **10**, 645.

⁸⁹¹ F. Dolder, *Biochim. Biophys. Acta*, 1971, **236**, 675.

⁸⁹² Y. S. Choi and R. A. Good, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2083.

⁸⁹³ R. T. Acton, P. F. Weinheimer, H. K. Dupree, E. E. Evans, and J. C. Bennett, *Biochemistry*, 1971, **10**, 2028.

⁸⁹⁴ R. T. Acton, P. F. Weinheimer, H. K. Dupree, T. R. Russell, M. Wolcott, E. E. Evans, R. E. Schrohenloher, and J. C. Bennett, *J. Biol. Chem.*, 1971, **246**, 6760.

⁸⁹⁵ L. W. Clem, *J. Biol. Chem.*, 1971, **246**, 9.

⁸⁹⁶ B. Zimmerman, N. Shalatin, and H. M. Grey, *Biochemistry*, 1971, **10**, 482.

of the 7.8s molecule is four times as long. If borne out by further work, this will be a most interesting observation.

A study of the hydrolysis of IgG1 and IgG2 of guinea-pig with papain and pepsin has been described:⁸⁹⁷ IgG1 is far more susceptible to proteolysis than IgG2. It has been found⁸⁹⁸ that the N-terminal aspartic acid or glutamic acid residues of light chains in intact antibodies are incapable of accepting arginine from Arg-tRNA in an enzyme-catalysed reaction (see also refs. 331, 423) whereas isolated light chains will serve as acceptors, suggesting that their N-terminal residues are folded away in the intact immunoglobulin.

A. Light Chains.—More than 95% of the light chains from chicken and turkey immunoglobulins appear to be homologous with mammalian λ -chains⁸⁹⁹ and the light chains of the African lungfish (*Protopterus aethiopicus*) also have N-terminal residues that are predominantly blocked.⁹⁰⁰ The unblocked class of chains has the N-terminal sequence Asp-() ()-Leu-Thr-Glx-Asx-Ala-Ser-, in which two deletions are postulated in order to maximize the homology with mammalian light chains,⁹⁰⁰ but this sequence is no more like that of human κ -chains than human λ -chains as far as it goes.

However, most recent work has been concerned with human light chains and Bence-Jones proteins. Large deletions, one of which is in the variable region, have been detected in two myeloma light chains,^{901, 902} but the relevance to normal antibody variability is obscure. Carbohydrate has been found in the variable region of two myeloma κ -chains⁹⁰² and in both cases the amino-acid sequence in the attachment site fits the postulate of sequence specificity for attachment (see last year's Report). The amino-acid sequences of several human κ -chains have also been reported:⁹⁰³⁻⁹⁰⁵ they all belong to subgroup κ_1 but indicate that that subgroup may need to be further divided. Similarly, the amino-acid sequences of two human λ -chains of subgroup II^{906, 907} and one of subgroup IV⁹⁰⁸ have been determined. One of the chains in subgroup II has histidine as N-terminal residue,⁹⁰⁶ which is unique in the primary structures of light chains so far reported. Moreover, the existence of genetic polymorphism involving a Ser/Gly interchange at position 154 in the constant region of human λ -chains has been firmly

⁸⁹⁷ R. G. Q. Leslie, M. D. Melamed, and S. Cohen, *Biochem. J.*, 1971, **121**, 829.

⁸⁹⁸ R. L. Soffer and J. D. Capra, *Nature New Biol.*, 1971, **233**, 44.

⁸⁹⁹ J. A. Grant, B. Sanders, and L. Hood, *Biochemistry*, 1971, **10**, 3123.

⁹⁰⁰ G. W. Litman, A. C. Wang, H. H. Fudenberg, and R. A. Good, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2321.

⁹⁰¹ O. Smithies, D. Gibson, E. M. Fanning, M. E. Percy, D. M. Parr, and G. E. Connell, *Science*, 1971, **172**, 574.

⁹⁰² C. P. Milstein and C. Milstein, *Biochem. J.*, 1971, **121**, 211.

⁹⁰³ C. P. Milstein and E. V. Deverson, *Biochem. J.*, 1971, **123**, 945.

⁹⁰⁴ H. Schiechl and N. Hilschmann, *Z. physiol. Chem.*, 1971, **352**, 111.

⁹⁰⁵ M. Braun, W. Leibold, H.-U. Barnikol, and N. Hilschmann, *Z. physiol. Chem.*, 1971, **352**, 647.

⁹⁰⁶ H. Ponstingl and N. Hilschmann, *Z. physiol. Chem.*, 1971, **352**, 859.

⁹⁰⁷ F. A. Garver and N. Hilschmann, *F.E.B.S. Letters*, 1971, **16**, 128.

⁹⁰⁸ H. Ponstingl, M. Hess, and N. Hilschmann, *Z. physiol. Chem.*, 1971, **352**, 247.

established.^{909, 910} The interchange is not the result of allelic genes and there appears to be no restriction on the combination of the two possibilities for position 154 with the two possibilities (Lys/Arg) for the Oz interchange at position 191.^{909b, 910} In addition, the same variation is found in the constant regions of normal human λ -chains as well as those associated with myelomatosis,⁹¹⁰ and any of the possible λ -chain constant regions seems able to fuse with any of the λ -chain variable-region subgroups.^{909b} Formal proof of the non-allelic nature of the variable-region subgroups for human λ -chains has now been produced⁹¹¹ and the first amino-acid sequence of a mouse myeloma light chain, MOPC 104, has been determined.⁹¹²

During the fractionation of a human Bence-Jones protein, Au, it was observed⁹¹³ that the variable region was released (probably by proteolysis in the urine) and that the fragment could be crystallized. In line with the idea that variable and constant regions arose by gene duplication and fusion, the independent folding of variable and constant regions of a λ -chain has been reported.⁹¹⁴ The common folded structure of Bence-Jones proteins has been demonstrated in a study of the reactivity of tyrosine and histidine residues towards iodination.⁹¹⁵

Amyloidosis is a disease of unknown aetiology characterized by the deposition of a fibrous protein in the extracellular connective tissue of the organ involved. In some cases the deposition of amyloid protein in man is also associated with multiple myeloma, and N-terminal sequence analysis of two such proteins (using a sequenator for 35 and 36 residues respectively) shows⁹¹⁶ that both proteins are derived from homogeneous κ -chains of variable-region subgroup I. On the other hand, human and monkey amyloid proteins of the typical kind (a variety of amyloidosis associated with chronic inflammation) have major components with the following N-terminal sequences:⁹¹⁷

Human	Arg-Ser-Phe-Phe-Ser-Phe-Leu-Gly-Glu-Ala-Phe-Asp-Gly-Ala-Arg-
Monkey	Arg-Ser-Trp-Phe-Ser-Phe-Leu-Gly-Glu-Ala-Tyr-Asp-Gly-Ala-Arg-
	1 10
Human	Asp-Met-Trp-Arg-Ala-Tyr-Ser-Asp-Met-
Monkey	Asp-Met-Trp-Arg-Ala-Tyr-Ser-Asp-Met-
	20

Again, a sequenator was used for the analysis.

⁹⁰⁹ (a) M. Hess and N. Hilschmann, *Z. physiol. Chem.*, 1971, **352**, 657; (b) M. Hess, N. Hilschmann, L. Rivat, C. Rivat, and C. Ropartz, *Nature New Biol.*, 1971, **234**, 58.

⁹¹⁰ D. Gibson, M. Levanon, and O. Smithies, *Biochemistry*, 1971, **10**, 3114.

⁹¹¹ F. W. Tischendorf, B. Michelitsch, G. Ledderose, and M. M. Tischendorf, *J. Mol. Biol.*, 1971, **61**, 261.

⁹¹² E. Appella, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 590.

⁹¹³ H. J. Schramm, *Z. physiol. Chem.*, 1971, **352**, 1134.

⁹¹⁴ I. Björk, F. A. Karlsson, and I. Berggård, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1707.

⁹¹⁵ (a) B.-K. Seon, O. A. Roholt, and D. Pressman, *J. Biol. Chem.*, 1971, **246**, 887; (b) B.-K. Seon, O. A. Roholt, and D. Pressman, *Biochim. Biophys. Acta*, 1971, **229**, 396.

⁹¹⁶ G. G. Glenner, W. Terry, M. Harada, C. Isersky, and D. Page, *Science*, 1971, **172**, 1150.

⁹¹⁷ E. P. Benditt, N. Eriksen, M. A. Hermodson, and L. H. Ericsson, *F.E.B.S. Letters*, 1971, **19**, 169.

B. Heavy Chains.—The amino-acid sequence of the variable region of a human myeloma μ -chain has been determined and the evolutionary origins of μ - and γ -chains have been discussed.⁹¹⁸ Further work has also been described on the VH_{III} subgroup of human heavy chains characterized by an unblocked glutamic acid residue at the N-terminus. Thus, hyper-variability has been reported^{919, 920} for the region of residues 30—37 (identical results have already been obtained for light chains) and a study of cyanogen bromide fragments^{920b} indicates that residues 86—91 and 101—109 are also hypervariable. Further, one IgG and IgM from a single myeloma patient show the same N-terminal sequence for 34 residues, suggesting that the same VH_{III} variable region exists on two different classes of heavy chain,⁹¹⁹ but it is also possible that the subgroup distinctions may not extend throughout the variable region.^{920b}

Allotypically related sequences have been described in the variable region of rabbit heavy chains for allotypes Aa1, Aa2, and Aa3⁹²¹ (Figure 23). No such allotypic variation was detected in the constant region of the chains. A total of 16 residues, including six consecutively, show the correlation, which is a remarkably high number for allelic variation (see Section 7E) and the results emphasize the hypervariability of residues 95—115 reported previously from the same laboratory. On the other hand, the A14/A15 allotypes of rabbit IgG have been shown⁹²² to correlate with a Thr/Ala interchange at position 309 in the Fc region (using the human Eu numbering). Work is in progress on IgG-2 from inbred guinea-pig. Thus, five fragments that together account for 303 residues from the C-terminus of the γ 2-chain have been isolated after cyanogen bromide digestion⁹²³ and the amino-acid sequence of a fragment from the variable region (49 residues derived from positions 35—83) has been established.⁹²⁴

The C-terminal sequence of the α -chain in human IgA1 and IgA2 has been found to be:⁹²⁵

-Met-Ala-Glu-Val-Asp-Gly-Thr-Cys-Tyr

with the penultimate residue probably involved in an intrachain disulphide bridge. Carbohydrate has been shown to be attached at five specific sites in the constant region of the human μ -chain⁹²⁶ but there was no obvious

⁹¹⁸ A. Shimizu, C. Paul, H. Köhler, T. Shinoda, and F. W. Putnam, *Science*, 1971, **173**, 629.

⁹¹⁹ A. C. Wang, H. H. Fudenberg, and J. R. L. Pink, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1143.

⁹²⁰ (a) J. D. Capra, *Nature New Biol.*, 1971, **230**, 61; (b) J. McKehoe and J. D. Capra, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2019.

⁹²¹ L. E. Mole, S. A. Jackson, R. R. Porter, and J. M. Wilkinson, *Biochem. J.*, 1971, **124**, 301.

⁹²² E. Appella, A. Chersi, R. G. Mage, and S. Dubiski, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1341.

⁹²³ B. K. Birshtein, K. J. Turner, and J. J. Cebra, *Biochemistry*, 1971, **10**, 1.

⁹²⁴ B. K. Birshtein and J. J. Cebra, *Biochemistry*, 1971, **10**, 4930.

⁹²⁵ J. W. Prahl, C. A. Abel, and H. M. Grey, *Biochemistry*, 1971, **10**, 1808.

⁹²⁶ A. Shimizu, F. W. Putnam, C. Paul, J. R. Clamp, and I. Johnson, *Nature New Biol.*, 1971, **231**, 73.

1		10		20	
Aa1 Pool	Glp—	Val—Glu-Glu-Ser-Gly-Gly—Arg	Leu-Val—Thr—Pro—Thr-Pro-Gly	Leu-Thr-Leu-Thr-Cys-Thr—Val-Ser-Ala	
Aa2 Single	Glp—	Ser—Val-Lys-Glu-Ser-Glu-Gly—Gly	Leu-Phe-Lys—Pro—Thr-Asn-Thr	Leu-Thr-Leu-Thr-Cys-Thr—Val-Ser-Ala	
Aa3 Pool	Glp-Glu-Gln	Ser—Leu-Glu-Glu-Ser-Gly-Gly—Val	Leu-Val—Lys—Pro—Gly—()	Leu-Thr-Leu-Thr-Cys-Thr—Ala-Ser—	
		30		40	
Aa1 Pool	Gly—Phe-Ser—Leu—Ser-Ser-Tyr—Ala—Met—Gly—Trp—Val—Arg-Gln-Ala—Pro-Gly-Lys-Gly—Leu-Glu-Tyr				
Aa2 Single	Gly—Ile—Asp—Leu—Ser-Ser-Tyr—Gly—Val—Ser—Ser—Trp—Val—Arg-Gln-Ala—Pro-Gly—Asp—Glu—Leu-Glu-Trp—Ile-Gly—				
Aa3 Pool	Gly—Phe—Asn—Ser—Ser—Phe—Tyr—Met—Gly—Ala—Pro-Gly-Lys—				
		50		70	
Aa1 Pool	Phe Ile Asp Ile Val () ——— (Gly-Thr-Ser) Tyr-Tyr-Ala-Ser—Trp—Ala-Lys-Gly-Arg-Phe-Thr-Ile-Ser-Lys-Thr-Ser-Thr-Thr—				
Aa2 Single	Ala-Ile—Asp-Gly-Tyr-Gly-Thr-Thr-Tyr-Tyr-Ala-Ser—Trp—Ala-Lys-Ser—Arg				
Aa3 Pool					
		80		94	
Aa1 Pool	Val—Asp—Leu—Met—Lys—Leu—Thr-Ser—Pro—Thr-Gln—Asp—Thr-Ala—Thr-Tyr-Phe-Cys-Ala—Arg				
Aa3 Pool	Val, Glu, Leu () ——— Met—Thr-Ser—Leu—Thr-Ala—Ala—Asp—Thr-Ala—Thr-Tyr-Phe-Cys-Ala—Arg				

Figure 23 Comparison of the variable-region sequences of Aa1, Aa2, and Aa3 rabbit heavy chains. Residues in boxes are those that vary between the Aa1, Aa2, and Aa3 sequences, and those in parentheses are minor variants in each sequence. The bars at positions 2, 53, and 54 indicate a presumed deletion
(Reproduced by permission from *Biochem. J.*, 1971, 124, 301)

C. Disulphide Bridges.—Full details have now been published of the arrangement of the disulphide bridges in the human $\gamma 2$ -chain⁹²⁷ and five interchain disulphide bridges have been described in the γ -chains of pig immunoglobulin, the results being consistent with the existence of more than one subclass of γ -chain in the pig.⁹²⁸ The amino-acid sequence in the hinge region of the IgG2 of the inbred strain 13 of guinea-pig has also been determined.⁹²⁹ Three inter-heavy-chain disulphide bridges were found in a sequence comparable with that for the single inter-heavy-chain bridge of rabbit IgG:^{929a}

Guinea-pig Asx-Pro-Cys-Thr-Cys-Pro-Lys-Cys-Pro-Pro-Pro-Glu-Asn-Leu-Gly-

Rabbit ————— Ser-Lys-Pro-Thr-Cys-Pro-Pro-Pro-Glu-Leu-Leu-Gly

Heavy Heavy Heavy Heavy

Rabbit Gly-Pro-Ser-Val-Phe-Ile-Phe-Pro-Pro-Lys-Pro-Lys-Asp-Thr-Leu-Met-


The light chain in guinea-pig IgG2 is linked to the heavy chain by a disulphide bridge sited approximately one-quarter of the way along the heavy chain from the N-terminus,⁹³⁰ like that of all other IgG except human IgG1. Other experiments⁹³¹ show that the interchain disulphide bridges of goat IgG closely resemble those of the rabbit:

(Light chain) -Lys-Thr-Val-Lys-Pro-Ser-Glu-Cys-Ser
-Thr-Ser-Thr-Pro-Pro-Lys-Val-Tyr-Pro-Leu-Thr-Ser -Cys-Cys-Gly-Asx-Thr-Ser-Ser-
120 **130**
(Heavy chain)
-Lys-Cys-Pro-Lys-Gln-Pro-Cys-Val-Arg-Gly-Pro-Ser-Val-
220
Heavy chain

Human IgA exists in two subclasses, IgA1 and IgA2. Subclass IgA2 can be further divided into two forms, Am2(+), the common variant, which has no disulphide bridge linking heavy and light chains and Am2(-), the minor variant, which has. It is reported that the amino-acid sequence in this

⁹³¹ P. H. Strausbach, E. Hurwitz, and D. Givol, *Biochemistry*, 1971, 10, 2231.


bridge region is the same for γ A1- and γ A2Am2(-)-chains⁹³² but that differences occur in the amino-acid sequence of the hinge region of the γ A1- and γ A2-chains.⁹³³ The primary structure of the hinge region of a human μ -chain has also been determined:⁹³⁴



Little sequence homology with γ -chains is apparent in this region. Potentially useful derivatives for X-ray crystallography have been produced by inserting mercury into the disulphide bridges of a human IgG1 myeloma protein.⁹³⁵

There have been further reports of J-chains in IgM^{936, 937} and colostral IgA.⁹³⁶ It is probable that the J-chain (m. wt. 26 000, but not a light chain) is covalently attached to the immunoglobulin by disulphide bridges and that it is identical in IgM and IgA.⁹³⁶

D. Antibody Binding Sites.—The golden fleece of molecular immunology, to coin a phrase, is a chemically homogeneous antibody of defined specificity, preferably one that crystallizes. The role of Jason is hotly contested. Thus, work is in progress on the structure of different antibodies from inbred strains of guinea-pig^{924, 929a, 930} and of relatively homogeneous rabbit antibodies against group C streptococcal carbohydrate⁹³⁸ and type III pneumococci.⁹³⁹ Homogeneous rabbit antibodies against the *p*-azophenyltrimethylammonium hapten have been reported⁹⁴⁰ and the N-terminal sequence of light chains from a homogeneous rabbit anti-*p*-azobenzoate antibody has been established:⁹⁴¹



The N-terminal valine residue is unique in rabbit light chains examined so far.

The next best thing to a natural antibody is a myeloma protein to which an antibody specificity can be assigned. The mouse myeloma IgM, MOPC

⁹³² E. Mihaesco, M. Seligman, and B. Frangione, *Nature New Biol.*, 1971, **232**, 220; C. Wolfenstein, B. Frangione, E. Mihaesco, and E. C. Franklin, *Biochemistry*, 1971, **10**, 4140.

⁹³³ C. A. Abel and H. M. Grey, *Nature New Biol.*, 1971, **233**, 29.

⁹³⁴ C. Paul, A. Shimizu, H. Köhler, and F. W. Putman, *Science*, 1971, **172**, 69.

⁹³⁵ L. A. Steiner and P. M. Blumberg, *Biochemistry*, 1971, **10**, 4725.

⁹³⁶ J. Mestecky, J. Zikan, and W. T. Butler, *Science*, 1971, **171**, 1163.

⁹³⁷ B. Frangione, F. Prelli, C. Mihaesco, and E. C. Franklin, *Proc. Nat. Acad. Sci. U.S.A.* 1971, **68**, 1547.

⁹³⁸ J. B. Fleischman, *Biochemistry*, 1971, **10**, 2753.

⁹³⁹ J.-C. Jaton, M. D. Waterfield, M. N. Margolies, K. J. Bloch, and E. Haber, *Biochemistry*, 1971, **10**, 1583.

⁹⁴⁰ M. H. Freedman and R. H. Painter, *J. Biol. Chem.*, 1971, **246**, 4340.

⁹⁴¹ E. Appella, A. Chersi, O. A. Roholt, and D. Pressman, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2569.

104E, has specificity for carbohydrate haptens ⁹⁴² and the primary structure of the light chains has been described.⁹¹² However, most work has so far been carried out with the mouse IgA myeloma protein, MOPC 315, which has anti-Dnp activity (see last year's Report). The tentative amino-acid sequence of the light chains has now been established ⁹⁴³ (Figure 24). When




Figure 24 The tentative amino-acid sequence of the light chain from mouse myeloma protein MOPC 315

compared with the light chain of MOPC 104, multiple differences in the constant region are apparent despite the fact that both are λ -chains. Assuming that these are not allelic differences, the most probable explanation is that there is polymorphism in the genes for the constant region of mouse λ -chains.⁹⁴³ This has already been established for human λ -chains (see above). Crystallization with hapten of the Fab' fragment of MOPC 315 (produced by peptic digestion) has also been reported.⁹⁴⁴

Rabbit and mouse antibodies against the *p*-azophenyltrimethylammonium determinant have been allowed to react with the affinity label *p*-trimethylammonium-benzenediazonium difluoroborate.⁹⁴⁵ tyrosine residues in both heavy and light chains were specifically modified and further experiments suggested that the same local region in various antibodies is used to form

⁹⁴² N. M. Young, I. B. Jocius, and M. A. Leon, *Biochemistry*, 1971, **10**, 3457.

⁹⁴³ E. P. Schulenberg, E. S. Simms, R. G. Lynch, R. A. Bradshaw, and H. N. Eisen, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2623.

⁹⁴⁴ D. Inbar, M. Rotman, and D. Givol, *J. Biol. Chem.*, 1971, **246**, 6272.

⁹⁴⁵ J. W. Fenton and S. J. Singer, *Biochemistry*, 1971, **10**, 1429.

active sites of different specificities. A series of bromoacetyl derivatives related to Dnp has been proposed for mapping the binding site of anti-Dnp antibodies⁹⁴⁶ and used to study the mouse myeloma MOPC 315.⁹⁴⁷ In particular, a bifunctional affinity label was found that cross-linked a tyrosine residue in the light chain and a lysine residue in the heavy chain, tentatively identified as residues 34 and 54 in the respective chains.⁹⁴⁷ Another attempt⁹⁴⁸ at cross-linking in the active site of MOPC 315 involved labelling Tyr-34 in the light chain using *m*-nitrobenzenediazonium fluoroborate and reducing the resulting azotyrosine to 3-aminotyrosine. By taking advantage of its low *pK*, the new amino-group thus introduced can, in principle, be cross-linked specifically to other nucleophiles using F₂DNB.⁹⁴⁹ For some reason this was not possible with MOPC 315 but cross-links to light- and heavy-chain residues were produced. Their identity remains to be determined.⁹⁴⁸ Nitration of a nitrophenyl-binding Waldenström macroglobulin using tetranitromethane has been reported⁹⁵⁰ to inactivate the molecule by modification of tyrosine residues, the critical residues being located predominantly in the Fd fragment.

A study of the hapten-binding activity in reconstituted mouse myeloma proteins with anti-Dnp specificity suggests that unique pairs of heavy and light chains are required for a particular binding site.⁹⁵¹ If different heavy and light chains – even chains from other anti-Dnp myeloma proteins – were used, no activity could be recovered.

E. Some Problems of Biosynthesis.—This topic is properly beyond the scope of this Report and is covered in depth in various reviews.^{887, 888} A few points, however, deserve to be noticed. The subunits of IgM⁹⁵² and IgA⁹⁵³ accumulate intracellularly because the thiol groups that eventually form the disulphide bridges necessary for assembly are blocked. The nature of the blocking group is unknown (perhaps it is cysteine or glutathione) but its removal allows intracellular assembly to occur.⁹⁵² Addition of the carbohydrate found in many immunoglobulins appears to take place in several steps at different sites within the myeloma cell but it is not yet clear whether carbohydrate addition is necessary for secretion of the immunoglobulin.⁹⁵⁴

Moreover, the problem of the fusion of the genes for the variable and constant regions of immunoglobulin polypeptide chains is still with us. The

⁹⁴⁶ P. H. Strausbauch, Y. Weinstein, M. Wilchek, S. Shaltiel, and D. Givol, *Biochemistry*, 1971, 10, 4342.

⁹⁴⁷ D. Givol, P. H. Strausbauch, E. Hurwitz, M. Wilchek, J. Haimovich, and H. N. Elsen, *Biochemistry*, 1971, 10, 3461.

⁹⁴⁸ N. M. Hadler and H. Metzger, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, 68, 1421.

⁹⁴⁹ P. Cuatrecasas, S. Fuchs, and C. B. Anfinsen, *J. Biol. Chem.*, 1969, 244, 406.

⁹⁵⁰ N. S. Otchin and H. Metzger, *J. Biol. Chem.*, 1971, 246, 7051.

⁹⁵¹ S. H. Bridges and J. R. Little, *Biochemistry*, 1971, 10, 2525.

⁹⁵² B. A. Askonas and R. M. E. Parkhouse, *Biochem. J.*, 1971, 123, 629.

⁹⁵³ R. M. E. Parkhouse, *F.E.B.S. Letters*, 1971, 16, 71.

⁹⁵⁴ F. Melchers, *Biochemistry*, 1971, 10, 653; Y. S. Choi, P. M. Knopf, and E. S. Lennox, *ibid.*, 1971, 10, 668.

synthesis of a mouse light chain in a cell-free system from rabbit reticulocytes at the direction of an RNA fraction from a mouse myeloma provides formal proof that the immunoglobulin chain is not formed by a fusion of two distinct polypeptides.⁹⁵⁵ More direct evidence that distinct genes control the variable and constant regions comes from a preliminary report⁹⁵⁶ that recombination has been detected between markers in the variable region (*a* locus) and constant region (A14/A15 locus) of rabbit γ -chains. Polymorphism for the genes coding for the constant regions of human λ -chains is established.^{909, 910} However, opinion remains divided about how many genes are required to code for the variable regions. Germ-line theories have been urged by some⁹⁰⁶⁻⁹⁰⁸ (see also refs. 887 and 888) but the detailed report of allotypically related sequence changes in the variable region of rabbit heavy chains⁹²¹ argues strongly in favour of one or a small number of copies of each allele. It is not unreasonable to hope, *pace* Franklin,⁹⁵⁷ that continued study of the primary structure of immunoglobulins and their genetic markers will eventually provide an answer to the riddle.⁹⁵⁸

8 Membrane Proteins

The reader will be aware that this is a rapidly advancing field, and again only the characterization of membrane proteins, not their function, will be the concern of this section. Recent attempts to label and isolate transport systems, drug receptors, and enzymes in membranes have been neatly reviewed,⁹⁵⁹ and the distinction has been made (see also last year's Report) between the affinity-labelling approach and characterization of proteins from solubilized whole membrane preparations, the latter being advocated.⁹⁵⁹ However, there are ways of avoiding the non-specific labelling held to be a disadvantage of the former method, and its success in certain cases is not denied.⁹⁵⁹ A brief survey of the possible modes of organization of protein molecules in membranes comes down in favour of a fluid structure in which protein molecules float in a pool of lipid, rather than the rigidity which the 'structural protein' concept conveys,⁹⁶⁰ and chemical modification of whole microsomal membranes has revealed⁹⁶¹ that tryptophan in the proteins is buried and a higher proportion of tyrosine residues and a lower proportion of lysine residues are exposed than in ordinary globular proteins.

A. Solubilization and Fractionation.—It is highly desirable that proteins from membranes should be obtained in their native conformations, and

⁹⁵⁵ J. Stavnezer and R. C. C. Huang, *Nature New Biology*, 1971, **230**, 172.

⁹⁵⁶ R. G. Mage, G. O. Young-Cooper, and C. Alexander, *Nature New Biology*, 1971, **230**, 63.

⁹⁵⁷ 'He that lives upon hope will die fasting', Benjamin Franklin, 'Poor Richard's Almanac'.

⁹⁵⁸ 'When you have eliminated the impossible, whatever remains, however improbable, must be the truth', Sir Arthur Conan Doyle, 'The Sign of Four'.

⁹⁵⁹ S. I. Chavin, *F.E.B.S. Letters*, 1971, **14**, 269.

⁹⁶⁰ N. M. Green, *Biochem. J.*, 1971, **122**, 37P.

⁹⁶¹ A. S. Khandwala and C. B. Kasper, *Biochim. Biophys. Acta*, 1971, **233**, 348.

mild methods of extraction are thus needed. Solubilization of most of the proteins of erythrocytes with no evidence of conformational change was achieved with 5 mmol l⁻¹ edta alone,⁹⁶² suggesting that inorganic cations participate in stabilization of protein-lipid interaction in this system, and 0.1 mol l⁻¹ tetramethylammonium bromide (90% solubilization) was accordingly much more effective than 0.1M-NaCl (10% solubilization).⁹⁶² Dilute acetic acid is also a useful mild solvent for erythrocyte membrane proteins,⁹⁶³ but rather less effective than edta. Guanidine hydrochloride is often used to solubilize membranes, although it now appears that, in some cases at least, it may fail since some carbohydrate-rich proteins of erythrocyte membranes remained associated with lipid in 6M guanidine hydrochloride.⁹⁶⁴ For the extraction of glycoproteins from membranes, lithium di-iodosalicylate is recommended.⁹⁶⁵

One or two improvements in procedures for fractionating membrane proteins by polyacrylamide-gel electrophoresis have been described. Thus the inclusion of 5% 2-mercaptoethanol in the phenol-acetic acid-urea system gives sharper bands⁹⁶⁶ and the three major proteins of rat brain myelin were purified by preparative SDS-gel electrophoresis (10–15 mg of total protein on a gel of dimensions 10.5 × 2.4 cm).⁹⁶⁷ This is obviously a method of general application made more attractive by the possibility of renaturation of proteins from solution in SDS,^{164, 166} as mentioned earlier (Section 2E). Non-ionic detergents such as Triton X-100 and deoxycholate are frequently used to disrupt membranes and the components are then resolved by gel chromatography in the presence of detergents. In an improved procedure for this step⁹⁶⁸ a decreasing (top to bottom) detergent gradient is set up in the column before the sample is applied, and the sample is then eluted with the strongest detergent (necessary initially to keep the sample soluble). The large proteins travel faster than the strong detergent and thus suffer minimal damage. Thus the mitochondrial oligomycin-sensitive ATPase was purified in active form on agarose with a 0–0.3% deoxycholate gradient, whereas irreversible inactivation resulted when 0.3% deoxycholate was used throughout for the chromatography.⁹⁶⁸

B. Red Blood Cell Membranes.—The distribution of proteins on the inside and outside of the erythrocyte membrane has been the subject of many investigations (see also last year's Report). Susceptibility to proteolytic attack or to chemical modification identifies proteins on the outside of the membrane, and the protein bands concerned are easily identified on SDS gels, either by virtue of their radioactivity as a result of modification or

⁹⁶² J. A. Reynolds and H. Trayer, *J. Biol. Chem.*, 1971, **246**, 7337.

⁹⁶³ A. H. Maddy and P. G. Kelly, *Biochim. Biophys. Acta*, 1971, **241**, 290.

⁹⁶⁴ A. H. Maddy and P. G. Kelly, *Biochim. Biophys. Acta*, 1971, **241**, 114.


⁹⁶⁵ V. T. Marchesi and E. P. Andrews, *Science*, 1971, **174**, 1247.

⁹⁶⁶ T. K. Ray and G. V. Marinetti, *Biochim. Biophys. Acta*, 1971, **233**, 787.

⁹⁶⁷ T. V. Waehneltdt, *Analyt. Biochem.*, 1971, **43**, 306.

⁹⁶⁸ P. Swanlung, *Analyt. Biochem.*, 1971, **43**, 382.

through a change of molecular weight as a result of proteolysis. ^{35}S -Labelled formylmethionyl sulphone methyl phosphate (20), which is extremely reactive towards amino-groups (Scheme 6), labels a carbohydrate-free protein (m. wt. 105 000) which is a major component of the



Scheme 6

external membrane ⁹⁶⁹ and a glycoprotein. The molecular weight of the latter was initially given as 90 000 from SDS-gels ⁹⁶⁹ but was later re-estimated ⁹⁷⁰ as 34 000, since glycoproteins have anomalous mobilities (see below). This glycoprotein contains 70% of the cell-surface sialic acid and is the MN blood-group glycoprotein.⁹⁷⁰ Although proteins have not generally been regarded as passing through the lipid bilayer, peptide mapping suggests that both the glycoprotein and the component of molecular weight 105 000 pass right through the membrane.^{970, 165} The component of molecular weight 90 000 which can be iodinated specifically on the outside of the membrane with lactoperoxidase (see also last year's Report) is claimed ⁹⁷¹ not to be the same as the component of molecular weight 105 000 in the previous study (ref. 969). If this is so then it is worth bearing in mind that the number of external proteins depends to some extent on the method of investigation. In fact, a further study ⁹⁷² shows that two proteins of molecular weight 90 000 and 105 000 unique to the outer membrane are digested by Pronase, and formation of a stable fragment of molecular weight 65 000 indicates that the proteins are only partly exposed. The anomalous molecular weights of glycoproteins in SDS-gels means that the glycoprotein labelled with [^{35}S]formylmethionyl sulphone methyl phosphate,⁹⁷⁰ that labelled with lactoperoxidase ⁹⁷¹ (previously ⁹⁷³ not distinguished from the non-glycoprotein on gels), and that with [^{35}S]sulphanilic acid diazonium salt ⁹⁷⁴ (see also last year's Report) are probably the same protein. In fact, decreased binding of SDS to oligosaccharide side-chains relative to the polypeptide backbone has been conclusively demonstrated ⁹⁷⁵ and shown not to be corrected by the removal of sialic acid. Glycoproteins

⁹⁶⁹ M. S. Bretscher, *J. Mol. Biol.*, 1971, **58**, 775.

⁹⁷⁰ M. S. Bretscher, *Nature New Biol.*, 1971, **231**, 229.

⁹⁷¹ D. R. Phillips and M. Morrison, *F.E.B.S. Letters*, 1971, **18**, 95.

⁹⁷² D. R. Phillips and M. Morrison, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1103.

⁹⁷³ D. R. Phillips and M. Morrison, *Biochemistry*, 1971, **10**, 1766.

⁹⁷⁴ W. W. Bender, H. Garan, and H. C. Berg, *J. Mol. Biol.*, 1971, **58**, 783.

⁹⁷⁵ J. P. Segrest, R. L. Jackson, E. P. Andrews, and V. T. Marchesi, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 390.

thus have anomalously high molecular weights and the most accurate values are obtained in gels of greater than 10% cross-linking, *i.e.* when the sieving effect is greatest. The molecular weight of the major glycoprotein of erythrocytes was estimated as 50 000—55 000 in 12.5% gels (5% gels gave 92 000).⁹⁷⁵ An independent study⁹⁷⁶ confirmed that the protein labelled from the outside with [³⁵S]sulphanilic acid diazonium salt was the glycoprotein by comparing human and bovine erythrocytes, since the bovine (unlike the human) glycoprotein is clearly resolved from other proteins on gels and its identification as the sole site of radioactive labelling was therefore unambiguous. This comparative approach will probably prove useful in other similar instances.

The effect on various membrane properties when proteins on the outside are digested with Pronase has been studied.⁹⁷⁴ All the major proteins and glycoproteins in the erythrocyte membrane have been separated in SDS-gels and the proteins released under various conditions compared.⁹⁷⁷ Proteins on the interior of the membrane, neatly studied using inside-out vesicles from erythrocyte ghosts,⁹⁷⁸ proved to be decidedly resistant to pronase and only one component was slowly attacked. This had a molecular weight of 89 000 (using reduced proteins as markers in SDS-gels) and had previously been identified⁹⁷⁷ as the major component of the erythrocyte membrane (about 30% of the total protein); it was also digested quite rapidly from the outside, again suggesting that there is at least one component which spans the membrane.⁹⁷⁸ Other studies with Pronase had also suggested this possibility.⁹⁷⁴ Another investigation has also been concerned with the electrophoretic analysis of the proteins of red blood cell membranes⁹⁷⁹ and again emphasizes the need to use reduced proteins for calibration in molecular weight determinations; 40% of the proteins were found to have high molecular weights, between 200 000 and 220 000.

It was reported last year that the water-soluble protein spectrin (subunit m. wt. 140 000) represented 20% of the total membrane protein of erythrocytes. Another water-soluble protein, tetkin A, also 20% of the protein, has now been described.⁹⁸⁰ It appears to be a dimer with chains of m. wt. *ca.* 220 000 and 240 000 and there is no evidence to suggest that it is a 'precursor' of spectrin. Their relation, if any, to proteins seen as a hollow cylinder and a torus, respectively, in the electron microscope, and released from erythrocyte ghosts at low ionic strength,⁹⁸¹ is unknown.

C. Mitochondrial and Other Membranes.—A lipoprotein in ox-heart mitochondrial membranes that appears to be involved in oxidative

⁹⁷⁶ K. L. Carraway, D. Kobylka, and R. B. Triplett, *Biochim. Biophys. Acta*, 1971, **241**, 934.

⁹⁷⁷ G. Fairbanks, T. L. Steck, and D. F. H. Wallach, *Biochemistry*, 1971, **10**, 2606.

⁹⁷⁸ T. L. Steck, G. Fairbanks, and D. F. H. Wallach, *Biochemistry*, 1971, **10**, 2617.

⁹⁷⁹ H. R. Trayer, Y. Nozaki, J. A. Reynolds, and C. Tanford, *J. Biol. Chem.*, 1971, **246**, 4485.

⁹⁸⁰ M. Clarke, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1063.

⁹⁸¹ J. R. Harris, *Biochem. J.*, 1971, **122**, 38P; *Biochim. Biophys. Acta*, 1971, **229**, 761.

phosphorylation can be specifically labelled *in situ* with [^{14}C]dicyclohexylcarbodi-imide;⁹⁸² the molecular weight on gels is as low as 10 000. The ATPase of beef-heart⁹⁸³ and rat-liver^{983, 984} mitochondria has a molecular weight in the region of 360 000—380 000 and a complex subunit structure, suggested as $\alpha_3\beta_3\gamma$ in one case⁹⁸⁴ and $\alpha\beta\gamma\delta\epsilon_6$ in the other,^{983b} one of the subunits in this case having a molecular weight of 10 500 daltons and possibly fulfilling the role of the mitochondrial ATPase inhibitor protein.⁹⁸⁵ The $\text{Na}^+ - \text{K}^+$ -dependent ATPase from canine renal medulla, obtained in active form by extraction with deoxycholate, probably contains two types of chain,⁹⁸⁶ and the ATPase has also been purified in high yield from Lubrol-solubilized brain membranes,⁹⁸⁷ the chain molecular weight of the phosphorylated subunit being estimated as 94 000.

Claims that sarcoplasmic reticulum membranes are composed largely of a polypeptide of m. wt. 6000 (see last year's Report) now appear to have been conclusively disproved,⁹⁸⁸ a repeat of the 'mini-proteins' story for erythrocyte membranes. Sarcoplasmic reticulum is instead very heterogeneous, the components having molecular weights in the range 30 000—300 000. One of the three major proteins was the calcium-dependent ATPase which had a molecular weight (estimated in SDS-gels) of 106 000 before reduction and two types of chain (m. wt. 20 000 and 60 000) after reduction.⁹⁸⁸ In another study⁹⁸⁹ the ATPase obtained in active form from membranes solubilized with Triton X-100 had subunit m. wt. 80 000—90 000, and the presence of low-molecular-weight material on the gels was also noted. The active-centre phosphopeptide of the ATPase is being studied⁹⁸⁸ and the purified ATPase has been shown to form membranes (possibly one particle thick) with deoxycholate-extracted components, presumably phospholipids.⁹⁹⁰ It is thus concluded that the ATPase probably has a structural as well as a functional subunit. Further, it is suggested that the ATPase has all the known properties of the Ca^{2+} -transport system and has a molecular weight of 102 000, with probably one active site per mole.⁹⁹⁰ Another study agrees that there are three major protein components of sarcoplasmic reticulum membranes,⁹⁹¹ one of which is the ATPase (m. wt. 100 000) and another of which (m. wt. 62 000) is probably the calcium-binding protein; together

⁹⁸² K. J. Cattell, C. R. Lindop, I. G. Knight, and R. B. Beechey, *Biochem. J.*, 1971, **125**, 169.

⁹⁸³ (a) D. O. Lambeth, H. A. Lardy, A. E. Senior, and J. C. Brooks, *F.E.B.S. Letters*, 1971, **17**, 330; (b) A. E. Senior and J. C. Brooks, *ibid.*, p. 327.

⁹⁸⁴ W. A. Catterall and P. L. Pederson, *J. Biol. Chem.*, 1971, **246**, 4987.

⁹⁸⁵ J. C. Brooks and A. E. Senior, *Arch. Biochem. Biophys.*, 1971, **147**, 467.

⁹⁸⁶ J. Kyte, *J. Biol. Chem.*, 1971, **246**, 4157.

⁹⁸⁷ S. Uesugi, N. C. Dulak, J. F. Dixon, T. D. Hexum, J. L. Dahl, J. F. Perdue, and L. E. Hokin, *J. Biol. Chem.*, 1971, **246**, 531.

⁹⁸⁸ A. Martonosi and R. A. Halpin, *Arch. Biochem. Biophys.*, 1971, **144**, 66.

⁹⁸⁹ B. H. McFarland and G. Inesi, *Arch. Biochem. Biophys.*, 1971, **145**, 456.

⁹⁹⁰ D. H. MacLennan, P. Seeman, G. H. Iles, and C. C. Yip, *J. Biol. Chem.*, 1971, **246**, 2702.

⁹⁹¹ N. Ikemoto, G. M. Bhatnagar, and J. Gergely, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 1510.

these constitute 50% of the total protein. In an independent study an acidic calcium-binding protein isolated by deoxycholate-KCl extraction had m. wt. 44 000 and was monomeric in aqueous solution.⁹⁹² Named calsequestrin, it binds 43 mol Ca^{2+} (mol protein)⁻¹ and is believed to be hydrophobically bonded to the interior of the sarcoplasmic reticulum, and to be quite distinct from the Ca^{2+} -transport protein.

Proteins from plasma membranes, mitochondrial membranes, and endoplasmic reticulum of rat liver and kidney were compared by gel electrophoresis⁹⁹³ using the discontinuous sulphate-borate buffer system already mentioned (ref. 148, Section 2E). They were highly heterogeneous and there was evidence of common proteins only where the membranes were functionally related (*e.g.* mitochondrial membranes from liver and kidney). The plasma membranes had three bands in common, one of which (m. wt. 48 000), representing 3–10% of the protein in liver and kidney membranes and also present in erythrocyte membranes, was suggested as being possibly a structural rather than a catalytic component.⁹⁹³ Plasma membranes from pig lymphocytes retained some biological activity after solubilization of 95% of the membrane proteins with 2% deoxycholate.⁹⁹⁴ Studies of the glucagon-sensitive adenylyl cyclase in the plasma membranes of rat liver,²³³ and the preliminary isolation of the glucagon receptor by affinity chromatography²¹⁷ have already been mentioned briefly (Section 2E). The electrophoretic pattern of glycoproteins in cell surface is unique for a particular type of cell although some cells (*e.g.* liver and kidney brush border) appear to have some common subunits.⁹⁹⁵ A procedure is given for locating carbohydrate and protein bands in the same gel.⁹⁹⁵

Since the first report⁹⁹⁶ of specific labelling of the cholinergic receptor in the electroplax of the electric eel (*Electrophorus electricus*) with α -bungarotoxin (from snake venom, m. wt. 8 000), ¹³¹I-labelled bungarotoxin has been used similarly for the receptor in the electric tissue of the torpedo fish (*Torpedo marmorata*);⁹⁹⁷ this has one binding site for the toxin per subunit of m. wt. 80 000, and tetramers and other aggregates are formed in 1% Triton. An attempt has been made to purify the α -bungarotoxin-binding component in electric eel electroplax by fractionation on agarose⁹⁹⁸ and, rather more effectively, by affinity chromatography on an insolubilized toxin related to α -bungarotoxin²¹⁶ as already mentioned (Section 2E). There is every hope that specific binding of α -bungarotoxin will also lead to isolation of the acetylcholine receptor at neuromuscular junctions in higher animals. It has already permitted estimation of the number of cholinergic

⁹⁹² D. H. MacLennan and P. T. S. Wong, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1231.

⁹⁹³ D. M. Neville, jun., and H. Glossmann, *J. Biol. Chem.*, 1971, **246**, 6335.

⁹⁹⁴ D. Allan and M. J. Crumpton, *Biochem. J.*, 1971, **123**, 967.

⁹⁹⁵ H. Glossmann and D. M. Neville, jun., *J. Biol. Chem.*, 1971, **246**, 6339.

⁹⁹⁶ J.-P. Changeux, M. Kasai, and C.-Y. Lee, *Proc. Nat. Acad. Sci. U.S.A.*, 1970, **67**, 1241.

⁹⁹⁷ R. Miledi, P. Molinoff, and L. T. Potter, *Nature*, 1971, **229**, 554.

⁹⁹⁸ M. A. Raftery, J. Schmidt, D. G. Clark, and R. G. Wolcott, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1622.

receptor sites in frog sartorius and rat diaphragm muscle⁹⁹⁹ and in mouse skeletal muscle junctions,¹⁰⁰⁰ which turn out to be the same as the number of acetylcholine-active centres (estimated with ³²P-labelled DFP), a situation that also applies in electric organs of torpedo fish⁹⁹⁷ and of electric eels⁹⁹⁵ and whose significance is still something of a puzzle. It seems clear, however, that the binding sites are different, *i.e.* the acetylcholine receptor and acetylcholinesterase do not share a common structural element. The acetylcholine receptor in the electroplax has also been affinity labelled *in situ* by reacting its thiol groups with the tritiated quaternary ammonium compound 4-maleimido- α -benzyl-trimethylammonium iodide, an acetylcholine analogue.¹⁰⁰¹ There was some difficulty with non-specific labelling (*cf.* ref. 959) which may perhaps be the reason why the number of catalytic sites of acetylcholinesterase in this case turns out to be 4–7-fold greater than the number of cholinergic receptor sites. Another quaternary ammonium compound, 3-bromomethyl-3'-trimethylammonium-methylazobenzene bromide, activates the membrane by binding covalently to the acetylcholine receptor, apparently to thiol groups.¹⁰⁰² Only the *trans*-isomer is effective. Pure acetylcholinesterase binds covalently two moles of ¹⁴C-labelled *NN*-dimethyl-2-phenylaziridinium chloride per 65 000 daltons, one mole of which appears to be bound at the tubocurarine-binding site,¹⁰⁰³ supporting the idea that some part of acetylcholinesterase serves as a natural curare receptor in excitable membranes. It has been known for some time that tubocurarine prevents binding of α -bungarotoxin to the cholinergic receptor.

An enzyme from a bacterial membrane is claimed to be the most highly purified lipoprotein enzyme and the most non-polar protein (58% hydrophobic residues) so far reported, properties which would make it well suited to location in the interior of the membrane. It is the C₆₅-isoprenoid alcohol phosphokinase extracted from the membrane of *Staphylococcus aureus* with butanol and has a single chain (m. wt. 17 000).¹⁰⁰⁴ A rhodopsin-like protein which contains one mole of retinal per 26 000 daltons has been reported to occur in the purple membrane of *Halobacterium halobium*,¹⁰⁰⁵ of interest because it has otherwise been found only in the retinae of higher animals. Before it can be said with certainty that some membrane proteins of *Micrococcus lysodeikticus* share common peptide chains,¹⁰⁰⁶ the possibility that all the proteins studied are contaminated will have to be disproved.

⁹⁹⁹ R. Miledi and L. T. Potter, *Nature*, 1971, **233**, 599.

¹⁰⁰⁰ E. A. Barnard, J. Wieckowski, and T. H. Chiu, *Nature*, 1971, **234**, 207.

¹⁰⁰¹ A. Karlin, J. Prives, W. Deal, and M. Winnik, *J. Mol. Biol.*, 1971, **61**, 175.

¹⁰⁰² E. Bartels, N. H. Wassermann, and B. F. Erlanger, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1820.

¹⁰⁰³ B. Belleau and V. Di Tullio, *Canad. J. Biochem.*, 1971, **49**, 1131.

¹⁰⁰⁴ H. Sandermann, jun., and J. L. Strominger, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2441.

¹⁰⁰⁵ D. Oesterhelt and W. Stoeckenius, *Nature New Biol.*, 1971, **233**, 152.

¹⁰⁰⁶ Y. Fukui, M. S. Nachbar, and M. J. R. Salton, *Biochim. Biophys. Acta*, 1971, **241**, 30.

9 Chemical Modification

Numerous examples of chemical modification have already arisen in this chapter where it was more appropriate to discuss them in relation to particular enzymes and proteins. This section will deal mainly with some points of general interest in the use of various reagents for chemical modification. A readable review¹⁰⁰⁷ surveys the applications of chemical modification to studies of the structure and function of proteins. Modification of the active site is cleanly achieved by affinity-labelling (see Section 9G). Alternatively, the aim may be to map the topography of the molecule by estimating the relative accessibility of various amino-acid side-chains. This is beset with pitfalls, not only because some reagents appear to react faster with buried residues (see below) but because the whole concept of 'buried' and 'exposed' groups in proteins is vague, as illustrated recently by computer analysis of surface residues in the X-ray models of some well-characterized proteins.¹⁰⁰⁸ Further, if residues which are found to be reactive cannot be precisely identified because the amino-acid sequence is not known, the approach is still weaker. In a recent study of carbonic anhydrase a whole battery of group-specific reagents was investigated,¹⁰⁰⁹ all lysine and arginine residues reacted without inactivation, and there was some evidence of participation of histidine and tryptophan at, or near, the active site and one tyrosine residue that became exposed when zinc was bound.

A. Amino-groups.—In the method of competitive labelling (already mentioned in connection with the pK_a of Ile-16 in chymotrypsin, Section 5A) the competition of particular amino-groups in proteins for small amounts of radioactive acylating agents is measured at various pH values. In this way the ionization constants and reactivities of individual amino-groups can be measured. Thus the amino-terminus of elastase was shown to have pK_a 9.7 and a reactivity much lower than normal.¹⁰¹⁰ In this case tritiated (rather than ¹⁴C-labelled) acetic anhydride gave the advantage of higher specific activity, and the disadvantage of not being able to detect the peptides on paper by autoradiography was overcome by running markers from a completely [¹⁴C]acetylated protein. Pyrylium salts have been suggested for modification of lysine residues¹⁰¹¹ (Scheme 7), the N-substituted pyridinium salt being stable to acid hydrolysis, and quantitative estimation of amino-groups with trinitrobenzenesulphonic acid (TNBS)¹² has already been mentioned (Section 2A). N-Hydroxysuccinimide acetate proved to be a highly reactive and selective acylating agent for amino-groups³⁸³ and showed that none of the three amino-groups in insulin was essential for activity. Modification of lysine residues in glutamate dehydrogenase with

¹⁰⁰⁷ R. B. Freedman, *Quart. Rev.*, 1971, **25**, 431.


¹⁰⁰⁸ B. Lee and F. M. Richards, *J. Mol. Biol.*, 1971, **55**, 379.

¹⁰⁰⁹ S. Nees, W. Schmidt, and F. Schneider, *Z. physiol. Chem.*, 1971, **352**, 355.

¹⁰¹⁰ H. Kaplan, K. J. Stevenson, and B. S. Hartley, *Biochem. J.*, 1971, **124**, 289.

¹⁰¹¹ M. H. O'Leary and G. A. Samberg, *J. Amer. Chem. Soc.*, 1971, **93**, 3532.



TNBS has been discussed (Section 5C), and the same reagent was used to show that a single lysine residue in pyruvate kinase was involved in ADP binding¹⁰¹² and that a single lysine in bovine serum albumin, in the sequence -Leu-Ala-Glu-Lys-Tyr-, was involved in binding fatty-acid anions.¹⁰¹³



Scheme 7

Reversible blocking of amino-groups by acylation with anhydrides to restrict tryptic cleavage, and an evaluation of various reversible amino-blocking groups for various purposes, has already been mentioned (see Section 2D). The increase in net negative charge of two for each amino-group modified by maleylation caused selective, reversible loss of the elastolytic but not the esterolytic or caseinolytic activity of elastase (total of three lysines);¹⁰¹⁴ it was concluded that ϵ -amino-groups are involved in the secondary binding sites of the enzyme for elastin. After maleylation haemoglobin did not bind haptoglobin,¹⁰¹⁵ but this was due to structural changes caused by the negative charges rather than to the importance of amino-groups *per se*, since retention of charge on amidination with ethyl acetimidate was without effect on formation of the haemoglobin-haptoglobin complex. The importance of charge was also shown in another study^{12b} in which guanidination or picolinimidation of amino-groups in bovine pancreatic deoxyribonuclease A did not destroy activity, in contrast to introduction of the much smaller carbamyl group which did.

The active picolinimidyl derivative of DNase would seem to be an eminently suitable candidate for the preparation of isomorphous derivatives for X-ray crystallography, by chelation of heavy-metal ions, *e.g.* (21). Details have now been published for another reagent (22) designed with the



¹⁰¹² P. F. Hollenberg, M. Flashner, and M. J. Coon, *J. Biol. Chem.*, 1971, **246**, 946.

¹⁰¹³ L.-O. Andersson, J. Brandt, and S. Johansson, *Arch. Biochem. Biophys.*, 1971, **146**, 428.

¹⁰¹⁴ A. Gertler, *European J. Biochem.*, 1971, **23**, 36.

¹⁰¹⁵ W. L. Lockhart and D. B. Smith, *Canad. J. Biochem.*, 1971, **49**, 148.

crystallographer in mind,¹⁰¹⁶ the thiol group in this case serving for attachment of heavy atoms. It is hoped that this will prove useful in the X-ray diffraction analysis of tobacco mosaic virus, in which there is only one thiol group per protein subunit and into which a single additional heavy-atom site is introduced as a result of the reaction between methyl 3-mercaptopropionimide (22) and one of the two lysine residues, Lys-68, in the protein subunit of the intact virus. This lysine residue may also be maleylated and the double bond thus introduced should also serve for the attachment of heavy atoms and permit preparation of isomorphous derivatives for X-ray crystallography.¹⁰¹⁷

Guanidination of the active-site lysine residue in trypsin inhibitor and cleavage of the homoarginyl bond by trypsin have already been mentioned (Section 5A); so have modification of the amino-groups of cobrotoxin⁴⁴⁴ and staphylococcal enterotoxin B⁴⁴³ (Section 4D). It is worth noting the use of 3,5-dimethyl-1-guanylpurazole and the nitroguanyl analogue as mild guanidinating agents in the latter case.⁴⁴³ Cross-linking with dimethyl suberimide to investigate the quaternary structure of oligomeric proteins has already been discussed (Section 2E), and modification of lysine residues in GPDH with pyridoxal phosphate⁶³² has been mentioned (Section 5C). Lysozyme modified with one dansyl group can be reversibly denatured, perhaps because the lysine residue to which it is attached is in a hydrophobic environment where a further hydrophobic group does not disrupt refolding.¹⁰¹⁸ Reversibility is lost when a further dansyl group is introduced.

B. Carboxy-groups.—Whereas elastolytic activity was lost selectively when the net negative charge on elastase and subtilisin was increased by maleylation¹⁰¹⁴ (see above), it can be conferred upon the slightly alkaline proteinase from *Aspergillus sojae* by modification of the carboxy-groups with a water-soluble carbodi-imide,¹⁰¹⁹ thus demonstrating the importance of net positive charge in the adsorption of enzymes on to elastin. However, additional positive charges introduced by coupling with ethylenediamine caused loss of enzymic activity. Similarly, coupling of eight carboxy-groups per subunit of tobacco mosaic virus with ethylenediamine produced monomers, under exceptionally mild conditions,¹⁰²⁰ as a result of the charge change. Modification of an essential carboxy-group in cobrotoxin with a water-soluble carbodi-imide was mentioned earlier (Section 4D), and the role of carboxy-groups in binding thorium ions to thrombin has been investigated.¹⁰²¹ It is reported that the reactivities of carboxy-groups in proteins to carbodi-imide in 6M guanidine hydrochloride are lower when the proteins have been reduced and carboxymethylated or cyanoethylated.¹⁰²² Formation

¹⁰¹⁶ R. N. Perham and J. O. Thomas, *J. Mol. Biol.*, 1971, **62**, 415.

¹⁰¹⁷ L. King and R. N. Perham, *Biochemistry*, 1971, **10**, 981.

¹⁰¹⁸ N. Okabe and T. Takagi, *Biochim. Biophys. Acta*, 1971, **229**, 484.

¹⁰¹⁹ A. Gertler, *F.E.B.S. Letters*, 1971, **19**, 255.

¹⁰²⁰ A. Z. Budzynski and G. E. Means, *Biochim. Biophys. Acta*, 1971, **236**, 767.



¹⁰²¹ R. W. Colman, *J. Biol. Chem.*, 1971, **246**, 4497.

¹⁰²² R. Frater, *F.E.B.S. Letters*, 1971, **12**, 186.

of salt bridges is held to be the cause, and accordingly the effect is less in carboxymethylated proteins, where the additional negative charges help to keep the protein unfolded, than in cyanoethylated samples. Guanidine hydrochloride appears to be not wholly effective in preventing the formation of salt bridges.¹⁰²²

C. Thiol Groups and Disulphide Bridges.—Several reports have dealt with the modification of disulphide bonds in proteins. They can be reduced with dithiothreitol in liquid ammonia and then alkylated with alkyl chlorides to give *S*-methyl derivatives,¹⁹ an alternative to methylation of thiol groups with methyl *p*-nitrobenzenesulphonate in aqueous solution, for which details have now been published¹⁰²³ (see also last year's Report). It will be recalled that *S*-methylation was initially suggested as a means of introducing additional points of chemical cleavage into denatured protein chains (see last year's Report); conversion of essential thiols to *S*-methyl derivatives would also be of considerable interest. Analogously, the effect of converting cystine in a disulphide bridge into two alanine residues, by desulphurization of the protein with Raney nickel under mild conditions,¹⁰²⁴ might be useful in elucidating the structural role of the disulphide bridge; desulphurization of peptides for mass spectrometry was described in last year's Report. It occurs much more readily for cysteine and cystine than for methionine, and the extent of desulphurization of proteins depends on the accessibility of the residues concerned.¹⁰²⁴ Conversion of the four disulphide bonds of ribonuclease A into $-S-Hg-S-$ derivatives⁷⁰¹ was mentioned earlier (Section 2E).

DL- α -Bromo- β -(5-imidazolyl)propionic acid (23) acted as a typical thiol reagent with the active thiol of papain, and it is suggested that it might prove useful as an affinity label for the enzymes of histidine metabolism.¹⁰²⁵ 4-(*p*-Trimethylammoniumphenylazo)-2-hydroxymercuriphenol (24) is a new



water-soluble mercurial for the spectrophotometric titration of thiol groups in 8M urea;¹⁰²⁶ addition of edta improves the sensitivity of the method by altering the pK_a of the free reagent. Kinetic analysis of the reaction of *p*-chloromercuribenzoate (PCMB) with the thiol groups of model compounds and of phosphorylase *b* shows¹⁰²⁷ that the reactivity of thiol

¹⁰²³ R. L. Henrikson, *J. Biol. Chem.*, 1971, **246**, 4090.

¹⁰²⁴ M. T. Perlstein, M. Z. Atassi, and S. H. Cheng, *Biochim. Biophys. Acta*, 1971, **236**, 174.


¹⁰²⁵ J. A. Yankeelov, jun., and C. J. Jolley, *Arch. Biochem. Biophys.*, 1971, **147**, 822.

¹⁰²⁶ J. Bloemmen and R. Lontie, *Biochim. Biophys. Acta*, 1971, **236**, 487.

¹⁰²⁷ B. B. Hasinoff, N. B. Madsen, and O. Avramovic-Zikic, *Canad. J. Biochem.*, 1971, **49**, 742.

groups in proteins is determined both by their pK_a values and by their accessibility to PCMB, which is what one might have expected. Other methods for the determination of thiol groups were given in Section 2A.

Modification of one of the three cysteines in NADP-specific isocitrate dehydrogenase from *Azotobacter vinelandii* with a variety of reagents gave almost complete inactivation whereas the thiocyanoalanyl derivative was active, showing that the reactive thiol is not essential for catalysis.¹⁰²⁸ The same observation had already been made for the thiocyanoalanyl derivative of the catalytic subunit of aspartate transcarbamylase.¹⁰²⁹ The thiol groups of formyltetrahydrofolate synthetase¹⁰³⁰ and of carbamyl phosphate synthetase¹⁰³¹ have been investigated, and the essential thiol groups of creatine kinase can be reversibly protected with DTNB [5,5'-dithiobis-(2-nitrobenzoate)].¹⁰³² Modification of haemoglobin with a series of N-substituted maleimides has already been mentioned (Section 6B) and so has affinity labelling of the acetylcholine receptor with a maleimide derivative of an acetylcholine analogue (Section 8C). Alkylation with N-ethylmaleimide was used to explore conformational changes during the catalytic steps of aspartate amino-transferase¹⁰³³ (see last year's Report for the use of tetranitromethane for this purpose), leading to the suggestion that two thiol groups are an order of magnitude more reactive in the ketimine complex than in the free enzyme or in any other intermediate. Three halogenomethyl ketones that are useful as reporter groups will alkylate a thiol group at the active site of transglutaminase;¹⁰³⁴ methyl N-(2-hydroxy-5-nitrophenylacetyl)-2-amino-4-oxo-5-chloropentanoate (25) is analogous to the natural substrate and is particularly effective.



D. Tyrosine.—The uncertainty in defining the terms 'buried' and 'exposed' as applied to residues in proteins¹⁰⁰⁸ mentioned above is borne out in a thorough study of the tyrosine residues in the subtilisins.¹⁰³⁵ There was no clear correlation between the pK values of the tyrosine residues and their

¹⁰²⁸ A. E. Chung, J. S. Franzen, and J. E. Braginski, *Biochemistry*, 1971, **10**, 2872.

¹⁰²⁹ T. C. Vanaman and G. R. Stark, *J. Biol. Chem.*, 1970, **245**, 3565.

¹⁰³⁰ T. Nowak and R. H. Himes, *J. Biol. Chem.*, 1971, **246**, 1285.

¹⁰³¹ R. Foley, J. Poon, and P. M. Anderson, *Biochemistry*, 1971, **10**, 4562.


¹⁰³² W. J. O'Sullivan, *Internat. J. Protein Res.*, 1971, **3**, 139.

¹⁰³³ W. Birchmeier and P. Christen, *F.E.B.S. Letters*, 1971, **18**, 209.

¹⁰³⁴ J. E. Folk and M. Gross, *J. Biol. Chem.*, 1971, **246**, 6683.

¹⁰³⁵ B. Myers, jun., and A. N. Glazer, *J. Biol. Chem.*, 1971, **246**, 412.

reactivity with *N*-acetylimidazole, and it is suggested that care is needed in interpreting results for *N*-acetylimidazole and tetranitromethane (TNM) since both reagents will react preferentially with tyrosine residues in a hydrophobic environment.¹⁰³⁵ This was clearly the case in horse-heart cytochrome *c* when the easily nitratable tyrosines were located in the *X*-ray structure,⁷⁷⁵ and caution wisely prevailed in equating reactivity with accessibility in the nitration of carbonic anhydrase B.¹⁰³⁶ The tyrosine nitrated in γ_M macroglobulin also appeared to be in a non-polar environment.¹⁰³⁷ It is worth bearing in mind that spectra of tyrosine derivatives are very sensitive to micro-environment and care is thus needed when extent of reaction is measured spectrophotometrically.¹⁰³⁵ Net loss of tyrosine during nitration, estimated from the final content of (tyrosine + nitrotyrosine), is evidence of side-reactions (see also last year's Report). There have been many indications of cross-linking of proteins, and accordingly biphenyl and triphenyl have now been identified in nitrated proteins and from nitration of tyrosine itself.¹⁰³⁸ It has been pointed out⁸⁸⁸ that the free-radical mechanism proposed earlier¹⁰³⁹ for the reaction of TNM with substituted phenoxide ions (Scheme 8) makes cross-linking (in retrospect) seem hardly



Scheme 8

surprising since the phenoxyl radical will be extremely reactive. Cross-linking does, however, demand the proximity of a second tyrosine residue, and nitration of proteins with TNM can presumably be clear-cut when this is not so. Another investigation using model tyrosine peptides suggested other, non-polymeric, ninhydrin-negative side-products.¹⁰⁴⁰ Despite side-reactions with TNM, it was possible to correlate loss of α -lactalbumin activity in the lactose synthetase reaction with loss of tyrosine,¹⁰⁴¹ and to show that a single tyrosine in pancreatic deoxyribonuclease was essential for activity and was protected from nitration by calcium ions.¹⁰⁴² In this case extensive side-reaction gave as much as 50% cross-linking at a TNM : DNase ratio of only 5 : 1, and the nitrated monomer was isolated from a polymeric mixture by gel-filtration.¹⁰⁴¹ Nitration implicated a tyrosine residue in the NADP-binding site of 6-phosphogluconate dehydrogenase¹⁰⁴³ and in the extended binding site for protein substrates in thrombin.¹⁰⁴⁴ The tyrosine

¹⁰³⁶ F. Dorner, *J. Biol. Chem.*, 1971, **246**, 5896.

¹⁰³⁷ N. S. Otchin and H. Metzger, *J. Biol. Chem.*, 1971, **246**, 7051.

¹⁰³⁸ J. Williams and J. M. Lowe, *Biochem. J.*, 1971, **121**, 203.

¹⁰³⁹ T. C. Bruice, M. J. Gregory, and S. L. Walters, *J. Amer. Chem. Soc.*, 1968, **90**, 1612.

¹⁰⁴⁰ N. D. Boyd and D. B. Smith, *Canad. J. Biochem.*, 1971, **49**, 154.

¹⁰⁴¹ W. L. Denton and K. E. Ebner, *J. Biol. Chem.*, 1971, **246**, 4053.

¹⁰⁴² T. E. Hugli and W. H. Stein, *J. Biol. Chem.*, 1971, **246**, 7191.

¹⁰⁴³ M. Rippa, C. Picco, M. Signorini, and S. Pontremoli, *Arch. Biochem. Biophys.*, 1971, **147**, 487.

¹⁰⁴⁴ R. L. Lunblad and J. H. Harrison, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1344.

residues of cobrotoxin⁴⁴⁶ and of human growth hormone⁴⁰⁶ were mentioned earlier (Section 4); nitration and acetylation of 40—50% of the tyrosine residues of stem bromelain with loss of activity was consistent with other studies.¹⁰⁴⁵

Reduction of nitrotyrosyl to aminotyrosyl residues in proteins is generally achieved with sodium dithionite ($\text{Na}_2\text{S}_2\text{O}_4$) but recently a hint of a complication comes with the detection of small amounts of a derivative tentatively identified as the aminosulphonic derivative of tyrosine when model nitrotyrosine compounds were reduced with dithionite.¹⁰⁴⁶ Reduction of six nitrated tyrosines in alkaline phosphatase, and acetylation or succinylation of the resultant amino-groups, showed that these tyrosine residues are not involved directly in catalysis, substrate binding, or metal binding,¹⁰⁴⁷ and in another study aminotyrosine-137 in trypsinogen permitted specific attachment of a dansyl group as a fluorescent probe for monitoring conformational changes on activation⁵²⁵ (see also Section 5A). The synthesis and spectral properties of two dansylated amines based on 3-aminotyrosine that are models for such fluorescent reporter groups in proteins have been presented.¹⁰⁴⁸ 3-Aminotyrosine residues can also be generated by reduction of azotyrosine residues with dithionite, and this was done successfully¹⁰⁴⁹ for Tyr-73 of ribonuclease; the azo-derivative had been formed by affinity labelling with the diazo-derivative of the substrate analogue PUDP [5'-(4-aminophenylphosphoryl)uridine 2'(3')-phosphate]. Such conversion of tyrosine into aminotyrosine at various sites in enzymes affords an opportunity to study the effects of relatively small changes and introduces possible points of attachment for reporter groups and cross-linking reagents, as done for staphylococcal nuclease some time ago.

Iodination may also occur preferentially at buried tyrosine residues⁷⁷⁵ and care is again required. The essential thiol groups in arginine kinase from lobster muscle were reversibly protected with tetrathionate, and then iodination of a single tyrosine was shown to result in inactivation.¹⁰⁵⁰ The relative reactivities to iodination of the tyrosine residues in the variable region of the Bence-Jones protein Col have now been determined^{915a} using the paired-label technique (see below), the constant region having been studied earlier (see last year's Report). The possibility that such differences arise from differences in primary structure around the tyrosines has been eliminated;¹⁰⁵¹ common micro-environments have been shown for tyrosine residues in seven Bence-Jones proteins.^{915b} (In the paired-label method the 'reactivity' of a tyrosine residue is the ratio of ^{125}I : ^{131}I incorporated when

¹⁰⁴⁵ K. Goto, N. Takahashi, and T. Murachi, *J. Biochem. (Japan)*, 1971, **70**, 157.

¹⁰⁴⁶ J. F. Riordan and M. Sokolovsky, *Biochim. Biophys. Acta*, 1971, **236**, 161.

¹⁰⁴⁷ P. Christen, B. L. Vallee, and R. T. Simpson, *Biochemistry*, 1971, **10**, 1377.

¹⁰⁴⁸ R. A. Kenner, *Biochemistry*, 1971, **10**, 545.

¹⁰⁴⁹ M. Gorecki, M. Wilchek, and A. Patchornik, *Biochim. Biophys. Acta*, 1971, **229**, 590.

¹⁰⁵⁰ A. Fattoum, R. Kassab, and L.-A. Pradel, *European J. Biochem.*, 1971, **22**, 445.

¹⁰⁵¹ Y. Takeda, B.-K. Seon, O. A. Roholt, and D. Pressman, *Biochim. Biophys. Acta*, 1971, **251**, 357.

the protein is iodinated to a low level with $^{125}\text{I}_2$ and to a higher level with $^{131}\text{I}_2$; the ratio of the labels gives no information about the micro-environment, but this can be deduced from the ratio di-iodotyrosine : mono-iodotyrosine since the introduction of the second iodine atom is favoured by a hydrophobic environment). Other reagents have also been used to investigate the tyrosine and tryptophan residues of Bence-Jones proteins.¹⁰⁵² Enzymic iodination with lactoperoxidase has been used to label proteins on the outside of erythrocyte membranes (see Section 8 and last year's Report) and more recently to compare the surface proteins of normal and neoplastic lymphocytes,¹⁰⁵³ and to produce labelled hormones of high specific activity for radio-immunoassay.¹⁰⁵⁴ A simplified preparation of lactoperoxidase from cow's milk has been reported.¹⁰⁵⁴ Thyroid peroxidase, which also catalyses iodination of proteins, unlike lactoperoxidase exhibits specificity for tyrosine residues in the sequence -Glu-Tyr-, consistent with the amino-acid composition of thyroglobulin, the presumed physiological substrate of thyroid peroxidase.¹⁰⁵⁵

E. Tryptophan, Arginine, and Histidine.—Dimethyl (2-hydroxy-5-nitrobenzyl)sulphonium halides, which are water-soluble, represent a promising improvement over 2-hydroxy-5-nitrobenzyl bromide for tryptophan modification¹⁰⁵⁶ and have already been used on carboxypeptidase⁴⁷⁵ (see Section 5A).

There is still no simple reversible chemical modification of arginine residues in proteins, but a method that is potentially useful as a method of reversible restriction of tryptic attack at arginyl bonds has been described.¹⁰⁵⁷ Tryptic attack is prevented by conversion of arginine into δ -(5-nitro-2-pyrimidyl)ornithine by reaction with nitromalondialdehyde, and susceptibility to tryptic attack is restored by reduction of the ornithyl derivative to the 1,4,5,6-tetrahydropyrimidyl derivative. The sequence has been carried out successfully on model compounds and holds promise for proteins. (Conversion of arginine in peptides into pyrimidylornithine derivatives for mass spectrometry was mentioned in last year's Report.) The reactions of the single arginine residue in insulin³⁸¹ and of the arginine residues of the basic pancreatic trypsin inhibitor⁵⁶¹ with phenylglyoxal were mentioned earlier (Sections 4A and 5A); and citraconic anhydride is recommended¹⁰⁵⁸ for reversible protection of lysine residues in proteins when arginine is being (irreversibly) modified with trimeric butane-2,3-dione. The unfolding caused by citraconylation also ensures that no cross-linking of arginine residues occurs. Modification of arginine with

¹⁰⁵² T. Azuma, K. Hamaguchi, and S. Migita, *J. Biochem. (Japan)*, 1971, **69**, 535.

¹⁰⁵³ J. J. Marchalonis, R. E. Cone, and V. Santer, *Biochem. J.*, 1971, **124**, 921.

¹⁰⁵⁴ J. I. Thorell and B. G. Johansson, *Biochim. Biophys. Acta*, 1971, **251**, 363.

¹⁰⁵⁵ M. M. Krinsky and J. S. Fruton, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 935.

¹⁰⁵⁶ W. P. Tucker, J. Wang, and H. R. Horton, *Arch. Biochem. Biophys.*, 1971, **144**, 730.

¹⁰⁵⁷ A. Signor, G. M. Bonora, L. Biondi, D. Nisata, A. Marzotto, and E. Scoffone, *Biochemistry*, 1971, **10**, 2748.

¹⁰⁵⁸ J. A. Yankeelov, jun. and D. Acre, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 886.

cyclohexanedione can be carried out in 0.1M triethylamine as solvent,¹⁰⁵⁹ much milder than the 0.2M-NaOH normally used, and without ill effects on disulphide bonds.

Reaction with diethyl pyrocarbonate showed that there was an essential histidine residue at or near the substrate-binding site in octopine dehydrogenase¹⁰⁶⁰ and at the active site of arginine oxygenase.¹⁰⁶¹ Exhaustive ethoxycarbonylation of histidine peptides for mass spectrometry has already been discussed (Section 2C). 5-Diazonium-1*H*-tetrazole reacts with both tyrosine and histidine residues; in a study of the reaction of the reagent with RNA polymerase¹⁰⁶² a careful analysis was made of the spectral properties of the azotetrazole derivatives of histidine and tyrosine, and a formula was presented for calculation of the concentration of each present.¹⁰⁶² The stability of *Im*-Dnp-histidine to acid hydrolysis⁴⁶ has been mentioned (Section 2B).

F. Photo-oxidation.—Studies of Rose-Bengal-sensitized photo-oxidation implicated a histidine residue (His-92) at the active centre of ribonuclease T_1 ¹⁰⁶³ and at the active centres of neutral subtilopeptidase *amylosacchariticus*¹⁰⁶⁴ and thermolysin,¹⁰⁶⁵ although in the latter case some oxidation of tyrosine and tryptophan also occurred. Photo-oxidation of the 30s ribosomal subunit (*E. coli*) in the presence of Rose Bengal appeared to modify a histidine residue in a single ribosomal protein involved in binding tRNA and poly-U,³³² and loss of activity on photo-oxidation of glucoamylase I in the presence of Methylene Blue appeared to be correlated with loss of tryptophan.¹⁰⁶⁶

Further success has been achieved in increasing the specificity of photo-oxidation by anchoring the photosensitizer at a definite point in the molecule (see last year's Report). Thus the catalytic thiol group in papain (Cys-25) was made the point of attachment for a dinitrophenyl group or a fluorescein thiocarbamyl group without conformational changes.¹⁰⁶⁷ Spectroscopic methods showed that the Dnp group was buried in the active-site cleft, and irradiation with visible light led to specific photo-oxidation of His-159 and Trp-177, consistent with *X*-ray and kinetic evidence. There was no conformational change, suggesting catalytic rather than structural roles for these groups. On the other hand, the fluorescein thiocarbamyl group appeared to be rotating fairly freely around Cys-25, and photo-oxidation in

¹⁰⁵⁹ A. F. S. A. Habeeb and J. C. Bennett, *Biochim. Biophys. Acta*, 1971, **251**, 181.

¹⁰⁶⁰ C. Huc, A. Olomucki, Lê-Thi-Lan, D. B. Pho, and N. van Thoai, *European J. Biochem.*, 1971, **21**, 161.

¹⁰⁶¹ F. Thomé-Beau, Lê-Thi-Lan, A. Olomucki, and N. van Thoai, *European J. Biochem.*, 1971, **19**, 270.

¹⁰⁶² F. Zaheer and B. H. Nicholson, *Biochim. Biophys. Acta*, 1971, **251**, 38.

¹⁰⁶³ K. Takahashi, *J. Biochem. (Japan)*, 1971, **69**, 331.

¹⁰⁶⁴ D. Tsuru, T. Hirose, and J. Fukumoto, *J. Biochem. (Japan)*, 1971, **70**, 699.

¹⁰⁶⁵ T. Abe, K. Takahashi, and T. Ando, *J. Biochem. (Japan)*, 1971, **69**, 363.

¹⁰⁶⁶ S. A. Barker, C. J. Gray, and M. E. Jolley, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 654.

¹⁰⁶⁷ G. Jori, G. Gennari, C. Toniolo, and E. Scoffone, *J. Mol. Biol.*, 1971, **59**, 151.

this case led to oxidation of Trp-26 as well as of the groups mentioned above, and to collapse of the tertiary structure, indicating a critical structural role for Trp-26, which the *X*-ray model shows to be buried. All the modified groups are within 5 Å of Cys-25. The haem group acts as a built-in photosensitizer in the cytochromes, and photo-oxidation of horse-heart ferrocytochrome *c* has now been reported,¹⁰⁶⁸ the oxidized form having been looked at earlier (see last year's Report). In ferrocytochrome *c*, Tyr-48 and Trp-59 become oxidized as well as His-18 and Met-80, which were oxidized in the ferri-form; presumably the known conformational change on reduction of cytochrome brings the tyrosine and tryptophan residues nearer the haem group. At pH greater than 8.5, photo-oxidation of spinach-leaf or rabbit-muscle (but not rabbit-liver) aldolase leads to loss of the C-terminal tyrosine,¹⁰⁶⁹ in contrast to loss of histidine which occurs at lower pH (see last year's Report).

Haematoporphyrin binds in the ratio 2 : 1 to lysozyme, and while it is not an active-site-directed photosensitizer it is effective in causing specific photo-oxidation of the protein. Only one of the binding sites for haematoporphyrin appears to contain photo-oxidizable side-chains since Met-12 is the sole residue modified,¹⁰⁷⁰ and again the fact that this is clearly buried in the *X*-ray model indicates that care is needed with photo-oxidation studies, as with others, in correlating the reactivity of a side-chain with the degree of exposure on the surface of the protein. Some degree of specificity in photo-oxidation can even be achieved with dye photosensitizers free in solution (see above) if paramagnetic ions such as Co^{2+} or Cu^{2+} are used to inhibit the photodynamic action of the dyes.¹⁰⁷¹ The protective effect is localized and the method might be a way of achieving fairly specific modification under non-specific conditions. Thus Trp-63 and Trp-123 in lysozyme seemed to be of minor importance for both structure and catalysis.¹⁰⁷¹

G. Affinity Labelling.—Photo-affinity labelling of chymotrypsin has been mentioned in Section 5A, and 'active-site-directed photo-oxidation' in Section 9F. Diazomalonyl derivatives of adenosine 3',5'-phosphate (cyclic AMP) are potentially useful photo-affinity labels for enzymes and other receptors that bind the nucleotide.¹⁰⁷² However, the diazoacetyl ester of the 3-hydroxymethyl derivative of NAD^+ bound to yeast alcohol dehydrogenase gave a mixture of products on photoactivation¹⁰⁷³ and it was thought likely that such a non-covalently bound molecule would not

¹⁰⁶⁸ G. Jori, G. Gennari, M. Folin, and G. Galiazzo, *Biochim. Biophys. Acta*, 1971, **229**, 525.

¹⁰⁶⁹ L. C. Davis, G. Ribereau-Gayon, and B. L. Horecker, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 416.

¹⁰⁷⁰ G. Jori, G. Galiazzo, and E. Scoffone, *Experientia*, 1971, **27**, 379.

¹⁰⁷¹ G. Jori, G. Gennari, G. Galiazzo, and E. Scoffone, *Biochim. Biophys. Acta*, 1971, **236**, 749.

¹⁰⁷² D. J. Brunswick and B. S. Cooperman, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1801.

¹⁰⁷³ D. T. Browne, S. S. Hixson, and F. H. Westheimer, *J. Biol. Chem.*, 1971, **246**, 4477.

turn out to be of general use for this reason. Some examples of active-site labelling that have been reported during the past twelve months (a few of which have already been mentioned) are collected in Table 3.

Table 3 *Some recently reported active-site-directed inhibitors*

<i>Protein</i>	<i>Active-site-directed compound</i>	<i>Residue modified</i>	<i>Ref.</i>
Acetylcholine receptor	4-Maleimido- α -benzyltri-methylammonium iodide	Cys	1001
	3-Bromomethyl-3'-trimethyl-ammonium-methyl-azobenzene bromide	Cys	1002
Adenylosuccinate lyase	Carboxylic-phosphoric mixed anhydride isosteric with AMP (see text)	?	1074
Alcohol dehydrogenase (liver)	Nicotinamide-[5-(bromo-acetyl)-4-methylimidazole]-dinucleotide	?	1075
Aldolase (yeast)	Halogenoacetol phosphates	Cys	1076
Aspartate transcarbamylase catalytic subunit (<i>E. coli</i>)	Permanganate ion	Cys	1077
Biotin transport system (yeast)	Biotinyl <i>p</i> -nitrophenyl ester	?	1078
Carboxypeptidase A_y	<i>N</i> -Bromoacetyl- <i>N</i> -methyl-L-Phe	Glu-270 (see text)	473
β -Galactosidase	<i>N</i> -Bromoacetyl- β -D-galactopyranosylamine	Met	1079
Glyceraldehyde 3-phosphate dehydrogenase	$\left. \begin{array}{l} \text{I} \cdot \text{CH}_2 \cdot \text{CO} \cdot \text{OR} \\ p\text{-NO}_2 \cdot \text{C}_6\text{H}_4 \cdot \text{O} \cdot \text{COR} \\ \text{H} \cdot \text{CO} \cdot \text{R} \end{array} \right\}^*$	Cys-149	634
Glutamate dehydrogenase	Bromoacetyldiethylstilboesterol	?	1080
20 β -Hydroxysteroid dehydrogenase	Cortisone 21-iodoacetate	His	1081
<i>Lac</i> repressor	2'-chloro-2'-cyanoethyl-1-thio- β -D-galactopyranoside	?	1082
Luciferase	2-Cyano-6-chlorobenzothiazole	Tyr ?	751
Lysine decarboxylase	L-Lysine bromomethyl ketone	?	1083
Pepsin (pig)	1,2-Epoxy-3-(<i>p</i> -nitrophenoxy)-propane	Asp or Glu	1084
Pepsin (bovine)	<i>N</i> -Diazoacetyl norleucine methyl ester	Asp	584
	1-Diazoacetyl-2-phenylethane	Asp	591
	1,1-Bis(diazoacetyl)-2-phenylethane	Asp + ?	591
	1-Diazoacetyl-1-bromo-2-phenylethane	Asp + ?	591
Ribonuclease (pancreatic)	Pyridoxal phosphate	Lys-7	1085

*R = $-(\text{CH}_2)_n-\text{C}(\text{Me})_2-\text{N}(\text{Me})_2$




Table 3 (cont.)

<i>Protein</i>	<i>Active-site-directed compound</i>	<i>Residue modified</i>	<i>Ref.</i>
Thrombin	<i>p</i> -Nitrobenzyloxycarbonyl-arginine chloromethyl ketone	His-43	532
	Tosyl-lysine chloromethyl ketone	His-43	532
Trypsin	<i>p</i> -Amidinophenacyl bromide	Ser-183	528
	<i>p</i> -Guanidinophenacyl bromide	Ser-183	528

One or two of the examples listed in Table 3 merit further comment. The adenosine 5'-phosphate analogue (26)¹⁰⁷⁴ and the NAD⁺ analogue¹⁰⁷⁵ could be useful for labelling many enzymes that bind AMP and NAD⁺ tightly, and lysine bromomethyl ketone¹⁰⁸³ for the enzymes of lysine metabolism. DL- α -Bromo- β -(5-imidazolyl)propionic acid¹⁰²⁵ as a potential candidate for covalent binding to the enzymes of histidine metabolism has already been mentioned (Section 8C). Permanganate is presumably acting on aspartate transcarbamylase as an analogue of the competitive inhibitor phosphate ion,¹⁰⁷⁷ and might thus be useful for probing the phosphate binding-sites of other enzymes. It is such a strong oxidizing agent that it shares with carbenes (generated in photo-affinity labelling) the advantage of extreme non-specificity of attack once it has been bound at a specific site. Pyridoxal phosphate is an affinity label for ribonuclease only by virtue of its phosphate group¹⁰⁸⁵ and it becomes attached to Lys-7 near the active site, not Lys-41 at the active site. The active-site-directed inhibitor for the *lac* repressor,¹⁰⁸² an analogue of a potent inducer, is a sulphur mustard (27), and the electrophilic carbon atom is substituted with the strongly electron-withdrawing cyanide group as well as with chloride. When pig pepsin was inactivated with the substrate-like epoxide (28),¹⁰⁸⁴ two moles of reagent became esterified to two carboxy-groups, one of which was protected by substrate and was therefore presumably at, or near, the active site. This was not the aspartyl side-chain that reacts with diazoacetyl-DL-norleucine methyl ester or *p*-bromophenacyl bromide, since two moles of the epoxide became bound even after pretreatment with these inhibitors. It is likely then

¹⁰⁷⁴ A. Hampton and P. J. Harper, *Arch. Biochem. Biophys.*, 1971, **143**, 340.

¹⁰⁷⁵ C. Woenckhaus and R. Jeck, *Z. physiol. Chem.*, 1971, **352**, 1417.

¹⁰⁷⁶ Y. Lin, R. D. Kobes, I. L. Norton, and F. C. Hartman, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 34.

¹⁰⁷⁷ W. F. Benisek, *J. Biol. Chem.*, 1971, **246**, 3151.

¹⁰⁷⁸ J. M. Becker, M. Wilchek, and E. Katchalski, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2604.

¹⁰⁷⁹ J. Yariv, K. J. Wilson, J. Hildesheim, and S. Blumberg, *F.E.B.S. Letters*, 1971, **15**, 24.

¹⁰⁸⁰ J. Kallos and K. P. Shaw, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 916.

¹⁰⁸¹ M. Ganguly and J. C. Warren, *J. Biol. Chem.*, 1971, **246**, 3646.




¹⁰⁸² R. R. Rando, *Nature New Biol.*, 1971, **234**, 183.

¹⁰⁸³ D. L. Miller and V. W. Rodwell, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 1227.

¹⁰⁸⁴ J. Tang, *J. Biol. Chem.*, 1971, **246**, 4510.

¹⁰⁸⁵ G. E. Means and R. E. Feeney, *J. Biol. Chem.*, 1971, **246**, 5532.

that a second essential carboxy-group reacts with the epoxide, consistent with indications from earlier work of the possible involvement of a second carboxy-group at the active centre of pepsin.



10 Conclusion

The subject grows yearly and it has not been possible to encompass within these pages all that has become known about primary structure and chemical modification of proteins in the year 1971. Much has been omitted, and we would warn our readers that we cannot say of our account what was said of the blessed St. Neot.¹⁰⁸⁶

PART II: X-Ray Studies by T. L. Blundell

1 Introduction

'Protein crystallography' came of age in 1971. To this date there have been forty independent, high-resolution structure analyses (see Table 1), and

¹⁰⁸⁶ 'That is all, and indeed rather more than all, that is known to men of the blessed St. Neot', J. H. Newman (ed.), 'Lives of the Saints'.

many of these spectacular advances have been chronicled in the report of the Cold Spring Harbor Symposium held in the summer of 1971. However, the workshop on protein crystallography held at Alpbach in March, 1972, showed that this report was soon out of date: four further structures have now been successfully elucidated (see Table 1).

Table 1 *Protein structures solved at ≤ 3.5 Å resolution*

<i>Reported during 1971</i>	<i>Reported before 1971</i>
Trypsin ⁴⁹	α -Chymotrypsin
Subtilisin Novo ⁵⁰	γ -Chymotrypsin
Nuclease ^{63, 64}	Chymotrypsinogen
Carbonic anhydrase ⁶⁸	Elastase
Ferri- and ferro-cytochrome <i>c</i> ^{69, 91}	Subtilisin BPN'
Cytochrome <i>b₆</i> ⁹³	Trypsin inhibitor
Flavodoxin ⁹⁷	Carboxypeptidase A
High-potential iron protein ⁹⁵	Papain
<i>Glycera</i> haemoglobin ¹⁰⁹	Ribonuclease A
Lamprey haemoglobin ^{109, 110}	Ribonuclease S
Calcium-binding protein ¹²⁹	Lysozyme
	Lactate dehydrogenase
<i>Solved but not published at high resolution in 1971</i>	Rubredoxin
	Oxyhaemoglobin
	Deoxyhaemoglobin
Ferredoxin	Sperm-whale myoglobin
Malate dehydrogenase	<i>Chironomus</i> haemoglobin
Thermolysin ⁵⁹ (recent)	(Erythrocrucorin)
Concanavalin	Insulin

Independent solution of structures previously solved

α -Chymotrypsin⁵¹
Ribonuclease A

The publications during 1971 have been of several types. There have been thoughtful reviews of the chemistry and biology in relation to the structures of carboxypeptidase,¹ nuclease,² subtilisin,³ chymotrypsin,⁴ elastase,⁵ papain,⁶ ribonuclease,⁷ and insulin.⁸ There have also been

¹ J. A. Hartsuck and W. N. Lipscomb, in 'The Enzymes', ed. P. D. Boyer, Academic Press, New York, 1971, vol. III, p. 1; W. N. Lipscomb, *Adv. Protein Chem.*, 1971, **25**, 1.

² F. A. Cotton and E. E. Hazen, in 'The Enzymes', ed. P. D. Boyer, Academic Press, New York, 1971, vol. IV, p. 153.

³ J. Kraut, in 'The Enzymes', ed. P. D. Boyer, Academic Press, New York, 1971, vol. III, p. 547.

⁴ D. M. Blow, in 'The Enzymes', ed. P. D. Boyer, Academic Press, New York, 1971, vol. III, p. 185.

⁵ J. Drenth, J. N. Jansonius, R. Koekoek, and B. G. Wolthers, in 'The Enzymes', ed. P. D. Boyer, Academic Press, New York, 1971, vol. III, p. 484; *Adv. Protein Chem.*, 1971, **25**, 79.

⁶ F. M. Richards and H. W. Wyckoff, in 'The Enzymes', ed. P. D. Boyer, Academic Press, New York, 1971, vol. IV, p. 647.

⁷ B. S. Hartley and D. M. Shotton, in 'The Enzymes', ed. P. D. Boyer, Academic Press, New York, 1971, vol. III, p. 323.

⁸ T. L. Blundell, E. J. Dodson, G. G. Dodson, D. C. Hodgkin, and M. Vijayan, *Recent Progr. Hormone Res.*, 1971, **26**, 1.

concise accounts of new structures. The emphasis on extracellular proteases appears to have given way to a study of metal-containing proteins. The protein crystallographer has now to be acquainted with inorganic chemistry as well as biochemistry, organic chemistry, physical chemistry, physics, and mathematics! A number of progress reports have been published for problems with subunits: intracellular enzymes of the glycolytic pathway, regulatory enzymes, and virus proteins.

There have been some very exciting reports on peptides of which actinomycin is perhaps the most spectacular, both from the point of view of *X*-ray analytical techniques as well as the interest in the principles of peptide binding to the DNA double helix.

2 Amino-acids and Peptides (See also Chapter 1, Section 3A)

X-Ray studies of amino-acids continue to be reported, but as Hendrickson and Karle⁹ comment, they 'hold no surprises'. The crystal and molecular structures of L-cysteic acid monohydrate,⁹ L-isoleucine,¹⁰ L-leucine hydriodide,¹¹ L-tyrosine,¹² an L-histidine complex of molybdenum(V),¹³ and bis-(L-prolinato)palladium(II)¹⁴ are described. Preliminary *X*-ray data from powder photographs are given for L-arginine, L-cysteine, DL-lysine, and DL-phenylalanine.¹⁵ The molecular structures of L-tyrosine-*O*-sulphate,¹⁶ a constituent of a number of polypeptide hormones such as gastrin, and of L-arginyl phosphate monohydrate,¹⁷ a model for guanidyl and phosphate interaction such as that found in staphylococcal nuclease, are also reported.

The results of studies on peptides are more interesting. A number of peptides have a hydrogen bond between the carbonyl of a residue and the amide group of the fourth residue further along—giving a ten-membered ring. An example is the structure of bromobenzoyloxycarbonylglycyl-L-prolyl-L-leucylglycyl-L-proline ethyl acetate monohydrate,¹⁸ which is a good substrate of the enzyme collagenase. The peptide (1) is folded back at the Pro-2 and Leu residues to give in this case two intramolecular hydrogen bonds at the glycine residues. The conformation has been termed 'U folding' or a ' β turn', and it is characteristic of the 3_{10} helix.

A similar conformation is reported by Rudko, Lovell, and Low in the crystal structure of the C-terminal tetrapeptide of oxytocin, *S*-benzyl-L-cysteinyl-L-prolyl-L-leucylglycinamide (2)¹⁹ and also in the almost isomorphous seleno-analogue. Further, it occurs in a series of new peptide

⁹ W. A. Hendrickson and J. Karle, *Acta Cryst.*, 1971, **B27**, 427.

¹⁰ K. Toni and Y. Iitaka, *Acta Cryst.*, 1971, **B27**, 2237.

¹¹ M. O. Chaney, O. Seely, and L. K. Steinrauf, *Acta Cryst.*, 1971, **B27**, 544.

¹² A. Mostad, H. M. Nissen, and Chr. Rømming, *Tetrahedron Letters*, 1971, 2131.

¹³ L. T. J. Delbaere and C. K. Prout, *Chem. Comm.*, 1971, 162.

¹⁴ T. Ito, F. Marumo, and Y. Saito, *Acta Cryst.*, 1971, **B27**, 1062.



¹⁵ B. Khawas, *Acta Cryst.*, 1971, **B27**, 1517.

¹⁶ D. C. Fries and M. Sundaralingam, *Acta Cryst.*, 1971, **B27**, 401.


¹⁷ K. Aoki, K. Nagano, and Y. Iitaka, *Acta Cryst.*, 1971, **B27**, 11.

¹⁸ T. Ueki, S. Bando, T. Ashida, and M. Kakudo, *Acta Cryst.*, 1971, **B27**, 2219.

¹⁹ A. D. Rudko, F. M. Lovell, and B. W. Low, *Nature New Biol.*, 1971, **232**, 18.




antibiotics called tuberactinomycins (TUM) which are effective against tubercular bacilli.²⁰ The compounds have the structure (3) where R^1 and R^2 can be either H or OH. The 16-membered peptide ring contains the ten-membered ring formed by a hydrogen bond.




²⁰ H. Yoshioka, T. Aoki, H. Goko, K. Nakatsu, T. Noda, H. Sakakibara, T. Take, A. Nagata, J. Abe, T. Wakamiya, T. Shiba, and T. Kaneko, *Tetrahedron Letters*, 1971, 2043.

The structures of acetyl-L-proline-*N*-methylamide,²¹ LiBr-L-alanylglycine,²² tosyl-L-prolyl-L-hydroxyproline monohydrate,²⁴ LiBr-glycylglycylglycine,²³ and glycyl-L-tryptophanatocopper(II) trihydrate,²⁵ are reported in detail; the degree of planarity of the peptide groups and the distortion from the regular bond angles are discussed.

The *X*-ray analysis of the product obtained by mild alkaline treatment of the *p*-nitrophenyl ester of *N*-benzyloxycarbonyl-L-alanyl-L-phenylalanyl-L-proline (4) provides an interesting historical footnote.²⁶ In 1936 Dorothy Wrinch suggested that cyclol structures, formed from intramolecular reactions involving amide groups, may be an important feature of protein architecture. Although the cyclol structure has not been of as general importance as Wrinch expected, evidence is conclusively provided for its existence in structure (5).



The successful analysis of a 1:2 crystalline complex of actinomycin D and deoxyguanosine has shed light on the stereochemistry of actinomycin binding to DNA.^{27, 28} Actinomycin D (6) is a cyclic polypeptide-containing



²¹ T. Matuzaki and Y. Iitaka, *Acta Cryst.*, 1971, **B27**, 507.

²² J. P. Declercq, R. Meulemans, P. Piret, and M. Van Meerssche, *Acta Cryst.*, 1971, **B27**, 539.

²³ R. Meulemans, P. Piret, and M. Van Meerssche, *Acta Cryst.*, 1971, **B27**, 1187.

²⁴ M. N. Sabesan and K. Venkatesan, *Acta Cryst.*, 1971, **B27**, 1879.

²⁵ H. B. Hursthouse, S. A. A. Jayaweera, G. H. W. Milburn, and A. Quick, *Chem. Comm.*, 1971, 207.

²⁶ S. Cerrini, W. Fedeli, and F. Mazza, *Chem. Comm.*, 1971, 1607.

²⁷ H. M. Sobell, S. C. Jain, T. D. Sakore, and C. E. Nordman, *Nature*, 1971, **231**, 200.

²⁸ H. M. Sobell, S. C. Jain, T. D. Sakore, G. Ponticello, C. E. Nordman, *Cold Spring Harbor Symposium*, 1972, **36**, 263.

antibiotic which binds specifically to deoxyguanosine residues of double-helical DNA and so inhibits RNA synthesis. Sobell *et al.* have shown that actinomycin has approximate two-fold symmetry as shown in Figure 1(a).




Figure 1 (a) Computer-drawn illustration of the actinomycin molecule viewed down its approximate two-fold axis; (b) same view, but with the deoxyguanosine molecules in place showing two-fold symmetry of the complex (Reproduced by permission of Prof. H. Sobell)

The dyad axis lies along a vector connecting the O—N bridging atoms of the phenoxazone ring, and the two polypeptide chains are also approximately related by the dyad. There are strong hydrogen bonds connecting the N—H of one D-valine residue with the C=O of the other D-valine residue. The complex shown in Figure 1(b) also has two-fold symmetry. The two deoxyguanosine residues stack on alternative sides of the phenoxazone ring system and interact with the peptides through two hydrogen bonds. There is a strong bond between the guanosine 2-amino-group and the carbonyl oxygen of the L-threonine residue, and a weaker bond connects the guanine N(3) ring nitrogen with the NH group of the same L-threonine residue. The sugar residues make van der Waals contacts with the isopropyl groups of the L-methylvaline residues.

Sobell *et al.* have shown that these contacts can be incorporated into a model for the binding of actinomycin to DNA so that the phenoxazone ring system intercalates between the base-paired dinucleotide sequence, GpC, while the peptide units lie in the narrow groove of the DNA helix and interact with the deoxyguanosine residues on opposite chains through specific hydrogen bonds. Sobell *et al.* suggest that this mode of binding demonstrates a general principle which several classes of proteins may utilize in recognizing symmetrically arranged sequences on the DNA helix.

3 Methods of Protein Structure Analysis

Although it is often asserted that the techniques of X-ray analysis of proteins are worked out, the number of papers published in this area seems as large as ever.

Akervall and Strandberg²⁹ describe a beautiful technique for growing and mounting protein crystals in a thin-walled capillary with a flattened portion which reduces slippage. Rosenbaum *et al.*³⁰ report preliminary results using synchrotron radiation as a source particularly for the X-ray diffraction studies of fibres. The imidoester methyl 3-mercaptopropion-imidate can be used to introduce thiol groups for the attachment of heavy-atom derivatives.³¹ A number of interesting theoretical studies and model calculations concerning the method of isomorphous replacement and the use of anomalous scattering are outlined.³²⁻³⁹

Now that many protein structures have been determined at high resolution, improving the fit of the protein model to the electron density has become a central problem. Of particular interest is the computer-controlled display system of Barry and North.⁴⁰ A number of studies designed to refine protein structures by crystallographic techniques are also discussed. They include real-space refinement,⁴¹ the use of difference Fourier,^{42, 43} the use of the tangent formula,⁴⁴ and the inverse Fourier transformation of squared electron density.⁴⁵ Perhaps the most spectacular advance has been the use of classical methods of refinement, least squares, and difference Fourier to improve the structure of the small protein rubredoxin to an agreement value of 0.132. This is the first case in which calculated phases have conclusively been shown to be better than those derived from isomorphous replacement.

In a neutron diffraction study of myoglobin, Schoenborn⁴⁶ convincingly shows that this technique provides further structural detail, and in particular can be used to identify the hydrogen-bonding pattern in proteins.

4 Globular Proteins

A. General Structural Principles.—The high-resolution structure analyses reported in 1971 continue to emphasize the variation of architecture

²⁹ K. Akervall and B. Strandberg, *J. Mol. Biol.*, 1971, **62**, 625.

³⁰ G. Rosenbaum, K. C. Holmes, and J. Witz, *Nature*, 1971, **230**, 434.

³¹ R. N. Perham and J. O. Thomas, *J. Mol. Biol.*, 1971, **62**, 415.

³² S. Parthasarathy and M. N. Sabesan, *Acta Cryst.*, 1972, **A28**, 51.

³³ S. Parthasarathy, *Acta Cryst.*, 1971, **A27**, 45.

³⁴ C. W. Bunn, *Acta Cryst.*, 1971, **B27**, 1780.

³⁵ T. L. Blundell, E. J. Dodson, G. G. Dodson, and M. Vijayan, *Contemp. Phys.*, 1971, **12**, 209.

³⁶ E. J. Dodson and M. Vijayan, *Acta Cryst.*, 1971, **B27**, 2402.

³⁷ R. H. Stanford, *Acta Cryst.*, 1971, **B27**, 2036.

³⁸ W. A. Hendrickson, *Acta Cryst.*, 1971, **B27**, 1474.

³⁹ W. A. Hendrickson, *Acta Cryst.*, 1971, **B27**, 1472.

⁴⁰ C. D. Barry and A. C. T. North, *Cold Spring Harbor Symposium*, 1972, **36**, 577.

⁴¹ R. Diamond, *Acta Cryst.*, 1971, **A27**, 436.

⁴² R. Henderson and J. K. Moffat, *Acta Cryst.*, 1971, **B27**, 1414.

⁴³ K. D. Watenpugh, L. C. Sieker, J. R. Herriott, and L. H. Jensen, *Cold Spring Harbor Symposium*, 1972, **36**, 359.

⁴⁴ C. L. Coulter, *Acta Cryst.*, 1971, **B27**, 1730.

⁴⁵ A. N. Barrett and M. Zwick, *Acta Cryst.*, 1971, **A27**, 6.

⁴⁶ B. P. Schoenborn, *Cold Spring Harbor Symposium*, 1972, **36**, 569.

between different proteins. Protein structures can contain variable percentages of helix, β -pleated sheet, and irregular non-repeating conformations. The structure of carbonic anhydrase shows that helices may be quite distorted from the geometry of the classical α -helix. The importance of extended β -pleated sheet (which may also be rather distorted) to the structure of protein molecules is further evidenced in carbonic anhydrase, flavodoxin, thermolysin, and nuclease.




Figure 2 Empirical peptide energy map for an 'average peptide unit' obtained by calculating the density of experimental values (Reproduced by permission from *Nature*, 1971, **234**, 277)

Pohl⁴⁷ has suggested using the conformational data of proteins determined at high resolution for the calculation of an empirical protein energy map, which is based on two assumptions: (a) that individual influences are averaged out for a large number of different observations, and (b) the conformational states of a peptide unit in a collection of proteins correspond to a Boltzmann distribution. The calculated energy maps (Figure 2) show interesting differences from the theoretical maps at A_2 and C_2 , where high density indicates that the carbonyls of helices are displaced to a position pointing away from the helix axis, possibly owing to interaction of the π -electrons of a peptide bond with the partial positive charge of the amide proton of the following amide; this also explains low density of A_3 and B_3 . Low density at A_1 is due to steric interference with peptides further away in the chain. Conformational data are also presented for glycines and aromatic side-chains.

Although it seems to be generally accepted that hydrophobic forces are important in the structure of proteins, changes of accessibility to solvent on chain folding have not been previously considered quantitatively. Lee and Richards⁴⁸ have designed a method of drawing static accessibility contours, and calculating the change of accessibility for different groups of atoms in

⁴⁷ F. M. Pohl, *Nature New Biol.*, 1971, **234**, 277.

⁴⁸ B. Lee and F. M. Richards, *J. Mol. Biol.*, 1971, **55**, 379.

the protein. They find that the overall accessibility per non-hydrogen atom of different proteins is remarkably constant. The nitrogen and oxygen atoms are 3.5 times as accessible as carbon and sulphur atoms in a native protein. However, the figure for an extended chain is twice. Thus the change in accessibility in going from an extended chain to the folded conformation for these atoms is only about 2. This perhaps sounds a note of caution in discussion on the importance of hydrophobic forces in protein structure.

B. Proteases.—Almost all the *X*-ray studies of proteolytic enzymes reported during 1971 concern the serine proteases. The high-resolution structure of trypsin⁴⁹ and of subtilisin Novo,⁵⁰ and a second independent study of α -chymotrypsin, are reported.⁵¹ Model-building studies on the α -lytic protease are also described.⁵² There have been studies on polypeptide inhibitors with elastase,⁵³ γ -chymotrypsin,⁵⁴ and subtilisin BPN'.⁵⁵ Further, the detailed structure of a trypsin inhibitor⁵⁶ and a postulated mechanism of binding to trypsin have been described.

Stroud, McKay, and Dickerson⁴⁹ report the structure at 2.7 Å resolution of DIP-inhibited bovine trypsin. As yet a detailed description of the electron-density map has not been published; rather, 5 Å models are shown. The analysis is based on four heavy-atom derivatives, only two of which make a significant contribution to the phasing out to 2.7 Å. The average figure of merit is 0.8 at 5 Å but falls to 0.45 at 2.7 Å.

Although only 24% of the residues are invariant between trypsin, chymotrypsin, and elastase, the trypsin analysis shows that this enzyme has similar polypeptide-folding, α -carbon positions, and active-site residues. Changes in the trypsin sequence from that of chymotrypsin are often compensated by further changes which allow the main chain-folding to be preserved. For instance, Met-104 of trypsin replaces a threonine in chymotrypsin, and the methionine side-chain occupies the position of Val-60 side-chain in chymotrypsin. Also, tryptophans at positions 27, 29, and 207 fill a depression in the surface of the enzyme which is occupied by the A-chain of chymotrypsin. The isopropyl group of the inhibitor blocks the active-site binding pocket. Nevertheless, the active site opens on to a

⁴⁹ R. M. Stroud, L. M. Kay, and R. E. Dickerson, *Cold Spring Harbor Symposium*, 1972, **36**, 125.

⁵⁰ J. Drenth, W. G. J. Hol, J. N. Jansonius, and R. Koekoek, *Cold Spring Harbor Symposium*, 1972, **36**, 107.

⁵¹ R. L. Vanden and A. Tulinsky, *Fed. Proc. Abs.*, 1971, **30**, 1129.

⁵² A. McLachlan and D. M. Shotton, *Nature New Biol.*, 1971, **229**, 202.

⁵³ D. M. Shotton, A. J. White, and H. C. Watson, *Cold Spring Harbor Symposium*, 1972, **36**, 91.

⁵⁴ D. M. Segal, G. H. Cohen, D. R. Davies, J. C. Powers, and P. E. Wilcox, *Cold Spring Harbor Symposium*, 1972, **36**, 85.

⁵⁵ J. Kraut, J. D. Robertus, J. J. Birktoft, R. A. Alden, P. E. Wilcox, and J. C. Powers, *Cold Spring Harbor Symposium*, 1972, **36**, 117.

⁵⁶ R. Huber, D. Kukla, A. Rühlmann, and W. Steigemann, *Cold Spring Harbor Symposium*, 1972, **36**, 141; A. Rühlmann, H. J. Schramm, D. Kukla, and R. Huber, *Cold Spring Harbor Symposium*, 1972, **36**, 148.

large region of solvent, in the crystal form studied, which makes it potentially useful for the study of substrate analogues.

The active-site binding pocket contains aspartic acid 189, which will be negatively charged at active pH. Model-building studies with arginine and lysine show that this is ideally placed to form a charge interaction with the substrate side-chains, and so explains the specificity of trypsin proteolysis. Asp-189 in the pocket appears to be hydrogen-bonded to Gln-221A, which may help to freeze the conformation of the aspartic acid in an advantageous way.

Stroud *et al.* suggest that the acidic N-terminal hexapeptide Val-(Asp)₄-Lys of trypsinogen interacts and is stabilized by a cluster of lysines at 145 or 188A, 15, 222, and 224. The acidic hexapeptide is probably also a calcium-binding site unique to trypsinogen. The close juxtaposition of carboxylates at 71, 77, and 153 on the surface are suggestive of the second calcium-binding site common to both the enzyme and its precursor.

McLachlan and Shotton⁵² have proposed a three-dimensional model for α -lytic protease based on the X-ray structures of α -chymotrypsin and elastase. They suggest that the differences are chiefly on the surface, where entire loops are missing and a new one is added, as shown in Figure 3. The hydrophobic core thus remains virtually unaltered, so that the two halves of the molecule form an active centre similar to that of elastase.

Drenth and his co-workers⁵⁰ have presented a comparison of subtilisin BPN' and subtilisin Novo. These have the same sequence but have been crystallized under very different conditions:

<i>Subtilisin</i>	<i>Crystallization conditions</i>	<i>Space group</i>	<i>Resolution</i>
BPN'	2.1 M ammonium sulphate, 0.05 M sodium acetate, pH 5.9	C2	2.5 Å
Novo	55 % (v/v) acetone-water, 0.05 M glycine-NaOH, pH 9.1	P2 ₁	2.8 Å

Although data on the related structures of α -chymotrypsin and chymotrypsinogen, and also ribonuclease A and ribonuclease S, have been published, this represents the first detailed comparison of two such structures in different crystals. Information from this study of the effect of the medium and lattice packing on the conformation is relevant to the question of whether the structure in the crystal is a reflection of the structure of the functioning molecule, either free in solution or attached to a specific surface such as a membrane.

The structures were first related together by comparison of the main-chain and C atoms. The best fit determined by an iterative least-squares method gave a r.m.s. difference of 1.32 Å. By further comparison of the Fouriers and also of each structure with the Fourier of the other, Hol, Drenth, and their co-workers estimate that 0.5 Å differences result from errors in the electron densities, the interpretation, and the model building.

Further errors of 0.8 \AA are estimated to result from the determination of the co-ordinates from the model. Thus differences of less than 1.3 \AA are not significant.




Figure 3 Ribbon diagram of the polypeptide chain conformation of α -lytic protease drawn on the known skeleton of α -chymotrypsin. Shaded areas are present in chymotrypsin but probably missing in the α -lytic protease; dotted lines are short cuts; striped sections are insertions; beaded lines are disulphide bridges; dark bars are cuts to allow insertions. The active site is in the centre (Reproduced by permission from *Nature New Biol.*, 1971, **229**, 202)

The r.m.s. difference in side-group positions— 1.92 \AA average—is much greater than for backbone positions. Most of the significant differences occur in surface side-chains, many of which correspond to intermolecular contacts. A significant difference of internal side-chains at Val-149 and Val-150 is thought to result from binding of a Ti^+ or K^+ to the nearby Asp-197 in subtilisin Novo, a consequence of the change of the crystallization medium. There are significant differences in only short regions of main chain such as Gly-46—Gly-47 and Pro-129—Ser-130.

The position of the essential Ser-221 is the same in both structures, but the β -C atom of Met-222 is pointing towards solution in Novo and inwards in BPN' (a difference of 4 Å). However, most active-site residues—for example, Asp-102, Ser-33, Asp-60, or Thr-66—occupy the same positions. In general, Drenth and his co-workers conclude that the difference in medium surrounding subtilisin Novo and subtilisin BPN' and the different intermolecular contacts in the crystals have not resulted in any major structural change of the subtilisin molecule. Comparative studies of subtilisins BPN' and Novo are also reported by Kraut *et al.*⁵⁷

A valid criticism of the diffraction results on α -chymotrypsin was that they were obtained at pH 4, well below the pK of His-57 involved at the active site. These objections can now be met in the light of the results obtained from studies on the pH dependence of the conformation of the serine proteases.

Vandlen and Tulinsky⁵¹ report a 3.5 Å resolution comparison of the structure of α -chymotrypsin at pH 6.7 with that at pH 3.9, which shows that there has been a conformational change between these pH values. However, a comparison of the structures of native elastase at pH 5 and pH 8.5 shows⁵³ that in both cases the active-site histidine is hydrogen-bonded to Asp-102 and Ser-195 as found previously in α -chymotrypsin. The only difference appears to be the presence of two bound sulphates at pH 5, one of which lies 6 Å from the side-chains of His-57 and Ser-195. In a similar way, there appears to be no conformational change in the crystals of DIP-inhibited trypsin between pH 5 and pH 9, although there are conformational changes in solution in both trypsin and trypsinogen between these pH values.⁴⁹

Henderson *et al.*⁵⁸ have published a concise account of the mechanism of action of α -chymotrypsin as proposed on the basis of X-ray studies. They have also studied the role of His-57 in the mechanism of action of α -chymotrypsin. His-57 can be specifically methylated with methyl *p*-nitrobenzenesulphonate. An electron-density difference-map of such a methylated α -chymotrypsin shows that His-57 moves 0.3 Å outwards from its position in native α -chymotrypsin, where it is hydrogen-bonded to the hydroxy-group of Ser-195. The methyl group substituted at N⁶² is clearly the largest feature in the map. The hydrogen bond between N⁶¹ and Asp-102 is retained. However, the γ -oxygens of Ser-195 occupy two alternative positions. Although the enzyme still binds substrate analogues, the catalytic rates for substrates are decreased by factors of between 5000 and 20 000. This decrease is thought to result partially from disorientation if the histidine flips so that N⁶¹ is used and partially from the absence of the polarizing effect of Asp-102.

⁵⁷ J. D. Robertus, R. A. Alden, and J. Kraut, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 334.

⁵⁸ R. Henderson, C. S. Wright, G. P. Hess, and D. M. Blow, *Cold Spring Harbor Symposium*, 1972, **36**, 63.

Because of the molecular packing in the crystals of α -chymotrypsin, particularly in the active-site region, attempts to bind larger substrates and substrate analogues than the *N*-formyl-L-tryptophan previously reported have been unsuccessful. However, this is not the case for the crystal forms of the other serine proteases.

Studies of γ -chymotrypsin by Segal *et al.*,⁵⁴ and of subtilisin by Kraut *et al.*,⁵⁵ with chloromethyl ketone analogues of good phenylalanine polypeptide substrates have indicated further similarities in substrate binding and specificity of these enzymes. It had previously been reported that both enzymes contain a serine at the active site which is acylated by ester substrates, a histidine hydrogen-bonded to this serine which is alkylated by active-site-directed halogenomethyl ketones, and an aspartate which is buried and hydrogen-bonded not only to the active-site histidine but also in each case to a further serine.

The studies now reported show that chloromethyl ketone polypeptide inhibitors bind in an antiparallel β -pleated sheet fashion to a length of extended backbone, Ser-125—Leu-126—Gly-127 in subtilisin, and Ser-214—Trp-215—Gly-216 in γ -chymotrypsin. In each case there are the same geometric relationships of the pleated sheet to the active serine, and glycine residues are involved in β -pleated sheet hydrogen-bonding in both (see Figure 4):

Subtilisin	Ser-125	Leu-126	Gly-127
γ -Chymotrypsin	Ser-214	Trp-215	Gly-216

In the case of γ -chymotrypsin these deductions were made from model building and a comparison of the Ala-Ala-Gly— and Ala-Ala—derivatives of phenylalanine chloromethyl ketone inhibitor complexes, as these involved a rotation of the molecule with respect to the native crystal structure. In both γ -chymotrypsin and subtilisin the subsite S_1 provides a hydrophobic binding pocket for a phenylalanine side-chain; the subsite S_2 is less well defined, while the subsite S_3 can give rise to two specific hydrogen bonds. Stroud *et al.*⁴⁹ suggest that trypsin may form a further β -pleated-sheet hydrogen-bond between the polypeptide substrate and the NH of residue 219 (218 is deleted in trypsin). These beautiful experiments show that convergence in evolution between subtilisin and the trypsin family of serine proteases may be quite extensive.

Unfortunately, studies by Shotton *et al.*⁵³ of elastase with various polypeptide competitive inhibitors indicate a different mode of enzyme substrate interaction. They report difference electron-density maps for complexes of elastase with Ala-Ala-Ala and *N*-acetyl-Ala-Ala at pH 4.2 (at which elastase has negligible activity), with *N*-acetyl-Pro-Ala-Pro-Ala, which is not hydrolysed, at pH 8.5 (the enzyme's optimum pH), and with Lys-Phe, which is the hydrolysis product of the excellent substrate Ala-Ala-Ala-Ala-Lys-Phe, at both pH 5 and pH 8.5. The difference studies of the complexes of Ala-Ala-Ala, *N*-acetyl-Ala-Ala, and *N*-acetyl-Pro-Ala-Pro-Ala all show electron density in the same region, indicating binding of

the C-terminal residue, P₁, beneath Ser-195 with the side-chain methyl extending towards Val-216. P₂ has its side-chain pointing into solution, whereas with P₃ His the side-chain is pointing towards the enzyme surface between the carbonyl of Thr-41 and the β -carbon of Gln-192. However,




Figure 4 Atomic model of chymotrypsin A inhibited by acetyl-Ala-Ala-Phe chloromethyl ketone. Only the portion of the enzyme which may interact with the inhibitor has been shown

(Reproduced by permission from *Cold Spring Harbor Symposium*, 1972, 36, 85)

the complex of *N*-acetyl-Ala-Ala shows a subsite in the same position as found by Segal *et al.* in γ -chymotrypsin. The difference electron-density maps showed no evidence of binding of the Lys-Phe peptide. Shotton *et al.* concede that the binding found by Segal *et al.* 'seems to be the more favourable', but further studies are clearly required.


The structure of the basic trypsin inhibitor of bovine pancreas has been studied at 2.5 Å resolution by Huber *et al.*⁵⁸ The *X*-ray analysis shows that this small protein of 58 amino-acids is pear-shaped with length of 29 Å and maximum diameter of 19 Å. The major determinant of the structure is a double-stranded anti-parallel β -sheet formed by a loop in the residues between Ala-16 and Gly-36. This β -sheet has a twist of 180°. The remaining polypeptide chain is folded to give one hydrogen bond of a triple-stranded sheet, and three turns of an α -helix at the carboxy-terminus. The structure is stabilized by a hydrophobic core and two further cystine disulphides. There is also a buried asparagine 43 which hydrogen-bonds

to the main chain at positions 5, 7, and 23, so that the segment 38—45 is also tightly held to the rest of the molecule. These interactions lead to a molecule that is stable towards denaturing agents and heat, as well as to almost all proteolytic enzymes.

The molecule has a distinct dipolar character; the binding region is on the positively charged side and involves a major site at Lys-15 and a minor site at Arg-39. The two sites are close together and mutually exclusive. They lie in a symmetrical way about the disulphide bridge, cystine 14—38. If cystine 14—38 is cleaved, the modified inhibitor binds to trypsin in a substrate-like manner and the peptide bonds at Lys-15—Ala-16 and Arg-39—Ala-40 are split. The trypsin inhibitor of soya bean also binds in a similar substrate-like fashion. The lack of peptide cleavage in the native pancreatic trypsin inhibitor is presumably a consequence of stabilization by the β -sheet hydrogen-bonds, the various hydrophobic interactions, and the disulphide 14—38. These would together hold the new C- and N-terminus to the body of the structure, and reduce the potential entropy gain on cleavage.

An homologous inhibitor from bovine colostran has 50% amino-acid changes. Nevertheless, the disulphides, the non-polar core, and the buried asparagine are retained so that a close structural similarity may be assumed. Furthermore, the surface region around the major binding site 12—16 and 35—38 is also retained, although the subsidiary site is different.

The pancreatic trypsin inhibitor binds to trypsin, chymotrypsin, plasmin, and kallikrein, but does not inhibit elastase and subtilisin. Model-building studies of the inhibitor chymotrypsin complex ⁵⁶ show that the enzyme and inhibitor have highly complementary structures. If Lys-15 (in a non-protonated form) is placed in the specificity pocket with the C and NH of Lys-15 in similar positions to those of tryptophan in the formyl-L-tryptophan-chymotrypsin complex, the residues on the N-terminal side of lysine then form an antiparallel β -structure with the enzyme similar to that proposed for γ -chymotrypsin (7), and there appear to be a number of



favourable hydrophobic interactions. As a result, the association rate is as high as that of substrates. If peptide cleavage occurs, dissociation—the deacylation steps—would be hindered owing to lack of access of water.

A similar mechanism in soya-bean inhibitor may explain the abnormal deacylation which is often observed. Preliminary *X*-ray data for the crystalline complexes of the pancreatic trypsin inhibitor with chymotrypsin and trypsin have been reported.⁵⁸

Matthews *et al.*⁵⁹ have determined the structure of the extracellular proteolytic enzyme thermolysin to 2.3 Å resolution. This enzyme of molecular weight 37 500 contains one zinc and four calcium ions, and is interesting because of its unusual heat stability. The active site contains a zinc atom tetrahedrally co-ordinated to histidine-142, histidine-146, glutamate-166, and a water molecule, and in this way resembles carboxypeptidase A. The precise details of the co-ordination of the calcium ions are not reported. However, it is of interest that two have a centre-to-centre distance of 3.8 Å and are located within an interior region of the protein, surrounded by carbonyl and carboxylate groups. Loss of calcium does not hinder proteolysis at room temperature, but the enzyme is no longer heat stable.

Preliminary *X*-ray data are also reported for the acidic protease from the fungus *Rhizopus chinensis*.⁶⁰

C. Nucleases.—Carlisle and his colleagues (unpublished work) have completed an independent analysis of ribonuclease A.

The data in the literature on the specificity and mechanism of action of ribonuclease have been reviewed by Richards and Wyckoff. The two-step reaction catalysed by ribonuclease⁶¹ is shown in Figure 5, along with a schematic view of the active centre of ribonuclease as deduced from *X*-ray data using the enzyme complex with the substrate analogue, dinucleoside phosphonate, UpcA. This substrate analogue is identical with the substrate, UpA, except that the 5'-oxygen of the adenosine residue has been converted into a methylene carbon atom, so that the P—C bond is not labile in the presence of RNA. Although the *X*-ray work cannot prove conclusively the mechanism of step 2, the same geometry is observed in the simultaneous binding of 3'-CMP and of the activator 3'-AMP, suggesting that His-119 plays a similar role in the steps of a push-pull mechanism.

A crystallographic study of the binding of cupric ion with ribonuclease S has been carried out⁶² in order to investigate its inhibitory effects with this enzyme. Allewell and Wyckoff have studied at 6 Å resolution the binding of Cu^{II} to RNase S, RNase E, and 41-Dnp-RNase S in the presence of 3M-(NH₄)₂SO₄ and acetate buffer. At pH 5.5 with 0.1M acetate buffer, there are four intramolecular binding sites which are close to His-119, His-105, and Glu-86, and a sulphate ion bound at the active centre on both RNase S and RNase E. There are a further three intermolecular sites. In the 41-Dnp-RNase there are minor changes and the

⁵⁸ B. W. Matthews, J. N. Jansonius, P. M. Colman, B. P. Schoenborn, and D. Dupourque, *Nature New Biol.*, 1972, **238**, 37.

⁶⁰ I. D. A. Swan, *J. Mol. Biol.*, 1971, **60**, 405.

⁶¹ F. M. Richards, H. W. Wyckoff, W. D. Carlson, N. M. Allewell, B. Lee, and Y. Mitsui, *Cold Spring Harbor Symposium*, 1972, **36**, 35.

⁶² N. M. Allewell and H. W. Wyckoff, *J. Biol. Chem.*, 1971, **246**, 4657.

site close to the sulphate is absent. At pH 7 in the presence of 0.67M acetate and 0.3M ethanolamine the binding at all sites is decreased, although the occupancies at the nitrogen ligands decrease less than those with oxygen ligands.




Figure 5 The diagram at the top is a schematic view of the active centre of ribonuclease as deduced from X-ray data from the protein and some substrate complexes. B₁, R₁, R₂, and B₂ represent the positions of the bases and riboses of a dinucleotide found for UpcA, and in certain other analogues. B'₂ is the probable position of the second pyrimidine in dinucleotides such as CpU; p₁ is a phosphate position occupied by SO₄²⁻ in the crystals. The reaction diagrams are meant to parallel the active-site diagram

(Reproduced by permission from 'The Enzymes', ed. P. D. Boyer, Academic Press, New York, 1971, vol. IV, p. 647)

Cotton *et al.*⁶³ report the high-resolution structure of an inhibitor complex of the extracellular nuclease of *Staphylococcus aureus*. The 2 Å resolution electron-density map was based on the analysis of two heavy-atom derivatives: one involves the replacement of the calcium ion for a barium, whereas the other uses 5-iododeoxyuridine 3',5'-diphosphate in place of thymidine 3',5'-diphosphate, a replacement of CH₃ by I. The report contains an interesting and useful discussion of the use of anomalous scattering in different stages of the X-ray analysis.

The electron-density map allows a complete tracing of the polypeptide chain except for a few residues at the chain termini, which are thought to

⁶³ A. Arnone, C. J. Bier, F. A. Cotton, V. W. Day, E. E. Hazen, jun., D. C. Richardson, J. S. Richardson, and A. Yonath, *J. Biol. Chem.*, 1971, **246**, 2302.

be disordered as they project into solvent. About 30 of the 149 residues form three separate sections of helix, while 24 residues form a rather irregular, antiparallel pleated sheet. The inhibitor is bound in a large pocket which is predominantly hydrophobic with the exception of the calcium and inhibitor ligands.

The calcium ion is co-ordinated by an approximately square array of carboxylate groups (Glu-43, Asp-21, Asp-40, and Asp-19) with the distance to Asp-19 being somewhat longer than the others.⁶⁴ There is also an outer co-ordination sphere comprising a complex array of hydrogen-bonded threonines, water molecules, and other structural elements. The 5'-phosphate of the inhibitor is bound to Arg-35 and Arg-87 and one oxygen lies *ca.* 4 Å from the calcium ion and is probably β -bridged by a hydroxy-group. The 3'-phosphate interacts with Tyr-85 and probably with Lys-84.

Simple esters of thymidine 5'-phosphate or pTTP are hydrolysed with cleavage of the 5'-C—O—P bond between phosphorus and oxygen. It is thought that a second calcium ion binds between the two phosphate groups. This calcium and the two arginines may then serve as general acid catalysts and facilitate the nucleophilic attack of the hydroxy-group (bound to the other calcium) on the 5'-phosphate groups, with expulsion of the 5'-oxygen atom.

D. Glycoside Hydrolases.—Although comparative biochemical studies have previously cast doubt on the expected homology of human and hen egg-white lysozymes, a 6 Å resolution Fourier of human lysozyme indicates that their tertiary structures are in fact very similar.⁶⁵


Human lysozyme, like hen egg-white lysozyme, has 129 amino-acid residues in its polypeptide chain, but 41% of the amino-acids are different. There is strong evidence that there is in fact one additional residue located between residues 47 and 48 in the hen egg-white chain, in a position on a hair-pin bend in the β -pleat structure which can easily be made to accommodate an extra residue. A compensating deletion occurs at Ser-100, which is also on the surface of the enzyme. As expected, most of the amino-acid changes occur on the surface of the enzyme where the side-chains protrude into solvent. A number of changes do, however, occur in the hydrophobic core, such as the replacement of the methionine residues, but these appear to be accommodated in the tertiary structure. Of the internal residues, 74% are invariant, a smaller percentage than for chymotrypsin and elastase.

The active site including residues Glu-35 and Asp-52 remains substantially unchanged, but there appear to be sequence changes in the residues comprising subsites A, B, and C. The major structural changes which may affect substrate binding appear in subsite A, which is thought to be the weakest in hen egg-white lysozyme.

⁶⁴ F. A. Cotton, C. J. Bier, V. W. Day, E. E. Hazen, jun., S. Larsen, *Cold Spring Harbor Symposium*, 1972, 36, 243.

⁶⁵ C. C. F. Blake and I. D. A. Swan, *Nature New Biol.*, 1971, 232, 12.

The binding of the spin label 4*N*-acetamido-2,2,6,6-tetramethylpiperidine *N*-oxide (8) with tetragonal lysozyme has been studied at 6 Å resolution. The spin label is rather different from the inhibitor, *N*-acetylglucosamine.



However, difference electron-density maps indicate two binding sites in the cleft close to sugar sites A and C, with interactions through the acetamido-group analogous to the binding of *N*-acetylglucosamine. There is also a stronger third binding site in a hydrophobic pocket near the surface, which does not appear to have biological significance.

Preliminary *X*-ray studies are reported for sweet-potato β -amylase.⁶⁷ These indicate a space group of *P*₄22 and a molecular weight of 206 000, which corresponds to a tetramer. At low resolution a pseudocell of the same space group indicates that the tetramer contains an approximate two-fold axis.

E. Carbonic Anhydrase.—Strandberg and his colleagues⁶⁸ have calculated a 2 Å resolution electron-density map of human erythrocyte carbonic anhydrase C. A polypeptide chain of 258 amino-acid residues is indicated and two sequenced fragments have been fitted in positions 1—88 and 224—258. The structure has a gross shape of 41 × 41 × 47 Å and is built essentially of three layers. Seven distorted sections of right-handed α -helix are in the surface layers. In contrast, the middle layer is an extensive mainly antiparallel pleated sheet structure with a total twist of 220° and comprising 37% of the total residues. There are aromatic regions between the central sheet and the surface layers.

The active site is a 15 Å deep conical cavity between the pleated sheet and the upper surface layer. The zinc atom is bound to N⁶² of His-93 and His-95, and N⁸¹ of His-117 (part of the pleated sheet). The distorted tetrahedral co-ordination is completed by a water molecule which is also bound to the O^γ of Thr-197. The active-site region also indicates two histidines, His-63 and His-128, which lie on opposite sides of the entrance to the cavity. There are eight solvent peaks, not all directly bound to protein functional groups, in the cavity.

⁶⁶ L. J. Berliner, *J. Mol. Biol.*, 1971, **61**, 189.

⁶⁷ P. M. Colman and B. W. Matthews, *J. Mol. Biol.*, 1971, **60**, 163.

⁶⁸ K. K. Kannan, A. Liljas, I. Waara, P.-C. Bergsten, S. Lovgren, B. Strandberg, U. Bengtsson, U. Carlbam, K. Fridborg, L. Jarup, and M. Pelef, *Cold Spring Harbor Symposium*, 1972, **36**, 221.

A series of difference Fouriers have been used to study the replacement of zinc with other metal ions and the nature of interaction of sulphonamides and anions with carbonic anhydrase C. Copper, cobalt, and manganese bivalent ions bind at the zinc site, but mercury is displaced by 0.6 Å from this position. Iodide, cyanide, and cyanate bind to the zinc whereas bromide and chloride bind *via* the zinc-bound water at *ca.* pH 6. 3-Acetoxymercuri-4-aminobenzenesulphonamide binds through a sulphonamide nitrogen or oxygen with a Zn—S distance of 3 Å. The strength of the inhibitor binding appears to result from hydrogen-bonding and van der Waals interactions, as well as from entropic contributions due to displacement of solvent. As HCO_3^- competes with anions it is deduced that this also binds to zinc. Little about the mechanism of action of this enzyme can be deduced at present from these structural studies.

F. Enzymes of the Glycolytic Pathway.—Work on the enzymes of the glycolytic pathway is being carried out in laboratories at Oxford, Bristol, Cambridge, and Yale; several of the studies have led to low-resolution electron-density maps and should give more detailed results in the very near future. These studies have been reviewed by Campbell *et al.*⁶⁹ and are summarized in Table 2. Certain of the studies demand more detailed discussion.

A preliminary study⁷² of the Patterson projections of hexokinase-B suggests that the molecules are identical and there is a molecular two-fold screw axis parallel to the crystallographic *c*-axis involving translation of 3.6 Å along this local axis.

A 6 Å resolution electron-density map of chicken triose phosphate isomerase (TIM) has been calculated by Banner *et al.*⁷⁵ This isomerase catalyses the reaction (*a*) in Scheme 1 and has an interesting advantage over most enzymes because the substrate dihydroxyacetone phosphate (DHAP) can be studied when bound to the crystals. The 6 Å map of the native enzyme shows that the dimer has a local two-fold axis and has dimensions 45 Å parallel to the local axis and 70 × 40 Å in the plane perpendicular to this. The DHAP-TIM complex has a slightly different crystal unit cell as shown in Table 2, but a low-resolution (8 Å) difference map indicates two substrate binding sites related by the local diad axis, although there appear to be conformational changes. Crystals of TIM with a bound transition state intermediate analogue phosphoglycollate (9)

⁶⁹ J. W. Campbell, E. Duee, G. Hodgson, W. D. Mercer, D. K. Stammers, P. L. Wendell, H. Muirhead, and H. C. Watson, *Cold Spring Harbor Symposium*, 1972, **36**, 165.

⁷⁰ F. S. Matthews, *Fed. Proc.*, 1967, **26**, 831.

⁷¹ R. K. Scopes and I. F. Penny, *Biochim. Biophys. Acta*, 1971, **236**, 409.

⁷² T. A. Steitz, *J. Mol. Biol.*, 1971, **61**, 695.

⁷³ P. A. M. Eagles, L. N. Johnson, M. A. Joynson, C. H. McMurray, and H. Gutfreund, *J. Mol. Biol.*, 1969, **43**, 533.

⁷⁴ A. I. Gobyunov, N. S. Andreyeva, and V. L. Shpitsberg, *Biofizika*, 1969, **14**, 1116.



⁷⁵ D. W. Banner, A. C. Bloomer, G. A. Petsko, D. C. Phillips, C. I. Pogson, *Cold Spring Harbor Symposium*, 1972, **36**, 151.

Table 2 X-Ray studies of enzymes in the glycolytic pathway

	Form	Molecular weight	Space groups	Ref.
<pre> graph TD Glycogen --> Phosphorylase Phosphorylase --> G1P G1P --> P-Glucomutase P-Glucomutase --> Glucose Glucose --> Hexokinase Hexokinase --> G5P G5P --> P-Glucoisomerase P-Glucoisomerase --> F6P F6P --> P-Fructokinase P-Fructokinase --> F16BP[F-1,6-di-P] F16BP --> Aldolase Aldolase --> PHAP Aldolase --> G3P PHAP --> G3P G3P --> TrioseP[Triose P-Isomerase] TrioseP --> G3P </pre>				
			$P2_1 [P4_12_12_4 \text{ or } P4_32_12^*]$	70
	Rabbit	63 000	Not suitable for X-ray studies	71
	Yeast	102 000	Dimer in asymmetric unit $P2_12_12_1$ $a = 215.2 \text{ \AA}$, $b = 58.5 \text{ \AA}$, $c = 90.7 \text{ \AA}$	72
	Pig	108 000 Dimer	$P4_12_12_2 \text{ or } P4_32_12$ $a = b = 95 \text{ \AA}$, $c = 138 \text{ \AA}$	69
No mammalian form crystallized				
	Rabbit		Monoclinic	73
			Hexagonal	74
	Chicken	49 000 Per dimer	$P2_12_12_1$	75
	Native + DHAP + phosphoglycollate		a 105.9 b 74.4 c 61.8 \AA a 102.1 b 74.4 c 62.2 \AA a 99.4 b 74.4 c 62.5 \AA	75

Glyceraldehyde 3-P-dehydrogenase	Lobster	150 000	$P2_12_12_1$	76
	Human	Tetramer	C2	77
1.3-di-P-G P-Glycerokinase	Crayfish		C2 $a = 128 \text{ \AA}, b = 100 \text{ \AA},$ $c = 80 \text{ \AA}, \beta = 114.3^\circ,$ 2 subunits/asymmetric unit	69
	Yeast	45 000	C2 $a = 126.6 \text{ \AA}, b = 54.4 \text{ \AA},$ $c = 98.0 \text{ \AA}, \beta = 133.9^\circ$	78
3-P-G P-Glyceromutase	Horse muscle	48 000 Monomer	$P2_1$ $a = 50.8 \text{ \AA}, b = 106.9 \text{ \AA},$ $c = 86.3 \text{ \AA}, \beta = 98.6^\circ$	79
	Yeast	110 700 Tetramer	C2 $a = 96 \text{ \AA}, b = 86 \text{ \AA}, c = 81 \text{ \AA},$ $\beta = 120^\circ$, 2 subunits/ asymmetric unit	69
2-P-G Enolase	Yeast	88 000 Dimer	P1 $a = 64 \text{ \AA}, b = 74 \text{ \AA},$ $c = 109 \text{ \AA}, \alpha = 100^\circ,$ $\beta = 92^\circ, \gamma = 107^\circ$	69
P-E-P Pyruvate kinase	Human muscle	240 000	I222	69
		Tetramer	$a = 87 \text{ \AA}, b = 117 \text{ \AA},$ $c = 129 \text{ \AA}$	
Pyruvate				

* Eagles *et al.*, unpublished observations.



Scheme 1

show further changes in cell dimensions as shown in Table 2, which may be a result of a further conformational change.

Crystallographic studies of both yeast and horse-muscle phosphoglycerate kinase (PGK) are progressing well. Watson *et al.*⁷⁸ have produced a good mercuric acetate derivative of the yeast enzyme and have recently calculated a 6 Å electron-density map. Blake *et al.*⁷⁹ have computed a 6 Å electron-density map of the horse-muscle enzyme which shows that the long polypeptide chain of *ca.* 420 residues is folded into two distinct globular units, which are clearly different in chain conformation. There is no suggestion that the molecule is composed of two polypeptide chains. A single active site has been located on one of the subunits by calculating difference electron-density maps on the isomorphous binary complex PGK—Mg—ADP.

G. Dehydrogenases.—A new map at 2.5 Å resolution of the apoenzyme of dogfish-muscle lactate dehydrogenase is reported by Rossmann and his

⁷⁸ H. C. Watson and L. J. Banaszak, *Nature*, 1964, **204**, 918.

⁷⁷ A. I. Gobyunov and N. S. Andreyeva, *Molekulyarnaya Biologiya*, 1967, **1**, 261.

⁷⁸ H. C. Watson, P. L. Wendell, and R. K. Scopes, *J. Mol. Biol.*, 1971, **57**, 623.

⁷⁹ C. C. F. Blake, P. R. Evans, and R. K. Scopes, *Nature New Biol.*, 1972, **235**, 195.

colleagues.⁸⁰ Although the gross conformation of the polypeptide chain derived from the 2.8 Å map is confirmed, a number of minor modifications have been made to the interpretation. More secondary structure is now included and the number of amino-acid residues is increased from 311 to 331; this secondary structure is illustrated in Figure 6. The unusual arrangement of the first 20 residues extending away from the rest of the subunit is confirmed. Tetraiodofluorescein binding to LDH has been the subject of a 4 Å resolution crystallographic study.⁸¹ The crystals are isomorphous with the apoenzyme and have one binding site for dye per monomer of the enzyme. The position of the dye is coincident with the adenosine portion of bound NAD⁺.

The structure at 5 Å resolution of the abortive ternary complex of lactate dehydrogenase, NAD, and pyruvate resembles that of the apoenzyme in that it has 222 symmetry, although the packing of subunits in the tetramer is different.⁸² The main-chain folding is similar in the structures except in one part close to the coenzyme binding site, where the chain stands out in the apoenzyme but moves *ca.* 12 Å to fold over the active site in the ternary complex. An improved electron-density map at 3 Å resolution with phases between 5 Å and 3 Å based on isomorphous and anomalous scattering differences from one mercury derivative confirms these conclusions. The conformation of the coenzyme is also described on the basis of the 3 Å electron-density map. The L-lactate molecule is thought to be oriented under the nicotinamide, with one carboxy-group interacting with the carboxamide of the nicotinamide. His-195 and Asp-168 are close to the essential thiol at Cys-165 and these three groups, lying inside the subunit, may form a charge relay system which enhances the negativity of the histidine, thought to be the 'source and sink' for the proton in the reaction.

The structure at 5 Å resolution of horse-liver alcohol dehydrogenase is described by Branden *et al.*⁸³ A two-fold crystallographic axis relates to two identical subunits of the dimeric enzyme. The subunit is *ca.* 45 × 55 × 110 Å. The binding site of one zinc atom per subunit is clearly identified in a cleft close to the surface of the enzyme. The position of the second zinc atom is not evident. The active-site cleft is clear but lies about 30 Å from the position of zinc atom found from the electron-density map, and so this zinc atom cannot be involved in biological activity.

The structure of pig heart-muscle malate dehydrogenase determined at 5 Å resolution, and more recently at 3 Å resolution by Tsernoglou *et al.*,

⁸⁰ M. G. Rossmann, M. J. Adams, M. Buehner, G. C. Ford, M. L. Hackert, P. J. Lentz, jun., A. McPherson, jun., R. W. Schevitz, and I. E. Smiley, *Cold Spring Harbor Symposium*, 1972, **36**, 179.

⁸¹ P. M. Wassarman and P. J. Lentz, jun., *J. Mol. Biol.*, 1971, **60**, 509.

⁸² I. E. Smiley, R. Koekoek, M. J. Adams, and M. G. Rossmann, *J. Mol. Biol.*, 1971, **55**, 467.

⁸³ C.-I. Brändén, E. Zeppezauer, B.-O. Söderberg, R. Boiwe, B. Nordström, G. Söderlund, M. Zeppezauer, P.-E. Warner, and A. Akeson, in 'Wenner-Gren Symposium on Structure and Function of Oxidation-Reduction Enzymes', ed. A. Akeson and A. Ehrenborg, in the press.




Figure 6 Schematic diagram of hydrogen bonds between main-chain atoms within one subunit of LDH
(Reproduced by permission from *Cold Spring Harbor Symposium*, 1972, 36, 179)

shows remarkable resemblances to lactate dehydrogenase.⁸⁴ The enzyme is a dimer, and this forms the crystallographic asymmetric unit. The two molecules of the dimer appear to have slightly different conformations, but are related by an approximate dyad axis at an angle of *ca.* 10–25° to the *b* axis. Only one of the two molecules has bound NAD⁺. The enzyme has the same chain-folding as lactate dehydrogenase, but lacks the N-terminal arm, which assists the formation of tetramers from dimers in the latter case. The molecular weight of the malate dehydrogenase dimer is 70 000 and this represents the largest unit determined at high resolution by X-ray analysis to date.

However, an even more ambitious project is the study of lipoyl transsuccinylase, the core of the α -ketoglutarate dehydrogenase complex from *E. coli*; preliminary X-ray studies are reported by DeRosier *et al.*^{85, 86} This core of the complex contains 24 identical subunits and can be crystallized in a face-centred cubic lattice, *F*432. Optical diffraction studies of the electron micrographs of these crystals give structural detail to 40 Å resolution, and indicate that the core complex has octahedral symmetry with the 24 globular units arranged near the vertices of a truncated cube. The information from the low-resolution electron-microscope images and from the subunit composition have been combined with the X-ray diffraction data to 18 Å resolution, in order to estimate phases and calculate an electron-density map. This shows 24 peaks at a radius of *ca.* 64 Å situated at the vertices of the truncated cube, and an indication of trimer clustering at a radius of *ca.* 42 Å. Studies with heavy-atom derivatives are now in progress.

H. Regulatory Enzymes.—Studies of two multi-subunit regulatory enzymes, glutamine synthetase⁸⁷ and aspartate transcarbamylase⁸⁸ are reported.

Glutamine synthetase catalyses the condensation of glutamate with ammonia to form glutamine, which serves as a nitrogen donor to various metabolites such as histidine, tryptophan, AMP, CTP, carbonyl phosphate, and glucosamine 6-phosphate. The enzyme is also regulated by changes in Mg²⁺ and Mn²⁺ concentrations. The enzyme contains 12 identical subunits of molecular weight 48 500, each of which has binding sites for the substrates and effectors. Crystals of 0.3 × 0.2 × 0.1 mm have been grown using the modified micro-diffusion-cell method of Weber and Goodkin in Eisenberg's laboratory.⁸⁷ X-Ray patterns to 7 Å resolution,

⁸⁴ D. Tsernoglou, E. Hill, and L. J. Banaszak, *Cold Spring Harbor Symposium*, 1972, **36**, 171.

⁸⁵ D. J. DeRosier, R. M. Oliver, and L. J. Reed, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1135.

⁸⁶ D. J. DeRosier and R. M. Oliver, *Cold Spring Harbor Symposium*, 1972, **36**, 199.

⁸⁷ D. Eisenberg, E. G. Heidner, P. Goodkin, M. N. Dastoor, B. H. Weber, F. Wedler, and J. D. Bell, *Cold Spring Harbor Symposium*, 1972, **36**, 291.

⁸⁸ D. C. Wiley, D. R. Evans, S. G. Warren, C. H. McMurray, B. F. P. Edwards, W. A. Franks, and W. N. Lipscomb, *Cold Spring Harbor Symposium*, 1972, **36**, 285.

⁸⁹ R. E. Dickerson, T. Takano, D. Eisenberg, O. B. Kallai, L. Samson, A. Cooper, and E. Margoliash, *J. Biol. Chem.*, 1971, **246**, 1511.

combined with knowledge of the arrangement of the subunits found from electron microscopy, indicate that the space group is probably $P4_2$. The results are consistent with a model based on a double hexagonal ring pattern 'like two benzene rings with their faces together', which may have either symmetry 6 or 622, but exclude a model based on 32 symmetry (see Figure 7).




Figure 7 Symmetries of the glutamine synthetase molecule consistent with molecular shapes seen in the electron micrographs. Symmetry 32 is inconsistent with the X-ray results

(Reproduced by permission from *Cold Spring Harbor Symposium*, 1972, 36, 285)

Studies of the regulatory enzyme aspartate transcarbamylase are further advanced.⁸⁸ This enzyme catalyses the first unique reaction in the pyrimidine biosynthetic pathway. The X-ray studies of Wiley *et al.*⁸⁸ show that this enzyme of molecular weight 310 000 containing six catalytic and six regulatory chains crystallizes in two forms with space groups $P3_21$ and $R3_2$. A 5.5 Å resolution electron-density map based on two derivatives has been computed for the $R3_2$ form; the molecule has 32 symmetry. A clear molecular boundary shows that the molecule has a triangular shape of side 105 ± 10 Å and is 92 ± 10 Å long. The centre of the molecule is empty and is ringed with areas of electron density. The dense areas connect across two-fold axes to form dimers, probably involving contacts between regulatory chains. Further from the centre the contacts, probably between catalytic chains, are trimeric. The active-site region located by a mercury-containing inhibitor appears to be in the plane of maximum contact within the trimer.

I. Redox Proteins.—The study of redox proteins by *X*-ray analysis has been very productive during the year. High-resolution structures of ferri- and ferro-cytochrome *c*, cytochrome *b₅*, ferredoxin, rubredoxin, high-potential iron protein, and two flavodoxins have now been worked out, although not all were published in 1971.

A series of exciting papers on cytochrome *c* by Dickerson *et al.*⁸⁹⁻⁹² includes a report on the structures at 2.8 Å resolution of horse and bonito ferricytochromes,⁸⁹ a speculative discussion on chain flexibility in ferri-cytochrome,⁹⁰ a report of tuna ferrocytochrome at 2.45 Å resolution⁹¹ and a discussion of sequence and structure homologies in bacterial and mammalian-type cytochromes.⁹²

The *X*-ray analysis of ferricytochrome⁸⁹ shows that the haem sits in a crevice with thioester bonds to Cys-14 and Cys-17. The iron is bound to His-18 on the right wall and to Met-80 on the left wall as viewed in Figure 8. One of the propionic side-chains is buried at the bottom of the crevice and is extensively hydrogen-bonded, while the other is on the surface. The molecule is constructed in two halves with residues 1—47 on the right side and residues 48—91 on the left. The C-terminal residues 92—104 are wrapped across the right half like a 'strap of a suitcase'.

The peptide is mainly an extended chain which is wrapped round the haem—one layer thick—with hydrophobic residues on the inside and hydrophilic on the outside. The N- and C-terminal residues form short helices. There are two channels leading to the haem; the left channel is lined with residues 52—74 and includes Tyr-74, Trp-59, and Tyr-67, which lie parallel to each other. The right channel is lined with residues 6—20 which are also mainly hydrophobic. The basic groups—including 19 lysines—are segregated into two groups on the surface around the two channels, and there is an acidic surface region between these.

X-Ray analysis of ferrocytochrome⁹¹ shows that this has a more closely packed structure, consistent with its increased resistance to proteolytic digestion, heat denaturation, denaturation at air-water interfaces, and the difficulty of replacement of Met-80 with cyanide or azide. The short C- and N-terminal helices and the peptide attached to the haem (12—18) have the same structure as in the oxidized form (see Figure 8). Nevertheless, there is a dramatic change in residues 77 through 83 on the left side; Phe-82 swings into the channel to block it while Ile-81 swings more to the surface. There is a smaller motion in residues 19 through 25, which results in the blocking of the right channel. Possible mechanisms of electron transfer have been considered: they involve the binding of the cytochrome oxidase to the right-hand side and of the reductase to the left-hand side—each with basic residues. It is postulated that binding of the reductase

⁸⁹ R. E. Dickerson, T. Takano, O. N. Kallai, and L. Samson, in ref. 83.

⁹¹ T. Takano, R. Swanson, O. B. Kallai, and R. E. Dickerson, *Cold Spring Harbor Symposium*, 1972, 36, 397.

⁹² R. E. Dickerson, *J. Mol. Biol.*, 1971, 57, 1.

constrains Phe-82 and Ile-81 to the oxidized structure. An electron is then transferred by way of overlap of aromatic π -electron clouds of Tyr-74 and Tyr-67 to Met-80 and thence to the Fe^{III} . This electron transfer may break a hydrogen bond of Tyr-67 with Thr-78, so that the conformational change to the reduced form is triggered.




Figure 8 The altered conformation of residues 19–25 and 77–82 in reduced cytochrome *c*, superimposed on the oxidized structure (Reproduced by permission from the *Cold Spring Harbor Symposium*, 1972, 36, 397)

Studies of the sequence changes in cytochrome *c* found in 30 species ranging from man through moth to castor bean show that the hydrophobic nature of the haem box is conserved. A number of residues on the left side including the aromatics Trp-59, Tyr-67, and Tyr-74 are conserved, which is consistent with the importance of this part of the molecule to electron transfer. The character of the basic region is also conserved, which explains the observation that cytochrome *c* from one species will react *in vitro* with cytochrome-oxidase preparations from distantly related species.

Model-building studies on bacterial cytochromes⁹³ show that the sequence of cytochrome c_2 from *Rhodospirillum rubrum*, with 114 amino-acids, can be easily accommodated in a similar tertiary structure. The cytochrome c_{551} from *Pseudomonas aeruginosa* containing 82 amino-acids can be fitted only with some difficulty, involving deletions in positions 60–80 as postulated previously. This results in the exposure of one side of the haem. However, a model with deletion of positions 30 through 47 is possible, with much smaller structural modifications.

The structure of calf-liver cytochrome b_5 has been determined⁹³ at 2.8 Å, and more recently at 2 Å resolution.⁹⁴ This protein has a molecular weight of 11 000 and contains 93 amino-acids. It interacts specifically with a flavoprotein, cytochrome b_5 reductase, which catalyses the transfer of electrons from NADH to the haem iron of the cytochrome.

The conformation of the polypeptide chain is shown in Figure 9. There are five short helical regions and four short segments of extended chain which form a pleated sheet structure. The haem group lies in a hydrophobic crevice, which comprises two antiparallel helical segments forming the walls and the pleated sheet structure forming the floor. The haem iron is co-ordinated by histidines 39 and 63. The haem group is oriented so that the vinyl groups are deeply buried while the propionic acid groups are in an aqueous environment, one being bound to the surface of the molecule while the other is free. The arrangement of the haem relative to the polypeptide thus more closely resembles that in myoglobin rather than in cytochrome c , where one of the propionic groups is buried. The surface of the molecule is polar and the protein is soluble. It is now thought that cytochrome b_5 has a further 40 amino-acid residues which are cleaved off when it is solubilized; these residues are involved in binding to the membrane.

A preliminary account of the structure, at 2.25 Å resolution, of the high-potential iron-sulphur protein (HiPIP) of *Chromatium vinosum* is reported by Kraut and co-workers.⁹⁵ As a result of oxidation by the X-ray beam during data collection, the reported structure is a hybrid of unknown proportions of the reduced and oxidized states. The molecule, which comprises 86 amino-acid residues, is a prolate ellipsoid of 35×20 Å built in two halves comprising residues 1–42 and 47–86. The inorganic cluster of four iron and four sulphur atoms lies in a hydrophobic environment between these halves and is bound to cysteines 43, 46, 63, and 77. One turn of 3_{10} helix connects Cys-43 and Cys-46.

The geometry of the iron-sulphur cluster derived from the electron-density map is confirmed by comparison with a ($F_0 - F_c$) difference Fourier (where F_c is calculated from the atomic positions excluding the inorganic and cysteine sulphur atoms) and a Bijvoet difference Fourier. The iron

⁹³ F. S. Mathews, M. Levine, and P. Argos, *Nature New Biol.*, 1971, **233**, 16.

⁹⁴ F. S. Mathews, P. Argos, and M. Levine, *Cold Spring Harbor Symposium*, 1972, **36**, 387.

⁹⁵ C. W. Carter, S. T. Freer, Ng. H. Xuong, R. A. Alden, and J. Kraut, *Cold Spring Harbor Symposium*, 1972, **36**, 381.

atoms are arranged in a tetrahedron with an inorganic sulphur atom bound above each triangular face to three iron atoms; the bond lengths given in Table 3 indicate the presence of covalent iron-iron interactions. At this stage there is no evidence for a distortion from tetrahedral symmetry, as




Figure 9 Stereo drawings of the α -carbons of cytochrome b_5 . The haem group and side-chain atoms of His-39 and -63 are included. Figures (a) and (b) show views parallel and perpendicular to the crystallographic axis c , respectively (Reproduced by permission from the Cold Spring Harbor Symposium, 1972, **36**, 387)

indicated by electron spin resonance and Mössbauer spectroscopy of the protein and actually found in the model compound $(C_5H_5FeS)_4$ (see Table 3).

The structure of rubredoxin, previously reported, has been refined at 1.5 Å resolution by Watenpaugh *et al.*,⁴³ and the sequence is now known. The iron co-ordination appears to have highly significant deviations from tetrahedral geometry. Jensen *et al.*⁹⁶ have also determined the structure of a ferredoxin, which contains two tetrahedral clusters of four iron atoms

⁹⁶ L. Jensen, personal communication.

which resemble the cluster found in the high-potential iron protein. Each iron cluster is co-ordinated to four cysteines and the relation of peptide to cluster in the two cases is very similar.

Table 3 Average bond lengths in the HiPIP cluster and its analogue ⁹⁵

Chromatium HiPIP Cluster				(C ₅ H ₅ FeS) ₄		
Bond type	Mean* /Å	Range /Å	Precision /Å	Bond type	Mean* /Å	Accuracy /Å
Fe—Fe	3.06	3.0–3.1	± 0.14	Fe—Fe	2.650	± 0.006
					3.365	± 0.006
Fe—S _{inorg}	2.35	2.1–2.9	± 0.24	Fe—S _{inorg}	2.206	± 0.002
					2.256	± 0.003
Fe—S _{cys}	2.01	1.8–2.1	± 0.26			
Mean Fe—S distance = 2.28 Å						

*Mean values represent average distances for similar bonds. Precisions given for the HiPIP cluster were calculated from the standard deviations of repeated measurements.

The structure of a clostridial flavodoxin at 3.25 Å is described by Ludwig *et al.*⁹⁷ The flavodoxins are small proteins of molecular weight *ca.* 15 000 which can replace ferredoxins in certain electron-transferring reactions. The proteins contain no iron; rather they have a non-covalently bound flavin mononucleotide prosthetic group. The clostridial flavodoxin crystallizes in space group *P*3₁21 in all oxidation states, but there are changes of cell dimensions and diffracted intensities between them.

A 3.25 Å resolution electron-density map of the semiquinone form shows that flavodoxin is a 'smorgasbord of secondary structures'. The chain folding shown in Figure 10 contains 35% helix, a central region of pleated sheet (one parallel pair and two pairs anti-parallel), and a number of 3₁₀ bends. The exact orientation of the FMN prosthetic group appears to be in some doubt. However, Jensen *et al.*⁹⁸ have recently computed a 2.5 Å electron-density map based on one samarium derivative for a closely related flavodoxin, which shows the same general chain folding and indicates clearly the orientation of the FMN group.

J. Haemoglobins.—Perutz and his colleagues have described a number of experiments designed to test their stereochemical interpretation of the co-operative effects in haemoglobin, presented in 1970. The experiments include *X*-ray studies of chemically modified and mutant haemoglobins.

The constraints which clearly distinguish the deoxy-form from the oxy-structure include the salt bridges formed by the C-terminal residues shown in Scheme 2. Perutz and Ten Eyck have studied crystallographically haemoglobins modified at these groups. 3.5 Å difference electron-density maps on human haemoglobins have shown that removal of histidine

⁹⁷ M. L. Ludwig, R. D. Anderson, P. A. Apgar, R. M. Burnett, M. E. Le Quesne, and S. G. Mayhew, *Cold Spring Harbor Symposium*, 1972, **36**, 369.

formation of the quaternary deoxy-structure even in the total absence of haem ligand. This shows that the subunit contacts in the deoxy-form are stressed even in the absence of oxygen, and that to remain in that conformation the tetramer must be clamped by the salt bridges.

A further series of chemical and X-ray studies lead to similar conclusions. Moffat and his colleagues have shown that in bis-(*N*-maleimidomethyl) ether-oxyhaemoglobin, and related derivatives, reaction at cysteine F9(93) β leads to a displacement of tyrosine HC2(145) β . The resulting disruption of the hydrogen bond formed by the tyrosyl hydroxy-group to the main-chain carbonyl group of valine FG5(98) β is thought to lead to the observed reduction of co-operativity.

Morimoto *et al.*⁹⁹ have interpreted in stereochemical terms the amino-acid* substitutions in abnormal haemoglobins, which produce clinical symptoms by altering the oxygen affinity. They find examples of changed affinity due to residues at the haem pocket which either restrict and/or increase oxygen binding (Zurich, Bristol, Hammersmith, and Bucuresti). They also find changes in residues which stabilize the tertiary structure of either the oxy- or deoxy-form and therefore change the oxygen affinity (Shepherd's Bush, Peterborough, and Agenoni). Finally, they find examples of changes which alter the balance of interactions between subunits (Hirose, Malmo, Yakima, Kempsey, Kansas, and Yoshizuka).

Perutz, Greer, and their colleagues have obtained more-detailed crystallographic information for certain abnormal haemoglobins. Table 4 summarizes the chemical and physiological properties of the mutants so far studied by difference Fourier techniques. Only one of these, haemoglobin M Iwate, crystallizes in a different space group and required a completely new X-ray analysis.

The changes in deoxyhaemoglobin Rainier^{100, 101} are represented schematically in Figure 11. The random mutation at the penultimate residues places a cysteine in a position to form a disulphide with perfect geometry and very little distortion of the rest of the molecule. The presence of the disulphide explains the high resistance of haemoglobin Rainier, particularly of the β -chain, to denaturation by alkali and to digestion by carboxypeptidase.

The two salt bridges made by the C-terminal histidine are disrupted as the terminal residue rotates to an α -helical conformation, and removal of the salt bridges contributes to lowering of the Bohr effect. The α -helical arrangement appears to allow a new hydrogen-bond between the carboxylate at the terminus with the α -amino-group of the opposite β -chain so that the oxy-form is relatively stabilized. This explains the increased oxygen affinity.

⁹⁸ M. F. Perutz and L. F. Ten Eyck, *Cold Spring Harbor Symposium*, 1972, **36**, 295.

⁹⁹ H. Morimoto, H. Lehmann, and M. F. Perutz, *Nature*, 1971, **232**, 408.

¹⁰⁰ J. Greer, *Cold Spring Harbor Symposium*, 1972, **36**, 315.

¹⁰¹ J. Greer and M. F. Perutz, *Nature New Biol.*, 1971, **230**, 261.

Table 4 *Physiological properties of abnormal haemoglobins, the structures of which have been investigated by X-ray diffraction*

Mutant	Position	From	To	n°	Oxygen affinity	Bohr effect ^a	Clinical symptom	X-Ray study of deoxy-haemoglobins (reference number)	
Rainier	β HC2 (145)	Tyr	Cys	1.5	Very high	Halved	Polycythemia	3.5 Å difference Fourier	(104)
Kansas	β G4 (102)	Asn	Thr	1.3	Very low	Large	Cyanosis ^a	5.5 Å difference Fourier	(101)
Richmond	β G4 (102)	Asn	Lys	2.5	Normal	Normal	Normal	4 Å difference Fourier	(101)
Chesapeake	α FG4 (92)	Arg	Leu	1.4	High	Normal	Polycythemia ^b	5.5 Å difference Fourier	(103)
J Capetown	α FG4 (92)	Arg	Gln	2.3	Slightly high	Normal	Normal	5.5 Å difference Fourier	(103)
M Iwate	α F8 (87)	His	Tyr	1.1	Low	None	Cyanosis	5.5 Å X-ray analysis, different space group	(102)
M Hyde Park	β F8 (92)	His	Tyr	1.3	Normal	Normal	Methemoglobinemia	3.5 Å difference Fourier	(102)
Hiroshima	β H24 (146)	His	Asp		High	Halved		3.5 Å difference Fourier	(105)

^a Cyanosis: blue colour of skin owing to deoxyhaemoglobin in capillaries. ^b Polycythemia: excess of red cells. ^c n : Hills constant, a measure of the interaction between the four haem groups. ^d Bohr effect: dependence of oxygen affinity on pH.

In haemoglobins Kansas and Richmond,¹⁰² an asparagine which is close to the haem group is changed. The lysine in this position in haemoglobin Richmond causes only local changes. On the other hand, the replacement of asparagine by threonine in Kansas would cause unfavourable steric




Figure 11 A schematic representation of the structures of deoxyhaemoglobin Rainier and normal deoxyhaemoglobin
(Reproduced by permission from *Cold Spring Harbor Symposium*, 1972, 36, 315)

interactions between the γ -methyl of the threonine and the methyl and vinyl side-chains of the haem group. The difference Fourier indicates that this is avoided by movement not only of the haem but also by helices F β , E β , and B β . These substantial changes give rise to a decrease of cooperativity, oxygen affinity, and Bohr effect.

Haemoglobins M Hyde Park and M Iwate¹⁰³ have a haem-linked histidine replaced by a tyrosine in the β - and α -chains, respectively. In

¹⁰² J. Greer, *J. Mol. Biol.*, 1971, 59, 99.

¹⁰³ J. Greer, *J. Mol. Biol.*, 1971, 59, 107.

deoxyhaemoglobin Hyde Park, 20–30% of β haem groups appear to be lost, but otherwise there are only local changes in structure. However, in haemoglobin M Iwate both the proximal tyrosine (induced by mutation) and the distal histidine appear to bind haem iron. Both the met- and the deoxy-forms have the deoxy-quaternary structure, and this explains the low oxygen affinity.

Crystallographic studies on haemoglobins J Capetown and Chesapeake¹⁰⁴ show that there are no structural distortions in the deoxy-forms of either mutant. On the other hand, replacement of the invariant arginine by leucine at α FG4(92) in Chesapeake appears to lead to impermissible van der Waals contacts in the oxy-form, which give rise to a distorted structure. Possibly in going from deoxy- to oxy-haemoglobin Chesapeake the β_2 -chain moves too far past FG α_1 , thus strengthening the oxy-form and increasing the oxygen affinity.

A crystallographic study of haemoglobin Hiroshima¹⁰⁵ has shown that the previously proposed amino-acid substitution histidine 143(H21) β to aspartic acid is incorrect. Although this change might account for a diminished Bohr effect, the normal response of its oxygen affinity to 2,3-DPG was inconsistent with the proposed role of histidine 143 in 2,3-DPG binding by haemoglobin. Difference electron-density maps of deoxyhaemoglobin Hiroshima have now revealed that the replacement occurs not in position 143 but in 146, thus supporting the role of histidine 146 β in the alkaline Bohr effect. These results have been confirmed by chemical methods.

The structure of horse carboxyhaemoglobin labelled with the spin label *N*-(1-oxyl-2,2,6,6-tetramethyl-4-piperidinyliodoacetamide) has been determined.¹⁰⁶ The label has two orientations, which correspond to the weakly immobilized and strongly immobilized components of the e.s.r. spectra found in solution and in crystals. One is free and the other displaces the C-terminus of the β -chain, causing perturbations in the β -chains, and to a lesser extent in the α -chains.

The small-angle scattering functions of haemoglobin for X-rays and neutrons have been calculated from the atomic co-ordinates of haemoglobin.¹⁰⁷ The theoretical scattering functions were compared with the experimental, and the good agreement gives confidence to the statement that the three-dimensional structures of haemoglobin in single crystals and in aqueous solution are the same.

The three-dimensional structures of a number of monomeric myoglobins and haemoglobins have been reported. As expected, all have the myoglobin

¹⁰⁴ J. Greer, *J. Mol. Biol.*, 1971, **62**, 241.

¹⁰⁵ M. F. Perutz, P. del Pulsinelli, L. Ten Eyck, J. V. Kilmartin, S. Shubata, I. Fuchi, T. Miyaji, and H. B. Hamilton. *Nature New Biol.*, 1971, **232**, 149.

¹⁰⁶ J. K. Moffat, *J. Mol. Biol.*, 1971, **55**, 135.

¹⁰⁷ R. Schneider, A. Mayer, W. Schmatz, J. Schelten, R. Franzel, and H. Eicher, *European J. Biochem.*, 1971, **20**, 179.

fold. The course of evolution of these globins is shown in Figure 12, and the percentage mismatch between pairs is illustrated in Table 5.




Figure 12 *Haemoglobin evolution. The line running from lower right to upper left represents the main course of evolution*

Table 5 *Percentage mismatch between pairs of amino-acid sequences from some globins*

Horse α Hb	54				
Lamprey Hb	75	70			
Sperm whale Mb	72	74	75		
<i>Glycera</i> Hb	77	77	80	76	
<i>Chironomus</i> Hb	82	79	79	79	85
	Horse β	Horse α	Lamprey	Sperm whale	<i>Glycera</i>

Huber *et al.*¹⁰⁸ compare the structure of the insect-larval haemoglobin from *Chironomus* (earlier mistakenly named erythrocrutorin) with the structure of sperm-whale myoglobin. They show that although only 21% of the amino-acids are identical in both proteins, the structures are closely similar. Of particular note is the absence of the distal histidine E7. This is invariant in all the known vertebrate haemoglobins, but in *Chironomus* is replaced by a glutamate, which protrudes into the surrounding solution. This indicates that a histidine is not essential for the function of haemoglobin as a reversible oxygen carrier.

¹⁰⁸ R. Huber, O. Epp, W. Steigemann, and H. Formanek, *European J. Biochem.*, 1971, 19, 142.

Love *et al.* have determined the structures of two other evolutionary remote haemoglobins.¹⁰⁹ The structure of lamprey haemoglobin determined^{109, 110} at 2 Å resolution shows that the extra C-terminal nonapeptide runs in an extended configuration along the H helix, making two hydrogen bonds and covering a methionine and an isoleucine which would otherwise be exposed to the solvent. A deletion of nine residues, G18 to H2, is accommodated by a shortening of the G and H helices. The structure of the annelid worm *Glycera* haemoglobin has been determined¹⁰⁹ at 2.5 Å resolution. The structure is similar to that of sperm-whale myoglobin. As in the *Chironomus* haemoglobin, the distal residue is not histidine, but in this case leucine. Lattman *et al.*¹¹¹ have shown that, at least at low resolution, yellow tuna-fin myoglobin has a similar 'myoglobin fold'.

At the present time the relation of structure to physiology has not been fully worked out for lamprey and *Glycera* haemoglobins, and further studies are under way. The study of the insect larval *Chironomus* haemoglobin is more advanced. This haemoglobin has been shown to undergo a conformational change in the crystalline state between pH 7 and pH 5.5, which is thought to be related to the dissociation of haem and globin at acidic pH, and may also give rise to the large changes in oxygen affinity observed in solution.¹¹²

K. Concanavalin A.—The structure of concanavalin A from jack bean has been studied in a number of different laboratories. This plant protein is capable of agglutinating various types of cells and inducing cellular transformation and mitosis. Each subunit of molecular weight 27 000 contains three mutually interacting binding sites for polysaccharides, Mn^{2+} , and Ca^{2+} . The protein aggregates to dimers below pH 6 and to tetramers above pH 7, and the subunit structure giving rise to more than one site may be responsible for the agglutination.

X-Ray studies on the same crystal form have been carried out in three different laboratories and are reported by Quiocho *et al.*^{113, 114} and by Hardman *et al.*¹¹⁵ Patterson syntheses have confirmed the space group as *I*222 with one subunit per asymmetric unit. The two electron-density maps, computed independently at 4 Å, are of very good quality with figures of merit 0.79 and 0.78. Electron-density maps at higher than 3 Å resolution

¹⁰⁹ W. E. Love, P. A. Klock, E. E. Lattman, E. A. Padlan, K. B. Ward, and W. A. Hendrickson, *Cold Spring Harbor Symposium*, 1972, **36**, 349.

¹¹⁰ W. A. Hendrickson and W. E. Love, *Nature New Biol.*, 1971, **232**, 197.

¹¹¹ E. E. Lattman, C. E. Nockolds, R. H. Kretsinger, and W. E. Love, *J. Mol. Biol.*, 1971, **60**, 271.

¹¹² R. Huber, O. Epp, and H. Formanek, *J. Mol. Biol.*, 1971, **57**, 377.

¹¹³ F. A. Quiocho, G. N. Reeke, J. W. Becker, W. N. Lipscomb, and G. M. Edelman, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1853.

¹¹⁴ G. N. Reeke, J. W. Becker, and F. A. Quiocho, *Cold Spring Harbor Symposium*, 1972, **36**, 277.

¹¹⁵ K. D. Hardman, M. K. Wood, M. Schiffer, A. B. Edmundson, and C. F. Ainsworth, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1393; *Cold Spring Harbor Symposium*, 1972, **36**, 271.

have also been computed, but their interpretation has not been published. The sequence is at present unknown.

Each subunit has a half ellipsoidal shape with base $46 \times 26 \text{ \AA}$ and height 42 \AA . The dimers are elongated ellipsoids formed by subunits related by the crystallographic two-fold axis parallel to the c axis. The dimers are paired at greater distances across points of 222 symmetry to form tetrahedral tetramers. Although large portions of the polypeptide chain can be clearly traced, an unambiguous interpretation has not been possible at this stage. However, a large depression on each subunit may be the binding site for saccharides, and this has been positively identified by difference Fourier studies at 2.8 \AA resolution.¹¹⁶ The metal-free protein has been crystallized in space group $P2_12_1$ with unit cell dimensions nearly equal to those of the native crystals,¹¹⁷ but with the asymmetric unit containing a dimer. The crystals revert to a form close to the native structure on soaking in Mn^{2+} and Ca^{2+} ions. Studies at 5.5 \AA resolution using the rotation and translation functions indicate the presence of a two-fold local axis at 7° to the c axis with a screw component involving a translation of $6 \pm 2 \text{ \AA}$ relative to this axis. These results are thought to indicate a large conformational change on demetallization.

L. Toxins.—Crystallographic studies on the small neurotoxic proteins of snake venoms are an important and exciting area of study which surely must attract much attention in the future. Low and her colleagues¹¹⁸ have now described their preliminary X -ray studies on two such toxins, erabutoxin a and erabutoxin b from the sea snake *Laticauda serrifasciata*. These toxins each have 62 amino-acids and differ only at one position in the sequence. They form isomorphous crystals of space group $P2_12_1$ and all dimensions are given in Table 6. Histidine 26 of erabutoxin b has been

Table 6 Cell parameters and estimated standard deviations for orthorhombic crystals of erabutoxins a and b and di-iodoerabutoxin b

Cell parameters	Erabutoxin a	Erabutoxin b	Di-iodoerabutoxin b
$a/\text{\AA}$	50.0 ± 0.1	49.76 ± 0.05	51.5 ± 0.5
$b/\text{\AA}$	46.5 ± 0.1	46.77 ± 0.04	47.4 ± 0.1
$c/\text{\AA}$	21.2 ± 0.1	21.58 ± 0.02	21.8 ± 0.1

specifically di-iodinated and this gives crystals which have the same space group and closely related cell dimensions to the native protein as shown in Table 6. All crystal forms appear to give good quality diffraction patterns, and data to 1.8 \AA resolution have been collected on the erabutoxin b .

M. Hormones.—Further details of the structure of zinc insulin hexamers based on a 2.8 \AA resolution electron-density map (see Figures 13 and 14)¹¹⁹

¹¹⁶ J. W. Becker, G. N. Reeke, and G. M. Edelman, *J. Biol. Chem.*, 1971, **247**, 6123.

¹¹⁷ A. Jack, J. Weinzierl, and A. J. Kalb, *J. Mol. Biol.*, 1971, **58**, 389.

¹¹⁸ B. W. Low, *J. Biol. Chem.*, 1971, **246**, 4366.

¹¹⁹ T. L. Blundell, J. F. Cutfield, S. M. Cutfield, E. J. Dodson, G. G. Dodson, D. C. Hodgkin, D. A. Mercola, and M. Vijayan, *Nature*, 1971, **231**, 506.

and the relation of the structure to the chemistry, sequence variation, and biological role of insulin have been discussed.¹²⁰

There is now a considerable body of evidence for the view that in solutions approximating physiological conditions, insulin retains an ordered and stable structure and resembles crystalline insulin.¹²⁰ The




Figure 13 *The atomic positions in the insulin monomer*

residues which form the compact non-polar core of the molecule are conserved in the twenty sequenced insulins. Chemical studies designed to examine the availability of different functional groups—whether they are buried or exposed—and also to study the geometric relations between parts of the molecule are in general agreement with the X-ray model. The general tertiary structure appears to be common to insulins of fishes and mammals, and is conserved in solution. These are features which are common to most enzyme structures, but may not be true of smaller polypeptide hormones. Evidence is presented concerning the three-dimensional structure and the role of the connecting peptide of proinsulin, the mode of

¹²⁰ T. L. Blundell, E. J. Dodson, G. G. Dodson, D. C. Hodgkin, and M. Vijayan, *Recent Progr. Hormone Res.*, 1971, 20, 1.




Figure 14 *The atomic positions in the insulin dimer as viewed along the local approximate two-fold axis*

storage of insulin in β granules, the aggregation of insulins of different species, and the active region of the molecule.

Preliminary *X*-ray and diffraction studies are reported for small crystals (1–5) of angiotensinamide II.¹²¹

N. Plasma Proteins.—Preliminary *X*-ray studies of the plasma protein prealbumin are reported.¹²² Prealbumin has a strong interaction with retinol (vitamin A alcohol) binding protein, and its principal function appears to relate to plasma transport of vitamin A, rather than *L*-thyroxine, which it also binds. The protein crystallizes in the orthorhombic system, but the molecular symmetry of the prealbumin molecule gives rise to pseudo body-centring. This has confused attempts to fix the space group, which now appears to be $P2_12_1$. The molecule is a tetramer of molecular weight $54\,000 \pm 5000$, composed of subunits with identical, or possibly two slightly different, tertiary structures arranged tetrahedrally.

O. Immunoglobulins.—Crystallographic studies of immunoglobulins are under way in a number of laboratories. These include studies of complete immunoglobulin molecules, of Bence-Jones proteins, and of fragments.

Davies and his colleagues have succeeded in obtaining a 6 Å resolution electron-density map of a human γ G1 immunoglobulin molecule.^{123, 124} This myeloma protein contains two light polypeptide chains of molecular weight 22 500 each and two heavy polypeptide chains of molecular weight 53 000, held together by disulphide bonds and by non-covalent forces. The crystals of space group $C2$ contain two immunoglobulin molecules of molecular weight 150 000. There is one half-molecule per asymmetric unit and the crystallographic two-fold axis coincides with the molecular two-fold axis relating the two halves of the molecule.

The *X*-ray data extend to *ca.* 4.5 Å resolution, but their quality is low outside the 6 Å sphere. The extreme sensitivity of the crystals of immunoglobulin to *X*-radiation presented considerable difficulties and *ca.* eight crystals were required to collect the 2000 reflections in the 6 Å sphere. The crystals were also very sensitive to many heavy-atom salts, but nevertheless three good derivatives have been prepared by soaking the crystals in (a) 10^{-3} M *p*-chloromercuribenzenesulphonate, (b) 10^{-2} M mercuric cyanide, (c) 10^{-3} M chloroplatinate ion. An electron-density map has been calculated at 6 Å with an average figure of merit of 0.73. The authors have not tried to interpret the chain folding at this resolution, rather they have attempted to define the boundary and the shape of the immunoglobulin molecule. The density in the region of the dyad axis at $z = 0$ has indicated

¹²¹ S. Fermandjian, J. L. Morgat, P. Fromageot, C. Legressus, and P. Maire, *F.E.B.S. Letters*, 1971, **16**, 192.

¹²² C. C. F. Blake, I. D. A. Swan, C. Rerat, J. Berthou, A. Laurent, and B. Rerat, *J. Mol. Biol.*, 1971, **61**, 217.

¹²³ V. R. Sarma, E. W. Silverton, D. R. Davies, and W. D. Terry, *J. Biol. Chem.*, 1971, **247**, 3753.

¹²⁴ L. W. Labaw and D. R. Davies, *J. Biol. Chem.*, 1971, **247**, 3760.

that this is the molecular axis. The density appears to be located in three globular regions. One of these regions around the dyad axis most probably corresponds to the F_c (the complement) fragment while the other two are related by the dyad axis and may be the F_{ab} (the antibody) fragments. The most difficult task has been to join the F_{ab} regions to the F_c region. There are four possible arrangements of which the T model is favoured.

These same immunoglobulin crystals have also been the subject of a study in the electron microscope.¹²⁵ The molecule in projection appears to have a shape varying between a Y and a T, in agreement with previous electron microscope studies and the X-ray diffraction investigation.

Edmundson *et al.*¹²⁶ also report crystallization and X-ray studies of a serum IgG (in this case a euglobulin) from a patient with multiple myeloma. Prismatic crystals as large as $0.6 \times 0.6 \times 3.0$ mm are obtained by a dialysis against deionized water at 4 °C using a microdiffusion method. Unfortunately—because they are grown at low ionic strength—the crystals dissolve when placed in certain solutions of heavy atoms. However, attempts to introduce ammonium or sodium sulphate into the crystals to which heavy atoms could be added without affecting the solubility were unsuccessful. The prismatic crystals have space group $C22_1$, with the asymmetric unit continuing one half-molecule, or one light and one heavy chain. The two halves are related by a two-fold rotation axis as in the cryoglobulin of Sarma *et al.*¹²³ The euglobulin crystals are less sensitive to radiation damage than those of the cryoglobulin, and reflections extend to 3.5 Å resolution.

Edmundson *et al.*¹²⁶ have also studied crystals of the λ -type Bence-Jones protein (the light chain of the immunoglobulin) from the same myeloma patient. The protein crystallizes in orthorhombic form from deionized water and as a trigonal form from ammonium sulphate. The orthorhombic form of space group $P2_12_12$ contains the M—S—S—M dimer. As with the euglobulin, the salt-free crystals dissolved in most heavy-atom compounds, but $PtCl_4^{2-}$ made the crystals less soluble, after which they could be treated by dilute solutions of heavy-atom salts; the rotation function has demonstrated the existence of a local two-fold axis, and a preliminary 6 Å map has been calculated based on the chloroplatinite derivative. The trigonal form also contains the M—S—S—M dimer. Unlike the orthorhombic form, the preparation of heavy-atom derivatives was not hampered by solubility problems in the trigonal form. Heavy-atom positions of three derivatives are being refined with a view to computation of a 6 Å map.

X-Ray studies of a second Bence-Jones protein of antigenic type (κ) are being carried out in Munich by Epp *et al.*¹²⁷

¹²⁵ V. R. Sarma, D. R. Davies, L. W. Labaw, E. W. Silverton, and W. D. Terry, *Cold Spring Harbor Symposium*, 1972, **36**, 413.

¹²⁶ A. B. Edmundson, M. Schiffer, M. K. Wood, K. D. Hardman, K. R. Ely, and C. F. Ainsworth, *Cold Spring Harbor Symposium*, 1972, **36**, 427.

¹²⁷ O. Epp, R. Huber, and W. Stergemann, unpublished results.

X-Ray studies on the F_{ab} fragments prepared by papain and pepsin fragmentation of human myeloma IgG's are being carried out by Poljak *et al.*¹²⁸ The preparation of heavy-atom derivatives has caused considerable difficulties. A 6 Å electron-density map has been computed, which shows two clear domains (unpublished work) and is clearly of good quality. The data have been collected to 3.5 Å resolution, and refinement of the heavy-atom positions of the derivatives has been completed and an electron-density map computed.

P. Muscle Proteins.—Kretsinger *et al.* have grown crystals and reported preliminary crystal data of three of the lower molecular weight albumins of carp.¹²⁹ They have succeeded in solving the structure at 2 Å resolution of one, a calcium-binding protein, which may be analogous to troponin-A of mammalian and avian muscle. It has a high percentage of phenylalanine (10%) and alanine (20%), little or no tryptophan, tyrosine, methionine, histidine, cystine, or arginine. The interpretation of the electron-density map was achieved by fitting the sequenced tryptic and thermolytic peptides with the aid of the homologous hake albumin sequence.

The polypeptide chain comprises 107 residues. There are three helices involving residues 42—50, 77—87, and 98—106. The molecule is a prolate spheroid with the amino-terminal tucked in so that the ten phenylalanines, which are invariant between hake and carp, are in internal positions. Two spherical peaks in the electron density are interpreted as calcium ions (Kretsinger, unpublished results).

X-Ray diffraction and electron microscopy studies of tropomyosin crystals by Cohen and co-workers¹³⁰ indicate that the crystal dynamics may be analogous to structural changes regulating contractile activity of muscle. Tropomyosin is a two-stranded α -helical coiled-coil which forms macroscopic crystals. As the crystals contain 95% water in the lattice they are quite disordered and show a mosaic spread of not less than 1° in their X-ray pictures. Nevertheless, by using electron micrographs to phase the X-ray projection data, Fouriers have been computed for the [100] and [001] views (see Figure 15), from which a model has been derived. The tropomyosin molecules, each 400 Å long, are bonded head-to-tail and cross-connected. The diagonally oriented strands observed in micrographs consist of a pair of parallel molecular filaments each 20 Å in diameter and separated by *ca.* the same distance. Separation between cross-over points in the lattice is alternately short (165—175 Å) and long (225—235 Å) and these dimensions are found in all polymorphic forms. The alternation of distances gives rise to a bending of the filaments. There is a continuous

¹²⁸ R. J. Poljak, L. M. Amzel, H. P. Avey, L. N. Becka, D. J. Goldstein, and R. L. Humphrey, *Cold Spring Harbor Symposium*, 1972, 36, 421.

¹²⁹ R. H. Kretsinger, C. E. Nockolds, C. J. Coffee, and R. A. Bradshaw, *Cold Spring Harbor Symposium*, 1972, 36, 217.

¹³⁰ C. Cohen, D. L. D. Caspar, D. A. D. Parry, and R. M. Lucas, *Cold Spring Harbor Symposium*, 1972, 36, 205.

range of lattice parameters of the tropomyosin crystals, which appears to be dependent on tryponin binding in the crystals. The changes in the crystals correspond to a scissor-like motion of the molecules relative to each other. An analogous structural change may occur when the filaments are bound in the grooves of the actin helix, and this may be the mode of communication between the calcium-binding troponin complex and actin.




Figure 15 Electron-density maps of [100] projection of two crystal forms of tropomyosin
(Reproduced by permission from *Cold Spring Harbor Symposium*, 1972, 36, 205)

Harrison *et al.*¹³¹ discuss the assembly of myosin. They have determined by *X*-ray analysis the helical arrangement of bridges on the thick filament. Placing rods of length 1450 Å on this surface lattice generates the molecular overlaps found in *in vitro* 'segment' aggregates.

Q. Viruses.—The Cold Spring Harbor Symposium has brought together a number of *X*-ray studies of viruses, and has shown how these studies relate to investigations on the mechanism and control of virus assembly.

Barrett *et al.*¹³² review the advances in *X*-ray techniques which have led to the present 10 Å resolution electron-density map of tobacco mosaic virus. Four heavy-atom derivatives of this helical virus have been used to calculate phase angles. Comparison of *X*-ray data for the virus with that for the repolymerized helical protein without RNA indicates that the RNA forms a helix having a radius of *ca.* 38 Å. A chain can be followed through

¹³¹ R. G. Harrison, S. Lowey, and C. Cohen, *J. Mol. Biol.*, 1971, 59, 531.

¹³² A. N. Barrett, J. Barrington Leigh, K. C. Holmes, R. Leberman, E. Mandelkow, P. von Sengbusch, and A. Klug, *Cold Spring Harbor Symposium*, 1972, 36, 433.

the electron density and this polypeptide forms a herring-bone pattern at the intersubunit contact. Three-dimensional image reconstruction of electron micrographs by Finch and Klug¹³³ are broadly consistent with this model. Studies with an electron microscope and ultracentrifuge¹³⁴⁻¹³⁸ indicate the way in which the tobacco mosaic virus aggregates to form this structure. The aggregation involves the intermediate formation of discs, built of rings of 17 subunits, which have also been studied by X-ray diffraction¹³⁹ and electron microscopy.¹⁴⁰ The initiation of the growth of the nucleoprotein helix is thought to be the binding of RNA to two protein discs which then dislocate into 'lock-washers' before further discs are stacked and dislocated to give the helix.

The use of the rotation function to study the arrangement of subunits in spherical viruses has led to some interesting discussion.¹⁴¹ A preliminary analysis of the X-ray data on the satellite tobacco necrosis virus crystals indicated that these might have octahedral rather than icosahedral symmetry. However, all solutions to the rotation function originally considered involved a particle two-fold axis parallel to the monoclinic two-fold axis. It has been demonstrated that if this restriction is relaxed, octahedral symmetry is generated in the Patterson by the packing of two virus particles of icosahedral symmetry.¹⁴² This special icosahedral solution appears to be definitely preferable to the octahedral solution.

Icosahedral structures with triangulation numbers of $T = 7$ and 3 are indicated by three-dimensional image reconstruction of human wart virus and tomato bushy stunt virus,¹⁴³ and a three-dimensional X-ray analysis at 30 Å resolution of the bushy stunt virus is consistent with this interpretation.¹⁴⁴

Although a complete virus is rather large to handle by presently available techniques, a study of the six-co-ordinated morphological units (hexons) from the surface of the adenovirus seems more feasible. The adenovirus type-2 hexon, which has a molecular weight of *ca.* 333 000, forms bi-pyramidal crystals of length up to 0.6 mm.¹⁴⁵ These have four hexons in a cubic unit cell with $a = 149.9$ Å, space group $P2_13$. Tetrahedral crystals of type-5 adenovirus hexon seem to be isomorphous with the type-2

¹³³ J. T. Finch and A. Klug, *Phil. Trans.*, 1971, **B261**, 211.

¹³⁴ P. J. G. Butler and A. Klug, *Nature New Biol.*, 1971, **229**, 47.

¹³⁵ A. C. H. Durham and A. Klug, *Nature New Biol.*, 1971, **229**, 42.

¹³⁶ A. C. H. Durham, J. T. Finch, and A. Klug, *Nature New Biol.*, 1971, **229**, 37.

¹³⁷ A. Klug and A. C. H. Durham, *Cold Spring Harbor Symposium*, 1972, **36**, 449.

¹³⁸ P. J. G. Butler, *Cold Spring Harbor Symposium*, 1972, **36**, 461.

¹³⁹ P. F. C. Gilbert, Ph.D. Thesis, University of Cambridge, 1970.

¹⁴⁰ R. A. Crowther and L. A. Amos, *J. Mol. Biol.*, 1971, **60**, 123.

¹⁴¹ K. Akervall, B. Strandberg, M. G. Rossmann, U. Bengtsson, K. Fridborg, H. Johannisen, K. K. Kanan, S. Lövgren, G. Petef, B. Öberg, D. Eaker, S. Hjerlén, L. Rydén, and I. Moring, *Cold Spring Harbor Symposium*, 1972, **36**, 469.

¹⁴² A. Klug, *Cold Spring Harbor Symposium*, 1972, **36**, 483.

¹⁴³ R. A. Crowther and L. A. Amos, *Cold Spring Harbor Symposium*, 1972, **36**, 489.

¹⁴⁴ S. C. Harrison, *Cold Spring Harbor Symposium*, 1972, **36**, 495.

¹⁴⁵ R. M. Franklin, U. Pettersson, K. Akervall, B. Strandberg, and L. Philipson, *J. Mol. Biol.*, 1972, **57**, 383.

crystals.¹⁴⁶ The diffraction patterns are of good quality to 2.8 Å resolution. The hexon contains three dimers (the asymmetric unit) related by a crystallographic three-fold axis. The present work indicates that the hexon does not have six-fold rotational symmetry, but that there may be an approximate dyad perpendicular to the three-fold axis. However, studies on hexon groups of nine suggest the hexon must be a polar oligomer, emphasizing that the perpendicular dyad must be interpreted with caution.¹⁴⁷

5 Fibrous Proteins

A. Keratins.—It is known that keratins giving the 'α-pattern' contain α helices coiled in pairs as two-stranded ropes, and it has been thought previously that these 'ropes' have an axial period of 198 Å. Fraser and MacRae¹⁴⁸ have used a high-resolution focusing X-ray camera to obtain diffraction patterns from several native keratins, and find that calculations based on the 198 Å period give discrepancies considerably in excess of experimental error between calculated and observed values of reflexions in their fibre X-ray patterns. Instead they suggest a 470 Å axial period, in which the microfibrils have an initial screw axis with 19 units in two turns. The pseudo-period of 198 Å is thought to be a consequence of the fact that units separated by this distance have almost identical environments, rather than an indication of molecular dimensions.

Fraser *et al.*¹⁴⁹ also present a model for feather keratin in which the two β-sheet units are symmetrically disposed about the fibre axis. These are built into a helical structure with four pairs of units per turn.

B. Silks.—Several investigations are relevant to the structure of silks, which may contain between 20 and 60% glycine. The structures of small crystals of poly-(L-Ala-Gly-Gly-Gly) I and II (AGGG I and II), poly-(L-Ala-Gly-Gly) II (AGG II), and poly-(L-Ala-Gly) II (AG II) have been studied by X-ray powder diffraction, selected-area electron diffraction, and electron microscopy.^{150–152} AGGG II has a structure similar to that of polyglycine II. AGG II has a structure also based upon a 3₁-helical conformation, but is composed of double layers of helices probably bridged by hydrogen-bonded water molecules. The unit cell of AG II is orthorhombic with cell dimensions $a = 4.72$ Å, $b = 14.4$ Å, and $c = 9.6$ Å. The structure proposed has dihedral angles alternately in the α- and β-conformations, and the resulting chains form hydrogen-bonded sheets. They have a screw-axis repeat of 9.6 Å resembling a highly contracted β-form. The powder diffraction pattern resembles that of silk I which

¹⁴⁶ G. Cormick, P. B. Sigler, and H. S. Ginsberg, *J. Mol. Biol.*, 1971, **57**, 397.

¹⁴⁷ R. M. Franklin, S. C. Harrison, U. Pettersson, L. Philipson, C. I. Brandén, and P.-E. Werner, *Cold Spring Harbor Symposium*, 1972, **36**, 503.

¹⁴⁸ R. D. B. Fraser and T. P. MacRae, *Nature*, 1971, **233**, 138.

¹⁴⁹ R. D. B. Fraser, T. P. MacRae, D. A. D. Parry, and E. Suzuki, *Polymer*, 1971, **12**, 35.

¹⁵⁰ B. Lotz and H. D. Keith, *J. Mol. Biol.*, 1971, **61**, 195.

¹⁵¹ B. Lotz and H. D. Keith, *J. Mol. Biol.*, 1971, **61**, 201.

¹⁵² J. C. Andries, J. M. Anderson, and A. G. Walton, *Biopolymers*, 1971, **10**, 1049.

suggests that this protein has a similar structure. AGG I possesses a supercoiled cross- β structure, long fibres of which show some twisting and intertwining.

C. Collagen.—Miller and Wray¹⁵³ describe the equatorial X-ray pattern of collagen fibrils and discuss the implications as to the lateral packing of the tropocollagen molecules, which are 2900 Å long, 15 Å wide, and have a triple-helical conformation. They propose a model involving a five-stranded rope.

The role of the tripeptide sequence Ala-Pro-Gly in the structure of collagen has been studied by X-ray analyses of oligomers and of a polymer containing this sequence.¹⁵⁴ The polymer and oligomers longer than the hexapeptide can adopt three different types of structure, two of which are composed of polyproline II-like helices, and the other is a triple helix. Solution studies show the polymer to be unordered in aqueous solution. Thus there is a striking difference of (Ala-Pro-Gly) from the previously studied (Pro-Ala-Gly), which is triple helical both in solid and in solution. The two sequences appear to have different roles in collagen structure.

D. Flagella.—X-Ray and optical diffraction patterns of flagella of different species of bacteria are closely similar¹⁵⁵ and show a 52 Å periodicity and width of 130–115 Å. The data are consistent with a helical arrangement of subunits having an 8₄ screw-axis.

PART III: Conformation and Interaction of Peptides and Proteins in Solution
edited by R. H. Pain, with contributions by P. M. Bayley, J. R. Brocklehurst, C. E. Johnson, G. Kellett, N. C. Price, H. W. E. Rattle, B. Robson, and R. M. Stephens

1 Theoretical Aspects of Protein Structure

contributed by B. Robson

There has been continuing interest in the possibility of predicting the conformation of a protein by starting simply with its amino-acid sequence. This section considers relevant work published subsequent to (or not covered by) the discussion of this topic in Volume 1¹ and other recent reviews^{2–5} on related subjects.

A. The General Approach using Energy Functions.—The method of predicting protein conformation using energy functions follows from experimental

¹⁵³ A. Miller and J. S. Wray, *Nature*, 1971, **230**, 437.

¹⁵⁴ B. B. Doyle, W. Traub, G. P. Lorenzi, and E. R. Blout, *Biochemistry*, 1971, **10**, 3052.

¹⁵⁵ J. N. Champress, *J. Mol. Biol.*, 1971, **56**, 295.

¹ P. M. Hardy, in 'Amino-acids, Peptides, and Proteins', ed. G. T. Young (Specialist Periodical Reports), The Chemical Society, London, 1969, **1**, 127.

² G. N. Ramachandran and V. Sasisekharan, *Adv. Protein Chem.*, 1968, **23**, 283.

³ H. A. Scheraga, *Chem. Rev.*, 1971, **71**, 195.

⁴ J. F. Brandts, in 'Structure and Stability of Biological Macromolecules' ed. S. N. Timasheff and G. D. Fasman, Marcel Dekker, New York, 1969, **2**, 213.

⁵ C. Tanford, *Adv. Protein Chem.*, 1970, **24**, 1.

evidence^{6, 7} that the native conformation of a protein is the conformation of lowest free energy which is available to it. This may exclude some cases in which there have been changes in covalent structure since biosynthesis.

The magnitude of the task requires a computer-aided approach. Firstly, a suitable representation of the covalent structure of the molecule is provided as input or is generated by the computer from the specified amino-acid sequence using, for example, a dictionary of data for the residue types and the tree concept of structure representation.⁸ Secondly, the conformational variables may be split into two data sets, one containing those bond-rotation angles which may be usefully varied, and the other containing the bond lengths and the angles between the bonds. This division is arbitrary but useful, since the former set represents both those variables that are most usually adjusted or preset by operator intervention, and the 'soft variables' in the sense used by Scheraga.³ Thirdly, the conformational energy is calculated as the sum of intrinsic bond-rotation potentials and of van der Waals, electrostatic, and hydrogen-bonding energies, estimated for every pair of interacting atoms. Because of theoretical and computational difficulties, interactions are treated as pair interactions despite the possibility that more-exact calculations may involve a many-body potential, as has been suggested for the van der Waals potential.⁹ A complete calculation should also take account of interactions with the solvent. Finally, the energy calculation is repeated again and again under the control of a procedure for minimizing the free energy of the molecule with respect to the conformational variables.

The principal problem in the above procedure is the complexity of the energy surface, which contains many minima. The search for better procedures for locating the global minimum continues, and a recent method¹⁰ is applicable to a discontinuous energy surface such as might in practice be encountered when taking the solvent conformation into account. The rapid increase in the complexity of the energy surface with molecular size accounts for the continued popularity of the small cyclic peptide gramicidin S as a testing ground for different computational methods.¹¹

It is necessary to note that a great deal of the work which has been done is based on an essentially static view of polypeptide conformation, whereas there are also internal vibrations and possibly also bond rotations which should be included in the free energy.^{3, 12} The reader is also referred to recent work^{13, 14} on the phonons of α -helices for a more dynamic picture.

⁶ C. B. Anfinsen, *Brookhaven Symp. Biol.*, 1962, **15**, 184.

⁷ C. B. Anfinsen, *Harvey Lectures*, 1967, **61**, 95.

⁸ J. Hermans and D. Ferro, *Biopolymers*, 1971, **10**, 1121.

⁹ I. R. McDonald and K. Singer, *Ann. Reports (A)*, 1970, **67**, 45.

¹⁰ S. N. Ghani, *Computer Aided Design*, 1972, **4**, 71.

¹¹ P. De Santis and A. M. Liquori, *Biopolymers*, 1971, **10**, 699.

¹² D. A. Brand, W. G. Miller, and P. J. Flory, *J. Mol. Biol.*, 1966, **23**, 47.

¹³ K. Itoh and T. Shimanouchi, *Biopolymers*, 1970, **9**, 383.

¹⁴ B. Fanconi, E. W. Small, and W. L. Peticolas, *Biopolymers*, 1971, **10**, 1277.

B. Solvent Effects.—There is currently no detailed understanding of the conformation of water around specific groups in specific conformations, and it remains to be seen just how good this understanding needs to be before satisfactory predictions of polypeptide conformation can be made. The most useful information at present in the prediction of the conformation of globular proteins is that the interior of a globular protein tends to consist of well-packed non-polar groups.¹⁵ Such a tendency is usually interpreted as the formation of a large number of 'hydrophobic interactions' between non-polar groups as a necessary prerequisite for a stable globular structure. Studies on the nature of this bond continue.^{16, 17} For the purpose of estimating the decrease in free energy when a group is transferred to the non-polar interior of a protein, an empirically derived scale of hydrophobicities has recently been constructed.¹⁸ The restriction which a distribution of polar and non-polar residues places on the geometry of the stably folded protein molecule, and the exposure to the solvent of the two classes, has been considered.¹⁹ These considerations suggest that introducing an artificial force of attraction between non-polar groups might be a reasonable choice for a first approximation. However, in using such an approximation it should not be forgotten that the van der Waals and hydrogen-bonding interactions with the solvent, as well as the high dielectric constant of the water environment, are all more or less independent factors which should be considered in their own right.

A great deal of work has been carried out neglecting solvent effects, *i.e.* *in vacuo*. However, although the system whose free energy is to be minimized consists both of the polypeptide and its surrounding solvent, the predominating importance of the van der Waals repulsive forces between the atoms of the polypeptide,² coupled with the fact that many parts of the polypeptide chain for which alternative possible conformations are to be compared are within the interior of the protein and away from the solvent, means that useful information can be obtained even when the solvent is neglected.

C. Studies on the Conformation of Single Residues using Energy Functions.—Because of the problem of multiple minima, there has been considerable interest in studying the conformational energies of individual residues; these continue to be *in vacuo* calculations. At the very least, such studies point to high-energy conformations for each residue which should be excluded from the search for the global energy minimum except as a last resort. At best, they may point to a small number of well-defined minima for the conformation of each residue, of which one might hopefully be the conformation of that residue in the stably folded protein. In the latter case,

¹⁵ B. Lee and F. M. Richards, *J. Mol. Biol.*, 1971, **55**, 379.

¹⁶ S. Lewin, *Nature*, 1971, **231**, 80.

¹⁷ A. Ray, *Nature*, 1971, **231**, 313.

¹⁸ Y. Nozaki and C. Tanford, *J. Biol. Chem.*, 1971, **246**, 2211.

¹⁹ R. E. Gates and H. F. Fisher, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2928.

we have the notion of a stereochemical code.²⁰ Conformational plots for single residues may be represented as contours of equal energy drawn on a plot of the dihedral angle ϕ around the bond N—C $^{\alpha}$ vs. the dihedral angle ψ around the bond C $^{\alpha}$ —CO.

The progress in developing ϕ - ψ plots over the past two years has been principally in extending the study to all types of side-chains which occur in proteins and to the effects on the ϕ - ψ plots of side-chain conformation.²¹⁻²³ Similar plots based on quantum-mechanical calculations²⁴⁻²⁸ have also been developed in the same direction.²⁹⁻³¹ Generally speaking, the amide bond continues to be treated as fixed, planar, and *trans*, despite the possibility that X-ray crystallographic data on lysozyme is not incompatible with deviations from this³² and despite experimental observations on small peptide analogues.³³ An empirical ϕ - ψ diagram, based upon the observed distribution of residue conformations in proteins of known conformation, has been devised for a generalized side-chain.³⁴

D. Predictions of Local Conformations in Polypeptides.—It is possible that the global minimum of the conformational energy of a polypeptide does not need to be found before the conformation of a particular local region of the polypeptide chain can be predicted. This would be the case if the conformation of the local region were determined entirely by interactions within that region. Moreover, such a region may have a nucleating function, guiding the folding of the rest of the polypeptide chain around it. Intuitive reasoning continues to support the concept of such nucleation sites as necessary requirements for the attainment of the native conformation in a sufficiently short period of time, for the protein in nature as well as for the protein in the computer.³⁵

For this reason there has been great interest in making predictions of local conformations based on statistical analysis of the available data from proteins of known sequence and conformation. Until recently, such studies were mainly confined to the conformation which occurred most frequently in the proteins of known conformation, the right-hand α -helix.

²⁰ A. M. Liquori, *Quart. Rev. Biophys.*, 1969, **2**, 65.

²¹ V. Sasisekharan and P. K. Ponnuswamy, *Biopolymers*, 1970, **9**, 1249.

²² P. K. Ponnuswamy and V. Sasisekharan, *Biopolymers*, 1971, **10**, 565.

²³ V. Sasisekharan and P. K. Ponnuswamy, *Biopolymers*, 1971, **10**, 583.

²⁴ R. Hoffman and A. Imamura, *Biopolymers*, 1969, **7**, 207.

²⁵ B. Pullman, 'Aspects de la Chimie Quantique Contemporaine', ed. R. Daudel and A. Pullman, Colloque International du CNRS, 1971, p. 263.

²⁶ B. Maigret, D. Perahia, and B. Pullman, *J. Theor. Biol.*, 1970, **29**, 275.

²⁷ B. Pullman, B. Maigret and D. Perahia, *Compt. rend.*, 1970, **270**, D, 1395.

²⁸ B. Pullman, B. Maigret, and D. Perahia, *Theor. Chim. Acta*, 1970, **18**, 99.

²⁹ B. Maigret, B. Pullman, and D. Perahia, *Biopolymers*, 1971, **10**, 107.

³⁰ B. Maigret, D. Perahia, and B. Pullman, *Biopolymers*, 1971, **10**, 491.

³¹ B. Maigret, D. Perahia, and B. Pullman, *Biopolymers*, 1971, **10**, 1649.

³² A. C. T. North, *Biochem. J.*, 1971, **125**, 86P.

³³ R. Lumley Jones, *Trans. Faraday Soc.*, 1970, **66**, 2491.

³⁴ F. M. Pohl, *Nature New Biology*, 1971, **234**, 279.

³⁵ Molecular Biology Correspondent, *Nature*, 1971, **233**, 523.

It may be noted that they were also restricted to identifying as helical those residues in the available data which occurred within at least one recognizable turn of α -helix, not only because the publication of such data has preceded the availability of good ϕ, ψ data by a considerable time, but because the property of interest to most workers seems to be the ability to 'help make' a right-hand α -helix in a particular situation. In addition, related studies have been made using values for the percentage helix in proteins obtained by o.r.d. measurements rather than from X-ray crystallographic data.³⁶ Thus they are really referring to a particular *helical state* of a residue which is something more than a particular pair of ϕ, ψ angles. More recently, studies have been made on other local conformations, namely the pleated sheet³⁷ and the β -fold.³⁸

The studies on statistical methods of predicting α -helical regions can be more generally viewed as an attempt to break the biological code relating amino-acid sequence to the α -helical conformation, and two main conclusions have been drawn concerning the way information is carried by this code. Information has been shown to reside in single residues on the one hand,³⁹⁻⁴² and in the arrangement of residues along the backbone on the other;^{41, 43-45} both conclusions lead to reasonable predictions of observed helical regions. By applying an information theory approach, it has been possible to measure just how much information each residue provides for its own tendency to be helical or non-helical, and how much it receives from its near neighbours.^{46, 47} Whereas the information in single residues can be identified with the relative magnitude of the energy of the right-hand α -helical region on the ϕ - ψ diagram,⁴⁸ the nature of the information provided by neighbours is less well understood. It must, however, by definition reside in residue-residue interactions in which either one or both side-chains is important. Some work emphasizes the nature of both side-chains,^{43, 44, 49, 50} while observations^{41, 51} that residues are not symmetrically distributed between the N- and C-termini of helices has led to

³⁶ D. E. Goldsack, *Biopolymers*, 1969, 7, 299.

³⁷ A. U. Finkelstein and O. B. Ptitsyn, *J. Mol. Biol.*, 1971, 62, 613.

³⁸ P. N. Lewis, H. Momany, and H. A. Scheraga, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, 68, 2293.

³⁹ A. V. Guzzo, *Biophys. J.*, 1965, 5, 809.

⁴⁰ J. W. Prothero, *Biophys. J.*, 1966, 6, 367.

⁴¹ O. B. Ptitsyn, *J. Mol. Biol.*, 1969, 42, 501.

⁴² D. Kotelchuck and H. A. Scheraga, *Proc. Nat. Acad. Sci. U.S.A.*, 1969, 62, 14.

⁴³ P. F. Periti, G. Quagliatori, and A. M. Liquori, *J. Mol. Biol.*, 1967, 24, 313.

⁴⁴ M. Schiffer and A. B. Edmunson, *Biophys. J.*, 1967, 7, 121.

⁴⁵ B. W. Low, F. M. Lovell, and A. D. Rudko, *Proc. Nat. Acad. Sci. U.S.A.*, 1968, 60, 1519.

⁴⁶ R. H. Pain and B. Robson, *J. Mol. Biol.*, 1971, 58, 237.

⁴⁷ R. H. Pain and B. Robson, *Proceedings of the 1st European Biophysics Congress*, 1971, 1, 33.

⁴⁸ B. Robson and R. H. Pain, *Nature*, 1970, 227, 62.

⁴⁹ T. Iio, *Biopolymers*, 1971, 10, 1583.

⁵⁰ D. Kotelchuck, M. Dygert, and H. A. Scheraga, *Proc. Nat. Acad. Sci. U.S.A.*, 1969, 63, 615.

⁵¹ D. A. Cook, *J. Mol. Biol.*, 1967, 26, 143.

the suggestion^{37, 41} that side-chain backbone interactions may be the important factor.

Another approach to the coding of the α -helix lies in obtaining empirical data from experimental studies on artificial polypeptides in solution.^{52, 53} Studies to obtain the appropriate parameters for predicting helical regions in globular proteins continue;⁵⁴⁻⁵⁷ note that these parameters are the analogue of single-residue information. These solution studies emphasize that a locally determined conformation prior to formation of the globular protein may be the most stable conformation other than the time-random coil, but that the time-random coil may be more stable. Tertiary interactions must therefore have a stabilizing influence. These factors have been experimentally investigated.⁵⁸

E. Predictions of the Stability of Globular Proteins.—The problem of predicting the stability of a globular protein in its native state is clearly related to finding the conformation of lowest energy. It does not necessarily follow, however, that the stereochemistry must be predicted in detail before reasonable predictions can be made. This is the case if the protein is treated as a monomolecular micelle with non-polar groups tending to be inside and with polar groups outside.

If the protein is to be treated as a micelle of this type with otherwise indeterminate internal stereochemistry, predicting the stability of the protein would seem to be a relatively simple task. However, this would only be true if exact measures of the factors involved were available, for the stability of a globular protein depends upon a small difference between countering forces of large magnitude. More specifically, the principal factors which contribute to the free energy of the native state with respect to the fully denatured, time-random coil are the difference in configurational entropy, and the change in free energy in going from polypeptide-water to intramolecular polypeptide contacts. More precise studies should take into account changes in electrostatic effects. Both Brandts⁴ and Tanford⁵⁹ have attempted to obtain estimates of the stability of globular proteins and the principal points of disagreement are in the change in configurational entropy of the backbone and the relative stabilities of polypeptide-water and intramolecular polypeptide hydrogen-bonds. The latter discrepancy is mainly due to the apparent inconsistency between measurements from hydrogen-bonded low-molecular-weight compounds and studies on the helix-coil transitions of artificial polypeptides.⁵⁹

⁵² D. Poland and H. A. Scheraga, 'Theory of Helix-Coil Transitions in Biopolymers', Academic Press, New York, 1970.

⁵³ P. N. Lewis, N. Gō, M. Gō, D. Kotelchuck, and H. A. Scheraga, *Proc. Nat. Acad. Sci. U.S.A.*, 1970, **65**, 810.

⁵⁴ A. Roig and M. Cortijo, *Biopolymers*, 1971, **10**, 321.

⁵⁵ A. Roig, F. G. Blanco, and M. Cortijo, *Biopolymers*, 1970, **10**, 329.

⁵⁶ D. Puett and A. Ciferri, *Biopolymers*, 1971, **10**, 547.

⁵⁷ V. E. Bychova, O. B. Ptitsyn, and T. F. Barskaya, *Biopolymers*, 1971, **10**, 2181.

⁵⁸ J. Hermans and D. Puett, *Biopolymers*, 1971, **10**, 895.

⁵⁹ C. Tanford, *Adv. Protein Chem.*, 1970, **24**, 1.

2 Spin Labels

contributed by N. C. Price

Spin-labelling has continued to be a widely used approach to examine various aspects of protein structure and function. Several excellent reviews of the technique are available.⁶⁰⁻⁶² This section deals with the literature which appeared in 1971.

A. Haemoglobin.—Haemoglobin (Hb) has been perhaps the most intensively studied protein. Since the *X*-ray diffraction data on both oxy- and deoxy-Hb are available,⁶³ many of the spin-labelling studies can be interpreted and discussed in considerable detail. McConnell has published a review article on the application of the spin-labelling technique to the study of co-operative oxygen binding to Hb.⁶⁴ In this he discusses the earlier experiments in which the β 93-Cys residues of the protein were allowed to react with spin-label derivatives of iodoacetamide.^{65, 66} As mentioned in last year's Report,⁶⁷ the interpretation of some of these experiments has been complicated by the finding (from *X*-ray studies) that the introduction of the bulky spin labels at the β 93 residues can cause considerable distortion of the Hb structure.⁶⁸ Two orientations of the spin label with respect to the protein molecule were found in the *X*-ray studies, corresponding to the weakly and strongly immobilized components of the e.s.r. spectrum of the label.⁶⁶ In one of the orientations the label is essentially free in solution on the surface of the protein; in the other orientation it displaces the amino-acid residues at the C-terminus of the β -chain. McConnell also describes⁶⁴ some hitherto-unpublished experiments in which a spin-label triphosphate derivative was shown to bind to ferrous Hb with a stoichiometry of one label per tetramer and a dissociation constant very similar to that for diphosphoglyceric acid, a well-known effector of Hb. By analogy with other organic phosphate derivatives, the spin label was assumed to bind close to the dyad symmetry axis of Hb. The label could detect a conformational change caused by the addition of carbon monoxide to the $\alpha_2(\beta$ -ferric cyanide)₂Hb molecule.

A new approach to the study of the ligand-induced structural changes in Hb, and the relationship of these to the co-operativity between ligand sites, has been reported by Asakura *et al.*⁶⁹ This involved the use of a spin-labelled protohaem, in which either the 6- or 7-positions, or both, of the

⁶⁰ C. L. Hamilton and H. M. McConnell, in 'Structural Chemistry and Molecular Biology', ed. A. Rich and N. Davidson, Freeman, San Francisco, 1968, p. 115.

⁶¹ O. H. Griffith and A. S. Waggoner, *Accounts Chem. Res.*, 1969, **2**, 17.

⁶² H. M. McConnell and B. G. McFarland, *Quart. Rev. Biophys.*, 1970, **3**, 91.

⁶³ M. F. Perutz, *Nature*, 1970, **228**, 726.

⁶⁴ H. M. McConnell, *Ann. Rev. Biochem.*, 1971, **40**, 227.

⁶⁵ S. Ogawa and H. M. McConnell, *Proc. Nat. Acad. Sci. U.S.A.*, 1967, **58**, 19.

⁶⁶ H. M. McConnell, S. Ogawa, and A. Horwitz, *Nature*, 1968, **220**, 787.

⁶⁷ N. C. Price, in 'Amino-acids, Peptides, and Proteins', ed. G. T. Young (Specialist Periodical Reports), The Chemical Society, London, 1971, **3**, 205.

⁶⁸ J. K. Moffat, *J. Mol. Biol.*, 1971, **55**, 135.

⁶⁹ T. Asakura, J. S. Leigh, jun., H. R. Drott, T. Yonetani, and B. Chance, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 861.

haem were labelled. These haem derivatives were then combined with the apoproteins of myoglobin, Hb, cytochrome *c* peroxidase, and horse-radish peroxidase. The e.s.r. spectra of the spin-labelled myoglobin and Hb were similar (the labels being weakly immobilized), indicating the similarity of the haem environments in these two proteins. In cytochrome *c* peroxidase, the label was quite strongly immobilized. Horse-radish peroxidase showed only one very broad line in the e.s.r. spectrum, which did not appear to result from simple immobilization of the label by the protein, since no similar spectrum could be observed by varying the viscosity of the medium of the free spin-label. Asakura *et al.* concluded that the spectrum in horse-radish peroxidase arose from interactions between the two spin labels on the protohaem group. In the other haemoproteins this interaction does not arise, presumably because the haem pockets in these proteins are sufficiently large to keep the two labels apart. Spin-spin interactions between the iron of the haem and the spin labels (of the type discussed by Leigh ⁷⁰) could be detected in these haemoproteins after the addition of ligands (fluoride, azide, or cyanide). Using the Leigh theory,⁷⁰ the distances between the iron atom and the labels could be calculated. In the case of haemoglobin, this calculated distance agrees well with that estimated from the X-ray structure.

Asakura and Drott have also used these spin-labelled haem derivatives to obtain evidence for haem-haem interactions in Hb.⁷¹ Two kinds of valency hybrid haemoglobins containing spin-labelled ferric haem in one type of subunit were prepared. The e.s.r. spectra of the (α -spin label Fe^{3+})₂ (β $\text{Fe}^{2+}\text{-O}_2$)₂ and (α $\text{Fe}^{2+}\text{-O}_2$)₂(β -spin label Fe^{3+})₂ haemoglobins were different, suggesting that the two chains have non-equivalent conformational properties in the Hb molecule. Deoxygenation of the α -labelled Hb altered the e.s.r. amplitude and lineshape reversibly, whereas that of the β -labelled Hb altered the lineshape. This change in the spectrum of the α -labelled Hb was explained by a change either in the haem-label distance or in the relaxation time of the haem iron in the α subunit on oxygenation of the β subunit.

Haptoglobin (an α -globulin) is known to bind to haemoglobin, forming a 1 : 1 complex and resulting in a marked alteration of the haem function (notably an increase in peroxidatic activity and the ability to halogenate certain organic molecules).⁷² The spin-labelling method was used together with optical spectra, circular dichroism, and other e.s.r. measurements to assess the extent of alteration of the Hb structure on complex formation.⁷² When Hb spin-labelled at the β 93-Cys residues was added to haptoglobin, the e.s.r. spectrum of the label showed no indication of the equilibrium between strongly and weakly immobilized states of the spin label which exists in oxy- (but not deoxy-) Hb.⁶⁶ It was concluded that the F helix of

⁷⁰ J. S. Leigh, jun., *J. Chem. Phys.*, 1970, **52**, 2608.

⁷¹ T. Asakura and H. R. Drott, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 1199.

⁷² M. W. Makinen and H. Kon, *Biochemistry*, 1971, **10**, 43.

the β -chain of Hb assumes a deoxy-like conformation on complex formation, independent of the state of oxidation or ligation of the haem iron.

B. Enzyme Binding Sites.—Creatine Kinase. The studies on spin-labelled creatine kinase first reported in 1969⁷³ have now been considerably extended.^{74, 75} An iodoacetamide-type spin label was allowed to react with the 'essential' cysteine residue of the enzyme. The e.s.r. spectrum of this labelled (inactive) enzyme suggested that the label was highly immobilized.⁷³ Addition of adenosine 5'-diphosphate (ADP) or adenosine 5'-triphosphate (ATP) to the labelled enzyme (designated E \cdot) resulted in small changes in the e.s.r. spectrum; no change was observed on the addition of creatine or creatine phosphate. In the presence of the obligatory bivalent metal ion, the nucleotides caused larger changes. Thus MgADP decreased the amplitude of the centre peak of the e.s.r. spectrum by about 20% and shifted the outer peaks. It was found, however, that the enhancement of the relaxation rate of water protons by the spin label attached to the enzyme was a more sensitive parameter with which to study the effects of ligands. Dissociation constants for the ternary complexes (e.g. E \cdot -Mg²⁺-ADP) were determined by this method and differences between the ternary complexes with ADP and ATP could be demonstrated. These differences in the properties of the various complexes are consistent with the conformational differences previously postulated on the basis of the reactivity of the essential cysteine residue.⁷⁶ Titrations of E \cdot with the Mn-nucleotide complexes were also performed.⁷⁵ In these cases, the binding of Mn²⁺ leads to a decrease in the amplitude of the e.s.r. spectrum of the labelled enzyme, with no change in line shape. Dissociation constants for MnADP and MnATP from the respective ternary complexes were evaluated as 0.064 mmol l⁻¹ and 0.13 mmol l⁻¹; these values are very close to the corresponding dissociation constants for the unmodified enzyme. Using the theory developed by Leigh to describe the interaction of two spins in a rigid matrix,⁷⁰ the distances between Mn²⁺ and the spin label in the ternary complexes were evaluated.⁷⁵

Glyceraldehyde 3-Phosphate Dehydrogenase. Some of the complexities which can arise in interpreting spin-labelling experiments are illustrated by the work with glyceraldehyde 3-phosphate dehydrogenase.⁷⁷ This enzyme has been under intensive investigation, particularly since the observation that negative co-operativity is displayed between the coenzyme binding sites.^{78, 79} Several types of spin labels were used in this study, some of varying chain length. They included analogues of iodoacetic acid (an

⁷³ J. S. Taylor, J. S. Leigh, jun., and M. Cohn, *Proc. Nat. Acad. Sci. U.S.A.*, 1969, **64**, 219.

⁷⁴ J. S. Taylor, A. McLaughlin, and M. Cohn, *J. Biol. Chem.*, 1971, **246**, 6029.

⁷⁵ M. Cohn, H. Diefenbach, and J. S. Taylor, *J. Biol. Chem.*, 1971, **246**, 6037.

⁷⁶ W. J. O'Sullivan and M. Cohn, *J. Biol. Chem.*, 1966, **241**, 3116.

⁷⁷ W. Balthasar, *European J. Biochem.*, 1971, **22**, 158.

⁷⁸ A. Conway and D. E. Koshland, jun., *Biochemistry*, 1968, **7**, 4011.

⁷⁹ J. J. M. de Vijlder and E. C. Slater, *Biochim. Biophys. Acta*, 1968, **23**, 167.

irreversible inhibitor of the enzyme) and two types of substrate analogue; all of these should react at the 'essential' Cys-149 residue. In addition, a non-covalently bound spin-label analogue of the coenzyme β -nicotinamide adenine dinucleotide (NAD^+), previously used in studies on alcohol dehydrogenase,^{80, 81} was employed. The inhibitor and substrate analogues reacted with the enzyme, but the resulting e.s.r. spectra were exceedingly complex. They appeared to represent the superposition of at least three different types of spectra (corresponding to weak, strong, and intermediate immobilization of the labels). The various spin-labelled enzyme derivatives differed only in the relative proportions of these three types of spectra. Addition of NAD^+ , which bound weakly to the modified enzymes, altered only the relative amounts of the three types. It was concluded that the active site geometry of the enzyme is complex and cannot be described as a simple cleft, but rather as a system of narrow and wider spaces which is altered by the binding of coenzyme.

Glycogen Phosphorylase b. Bennick *et al.* used spin-labelling in conjunction with n.m.r. and fluorescence measurements to determine the spatial relationship between the active and allosteric sites of glycogen phosphorylase *b*.⁸² A single cysteine residue per subunit (molecular weight 92 500) was spin-labelled; the resulting e.s.r. spectrum was characteristic of a fairly mobile radical, whose rotational correlation time (3×10^{-9} s) was 30 times shorter than that for the whole protein molecule. The labelled enzyme was fully active and had an adenosine 5'-monophosphate (AMP) activation curve identical to that of the unmodified enzyme, indicating that both the active sites and the subunit interactions in the dimeric molecule were unaffected by the labelling. Addition of AMP changed the e.s.r. spectrum of the labelled enzyme; the extent of this change correlated well with the extent of activation of the enzyme. The unpaired electron of the label also caused broadening of the n.m.r. lines of substrate (glucose 1-phosphate) and activator (AMP) protons. From the magnitude of these effects, the distances between the label and these various protons were calculated, using the Solomon-Bloembergen equations.^{83, 84} The resulting map of the various sites of the enzyme is of interest in that the active and allosteric sites are relatively close, compared with the overall dimensions of the protein molecule.⁸²

Monomeric Enzymes. Hydrolytic enzymes, especially the serine esterases, have been quite extensively studied by the spin-label method,^{85, 86} partly because the high reactivity of the 'essential' residues offers the possibility of

⁸⁰ A. S. Mildvan and H. Weiner, *Biochemistry*, 1969, **8**, 552.

⁸¹ A. S. Mildvan and H. Weiner, *J. Biol. Chem.*, 1969, **244**, 2465.

⁸² A. Bennick, I. D. Campbell, R. A. Dwek, N. C. Price, G. K. Radda, and A. G. Salmon, *Nature New Biology*, 1971, **234**, 140.

⁸³ I. Solomon, *Phys. Rev.*, 1955, **99**, 559.

⁸⁴ I. Solomon and N. Bloembergen, *J. Chem. Phys.*, 1956, **25**, 261.

⁸⁵ J. C. Hsia, D. J. Kosman, and L. H. Piette, *Biochem. Biophys. Res. Comm.*, 1969, **36**, 75.

⁸⁶ J. D. Morrisett, C. A. Broomfield, and B. E. Hackley, jun., *J. Biol. Chem.*, 1969, **244**, 5758.

selective attachment of spin labels to these enzymes. A note of caution, however, has been sounded recently by the results of Hoff *et al.*,⁸⁷ who studied the reaction of a substrate-like fluorophosphate spin label with the three enzymes atropinesterase, subtilisin, and α -chymotrypsin at pH values of *ca.* 8. In each case, a small amount of non-specific labelling occurred (*i.e.* two types of e.s.r. signal were observed). This side-reaction (which represented 1% of the total e.s.r. signal for atropinesterase and about 10% for the other two enzymes) could be minimized by using less than stoichiometric amounts of spin label in the reaction mixture. For each enzyme, the major component in the e.s.r. spectrum arose from a strongly immobilized label, whose rotational correlation time was of the same order as that for the whole enzyme molecule. These results are in contrast to those reported by Morrisett *et al.*,⁸⁸ who found that the same label reacted specifically with acetylcholinesterase and α -chymotrypsin (at pH 4), to yield derivatives in which the label was only partially immobilized relative to the protein. Clearly, a thorough study of these labelling reactions under various conditions is required.

In one of the first applications of the spin-label method, it was shown that a spin-label derivative of *p*-nitrophenyl acetate acts as a substrate for α -chymotrypsin, and that at low pH the acyl enzyme intermediate could be isolated.⁸⁸ This acyl enzyme has now been crystallized, and the e.s.r. spectrum has been studied as a function of the orientation of the crystal to the applied magnetic field.⁸⁹ The α -chymotrypsin unit cell consists of four molecules, essentially arranged as two dimers. When the applied magnetic field was perpendicular to the two-fold screw axis relating the two dimers, and also either parallel or perpendicular to the two-fold rotation axis relating the units of the dimer, only a single molecular orientation was revealed in the e.s.r. spectrum of the crystalline labelled enzyme. This shows that the spin group takes on a single orientation relative to the host protein, a situation which contrasts with that in spin-labelled Hb, where the label takes on two isomeric orientations relative to the protein molecule.^{66, 68}

A crystallographic study of the complex between lysozyme and a spin-label derivative of acetamide has been reported.⁹⁰ The label is an inhibitor of the enzyme, 50% inhibition occurring at a label concentration of 60 mmol l⁻¹. The X-ray study showed that the label binds at three sites on the enzyme. Two of these sites are relatively weak and occur at sub-sites A and C of the active-site cleft.⁹¹ A third, stronger site was found as a hydrophobic pocket near the surface of the molecule around the four-fold screw axis. The biological significance of this third binding site is not clear; however, it would appear not to be an artifact of crystallization, since preliminary n.m.r. measurements of lysozyme in the presence of the spin label suggest that this hydrophobic pocket also exists in solution.

⁸⁷ A. J. Hoff, R. A. Oosterbaan, and R. Deen, *F.E.B.S. Letters*, 1971, **14**, 17.

⁸⁸ L. J. Berliner and H. M. McConnell, *Proc. Nat. Acad. Sci. U.S.A.*, 1966, **55**, 708.

⁸⁹ L. J. Berliner and H. M. McConnell, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 651.

⁹⁰ L. J. Berliner, *J. Mol. Biol.*, 1971, **61**, 189.

⁹¹ C. C. F. Blake, L. N. Johnson, G. A. Mair, A. C. T. North, D. C. Phillips, and V. R. Sarma, *Proc. Roy. Soc.*, 1967, **B 167**, 378.

C. New Spin Labels.—Cooke and Duke, in a short communication,⁹² report the synthesis and some properties of a spin-label analogue of ATP (in which the amino-group at the 6-position is converted into thiol, which is subsequently caused to react with an iodoacetamide-type spin label). The spin-labelled nucleotide (designated NSL) could bind to actin and also cause superprecipitation of actomyosin, though under more forcing conditions than for ATP. In the presence of Mg^{2+} , NSL bound to creatine kinase, but subsequent addition of creatine caused no further changes in the e.s.r. spectrum. Detailed studies with this analogue are awaited, so that a more complete assessment of its ability to replace ATP in enzyme reactions can be made.

Elek and Keleti have described some studies with a new type of spin label.⁹³ This is an iron-nitric oxide complex (of average g -value 2.03) which can be bound to various amino-acids, particularly cysteine and histidine.⁹⁴ The cysteine and histidine complexes can be readily distinguished on the basis of their e.s.r. spectra. In the reaction of the complex with glyceraldehyde 3-phosphate dehydrogenase, it was shown that both cysteine and histidine residues of the enzyme took part in the reaction. Prior reaction of the cysteine groups (with p -chloromercuribenzoate or iodoacetic acid) hindered the development of the e.s.r. signal. Reaction with the complex inactivated the enzyme, the inhibition being competitive with respect to glyceraldehyde 3-phosphate but of a mixed type with respect to NAD^+ and phosphate. This new type of spin label may be of importance in that the unpaired electron is much closer to the amino-acid side-chain of the enzyme than is the case with the normal spin labels described in the rest of this section.

Other papers on spin labels appeared in 1971 in the following fields: theoretical aspects of correlation times,⁹⁵ studies with model compounds as hydrophobic probes,⁹⁶ polypeptide mobility,⁹⁷ protein microstructure,⁹⁸ muscle components,^{99, 100} nucleic acids,¹⁰¹ and membranes.^{102–110}

⁹² R. Cooke and J. Duke, *J. Biol. Chem.*, 1971, **246**, 6360.

⁹³ G. Elek and T. Keleti, *Acta Biochim. Biophys. Acad. Sci. Hung.*, 1971, **6**, 107.

⁹⁴ J. C. Woolum, E. Tiezzi, and B. Commoner, *Biochim. Biophys. Acta*, 1968, **160**, 311.

⁹⁵ G. Poggi and C. S. Johnson, jun., *J. Magn. Resonance*, 1970, **3**, 436.

⁹⁶ C. Jolicœur and H. L. Friedman, *J. Phys. Chem.*, 1971, **75**, 165.

⁹⁷ A. Sanson and M. Ptak, *Compt. rend.*, 1970, **271**, D, 1319.

⁹⁸ G. I. Likhtenshtein, Yu. B. Grebenshchikov, P. Kh. Bobodzhonov, and Yu. V. Kokhanov, *Mol. Biol. (U.S.S.R.)*, 1970, **4**, 682.

⁹⁹ J. C. Seidel, M. Chopek, and J. Gergely, *Arch. Biochem. Biophys.*, 1971, **142**, 223.

¹⁰⁰ R. W. Burley, J. C. Seidel, and J. Gergely, *Arch. Biochem. Biophys.*, 1971, **146**, 597.

¹⁰¹ A. S. Girshovich, M. A. Grachev, D. G. Knorre, V. P. Kumarev, and V. I. Levinthal, *F.E.B.S. Letters*, 1971, **14**, 199.

¹⁰² B. L. Bales and M. E. Baur, *Chem. Phys. Letters*, 1970, **7**, 341.

¹⁰³ J. C. Hsia, H. Schneider, and I. C. P. Smith, *Canad. J. Biochem.*, 1971, **49**, 614.

¹⁰⁴ J. C. Hsia, P. T. S. Wong, and D. H. MacLennan, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 88.

¹⁰⁵ J. Seelig and W. Hasselbach, *European J. Biochem.*, 1971, **21**, 17.

¹⁰⁶ J. K. Raison, J. M. Lyons, R. J. Mehlhorn, and A. D. Keith, *J. Biol. Chem.*, 1971, **246**, 4036.

¹⁰⁷ W. L. Hubbell and H. M. McConnell, *J. Amer. Chem. Soc.*, 1971, **93**, 314.

¹⁰⁸ J. F. W. Keana and R. J. Dinerstein, *J. Amer. Chem. Soc.*, 1971, **93**, 2808.

¹⁰⁹ P. Jost, L. J. Libertini, V. C. Herbert, and O. H. Griffith, *J. Mol. Biol.*, 1971, **59**, 77.

¹¹⁰ O. H. Griffith, L. J. Libertini, and G. B. Birrell, *J. Phys. Chem.*, 1971, **75**, 3417.

3 Fluorescence

contributed by J. R. Brocklehurst

The importance of the various fluorescence techniques for studying structural problems in proteins and peptides is reflected in the increasing number of papers dealing with the techniques. Several reviews have appeared this year covering all the aspects to be dealt with below. A general review of fluorescence and its applications to proteins and membranes, which was mentioned last year, appeared during 1971.¹¹¹ Stryer has reviewed the uses of fluorescent probes in studying proteins and membranes,¹¹² while Radda has reviewed the use of several probe techniques as applied to studies of conformational changes in proteins.¹¹³ Chen has reviewed the uses of depolarization and fluorescence lifetime studies in macromolecular chemistry.^{114, 115} A book on the fluorescence and phosphorescence of proteins and nucleic acids has also appeared.¹¹⁶ The proceedings of the 5th Johnson Foundation Colloquium were eventually published this year and contain a number of papers about the application of fluorescent probes, including a discussion of the interpretation of probe data^{117, 118} and their applications to horse-liver alcohol dehydrogenase¹¹⁹ and glutamate dehydrogenase.¹²⁰

A. Interpretation of Fluorescence.—The problems of interpretation of fluorescence (and especially fluorescent probe) data have received a good deal of attention. Brand and his co-workers in particular have been active in examining the physical chemistry of various types of probe. The solvent-dependent changes in fluorescence of the aminonaphthalenesulphonate-type of probe are governed by solvent reorientation energy, and the quantum yield of fluorescence is inversely proportional to the singlet-triplet energy separation.¹²¹ Intramolecular charge transfer is also an important factor in the fluorescence properties of these molecules.¹²² By resolving the fluorescence emission spectrum of 1-anilinonaphthalene 8-sulphonate (ANS) on a nanosecond time-scale it is possible to see shifts in the emission peak

¹¹¹ G. K. Radda, in 'Current Topics in Bioenergetics', ed. D. R. Sanadi, Academic Press, New York, vol. IV, 1971, p. 81.

¹¹² L. Stryer, in 'Molecular Properties of Drug Receptors', CIBA Foundation Symposium, ed. R. Porter, Churchill, London, 1970, p. 133.

¹¹³ G. K. Radda, *Biochem. J.*, 1971, **122**, 385.

¹¹⁴ R. F. Chen, *Fluorescence News*, 1970, **5**, 1.

¹¹⁵ R. F. Chen, *Analyt. Letters*, 1971, **4**, 459.

¹¹⁶ S. V. Konev, 'Fluorescence and Phosphorescence of Proteins and Nucleic Acids', Plenum, London, 1971.

¹¹⁷ B. Chance and G. K. Radda, in 'Probes of the Structure and Function of Macromolecules and Membranes', ed. B. Chance, C. P. Lee, and J. K. Blasie, Academic Press, New York, vol. 1, 1971, p. 11.

¹¹⁸ L. Brand, C. J. Seliskar, and D. C. Turner, in ref. 117, p. 17.

¹¹⁹ J. R. Gohlke, L. Brand, J. R. Heitz, and R. H. Conrad, in 'Probes of the Structure and Function of Macromolecules and Membranes', ed. B. Chance, T. Yonetani, and A. S. Mildvan, Academic Press, New York, vol. II, 1971, p. 37.

¹²⁰ J. R. Brocklehurst and G. K. Radda, in ref. 117, p. 59.

¹²¹ C. J. Seliskar and L. Brand, *Science*, 1971, **171**, 799.

¹²² C. J. Seliskar and L. Brand, *J. Amer. Chem. Soc.*, 1971, **93**, 5405.

owing to solvent reorientation during the excited-state lifetime of the fluorescing species. However, the shifts are not seen in very viscous media, which suggests that some ANS emission spectra in protein systems may give incorrect indications of local polarity.¹²³ Similar work has been done with 2-toluidinonaphthalene 6-sulphonate (TNS) bound to bovine serum albumin (BSA), showing how relaxation processes can be studied on a nanosecond time-scale.¹²⁴

B. Fluorescent Probes.—*Non-covalently Bound.* ANS binding to a number of proteins has been investigated. In yeast alcohol dehydrogenase there are two binding sites which are distinct from the coenzyme site (unlike the liver enzyme), and ANS appears to report a conformational change induced by coenzyme binding.¹²⁵ ANS binds to butyryl and acetyl cholinesterases with a blue shift and enhancement of its fluorescence, and competitively inhibits both enzymes. There are two and three binding sites, respectively, and binding constants have been derived from the fluorescence data.¹²⁶ Rabbit-liver fructose 1,6-diphosphatase enhances ANS fluorescence on binding. The enhancement is quenched reversibly when the substrate is bound. This quenching is not due to a change in the ANS dissociation constant, so it is postulated that a conformational change is induced by the substrate.¹²⁷ In a similar way substrates, substrate analogues, and metal ions enhance the fluorescence of ANS bound to an Na⁺- and K⁺-stimulated ATPase.¹²⁸

Various fluorescent probes have been used to look at structural changes in BSA following irradiation,¹²⁹ and to follow the kinetics of denaturation of horse-liver alcohol dehydrogenase.¹³⁰ Binding data suggest that the TNS response to the pepsin-pepsinogen conversion is due to a change in probe environment. The probe fluorescence is enhanced by the inhibitor peptide, which is released during activation.¹³¹ A new class of polarity-sensitive probes has been synthesized from 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) and has also been shown to be useful for studying the activation of pepsinogen.¹³² Other probes include 3-benzyl-4-methyl-7-diethylamino-coumarin, which binds to an 'aromatic' site in α -chymotrypsin uncovered by activation of chymotrypsinogen,¹³³ and chlorpromazine, which quenches aldolase fluorescence.¹³⁴

One of the problems in the use of fluorescent probes has always been a lack of specificity in their binding, and the related difficulty of locating the

¹²³ S. K. Chakrabarti and W. R. Ware, *J. Chem. Phys.*, 1971, **55**, 5494.

¹²⁴ L. Brand and J. R. Gohlke, *J. Biol. Chem.*, 1971, **246**, 2317.

¹²⁵ F. M. Dickinson, *F.E.B.S. Letters*, 1971, **15**, 17.

¹²⁶ S. T. Christian and R. Janetzko, *Arch. Biochem. Biophys.*, 1971, **145**, 169.

¹²⁷ H. Aoe, M. G. Sarngadharan, and B. M. Pogell, *J. Biol. Chem.*, 1970, **245**, 6383.

¹²⁸ M. Mayer and Y. Avi-dor, *Israel J. Med. Sci.*, 1970, **6**, 726.

¹²⁹ C.-G. Rosen, *Internat. J. Radiation Biol.*, 1971, **19**, 587.

¹³⁰ J. R. Heitz and L. Brand, *Arch. Biochem. Biophys.*, 1971, **144**, 286.

¹³¹ J. L. Wang and G. M. Edelman, *J. Biol. Chem.*, 1971, **246**, 1185.

¹³² R. A. Kenner and A. A. Aboderin, *Biochemistry*, 1971, **10**, 4433.

¹³³ Y. Nishimura, O. Takenaka, and K. Shibata, *J. Biochem. (Japan)*, 1971, **70**, 293.

¹³⁴ M. J. Seghatchian, *Biochem. Pharmacol.*, 1971, **20**, 683.

binding sites. (Two of the above papers are, however, exceptions.^{135, 136}) Various ways have been found to overcome this problem. One is the use of a more-specific probe. Thus lanthanide ions have been used as fluorescent probes of transferrin, the number of binding sites being one or two depending on the ionic radius. These sites are at least 43 Å from the ferric ion site since no energy transfer is observed.¹³⁵ An analogue of ATP [$\text{Dns-NH}\cdot\text{CH}_2\cdot\text{CH}_2\cdot\text{O}(\text{PO}_3)_2\text{PO}_3$] acts as a normal substrate for heavy mero-myosin ATPase. Its fluorescence is enhanced and blue-shifted on binding. Energy transfer from the protein to the substrate analogue is observed for the triphosphate derivative but not for the mono- or di-phosphates.¹³⁶

Two different methods of locating fluorescein binding sites have been used. In studies of the binding of tetraiodofluorescein to dogfish lactate dehydrogenase (by absorption spectroscopy, *not* by fluorescence), the existence of a unique binding site was confirmed by X-ray studies.¹³⁷ The binding of fluorescein to BSA was investigated by equilibrium dialysis. The binding sites were then located by covalently attaching fluorescein isothiocyanate to the protein. The two sites are very close and the amino-acid sequence around the sites was obtained after isolation of the labelled peptides.¹³⁸

The latter method has also been used to locate the reaction sites of dansyl chloride on bovine fibrinogen. The various sites involved the labelling of different amino-acids,¹³⁹ and on the basis of the fluorescence properties of the various dansyl amino-acids the heterogeneity in the fluorescence of the various conjugates could be explained.¹⁴⁰ Dansylated 3-aminotyrosine has been studied as a model for proteins modified by amination and subsequent dansylation.¹⁴¹ Dansylation of an amino-tyrosine in trypsin and trypsinogen causes 50% inhibition. The activation process causes a red shift and quenching of the dansyl fluorescence (though there is no concomitant change in tryptophan fluorescence), suggesting a localized conformational change.¹⁴²

Covalently Bound. Dansyl-cysteine covalently bound to actin acts as a probe of polymerization. The fluorescence of the probe is blue-shifted and enhanced on binding, and these changes are intensified by polymerization. From polarization studies a rotational relaxation time was calculated which was similar to the value expected for a spherical molecule of molecular weight 47 000.¹⁴³ The difficulties involved in this sort of calculation (particularly uncertainty in the measurement of fluorescence lifetimes)

¹³⁵ C. K. Luk, *Biochemistry*, 1971, **10**, 2838.

¹³⁶ M. Onodera and K. Yagi, *Biochim. Biophys. Acta*, 1971, **253**, 254.

¹³⁷ P. M. Wasserman and P. J. Lentz, *J. Mol. Biol.*, 1971, **60**, 509.

¹³⁸ L.-O. Andersson, A. Rehnström, and D. L. Eaker, *European J. Biochem.*, 1971, **20**, 371.

¹³⁹ E. Mihalyi and A. Albert, *Biochemistry*, 1971, **10**, 237.

¹⁴⁰ E. Mihalyi and A. Albert, *Biochemistry*, 1971, **10**, 243.

¹⁴¹ R. A. Kenner, *Biochemistry*, 1971, **10**, 545.

¹⁴² R. A. Kenner and H. Neurath, *Biochemistry*, 1971, **10**, 551.

¹⁴³ H. C. Cheung, R. Cooke, and L. Smith, *Arch. Biochem. Biophys.*, 1971, **142**, 333.

have been reviewed by Squire, who also suggested some ways of getting around the difficulties.¹⁴⁴ Fluorescence-polarization studies have also been used to calculate equilibrium and thermodynamic constants for the dansyl- α_{S1} -casein- κ -casein interaction. The authors were able to conclude that the interaction was largely hydrophobic in character.¹⁴⁵ Polarization of fluorescence measurements of a fluorescein mercuric acetate label at the active site have been used to measure isothermal uncoiling of lactate dehydrogenase.¹⁴⁶

Another type of covalently attached probe is pyridoxal (or pyridoxal 5'-phosphate). Model studies suggested that this probe would report different states of ionization around its binding site.¹⁴⁷ In fact it seems to measure the proton-donating properties of its environment and distinguishes between L-aspartate aminotransferase and phosphorylase *b*.¹⁴⁸ Polarization studies of pyridoxal 5'-phosphate-labelled lysozyme indicate two rotational relaxation times, both of which are shorter than those obtained with the fluorescein-labelled enzyme, and which do not correlate with molecular weight data.¹⁴² Model studies suggested that the shorter of the two was due to rotation of the Schiff base relative to the protein. An inhibitor-induced conformational change is suggested by the increase in polarization and lifetime of the bound pyridoxal on binding the inhibitor to lysozyme.¹⁴⁹

C. Protein Fluorescence.—The use of the native fluorescence of the biological system is in many ways preferable to the above approaches, since it does not involve introducing a perturbant into the system. The native fluorescence of proteins arises from tryptophan, and to lesser extents tyrosine and phenylalanine. Studies of the isolated amino-acids can yield information useful in studying them in a protein environment. Thus 3-aminotyrosine and simpler aminophenols have been studied as models for 3-aminotyrosine in proteins.¹⁵⁰ The mechanisms of the effect of pH on the quantum yield and lifetime of tyrosine fluorescence have been elucidated, the rate of protonation-deprotonation in the excited state being very important.¹⁵¹

The effect of solvent on the fluorescence decay of indole has been studied to help to interpret the fluorescence of tryptophan in proteins.¹⁵² The fluorescence of phosphorylase *b* is higher than (and blue-shifted relative to) that of a mixture of tryptophan and tyrosine of the same composition as the enzyme. Dissociation of the enzyme lowers its fluorescence, but only

¹⁴⁴ P. G. Squire, *Biochim. Biophys. Acta*, 1970, **221**, 425.

¹⁴⁵ R. Clarke and S. Nakai, *Biochemistry*, 1971, **10**, 3353.

¹⁴⁶ D. S. Markovich, N. V. Umrikhima, R. T. Fin, G. B. Krapivinskii, and M. V. Vol'kenshtein, *Doklady Akad. Nauk S.S.S.R.*, 1970, **194**, 1365.

¹⁴⁷ M. Arrio-Dupont, *Photochem. and Photobiol.*, 1970, **12**, 297.

¹⁴⁸ M. Arrio-Dupont, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 653.

¹⁴⁹ R. Irwin and J. E. Churchich, *Biochemistry*, 1971, **10**, 5329.

¹⁵⁰ R. W. Cowgill, *Photochem. and Photobiol.*, 1971, **13**, 183.

¹⁵¹ M. Fayet and Ph. Wahl, *Biochim. Biophys. Acta*, 1971, **229**, 102.

¹⁵² W. B. de Lauder and Ph. Wahl, *Biochim. Biophys. Acta*, 1971, **243**, 153.

urea causes a red shift.¹⁵³ A study of the tryptophan fluorescence of seventeen proteins has shown that there is no simple relation between the quantum yield of fluorescence and the degree of exposure to solvent, though after denaturation the quantum yields were spread over a much narrower range of values. This suggests that either the amino-acid sequence around tryptophan is important in determining its quantum yield, or that even after denaturation the tertiary structure around tryptophan is still intact.¹⁵⁴ U.v. inactivation of ribonuclease leads to quenching of tryptophan fluorescence, possibly by an S²⁻ group. Model studies showed that glutathione, dithioglycollic acid, *etc.* were indeed very efficient quenchers.¹⁵⁵

Binding of Small Molecules. One very important use of protein fluorescence is for studying substrate and coenzyme binding. In the Shethra flavoprotein there is tyrosine-to-tryptophan energy transfer which is interrupted on binding the flavin. The subsequent quenching of tryptophan fluorescence is used to determine the kinetics of flavin binding.¹⁵⁶ In D-amino-acid oxidase the tryptophan fluorescence is progressively blue-shifted as the two flavin molecules bind to the apoenzyme, suggesting that the tryptophan is close to the active site and is shielded by the two flavins.¹⁵⁷ The binding of NAD⁺ or its analogues to pig lipoyl dehydrogenase leads to quenching of bound flavin, though there is no direct correlation between this and the effect of NAD⁺ on the diaphorase activity of the enzyme.¹⁵⁸ In a model flavinyl-aromatic amino-acid peptide the fluorophores are mutually quenched, the quenching becoming more efficient as the chain length decreases. The efficiency of flavin quenching is, in the order tryptophan > tyrosine > phenylalanine.¹⁵⁹

Only one of the two tryptophans in each subunit of liver alcohol dehydrogenase is quenched by NADH or NAD⁺, and titration of this quenching has been used to determine coenzyme binding constants. The quenching could be due to a specific interaction between coenzyme and an active-site tryptophan, or could be caused by a conformational change.¹⁶⁰ More-recent work on this system has shown that the quenching is a result of energy transfer to the bound coenzyme. This energy transfer is more efficient to the first NADH molecule which binds. Excitation energy appears to be transferred between different subunits. In this study the quenching was also used to measure velocity constants.¹⁶¹

¹⁵³ S. Damjanovich, S. Toth, and J. Sümegi, *Acta Biochim. Biophys. Acad. Sci. Hung.*, 1970, **5**, 279.

¹⁵⁴ M. J. Kronman and L. G. Holmes, *Photochem. and Photobiol.*, 1971, **14**, 113.

¹⁵⁵ S. Arian, M. Benjamini, J. Feitelson, and G. Stein, *Photochem. and Photobiol.*, 1970, **12**, 481.

¹⁵⁶ J. A. D'Anna and J. A. Tollin, *Biochemistry*, 1971, **10**, 57.

¹⁵⁷ F. Y.-H. Wu, S.-C. Tu, C.-W. Wu, and D. B. McCormick, *Biochem. Biophys. Res. Comm.*, 1970, **41**, 381.

¹⁵⁸ G. Su and J. E. Wilson, *Arch. Biochem. Biophys.*, 1970, **143**, 253.

¹⁵⁹ F. Y.-H. Wu and D. B. McCormick, *Biochim. Biophys. Acta*, 1971, **229**, 440.

¹⁶⁰ P. L. Luisi and R. Favilla, *European J. Biochem.*, 1970, **17**, 91.

¹⁶¹ H. Theorell and K. Tatemoto, *Arch. Biochem. Biophys.*, 1971, **142**, 69.

The quenching of glyceraldehyde 3-phosphate dehydrogenase fluorescence by bound NAD^+ has been used to measure binding constants and the number of binding sites for NAD^+ .^{162, 163} The latter study showed that at a high enough NAD^+ concentration the fourth binding site can be detected,¹⁶³ in contrast to earlier work.¹⁶² NAD^+ also quenches UDP-galactose-4-epimerase fluorescence. Reduction of the coenzyme causes no increase in quenching, but a 50% efficient energy transfer to NADH is detected.¹⁶⁴ The fluorescence of pyruvate kinase (yeast) is quenched by K^+ , Mg^{2+} , and phosphoenol pyruvate, and even more so by fructose diphosphate. However, the fact that fructose diphosphate binding depends upon the presence of Mg^{2+} , *etc.*, suggests that FDP induces a conformational transition.¹⁶⁵ The fluorescence of Phe *t*RNA synthetase is specifically quenched by Phe *t*RNA but not by other *t*RNA's.¹⁶⁶ Similarly, valyl-*t*RNA synthetase fluorescence is quenched by valyl *t*RNA, valine, ATP, and Mg^{2+} . The effect of pH on the fluorescence and the binding constants suggested a possible interaction between the catalytic and *t*RNA binding sites.¹⁶⁷

In contrast, isoleucine-*t*RNA synthetase fluorescence is not quenched by substrates; substrate binding was measured using the substrate inhibition of urea denaturation.¹⁶⁸ However, TNS binds to this enzyme without affecting its activity. The enhanced TNS fluorescence is partially quenched when substrates bind to the enzyme, thus providing a much more sensitive method for measuring binding parameters.¹⁶⁹

Protein-Protein Interaction. The technique of fluorescence quenching has also been used to study protein-protein interactions. The tryptophan fluorescence of pepsin is quenched when suitable acceptors bind to the protein. The interaction between pepsin and haemoproteins was studied by using the haem group as acceptor. The influence of redox state, pH, *etc.*, suggest that the interaction is largely hydrophobic in nature, and that the haem group is remote from the area of contact between the proteins.¹⁷⁰

Protein Structure. Protein fluorescence can also be used as a tool for studying protein structure. Human and bovine serum albumins have one and two tryptophans, respectively, and the fluorescence of these residues is one example of the difference between the two proteins. Binding of alkyl derivatives enhances HSA fluorescence but quenches that of BSA.¹⁷¹ The one tryptophan in HSA displays two fluorescence lifetimes, but this could be

¹⁶² S. F. Velick, J. P. Baggott, and J. M. Sturtevant, in 'Pyridine Nucleotide Dependent Dehydrogenases', ed. H. Sund, Springer, Berlin, 1970, p. 229.

¹⁶³ N. C. Price and G. K. Radda, *Biochim. Biophys. Acta.*, 1971, **235**, 27.

¹⁶⁴ A. U. Bertland, *Biochemistry*, 1970, **9**, 4649.

¹⁶⁵ R. T. Kuczenski and C. H. Suelter, *Biochemistry*, 1971, **10**, 2862.

¹⁶⁶ J. G. Farelly, J. W. Longworth, and M. P. Stulberg, *J. Biol. Chem.*, 1971, **246**, 1266.

¹⁶⁷ C. Helene, F. Brun, and M. Yaniv, *J. Mol. Biol.*, 1971, **58**, 349.

¹⁶⁸ G. R. Penzer, E. L. Bennett, and M. Calvin, *European J. Biochem.*, 1971, **20**, 1.

¹⁶⁹ E. Holler, E. L. Bennett, and M. Calvin, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 409.

¹⁷⁰ R. A. Badley and F. W. J. Teale, *J. Mol. Biol.*, 1971, **58**, 567.

¹⁷¹ J. Steinhardt, J. Krijn, and J. G. Leidy, *Biochemistry*, 1971, **10**, 4005.

due to heterogeneity in the sample.¹⁷² BSA binds almost 100 molecules of sodium dodecyl sulphate (SDS); the first twelve bind very rapidly, and only these twelve affect the protein fluorescence. The fluorescence is first quenched, then blue-shifted and slightly enhanced, as the twelve molecules of SDS are titrated on.¹⁷³ Studies of the effect of pH and iodide ion suggest that the quenching is due to a neighbouring amino-group, while the enhancement and blue shift reflect a slightly more hydrophobic environment as SDS binds.¹⁷⁴ Polarization of protein fluorescence (and hence rotational relaxation times) has been used to study the reversible dicarboxylic anhydride modification of BSA. Conditions can be chosen such that the protein is in its expanded form (involving exposure of lysine groups) and equivalent to the native protein at pH 2 (where it is irreversibly expanded).¹⁷⁵ Fluorescence studies of the tryptophans in BSA and HSA during conformational changes (induced by urea, SDS, dioxan, *etc.*) indicate that these residues are located in a conformationally labile hydrophobic fold of the protein with a positive group at the entrance to the fold.¹⁷⁶

Tryptophan fluorescence was one of the properties used to compare a semi-synthetic staphylococcal nuclease with the native enzyme.¹⁷⁷ This enzyme undergoes an acid-base induced unfolding and refolding. The kinetics of refolding have been followed by measuring the tryptophan fluorescence in a stopped-flow apparatus.¹⁷⁸ The results obtained by this method correlated well with n.m.r. studies of the histidine residues of the enzyme.¹⁷⁹ Changes in fluorescence have been used to follow pH-induced conformational changes in native¹⁸⁰ and insolubilized¹⁸¹ chymotrypsin, and to examine changes in tryptophan environment following heat denaturation of BSA and trypsin.¹⁸² Ion quenching of tryptophan has been used in structural studies of glucagon,¹⁸³ lysozyme,¹⁸⁴ and several albumins.¹⁸⁵

An example of the way in which several fluorescence techniques may be used to tackle the same problem is a study of the apomyoglobins from *Aplysia* and sperm whale. Both proteins have two tryptophans, but fluorescence polarization and spectral data show that the two in the

¹⁷² W. B. de Lauder and Ph. Wahl, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 398.

¹⁷³ C. J. Halfman and T. Nishida, *Biochim. Biophys. Acta*, 1971, **243**, 294.

¹⁷⁴ C. J. Halfman and T. Nishida, *Biochim. Biophys. Acta*, 1971, **243**, 284.

¹⁷⁵ A. Jonas and G. Weber, *Biochemistry*, 1970, **9**, 4729.

¹⁷⁶ M. N. Ivkova, N. S. Vedenkina, and E. A. Burshtein, *Mol. Biol. (U.S.S.R.)*, 1971, **5**, 214.

¹⁷⁷ I. M. Chaiken, *J. Biol. Chem.*, 1971, **246**, 2948.

¹⁷⁸ H. F. Epstein, A. N. Schechter, R. F. Chen, and C. B. Anfinsen, *J. Mol. Biol.*, 1971, **60**, 499.

¹⁷⁹ H. F. Epstein, A. N. Schechter, and J. S. Cohen, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2042.

¹⁸⁰ J. R. Garel and B. Labouesse, *Biochimie*, 1971, **53**, 9.

¹⁸¹ D. Gabel, I. Z. Steinberg, and E. Katchalski, *Biochemistry*, 1971, **10**, 4461.

¹⁸² K. K. Turoverov and B. V. Shchelchkov, *Biofizika*, 1970, **15**, 965.

¹⁸³ H. Bornet and H. Edelhoch, *J. Biol. Chem.*, 1971, **246**, 1785.

¹⁸⁴ S. S. Lehrer, *Biochemistry*, 1971, **10**, 3254.

¹⁸⁵ E. A. Chernitskii and N. M. Kozlova, *Vestsi Akad. Nauk Beloruss. S.S.R., Ser. bujal. Navuk*, 1971, **1**, 47.

Aplysia protein are in different environments, and that one is mobile and in contact with an aqueous environment. The two in sperm-whale apomyoglobin are both in a rigid, non-polar environment. ANS binds in the haem crevice of both, but its environment is more polar in the *Aplysia* protein. Despite these differences, rotational relaxation measurements with dansyl-labelled proteins indicate that both are approximately spherical with a rotational relaxation time of *ca.* 30 ns.¹⁸⁶

In surveying the literature for 1971, it has been apparent (to the Reporter at least) that there is an increasing awareness of the limitations of fluorescence techniques and a desire to use them in a more meaningful way. The great interest in protein fluorescence is particularly refreshing since, despite the fact that it is technically more difficult to study than are fluorescent probes, the data are usually easier to interpret.

4 Mössbauer Spectroscopy

contributed by C. E. Johnson

The study of proteins by Mössbauer spectroscopy, while still not a large field, nevertheless showed a continuing progress of published papers in 1971. Virtually all the work done was confined to the isotope ⁵⁷Fe, and the studies were in the main directed towards obtaining information on the electronic state and the environment of iron at the active centres of biological molecules. The samples were usually in the form of a frozen aqueous solution of the molecules. An advantage of the Mössbauer technique in this kind of investigation is that it gives data local to the Mössbauer nucleus (*i.e.* ⁵⁷Fe) and does not depend upon a knowledge of the complete molecular structure. As in previous years, most of the work was concentrated on two kinds of molecule (*i*) proteins containing the haem group and (*ii*) the iron-sulphur proteins.

A complete and convenient source of information on this field is 'The Index of Publications in Mössbauer Spectroscopy of Biological Materials', compiled by Dr. Leopold May, Department of Chemistry, The Catholic University of America, Washington, D.C., 20017, U.S.A. The Index is kept up to date by additions three or four times a year, and has been the main source of references used in writing this section of this Report.

Review papers were given by Lang¹⁸⁷ at the International Conference on the Application of the Mössbauer Effect (Tihany, Hungary, 1969) and by Johnson¹⁸⁸ at the XVIth Conference on Magnetism and Magnetic Materials (Miami, U.S.A., 1970). A review article by May¹⁸⁹ on biological applications was included in a book on Mössbauer spectroscopy.

¹⁸⁶ S. R. Anderson, M. Brunori, and G. Weber, *Biochemistry*, 1970, 9, 4723.

¹⁸⁷ G. Lang, 'Proceedings of Conference on the Application of the Mössbauer Effect, 1969', ed. I. Dezsi, Akad. Kiado, Budapest, Hungary, 1971.

¹⁸⁸ C. E. Johnson, *J. Appl. Phys.*, 1971, 42, 1325; *Physics Today*, 1971, 24, 35.

¹⁸⁹ L. May, in 'An Introduction to Mössbauer Spectroscopy', ed. L. May, Plenum Press, New York, 1971, p. 180.

A. Haem Proteins.—A comprehensive review of work up to 1970 has been given by Lang,¹⁹⁰ which includes data and discussions on compounds of haemoglobin, myoglobin, and cytochromes. In these proteins the immediate environment of the iron (the haem group) is well known and has been extensively studied, but the state of the iron atoms may be Fe^{3+} or Fe^{2+} and either high or low spin, depending upon the other ligands. This state is often not easily determined in a large molecule by conventional chemical methods.

New measurements have been carried out to study the equilibrium between the high- and low-spin states in the undecapeptide of ferricytochrome *c*.¹⁹¹ Measurements on metmyoglobin and its derivatives have been made by Maeda *et al.*¹⁹² An investigation at high pressures¹⁹³ shows that changes in the state of the iron are a function of pressure, and may be used to study the equilibrium of the various charge and spin states. In all of this work, very small changes in the electronic state of the iron associated with the biochemical activity of the proteins may be detected using the Mössbauer effect.

B. Iron-Sulphur Proteins.—The nature of the iron atoms in these proteins has been of great interest since the magnetic properties were first studied by e.s.r. measurements. In contrast to the haem proteins, the structure is not completely known (though the amino-acid sequences have been determined), but the state of the iron atoms seems to be similar in all of them. The proteins appear to be magnetic when they are in the reduced state, and the e.s.r. signal shows a spin $S = \frac{1}{2}$ and unusual *g*-values which are slightly anisotropic, centred about $g = 1.94$. No e.s.r. signal is detected when they are oxidized. A review of their properties, including Mössbauer spectroscopy, has been given by Tsibris and Woody.¹⁹⁴

Mössbauer studies have centred on the observations and interpretation of the hyperfine interaction in the reduced (*i.e.* paramagnetic) proteins, the measurements being made at low temperatures and in large magnetic fields. Work has been centred on the simpler proteins which contain two iron atoms and two sulphur atoms per molecule, and which accept one electron per molecule on reduction. New data have been obtained on *Scenedesmus* and spinach ferredoxins,¹⁹⁵ on the two-iron ferredoxins from spinach, parsley, pig adrenal cortex, *Azotobacter vinelandii*, and *Clostridium*

¹⁹⁰ G. Lang, *Quart. Rev. Biophys.*, 1970, 3, 1.

¹⁹¹ R. Nassif, M. Sellers, and L. May, *Appl. Spectroscopy*, 1971, 25, 150; L. May, R. Nassif, and M. Sellers, in 'Applications of Low Energy X- and Gamma-rays', ed. C. A. Ziegler, Gordon and Breach, London, 1971, p. 257.

¹⁹² Y. Maeda, Y. Morita, and C. Yoshida: *J. Biochem. (Japan)*, 1971, 70, 509.

¹⁹³ D. C. Grenoble, C. W. Frank, C. R. Barger, and H. G. Drickamer, *J. Chem. Phys.*, 1971, 55, 1633.

¹⁹⁴ J. C. M. Tsibris and R. W. Woody, *Co-ordination Chem. Rev.*, 1970, 5, 417.

¹⁹⁵ K. K. Rao, R. Cammack, D. O. Hall, and C. E. Johnson, *Biochem. J.*, 1971, 122, 257; C. E. Johnson, R. Cammack, K. K. Rao, and D. O. Hall, *Biochem. Biophys. Res. Comm.*, 1971, 43, 564.

pasteurianum,¹⁹⁶ and on adrenodoxin¹⁹⁷ and putidaredoxin.¹⁹⁸ The results on all of these proteins are similar (though not identical) and show that the molecules in the reduced state contain one Fe^{3+} atom with spin $S_1 = \frac{5}{2}$ and one Fe^{2+} atom with spin $S_2 = 2$; the two iron atoms in the molecule are coupled together antiferromagnetically to give a resultant spin $S = S_1 + S_2$ of $\frac{1}{2}$. This is in accord with observations of e.s.r. and magnetic susceptibility and confirms the model proposed by Gibson *et al.*¹⁹⁹ to explain the g -values. In the oxidized state, one electron is lost by the molecule, and it is assumed that the strong antiferromagnetic coupling between two ferric atoms each with $S = \frac{5}{2}$ results in a non-magnetic molecule. Thus the model of a two-iron centre which explains the spectroscopic properties of these proteins now seems to be well established.

Interest in these proteins will be heightened by the recent X -ray determination²⁰⁰ of the molecular structure of one of them, the ferredoxin from the bacteria *Clostridium pasteurianum*, which contains eight iron atoms per molecule.

C. Other Proteins.—Further measurements have been made on haemerythrin, in its deoxy, oxy, and several oxidized (met) states.²⁰¹ This protein is a non-haem iron protein responsible for oxygen transport in the sipunculid worm *Golfingia gouldii*. The molecule consists of eight subunits, each containing two iron atoms and, on oxygenation, each subunit binds one molecule of oxygen. Cyclic oxygenation and deoxygenation experiments were performed to distinguish between oxidized and oxygenated forms. Oxyhaemerythrin gave a Mössbauer spectrum consisting of two doublets of equal intensity. The iron atoms in the oxygenated protein were shown to have different environments and are antiferromagnetically coupled together so that each subunit is non-magnetic.

The methaemerythrin complexes were also shown to be non-magnetic, from the absence of hyperfine interaction in their Mössbauer spectra measured at low temperatures (4.2 K) and in large magnetic fields (30 kG). These compounds appear to contain pairs of antiferromagnetically coupled Fe^{3+} atoms in closely similar environments. The sign of the electric field gradient at the iron nuclei for the complex metisothiocyanatohaemerythrin was found to be negative. By comparing the postulated structures of

¹⁹⁶ W. R. Dunham, A. J. Bearden, I. T. Salmeen, G. Palmer, R. H. Sands, W. H. Orme-Johnson, and H. Beinert, *Biochim. Biophys. Acta*, 1971, 253, 134; W. R. Dunham, G. Palmer, R. H. Sands, A. J. Bearden, H. Beinert, and W. H. Orme-Johnson, *Biochem. Biophys. Res. Comm.*, 1971, 45, 1119.

¹⁹⁷ R. Cammack, K. K. Rao, D. O. Hall, and C. E. Johnson, *Biochem. J.*, 1971, 125, 849.

¹⁹⁸ E. Münck, P. G. Debrunner, J. C. M. Tsibris, and I. C. Gunsalus, *Biochemistry*, 1972, 11, 855.

¹⁹⁹ J. F. Gibson, D. O. Hall, J. H. M. Thornley, and F. R. Whatley, *Proc. Nat. Acad. Sci. U.S.A.*, 1966, 56, 987.

²⁰⁰ L. C. Sieker, E. Adman, and L. H. Jensen, *Nature*, 1972, 235, 42.

²⁰¹ K. Garbett, C. E. Johnson, I. M. Klotz, M. Y. Okamura, and R. J. P. Williams, *Arch. Biochem. Biophys.*, 1971, 142, 574.

oxyhaemerythrin and deoxyhaemerythrin, a possible mechanism and kinetic behaviour for the oxygenation equilibrium has been suggested.

Measurements have also been reported on the iron storage proteins ferritin²⁰² and haemosiderin.¹⁸⁸

5 Nuclear Magnetic Resonance

contributed by H. W. E. Rattle

Slowly but surely, n.m.r. is beginning to fulfil some of its early promise as a tool for the investigation of polypeptides and proteins. Notable among the 1971 papers is an increasing tendency to forsake 'straight' analysis of proton spectra in favour of techniques which sidestep lack of resolution, for example by considering resonances whose chemical shifts or relaxation times are perturbed by paramagnetic ions, by changing to the observation of other nuclei, notably ^{19}F and ^{13}C , or by selective deuteration. These more subtle approaches show greater promise of producing meaningful biological information, in that they may be more readily tailored to the investigation of specific problems. The era of recording n.m.r. data simply because it was readily available, without regard for biological realities, appears at last to have ended.

A. Peptides and Polypeptides.—Two papers have appeared which may make the analysis of proton spectra easier in some cases; one, from Giessner-Prettre and Pullman,²⁰³ presents curves of calculated ring-current shifts, whereas Ramachandran and Chandrasekaran^{204, 205} have employed model compounds to compile tables of the $\alpha\text{-CH-NH}$ coupling constants and their variation with dihedral angle, which may well prove useful in the conformational analysis of smaller peptide molecules. Workers who are synthesizing peptides by solid-phase methods may be interested in a method developed by Bayer *et al.*,²⁰⁶ in which the ^{19}F chemical shifts of trifluoroacetyl groups bonded to the end of the peptide at any stage of the synthesis provide the basis for a sensitive end-group analysis, enabling the purity of the product to be estimated. Small peptides and oligopeptides provide a rich field for structural analysis by n.m.r., as evidenced by papers such as that of Tonelli *et al.*,²⁰⁷ whose n.m.r. data on the structure of the cyclic decapeptide antamanide are consistent with the predictions from energy calculations. Data useful to workers in this and other sections of the field have been produced by Cohen,²⁰⁸ who gives shift data for some

²⁰² J. F. Boas and G. J. Troup, *Biochim. Biophys. Acta*, 1971, **229**, 68.

²⁰³ C. Giessner-Prettre and B. Pullman, *J. Theor. Biol.*, 1971, **31**, 287.

²⁰⁴ G. N. Ramachandran, R. Chandrasekaran, and K. D. Kopple, *Biopolymers*, 1971, **10**, 2113.

²⁰⁵ G. N. Ramachandran and R. Chandrasekaran, *Biopolymers*, 1971, **10**, 935.

²⁰⁶ E. Bayer, P. Hunziker, M. Mutter, R. E. Sievers, and R. Ullman, *J. Amer. Chem. Soc.*, 1972, **94**, 265.

²⁰⁷ A. E. Tonelli, D. J. Patel, M. Goodman, F. Naider, H. Faulstich, and T. Wieland, *Biochemistry*, 1971, **10**, 3211.

²⁰⁸ J. S. Cohen, *Biochim. Biophys. Acta*, 1971, **229**, 603.

oligopeptides containing aromatic residues, including some secondary structure effects on the aromatic resonances.

In the polypeptide field, the interesting left-handed aspartate helices have been the subject of several studies, notably by Bradbury *et al.*,²⁰⁹ Temussi and Goodman,²¹⁰ Paolillo *et al.*,²¹¹ and Silverman *et al.*²¹² Chemical shifts of the α -CH and NH appear to differ between left- and right-handed versions of the same polymer, but there is no evidence of ring interactions in the left-handed helical forms of poly- β -benzyl-L-aspartate. Meanwhile, the old controversy about the origin of the separate peaks of the helical and random forms of polypeptides in trifluoroacetic acid-deuteriochloroform solutions has been revived by Tam and Klotz²¹³ and their contentions have been answered by Bradbury *et al.*²¹⁴ Two papers on poly-L-proline by Torchia and Bovey²¹⁵ and Torchia²¹⁶ cast some new light on this interesting polymer, while fresh evidence for the rapid internal motions of poly- β -alanine is produced by Applequist and Glickson.²¹⁷

Small biological polypeptides, notably oxytocin and vasopressin, have been the subject of work by several groups.²¹⁸⁻²²⁰ Spectral assignments, information on hydrogen-bonding or the lack of it, and other conformational data are presented. Chemical-shift changes and conformational effects in the ^{13}C spectrum of valinomycin on complexing with potassium ions are reported.²²¹

B. Proteins.—Moving on to proteins, evidence of the increasing availability of ^{13}C spectrometers is found in the presentation of the ^{13}C spectrum of lysozyme²²² and of the first fifteen residues of RNase, prepared synthetically.²²³ Analysis of ^{13}C spectra may be assisted by the data presented by Voelter *et al.*²²⁴ on chemical shift values for amino-acids, and by some

²⁰⁹ E. M. Bradbury, B. G. Carpenter, C. Crane-Robinson, and H. Goldman, *Macromolecules*, 1971, **4**, 557.

²¹⁰ P. A. Temussi and M. Goodman, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1767.

²¹¹ L. Paolillo, P. A. Temussi, E. Trivellone, E. M. Bradbury, and C. Crane-Robinson, *Biopolymers*, 1971, **10**, 2555.

²¹² D. N. Silverman, G. T. Taylor, and H. A. Scheraga, *Arch. Biochem. Biophys.*, 1971, **146**, 587.

²¹³ I. M. Klotz and J. W. O. Tam, *J. Amer. Chem. Soc.*, 1971, **93**, 1313.

²¹⁴ E. M. Bradbury, P. Cary, C. Crane-Robinson, L. Paolillo, T. Tancredi, and P. A. Temussi, *J. Amer. Chem. Soc.*, 1971, **93**, 5916.

²¹⁵ D. A. Torchia and F. A. Bovey, *Macromolecules*, 1971, **4**, 246.

²¹⁶ D. A. Torchia, *Macromolecules*, 1971, **4**, 440.

²¹⁷ J. Applequist and J. D. Glickson, *J. Amer. Chem. Soc.*, 1971, **93**, 3276.

²¹⁸ V. J. Hruby, A. I. Brewster, and J. A. Glasel, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 450.

²¹⁹ P. H. Von Dreele, A. I. Brewster, H. A. Scheraga, M. F. Ferger, and V. Du Vigneaud, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1028.

²²⁰ J. Feeney, G. C. K. Roberts, J. H. Rockey, and A. S. V. Burgen, *Nature New Biol.*, 1971, **232**, 108.

²²¹ M. Ohnishi, M. C. Fedarke, J. D. Baldeschweiler, and L. F. Johnson, *Biochem. Biophys. Res. Comm.*, 1972, **46**, 312.

²²² J. C. W. Chien and J. F. Brandts, *Nature New Biol.*, 1971, **230**, 209.

²²³ M. H. Freedman, J. S. Cohen, and I. M. Chaiken, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 1148.

²²⁴ W. Voelter, G. Jung, E. Breitmaier, and E. Bayer, *Z. Naturforsch.*, 1971, **26b**, 213.

measurements²²⁵ of longitudinal relaxation time (T_1) which show a ten-fold shortening of T_1 in the rigid side-chain of lysine compared with that of the ϵ -carbon. The longer-established technique of using n.m.r. to follow the titration of histidine resonances in enzymes is this year represented by work on ribonuclease,²²⁶ staphylococcal nuclease,¹⁷⁹ and human carbonic anhydrase.²²⁷ The latter study is followed by one²²⁸ which utilizes ^1H and ^{19}F resonance to establish association and dissociation constants for the binding of various carboxylate ligands to human carbonic anhydrase. Other inhibitor or substrate binding studies have been carried out on lysozyme²²⁹⁻²³¹ and on liver alcohol dehydrogenase,²³² chymotrypsin,²³³ acetylcholinesterase,²³⁴ and ribonuclease.²³⁵ These all use the fairly well-established technique of observing differential broadening and shift of those enzyme and substrate/inhibitor resonances which are visible. A fairly new development is the use of a ^{19}F -containing substrate or inhibitor to provide an uncluttered spectrum in which to seek changes. An interesting development in this direction is reported by Raftery and Huestis,²³⁶ who bound covalently a small ^{19}F -containing 'reporter' molecule near the active site of ribonuclease S to obtain information on conformational changes. Another approach to the study of enzyme binding is to use a substrate or inhibitor containing a paramagnetic ion which perturbs the spectrum of the protein in regions representing the binding site. Binding of metal ions to bovine serum albumin^{237, 238} has been reported, and Krugh²³⁹ describes the use of a paramagnetic analogue of ATP as a spin label in the study of the active site of DNA-polymerase.

Of course, many proteins contain one or more metal ions at the active site, and the changes induced in the protein spectrum by oxidation, reduction, or removal of the metal can be most informative. Studies of the binding of carbon monoxide²⁴⁰ and n-butyl isocyanide²⁴¹ to haemoglobin, and work on the linkage between the haem groups of the different subunits

²²⁵ A. Allerhand, D. Doddrell, V. Glushko, D. W. Cochran, E. Wenkert, P. J. Lawson, and F. R. N. Gurd, *J. Amer. Chem. Soc.*, 1971, **93**, 544.

²²⁶ N. L. R. King and J. H. Bradbury, *Nature*, 1971, **229**, 404.

²²⁷ R. W. King and G. C. K. Roberts, *Biochemistry*, 1971, **10**, 558.

²²⁸ P. W. Taylor, J. Feeney, and A. S. V. Burgen, *Biochemistry*, 1971, **10**, 3866.

²²⁹ P. W. Kent and R. A. Dwek, *Biochem. J.*, 1971, **121**, 11P.

²³⁰ B. Capon, H. Ashton, and R. L. Foster, *Chem. Comm.*, 1971, 512.

²³¹ J. F. Studebaker, B. D. Sykes, and R. Wien, *J. Amer. Chem. Soc.*, 1971, **93**, 4579.

²³² R. H. Sarma and C. L. Woronick, *Res. Comm. Chem. Pathol. Pharmacol.*, 1971, **2**, 177.

²³³ B. Capon and H. Ashton, *Chem. Comm.*, 1971, 513.

²³⁴ G. Kato and J. Yung, *Mol. Pharmacol.*, 1971, **7**, 33.

²³⁵ H. Ruterjans and O. Pongs, *European J. Biochem.*, 1971, **18**, 313.

²³⁶ M. A. Raftery and W. H. Heustis, *Biochemistry*, 1971, **10**, 1181.

²³⁷ J. L. Sudmeier and J. J. Pesek, *Inorg. Chem.*, 1971, **10**, 860.

²³⁸ J. L. Sudmeier and J. J. Pesek, *Analyt. Biochem.*, 1971, **41**, 39.

²³⁹ T. R. Krugh, *Biochemistry*, 1971, **10**, 2594.

²⁴⁰ R. Cassoly, Q. H. Gibson, S. Ogawa, and R. G. Shulman, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 1015.

²⁴¹ T. R. Lindstrom, J. S. Olson, N. H. Mock, Q. H. Gibson, and C. Ho, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 22.

of this molecule²⁴² use this technique, while a great deal of information on the precise state of the iron in ferredoxins has emanated from the Du Pont laboratories.²⁴³⁻²⁴⁵ Other studies on metal-containing proteins which may be noted concern liver alcohol dehydrogenase,²⁴⁶ cytochrome *c*,^{247, 248} and an interesting proton relaxation enhancement study on the contribution of manganese to the activity of arginase.²⁴⁹

After the excitement of papers containing results from selectively deuteriated proteins, very little further has appeared. However, Cohen *et al.*²⁵⁰ have used partially deuteriated tyrosines in staphylococcal nuclease to simplify the spectrum for inhibition studies. Another contribution which stands out as a little unusual is that of Phillips *et al.*,²⁵¹ in which the indole NH resonances of the tryptophan in lysozyme are identified by various means, including deuterium exchange and chemical modification.

Among proteins, the histones stand out as unique in their relatively simple n.m.r. spectra, dominated as they are by a few types of residue, and by the asymmetric distribution of the residues along the molecule. Reports on the binding of histone fractions to DNA²⁵² and their interaction with each other²⁵³ hold the promise of greater things to come.

Finally, a look back to one of the earliest applications of n.m.r., the binding of water to large molecules, shows that the method is still alive and well. Collagen,^{254, 255} keratin,²⁵⁶ and poly- α -amino-acids²⁵⁷ have been studied.

All in all, 1971 will probably be looked on as a year of consolidation rather than of dramatic advance in the application of n.m.r. to biological molecules.

²⁴² D. G. Davis, T. R. Lindstrom, N. H. Mock, J. J. Baldassare, S. Charache, R. T. Jones, and C. Ho, *J. Mol. Biol.*, 1971, **60**, 101.

²⁴³ M. Poe, W. D. Phillips, J. D. Glickson, and C. C. McDonald, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 68.

²⁴⁴ J. D. Glickson, W. D. Phillips, C. C. McDonald, and M. Poe, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 271.

²⁴⁵ M. Poe, W. D. Phillips, C. C. McDonald, and W. H. Orme-Johnson, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 705.

²⁴⁶ R. L. Ward and J. A. Happe, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1444.

²⁴⁷ G. E. Krejcarek, L. Turner, and K. Dus, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 983.

²⁴⁸ R. K. Gupta and S. H. Koenig, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1134.

²⁴⁹ H. Hirsch-Kolb, J. Helmut, and D. J. Greenberg, *J. Biol. Chem.*, 1971, **246**, 395.

²⁵⁰ J. S. Cohen, M. Feil, and I. M. Chaiken, *Biochem. Biophys. Acta*, 1971, **236**, 468.

²⁵¹ W. D. Phillips, J. D. Glickson, and J. A. Rupley, *J. Amer. Chem. Soc.*, 1971, **93**, 4031.

²⁵² M. Boublik, E. M. Bradbury, C. Crane-Robinson, and H. W. E. Rattle, *Nature New Biol.*, 1971, **229**, 129.

²⁵³ E. M. Bradbury, P. D. Cary, C. Crane-Robinson, P. L. Riches, and E. W. Johns, *Nature New Biol.*, 1971, **233**, 265.

²⁵⁴ B.-M. Fung and P. Trautmann, *Biopolymers*, 1971, **10**, 391.

²⁵⁵ A. A. Khanagov, *Biopolymers*, 1971, **10**, 789.

²⁵⁶ L. J. Lynch and K. H. Marsden, *Search*, 1971, **2**, 95.

²⁵⁷ I. D. Kuntz, *J. Amer. Chem. Soc.*, 1971, **93**, 514.

6 Infrared Spectroscopy

contributed by R. M. Stephens

A. Model Compounds, Amino-acids, and Oligopeptides.—*N*-Methylacetamide and its derivatives have for a long time been used as model compounds for interpreting the i.r. spectra of proteins and polypeptides, and the i.r. spectra of *N*-acetyl amino-acid methylamides, *N*-isopropylacetamide, *N*-methylisobutyramide and their *N*-deuteriated homologues have been recorded down to 300 cm^{-1} .²⁵⁸ The $\text{C}=\text{O}$ in-plane and out-of-plane bending vibration bands of the $\text{CH}_3\cdot\text{CO}\cdot\text{NH}\cdot\text{C}^\alpha$ group (amides IVa and VIa) and those of the $\text{C}^\alpha\cdot\text{CO}\cdot\text{NH}\cdot\text{CH}_3$ group (amides IVb and VIb) have been assigned. Two crystalline modifications, form I and form II, were found from the compounds prepared from L-alanine, DL-leucine, L-aspartic acid, and DL-phenylalanine. The two forms show quite different skeletal vibrations, which suggests rotational isomerism. The two amide bands were found near 630 cm^{-1} and 600 cm^{-1} in form II; the X-ray structure analyses suggest that these two forms have different hydrogen-bond structures.

Normal-co-ordinate calculations have been made on dimethylformamide and various isotopic substituted forms using Urey-Bradley, modified Urey-Bradley, and symmetrized valence force fields.²⁵⁹ The frequency shifts on isotopic substitution have been explained and the results of the calculations are discussed in comparison with other related models. Calculations using adiabatic approximation methods have shown that the splitting of the amide I and II bands was due to coupling between CO and NH groups, resulting from vibrational excitation between these groups.²⁶⁰ Low-temperature spectra of a number of amino-acids have been studied between 400 and 33 cm^{-1} , enabling additional analytical information to be obtained when the amino-acids are in the zwitterion form.²⁶¹

Conformational analyses using i.r. and n.m.r. spectroscopy have been made on *N*-benzyloxycarbonylglycyl-L- and -D-leucine methyl esters and several other related dipeptides, showing that 7-membered rings were present in polypeptide esters which had *cis*-rotamers of the N(6)—C(5) bond.²⁶² The i.r. spectra of the oligoglycines $\text{Me}(\text{NH}\cdot\text{CH}_2\cdot\text{CO})_n\text{NH}\cdot\text{Et}$ ($1 \leq n \leq 4$) and their *N*-deuteriated homologues in the solid state, have been analysed between 3500 and 200 cm^{-1} .²⁶³ The similarity of these spectra to those of polyglycine II shows that all the oligomers have an analogous structure. The effect of solvent on the conformation of films of low-molecular-weight poly-(γ -benzyl-L-glutamate) has shown that mainly

²⁵⁸ K. Yasushi, T. Shimanouchi, M. Sato, and T. Tatsuno, *Biopolymers*, 1971, 10, 1059.

²⁵⁹ G. Durgaprasad, D. N. Sathyanarayana, and C. C. Patel, *Bull. Chem. Soc. Japan*, 1971, 44, 316.

²⁶⁰ J. M. Konarski, *Chem. Phys. Letters*, 1971, 9, 54.

²⁶¹ W. R. Fairheller and J. T. Millo, *Appl. Spectroscopy*, 1971, 25, 175.

²⁶² S. V. Zenin, N. Ya. Krasnobrizhii, V. E. Minaev, N. A. Poddubnaya, and C. B. Sergeev, *Zhur. obshchei Khim.*, 1971, 41, 665.

²⁶³ M. Avignon and C. Garrigou-Lagrange, *Spectrochim. Acta*, 1971, 27A, 297.

helices are formed from chloroform and that the amount of β structure present increases with increasing amounts of either benzene, dioxan, *m*-cresol, or dimethylformamide.²⁶⁴

The interaction of hydroxocobalamine (vitamin B_{12b}) with α -amino-acids and peptides has been studied using i.r. analysis.²⁶⁵ The results show that charge donation occurs from the N of the amino-acid, in the un-ionized form. It was seen that vitamin B_{12b} forms a complex more readily with glycine than with other amino-acids, and also to peptides with N-terminal glycine.

B. Synthetic Polypeptides.—Hexafluoroisopropanol is a solvent for most proteins and non-ionic polypeptides, and the conformations of several polypeptides have been determined in this solvent using i.r. and u.v. spectroscopy, circular dichroism, and optical rotatory dispersion.²⁶⁶ Most polymers studied, including poly(methyl-L-glutamate), poly-(L-methionine), poly-(*N*-benzyloxycarbonyl-L-lysine), and poly-(L-homoserine), had an α -helical conformation, whereas poly-[(γ -morpholinylethyl)-L-glutamamide] had a random-coil conformation. Spectroscopic studies of alternating polypeptides, *e.g.* poly-(γ -benzyl-L-glutamate : γ -benzyl-D-glutamate), have indicated that, in helicogenic solvents, conformations are present which are different from the normal α -helix.²⁶⁷ The properties of such polypeptides in which polymerization was accompanied by appreciable racemization were similar to those of poly-(L-aspartic acid esters) and a distorted type of α -helical conformation was suggested. When racemization was negligible a new conformation, the nature of which was uncertain, was apparently formed. Conformational analyses²⁶⁸ of ethyl-L-glutamate oligopeptides and of co-oligopeptides containing glutamate residues have been made for both solution and solid state by observing the amide I and II absorption frequencies. Trimethyl phosphate supports the folded structure of oligomers above the heptamer, whereas in chloroform solutions these oligomers assume the extended β structure above the pentamer. Conformations of polypeptides and proteins in aqueous solutions can be studied using i.r. spectroscopy only if D₂O solutions are used. Poly-(*S*-carboxyethyl-L-cysteine), a higher side-chain homologue of poly-(*S*-carboxymethyl-L-cysteine), is soluble in D₂O, and its conformation is dependent upon the pD of the solution.²⁶⁹ At high ionization the polymer is randomly coiled, but below pH 5.5 it has a pleated sheet structure. Poly-(L-tyrosine) in water-ethanol solvents has a conformation depending on the concentration of ethanol.²⁷⁰ Between 20 and 40% ethanol concentration the polymer can

²⁶⁴ T. Iio, *Bull. Chem. Soc. Japan*, 1971, **44**, 859.

²⁶⁵ J. G. Heathcote, G. H. Moxon, and M. A. Slifkin, *Spectrochim. Acta*, 1971, **27A**, 1391.

²⁶⁶ J. R. Parrish and E. R. Blout, *Biopolymers*, 1971, **10**, 1491.

²⁶⁷ H. N. Rydon, P. M. Hardy, J. G. Haylock, D. I. Marlborough, H. T. Storey, and R. C. Thompson, *Macromolecules*, 1971, **4**, 435.

²⁶⁸ M. Goodman, Y. Masuda, and S. Verdini, *Biopolymers*, 1971, **10**, 1031.

²⁶⁹ H. Maeda and S. Ikeda, *Biopolymers*, 1971, **10**, 1635.

²⁷⁰ G. Conio, E. Patrone, and F. Salario, *Macromolecules*, 1971, **4**, 283.

exist as either the α -helical or β -conformation depending upon kinetic factors, but at concentrations of ethanol of 45% and above, only the α -helical form was observed.

I.r. and X-ray diffraction studies on atoms of polypeptides and oligopeptides with repeating sequences of L-alanyl-L-prolylglycine have shown that polymers and oligomers longer than the hexapeptide could adopt three different forms, depending upon the solvent to which they have been exposed:²⁷¹ (i) hydrogen-bonded sheets of 'polyproline II-like' helices, when dried from aqueous solution, (ii) a more compact hydrogen-bonded 'polyproline II-type' sheet structure, when precipitated from organic solvents or aqueous solution, and (iii) a triple helical structure, when dried from trifluoroethanol. The solid-state i.r. spectra of the polymer and higher oligomers of the three forms showed a clear correlation between the amide frequencies and their structures. I.r. and c.d. solution studies indicated that (Ala-Pro-Gly)_n and the oligomers were unordered in aqueous solution, partly ordered in trifluoroethanol solution, and highly structured in ethylene glycol-hexafluoroisopropyl alcohol solution. These conformations were different, however, from that of (Pro-Ala-Gly)_n, which was found to be triple helical in the solid state and in solution.

Poly(L-histidine) films at different degrees of protonation have been produced and subjected to an i.r. study between 4000 and 650 cm⁻¹ using N-deuteriated films.²⁷² The amide II and III bands showed that the peptide group was present in the *trans*-form. The amide I and II bands were present at between 0 and 50% protonation, indicating that the poly(L-histidine) was α -helical; at 100% protonation it had a random-coil conformation with a little β -material present. Between 0 and 50% protonation, no hydration water was bound to the backbone. At 0% protonation all NH groups were linked to each other or to water molecules, whereas at 50% protonation, N⁺H · · · H bonds formed between imidazole rings, and the chloride ions were bonded to NH groups. At 100% protonation, water of hydration was also bonded to the C=O group of the backbone. The NH groups of the backbone, like those of the rings, endeavour to bond to the Cl⁻ ions, which leads to a strong steric constraint of the random coil.

C. Solvation and Structure.—The effect of water on the structure of proteins can be observed by recording their i.r. spectra at different relative humidities (RH). I.r. spectra of undenatured bovine tendon collagen²⁷³ have been recorded at 25 °C and at relative humidities between 0 and 95%. The samples were examined by electron microscopy before and after they had been exposed to i.r. radiation, to see if denaturation had taken place. The frequencies and intensities of the amide bands changed gradually over the RH range 0–75%. Pronounced changes were seen in the amide II vibration as water molecules gradually attached themselves to peptide NH

²⁷¹ B. B. Doyle, W. Taub, G. P. Lorenzi, and E. R. Blout, *Biochemistry*, 1971, 10, 3052.

²⁷² J. Muehlinghaus and G. Zundel, *Biopolymers*, 1971, 10, 711.

²⁷³ H. Susi, J. S. Ard, and R. J. Carroll, *Biopolymers*, 1971, 10, 1597.

bonds within the triple helix over a wide range of relative humidities. Changes in the CH deformation bands suggest that hydrogen-bonding between CH and O also occurs, and that it is stronger at high humidity. The effect of concentrated aqueous solutions of LiBr on randomly coiled sodium poly(L-glutamate) have been followed using i.r. and n.m.r. techniques.²⁷⁴ Between 0 and 4 mol l⁻¹ LiBr, water is removed from the polymer by an electrostriction effect. However, above 4 mol l⁻¹ LiBr a stronger interaction occurs in which competition for the available water in the system forces the electrolyte to form an association with the peptide group either as a fully or partially hydrated species. It was proposed that the anion is associated with the nitrogen atoms of the peptide group, and that the cation is situated within the vicinity of the carbonyl oxygen. The i.r. spectra of several peptides, and of serum albumin and its hydrolysate, have been recorded between 1580 and 1800 cm⁻¹ in D₂O solution. The absorption band observed at 1620—1685 cm⁻¹ was attributed to the free carbonyl group in the peptide chain.²⁷⁵

By observing changes in the amide frequencies, attempts have been made to examine the nature of the interaction of trifluoroacetic acid with poly(L-alanine).²⁷⁶ It has been shown that this polypeptide is not protonated by the acid, and that hydrogen-bonding occurs between the acid and the peptide group. Interactions between proteins and polysaccharides have been studied using attenuated total reflectance spectroscopy.²⁷⁷ Considerable frequency shifts were observed for the amide I and II bonds of the protein and for the OH deformation of the polysaccharide, suggesting that hydrogen-bonding was involved.

7 Circular Dichroism and Optical Rotatory Dispersion*

contributed by P. M. Bayley

The volume of published work continues to increase. Circular dichroism is becoming the predominant technique for peptide structure determination. Commercial instruments are generally available, and the results are more generally interpretable. Unless explicitly stated otherwise, reference is to c.d. work.

The major fields of activity and the corresponding parts of this section of the Report are: theoretical, in A; structural studies on small model systems and synthetic polypeptides, in B; criteria of folding and refolding in proteins, in C; perturbation of protein structure by non-chromophoric ligands and the induced optical activity of chromophores bound to proteins, in D; and membrane systems, in H.

²⁷⁴ C. B. Baddiel, D. Chaudhuri, and B. C. Stace, *Biopolymers*, 1971, 10, 1169.

²⁷⁵ M. A. Sem'onov and V. Ya. Maleev, *Dopovidi Akad. Nauk Ukrain. R.S.R. Ser. B*, 1971, 33, 136.

²⁷⁶ P. Combélas and C. Garrigou-Lagrange, *Compt. rend.*, 1971, 272, C, 153.

²⁷⁷ G. F. Trott and E. E. Woodside, *J. Colloid Interface Sci.*, 1971, 36, 40.

* See also Chapter 1, Section 3C.

A. General.—Reviews. A general guide to the application of o.r.d. and c.d. to the study of biopolymers presents the physical basis of the methods without excessive reliance on theoretical development.²⁷⁸ The relationship between optical activity and molecular structure is illustrated with reference to simple model systems in the peptide and nucleotide field, and to polynucleotides, proteins, and aggregates (membranes, ribosomes, and viruses). The analysis of peptide c.d. and the use of aromatic c.d. as a probe for limited conformational changes have been discussed for some intensively studied systems.²⁷⁹ O.r.d. and c.d. of biological macromolecules have been reviewed: relative merits of the two techniques, applications of m.c.d., u.v., and i.r., and the study of oriented specimens are briefly discussed.²⁸⁰ Specialized reviews deal with the study of drug interaction with biological systems,²⁸¹ the binding of small molecules by macromolecules,²⁸² and the molecular size and conformation of immunoglobulins.²⁸³

Theory. A non-perturbation method for computing the rotational strength of transitions in helical poly(L-alanine) using Bogoliubov exciton theory includes the effects of the high-energy $\pi^+-\pi^-$ transition (148 nm) on properties associated with the two principal transitions of the peptide link, $n-\pi^-$ (210 nm) and $\pi^0-\pi^-$ (191 nm). The method is suitable for structures of helical symmetry and avoids the problem of solving large matrices.²⁸⁴ Whereas first-order perturbation theory adequately represents the absorption properties, being relatively insensitive to doubling the effective oscillator strength at 148 nm, the rotational strength calculations were more sensitive to the assumed properties in this region, indicating a preference for non-perturbation methods in this case.

Monte Carlo methods have been applied to the generation of a set of random polypeptide conformations, in conformity with calculated conformational energies, and the rotational properties associated with various subsets of 5 or 10 peptides have been computed,²⁸⁵ using methods which have previously been used for computations on α and β structures.²⁸⁶ For a simulated random polypeptide, short-wavelength $\pi-\pi^*$ rotational strength is negative below 190 nm, whereas longer wavelength $\pi-\pi^*$ components generate positive rotational strength above 200 nm, in opposition to the negative rotational strength associated with the $n-\pi^*$ transition. This result is at variance with the usual assignment of the characteristic

²⁷⁸ I. Tinoco, jun. and C. R. Cantor, *Methods Biochem. Analysis*, 1970, **18**, 81.

²⁷⁹ S. N. Timasheff, in 'The Enzymes', ed. P. D. Boyer, Academic Press, New York, 3rd edn., 1970, vol. 2, p. 398.

²⁸⁰ C. A. Bush, in 'Physical Techniques in Biological Research', ed. G. Oster, Academic Press, New York, 2nd edn., vol. 1, 1971, p. 347.

²⁸¹ C. F. Chignell, *Adv. Drug Res.*, 1970, **5**, 55.

²⁸² J. H. Perrin and P. A. Hart, *J. Pharm. Sci.*, 1970, **59**, 431.

²⁸³ K. J. Dorrington and C. Tanford, *Adv. Immunology*, 1970, **12**, 333.

²⁸⁴ F. M. Loxsom, L. Tterlikkis, and W. Rhodes, *Biopolymers*, 1971, **10**, 2405.

²⁸⁵ V. A. Zubkov, T. M. Birshtein, I. S. Milevskaya, and M. V. Volkenstein, *Biopolymers*, 1971, **10**, 2051.

²⁸⁶ V. A. Zubkov and M. V. Volkenstein, *Mol. Biol.*, 1970, **4**, 599.

positive ellipticity in random polypeptides at 220 nm as deriving from $n-\pi^*$, but agrees with other recent calculations.²⁸⁷

In computations using the Kirkwood formulation of natural optical activity, the local origins of groups must be carefully chosen to eliminate local transition dipoles where these are computed from wave-functions based upon atomic co-ordinates.²⁸⁸

Theories of the differential scattering of right- and left-handed circularly polarized light and for the distortion of absorption bands by flattening, phenomena which are of importance in the observation of o.r.d. and c.d. of suspensions of optically active particles, have generally treated the two effects as mutually separable. A new treatment of Mie scattering considers the absorption and refraction as the imaginary and real parts of a single complex analytic function²⁸⁹ (see also ref. 290), and results are presented for solid spheres and for shells of dimensions equivalent to biological membranes.

The theoretical treatment of the conformational dependence of optical activity achieves a new level of refinement, in treating the origins of optical activity in chromophores extrinsic to the polypeptide backbone. Using methods as previously described,^{291, 292} calculation of the rotational strengths of the transitions in four possible structures of poly-(L-tyrosine) produced agreement with experimental data only for the structure with right-handed α -helical peptide conformation.²⁹³ The orientation of phenolic side-chains allows some degree of flexibility. In a detailed study of the origin of the haem Cotton effects in myoglobin and haemoglobin,^{294, 295} the only mechanism able to account for the rotational strength of the Soret transitions derives from the coupling of the porphyrin transitions with the $\pi-\pi^*$ transitions of nearby aromatic residues. Contributions from coupling with the peptide transitions are negligible. Principal contributors are within 4–6 Å (centre-to-centre distance), though tyrosine residues up to 12 Å make significant contributions. In haemoglobin, coupling of haem transitions with the aromatic residues of adjacent subunits is significant. The characteristic asymmetric shape of the Soret c.d. is shown to derive from oppositely signed strong effects of different magnitudes in the near-degenerate transitions; orientations have been proposed for these transitions. These results establish the theoretical rationale for the use of chromophoric probes for conformation, and indicate the complexity and multiplicity of effects which can contribute to the rotational strength of an extrinsic chromophore.

²⁸⁷ D. Aebersold and E. S. Pysh, *J. Chem. Phys.*, 1970, **53**, 2156.

²⁸⁸ P. J. Stiles, *Mol. Phys.*, 1971, **22**, 731.

²⁸⁹ D. J. Gordon, *Biochemistry*, 1972, **11**, 413.

²⁹⁰ A. S. Schneider, *Chem. Phys. Letters*, 1971, **8**, 604.

²⁹¹ I. Tinoco, jun., *Adv. Chem. Phys.*, 1962, **4**, 113.

²⁹² R. W. Woody, *J. Chem. Phys.*, 1968, **49**, 4797.

²⁹³ A. K. Chen, and R. W. Woody, *J. Amer. Chem. Soc.*, 1971, **93**, 29.

²⁹⁴ M. C. Hsu and R. W. Woody, *J. Amer. Chem. Soc.*, 1971, **93**, 3515.

²⁹⁵ M. C. Hsu and R. W. Woody, *J. Amer. Chem. Soc.*, 1969, **91**, 3679.

The theory has been presented for the temperature-dependent optical activity due to quantized molecular rotation, which is likely to be implicated in low-temperature i.r. work.²⁹⁶ Expressions are also given for the optical rotation of oriented molecules, for asymmetric molecules belonging to a few simple groups.

Analysis. Following extremely careful calibration of an instrument for o.r.d. and c.d., essentially perfect agreement has been found between the o.r.d. spectrum and the Kronig-Kramers transform of the observed c.d. spectrum both for helical poly-(L-lysine) (in 0.5 mol l⁻¹ sodium perchlorate, pH 6.30 and 25.0 °C) and helical poly(methyl-L-glutamate) (in trifluoroethanol at 25.0 °C);²⁹⁷ solvent corrections were omitted. The absence of divergence between the o.r.d. and c.d. (from 185 nm upwards) is used to question the theoretical predictions of exciton theory. Although this is unlikely to gain general acceptance, the absence of dispersive effects originating from higher-energy transitions is surprising, and requires examination in other systems.

The properties of Standard α , β -I, β -II, and random conformations have been reviewed.²⁷⁹ The analysis of protein c.d. spectra as a linear combination of contributions from α -helical, β -structured, and irregular regions is claimed to correlate better with the fractional contents of these forms determined by X-ray crystallography if the spectrum of poly-(L-serine) in 8 mol l⁻¹ lithium chloride is used as the reference component for random coil.²⁹⁸ An alternative to the multicomponent analysis can be expressed as:

$$[\theta] = \sum x_i [\theta]_i = x_\alpha [\theta]_\alpha + x_\beta [\theta]_\beta + x_R [\theta]_R$$

assuming that the observed c.d. spectrum $[\theta]$ can be expressed as the sum of fractional contributions x_i of three types of structure correlating with α -helix, β -structure, and the remaining structure, R. Using the spectral data for three proteins (ribonuclease, lysozyme, and myoglobin) and the values of x_i for each (from X-ray data), the reference spectra $[\theta]_\alpha$, $[\theta]_\beta$, and $[\theta]_R$ are found, respectively, to correlate highly with α -helix, but less so with β -structure or random polypeptide. These three spectra gave an analysis of carboxypeptidase A in good agreement with X-ray data, but were less successful for chymotrypsin and chymotrypsinogen.²⁹⁹

A similar approach using the values of x_i in conjunction with a spectroscopic parameter P , where P could be b_0 , $[m]_{233}$, or $[\theta]_{222}$, may be formulated:

$$P_{\text{obs}} = \sum x_i P_i$$

Based upon the X-ray data for the same three reference proteins, plus papain and lactate dehydrogenase, good parameters are found for the α -helix, but less satisfactory results for the other identifiable structures.³⁰⁰

²⁹⁶ Y. N. Chiu, *J. Chem. Phys.*, 1970, **52**, 1042.

²⁹⁷ J. Y. Cassim and J. T. Yang, *Biopolymers*, 1970, **9**, 1475.

²⁹⁸ H. Rosenkranz and W. Scholtan, *Z. physiol. Chem.*, 1971, **352**, 896.

²⁹⁹ V. P. Saxena and D. B. Wetlaufer, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 969.

³⁰⁰ Y.-H. Chen and J. T. Yang, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 1285.

Variability of helix parameters for different models in the same solvent have been noted in ref. 352. These methods suffer the disadvantage of treating the structure of globular proteins as composed of a limited number of structures of invariant properties and with additivity between the components.

Instrumental. C.d. measurements into the vacuum-u.v. to 135 nm at 1.6 nm spectral bandwidth and with resolution of the order of 10^{-5} O.D. units at 10 s time-constant have been reported,³⁰¹ allowing work on model compounds in the vapour state, and hopefully, as for absorption,³⁰² on films of polypeptides.

Cleavage of the peptide backbone has been observed after u.v. irradiation during spectropolarimetric measurements in aqueous solution; the $n-\pi^*$ region was found to be more sensitive than the $\pi-\pi^*$ region.³⁰³

Modifications of commercial instruments have been made to allow simultaneous recording of absorption and c.d. data, facilitating work on turbid preparations,³⁰⁴ to provide automatic scanning of temperature,³⁰⁵ and to cover the range 1.1–1.8 μm using quarter-wave plates of mica in studying the highly dichroic spectra of metalloproteins.³⁰⁶ O.r.d. studies have also been reported in the range 0.7–2.0 μm for synthetic polypeptides, from which a new property, specifically characteristic of β -structure, has been inferred.^{307, 308}

Low-temperature studies at 77 K in transparent water-glycerol glasses continue to improve the resolution of fine structure in aromatic transitions,³⁰⁹ and to identify conformational states which have only a transient lifetime at normal temperatures.³¹⁰ Computer summation of repeated scans is necessary. Individual stages of conformational transitions have also been observed at -40°C in fluid aqueous ethylene glycol mixtures.³¹¹

Magnetic circular dichroism (m.c.d.) measurements on model aromatic compounds show a dominant effect from tryptophan, readily resolved from a smaller effect due to tyrosine and a negligible effect of phenylalanine.³¹² The quantitative determination of tryptophan content of a range of proteins was in good agreement with analytical data.³¹³

³⁰¹ W. C. Johnson, jun., *Rev. Sci. Instr.*, 1971, **42**, 1283.

³⁰² J. Brahms, J. Pilet, H. Damany, and V. Chandrasekharan, *Proc. Nat. Acad. Sci. U.S.A.*, 1968, **60**, 1130.

³⁰³ W. D. Wilson and J. F. Foster, *Biochem. Biophys. Res. Comm.*, 1970, **38**, 552.

³⁰⁴ J. R. Krivacic, D. E. Wisnosky, and D. W. Urry, *Analyt. Biochem.*, 1971, **43**, 547.

³⁰⁵ W. W. Martz and S. Aktipis, *Analyt. Biochem.*, 1971, **39**, 327.

³⁰⁶ W. A. Eaton and W. Lovenberg, *J. Amer. Chem. Soc.*, 1970, **92**, 7195.

³⁰⁷ Yu. N. Chirgadze, S. Yu. Venyaminov, and V. M. Lobachev, *Biopolymers*, 1971, **10**, 809.

³⁰⁸ S. Yu. Venyaminov and Yu. N. Chirgadze, *Doklady Akad. Nauk S.S.S.R.*, 1970, **195**, 722.

³⁰⁹ J. Horwitz and E. H. Strickland, *J. Biol. Chem.*, 1971, **246**, 3749.

³¹⁰ J. Horwitz and J. Heller, *Biochemistry*, 1971, **10**, 1402.

³¹¹ P. Douzou, R. Sireix, and F. Travers, *Proc. Nat. Acad. Sci. U.S.A.*, 1970, **66**, 787.

³¹² G. Barth, R. Records, E. Bunnenberg, C. Djerassi, and W. Voelter, *J. Amer. Chem. Soc.*, 1971, **93**, 2545.

³¹³ G. Barth, W. Voelter, E. Bunnenberg, and C. Djerassi, *J. Amer. Chem. Soc.*, 1972, **94**, 1293.

Optical rotation has been used to follow the relaxation of poly(benzyl-L-glutamate) over the millisecond range following electric field orientation.³¹⁴ Electric dichroism studies themselves on this polymer show highly resolved vibrational structure in the dichroic spectra.^{315, 316} Optical rotation has also been used to follow sedimentation during analytical ultracentrifugation.³¹⁷

Determination of the optical purity of a sample by means of the dissymmetry of the luminescent emission from an asymmetric sample excited with circularly polarized light of either sense has been presented in theory,³¹⁸ following the principles involved in measuring the optical activity in racemic mixtures.^{319, 320}

B. Small Molecules, Model Compounds, and Synthetic Polymers.—*Amino-acids and Derivatives.* Careful examination of the c.d. of α -amino-acids and their esters^{321–323} and of α -hydroxy-acids^{322, 323} indicates a weak negative band at 230–245 nm approximately two orders of magnitude less than the well-resolved positive effect at 206–209 nm which has generally been assigned to the $n-\pi^*$ carboxyl transition. The band is absent for ester hydrochlorides in 95% ethanol,³²³ but present in aqueous solution.³²¹ At elevated temperatures and in solvents of low polarity the band increases, whereas at 206–209 nm it decreases, suggesting a conformational equilibrium.^{322, 324} The $n-\pi^*$ origin of the effect is generally accepted, but the relevant n -electron may derive from the heteroatom at C_α,³²² or from the carboxylic function,³²⁴ in the latter case the heteroatom is considered to be nodal to the chromophore.

Distinctions between carboxamide and carboxyl function are drawn in a study of amino-sugars and sialic acids and polymers derived from them. The stereochemistry of gangliosides, which contain both components, may be partially assigned.^{325, 326}

Chromophoric derivatives of α -amino-acids are sought for identification of amino-acid chirality: methyl isothiocyanate adducts show faster reaction, enhanced water solubility, and simpler spectra compared with the phenyl isomers.³²⁷ The sign of the effect at 260–270 nm was independent of solvent for water, methanol, chloroform, or dioxan. The derivative with

³¹⁴ B. R. Jennings and E. D. Baily, *Nature*, 1970, **228**, 1309.

³¹⁵ J. B. Milstien and E. Charney, *Biopolymers*, 1970, **9**, 991.

³¹⁶ E. Charney, J. B. Milstien, and K. Yamaoka, *J. Amer. Chem. Soc.*, 1970, **92**, 2657.

³¹⁷ A. J. Sophianopoulos, *Analyt. Biochem.*, 1970, **34**, 278.

³¹⁸ S. S. Eaton, *Chem. Phys. Letters*, 1971, **8**, 251.

³¹⁹ H. P. J. M. Dekkers, C. A. Emeis, and L. J. Oosterhoff, *J. Amer. Chem. Soc.*, 1969, **91**, 4589.

³²⁰ C. A. Emeis and L. J. Oosterhoff, *Chem. Phys. Letters*, 1967, **1**, 129.

³²¹ C. Toniolo, *J. Phys. Chem.*, 1970, **74**, 1390.

³²² J. C. Craig and W. E. Pereira, jun., *Tetrahedron*, 1970, **26**, 3457.

³²³ J. C. Craig and W. E. Pereira, jun., *Tetrahedron Letters*, 1970, 1563.

³²⁴ I. Listowsky, G. Avigad, and S. England, *J. Org. Chem.*, 1970, **35**, 1080.

³²⁵ A. L. Stone and E. H. Kolodny, *Chem. and Phys. Lipids*, 1971, **6**, 274.

³²⁶ A. L. Stone, *Biopolymers*, 1971, **10**, 739.

³²⁷ C. Toniolo, *Tetrahedron*, 1970, **26**, 5479.

cysteine, though reacting slowly, may have some analytical value.³²⁸ *N*-Acetoacetyl-amino-acids exhibit a solvent-dependent c.d. and a pH dependence corresponding to carboxyl ionization and enolization; tertiary amides (e.g. proline) show inverted effects.³²⁹ The β -carbonylamides give rise to azlactones, the geometric isomers of which exhibit distinctive c.d. effects.³³⁰ *N*-Dithioethoxycarbonyl- α -methyl-amino-acids exhibit similarly signed c.d. independent of solvents (methanol, dioxan, chloroform, or benzene) but aromatic amino-acid (e.g. α -methylphenylalanine) derivatives, though solvent-insensitive, are oppositely signed. Of the hydantoin derivatives, only the α -methyl- α -phenylglycine derivative was exceptional.³³¹ A new and rapid resolution of DL- α -methylphenylalanine is reported.³³²

The spectroscopic properties of the disulphide component of L-cystine have been examined in the crystalline state in isotropic preparations in KBr discs.³³³ The anomalous, split c.d. of L-cystine is attributed to the proximity of adjacent disulphides in the crystal, whereas in L-cystine hydrochloride no such effects occur, owing to the interposition of the chloride ion. The latter compound, exhibiting a broad negative effect from 250 to beyond 300 nm,³³⁴ correlates with symmetry assignments made on the basis of solution properties of restricted molecules.³³⁵

Metal complexes of the chiral amino-acids are optically active in the visible spectrum: an empirical rule is derived from the observed additive properties of asymmetric ligands bound to copper(II), in which the metal and chelating atoms are on nodal planes, and only the amino-acid side-group acts as perturbant.³³⁶ Studies of the mixed complexes of copper(II) with glycine and histidine derivatives suggest that histidine complexes resemble histamine rather than glycine.³³⁷ Alcoholic solutions of amino-acid esters form dipeptides in the presence of copper(II), a synthetic activity which complements the hydrolysis properties of copper(II)-peptide complexes.³³⁸ Individual components of the complex ligand-field transition in carboxylatopenta-aminocobalt(III) complexes involving L-amino-acids have been resolved by the effects in c.d. spectra of adding polarizable oxyanions: the component of A_{2g} origin is negative; those of E_g origin are of opposite sign, being positive at lower energy.³³⁹

³²⁸ C. Toniolo and G. Jori, *Biochim. Biophys. Acta*, 1970, **214**, 368.

³²⁹ C. Toniolo, F. Filira, and C. DiBello, *Biopolymers*, 1971, **10**, 2275.

³³⁰ C. DiBello, F. Filira, and C. Toniolo, *Biopolymers*, 1971, **10**, 2283.

³³¹ K. Achiwa, S. Terashima, M. Hatsuhiro, N. Takamura, T. Kitagawa, K. Ishikawa, and S. Yamada, *Chem. and Pharm. Bull. (Japan)*, 1970, **18**, 61.

³³² F. W. Bollinger, *J. Medicin. Chem.*, 1971, **14**, 373.

³³³ N. Ito and T. Takagi, *Biochim. Biophys. Acta*, 1970, **221**, 430.

³³⁴ P. C. Kahn and S. Beychok, *J. Amer. Chem. Soc.*, 1968, **90**, 4168.

³³⁵ M. Carmack and L. A. Neubert, *J. Amer. Chem. Soc.*, 1967, **89**, 7134.

³³⁶ J. M. Tsangaris and R. B. Martin, *J. Amer. Chem. Soc.*, 1970, **92**, 4255.

³³⁷ H. Sigel, R. E. Mackenzie, and D. B. McCormick, *Biochim. Biophys. Acta*, 1970, **200**, 411.

³³⁸ S. I. Yamada, S. Terashima, and M. Wagatsuma, *Tetrahedron Letters*, 1970, 1501.

³³⁹ C. J. Hawkins and P. J. Lawson, *Inorg. Chem.*, 1970, **9**, 6.

Dipeptides and Oligopeptides. Optical rotatory properties of molecules containing two peptide groups have been obtained for *N*-acetyl-L-prolinamide, L-3-acetamidopyrrolidin-2-one, L-pyroglutamide, and L-alanine-dioxopiperazine, which have their conformation partially restricted by cyclic structures.³⁴⁰ Results for water and dioxan are in keeping with theoretical calculations for a four-transition dipeptide model.³⁴¹

The 3-cephem chromophore, present in cephalosporin antibiotics, contains a homoconjugated π -system composed of a tertiary amide and an enamine held dissymmetrically in a rigid conformation. Intense and oppositely signed effects at 260 nm (positive) and 230 nm (negative) are assigned respectively to a π - π^* and, from solvent effects, to an n - π^* transition, respectively.³⁴² The latter assignment appears dubious because of the intensity and molecular structure.

Cyclic hexapeptides with one and two side-chains (for which n.m.r. indicates the presence of two transannular hydrogen bonds) appear to exist in two conformations; *cyclo*-(Gly-Gly-Leu-Gly-Gly-Leu-) is assigned a C_2 symmetry. The monoleucyl derivative exhibits c.d. apparently similar to that of random poly(L-glutamate); in the cyclohexapeptide, however, both the positive 214 nm and the weaker negative 222 nm effects are attributed to n - π^* transitions, the difference in energies deriving from the intramolecular hydrogen-bonding.³⁴³

The synthetic cyclonona-peptide cyclolinopeptide A, [*cyclo*-(Leu-Ile-Ile-Leu-Val-Pro-Pro-Phe-)] exhibits solvent dependence in hexafluoroisopropanol, trimethyl phosphate, or trifluoroethanol, under conditions where the rigid model compound camphorolactone showed minor solvent shifts. Considerable conformational flexibility evidently exists for this cyclic nonapeptide.³⁴⁴

A bicyclic peptide, *SS'*-bis-*cyclo*-(Gly-Cys-Gly-Gly-Pro-), containing two homodetic peptide rings, has been shown to undergo a progressive conformational change in the presence of 0–4.0M-KCl. The dichroism at 260 nm indicates a right-handed (P) chirality for the disulphide, with dihedral angle 75–90°.³⁴⁵ In the cyclic synthetic decapeptide [2,7-cystine]-gramicidin S, containing an intramolecular disulphide, P chirality and the unique feature of a dihedral angle greater than 90° are inferred from the chemical shift of valine protons perturbed by the sulphur *p*-orbitals.³⁴⁶ The observation of a well-defined, broad, negative c.d. band with peak at 271 nm correlates with the predicted quadrant rule for organic disulphides.³⁴⁷

³⁴⁰ E. B. Nielsen and J. A. Schellman, *Biopolymers*, 1971, **10**, 1559.

³⁴¹ P. M. Bayley, E. B. Nielsen, and J. A. Schellman, *J. Phys. Chem.*, 1969, **73**, 228.

³⁴² R. Nagarajan and D. O. Spry, *J. Amer. Chem. Soc.*, 1971, **93**, 2310.

³⁴³ S. M. Ziegler and C. A. Bush, *Biochemistry*, 1971, **10**, 1330.

³⁴⁴ F. Naider, E. Benedetti, and M. Goodman, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1195.

³⁴⁵ R. Schwyzer, A. Tun-kyi, P. Moser, and M. Caviezel, *Helv. Chim. Acta*, 1970, **53**, 15.

³⁴⁶ U. Ludescher and R. Schwyzer, *Helv. Chim. Acta*, 1971, **54**, 1637.

³⁴⁷ J. Linderberg and J. Michl, *J. Amer. Chem. Soc.*, 1970, **92**, 2619.

For linear oligopeptides of isoleucine in trifluoroethanol, u.v. absorption and c.d. indicate the onset of ordered structure at the heptamer and octamer level, with spectra typical for β -conformations. These structures appear to be more stable than the oligomers of alanine, and an intermolecular association is inferred from the disappearance of characteristic spectra on dilution.^{348, 349} For oligomers of lysine in water at pH 11.9 and in methanolic solutions, the appearance of an ordered structure is only partial even at 22 residues. Helix-coil data can be obtained from the dependence of helicity on chain length.³⁵⁰ It is notable that at pH 3.8 the intensity of c.d. bands of the random form continues to increase up to DP = 156.³⁵¹

Polypeptides. The use of hexafluoroisopropanol as a solvent for proteins and synthetic polypeptides allows observation of u.v., visible, and i.r. spectroscopic properties.³⁵² The solvent is less polarizable than water, with $n_{589} = 1.2752$. The homopolymers of γ -methyl L-glutamate, L-methionine, ϵ -N-benzoyloxycarbonyl-L-lysine, and L-homoserine exhibit α -helical o.r.d. and c.d. spectra with small but significant differences; the parameters $[m]_{199}$ and $[\theta]_{222}$ showed least variability.

The stabilities of α -helical homopolymers of L-lysine, L-ornithine, and L-diaminobutyric acid, investigated as a function of pH at 25 °C and as a function of temperature at pH 11.75, indicate that the side-chains make an important contribution to the stability, with a progressive decrease as the number of methylenes is decreased.³⁵³ Chemical cross-linking of poly-(L-lysine) stabilizes the helical structure against thermal transitions on heating in aqueous solution at pH 11.5.³⁵⁴ The helix content of poly-(L-arginine) and poly-(L-lysine) undergoes a sharp increase as the proportion of alcohol in aqueous alcohol mixtures exceeds 75–80% by volume for trifluoroethanol, 2-chloroethanol, or methanol. Calf thymus histone, fractionated or unfractionated, showed a steady increase, attributed to the presence of a range of regions of varying helix-forming capability.³⁵⁵

Further effects of side-chain composition on conformation in aqueous solution are shown by poly-(L-lysine) substituted at the ϵ -amino-group with amino-acids. The glycyl derivative appeared random under conditions where the phenylalanyl and leucyl derivatives were helical.³⁵⁶ Introduction of L-alanyl residues into the sequentially random copolymer with L-lysine results in a helical conformation of lower thermodynamic stability.³⁵⁷

³⁴⁸ C. Toniolo, *Biopolymers*, 1971, **10**, 1707.

³⁴⁹ M. Goodman, F. Naider, and C. Toniolo, *Biopolymers*, 1971, **10**, 1719.

³⁵⁰ A. Yaron, E. Katchalski, A. Berger, G. D. Fasman, and H. A. Sober, *Biopolymers*, 1971, **10**, 1107.

³⁵¹ G. E. Perlmann and K. Grizzuti, *Biochemistry*, 1971, **10**, 4168.

³⁵² J. R. Parrish, jun. and E. R. Blout, *Biopolymers*, 1971, **10**, 1491.

³⁵³ M. J. Grouke and J. H. Gibbs, *Biopolymers*, 1971, **10**, 795.

³⁵⁴ I. M. Klotz and J. U. Harris, *Biochemistry*, 1971, **10**, 923.

³⁵⁵ M. Boublik, E. M. Bradbury, C. Crane-Robinson, and H. W. E. Rattle, *European J. Biochem.*, 1970, **12**, 258.

³⁵⁶ N. Anand, N. S. R. K. Murthy, F. Naider, and M. Goodman, *Macromolecules*, 1971, **4**, 564.

³⁵⁷ H. Sugiyama and H. Noda, *Biopolymers*, 1970, **9**, 459.

Poly-(*S*-carboxyethylcysteine) changes from a random conformation to β -structure as the pH is reduced below 5.5; intermolecular association is involved.³⁵⁸ This behaviour parallels that of the methyl analogue in forming β -structure in aqueous solution, and high molecular weight favours the conversion.^{359, 360} Spectra qualitatively resembling β -structure are shown by poly-(*L*-histidine) in aqueous solution at pH 5.2. This conformation is reached by a two-stage process from the random conformation as the pH is increased from 4.2.³⁶¹ A specific interaction between perchlorate and the side-chains of poly-(1-benzyl-*L*-histidine) in trifluoroethanol is implicated in the formation of a characteristic ordered structure when perchloric acid is added to protonate the polymer stoichiometrically. The c.d. shows a strong positive band at 225 nm and a stronger negative band at 198 nm; other acids give randomization.³⁶²

The origins of rotational strength in poly-(*L*-tyrosine) have been examined theoretically, and interactions between peptide and aromatic transitions are important.²⁹³ Simple additivity of helical and aromatic effects is therefore unreliable. Tyrosine oligopeptides up to $n = 12$ are random in dimethyl sulphoxide, 1,2-propanediol, or dimethylformamide.³⁶³ The helical conformation of the polymer in the latter two solvents is destabilized sharply when dimethyl sulphoxide is added to 80% or 50% by volume, respectively. For poly-(*L*-tyrosine) in aqueous solution, changes in c.d. spectra between pH 10.6 and 11.2 are attributed to the partial ionization of phenolic chromophores, with the conformation of the helical backbone remaining essentially unchanged.³⁶⁴

The polytripeptide poly Tyr-Ala-Glu shows a helix-coil transition above pH 6 in low, and above pH 11 in high salt concentrations. At intermediate pH values the transition can be induced by decreasing the salt concentration.³⁶⁵ Stabilization is due to hydrogen-bonding between the i th glutamate and the $(i + 4)$ th tyrosine side-chain, attached to an α -helical backbone. The resulting array of phenolic chromophores contributes characteristically to the o.r.d. at 220–240 nm and shows 8% hyperchromicity at 278 nm.

Poly-(β -benzyl-*L*-aspartate) is known to adopt the left-handed α -helix in chloroform, whereas substituted benzyl derivatives adopt the right-handed α -helix in the same solvent. This critical dependence of conformation upon interactions of side-chains with solvent is further shown by the appearance of a mirror-image spectrum for the polymer itself in trimethyl

³⁵⁸ H. Maeda and S. Ikeda, *Biopolymers*, 1971, **10**, 1635.

³⁵⁹ S. Makino and S. Sugai, *Biopolymers*, 1970, **9**, 1049.

³⁶⁰ L. Stevens, R. Townend, S. N. Timasheff, G. D. Fasman, and J. Potter, *Biochemistry*, 1968, **7**, 3717.

³⁶¹ Y. P. Myer and E. A. Barnard, *Arch. Biochem. Biophys.*, 1971, **143**, 116.

³⁶² A. Cosani, E. Peggion, M. Terbojevich, and M. Acampora, *Macromolecules*, 1971, **4**, 390.

³⁶³ J. Engel, E. Liehl, and C. Sorg, *European J. Biochem.*, 1971, **21**, 22.

³⁶⁴ S. Friedman and P. O. Ts'o, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 510.

³⁶⁵ J. Ramachandran, A. Berger, and E. Katchalski, *Biopolymers*, 1971, **10**, 1829.

phosphate, indicating that it too can have the right-handed helical conformation.³⁶⁶

In continuation of studies of synthetic analogues of the proline-rich regions of collagen, sequential copolypeptides (alternating) of the form (Pro-Ala)_n, (Pro-Gly)_n, and (4-Hyp-Gly)_n at -45 °C in ethylene glycol-water, show c.d. resembling poly-proline-II and native collagen with the characteristic strong positive band at 220 nm.³⁶⁷ At higher temperatures the spectra resemble that of heat-denatured collagen. The presence of proline (or hydroxyproline) at every third residue does not seem a necessary condition for adopting the collagen conformation. The stability of the ordered structure in the hydroxylated derivative is enhanced by intramolecular hydrogen-bonding:³⁶⁸ ordered structures are achieved at -25 °C in trifluoroethanol. Collagen-like structures are formed by poly Pro-Ser-Gly and poly Pro-Ala-Gly in propanediol at normal temperatures, but not in aqueous solution.³⁶⁹ A three-fold increase in molecular weight for either polymer indicates formation of a triple helix. Trimerization occurs with poly (Pro-Pro-Gly)_n for $n = 10, 15$, or 20 , and dissociation at high temperature is accompanied by a change in optical rotation resembling the thermal transition of collagen.³⁷⁰

Model polytripeptides for the non-proline regions of collagen of the form poly Ala-Glu(OEt)-Gly and poly Ala-Gly-Gly are generally insoluble in aqueous solution.³⁷¹⁻³⁷³ Studied as a suspension or film, the former shows c.d. resembling antiparallel β -structure, whereas the latter resembles a random conformation, or the poly-proline-II spectrum shifted to the blue. I.r. measurements support the first assignment; X-ray diffraction suggests a poly-glycine-II conformation in the second case.

Asymmetric polyamides deriving from optically active dicarboxylic acids of cyclo-propane, -butane, and -pentane and the diamide derivatives of piperazine and ethylenediamine exhibit c.d. similar to the polypeptides. Piperazine derivatives give rigid polymers with strong c.d. bands at 220 nm. Both simple bands and oppositely-signed bands are observed, depending upon solvent.³⁷⁴

C. Denaturation.—*Detergents and Neutral Salts.* Sodium dodecyl sulphate (SDS), at low concentrations close to the critical micelle concentration, changes the c.d. spectrum of many globular proteins to a characteristic

³⁶⁶ V. Gianconti, F. Quadrioglio, and V. Crescenti, *J. Amer. Chem. Soc.*, 1972, **94**, 297.

³⁶⁷ W. L. Mattice and L. Mandelkern, *J. Amer. Chem. Soc.*, 1970, **92**, 5285.

³⁶⁸ W. L. Mattice and L. Mandelkern, *Biochemistry*, 1971, **10**, 1926.

³⁶⁹ F. R. Brown, tert., A. DiCorato, G. P. Lorenzi, and E. R. Blout, *J. Mol. Biol.*, 1972, **63**, 85.

³⁷⁰ Y. Kobayashi, R. Sakai, K. Kakiuchi, and T. Isemura, *Biopolymers*, 1970, **9**, 415.

³⁷¹ J. M. Anderson, W. B. Rippon, and A. G. Walton, *Biochem. Biophys. Res. Comm.*, 1970, **39**, 802.

³⁷² W. B. Rippon and A. G. Walton, *Biopolymers*, 1971, **10**, 1207.

³⁷³ W. B. Rippon, J. M. Anderson, and A. G. Walton, *J. Mol. Biol.*, 1971, **56**, 507.

³⁷⁴ C. G. Overberger and Y. Shimokawa, *Macromolecules*, 1971, **4**, 718.

form, which has some features in common with that of the α -helix.³⁷⁵ Ribonuclease is affected only after reduction and carboxymethylation. With immunoglobulin fragment Fc, alkyl sulphates of chain length up to C_{14} were progressively more effective, though the relative magnitudes of the resulting spectral bands differed in detail.³⁷⁶ Elastase, chymotrypsin, and pepsin are transformed by SDS; trypsin and lysozyme less so. After dialysis, all were inactive and had spectra characteristic of a high content of β -structure, for which confirmation was obtained from i.r.³⁷⁷ The exact nature of the conformations adopted in SDS is unclear: from the effect of chain length, hydrophobic factors are evidently involved, together with the micellization of the protein-detergent complex. Remarkable constancy for widely different proteins is observed in the effect of SDS, and apparently for transformations which follow upon dialysis. Aromatic c.d. is in general reduced in intensity in SDS³⁷⁵⁻³⁷⁷ but rarely eliminated.

Binding of alkane derivatives in the range C_8 — C_{14} by bovine serum albumin causes limited unfolding which occurs in several steps; again, C_{12} and C_{14} derivatives are more effective.³⁷⁸ In the interaction of alkyl-pyridinium chloride with oxymyoglobin, derivatives with alkanes C_{12} and C_{14} were ineffective, while C_{16} — C_{20} effected a drop in Soret absorbance which paralleled a 20% decrease in $[m']_{235}$.³⁷⁹

The protein-bacteriochlorophyll complex from a green photosynthetic bacterium undergoes dissociation in SDS, with transformation of the protein conformation.³⁸⁰ Cationic and non-ionic detergents effect dissociation only. In the case of the bacteriochlorophyll complex from purple bacteria, the mild detergent action of octanoic acid produces a soluble complex with apparently monomeric c.d. properties at 860 nm (compared with the dimeric properties of chromatophore suspensions). Organic solvents effect solution, but with spectra shifted to 770 nm.³⁸¹ Various degrees of potency are thus available in the detergents, which may be utilized to simulate essentially hydrophobic interactions between proteins and ligands, and for inter- and intra-molecular effects in protein structure.

Denaturation and unfolding is generally accomplished with concentrated guanidine hydrochloride (GHCl); the thiocyanate salt is apparently even more potent.³⁸² Pancreatic trypsin-inhibitor is resistant to a concentration of 6 M-GHCl,³⁸³ and combination of this and analogous inhibitors to trypsin stabilizes the latter against unfolding by 8 mol l⁻¹ urea.³⁸⁴ Of

³⁷⁵ B. Jirgensons and S. Capetillo, *Biochim. Biophys. Acta*, 1970, **214**, 1.

³⁷⁶ P. K. Lee and B. Jirgensons, *Biochim. Biophys. Acta*, 1971, **229**, 631.

³⁷⁷ L. Visser and E. R. Blout, *Biochemistry*, 1971, **10**, 743.

³⁷⁸ J. Steinhardt, J. Krijn, and J. G. Leidy, *Biochemistry*, 1971, **10**, 4005.

³⁷⁹ K. Nakaya, K. Yamada, M. Onozawa, and Y. Nakamura, *Biochim. Biophys. Acta*, 1971, **251**, 7.

³⁸⁰ Y. D. Kim, *Arch. Biochem. Biophys.*, 1970, **140**, 354.

³⁸¹ H. Steffen and M. Calvin, *Biochem. Biophys. Res. Comm.*, 1970, **41**, 282.

³⁸² S. Lapanje, *Biochim. Biophys. Acta*, 1971, **243**, 349.

³⁸³ J. P. Vincent, R. Chicheportiche, and M. Lazdunski, *European J. Biochem.*, 1971, **23**, 401.

³⁸⁴ N. Levilliers, M. Peron, B. Arrio, and J. Pudles, *Arch. Biochem. Biophys.*, 1970, **140**, 474.

considerable potency are the concentrated solutions of lithium salts which apparently randomize synthetic polypeptides,^{385, 386} but are less effective than GHCl in unfolding bovine serum albumin.³⁸⁷ The denaturing efficiency of the amides with myoglobin, cytochrome *c*, and chymotrypsinogen, like that of the alcohols, glycols, and ureas, increases with increasing hydrocarbon content and alkyl substitution, suggesting a predominantly hydrophobic mechanism for these agents.^{388, 389}

Unfolding and Refolding. The zymogen of Streptococcal proteinase ($M = 44\,000$) unfolds to a random coil in 6 M-GHCl; following dialysis, the protein can be reactivated by 90%, indicating effectively full restoration of native conformation. The proteolysed zymogen, formed by removal of the first 100 residues, is irreversibly denatured by GHCl.³⁹⁰ The regeneration of activity from unfolded reduced lysozyme is accelerated by the presence of a mixture of thiol and disulphide reagents; rapid refolding of the chain (relative to regeneration of disulphides) occurs on dilution of the denaturant, since the kinetics of recovery of activity are constant for refolding from different states.³⁹¹ Refolding of bacteriophage MS2 coat protein to a capsid of normal size and antigenicity occurs on removal of GHCl.³⁹² The native and refolded conformations are high in β -structure, demonstrating, as with the immunoglobulins (section F), that refolding is realizable with a wide range of conformations.

D. Proteins.—This section is divided into aromatic (and disulphide) chromophores whose c.d. properties reflect local environmental effects; non-chromophoric proteins, whose peptide chromophores indicate backbone conformation; proteins with natural additional chromophores, whose (extrinsic) properties are determined by binding modes which are relevant to biological function; and extrinsic properties of added unnatural ligands which are dependent on binding-site conformation. Changes in any of these properties with added (non-chromophoric) ligands may indicate conformational changes.

Aromatic and Disulphide Chromophores. These chromophores present useful probes for protein structures, *e.g.* in chymotrypsin ribonuclease, carbonic anhydrase, or pyrocatechase.²⁷⁹ Theoretical interpretation of the spectrum of poly-L-tyrosine shows the mechanism for generating rotational strength at 277 nm and 227 nm (both positive) in the phenol chromophore.²⁹³ The $\pi-\pi^*$ transitions of the peptide and the 192.5 nm phenol transitions are not resolvable and cannot be characterized simply from the extrema

³⁸⁵ M. L. Tiffany and S. Krimm, *Biopolymers*, 1969, **8**, 347.

³⁸⁶ D. G. Dearborn and D. B. Wetlaufer, *Biochem. Biophys. Res. Comm.*, 1970, **39**, 314.

³⁸⁷ M. E. Noelken, *Biochemistry*, 1970, **9**, 4117.

³⁸⁸ T. T. Herskovits, H. Jaillet, and T. Desena, *J. Biol. Chem.*, 1970, **245**, 6511.

³⁸⁹ T. T. Herskovits, H. Jaillet, and B. Gadegbeku, *J. Biol. Chem.*, 1970, **245**, 4544.

³⁹⁰ M. C. Lin and M. Bustin, *J. Biol. Chem.*, 1970, **245**, 3384.

³⁹¹ V. P. Saxena and D. B. Wetlaufer, *Biochemistry*, 1970, **9**, 5015.

³⁹² P. J. Oriel, P. Lindsey, and C. Schueneman, *Biopolymers*, 1971, **10**, 1661.

of the total c.d. envelope. Synthetic systems involving tyrosine³⁶³⁻³⁶⁵ and histidine³⁶¹ have been mentioned; as with disulphides,^{333-335, 345, 346} direct conformational evidence is derivable mainly from the longest-wavelength transitions.

The enhanced resolution available from low-temperature studies indicates that a single tyrosine residue with 0-0 band at 288.5 nm in ribonuclease-A is shifted 2.5 nm to the blue in ribonuclease-S.³⁰⁹ X-Ray evidence suggests that Tyr-25 is partially exposed in the latter, though its phenolic OH is still buried and hydrogen-bonded. Low-temperature results so far obtained correlate well with those at normal temperature, and the extra degree of resolution represents the most powerful method of analysing the overlapping effects in this region.

Assignments and resolution of individual aromatic amino-acids have been given for the coat protein of tobacco mosaic virus: from model compounds and pH dependence of spectra, contributions from phenyl-alanine (248, 252, and 257 nm), tyrosine (265, 274, and 281 nm), and tryptophan (291 and 296 nm) have been detected.³⁹⁸ Spectra of the proteins from other strains and mutants differing in amino-acid composition show that replacements of aliphatics do not affect aromatic c.d., whereas replacements of the aromatics cause significant changes, offering a means of resolving the total spectrum. If this method could be coupled with information about the degree of burying of replaced residues of known sequence, e.g. by low-temperature studies,³⁰⁹ a direct relationship between primary sequence and conformation in solution would be available. Mutation provides selective alteration of primary sequence which has previously been achieved by chemical modification for resolution of aromatic c.d. for lysozyme.³⁹⁴

Pancreatic ribonuclease-A, containing no tryptophan residues, is frequently used as a standard system, though a range of environments for tyrosine and cysteine complicates the interpretation of the origins of the c.d. effects. The effect of acid is to alter the aromatic c.d. preferentially;³⁹⁵ at constant pH and ionic strength, increasing the concentration of acetic acid in the buffer gives progressive diminution of c.d. by a reversible and co-operative effect. Changes in o.r.d. at 228 nm between pH 6.5 and 1.2 are not paralleled by changes in c.d. below 230 nm, suggesting that these effects originate with the aromatic residues rather than with peptides.³⁹⁶ The reduction in c.d. (276 nm, less negative; 241 nm, less positive) follows $pK = 1.5$. Photo-oxidation with haematoporphyrin at different stages of acid transition allows formation of sulfoxide at Met-29 alone, or with Met-13, or at all four methionine residues together.³⁹⁷ Whereas the first

³⁹³ A. Z. Budzynski, *Biochim. Biophys. Acta*, 1971, **251**, 292.

³⁹⁴ V. I. Teichberg, C. Kay, and M. Sharon, *European J. Biochem.*, 1970, **16**, 55.

³⁹⁵ J. R. Cann, *Biochemistry*, 1971, **10**, 3713.

³⁹⁶ P. McPhie, *J. Biol. Chem.*, 1971, **246**, 5537.

³⁹⁷ G. Jori, G. Galiazzo, A. M. Tamburro, and E. Scoffone, *J. Biol. Chem.*, 1970, **245**, 3375.

product retains the major portion of the aromatic c.d., after modification of Met-13 most of this c.d. is lost and the peptide region appears significantly randomized.

By contrast, elongation of the disulphides by formation of (Cys)₂Hg bridges gives a derivative with the gross conformation and a small amount of the activity of the native enzyme. Peptide c.d. is retained, but the aromatic region is reduced to approximately 25%.³⁹⁸ Elongation of cystine-II—VII would force Asp-38 and (buried) Tyr-92 apart. These results suggest that the major contribution to the c.d. at 275 nm² comes from tyrosine residues, and probably from Tyr-92. Significant contributions from disulphide transitions would presumably correlate with retention of peptide c.d. Their absence from the enzyme after conformational transition in acid and the similarity in c.d. of this form with the mercurated derivative suggests that their contribution in the native form is minor; they may be more significant at 77 K.³⁹⁹

Studies on the deoxyribonucleases from different sources (the acid, pancreatic, and *S. aureus* enzymes) show that considerable structural differences exist between these functionally related enzymes.⁴⁰⁰ Thus the aromatic c.d. is positive, weakly positive and negative, and strongly negative in the three cases, and helical content is low in each. The pancreatic enzyme has a partially reversible thermal transition between two states differing in tyrosine environments,⁴⁰¹ but otherwise the deoxyribonucleases show little resemblance to the pancreatic ribonuclease.

The effects of solvents on the aromatic c.d. of lysozyme show two stages: at concentrations up to 40% aqueous ethanol, the positive c.d. (mainly tryptophan) is intensified, and fine structure is better resolved. At 90% ethanol, a dramatic reversal of sign occurs in the 280—290 nm region, the negative region at 250—260 nm is less intense, and the system exhibits an isodichroic point at *ca.* 275 nm. Simultaneously the 210—225 nm region is intensified and indicates adoption of a more helical conformation.⁴⁰² Similar effects are observed with a number of alcohols, only ethylene glycol being relatively ineffective. Inversion has been observed for *N*-acetyl-L-tyrosine derivatives on changing from dioxan to methane;³⁹⁹ the dependence of tyrosine c.d. upon side-chain orientation has been treated theoretically.⁴⁰³

Conformational transitions induced by change of the external medium include: for asparaginase, aromatic c.d. which is constant from pH 4.5 to 7.5, but showing intensification of the 250 nm region at pH 11—12, although the far-u.v. indicates extensive randomization;⁴⁰⁴ for insulin, some intensity retained at 70 °C, reduction of intensity with retention of fine-structure in

³⁹⁸ R. Sperling and I. Z. Steinberg, *J. Biol. Chem.*, 1971, **246**, 715.

³⁹⁹ J. Horwitz, E. H. Strickland, and C. Billups, *J. Amer. Chem. Soc.*, 1970, **92**, 2119.

⁴⁰⁰ S. N. Timasheff and G. Bernardi, *Arch. Biochem. Biophys.*, 1970, **141**, 53.

⁴⁰¹ S. B. Zimmerman and N. F. Coleman, *J. Biol. Chem.*, 1971, **246**, 309.

⁴⁰² K. Ikeda and K. Hamaguchi, *J. Biochem. (Japan)*, 1970, **68**, 785.

⁴⁰³ T. M. Hooker, jun. and J. A. Schellman, *Biopolymers*, 1970, **9**, 1319.

⁴⁰⁴ H. Rosenkranz and W. Scholtan, *Z. physiol. Chem.*, 1971, **352**, 1081.

80% acidic methanol or 70% 2-chloroethanol, related to changes in side-chain conformation rather than non-conformational solvent effects;^{405, 406} for pepsinogen, reversible conversion by alcohols into a specific conformation from which pepsin activity cannot be obtained by acidic hydrolysis and which is characterized by low c.d.;⁴⁰⁷ for human and bovine growth hormone, distinctive aromatic c.d. which also allows differentiation of the three components of the human hormone (in spite of similar amino-acid compositions), and distinctive far-u.v. spectra, with higher helical structure for the bovine hormone, though hormonal activity is also associated with its peptide fragment, which is richer in β -structure;⁴⁰⁸ and for the human chorionic somatomammotropin, stable conformation from pH 12—4, small changes in aromatic conformation at pH 3.6, and total loss of order in 50% acetic acid (both reversible), the unfolding behaviour resembling bovine growth hormone and ovine prolactin.^{409, 410}

With N-terminal fragments of angiotensin-II, ordered structures resembling β -structure appear at the heptapeptide level (in trifluoroethanol, or in aqueous solution at 60 °C), and at the octapeptide level the addition of the functionally important phenylalanine residue (adjacent to proline) has striking spectroscopic consequences.⁴¹¹

More-specific effects observable by the aromatic c.d. are: for concanavalin A, involvement of tyrosine and tryptophan in pH-dependent conformational changes, predominant involvement of tyrosine in changes induced by Ca^{2+} and α -methyl D-glucopyranoside,⁴¹² and by α -methyl D-mannoside, the ligand not conferring stability against the dramatic loss of structure at pH 9;⁴¹³ for thyroxine-binding prealbumin, stable conformation from pH 12—3.5, expansion over pH 3.5—2.5 with loss of tryptophan-like spectrum;⁴¹⁴ for pyruvate kinase, a large increase in intensity in going from 37 to 5 °C, conformational transitions inducible by 0.1 mol l⁻¹ K⁺ (activating) or 0.1 mol l⁻¹ Li⁺ (non-activating), independent of Mg²⁺ and phosphoenol pyruvate;⁴¹⁵ for fructose 1,6-diphosphatase (rabbit liver), intensification of the aromatic c.d. occurs in the presence of fructose 1,6-diphosphate and AMP together, but not individually, with fine-structure more resolved at pH 9.1 than 7.5, and the enzyme generally being little affected in peptide conformation by pH or SDS, although the latter

⁴⁰⁵ M. J. Ettinger and S. N. Timasheff, *Biochemistry*, 1971, **10**, 824.

⁴⁰⁶ M. J. Ettinger and S. N. Timasheff, *Biochemistry*, 1971, **10**, 831.

⁴⁰⁷ H. Neumann and M. Shinitzky, *Biochemistry*, 1971, **10**, 4335.

⁴⁰⁸ M. Sonenberg and S. Beychok, *Biochim. Biophys. Acta*, 1971, **229**, 88.

⁴⁰⁹ T. A. Bewley and C. H. Li, *Arch. Biochem. Biophys.*, 1971, **144**, 589.

⁴¹⁰ S. Aloj and H. Edelhoch, *J. Biol. Chem.*, 1971, **246**, 5047.

⁴¹¹ S. Fermandjian, J.-L. Morgat, and P. Fromageot, *European J. Biochem.*, 1971, **24**, 252.

⁴¹² W. D. McCubbin, K. Oikawa, and C. M. Kay, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 666.

⁴¹³ M. N. Pflumm, J. L. Wang, and G. M. Edelman, *J. Biol. Chem.*, 1971, **246**, 4369.

⁴¹⁴ W. T. Branch, J. Robbins, and H. Edelhoch, *J. Biol. Chem.*, 1971, **246**, 6011.

⁴¹⁵ R. A. Wildes, H. J. Evans, and R. R. Becker, *Biochim. Biophys. Acta*, 1971, **229**, 850.

eliminates the aromatic effects;⁴¹⁶ for carbonic anhydrase (parsley), less-intense aromatics than the mammalian enzyme, with no positive dichroism, correlating with the lower tryptophan content;⁴¹⁷ for human lysozyme, which has more-intense tryptophan c.d. than the hen egg-white enzyme, and which shows a band at 313 nm due possibly to a tryptophan-tyrosine interaction whose intensity increases with pH, perturbation of the whole region, including the new band formed on binding *N*-acetyl-D-glucosamine;⁴¹⁸ for phospholipase A₂ from *Crotalus adamanteus* venom, intense tryptophan spectrum, associated with a dimeric protein of high α -helix content;⁴¹⁹ for allantoicase, two-fold reduction of aromatic c.d. on binding the competitive inhibitor *N*-carbamoyl-D-asparagine (plus a lesser reduction of an extrinsic effect at 418 nm attributed to asymmetrically bound Mn²⁺), with effectively identical behaviour for both the 0.9 S and 10.8 S forms of the enzyme.⁴²⁰

Aromatic c.d. is also a useful indicator of the degree of conformational perturbation which occurs on association of two protein components as in the haemoglobin-haptoglobin complex,⁴²¹⁻⁴²³ immunoglobulin structure,²⁸³ and the troponin-tropomyosin association which forms the relaxing protein.⁴²⁴ In the latter case, the helix content of the components is 42% and 98%, respectively, and that of the complex 72%, representing additivity. The aromatic region is non-additive, with the characteristic positive dichroism of troponin at 295 nm disappearing, and the complex being altogether more negative from 260-275 nm than either component, indicating that conformational rearrangements of at least the aromatic side-chains have occurred.

Non-chromophoric Proteins. A significant change in the peptide c.d. of α -elastin solubilized in trifluoroethanol is effected by Ca²⁺.⁴²⁵ Since the effect is also found in the presence of 4% trifluoroacetic acid, metal binding at neutral sites is implicated, effects due to direct perturbation of the $n-\pi^*$ by the metal ion being considered of secondary importance. More generally, the absence of significant perturbation of peptide c.d. is taken as evidence of the maintenance of identical overall conformation, though subtler conformational effects may be involved with specific ligands. Thus while histidine, as end-product inhibitor, affects a difference

⁴¹⁶ A. M. Tamburro, A. Scatturin, E. Grazi, and S. Pontremoli, *J. Biol. Chem.*, 1970, **245**, 6624.

⁴¹⁷ A. J. Tobin, *J. Biol. Chem.*, 1970, **245**, 2656.

⁴¹⁸ J. P. Halper, N. Latovitzki, H. Bernstein, and S. Beychok, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 517.

⁴¹⁹ M. A. Wells, *Biochemistry*, 1971, **10**, 4078.

⁴²⁰ E. J. S. Gravenmade, C. Van der Drift, and G. D. Vogels, *Biochim. Biophys. Acta*, 1971, **251**, 393.

⁴²¹ M. W. Makinen and H. Kon, *Biochemistry*, 1971, **10**, 43.

⁴²² H. Hamaguchi, A. Isomoto, Y. Miyake, and H. Nakajima, *Biochemistry*, 1971, **10**, 1741.

⁴²³ M. Waks, P. C. Kahn, and S. Beychok, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1232.

⁴²⁴ I. Staprans and S. Watanabe, *J. Biol. Chem.*, 1970, **245**, 5962.

⁴²⁵ D. W. Urry, J. R. Krivacic, and J. Haider, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 6.

spectrum in phosphoribosyl transferase equivalent to the burying of several tyrosine residues, only minor effects are observed in the 210—225 nm region in c.d.⁴²⁶ Indole increases the reactivity of sulphydryl groups in the alpha subunit of *E. coli* tryptophan synthetase, but indole glycerol phosphate has the opposite effect; neither affects the far-u.v. c.d.⁴²⁷ The activation of α -amylase from *B. subtilis* by Ca^{2+} can also be effected by a range of lanthanide ions, with the activation decreasing with increasing ionic radius; no large structural changes are observed on removal of the activating ions.⁴²⁸ Characterization of these subtler effects requires more-sensitive probe techniques.

Conformational effects associated with the binding of substrates and cofactors, observed by changes in far-u.v. properties, are found with the dissociation of ATP from bovine cardiac globular actin by treatment with Dowex 1 and obligatory dialysis against H_4edta ,⁴²⁹ and with the binding of aspartate to the allosteric phosphoenol pyruvate carboxylase from *E. coli*.⁴³⁰

The α -crystallin from ocular lens has a very high proportion of β -structure (as well as highly resolved fine-structure in the aromatic region). γ -Crystallin has similar properties, although the far-u.v. c.d. includes an additional negative band at 203 nm, with predominant β -structure, and a functional significance for this form in producing the transparent macro-structure of lens is suggested.⁴³¹ The phosphoprotein phosvitin is known to have a random conformation at pH 3—5, and to adopt a β -structure at pH 2.⁴³² This form is also induced reversibly at pH 3—5 by addition of alcohols, glycols, or dioxan.⁴³³ At pH 2, the organic solvents intensify the c.d. at 195 nm but do not affect the magnitude at 222 nm. Also, at pH values where phosvitin itself would be random, addition of poly-L-lysine to give a molar equivalence between charged lysine and phosphate residues induces β -structure. The process is more efficient with high-molecular-weight polymer ($M = 24\,000$ and above); similar results are obtained with protamine.⁴³¹ This result indicates that two random polymers can interact in aqueous solution to form a structure of high order.

The tropomyosins of different species (crayfish, oyster, abalone, and blowfly) have been compared in their o.r.d. properties; the high proportion of α -helix found in the mammalian form is also found for these invertebrates. Molecular weight and electron-microscopic appearance indicate close similarities in subunit structure.⁴³⁴ Far-u.v. o.r.d. properties have been used to characterize the ageing process of bovine mercaptalbumin.⁴³⁵

⁴²⁶ F. Blasi, S. M. Aloj, and R. F. Goldberger, *Biochemistry*, 1971, **10**, 1409.

⁴²⁷ W. B. Freedberg and J. K. Hardman, *J. Biol. Chem.*, 1971, **246**, 1449.

⁴²⁸ G. E. Smolka, E. R. Birnbaum, and D. W. Darnall, *Biochemistry*, 1971, **10**, 4556.

⁴²⁹ W. D. McCubbin and C. M. Kay, *Biochim. Biophys. Acta*, 1970, **214**, 272.

⁴³⁰ T. Yoshinaga, K. Izui, and H. Katsuki, *J. Biochem. (Japan)*, 1970, **68**, 747.

⁴³¹ H. A. Jones and S. Lerman, *Canad. J. Biochem.*, 1971, **49**, 426.

⁴³² G. Taborsky, *J. Biol. Chem.*, 1970, **245**, 1054.

⁴³³ G. E. Perlmann and K. Grizzuti, *Biochemistry*, 1971, **10**, 258.

⁴³⁴ E. F. Woods and M. J. Pont, *Biochemistry*, 1971, **10**, 270.

⁴³⁵ H. J. Nikkel and J. F. Foster, *Biochemistry*, 1971, **10**, 4479.

A discrete product is formed, for which the $N \rightarrow F$ transition and the acid expansion of the native protein are continuous. This product is formed by disulphide interchange. Dissociation of multimers of urease to give the species with $M = 240\,000$ is effected by 90% propane-1,2-diol without conformational effects in $[m]_{235}$, indicating the mildness but effectiveness of the glycol as a dissociating agent.⁴³⁶

Chromophoric Proteins. NAD(P)-dehydrogenases. L-Glutamate dehydrogenase binds one molecule NADH per protomer in the presence of the substrate L-glutamate, with production of a positive c.d. band at 340 nm. In the presence of the allosteric effector guanosine triphosphate or Zn^{2+} , this band doubles in intensity;⁴³⁷ assuming identical c.d. effect for all bound species, the unmasking of a second site for NADH by the effector is suggested. The positive band of the complex between enzyme and NADPH undergoes a remarkable inversion in the presence of L-glutamate, independently of the presence of GTP. The binding of NADPH to dihydrofolate reductase is accompanied by dichroism at 340 nm, plus a small perturbation of the whole aromatic region.⁴³⁸ Conformational mobility, induction of increased c.d. in NADPH, and the possibility of inversion of the symmetry are characteristics of these NADH binding-sites.

Flavoproteins. A detailed study of the flavin chromophore in model compounds and flavoproteins shows that at least six vibronic bands corresponding to three $\pi \rightarrow \pi^*$ transitions occur within the total absorption and c.d. envelope; no $n \rightarrow \pi^*$ transitions were located.⁴³⁹ Resolution of these bands is performed for model compounds in organic solvents, and provides the basis for assignments in aqueous solution. The magnitude and sign of the rotational strength of the long-wavelength vibronic components are sensitive to the interaction of the ribityl hydroxy-group with the isoalloxazine ring, and allows similarities within the flavin oxidases and dehydrogenases to be established. Resolution and reconstitution of the Shethna flavoprotein are reported; similarities with two other flavoproteins extend into the far-u.v.⁴⁴⁰ No major differences are found in the protein when the flavin is reduced to the semiquinone or hydroquinone forms. Similarly, no strong perturbation of the tryptophan c.d. is found when apoenzyme is combined with a range of flavin analogues, suggesting that the tryptophan-flavin interaction inferred from other spectral data has no direct counterpart in c.d.⁴⁴¹ A similar extensive resolution of the flavin bands in reduced and oxidized mammalian lipoamide dehydrogenase shows that all features are accounted for in terms of bands present in FAD, whether the enzyme itself is reduced or not.⁴⁴² These gaussian resolutions bring a further dimension into the

⁴³⁶ C. C. Contaxis and F. J. Reithel, *J. Biol. Chem.*, 1971, **246**, 677.

⁴³⁷ J.-M. Jallon and M. Iwatsubo, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 964.

⁴³⁸ J. H. Freisheim and L. D'Souza, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 803.

⁴³⁹ D. E. Edmondson and G. Tollin, *Biochemistry*, 1971, **10**, 113.

⁴⁴⁰ D. E. Edmondson and G. Tollin, *Biochemistry*, 1971, **10**, 124.

⁴⁴¹ D. E. Edmondson and G. Tollin, *Biochemistry*, 1971, **10**, 133.

⁴⁴² A. H. Brady and S. Beychok, *J. Biol. Chem.*, 1971, **246**, 5498.

use of the natural chromophoric probes, and the methods are of general applicability to all attached chromophores.

A similar distinction between the flavin c.d. properties of oxidases and dehydrogenases has been made on the basis of the properties of the pyridine nucleotide transhydrogenase from *Azotobacter vinelandii*.⁴⁴³ The holo-enzyme (containing FAD) resembles FMN, with signs of the bands distinct from those of the Shethna protein. The importance of asymmetry and the ability of different but related bands to act independently are shown by the elimination of c.d. from the 430 nm band of D-amino-acid oxidase on binding *p*-aminobenzoate. The 380 nm band retains its c.d. and both bands are present in absorption.⁴⁴⁴ Small perturbations of the flavin c.d. in *p*-hydroxybenzoate hydroxylase from *Pseudomonas putida* are effected by the substrate analogues benzoate and *p*-fluoro- (but not *p*-amino-)benzoate.⁴⁴⁵ Also, changes in the oxidized enzyme c.d. with NADPH (anaerobically) indicate complex formation.

Pyridoxal enzymes. A similar effect to the above is observed with L-glutamate decarboxylase on binding cyclic analogues of L-glutamate. The characteristic pyridoxal phosphate band at 420 nm is slowly converted into one at 380 nm with loss of c.d., but addition of substrate restores the band and the activity.⁴⁴⁶ Similar effects have been reported for enzyme-substrate complexes of (supernatant) aspartate aminotransferase.⁴⁴⁷ The mitochondrial and supernatant enzymes⁴⁴⁸ are closely similar in their peptide c.d., and, although the former enzyme shows more pronounced aromatic effects, no significant differences were observed between the subforms (A, B, C and α , β , γ) of the two enzymes. Similar behaviour in enzyme-substrate and -inhibitor complexes is found; the slow substrate *erythro*- β -hydroxyaspartate produces an intense negative band at 492 nm, characteristic of a quinone-like intermediate of the reaction scheme; the more-rapid substrate α -methyl aspartate produces absorption at 430 and 360 nm, with only the latter active in c.d.⁴⁴⁸ Where these bands are linked by protonic equilibria, either a difference in binding of the two forms or a symmetrical environment (determined by rigidity or by a flexible, time-averaged effect) seems to be indicated for one form.

Conformational changes accompanying photo-oxidation of the supernatant enzyme are indicated by the virtual disappearance of dichroism when photo-oxidized apo-enzyme binds pyridoxamine phosphate, whereas the dichroism in the amino-form of the enzyme derived from photo-oxidized holo-enzyme is well-defined. Only histidine is destroyed in the

⁴⁴³ H. W. J. Van den Broek, J. S. Santema, and C. Veeger, *European J. Biochem.*, 1971, **24**, 55.

⁴⁴⁴ K. Yagi, N. Nodi, M. Nishikimi, and A. Kotaki, *J. Biochem. (Japan)*, 1970, **68**, 293.

⁴⁴⁵ N. Teng, G. Kotowycz, M. Calvin, and K. Hosokawa, *J. Biol. Chem.*, 1971, **246**, 5448.

⁴⁴⁶ L. P. Saschenko, E. S. Severin, D. E. Metzler, and R. M. Khomotov, *Biochemistry*, 1971, **10**, 4888.

⁴⁴⁷ V. I. Ivanov and M. Y. Karpeisky, *Adv. Enzymol.*, 1969, **32**, 21.

⁴⁴⁸ M. Martinez-Carrion, D. C. Tiemeier, and D. L. Peterson, *Biochemistry*, 1970, **9**, 2574.

process.⁴⁴⁹ A further example of the highly absorbing complex at 492 nm is given by cystathionine gamma-synthetase from *Salmonella* in the presence of the slow substrate *O*-succinylserine.⁴⁵⁰ If the extended conjugation of the absorbing intermediate is twisted away from planarity, strong effects (e.g. see ref. 448) of either sign are to be expected.

Haem-proteins. The origins of rotational strength in the Soret transitions of haem proteins have been treated theoretically.^{294, 295} The striking features of the system are (i) the wide range of aromatic groups with which the haem transitions interact (the distal His-64, His-97, Phe-33, Tyr-103, and Tyr-146) though, since asymmetry is the prime consideration, proximity as such, e.g. of the His-93 residue which acts as the fifth ligand, does not confer strong perturbing power, and (ii) the resultant spectra derive from two near-degenerate transitions of high rotational strength, whose relative magnitudes are determined by orientation of the haem relative to its perturbing environment and the degree and nature of the chemical substituents in the porphyrin ring. Variations in these factors will affect the resultant c.d. profile. The multiplicity of Soret Cotton effects, most clearly seen in c.d., can be explained for many haem proteins in terms of the overlap of these oppositely signed and unequal bands located at different wavelengths. Even the apparently symmetrical, oppositely signed couplet can be produced in this way and, in the absence of other evidence of intermolecular aggregation, the assignment of this type of spectrum to asymmetric stacking of chromophores is inconclusive when the chromophore itself contains near-degenerate transitions.

Examination of eight mammalian myoglobins shows that human and monkey myoglobins differ from the remainder in having lower helical content and a lower ratio for the c.d. values at 208 nm and 220 nm.⁴⁵¹ However, these species were still able to cross-react immunologically with several others; only sperm-whale myoglobin was distinct in its cross-reactivity. There is therefore little correlation between the cross-reactivity and the gross conformation as judged by helical content.

Comparison of a variety of haemoglobins shows the close similarity in conformation of mammalian haemoglobins; those of the lamprey and toad are noticeably different. In general, similarities between γ and β are seen, and these are distinct from α . Reduction of the 430 nm c.d. of deoxy-Hb by dialysis (and the smaller effect with oxy-Hb) may be reversed by adding back 2,3-diphosphoglycerate. Carboxypeptidase treatment also diminishes the Soret c.d. of deoxy-Hb. The protoporphyrin complex with apo-Hb has distinctive positive and slightly asymmetric Soret c.d., resembling Hb, but shows four distinctive bands at 510, 545, 575, and 630 nm (all positive), compared with the 535 and 575 nm bands of the haem, correlating with the

⁴⁴⁹ M. Martinez-Carrion, R. Kuczynski, D. C. Tiemeier, and D. L. Peterson, *J. Biol. Chem.*, 1970, **245**, 799.

⁴⁵⁰ S. Guggenheim and M. Flavin, *J. Biol. Chem.*, 1971, **246**, 3562.

⁴⁵¹ M. Z. Atassi, *Biochim. Biophys. Acta*, 1970, **221**, 612.

extra transitions observed in the absorption spectra.⁴⁵² A number of unnatural haems complexed with apo-Hb have been found to have oxygen affinities which correlate inversely with the negative inductive effects of substituents in side-chains 2 and 4.⁴⁵³

The spectroscopic coupling between the haem associated with one chain and the aromatic residues of another, predicted by theory,²⁹⁴ is found to be more significant in semi-haemoglobins lacking the haem from the α -chain,⁴⁵⁴ since this species differs considerably from that of isolated β . By contrast, the species lacking haem from the β -chain closely resembles isolated α -chain in its Soret c.d.

In studying the effect of chloroform-saturated buffers on haem proteins, myoglobin is effectively inert, whereas oxy-Hb shows small effects in $[m']_{233}$. The largest effect is given by met-Hb with dichloromethane, when a 25% reduction is observed.⁴⁵⁵ Similarly, the anaesthetic halothane, 2-bromo-2-chloro-1,1,1-trifluoroethane, causes a reversible effect on $[m']_{233}$ of oxy-, deoxy-, and met-Hb, with the predominant effect, in isolated chains, being on the β -chain.⁴⁵⁶

In the 1:1 complex between haptoglobin and haemoglobin, the haem function is altered and is more susceptible to peroxidatic activity.⁴²¹ Structural alterations in the region of haem are observed by loss of the characteristic negative portion of the Soret c.d. of oxy-, deoxy-, and met-Hb, and by the red-shift of the maxima.⁴²² Even so, only small deviations from additivity of the two components are observed in the peptide and aromatic c.d. on complex formation, though the haem transition at 251 nm does indicate a change in environment.⁴²³ The haptoglobin itself contains significant amounts of β -structure. In the serum β -glycoprotein haemopexin, when complexed with haem (for which it is transporter), the Soret effect (positive) is relatively symmetrical: like apo-Hb, there is evidence for a conformational change on binding haem, though this is much smaller.⁴⁵⁷ Soret effects of both sign are found with cytochrome b_5 (microsomal, pig liver) where, for both ferrous and ferric forms, the predominant effect at 430 nm is negative.⁴⁵⁸ Again, significant differences are found at 200–220 nm between the holo- and apo-protein, the latter having lost the aromatic fine-structure, and the holo-protein can be reconstituted.

Cytochrome c contains meso-haem as prosthetic group; the oxidized state of this cytochrome from a wide variety of sources is found to have very similar dichroic features, in the Soret region, though some differences exist in the α and β bands.⁴⁵⁹ In the far-u.v., a significant amount of α -helix is indicated, and a minimum at 190 nm following the 194 nm

⁴⁵² Y. Sugita, M. Nagai, and Y. Yoneyama, *J. Biol. Chem.*, 1971, **246**, 383.

⁴⁵³ Y. Sugita and Y. Yoneyama, *J. Biol. Chem.*, 1971, **246**, 389.

⁴⁵⁴ R. Cassoly and R. Banerjee, *European J. Biochem.*, 1971, **19**, 514.

⁴⁵⁵ D. J. Bucher and W. D. Brown, *Biochemistry*, 1971, **10**, 4239.

⁴⁵⁶ L. H. Laasberg and J. Hedley-Whyte, *J. Biol. Chem.*, 1971, **246**, 4886.

⁴⁵⁷ U. Muller-Eberhard and K. Grizzuti, *Biochemistry*, 1971, **10**, 2062.

⁴⁵⁸ E. Schnellbacher and L. Lumper, *Z. physiol. Chem.*, 1971, **352**, 615.

⁴⁵⁹ Y. P. Myer, *Biochim. Biophys. Acta*, 1970, **214**, 94.

maximum is a characteristic feature. The c.d. properties of the weak band at 650 nm associated with the reducibility of ferricytochrome *c* by ascorbate is found not to correlate with the behaviour of α and β bands as a function of pH.⁴⁶⁰ The band can be eliminated without a major conformational change: its simulation with the undeca-peptide of cytochrome *c* on addition of *N*-acetylmethionine suggests a specific liganding mechanism.⁴⁶⁰ Cardiac cytochrome *c*₁ contains the same prosthetic group as cytochrome *c*, but is distinguished by a major positive band in the Soret region for the oxidized and reduced form and, in the latter, by the high degree of fine structure in the α and β bands at 500—570 nm.⁴⁶¹ These differences can be accounted for by relatively small differences in haem environment, following the derivation above, which would still allow considerable structural homology between the two systems.

Resolution of o.r.d. effects in the Soret region of cytochrome oxidase in oxidized and reduced forms indicates that the rotational strength of 0.5 DM is associated with an asymmetric c.d. profile, which may be represented by two relatively narrow, positive, gaussian bands.⁴⁶² The recent theoretical advances show this assignment to have empirical value only.²⁹⁴ However, they do allow a fuller interpretation of the difference in rotational strength of the far-u.v. peptide transitions between oxidized and reduced forms. Since the haem chromophore does not derive rotational strength from interaction with the helical transitions (by analogy with myoglobin), these differences enforce the argument of a different helical content with different oxidation states. These differences have been directly observed in c.d.,⁴⁶³ as have the asymmetric (and therefore multi-component) Soret c.d. effects in the oxidized, reduced, and CO-reduced complexes. The ability of deoxycholate to render the Soret peak of the reduced complex a symmetrical band signifies a change in environment of the chromophore, but not necessarily an environment of higher symmetry.

Small Cotton effects persist with alkali-denatured cytochrome oxidase, and the reduced form shows a considerable change in bandshape.⁴⁶⁴ These effects are considerably smaller than those seen in haem complexed with α -helical poly-lysine of D- or L-configuration. These effects are complicated by the tendency of the components to aggregate. A simpler picture is presented by complexes involving protohaem, where the effects appear generally to be accounted for by oppositely signed bands, whose intensities and relative intensities change as a function of the titration of the polymer. The theoretical considerations²⁹⁴ also help to enforce the inference of different conformation in the oxidized and reduced forms of cytochrome P-450; the Soret Cotton effect is present in oxidized and CO-reduced

⁴⁶⁰ C. Greenwood and M. T. Wilson, *European J. Biochem.*, 1971, **22**, 5.

⁴⁶¹ C. A. Tu, F. C. Yong, L. Yu, and T. E. King, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 508.

⁴⁶² T. E. King, P. M. Bayley, and F. C. Yong, *European J. Biochem.*, 1971, **20**, 103.

⁴⁶³ Y. P. Myer, *J. Biol. Chem.*, 1971, **246**, 1241.

⁴⁶⁴ F. C. Yong and T. E. King, *European J. Biochem.*, 1971, **20**, 111.

P-450, but lacking in reduced P-450.⁴⁶⁵ Since the oxidation state appears not to influence the orientation of the porphyrin Soret transitions,²⁹⁴ this difference is attributable to a change in the environment of the haem. Likewise, the appearance of a negative Soret c.d. in lactoperoxidase, and its cyanide, azide, and fluoride complexes, indicates its characteristic environment.⁴⁶⁶ Negative Soret c.d. is found for both oxidized (418 nm) and reduced (429 nm and 406 nm) cytochrome *b*-563 from larvae of the housefly.⁴⁶⁷ Changes in aromatic and far-u.v. c.d. are observed with change of oxidation state. Cytochrome P-450 (the camphor methylene hydroxylase from *Pseudomonas putida*) can be studied in the presence of the substrate camphor, being inactive in the absence of the electron-donor putidaredoxin and its reductase, when significant changes in the negative Soret transition (from 418 to 392 nm) and in the α and β bands occur on binding camphor.⁴⁶⁸

The appearance of split, oppositely signed c.d. effects in the bacteriochlorophyll-protein complex of the green photosynthetic bacterium *Chloropseudomonas ethylicum* is at least partially due to molecular aggregation in an asymmetric stack; the split c.d. at 809 and 400 nm is lost at acidic and alkaline pH, and considerably modified by methanol. The bacteriochlorophyll chromophore itself shows marked asymmetric aggregation.^{380, 469} The complex ($M = 150\ 000$) contains 20 bacteriochlorophyll molecules in four subunits, and associates further in the chloroplast. The chromophore-chromophore interaction here is of potential functional significance. The characteristic extrinsic effect (in o.r.d.) when hydrogen peroxide is added to horse-radish peroxidase is not observed at -60°C but appears on warming to 10°C . The process is reversible, and interconvertible conformational states are suggested.³¹¹

Metalloproteins. A review of the state and function of copper in biological systems discusses studies of c.d. of the copper transitions in stellacyanin, plastocyanin, azurin, and *Polyporus* laccase.⁴⁷⁰ The cupro-zinc protein from bovine erythrocytes is unique in having positive bands at 610, 440, and 350 nm; the presence of the metal stabilizes against urea denaturation.⁴⁷¹ Denaturation of spinach ferredoxin by urea ($5\ \text{mol l}^{-1}$) is promoted by low ionic strength,⁴⁷² and the system can be reconstituted with restoration of the 400 nm extrinsic effects.⁴⁷³ Perturbation of these transitions occurs when the protein combines with ferredoxin-NADP reductase, although there is no e.s.r. change in the reduced ferredoxin when complexed.⁴⁷⁴

⁴⁶⁵ F. C. Yong, T. E. King, S. Oldham, M. R. Waterman, and H. S. Mason, *Arch. Biochem. Biophys.*, 1970, **138**, 96.

⁴⁶⁶ R. J. Maguire and H. B. Dunford, *Canad. J. Biochem.*, 1971, **49**, 666.

⁴⁶⁷ Y. Okada and K. Okunuki, *J. Biochem. (Japan)*, 1970, **67**, 603.

⁴⁶⁸ J. A. Peterson, *Arch. Biochem. Biophys.*, 1971, **144**, 678.

⁴⁶⁹ Y. D. Kim and B. Ke, *Arch. Biochem. Biophys.*, 1970, **140**, 341.

⁴⁷⁰ R. Malkin and B. G. Malstrom, *Adv. Enzymol.*, 1970, **33**, 177.

⁴⁷¹ E. Wood, D. G. Dalgleish, and W. Bannister, *European J. Biochem.*, 1971, **18**, 187.

⁴⁷² D. H. Petering and G. Palmer, *Arch. Biochem. Biophys.*, 1970, **141**, 456.

⁴⁷³ D. Petering, J. A. Fee, and G. Palmer, *J. Biol. Chem.*, 1971, **246**, 643.

⁴⁷⁴ R. Cammack, J. Neumann, N. Nelson, and D. O. Hall, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 292.

The removal of metal from ferritin increases the intensity of 200–300 nm c.d., suggesting an increase in order, and a partial disordering at pH 2.8–2.5 is observed in the aromatic c.d.⁴⁷⁵

Visual pigments. An exciting experiment on bovine visual pigment 500 at 77 K shows circular dichroism effects associated with the photochemical processes following illumination, thus extending the concepts of asymmetry to the investigation of different absorbing species involved in the visual process.³¹⁰ Illumination at 500 nm generates large c.d. effects (state-I) with 560 nm (positive) and 480 nm (negative), which persist in the absence of illumination; a second stable species (state-II) is obtained by further illumination at greater than 560 nm, and this is characterized by effects of sign opposite to state-I. Interconversion of the two is possible by appropriate illumination, with an isodichroic point at 512–518 nm. The native pigment is not isodichroic with this system, nor can it be regenerated from state-I or state-II. While the exact nature of these species awaits elucidation, a new means of studying these complex interconversions has now been established.

C.d. criteria have been used for establishing the regeneration of native rhodopsin following digitonin extraction, when it is found that phospholipid is necessary for optimal regeneration, possibly through stabilization of the opsin conformation.⁴⁷⁶ Extrinsic effects are observable in the 230 nm region in the complex of vitamin A with retinol-binding protein and prealbumin.⁴⁷⁷

Added Extrinsic Chromophores. Naphthalenesulphonate derivatives. A number of dyes related to anilinonaphthalenesulphonate (ANS) give characteristically different extrinsic c.d. when bound to apo-haemoglobin. Thus whereas ANS shows a negative band at 370 nm and 330 nm (– 0.08 DM, *i.e.* weak compared with haem),²⁹⁴ 1-benzylaminonaphthalene-8-sulphonate shows no c.d., and *N*-iodoacetyl-*N'*-(8-sulphonyl-1-naphthoyl)-ethylenediamine shows a positive band (370 nm) and a negative (330 nm).⁴⁷⁸ From the enhanced fluorescence yield on binding, it is inferred that all three bind at the same site, though the orientation of the naphthalene component is evidently different for each. Different c.d. properties are found for the bis-(ANS) derivative on binding to the H and M isozymes of lactic dehydrogenase; the hybrids show intermediate properties, but are not a proportionate combination of H and M, although only the two spectroscopic species are present.⁴⁷⁹ The primary sites for covalent attachment of dimethylaminonaphthalenesulphonate (DNS) are the exterior NH₂ groups. By contrast with non-covalently bound ANS, DNS retains considerable mobility, and no extrinsic effects are found at low levels of

⁴⁷⁵ G. C. Wood and R. R. Crichton, *Biochim. Biophys. Acta*, 1971, **229**, 83.

⁴⁷⁶ H. Shichi, *J. Biol. Chem.*, 1971, **246**, 6178.

⁴⁷⁷ L. Rask, P. A. Peterson, and I. Bjork, *Biochemistry*, 1972, **11**, 264.

⁴⁷⁸ M. C. Hsu and R. W. Woody, *Biopolymers*, 1971, **10**, 1421.

⁴⁷⁹ S. R. Anderson, *Biochemistry*, 1971, **10**, 4162.

labelling with fibrinogen⁴⁸⁰ or lysozyme.⁴⁸¹ Higher degrees of labelling lead to irreversible conformational changes.

Purine and pyrimidine nucleotides. 5'-GMP, at concentrations below the level at which it induces aggregation to specific helical form, binds to poly-lysine at pH 7, when the polypeptide is random, to form a characteristic complex with a high degree of order.⁴⁸² The same complex is formed from the L- or D-polypeptide, indicating that the nucleotide provides the dominant stereochemistry in these diastereoisomeric complexes. The band is blue-shifted relative to that of the gel, possibly indicating a different geometry or a lesser size. The polypeptide evidently changes conformation, and only the guanosine nucleotide is effective.

Binding of the adenine cofactors and analogues ADP, dADP, or ATP to creatine phosphokinase produces a positive extrinsic effect at 260 nm, which is unaffected by metals or substrates.⁴⁸³ The intensification of the cofactor c.d. (20-fold for ADP, plus a reversal of sign) is attributed to interaction with far-u.v. transitions of tryptophan, but the effect of immobilization must also be considered (see refs. 486 and 487). 6-Mercaptopurine ribonucleotide triphosphate (an ATP analogue) binds to G-actin without any change in its c.d., but the consequent polymerization to F-actin causes a three-fold increase.⁴⁸⁴ The aromatic spectrum is intensified in the F-actin, and tyrosine contributions are evidently reversed; such conformational effects could alter the mobility of the purine cofactor also.

A detailed study of the interaction of ribonuclease-T-1 with 2'-GMP and 3'-GMP shows that the c.d. spectra of the enzyme and inhibitor are non-additive for the complex.⁴⁸⁵ The enzyme shows tyrosine bands at 280 nm, with high intensity at 241 nm, and a single minimum at 210 nm, indicating little α -helix or β -structure. Following a sharp thermal transition at 40 °C, both tyrosine regions are lost. The possibility of coupling between the purine and aromatic residues is discussed in accounting for the generation of dichroism (280 nm negative, 250 nm positive) in the complex. An alternative interpretation, deriving from binding of 3'-GMP to RNase-T-1, is that binding freezes the nucleotide in the *syn*-conformation, the biphasic difference spectrum resembling an intensified version of the acidic spectrum of 3'-GMP.⁴⁸⁶ The same immobilization mechanism is invoked to account for the enhanced c.d. of 2'-CMP bound to pancreatic ribonuclease A, where the bound form is designated the *anti*-conformation.⁴⁸⁷

Ribonuclease-St (from *Streptomyces erythreus*), differing from T-1 in having no tryptophan, will bind both guanosine and cytosine nucleotides.⁴⁸⁸

⁴⁸⁰ E. Mihalyi and A. Albert, *Biochemistry*, 1971, **10**, 237.

⁴⁸¹ N. Okabe and T. Takagi, *Biochim. Biophys. Acta*, 1971, **229**, 484.

⁴⁸² K. Wulff, H. Wolf, and K. G. Wagner, *Biochem. Biophys. Res. Comm.*, 1970, **39**, 870.

⁴⁸³ J. H. R. Kagi, T. K. Li, and B. L. Vallee, *Biochemistry*, 1971, **10**, 1007.

⁴⁸⁴ A. J. Murphy, *Biochemistry*, 1971, **10**, 3723.

⁴⁸⁵ C. Sander and P. O. Ts'o, *Biochemistry*, 1971, **10**, 1953.

⁴⁸⁶ T. Oshima and K. Imahori, *J. Biochem. (Japan)*, 1971, **70**, 197.

⁴⁸⁷ T. Oshima and K. Imahori, *J. Biochem. (Japan)*, 1971, **70**, 193.

⁴⁸⁸ N. Yoshida, K. Kuriyama, T. Iwata, and H. Otsuka, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 954.

The free enzyme also shows a strong 234 nm tyrosine effect. 3'-GMP binds to produce additional effects as with T-1; a three-fold enhancement of 2'-(3')-CMP c.d. on binding to RNase-A and a similar enhancement for this ligand with RNase-St are observed. Coupling with aromatics is again suggested. (A buried tyrosine is exposed when 3'-CMP binds to RNase-A.⁴⁸⁹)

Discrepancies exist in the absolute magnitudes of the enhancements for these nucleotides. The intensifications observed in fully rigid model compounds suggest that immobilization could account for an enhancement of several fold over the value in free solution.⁴⁹⁰

Metals. The replacement of zinc in enzyme systems by cobalt(n) provides absorption and c.d. bands in the visible region whose properties reflect the conformational state of the active site.⁴⁹¹⁻⁴⁹³ In alcohol dehydrogenases, the metal and NADH (or phenanthroline) interact mutually;⁴⁹¹ in yeast aldolase, binding of fructose 1,6-diphosphate affects the cobalt bands (while the activator, K^+ , has no effect), and the loss of activity below pH 8 is paralleled by a loss of asymmetry in the cobalt transitions;⁴⁹² in carboxypeptidase, the optical activity of the cobalt transitions is affected variously by a range of inhibitors—those with complex kinetics show multiple spectral changes, the most striking effect being with glycyl-L-tyrosine, which inverts the transitions, intensifying them several-fold, while still maintaining the same basic co-ordination to the metal.⁴⁹³

Other extrinsic effects. The reaction of 1.7 moles of tyrosine per mole of procarboxypeptidase with diazotized arsanilic acid produces an arsanilazo-procarboxypeptidase with extrinsic effects at 305, 400, and 500 nm associated with a broad, featureless absorption band.⁴⁹⁴ Activation of the complex ($M = 87\,000$) to carboxypeptidase ($M = 34\,600$) doubles the intensity at 438 nm, and shifts the lower band to 525 nm. The kinetics of activation can be followed by these changes, which reflect conformational transitions associated with the complex activation process. The inhibitor β -phenylpropionate alters the c.d. of the labelled enzyme, but not the labelled precursor, suggesting that the labelled residues are close to the active site.

Induced optical activity at 320 and 280 nm is reported for thiamine pyrophosphate binding to transketolase from baker's yeast,⁴⁹⁵ and at 245 and 280 nm for α - and β -naphthylamidines, which are competitive inhibitors

⁴⁸⁹ E. R. Simons, *Biochim. Biophys. Acta*, 1971, **251**, 126.

⁴⁹⁰ D. W. Miles, R. K. Robins, and H. Eyring, *Proc. Nat. Acad. Sci. U.S.A.*, 1967, **57**, 1138.

⁴⁹¹ D. E. Drum and B. L. Vallee, *Biochem. Biophys. Res. Comm.*, 1970, **41**, 33.

⁴⁹² R. T. Simpson, R. D. Kobes, R. W. Erbe, W. J. Rutter, and B. L. Vallee, *Biochemistry*, 1971, **10**, 2466.

⁴⁹³ S. A. Latt and B. L. Vallee, *Biochemistry*, 1971, **10**, 4263.

⁴⁹⁴ W. D. Behnke and B. L. Vallee, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 760.

⁴⁹⁵ G. A. Kochetov, R. A. Usmanov, and V. P. Merzlov, *Biochemistry (U.S.S.R.)*, 1970, **35**, 1085.

for trypsin.⁴⁹⁶ The binding of the drugs chlorothiazide⁴⁹⁷ and phenylbutazone, flufenamic acid, and dicoumarol⁴⁹⁸ to serum proteins causes extrinsic effects which may be used to assess the stoichiometry and affinity of the binding processes. Heterogeneity of binding is most likely for aromatic ligands with serum proteins, and the induction of c.d. may be different at different sites.

Differences in the binding of substrate analogues and non-metabolizable competitive inhibitors are indicated from the inability of the latter to generate extrinsic effects with *meta*-pyrocatechase, and their ability to reduce the effect at 317 nm which is characteristic of the anaerobic complex with catechol.⁴⁹⁹

The induction of c.d. in acridine orange on binding to a polypeptide with β -structure produces effects of opposite sign to those found on binding to α -helix;⁵⁰⁰ with lower molecular weight polypeptides, different effects are observed, including inversion. The self-association of the ligand complicates the interpretation; such association may change the polymer conformation.

Binding of 4-(8-hydroxy-5-quinolylazo)-1-naphthalenesulphonate to bovine carbonic anhydrase generates extrinsic effects in the ligand. The presence of zinc, to which the ligand chelates, is obligatory.⁵⁰¹ Relatively non-specific, but still optically active, zinc complexes are formed in the presence of excess zinc, but these may be removed selectively by H₄edta. Binding of aquocobalamin to bovine serum albumin results in typical c.d. which can be simulated with corrinoid complexes with histidine, suggesting that this is the ligand for the sixth position in complexes with albumin.⁵⁰²

Chemical Modification and Peptide Cleavage. Chemical modification of tyrosine to the amino-derivative (*via* nitro-tyrosine) gives no net change of c.d. spectrum of the alkaline phosphatase of *E. coli*.⁵⁰³ Formation of the di-isopropyl phosphofluoridate derivative of trypsin causes little change in c.d. spectra of the aromatics, while solvent perturbation spectra indicate fractional extra burying of both tyrosine and tryptophan.⁵⁰⁴ Attachment of one 5-mercapto-2-nitrobenzoic acid residue to the sulphhydryl of yeast inorganic pyrophosphatase, with retention of full activity, does not generate extrinsic dichroism, presumably because of effective symmetry of the chromophore through mobilization.⁵⁰⁵

⁴⁹⁶ K. Tanizawa, S. Ishii, K. Hamaguchi, and Y. Kanaoka, *J. Biochem. (Japan)*, 1971, **69**, 893.

⁴⁹⁷ A. Breckenridge and A. Rosen, *Biochim. Biophys. Acta*, 1971, **229**, 610.

⁴⁹⁸ C. F. Chignell and D. K. Starkweather, *Mol. Pharmacol.*, 1971, **7**, 229.

⁴⁹⁹ F. Hirata, A. Nakazawa, M. Nozaki, and O. Hayaishi, *J. Biol. Chem.*, 1971, **246**, 5882.

⁵⁰⁰ S. Ikeda and T. Imae, *Biopolymers*, 1971, **10**, 1743.

⁵⁰¹ R. W. Henkens and J. M. Sturtevant, *Biochemistry*, 1972, **11**, 206.

⁵⁰² R. T. Taylor and M. L. Hanna, *Arch. Biochem. Biophys.*, 1970, **141**, 247.

⁵⁰³ P. Christen, B. L. Vallee, and R. T. Simpson, *Biochemistry*, 1971, **10**, 1377.

⁵⁰⁴ G. B. Villanueva and T. T. Herskovits, *Biochemistry*, 1971, **10**, 4589.

⁵⁰⁵ T. Negi, T. Samejima, and M. Irie, *J. Biochem. (Japan)*, 1971, **70**, 359.

Non-chromophoric chemical modifications with conformational consequences are: reaction of Trp-140 in Staphylococcal nuclease with nitrophenylsulphenyl halides, when 40% reduction in helix content is observed (the Trp-140 residue being located between two helical regions) although immunological effectiveness is unimpaired;⁵⁰⁶ and formation of the non-aggregated species maleyl-, glutaryl-, and succinyl- β -casein (a protein of low helical content), which can still show a temperature transition similar to that of the unmodified protein.⁵⁰⁷

Peptide cleavage allows examination of the conformation of a portion of primary structure in isolation: fragments of angiotensin-II,⁴¹¹ ribonuclease,⁵⁰⁸ lysozyme,⁵⁰⁹ and myoglobin⁵¹⁰ can generally be induced to take on conformations different from those of the same sequence in the total structure by suitable choice of solvents. With sufficiently large fragments, *e.g.* the overlapping fragments 1—126 and 99—149 of Staphylococcal nuclease, the original conformations can be established, in this case even in the presence of 28 redundant residues, though the regenerated activity is low.⁵¹¹ By contrast, lysozyme structure collapses on cleavage at two methionine residues, although reactivation may be possible.⁵¹²

Fragments D and E of fibrinogen, obtained by plasmin treatment, are found to contain higher helical contents than the parent protein. D ($M = 66\,000$) resembles fibrinogen in the near-u.v., whereas E ($M = 22\,000$) is markedly different.⁵¹³ Such large fragments would be expected to retain most of their original conformation.

E. Nucleic Acid-Protein Complexes.—Two aspects are of interest with respect to protein conformation, namely the ability of synthetic polypeptides to form complexes and conformational effects in the nucleotide and protein components of the complex.

Model Systems. In forming the complex between poly-L-lysine and double-stranded polyadenylic acid, the polynucleotide c.d. is effectively halved when the ratio of lysine residue to phosphate is unity.⁵¹⁴ These changes may be due to base orientation or to large aggregate formation. However, they are in marked contrast to the behaviour of the complexes of the same polypeptide with DNA,⁵¹⁵ or with polyuridylic acid,⁵¹⁶ when a strikingly enhanced c.d. is observed (at lysine: phosphate = 0.7). Poly-lysine of

⁵⁰⁶ I. Parikh and G. S. Omenn, *Biochemistry*, 1971, **10**, 1173.

⁵⁰⁷ M. T. Evans, L. Irons, and M. Jones, *Biochim. Biophys. Acta*, 1971, **229**, 411.

⁵⁰⁸ J. E. Brown and W. A. Klee, *Biochemistry*, 1971, **10**, 470.

⁵⁰⁹ C. A. Benassi, R. Ferroni, M. Guarneri, A. Gugli, A. M. Tamburro, R. Tomatis, and R. Rocchi, *F.E.B.S. Letters*, 1971, **14**, 346.

⁵¹⁰ R. P. Singhal and M. Z. Atassi, *Biochemistry*, 1971, **10**, 1756.

⁵¹¹ H. Taniuchi and C. B. Anfinsen, *J. Biol. Chem.*, 1971, **246**, 2291.

⁵¹² Y. Ota, Y. Hibino, K. Asaba, K. Sugiura, and T. Samejima, *Biochim. Biophys. Acta*, 1971, **236**, 802.

⁵¹³ A. Z. Budzynski, *Biochim. Biophys. Acta*, 1971, **229**, 663.

⁵¹⁴ B. Davidson and G. D. Fasman, *Arch. Biochem. Biophys.*, 1971, **144**, 650.

⁵¹⁵ D. Carroll, *Biochemistry*, 1972, **11**, 421.

⁵¹⁶ D. Carroll, *Biochemistry*, 1972, **11**, 426.

very high molecular weight is relatively ineffective at producing these effects, as are poly-L-arginine and protamine. Similar enhanced c.d. effects have been observed with native DNA in the presence of f1 and f2a1 histones, and characteristic aggregated and extended structures have been observed by electron microscopy.⁵¹⁷ Formation of these structures depends upon the initial state of the protein component and is most effective for histone, which is largely unfolded.

Natural Systems. Three calf thymus histones have different conformations, which change in the presence of salt and organic solvents;⁵¹⁸ conformational changes in the binding of histone f2a1 to poly(vinylphosphate) and DNA are observed at a ratio of basic residues to phosphate of 0.3, and the peptide conformation is qualitatively helix-like, although the c.d. intensity is attenuated.⁵¹⁹ Conversely, total histone affects the polynucleotide conformation.⁵²⁰ Using purified fractions, the lysine-rich histone f1 causes a change in polynucleotide c.d. on binding to DNA; phosphorylated f1 is less effective, suggesting a mechanism for controlling DNA conformation *via* phosphorylation.⁵²¹ The C-terminal fragment ($M = 15\,000$), with a higher lysine content, is even more potent than f1, whereas the N-terminal fragment alone ($M = 6\,000$) is ineffective, and hence in DNA complexes with f1 the N-terminal portion evidently modulates the action of the C-terminal portion.⁵²²

Conditions of ionic strength are clearly critical in determining interactions of histones and nucleic acids. The absence of conformational effects in forming nucleohistone IV (DNA plus histone f2a1) is reported, the complex being formed by dialysis from urea into 5 mM-tris.⁵²³ However, annealing of the components in the presence of 5 M urea, followed by dialysis with 0.15 M-NaCl, allows formation of the characteristic complex, differing in c.d. properties from DNA.⁵²⁴ The free histone is partially, helical in 0.14 M-NaF, but largely unfolded in 0.01 M-NaF. These properties suggest that although randomized histones are more effective at forming the complexes, as with the extended structures, the complexes once formed are stabilized by conditions under which they are more structured. Even so, the c.d. of bound f1, unlike f2a1, appears to be predominantly an extended form; the two histones act antagonistically, f1 being more effective at blocking changes due to f2a1 than *vice versa*.⁵²⁵ The general picture is one of a subtle balance between conformational effects in both polynucleotide and polypeptide components.

⁵¹⁷ D. E. Olins and A. L. Olins, *J. Mol. Biol.*, 1971, **57**, 437.

⁵¹⁸ Y. H. Oh, *J. Biol. Chem.*, 1970, **245**, 6404.

⁵¹⁹ T. E. Wagner, *Nature*, 1970, **227**, 65.

⁵²⁰ I. Fric and J. Sponar, *Biopolymers*, 1971, **10**, 1525.

⁵²¹ A. J. Adler, B. Schaffhausen, T. A. Langan, and G. D. Fasman, *Biochemistry*, 1971, **10**, 909.

⁵²² G. D. Fasman, M. S. Valenzuela, and A. J. Adler, *Biochemistry*, 1971, **10**, 3795.

⁵²³ H. J. Li, I. Isenberg, and W. C. Johnson, jun., *Biochemistry*, 1971, **10**, 2587.

⁵²⁴ T. Y. Shih and G. D. Fasman, *Biochemistry*, 1971, **10**, 1675.

⁵²⁵ T. Y. Shih and G. D. Fasman, *Biochemistry*, 1972, **11**, 398.

F. Immunological Systems—Immunoglobulins. In a review of the molecular size and conformation of immunoglobulins, particular reference is made to the dissociation, unfolding, and reconstitution of the complexes, and the specificity involved in interactions between heavy and light chains.⁵²³ The non-additivity of the two components in the complex, and the prevalence of β -structure, are particularly notable. Reconstitution of the heavy and light chains of IgG (myeloma and pooled) at pH 5.4, when both species are dimerized non-covalently, leads to an IgG product which is effective immunologically, but which resembles the original only when homologous pairing is involved.⁵²⁸ Restoration of the original conformation is inferred from c.d. for the recombination of heavy and light chains from rabbit IgG, removing the requirement for unique complementarity between the two components which had previously been proposed.^{527–529}

Studies on the variable and constant halves of κ -type Bence-Jones protein show the latter to be richer in β -structure, and the two halves to be additive at 230 nm, although non-additivity in the aromatic region suggests that some orientation of side-chains occurs between the two moieties.⁵³⁰ Tryptic digestion of the human IgG and IgM allows comparison of their Fab and Fc fragments, showing the former to be similar, but the latter to differ in their β -structure content and their pH-dependent conformational changes.⁵³¹ The papain fragments of the atypical myeloma IgG (Sackfield) show that the Fab portion is unusually short and has a more intense $[m]_{225}$ trough.⁵³²

Comparison of IgG of widely different phylogenetic background shows the remarkable constancy of conformation in this class of proteins.⁵³³ Studies on turtle,⁵³⁴ bowfin,⁵³⁵ and eel⁵³⁶ are reported, and wider comparisons show only the lamprey IgG to contain any significant amount of α -structure. Otherwise the domination of the c.d. profiles by the 217 nm trough indicates the prevalent β -structure. Possible evolutionary significance of this structure is discussed; being an open structure, relatively few substitution sites would be necessary to achieve a variety of conformational changes suitable for promoting multi-domain interactions.⁵³⁷

⁵²⁶ G. T. Stevenson and K. J. Dorrington, *Biochem. J.*, 1970, **118**, 703.

⁵²⁷ I. Bjork and C. Tanford, *Biochemistry*, 1971, **10**, 1271.

⁵²⁸ I. Bjork and C. Tanford, *Biochemistry*, 1971, **10**, 1280.

⁵²⁹ I. Bjork and C. Tanford, *Biochemistry*, 1971, **10**, 1289.

⁵³⁰ A. C. Ghose and B. Jirgensons, *Biochim. Biophys. Acta*, 1971, **251**, 14.

⁵³¹ A. C. Ghose, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1144.

⁵³² G. E. Connell, K. J. Dorrington, A. F. Lewis, and D. M. Parr, *Canad. J. Biochem.*, 1970, **48**, 784.

⁵³³ G. W. Litman, R. A. Good, D. Frommel, and A. Rosenberg, *Proc. Nat. Acad. Sci. U.S.A.*, 1970, **67**, 1085.

⁵³⁴ S. L. Chartrand, G. W. Litman, N. Lapointe, R. A. Good, and D. Frommel, *J. Immunol.*, 1971, **107**, 1.

⁵³⁵ G. W. Litman, D. Frommel, J. Finstad, and R. A. Good, *J. Immunol.*, 1971, **106**, 747.

⁵³⁶ B. Jirgensons, G. F. Springer, and P. R. Desai, *Comparative Biochem. Physiol.*, 1970, **34**, 721.

⁵³⁷ G. W. Litman, D. Frommel, A. Rosenberg, and R. A. Good, *Biochim. Biophys. Acta*, 1971, **236**, 647.

Antibody-Hapten Interactions. The ability of the hapten ϵ -DNP-lysine to stabilize the Fab fragment of anti-DNP antibody against unfolding by 4 mol l⁻¹ guanidine hydrochloride is indicated by the retardation of loss of 233 nm c.d. and the persistence of aromatic c.d.⁵³⁸ The hapten *p*-azobenzenearsonate attached to the helical poly Tyr-Ala-Glu shows positive c.d. at 420 nm, and a smaller negative c.d. when attached to the random copoly Tyr,Ala,Glu, which also has random conformation.⁵³⁹ On binding univalent antibody for the hapten, the c.d. of the random system increases two-fold, whereas that of the helical system inverts and shifts to 465 nm. Different antibody-hapten conformations are indicated; the conformational sensitivity of this extrinsic chromophore is also recognized in enzyme systems.⁴⁹⁴

Similar subtle effects are shown in the interaction of the haptens 2,4-DNP-lysine and 2,4,6-TNP-lysine with the mouse myeloma protein MOPC-315, and with pooled mouse anti-DNP and anti-TNP.⁵⁴⁰ For either ligand, the c.d. spectrum for each antibody complex is distinct, and for any antibody, the c.d. spectrum with either ligand is different. The MOPC-315 complexes show more varied spectra, with bands of both sign. The development of weak c.d. in the DNP transition of the complex of DNP-lysine with MOPC-315 was used to establish 1.7 binding sites per mole of $M = 153\,000$.⁵⁴¹

G. Antibiotics and Hormones.—Peptides of these types tend to be of intermediate size, often with cyclic structures, and with interesting conformational possibilities. The most striking development has been the proposal of the π (L-D) helix as the conformation for the membrane-active gramicidin-A.⁵⁴² The alternating sequence of D- and L-amino-acids can be fitted into a helix with intramolecular hydrogen-bonding running axially, and the diameter of the resulting cylindrical structure, determined by the number of residues per turn, could accommodate the cations whose transport is promoted by gramicidin-A. A head-to-head arrangement of two molecules would span the lipid bilayer.⁵⁴³ Spectroscopic and chemical evidence in favour of the hypothesis has been presented.^{544, 545} C.d. spectra are markedly solvent-sensitive, the spectrum in trifluoroethanol bearing some resemblance to a left-handed helix, and this is proposed to be the characteristic spectrum for the π (L-D) helix.⁵⁴⁵

The conformation of the membrane-active cyclic peptide alamethicin has been shown to be strongly solvent-sensitive, and to take on a highly

⁵³⁸ R. E. Cathou and T. C. Werner, *Biochemistry*, 1970, **9**, 3149.

⁵³⁹ A. Conway-Jacobs, B. Schechter, and M. Sela, *Biochemistry*, 1970, **9**, 4870.

⁵⁴⁰ M. Glaser and S. J. Singer, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2477.

⁵⁴¹ J. M. Rockey, K. J. Dorrington, and P. C. Montgomery, *Nature*, 1971, **232**, 192.

⁵⁴² D. W. Urry, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 672.

⁵⁴³ D. W. Urry, M. C. Goodall, J. D. Glickson, and D. F. Mayers, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1907.

⁵⁴⁴ J. D. Glickson, D. F. Mayers, J. M. Settine, and D. W. Urry, *Biochemistry*, 1972, **11**, 477.

⁵⁴⁵ D. W. Urry, J. D. Glickson, D. F. Mayers, and J. Haider, *Biochemistry*, 1972, **11**, 487.

ordered structure in apolar and lipid-like environments, when it is also known to be monomeric.⁵⁴⁶

The correlation between conformation and biological activity of gramicidin-S analogues shows that the inactive 5,5'-alanine derivative has an inverted o.r.d. profile, in contrast to the parent molecule. However, other replacements at this position, *e.g.* the disarcosyl derivative, are active, suggesting that the presence of proline at positions 5 and 5' is not obligatory.⁵⁴⁷ The 2,2'-diaminobutyric acid derivative (active) exhibits an even more intense o.r.d. spectrum than gramicidin-S itself.

Development of ordered structure in small peptides is not solely a function of chain length; bradykinin (9 residues) is random, secretin (27 residues) resembles lysozyme, and there is evidence of intramolecular interaction between the terminal regions, whereas cholecystokinin-pancreozymin (33 residues) is apparently random.⁵⁴⁸ For these small and potentially mobile molecules, interaction with the receptor must also be important in defining biological specificity and activity. The sequence requirements for the interaction of the neurophysins with the hormones oxytocin and vasopressin have been studied by means of the effects of synthetic tripeptides analogous to the terminal regions of the hormone, on the 260–300 nm c.d. (mainly disulphide) of the neurophysins. It is found that the α -NH₂ and the nature of residues 2 and 3 are critical.⁵⁴⁹

H. Membrane Systems.—Artefacts. The distortion of spectroscopic properties of particulate systems by absorption flattening and light scattering has been recognized as a source of artefacts in c.d. and o.r.d. measurements on membrane systems. In treating these distortions quantitatively, expressions have been derived for the simultaneous occurrence of the two phenomena, by considering the real and imaginary parts of the particle refractive index and its intrinsic optical activity.^{289, 290} The neglect of scattering (because Rayleigh scattering overestimates the scattering intensity from large particles) is not justified.²⁹⁰ The flattening effect has been evaluated for three idealized shapes⁵⁵⁰ and applied explicitly to the artefacts encountered with erythrocyte ghosts.⁵⁵¹ Explicit treatments of the two interrelated phenomena are given for spheres and ghost-like particles.²⁸⁹

Other treatments include scattering functions for left- and right-circularly polarized light,⁵⁵² and the experimental confirmation of distortions occurring (to different extents) in measurement of c.d. and (unpolarized) absorption

⁵⁴⁶ A. I. McMullen, D. I. Marlborough, and P. M. Bayley, *F.E.B.S. Letters*, 1971, **16**, 278.

⁵⁴⁷ T. Kato, M. Waki, S. Matura, and N. Izumiya, *J. Biochem. (Japan)*, 1970, **68**, 751.

⁵⁴⁸ A. Bodanszky, M. Bodanszky, E. J. Jorpes, V. Mutt, and M. A. Ondetti, *Experientia*, 1970, **26**, 948.

⁵⁴⁹ E. Breslow, H. L. Aanning, L. Abrash, and L. Schmir, *J. Biol. Chem.*, 1971, **246**, 5179.

⁵⁵⁰ D. J. Gordon and G. Holzwarth, *Arch. Biochem. Biophys.*, 1971, **142**, 481.

⁵⁵¹ D. J. Gordon and G. Holzwarth, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2365.

⁵⁵² D. W. Urry and J. Krivacic, *Proc. Nat. Acad. Sci. U.S.A.*, 1970, **65**, 845.

on membranes.⁵⁵³ Thus, the distortion of c.d. of erythrocyte ghosts at 222 nm was found to be insignificant, no effects of fragmentation being observed, while at other wavelengths the red-shift and attenuation effects were found to vary with molecular aggregation as predicted by theory.⁵⁵³ This subject has recently been reviewed.⁵⁵⁴

Membrane Proteins. Extraction of erythrocyte membranes with 6 mol l⁻¹ guanidine hydrochloride and β -mercaptoethanol resolves a protein of $M = 200\,000$, so far studied only as a random coil in the presence of the denaturant.⁵⁵⁵ The encephalitic protein extractable from normal human myelin retained a random conformation in the presence of a variety of detergents, and only lysolecithin at pH 5.0 affected the c.d., suggesting that lipid-protein interactions are important in determining conformation.⁵⁵⁶ The proteins from human and bovine brain and spinal cord are closely similar in conformational properties.^{557, 558} A lipoprotein extracted from brain by chloroform-methanol shows high helical content in this solvent, and even higher in trifluoroethanol.⁵⁵⁹ The high proportion of apolar amino-acids and the relative absence of polar side-chains accounts for its solubility properties. A basic protein extracted from pig brain shows random conformation in water, and increasing helical content in 50% aqueous n-propanol and 90% trifluoroethanol.⁵⁶⁰ The apo-lipoproteins from very-low-density lipoproteins of human plasma, distinguishable by their C-terminal residues, also exhibit characteristic conformational differences in aqueous solution.⁵⁶¹

Phospholipid Micelles. Liposomal preparations of phosphatidylserine interact with random poly-L-lysine, converting it into a form with intense c.d. at 225 nm, closely resembling the α -helix.⁵⁶² The interaction, which can be reduced by increased salt concentration, converts the liposomes into vesicles and immobilizes the hydrocarbon chains. Inclusion of phosphatidylcholine in the liposomes reduced the effectiveness of generating the helical form.

An interesting micellar effect is found in which optical activity is induced in a symmetrical dye by inclusion in micelles made from an optically active surfactant. Sulphethidole with L- or D-N-decyl-NN-dimethylalanine hydrobromide, when peaks of opposite sign at 288 and 255 nm are found. The L-isomer gives the same signs as the dye on bovine serum albumin.⁵⁶³

⁵⁵³ M. Glaser and S. J. Singer, *Biochemistry*, 1971, **10**, 1780.

⁵⁵⁴ D. W. Urry, *Biochim. Biophys. Acta*, 1972, **265**, 115.

⁵⁵⁵ J. T. Gwynne and C. Tanford, *J. Biol. Chem.*, 1970, **245**, 3269.

⁵⁵⁶ J. S. Anthony and M. A. Moscarello, *Biochim. Biophys. Acta*, 1971, **243**, 429.

⁵⁵⁷ L. P. Chao and E. R. Einstein, *J. Neurochem.*, 1970, **17**, 1121.

⁵⁵⁸ Y. Oshiro and E. H. Eylar, *Arch. Biochem. Biophys.*, 1970, **138**, 606.

⁵⁵⁹ G. Sherman and J. Folch-Pi, *J. Neurochem.*, 1970, **17**, 597.

⁵⁶⁰ S. E. Kornguth and J. H. Perrin, *J. Neurochem.*, 1971, **18**, 983.

⁵⁶¹ W. V. Brown, R. I. Levy, and D. S. Fredrickson, *J. Biol. Chem.*, 1970, **245**, 6588.

⁵⁶² G. G. Hammes and S. E. Schullery, *Biochemistry*, 1970, **9**, 2555.

⁵⁶³ J. H. Perrin and P. Idsvoog, *J. Pharm. Sci.*, 1970, **59**, 1525.

8 Dissociation and Association of Proteins

contributed by G. L. Kellett

In 1963, approximately thirty proteins were noted by Reithel⁵⁶⁴ as likely to consist of subunits. It is a measure of how far the study of subunit systems has progressed that in 1971 Frieden⁵⁶⁵ was able to draw a useful distinction between those enzyme systems which do or do not undergo reversible polymerization. Since the forces involved in either intra- or inter-enzyme interactions are very similar, the distinction is made on functional grounds, and Frieden has listed no less than thirty-one enzymes in which reversible association-dissociation processes may be of significance in controlling the rate of catalysis *in vivo*. We will first consider recent changes in some of the techniques which have made this advance possible.

A. Analytical Ultracentrifugation Techniques.—Most users of the analytical ultracentrifuge have adopted the sedimentation-diffusion equilibrium technique^{566, 567} for quantitative work,^{568–571} rather than velocity sedimentation. The latter still serves a powerful role in the detection of associating-dissociating systems through the effect of interaction on the shape of the boundary profile,^{572–574} but its apparent relegation to a diagnostic role is unfortunate in view of the relative ease with which velocity sedimentation data may be quantitatively analysed.⁵⁷⁵ The balance in the application of the two techniques is likely to be redressed, however, for whereas progress in sedimentation-diffusion equilibrium methods has been confined primarily to a consolidation of computer routines for data analysis,⁵⁷⁶ two potentially invaluable velocity techniques, those of difference⁵⁷⁷ and active-enzyme⁵⁷⁸ sedimentation, have come to fruition.

Three recent sedimentation-diffusion equilibrium data analyses all avoid conversion of the c vs. r^2 distribution into one of M vs. c , as has previously been customary.⁵⁷⁹ In contrast, the new methods analyse c vs. r^2 data directly by expressing the equilibrium concentration distribution as a sum

⁵⁶⁴ F. J. Reithel, *Adv. Protein Chem.*, 1963, **18**, 124.

⁵⁶⁵ C. Frieden, *Ann. Rev. Biochem.*, 1971, **40**, 653.

⁵⁶⁶ D. A. Yphantis, *Biochemistry*, 1964, **3**, 297.

⁵⁶⁷ E. G. Richards, D. C. Teller, and H. K. Schachman, *Biochemistry*, 1968, **7**, 1054.

⁵⁶⁸ E. T. Adams, jun. and H. Fujita, in 'Ultracentrifugal Analysis in Theory and Experiment', ed. J. W. Williams, Academic Press, New York, 1962, p. 119.

⁵⁶⁹ E. T. Adams, jun. and J. W. Williams, *J. Amer. Chem. Soc.*, 1964, **86**, 3454.

⁵⁷⁰ E. T. Adams, jun., *Biochemistry*, 1965, **4**, 1646.

⁵⁷¹ E. T. Adams, jun. and D. L. Filmer, *Biochemistry*, 1966, **5**, 2971.

⁵⁷² G. A. Gilbert, *Proc. Roy. Soc.*, 1959, **A250**, 377.

⁵⁷³ G. A. Gilbert and R. C. L. Jenkins, *Proc. Roy. Soc.*, 1959, **A253**, 420.

⁵⁷⁴ G. A. Gilbert, *Proc. Roy. Soc.*, 1963, **A276**, 354.

⁵⁷⁵ E. Chiancone, L. M. Gilbert, G. A. Gilbert, and G. L. Kellett, *J. Biol. Chem.*, 1968, **243**, 1212.

⁵⁷⁶ 'Advances in Ultracentrifugal Analysis', ed. D. A. Yphantis, *Ann. New York Acad. Sci.*, 1969, vol. 164.

⁵⁷⁷ M. W. Kirschner and H. K. Schachman, *Biochemistry*, 1971, **10**, 1900, 1919.

⁵⁷⁸ R. Cohen and M. Mire, *European J. Biochem.*, 1971, **23**, 267, 276.

⁵⁷⁹ P. D. Jeffrey and J. H. Coates, *Biochemistry*, 1966, **5**, 489.

of the exponential distributions of the individual species present. Haschemeyer and Bowers⁵⁸⁰ have tested a least-squares extension of Newton's method with simulated data. Kellett⁵⁸¹ has extended a method previously applied with success to gel chromatography and velocity sedimentation data,⁵⁷⁵ and has analysed experimental data on the haemoglobin tetramer-dimer dissociation-association equilibrium. Dyson and Isenberg⁵⁸² have used an extension of Bay's work on moments and introduced a smoothing routine. They tested their analysis with mixtures of serum albumin and ovalbumin, while Kelly and Reithel have applied it to fit the β -lactoglobulin monomer-dimer system at isoelectric pH.⁵⁸³ The self-association of chymotrypsinogen A⁵⁸⁴ has been analysed using the routine of Teller *et al.*⁵⁸⁵ Roark and Yphantis⁵⁸⁶ have theoretically analysed the influence of the Donnan effect in sedimentation-diffusion equilibrium.

Difference Sedimentation. Richards and Schachman^{587, 588} showed some years ago that the differences in two sedimentation coefficients could in principle be measured directly with great precision by utilizing the Rayleigh interference system to subtract the concentration distribution curves for two solutions contained in a double-sector ultracentrifuge cell. Kirschner and Schachman⁵⁷⁷ have now identified the systematic errors which prevented the rapid development of the original study. These errors, which resulted from differences between double-sector compartments, alignment of the Rayleigh mask, and fringe displacements across the difference boundary owing to unequal dilution effects, may be overcome by a combination of devices, including the use of unfilled epoxy-cells, the design of a new Rayleigh mask and improvement in alignment procedures,^{589, 590} and a single baseline correction. Fringe bowing, which occurs in the region of large concentration gradients, may be eliminated by measurement of the zero-order fringe selected by 'white light' exposure.

When applied to proteins in the molecular weight range 30 000—300 000 dalton, changes in sedimentation coefficient of 0.01 *s* can be measured readily to an accuracy of better than 5% (0.0005 *s*). The percentage accuracy is independent of the size of the difference measured. It is tempting to ascribe small changes in sedimentation coefficient upon binding ligand

⁵⁸⁰ R. H. Haschemeyer and W. F. Bowers, *Biochemistry*, 1970, **9**, 435.

⁵⁸¹ G. L. Kellett, *J. Mol. Biol.*, 1971, **59**, 401.

⁵⁸² R. D. Dyson and I. Isenberg, *Biochemistry*, 1971, **10**, 3233.

⁵⁸³ M. J. Kelly and F. J. Reithel, *Biochemistry*, 1971, **10**, 2639.

⁵⁸⁴ D. D. Miller, T. A. Horbett, and D. C. Teller, *Biochemistry*, 1971, **10**, 4641.

⁵⁸⁵ D. C. Teller, T. A. Horbett, E. G. Richards, and H. K. Schachman, *Ann. New York Acad. Sci.*, 1969, **164**, 66.

⁵⁸⁶ D. E. Roark and D. A. Yphantis, *Biochemistry*, 1971, **10**, 3241.

⁵⁸⁷ E. G. Richards and H. K. Schachman, *J. Amer. Chem. Soc.*, 1957, **79**, 5324.

⁵⁸⁸ E. G. Richards and H. K. Schachman, *J. Phys. Chem.*, 1959, **63**, 1578.

⁵⁸⁹ M. W. Kirschner, Ph.D. Thesis, Univ. of Calif., Berkeley, Calif., 1971.

⁵⁹⁰ E. G. Richards, D. C. Teller, V. D. Hoagland, jun., R. H. Haschemeyer, and H. K. Schachman, *Analyt. Biochem.*, 1971, **41**, 215.

to induced conformational change, as is the case with aspartate transcarbamylase. However, a 3% increase in the sedimentation coefficient of glyceraldehyde 3-phosphate dehydrogenase upon binding of nucleotide to all four sites⁵⁹¹ can be accounted for within experimental error solely by increase in molecular weight and decrease in apparent specific volume.⁵⁷⁷ Changes in sedimentation coefficient resulting from association-dissociation processes can in principle be resolved by studies of concentration dependence.

The wedge-window technique for the comparison of sedimentation coefficients, introduced by Gerhart and Schachman⁵⁹² and extended by Schumaker and co-workers,⁵⁹³ has been applied to several proteins. Poillon and Fiegelson⁵⁹⁴ have observed a 6.6% increase in $s_{20,w}$ upon the binding of the allosteric effector tryptophan to tryptophan oxygenase. Charlwood⁵⁹⁵ has found that $s_{20,w}$ of apoferritin increases by 1.8% upon the binding of two atoms of iron per mole, while Atkinson and associates⁵⁹⁶ have used the method for the accurate determination of the sedimentation coefficient of isocitrate dehydrogenase.

Terminology for Sedimentation and Gel-filtration Experiments. There is a need for an established terminology for the different kinds of experiments and boundaries which may be used in the formally analogous techniques^{597, 598} of ultracentrifugation and gel chromatography, especially for measurements designed to increase sensitivity to changes in sedimentation coefficient, s , and elution volume, V . Kirschner and Schachman⁵⁷⁷ have applied the term 'difference sedimentation' to the Rayleigh subtraction technique described above, and have preferred to reserve the original term of 'differential sedimentation'⁵⁸⁸ for layering experiments with concentration boundaries.⁵⁹⁹ A number of these experiments have also been performed by gel chromatography, both with polymerizing⁵⁷⁵ and non-polymerizing systems,⁶⁰⁰ by Gilbert and associates, who have defined several boundary types. Moreover, Gilbert⁶⁰¹ has also introduced the term 'differential gel-chromatography' independently to describe a technique for the measurement of a small difference, ΔV , in elution volume, in which a boundary is formed by layering.

The fluxes J_1 and J_2 , across any given plane in the plateau region of each of two solutions forming a boundary, are given by $v_1 c_1$ and $v_2 c_2$, respectively; c is concentration and v is the velocity of molecules at the given concentration; v thus represents either sedimentation coefficient or elution volume

⁵⁹¹ R. Jaenicke and W. B. Gratzner, *European J. Biochem.*, 1969, **10**, 158.

⁵⁹² J. C. Gerhart and H. K. Schachman, *Biochemistry*, 1968, **7**, 538.

⁵⁹³ V. Schumaker and P. Adams, *Biochemistry*, 1968, **7**, 3422.

⁵⁹⁴ W. N. Poillon and P. Fiegelson, *Biochemistry*, 1971, **10**, 753.

⁵⁹⁵ P. A. Charlwood, *Biochem. J.*, 1971, **125**, 1019.

⁵⁹⁶ L. D. Barnes, G. D. Kuehn, and D. E. Atkinson, *Biochemistry*, 1971, **10**, 3939.

⁵⁹⁷ G. K. Ackers and T. E. Thompson, *Proc. Nat. Acad. Sci. U.S.A.*, 1965, **53**, 342.

⁵⁹⁸ G. A. Gilbert, *Nature*, 1966, **210**, 299.

⁵⁹⁹ R. T. Hersh and H. K. Schachman, *J. Amer. Chem. Soc.*, 1955, **77**, 5258.

⁶⁰⁰ G. A. Gilbert and G. L. Kellett, *J. Biol. Chem.*, 1971, **246**, 6079.

⁶⁰¹ G. A. Gilbert, L. M. Gilbert, C. E. Owens, and N. A. Shawky, *Nature New Biol.* 1972, **235**, 110.

since these are analogues.^{597, 598} The difference in flux, ΔJ , is given by

$$\Delta J = J_1 - J_2 = v_1 c_1 - v_2 c_2 \quad (1)$$

The distinction in the use of terms is then based on whether what is measured is the difference in flux, ΔJ , or the differential with respect to concentration, dJ/dc . We may therefore distinguish between four boundary types: differential, finite-difference, difference, and integral. Their velocity parameters will be denoted by \mathcal{V} , V_Δ , ΔV , and V respectively.

By definition, a 'differential boundary' is one formed between two solutions differing by an infinitely small increment in concentration. The velocity of such a boundary is given by

$$\mathcal{V} = dJ/dc \quad (2)$$

This definition necessarily implies that no constituent disappears across the boundary. In practice, of course, a differential boundary cannot be studied directly. Use is therefore made of the 'finite-difference' boundary that is formed between two solutions which differ by a finite percentage, say 10–20%, of their average concentration, $(c_1 + c_2)/2$. The value of V_Δ is measured experimentally and extrapolation of V_Δ *vs.* c , for a series of boundaries formed at constant $(c_1 + c_2)/2$, to $c = 0$ gives the value of \mathcal{V} for a differential boundary at $(c_1 + c_2)/2$. The velocity of a finite-difference boundary is given by the integral form of equation (2) as $V_\Delta = \Delta J/\Delta c$. When at least one, but not all, of the constituents disappears across the boundary, the difference is no longer finite. The boundary is therefore simply called a 'difference boundary'. This may be formed between two solutions of the same protein at identical concentration, but differing in the presence or absence of effector, for example, or between two solutions of closely related but distinct proteins, such as different haemoglobins. This forms the basis of the technique of 'difference gel-chromatography' (see below), in which ΔJ is measured directly. Since the experiment is designed such that $c_1 = c_2 = c$, equation (1) shows that

$$\Delta V = \Delta J/c = v_1 - v_2 \quad (3)$$

The extreme case of a difference boundary occurs when all components disappear across it, that is $c_2 = 0$, and the boundary is between solution (c_1) and solvent. Combination of equations (1) and (3) gives the velocity of the boundary as

$$V = J_1/c_1 = v_1 \quad (4)$$

Since v is the integral velocity corresponding to the velocity of molecules at the plateau concentration c , the boundary between solution and solvent is termed the 'integral boundary'. The 'differential boundary' has a special significance in boundary theory. Thus an integral boundary may be considered to be constructed from a series of differential boundaries, and

the application of equation (2) at a series of concentrations from the plateau to solvent will describe the integral profile shape.^{602, 603}

We see then that 'differential sedimentation' measures \mathcal{V} or the nearest accessible experimental quantity V_Δ , which represents the way in which J changes with c , by the use of a differential or finite-difference boundary, respectively. 'Difference sedimentation' directly measures the ΔJ between two independent integral boundaries by Rayleigh subtraction. The equivalent subtraction in 'difference gel-chromatography' is most easily achieved by layering to form a difference boundary. Since equation (4) identifies V with v , the resulting ΔV is given by equation (3) as $V_1 - V_2$. Thus each half of the 'difference boundary' may be regarded as an integral boundary. The wedge-window technique⁵⁹² measures directly neither a difference nor a differential. It is simply a technique which allows a more accurate comparison of the progress of two integral boundaries without the technical demands of difference sedimentation. The wedge-window technique might well be called 'comparative sedimentation'.

Active-enzyme Sedimentation. Cohen and Mire have now described⁵⁷⁸ in full the technique of analytical active-enzyme centrifugation, in which the band sedimentation of enzyme through a substrate-containing solution is followed by the changes in absorbance caused by appearance of product or disappearance of substrate. The considerations to be observed include the correct enzyme amount in relationship to rotor speed so that the reaction can be monitored over the desired period, the physical conditions to afford convection-free band sedimentation, the relative concentrations of reactants to ensure a uniform rate of catalysis throughout the band, and the relative sedimentation rates of other enzymes in coupled assay systems. The utilization of the assay system for observation confers not only the obvious advantage of permitting the investigation of an enzyme in its active state, but also both selectivity, so that impure preparations can be studied, and sensitivity, which can be modulated by choice of observation wavelength. In a representative experiment, 10–20 μl of enzyme are applied at an initial concentration of 10 $\mu\text{g ml}^{-1}$ to result in a concentration at band centre as low as 0.1 $\mu\text{g ml}^{-1}$. Clearly, this enormous sensitivity lends the method readily to the determination of the minimum size of the active unit in reversibly polymerizing systems under the influence of substrates or effectors. Thus, at the concentrations used for kinetic studies, the active form of glucose 6-phosphate dehydrogenase is found to be the dimer,⁵⁷⁸ even though NADP promotes association to the tetramer at high concentrations.⁶⁰⁴ Similarly, the 13S-oligomer of beef-liver glutamate dehydrogenase displays both glutamate and alanine dehydrogenase activities at concentrations

⁶⁰² L. M. Gilbert and G. A. Gilbert, *Biochem. J.*, 1965, **97**, 90.

⁶⁰³ L. M. Gilbert and G. A. Gilbert, in 'Regulation of Enzyme Activity and Allosteric Interactions', Fed. European Biochem. Soc. Symp., ed. E. Kvamme and A. Pihl, Academic Press, London, vol. 73, 1968.

⁶⁰⁴ R. Yue, E. Noltmann, and S. Kirby, *J. Biol. Chem.*, 1969, **244**, 1353.

which are so low that the effectors ADP and GTP have no influence on the state of polymerization. At higher concentrations, earlier work has shown that GTP promotes polymerization and glutamate dehydrogenase activity, while ADP promotes dissociation and alanine dehydrogenase activity.⁶⁰⁵

The optical absorption photoelectric scanning system⁶⁰⁶ possesses clear attributes for following the sedimentation of active enzymes and other proteins selectively, although few applications have been reported.⁶⁰⁷ This facility is particularly powerful when more than one wavelength is used, and has recently been applied twice in this way; first,⁵⁸¹ to ensure the integrity of ligand-free haemoglobin at very low concentrations, where it may readily be oxygenated or oxidized to methaemoglobin, by monitoring at the Soret peaks for each species in turn; secondly,⁶⁰⁸ to demonstrate all-or-none dissociation of glyceraldehyde 3-phosphate dehydrogenase by mercurial, by monitoring the mercaptide absorption at 254 nm and the protein absorption at 280 nm.

B. Gel Chromatography.—The attributes of selectivity and sensitivity, possessed in common by all methods based upon absorption optics, are combined in the technique of gel chromatography with the virtue of relatively inexpensive apparatus. Moreover, gel chromatography has unique advantages for the study of interacting systems, namely: the use of frontal analysis provides both a leading and trailing profile, so that non-enantiographic effects resulting from interaction may be assessed; column parameters may be altered by use of gels of different porosity, so as to modify profile shapes; layering experiments for the formation of difference boundaries may be performed with the minimum of technical difficulty. Gilbert and Kellett⁶⁰⁹ have shown that elution volume data on the interaction of ovalbumin and myoglobin are consistent with the formation of a 1 : 1 complex at pH 6.8, with a 0.01 mol l⁻¹ phosphate buffer at 20.0 °C. By monitoring the column effluent at 280 and 410 nm, they were able to follow the constituent concentrations independently and to show that the centroids of the \bar{V}_A^α and \bar{V}_B^β boundaries (Longsworth notation)⁶⁰⁹ are not coincident. Although the separation of centroids in cases of this kind has been recognized for some while,⁶⁰⁹ it has not previously been taken into account because it has not been possible to follow constituents independently. Neglect of this separation for ovalbumin and myoglobin is shown to lead to large errors in the calculated equilibrium constant. The ovalbumin-myoglobin elution profiles are markedly non-enantiographic, and, to the Reporter's knowledge, represent the only published example of profiles for a system which follows the general case ($A + B \rightleftharpoons C$) predicted

⁶⁰⁵ C. Frieden, *J. Biol. Chem.*, 1959, **234**, 809.

⁶⁰⁶ H. K. Schachman and S. J. Edelstein, *Biochemistry*, 1966, **5**, 2681.

⁶⁰⁷ I. Z. Steinberg and H. K. Schachman, *Biochemistry*, 1966, **5**, 3728.

⁶⁰⁸ G. D. Smith and H. K. Schachman, *Biochemistry*, 1971, **10**, 4576.

⁶⁰⁹ L. G. Longsworth, in 'Electrophoresis', ed. M. Bier, Academic Press, New York, 1959.

by Gilbert and Jenkins⁵⁷³ in which $V_C < V_B < V_A$. Finite-difference boundary experiments were used to establish the dependence of the elution volumes of the free species upon concentration.

Difference Chromatography. The technique of difference gel chromatography has been developed by Gilbert^{601, 610} for the precise measurement of a small difference, ΔV , in the elution volumes of two closely related proteins. This difference can then be related to the differences in hydrodynamic parameters, and also to differences in the subunit interaction energies of associating-dissociating systems. In the difference mode of gel chromatography, sufficient solution of the first protein is applied to the column to achieve a plateau in the effluent. The second solution, at identical protein concentration, is then layered onto the column directly. When the effluent is scanned at an isosbestic point for the two proteins, a net deviation from the plateau concentration, either a hump or a dip, is seen only if they differ in elution volume. The area of the net deviation gives a direct measure of the difference between the masses occluded by the column [equation (3)] in the steady states corresponding to saturation with each solution independently. The power of the technique is illustrated by its use in determining the dimer-tetramer association constant for the hybrid formed between met- and oxy-haemoglobins in dilute salt at neutral pH.

The value of the association constant for pure oxyhaemoglobin has been established by absolute methods to be 250 dl g⁻¹.⁵⁷⁵ The exact value of the constant for methaemoglobin, relative to oxyhaemoglobin, was then established by difference experiments between oxy- and met-Hb. Further experiments in which oxy-met mixtures were layered over pure oxy provided the information to calculate the hybrid constant. The ratio of the association constant for met to that of oxy was found to be 0.62 ± 0.01 , corresponding to a difference in dimer-dimer interaction energy of 1.11 kJ mol⁻¹. The ratio for the hybrid to oxy was 1.6, a value indicative of perfect dimer-dimer hybridization (when statistical factors are taken into account).

Zimmerman and Ackers^{611, 612} have theoretically simulated the effects of column parameters such as axial dispersion, gel bead size, gel porosity, and flow rate on the changes in profile shapes as the protein moves through the gel. They emphasize that gel columns are always non-uniformly packed, so that the column partition coefficient for a species in the plateau region is not constant. As a consequence, the direct scanning approach for the study of developing profile shapes⁶¹³ is less efficient than its analogue, velocity sedimentation, but the necessary corrections may be made. Kerestes-Nagy and Orman⁶¹⁴ have reported that yeast enolase exists as an

⁶¹⁰ G. A. Gilbert, *Nature*, 1966, **212**, 296.

⁶¹¹ J. K. Zimmerman and G. K. Ackers, *J. Biol. Chem.*, 1971, **246**, 1078.

⁶¹² J. K. Zimmerman, D. J. Cox, and G. K. Ackers, *J. Biol. Chem.*, 1971, **246**, 4242.

⁶¹³ E. E. Brumbaugh and G. K. Ackers, *J. Biol. Chem.*, 1968, **243**, 6315.

⁶¹⁴ S. Kerestes-Nagy and R. Orman, *Biochemistry*, 1971, **10**, 2506.

active monomer at concentrations below $0.7 \mu\text{g ml}^{-1}$ at temperatures above 40°C at pH 7.4. This is so even in the presence of Mg^{2+} and substrate, 2-phosphoglycerate, both of which are known to enhance the formation of dimer.⁶¹⁵ Monomers produced previously by high concentrations of salt were inactive.⁶¹⁵

C. Light Scattering.—Light scattering has traditionally suffered from a lack of sensitivity both towards low concentrations and low molecular weights, primarily because of the lack of a sufficiently powerful light source. This situation has altered quite dramatically with the advent of the laser. The York group⁶¹⁶ have described the construction of a photometer employing a 50 mW argon-ion laser and have measured the excess scattering of lysozyme solutions over solvent with a range of only 5.3% at protein concentrations ($\sim 25 \mu\text{g ml}^{-1}$) over one hundred-fold lower than those previously reported⁶¹⁷ to yield a molecular weight of $(14\,000 \pm 240)$ dalton. The extension of the concentration scale facilitated extrapolation to zero concentration and a small negative dependence of $[Kc/R(90)]$ was observed, consistent with the existence of the monomer–dimer equilibrium previously reported.⁶¹⁸ The molecular weight distribution of Tamm–Horsfall urinary glycoprotein has been studied directly at concentrations as low as $2 \mu\text{g ml}^{-1}$.⁶¹⁹ An alternative approach combined independent measurements of sedimentation and diffusion coefficients.⁶²⁰ It is here that the use of the laser really comes into its own, for diffusion coefficients may be measured very precisely in as little as two minutes by intensity-fluctuation spectroscopy.⁶²¹ The two alternative studies of Tamm–Horsfall glycoprotein^{619, 622} at the microgram level are in good agreement and yield a minimum molecular weight of about 14×10^6 dalton. The equilibrium constant of the myosin monomer–dimer system has been determined from measurements of the spectral broadening and intensity of scattered laser light.⁶²³

D. Transport Studies.—The interpretation of transport data on interacting protein systems depends greatly on the relative rates of attainment of equilibrium between species and their separation due to transport.⁶²⁴ Only when the separation rate is much greater than that of equilibration will Schlieren peaks in the ultracentrifuge correspond to individual species. These peaks will be fully or partially resolved depending upon the relative

⁶¹⁵ T. H. Gawronski and E. W. Westhead, *Biochemistry*, 1969, **8**, 4261.

⁶¹⁶ J. A. Finnigan, D. J. Jacobs, and J. C. Marsden, *J. Colloid Interface Sci.*, 1971, **37**, 102.

⁶¹⁷ M. Halwer, G. C. Nutting, and B. A. Brice, *J. Amer. Chem. Soc.*, 1951, **73**, 2786.

⁶¹⁸ M. R. Bruzzesi, E. Chiancone, and E. Antonini, *Biochemistry*, 1965, **4**, 1796.

⁶¹⁹ J. A. Finnigan, D. J. Jacobs, and J. C. Marsden, *Biochim. Biophys. Acta*, 1971, **236**, 52.

⁶²⁰ C. J. Oliver, E. R. Pike, A. J. Cleave, and A. R. Peacocke, *Biopolymers*, 1971, **10**, 173.

⁶²¹ R. Foord, E. Jakeman, C. J. Oliver, E. R. Pike, R. J. Blagrove, E. Wood, and A. R. Peacocke, *Nature*, 1970, **227**, 242.


⁶²² G. L. Kellett and H. Gutfreund, *Nature*, 1971, **227**, 921.

⁶²³ T. J. Herbert and F. D. Carlson, *Biopolymers*, 1971, **10**, 2231.

⁶²⁴ L. G. Longworth and D. A. MacInnes, *J. Gen. Physiol.*, 1942, **25**, 507.

sedimentation coefficient of each species. On the other hand, when the equilibration rate is greater than that of separation, fully resolved peaks are never seen and only partial resolution is achieved for systems more complex than monomer-dimer. The latter shows only a single asymmetric peak.⁵⁷² However, if protein-solvent interactions are present, then, when the rate of equilibration is greater than that of separation, even a single protein which does not undergo self-association or dissociation may exhibit partial resolution.⁶²⁴⁻⁶²⁶

We see then that partial resolution may be a consequence of at least three fundamentally different alternatives and it thus becomes extremely important to distinguish between them. A case in point is the ultracentrifuge study by Morimoto and Kegeles⁶²⁷ of the haemocyanin (17S)-monomer-(25S)-dimer equilibrium. At pH 9.4-9.7, instead of the expected single asymmetric peak, they observed partial resolution of the Schlieren pattern. They were able to show from pressure-dependence effects described below that equilibrium was achieved rapidly compared with separation. Since the presence of no other protein components could be detected, they attributed the partial resolution to the dependence of the equilibrium on Ca^{2+} concentration in the supporting solvent. Further studies on Ca^{2+} and pH dependence showed that the dimerization could be described by the equation:



The dimerization is accompanied by a large molar volume of reaction and is therefore pressure-dependent. A rapid increase in rotor speed for solutions overlaid with mineral oil caused an increase in size of the leading peak. The original Schlieren pattern was restored immediately upon return to the lower speed.

E. Kinetic Studies.—There is now a body of known associating-dissociating systems for which equilibrium between species is likely to be attained rapidly compared with their separation due to transport in the ultracentrifuge.⁵⁶⁵ The partially resolved Schlieren peaks displayed by such systems do not correspond to individual species, for the dynamic equilibrium exists throughout the whole boundary. If it were possible by some means to increase the rate of separation to be greater than that of equilibration then, as noted earlier, the peaks would correspond to individual species and the areas would provide a direct measure of their equilibrium concentrations. One way to speed up 'separation' is to make use of an alternative technique, such as the use of a kinetic property which can be measured so quickly that equilibrium is 'frozen' during that period. Thus Gibson and co-workers⁶²⁸ have found that above pH 10 in dilute salt,

⁶²⁵ J. R. Cann, 'Interacting Macromolecules', Academic Press, New York, 1970.

⁶²⁶ J. R. Cann and W. B. Goad, *J. Biol. Chem.*, 1965, **240**, 148.

⁶²⁷ K. Morimoto and G. Kegeles, *Arch. Biochem. Biophys.*, 1971, **142**, 247.

⁶²⁸ M. E. Anderson, J. K. Moffat, and Q. H. Gibson, *J. Biol. Chem.*, 1971, **246**, 2796.

deoxyhaemoglobin dissociates to dimers, while Kellett⁶²⁹ has observed similar dissociation in 2 M-NaI at pH 7.0. The combination curve of haemoglobin with carbon monoxide in these conditions is biphasic. The fast phase is due to dimer, which combines at a rate some twenty-fold greater than that of the slow phase due to tetramer. (The fast rate is in fact the same as that for isolated chains, showing that the dimer is non-co-operative in ligand-binding reactions.)

At the concentrations studied, the rate of attainment of equilibrium between tetramer and dimer is slow ($t_{\frac{1}{2}}$ is several seconds) compared with the rate of carbon monoxide combination ($t_{\frac{1}{2}} = 50$ ms) so that the amplitudes of the fast and slow phases directly represent the concentrations of dimer and tetramer in the deoxyhaemoglobin. Similar considerations are responsible for the observation of rapidly reacting haemoglobin in flash photolysis experiments.⁶³⁰

Ligand-induced Association-Dissociation. The addition or removal of ligand also induces further dissociation of tetramer or association of dimer, respectively.⁵⁸¹ Since the latter processes are usually slow compared with the former, they can be separated. Kellett and Gutfreund⁶²² have made use of this fact to measure the rate constant of dimer self-association (4.4×10^5 l mol⁻¹ s⁻¹) from a change in extinction accompanying dimer to tetramer association induced by removal of oxygen. For some enzymes, the rate of ligand-induced polymerization may be comparable to the rate of catalysis and the latter will be dependent upon the former if the polymerization is between species of different catalytic activities. This seems to be so for phosphofructokinase,^{631, 632} which shows a concentration-dependent lag in the initiation of catalysis, presumably owing to substrate-induced association of inactive subunits. This association may be dependent upon a prior conformational change. Recovery of activity is at present perhaps the most general of the techniques available for following reassociation on short time-scales, *i.e.* of the order of minutes. β -Galactosidase tetramer dissociates to monomer in 90% glycerol at pH 9.2.⁶³³ Direct titration to pH 7 is accompanied by full restoration of activity within 2—3 minutes, which proceeds without the electrophoretically detectable intermediates. The reassociation of *N*(10)-formyltetrahydrofolate synthetase is cation-dependent and proceeds in two steps, the first having low cation specificity and the second having an absolute requirement for monovalent cations, especially NH_4^+ .⁶³⁴ Two methods which may offer more general physical means of following association-dissociation reactions are the use of a

⁶²⁹ G. L. Kellett, *Nature New Biol.*, 1971, **234**, 189.

⁶³⁰ S. J. Edelstein, M. J. Rehmar, J. S. Olson, and Q. H. Gibson, *J. Biol. Chem.*, 1970, **245**, 4372.

⁶³¹ E. C. Hulme and K. F. Tipton, *F.E.B.S. Letters*, 1971, **12**, 197.

⁶³² H. W. Hofer, *Z. physiol. Chem.*, 1971, **352**, 997.

⁶³³ C. C. Contaxis and F. J. Reithel, *Biochem. J.*, 1971, **124**, 623.

⁶³⁴ R. E. MacKenzie and J. C. Rabinowitz, *J. Biol. Chem.*, 1971, **246**, 3731.

fluorescent probe⁶³⁵ and light scattering.⁶³⁶ Radda and co-workers⁶³⁵ have studied the AMP-induced association of phosphorylase *b* from the enhancement in fluorescence of bound 2-methylanilino-naphthalene-6-sulphonate. Tai and Kegeles⁶³⁶ have investigated the temperature-dependent relaxation of haemocyanin association-dissociation by observation of scattered light at the 546 nm mercury line. There seems to be no reason why the replacement of the mercury arc with a powerful laser should not allow this scattering to be observed by rapid-reaction techniques for much smaller molecules than haemocyanin and at much lower concentrations.

F. Subunit Structure of Proteins.—It is now a routine procedure to determine the subunit structure of newly isolated proteins. Determination of subunit molecular weight is perhaps the most direct method. The table lists the molecular weights for native protein and subunits, together with the dissociating reagent used, for some of the proteins investigated in 1971.

Table Subunit structure of some proteins

<i>Protein</i>	<i>Native</i>	<i>Subunits</i>	<i>Number</i>	<i>Dissociating reagent</i>
Aequorin ^a	31 000	31 000	1	SDS
Lactose synthetase A protein ^b	42 900	44 000	1	SDS, 6 M-GHCl
Cyclic AMP receptor protein ^c (mediating cyclic-AMP-dependent gene transcription in <i>E. coli</i>)	45 500	25 500	2	6 M-GHCl
Haemagglutinin ^d (<i>Lens culinaris</i> A and B)	49 000	24 500	2	SDS, 6 M-GHCl
α -Amylase ^e (porcine pancreas)	50 000	25 000	2	SDS
ω -Amidase ^f (rat liver)	58 000	27 000	2	7 M-GHCl
Hydrogenase ^g (<i>Clostridium pasteurianum</i>)	60 000	30 000	2	SDS
Prealbumin ^h (human)	62 500	15 500	4	6 M-GHCl SDS
17 β -Oestradiol dehydrogenase ⁱ (human placenta)	67 700	33 500	2	SDS
Thymidylate synthetase ^j (amethopterin-resistant <i>Lactobacillus casei</i>)	70 000	35 000	2	SDS

⁶³⁵ D. J. Birkett, R. A. Dwek, G. K. Radda, R. E. Richards, and A. G. Salmon, *European J. Biochem.*, 1971, **20**, 494.

⁶³⁶ M. S. Tai and G. Kegeles, *Arch. Biochem. Biophys.*, 1971, **142**, 258.

Table (cont.)

<i>Protein</i>	<i>Native</i>	<i>Subunits</i>	<i>Number</i>	<i>Dissociating reagent</i>
D-Glycerate dehydrogenase ^k	70 000	34 000	2	SDS
2-Keto-3-deoxy-6-phosphogluconate aldolase ^l (<i>Pseudomonas putida</i>)	73 000	24 000	3	SDS
2-Decylcitrate synthase ^m (<i>Penicillium epiculisporum lehman</i>)	90 000	45 000	2	SDS
Succinic dehydrogenase ⁿ	105 000	70 000 + 27 000	1 1	SDS
Transketolase ^o (baker's yeast)	140 000	70 000	2	SDS
Aldolase ^p (<i>Mustelus canis</i>)	160 000	40 000	4	6 M-GHCl
Pyruvate kinase ^q (<i>Saccharomyces cerevisiae</i>)	161 000	19 600	8	SDS 6 M-GHCl
Invertase ^r (<i>Neurospora crassa</i>)	210 000	51 000	4	6 M-GHCl
Glycerol kinase ^s (<i>E. coli</i>)	217 000	56 000	4	SDS 6 M-GHCl
δ-Aminolevulinate dehydratase ^t (<i>Rhodopseudomonas spheroides</i>)	250 000	40 000	6	SDS
δ-Aminolevulinate dehydratase ^u (mouse liver)	250 000	39 500	6	SDS 6 M-GHCl
AMP deaminase ^v (rabbit muscle)	278 000	73 000	4	SDS 6 M-GHCl
Phenylalanyl t-RNA synthetase ^w (yeast)	280 000	75 000 + 63 000	2 2	SDS
Anthranilate synthetase-anthranilate-5-phosphoribosyl pyrophosphate phosphoribosyltransferase ^x (<i>S. typhimurium</i>)	280 000	62 000	2	SDS 8 M-urea
Isocitrate dehydrogenase (DPN) ^y (yeast)	300 000	39 000	8	SDS
Aspartate transcarbamylase ^z (<i>E. coli</i>)	310 000	33 500 + 17 000	3 3	SDS
Leucine aminopeptidase ^{aa}	327 000	57 000	6	SDS

Table (cont.)

Protein	Native	Subunits	Number	Dissociating reagent
N-Methylglutamate synthetase ^{bb} (<i>Pseudomonas</i> M.A.)	350 000	30 000	12	Succinylation 7 M-GHCl
Phosphoenolpyruvate decarboxylase ^{cc} (<i>E. coli</i>)	402 000	102 000	4	SDS 3.5 M-GHCl
Apo ferritin ^{dd, ee} (horse spleen)	440 000— 465 000	18 000— 18 500	23—25	6 M-GHCl
		18 300— 18 800	23—25	6 M-GHCl SDS

- ^a Y. Kohama, O. Shimomura, and F. H. Johnson, *Biochemistry*, 1971, **10**, 4149;
^b I. P. Trayer and R. L. Hill, *J. Biol. Chem.*, 1971, **246**, 6666; ^c W. B. Anderson, A. B. Schneider, M. Emmer, R. L. Perlman, and I. Pastan, *J. Biol. Chem.*, 1971, **246**, 5929;
^d I. K. Howard, H. J. Sage, M. D. Stein, N. M. Young, M. A. Leon, and D. F. Dyckes, *J. Biol. Chem.*, 1971, **246**, 1590; ^e J. F. Robyt, C. G. Chittenden, and C. T. Lee, *Arch. Biochem. Biophys.*, 1971, **144**, 160; ^f L. B. Hersh, *Biochemistry*, 1971, **10**, 2884; ^g G. N. Nakos and L. E. Mortenson, *Biochemistry*, 1971, **10**, 2442; ^h L. Rask, P. A. Peterson, and S. F. Nilsson, *J. Biol. Chem.*, 1971, **246**, 6087; G. Gonzalez and R. E. Offord, *Biochem. J.*, 1971, **125**, 309; C. C. F. Blake, I. D. A. Swan, C. Rerat, J. Berthon, A. Laurent, and B. Rerat, *J. Mol. Biol.*, 1971, **217**, 61; ⁱ D. J. W. Burns, L. L. Engel, and J. L. Bethune, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 786; ^j R. B. Dunlop, N. G. L. Harding, and F. M. Huennekens, *Biochemistry*, 1971, **10**, 88; ^k I. Y. Rosenblum, D. H. Antkowiak, H. J. Sallach, L. E. Flanders, and L. A. Fahren, *Arch. Biochem. Biophys.*, 1971, **144**, 375;
^l R. H. Hammerstedt, H. Mohler, K. A. Dekker, and W. A. Wood, *J. Biol. Chem.*, 1971, **246**, 2069; ^m A. Mahlen, *European J. Biochem.*, 1971, **22**, 104; ⁿ K. A. Davis and Y. Hatefi, *Biochemistry*, 1971, **10**, 2509; ^o C. P. Heinrich and O. Wiss, *F.E.B.S. Letters*, 1971, **14**, 251; ^p C. E. Caban and L. F. Hass, *J. Biol. Chem.*, 1971, **246**, 6807; ^q K. Ashton and A. R. Peacocke, *F.E.B.S. Letters*, 1971, **246**, 6807; ^r Z. D. Meachum, H. J. Colvin, and H. D. Braymer, *Biochemistry*, 1971, **10**, 326; ^s J. W. Thorner and H. Paulus, *J. Biol. Chem.*, 1971, **246**, 3885; ^t S. V. Heyning and D. Shemin, *Biochemistry*, 1971, **10**, 4676; ^u D. Doyle, *J. Biol. Chem.*, 1971, **246**, 4965; ^v A. Boosman, D. Sammons, and O. Chilson, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1025; ^w J. Schmidt, R. Wang, S. Stanfield, and B. R. Reid, *Biochemistry*, 1971, **10**, 3264; ^x E. J. Henderson and H. Zalkin, *J. Biol. Chem.*, 1971, **246**, 6891; ^y L. D. Barnes, G. D. Kuehn, and D. E. Atkinson, *Biochemistry*, 1971, **10**, 3939; ^z V. Pigiet, E. A. Meighen, H. K. Schachman, J. P. Rosenbuch, and K. Weber, *J. Biol. Chem.*, 1971, **246**, 144; ^{aa} S. W. Mellbye and F. H. Carpenter, *J. Biol. Chem.*, 1971, **246**, 2459; ^{bb} R. J. Pollock and L. B. Hersh, *J. Biol. Chem.*, 1971, **246**, 4737; ^{cc} T. E. Smith, *J. Biol. Chem.*, 1971, **246**, 4234; ^{dd} I. Bjork and W. W. Fish, *Biochemistry*, 1971, **10**, 2844; ^{ee} C. F. A. Bryce and R. R. Crichton, *J. Biol. Chem.*, 1971, **246**, 4198.

SDS Gel Electrophoresis. SDS gel electrophoresis has become by far the most widely applied method. Originally introduced as an empirical procedure by Shapiro and co-workers,⁶³⁷ and confirmed in its reliability with some forty proteins by Weber and Osborn,⁶³⁸ the method has now acquired a theoretical basis for its success. Reynolds and Tanford have shown that at SDS monomer concentrations in excess of 8×10^{-4} mol l⁻¹,

⁶³⁷ A. L. Shapiro, E. Vanuela, and J. V. Maizel, *Biochem. Biophys. Res. Comm.*, 1967, **28**, 815.

⁶³⁸ K. Weber and M. Osborn, *J. Biol. Chem.*, 1969, **244**, 4406.

all proteins bind 1.4 g SDS per g protein⁶³⁹ and that the complex is a rod-like particle whose length is a unique function of molecular weight.⁶⁴⁰ Charge effects resulting from the protein are apparently swamped by those from SDS, so that the charge per unit mass of the complex is constant. However, charge effects from the protein may be important for those which have undergone prior extensive chemical modification, *e.g.* by maleylation.⁶⁴¹ Recent variations of the technique include the covalent labelling of proteins with *NN*-dimethylanilinonaphthalene sulphonate, so that bands may be detected visually by fluorescence,^{642, 643} and the introduction of a discontinuous buffer system to improve resolution.⁶⁴⁴ The polypeptide chains within an oligomeric protein may be cross-linked by selective chemical modification of lysyl residues with dimethyl suberimide.⁶⁴⁵ Subsequent electrophoresis in SDS gels resolves a series of bands representing integral multiples from the protomer molecular weight up to the oligomer. Weber and Kuter⁶⁴⁶ have demonstrated reversible denaturation of proteins by SDS and have achieved partial recovery of enzyme activity upon reconstitution of chains separated by SDS gel electrophoresis.

A unified theory of gel chromatography and electrophoresis has been presented in different forms. Morris and Morris⁶⁴⁷ have confirmed the simple linear relationship between reduced electrophoretic mobility (ratio of the mobility at the measured gel concentration to that at zero gel concentration) and molecular-sieve partition coefficient proposed by them earlier.⁶⁴⁸ Rodbard and Chrambach have provided an alternative formulation valid for non-spherical particles.^{649, 650}

Measurements in Guanidine Hydrochloride. Gel chromatography on agarose in either SDS^{651, 652} or 6 mol l⁻¹ guanidine hydrochloride⁶⁵³ represent alternative methods of determining subunit molecular weight,⁶⁵³⁻⁶⁵⁵ though these suffer in comparison to SDS gel electrophoresis from a lack of resolution. Guanidine hydrochloride at 6 mol l⁻¹ is, of course, a popular solvent for sedimentation equilibrium studies in which the slope of the

⁶³⁹ J. A. Reynolds and C. Tanford, *Proc. Nat. Acad. Sci. U.S.A.*, 1970, **66**, 1002.

⁶⁴⁰ J. A. Reynolds and C. Tanford, *J. Biol. Chem.*, 1971, **245**, 5161.

⁶⁴¹ J.-S. Tung and C. A. Knight, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 1117.

⁶⁴² K. R. Shelton, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 367.

⁶⁴³ D. N. Talbot and D. A. Yphantis, *Analyt. Biochem.*, 1971, **44**, 246.

⁶⁴⁴ D. M. Neville, *J. Biol. Chem.*, 1971, **246**, 6328.

⁶⁴⁵ G. E. Davis and G. R. Stark, *Proc. Nat. Acad. Sci. U.S.A.*, 1970, **66**, 651.

⁶⁴⁶ K. Weber and D. J. Kuter, *J. Biol. Chem.*, 1971, **246**, 4504.

⁶⁴⁷ C. J. O. R. Morris and P. Morris, *Biochemistry*, 1971, **124**, 517.

⁶⁴⁸ C. J. O. R. Morris, in 'Protides of the Biological Fluids', ed. H. Peeters, Elsevier, Amsterdam, 1967, vol. 14, p. 453.

⁶⁴⁹ D. Rodbard and A. Chrambach, *Proc. Nat. Acad. Sci., U.S.A.*, 1970, **65**, 970.

⁶⁵⁰ D. Rodbard and A. Chrambach, *Analyt. Biochem.*, 1971, **40**, 95.

⁶⁵¹ J. P. Rosenbuch and K. Weber, *J. Biol. Chem.*, 1971, **246**, 1644.

⁶⁵² W. W. Fish, J. A. Reynolds, and C. Tanford, *J. Biol. Chem.*, 1970, **245**, 5166.

⁶⁵³ I. P. Trayer and R. L. Hill, *J. Biol. Chem.*, 1971, **246**, 6666.

⁶⁵⁴ I. Bjork and W. W. Fish, *Biochemistry*, 1971, **10**, 2844.

⁶⁵⁵ L. Rask, P. A. Peterson, and S. J. Nillson, *J. Biol. Chem.*, 1971, **246**, 6087.

$\log c$ vs. r^2 plot is given by $M_2(\partial\rho/\partial c_2)_\mu$. M_2 is the molecular weight of anhydrous protein and $(\partial\rho/\partial c_2)_\mu$ the reduced density increment at dialysis equilibrium with supporting solvent. This formulation is valid for the three-component system which exists at high guanidine hydrochloride concentrations.⁶⁵⁶ $(\partial\rho/\partial c_2)_\mu$ is also equal to $(1 - \phi'\rho_0)$, where ϕ' is the apparent specific volume of the protein and ρ_0 the solvent density. Since ρ_0 is high for guanidine hydrochloride solutions, any error in assuming a value for ϕ' , which is subject to the effects of preferential solvation, is greatly magnified. The only sure way to determine M_2 is therefore by the independent determination of $(\partial\rho/\partial c_2)_\mu$.⁶⁵⁷ This is demanding experimentally if the high level of precision necessary in the determination of subunit molecular weights is to be achieved. Small changes in the partial specific volume of proteins as a result of exposure to denaturing solvents are often attributed to the effects of preferential interaction. There is, however, always a small volume change ($\Delta\bar{V} \approx -0.015 \text{ ml g}^{-1}$) accompanying unfolding,⁶⁵⁸ which should be taken into account.⁶⁵⁹ Indeed, the change is sufficiently large that dilatometric studies may be used to follow denaturation.⁶⁶⁰ The use of SDS in ultracentrifuge experiments has been reinvestigated.⁶⁶¹

Hybridization Techniques. Isozymes. The hybridization of isozymes has provided much useful information about the subunit structure of those enzymes for which naturally occurring electrophoretic variants are available.⁶⁶² In general, for a protein containing n subunits, $(n + 1)$ bands will be observed upon electrophoresis of the hybridization mixture. Meighen and Schachman have recently extended this approach to those proteins for which variants are unavailable naturally, by their production through chemical modification.⁶⁶³ Following earlier observations on haemerythrin,⁶⁶⁴ they selectively succinylated lysyl residues and, from the resulting mixture of dissociated and undissociated protein, isolated the latter for use as a homogeneous electrophoretic variant.

Hybridization of native and succinylated aldolase resulted in the appearance of five bands, consistent with a tetrameric structure, as did glyceraldehyde 3-phosphate dehydrogenase.⁶⁶⁵ Experiments utilizing both inter- and intra-subunit hybridization showed that aspartate transcarbamylase contains two catalytic subunits, each consisting of three

⁶⁵⁶ E. F. Casassa and H. Eisenberg, *Adv. Protein Chem.*, 1964, **19**, 287.

⁶⁵⁷ E. Reisler and H. Eisenberg, *Biochemistry*, 1969, **8**, 4572.

⁶⁵⁸ M. Cassman and H. K. Schachman, *Biochemistry*, 1971, **10**, 1015.

⁶⁵⁹ T. J. Bowen and M. G. Mortimer, *European J. Biochem.*, 1971, **23**, 262.

⁶⁶⁰ S. Katz and J. E. Miller, *Biochemistry*, 1971, **10**, 3569.

⁶⁶¹ W. Barnett and S. P. Spragg, *Nature*, 1971, **234**, 191.

⁶⁶² C. L. Markert, *Ann. New York Acad. Sci.*, 1968, **151**, 14.

⁶⁶³ E. A. Meighen and H. K. Schachman, *Biochemistry*, 1970, **9**, 1163.

⁶⁶⁴ S. Kerestes-Nagy, L. Lazer, M. H. Klapper, and I. M. Klotz, *Science*, 1965, **150**, 357.

⁶⁶⁵ E. A. Meighen and H. K. Schachman, *Biochemistry*, 1970, **9**, 1177.

chains.⁶⁶⁶ Maleylation⁶⁶⁷ provides an alternative to succinylation and has the advantage of being readily reversible.⁶⁶⁸ The construction of electrophoretic variants by genetic manipulation has been used to show that both histidinol dehydrogenase and 6-phosphogluconate dehydrogenase are dimers.⁶⁶⁹

Haemoglobins. The formation of hybrids containing active and inactive subunits provides a means whereby subunit interactions and the contributions made by individual subunits to oligomeric structures may be assessed. For example, artificially prepared haemoglobin intermediates of the type $\alpha_2\beta_2^{\text{CN}+}$ or $\alpha_2^{\text{CN}+}\beta_2$ formed between normal and inactive cyanomet (CN+) subunits do not bind oxygen co-operatively but have an undiminished Bohr effect.⁶⁷⁰ The production of succinylated variants allows other proteins to be studied in this way, for the succinylated subunits are inactive, not only in the pure species but also in the hybrids. The normal subunits are active within the oligomer and, in the case of aldolase, the ratios of the observed activities for each of the three hybrids to that of native aldolase are 1 : 2 : 3 : 4, respectively. Thus each subunit contributes equally and independently to enzyme activity, even though isolated unmodified subunits are inactive. Clearly, some subunit interaction responsible for activity exists within the oligomer. Similar observations have been made using naturally occurring aldolase variants by Penhoet and Rutter,⁶⁷¹ as well as for glyceraldehyde-3-phosphate dehydrogenase.⁶⁶⁵

Bacterial luciferase. The value of the approach is well illustrated by studies on bacterial luciferase, which consists of dissimilar subunits, α and β , of unknown function. Meighen and co-workers⁶⁷² found that hybridization of native and succinylated luciferase gave three bands upon electrophoresis, confirming the dimeric structure. Quantitative complementation of isolated α and β subunits with the inactive succinylated derivative, $\alpha_s\beta_s$, was used to prepare the hybrids $\alpha_s\beta$ and $\alpha\beta_s$. The former had at least half the specific activity of the native molecule, whereas the latter was inactive, suggesting that the subunits have different functions. Further studies showed that several catalytic centre properties were altered only in molecules possessing an altered α subunit. It was therefore concluded that the α subunit was involved in the catalytic steps of the bioluminescence reaction. The role of the β subunit is as yet unknown.

The bacterial luciferase consists of non-identical subunits and, as such, is distinct from the earlier class of enzymes which consist of apparently identical subunits, each contributing independently and equivalently to the

⁶⁶⁶ E. A. Meighen, V. Pigiet, and H. K. Schachman, *Proc. Nat. Acad. Sci. U.S.A.*, 1970, **65**, 234.

⁶⁶⁷ R. H. Hammerstedt, H. Mohler, K. A. Decker, and W. A. Wood, *J. Biol. Chem.*, 1971, **246**, 2069.

⁶⁶⁸ P. J. G. Butler, J. I. Harris, and R. Lebermann, *Biochem. J.*, 1967, **103**, 78.

⁶⁶⁹ K. K. Lew and J. R. Roth, *Biochemistry*, 1971, **10**, 204.

⁶⁷⁰ M. Brunori, G. Amiconi, E. Antonini, and J. Wyman, *J. Mol. Biol.*, 1970, **49**, 461.

⁶⁷¹ E. E. Penhoet and W. J. Rutter, *J. Biol. Chem.*, 1971, **318**, 246.

⁶⁷² E. A. Meighen, M. Z. Nicoli, and J. W. Hastings, *Biochemistry*, 1971, **10**, 4062.

activity of the oligomer. However, even with these enzymes conditions can be chosen such that only half-of-the-sites activity is displayed. Koshland and co-workers have recently added cytidine triphosphate synthetase to the growing list of such enzymes.⁶⁷³ In this enzyme, only half the glutamine sites bind the affinity label 6-diazo-5-oxonorleucine, whereas total glutamine activity is lost. The labelled enzyme, however, retains its activity towards ammonia and nucleotides. The phenomenon of negative co-operativity, in which ligand binding to the first site induces a conformational change which renders the second site incapable of reaction, may afford a general mechanism for half-of-the-sites activity. The principal condition for this behaviour appears to be the use of a relatively poor substrate, although alkaline phosphatase is in this respect an exception.⁶⁷⁴

Cold Inactivation. Reversible dissociation of active, oligomeric enzyme into inactive subunits provides one mechanism for the phenomenon of cold inactivation.⁶⁷⁵ Several more enzymes have been added this year to the list reviewed by Utter and associates.⁶⁷⁵ Cold inactivation of chicken-liver phosphofructokinase is accompanied by dissociation of a 14S-species to 5S fragments.⁶⁷⁶ The rate of inactivation increases with decreasing temperature and decreasing concentration, while the reaction product, fructose 1,6-diphosphate, which is known to promote association,⁶⁷⁷ protects against inactivation. Similarly, the allosteric modifier L-leucine protects against cold inactivation at low concentrations of L-threonine deaminase from *Rhodospirillum rubrum*.⁶⁷⁸ Inactivation is accompanied by dissociation of tetramer to dimer. Fatty-acid synthetase from the mammary gland of lactating rat dissociates in the cold with loss of activity from a 13S- to a 9S-species.⁶⁷⁹ Bovine-kidney arginosuccinase⁶⁸⁰ behaves similarly in respect of cold inactivation to the enzyme from bovine liver.⁶⁸¹

G. Protein-Small Molecule Equilibria.—The presentation by Klotz of the theory of equilibria between proteins and small molecules has been predominant in this field since it was first written.⁶⁸² This theory has been extended with a study by Klotz and Hunston⁶⁸³ of the properties of graphical representations of multiple classes of binding sites. Thompson and Klotz⁶⁸⁴ have also re-analysed the problem in terms of probabilistic considerations rather than equilibrium ones. A log-log plot of moles of

⁶⁷³ A. Levitzki, W. B. Stallcup, and D. E. Koshland, jun., *Biochemistry*, 1971, **10**, 3371.

⁶⁷⁴ D. R. Trentham and H. Gutfreund, *Biochem. J.*, 1968, **106**, 455.

⁶⁷⁵ J. J. Irias, M. R. Olmsted, and M. F. Utter, *Biochemistry*, 1969, **8**, 5136.

⁶⁷⁶ N. Kono and K. Uyeda, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 1095.

⁶⁷⁷ A. Parmeganni, J. H. Luft, D. S. Love, and E. G. Krebs, *J. Biol. Chem.*, 1966, **241**, 4625.

⁶⁷⁸ R. S. Feldberg and P. Datta, *European J. Biochem.*, 1971, **21**, 447.

⁶⁷⁹ S. Smith and S. Abraham, *J. Biol. Chem.*, 1971, **246**, 6428.

⁶⁸⁰ R. C. Bray and S. Ratner, *Arch. Biochem. Biophys.*, 1971, **146**, 531.

⁶⁸¹ E. A. Havir, H. Tamir, S. Rather, and R. C. Warner, *J. Biol. Chem.*, 1965, **240**, 3079.

⁶⁸² I. M. Klotz, in 'The Proteins', ed. H. Neurath, vol. 1, 1953, p. 727.

⁶⁸³ I. M. Klotz and D. L. Hunston, *Biochemistry*, 1971, **10**, 3065.

⁶⁸⁴ C. J. Thompson and I. M. Klotz, *Arch. Biochem. Biophys.*, 1971, **147**, 178.

ligand bound *vs.* free ligand is suggested as the most convenient way of presenting the binding data. Laiken and Nemethy⁶⁸⁵ have adopted a new approach to the question of multiple binding in considering the binding of flexible ligands to proteins. The flexible ligand may adopt a number of configurations and as a consequence cannot be regarded as binding either independently or even in identical configurations, in contrast to the Klotz theory. The ΔpH method of Scatchard and Black for the determination of the binding of ionic ligands to proteins has been reinvestigated.⁶⁸⁶ Cann has continued his outstanding series of studies on the interaction of aliphatic acids with proteins.⁶⁸⁷

H. Examples of Association-Dissociation Equilibria.—Enzymes. In addition to those systems already mentioned which display concentration-dependent association-dissociation phenomena, others investigated in 1971 include chymotrypsin,⁶⁸⁸ phycocyanin,^{689, 690} phosphoribosyl pyrophosphate synthetase,⁶⁹¹ fumarase,⁶⁹² follicle-stimulating hormone,⁶⁹³ and D-amino-acid oxidase.⁶⁹⁴ Systems which display concentration-dependent effects only in the presence of dissociating reagents include prealbumin⁶⁹⁵ and aldolase A,⁶⁹⁶ while lactate dehydrogenase in the presence of bis-(1-anilino-8-naphthalenesulphonate) exhibits association of the tetramer which can be reversed by the addition of NADH.⁶⁹⁷ The reported dissociation of bovine fibrinogen⁶⁹⁸ has been refuted.⁶⁹⁹ The molecular weight of beef-heart mitochondrial ATPase has been determined to be 360 000 dalton,⁷⁰⁰ the earlier and lower values of *ca.* 280 000 being attributed to inaccuracies in the assessment of dissociation phenomena. The rat-liver enzyme has been reported to have a molecular weight of 384 000 dalton,⁷⁰¹ raising the possibility that the enzyme species obtained from different sources are similar. Use has been made of the weak interaction between the A protein of lactose synthetase with α -lactalbumin to purify the A protein by affinity chromatography using an α -lactalbumin-sepharose column. The A protein binds in the presence of glucose and may be eluted by glucose omission.⁶⁵³

⁶⁸⁵ N. Laiken and G. Nemethy, *Biochemistry*, 1971, **10**, 2101.

⁶⁸⁶ C. J. Halfman and J. Steinhardt, *Biochemistry*, 1971, **10**, 3564.

⁶⁸⁷ J. R. Cann, *Biochemistry*, 1971, **10**, 3707, 3713.

⁶⁸⁸ K. C. Aune and S. N. Timasheff, *Biochemistry*, 1971, **10**, 1609.

⁶⁸⁹ R. MacColl, J. J. Lee, and D. S. Berns, *Biochem. J.*, 1971, **122**, 421.

⁶⁹⁰ O. Kao, D. S. Berns, and R. MacColl, *European J. Biochem.*, 1971, **19**, 595.

⁶⁹¹ I. H. Fox and W. N. Kelley, *J. Biol. Chem.*, 1971, **246**, 5739.

⁶⁹² J. W. Tiepel and R. L. Hill, *J. Biol. Chem.*, 1971, **246**, 859.

⁶⁹³ B. B. Saxena and P. Rathnam, *J. Biol. Chem.*, 1971, **246**, 3549.

⁶⁹⁴ K. Shiga and T. Shiga, *Arch. Biochem. Biophys.*, 1971, **145**, 701.

⁶⁹⁵ L. Rask, P. A. Peterson, and S. F. Nillson, *J. Biol. Chem.*, 1971, **246**, 6087.

⁶⁹⁶ C. J. Masters and D. J. Winzor, *Biochem. J.*, 1971, **121**, 735.

⁶⁹⁷ S. R. Anderson, *Biochemistry*, 1971, **10**, 4163.

⁶⁹⁸ F. C. Capet-Antonini and S. Guinand, *Biochim. Biophys. Acta*, 1970, **200**, 486.

⁶⁹⁹ G. F. Endres and H. A. Scheraga, *Arch. Biochem. Biophys.*, 1971, **144**, 519.

⁷⁰⁰ D. O. Lambeth, H. A. Lardy, A. E. Senior, and J. C. Brooks, *F.E.B.S. Letters*, 1971, **17**, 330.

⁷⁰¹ W. A. Catterall and P. L. Pedersen, *J. Biol. Chem.*, 1971, **246**, 4987.

Haemoglobin. Antonini and Brunori have reviewed the field of haemoglobin association-dissociation equilibria not long ago.⁷⁰² The comments here will therefore be limited to the most recent data available in so far as the latter are directly relevant to studies on the functional properties of haemoglobin. Detectable dissociation of the tetramer into $\alpha_1\beta_1$ dimers (Perutz notation) does not occur at erythrocyte concentrations, but does so within the technically accessible range. Although further dissociation of dimers into monomers at neutral pH has been reported in the past, a recent ultracentrifuge study of oxyhaemoglobin using photoelectric scanning optics has shown that at concentrations down to $1 \mu\text{g ml}^{-1}$ monomer formation does indeed occur in the absence of H_4edta , but that it is irreversible.⁷⁰³ Monomer formation at pH 7 from oxy- or met-haemoglobin is inhibited by $10^{-3} \text{ mol l}^{-1} \text{H}_4\text{edta}$.

Bucci⁷⁰⁴ was unable to find any monomer formation at the microgram level using complement fixation as a means of detecting hybrid formation which proceeds through monomer formation.⁷⁰⁵ The presence of monomers need not normally be considered therefore in the interpretation of solution studies at pH 7.

An important problem in the elucidation of haemoglobin mechanism, therefore, is whether the dimer possesses the functional interactions responsible for co-operativity within the tetramer. One approach to this problem, developed by the Rome group, is to establish criteria of co-operativity based upon a comparison of the kinetic, spectral, and equilibrium properties of the co-operative tetramer with those of the non-co-operative, isolated chains. The 'dimer model' for haemoglobin is based, then, upon the finding that haemoglobin maintains its tetrameric characteristics even in high salt conditions where the dissociation of tetramer to dimer of both oxy- and deoxy-haemoglobin has been reported to be almost complete.⁷⁰⁶⁻⁷⁰⁹ The 'dimer model' attributes a very high degree of co-operativity to the free dimer. However, since the maximum value of the Hill coefficient, n , is two for a dimer and the observed value in high salt is three, a thermodynamic paradox exists.⁷¹⁰ The excess is attributed to weak inter-dimer interactions, *i.e.* within the tetramer, in contrast to strong intra-dimer interactions.

An alternative explanation for the 'salt-paradox' has been recently advanced, based in part upon ultracentrifuge investigations of haemoglobin at microgram concentrations in high salt concentrations.⁵⁸¹ After

⁷⁰² E. Antonini and M. Brunori, *Ann. Rev. Biochem.*, 1970, **39**, 977.

⁷⁰³ G. L. Kellett and H. K. Schachman, *J. Mol. Biol.*, 1971, **59**, 387.

⁷⁰⁴ E. Bucci, *J. Mol. Biol.*, 1971, **55**, 401.

⁷⁰⁵ J. Vinograd and W. D. Hutchinson, *Nature*, 1960, **187**, 216.

⁷⁰⁶ A. Rossi-Fanelli, E. Antonini, and A. Caputo, *Adv. Protein Chem.*, 1964, **19**, 73.

⁷⁰⁷ G. Guidotti, *J. Biol. Chem.*, 1967, **242**, 3673.

⁷⁰⁸ N. M. Anderson, E. Antonini, M. Brunori, and J. Wyman, *J. Mol. Biol.*, 1970, **47**, 205.

⁷⁰⁹ G. Amiconi, E. Antonini, M. Brunori, E. Chiancone, and P. Vecchini, *J. Biol. Chem.*, 1971, **246**, 1883.

⁷¹⁰ A. Rossi-Fanelli, E. Antonini, and A. Caputo, *J. Biol. Chem.*, 1961, **236**, 391, 397.

taking several precautions to prevent oxygenation or oxidation of haemoglobin during sedimentation velocity and equilibrium experiments, and making appropriate corrections for three-component systems,⁶⁵⁶ no dissociation of deoxyhaemoglobin at neutral pH could be detected. Failure to observe the necessary precautions always resulted in low molecular weights and apparent dissociation, indicated by curvature of $\ln c$ vs. r^2 plots. Failure to correct for preferential solvation effects also resulted in low molecular weights. Dissociation of deoxyhaemoglobin was not detectable even at $10 \mu\text{g ml}^{-1}$ in either 2 M-NaCl or 1 M-NaI solution at pH 7. The latter electrolyte is a particularly powerful dissociating agent for oxyhaemoglobin and a comparison of the two led to the conclusion that the degree of dissociation of oxyhaemoglobin was *not less* than 10^5 times that of deoxyhaemoglobin. This finding provides an explanation for the salt paradox, since co-operative effects may take place in the tetrameric deoxy-form, followed by dissociation into dimers upon oxygenation. Furthermore, this independent study is in agreement with the published X-ray high-resolution models of haemoglobin which show that six inter-dimer hydrogen-bonds exist in the deoxy-form that are absent in oxyhaemoglobin.^{711, 712}

Perutz has argued strongly that the tetramer is the functional co-operative unit of haemoglobin and has proposed a detailed mechanism in which the interaction energy of co-operativity is derived from the stepwise release of the constraining hydrogen-bonds in the deoxy quaternary structure as each chain is oxygenated.⁷¹³ This mechanism implies that the $\alpha_1\beta_1$ dimer is non-co-operative in ligand-binding reactions.

Several studies have been made of the properties of transient deoxyhaemoglobin dimers using rapid-reaction techniques. Some of the factors in their design have been outlined earlier in a consideration of the rates of association-dissociation reactions.

The reactions of deoxy-dimers have been studied using a difference in extinction between deoxy-dimer and tetramer in the Soret region,⁶²² by means of the change in tyrosine ionization above pH 10 accompanying tetramer dissociation,⁷¹⁴ and in flash photolysis studies which make use of differences in reactivity towards ligand.⁶³⁰ These studies have shown that the kinetic and spectral properties of transient deoxy-dimers are the same as those of non-co-operative chains.

Conditions have recently been devised in which stable deoxyhaemoglobin dimers can be titrated with ligand. Kellett has shown that deoxyhaemoglobin exists in a tetramer-dimer dissociation-association equilibrium in 2 M-NaI at pH 7.0.⁶²⁹ The value of n is concentration-dependent

⁷¹¹ M. F. Perutz, H. Muirhead, J. M. Cox, L. C. G. Goaman, F. S. Matthews, E. L. McGandy, and L. E. Webb, *Nature*, 1968, **219**, 29.

⁷¹² H. Muirhead and J. Green, *Nature*, 1970, **228**, 516.

⁷¹³ M. F. Perutz, *Nature*, 1970, **228**, 726.

⁷¹⁴ M. E. Anderson, J. K. Moffat, and Q. H. Gibson, *J. Biol. Chem.*, 1971, **246**, 2796.

and reversible, being about 2.0 at 84 $\mu\text{mol l}^{-1}$ (10% dimer) and decreasing to 1.0 at 0.5 $\mu\text{mol l}^{-1}$ (75% dimer). Perutz and associates have also come to the conclusion that the dimer is non-co-operative, from an independent and simultaneous study on des-Arg^{141 α} -haemoglobin.⁷¹⁵ Removal of Arg-141 α by digestion with carboxypeptidase B results in the elimination of four of the six inter-dimer hydrogen-bonds, but leaves unchanged the structure of the $\alpha_1\beta_1$ dimer. Sedimentation velocity studies at pH 7 show that des-Arg^{141 α} -haemoglobin is dissociated into dimer in 0.9 M-MgCl₂ when the value of n is 1.0. It exists as a tetramer in 0.1 mol l⁻¹ phosphate when the value of n is 2.0. This behaviour is reversible.

A thorough study of the role of association-dissociation equilibria in the co-operativity of lamprey haemoglobin has been presented by Anderson and Gibson.^{716, 717} The co-operative characteristics of haemoglobin (containing about 192 haems!) from earthworm have also been studied.⁷¹⁸

Cyclic-AMP-dependent Protein Kinases. The specific site of action of cyclic AMP in a physiological process has been identified for the first time, following a proposal by Krebs and co-workers concerning the mechanism of cyclic-AMP-dependent protein kinases in the regulation of phosphorylase a formation in skeletal muscle.⁷¹⁹ The occurrence of cyclic-AMP-dependent protein kinases is widespread and they possess a broad specificity. Thus the enzyme from muscle, in addition to histone and casein, will phosphorylate phosphorylase kinase and glycogen synthetase.

A series of recent publications from Krebs' laboratory has now dealt with the mechanism of the protein kinase in some detail.⁷¹⁹⁻⁷²³ The inactive form of the kinase consists of a regulatory and a catalytic subunit. Activation occurs as a result of dissociation of the subunits induced by binding of cyclic AMP to the regulatory subunit. The separation of these subunits of the protein kinases from adrenal cortical tissue,^{724, 725} erythrocyte,⁷²⁶ and skeletal muscle⁷²⁷ has recently been achieved. The dissociation is fully reversible upon removal of cyclic AMP. The system

⁷¹⁵ J. A. Hewitt, J. V. Kilmartin, L. F. Ten Eyck, and M. F. Perutz, *Proc. Nat. Acad. Sci. U.S.A.*, 1972, **69**, 203.

⁷¹⁶ M. E. Andersen, *J. Biol. Chem.*, 1971, **246**, 4800.

⁷¹⁷ M. E. Andersen and Q. H. Gibson, *J. Biol. Chem.*, 1971, **246**, 4790.

⁷¹⁸ K. J. Boelts and L. J. Parkhurst, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 637.

⁷¹⁹ M. A. Brostrom, E. M. Reimann, D. A. Walsh, and E. G. Krebs, *Adv. Enzyme Regulat.*, 1970, **8**, 191.

⁷²⁰ D. A. Walsh, J. P. Perkins, C. O. Brostrom, E. S. Ho, and E. G. Krebs, *J. Biol. Chem.*, 1971, **246**, 1968.

⁷²¹ D. A. Walsh, C. D. Ashby, C. Gonzalez, D. Calkins, E. H. Fincher, and E. G. Krebs, *J. Biol. Chem.*, 1971, **246**, 1977.

⁷²² E. M. Reimann, D. A. Walsh, and E. G. Krebs, *J. Biol. Chem.*, 1971, **246**, 1986.

⁷²³ C. O. Brostrom, J. D. Corbin, C. A. King, and E. G. Krebs, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2444.

⁷²⁴ G. N. Gill and L. D. Garren, *Biochem. Biophys. Res. Comm.*, 1970, **39**, 335.

⁷²⁵ G. N. Gill and L. D. Garren, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 786.

⁷²⁶ M. Tao, M. L. Salas, and F. Lipmann, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **67**, 408.

⁷²⁷ E. M. Reimann, C. D. Brostrom, J. D. Corbin, C. A. King, and E. G. Krebs, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 187.

behaves as a 'V' system as defined by Monod, Wyman, and Changeux, since cyclic AMP increases the V_{\max} but not K_m for substrates. As a result, co-operativity is observed only for cyclic AMP, but not for substrates such as casein and ATP. The classic allosteric enzyme, aspartate transcarbamylase, had previously been unique in containing distinct subunits for catalytic and regulatory properties. ATCase does not dissociate except under the influence of group-specific reagents such as mercurial.⁷²⁸

I. Comment.—The particular examples of haemoglobin and cyclic-AMP-dependent protein kinases illustrate the study of associating–dissociating systems in two distinct ways.

The association and dissociation of the catalytic and regulatory subunits in protein kinases is important for *in vivo* regulation of activity. The association–dissociation reactions therefore have an intrinsic interest *per se* as a means of control. On the other hand, detectable dissociation of haemoglobin does not occur at erythrocyte concentrations. The association–dissociation reactions therefore have no physiological significance. However, since the equilibria established reflect directly the strength of the subunit interactions and quaternary constraints which exist within the oligomer, the association–dissociation reactions provide an important probe for the investigation of the tetramer structure–function relationships.

⁷²⁸ J. C. Gerhart and H. K. Schachman, *Biochemistry*, 1965, 4, 1054.

3

Peptide Synthesis

BY J. H. JONES AND B. RIDGE

1 Introduction

Those who provide the material for this chapter continue to be as busy as bees. Indeed the activities of the world's peptide chemists are in many respects comparable to the behaviour of the honey-bee. For example, when a foraging worker bee discovers a new source of food she returns to the hive and there performs a frantic dance, infecting the other workers with her enthusiasm so that they join in and then rush out to find the new food.¹ In the past year or so the new sources of sustenance have been provided, *inter alia*, by the elucidation of the structures of several synthetically accessible potent oligopeptides with important pharmacological effects (see Section 3). The dancing bees have quite rightly reported their discoveries with alacrity, and there are already signs that many workers are in hot pursuit—so much that in some cases different workers appear to be sucking at the same flower. The analogy can be developed further, but breaks down in one embarrassing particular: bees are able to produce a range of pharmacologically active peptides in relatively large amount with effortless superiority.²

Retrospective literature searching in peptide chemistry is greatly facilitated by the availability of such comprehensive sources as Greenstein and Winitz,³ and Schröder and Lübke,⁴ which cover up to the early 1960's. We hope that this series performs a similar function starting from the late 1960's. It can be seen, however, that there is a gap between these periods which has not been comprehensively dealt with, and news of a compilation by Pettit⁵ of the peptide-synthesis literature published during this period was therefore very welcome. The book will serve a useful function but will no doubt provoke considerable criticism among its users. It is stated in the Introduction and Glossary that 'In general, nomenclature follows current

¹ K. von Frisch, 'The Dancing Bees', translated by D. Isle and N. Walker, Methuen, London, 2nd edn., 1966.

² C. R. Diniz and A. P. Corrado, in 'Pharmacology and Toxicology of Naturally Occurring Toxins', ed. H. Raskova, Pergamon Press, Oxford, 1971, vol. II, part IV.

³ J. P. Greenstein and M. Winitz, 'Chemistry of the Amino Acids', Wiley, New York, 1961, vol. 2, ch. 10.

⁴ E. Schröder and K. Lübke, 'The Peptides', vols. 1 and 2, Academic Press, New York, 1965 and 1966.

⁵ G. R. Pettit, 'Synthetic Peptides', Van Nostrand Reinhold, New York, 1970, vol. 1.

IUPAC-IUB commission recommendations', but in fact the mode of use of abbreviated nomenclature deviates grossly from that which has been recommended: this is to be deplored in such a publication since it is obviously liable to perpetuate abuse. In addition many users would have found it more useful to have peptide derivatives with sequences related to any particular natural peptide listed in one place than to have entries for the most part classified according to the arbitrary criterion of chain length.

Wünsch⁶ has written an authoritative, concise summary of the arguments for and against different strategies of peptide synthesis which is an admirable survey of current thinking and which will no doubt influence future development considerably, since many suggestions for improvements are made. A number of other general reviews of the subject have appeared, and the proceedings^{7, 8} of two important symposia of general relevance have been published in full: the proceedings of two others have appeared in abstracted form.^{9, 10} There have been a large number of new books, reviews, and conference proceedings concerned with biological applications of synthetic peptides—these are listed in Section 3.

2 Methods

A number of reviews have appeared.^{10a-10g}

A. Protective Groups.—Established Methods of Amino-group Protection. A preliminary report¹¹ has appeared concerning a new water-soluble reagent which can be used for the t-butoxycarbonylation of amines. The reagent, 4-dimethylamino-1-t-butoxycarbonylpyridinium chloride (1), which is prepared by adding 4-dimethylaminopyridine to an excess of unstable t-butoxycarbonyl chloride, is claimed to be stable at 0 °C in the dry state,

⁶ E. Wünsch, *Angew. Chem. Internat. Edn.*, 1971, **10**, 786.

⁷ Proceedings of the Tenth European Peptide Symposium held at Abano, Italy, 1969, 'Peptides 1969', ed. E. Scoffone, North-Holland Publishing Co., Amsterdam 1971.

⁸ Proceedings of a Symposium on the Chemistry of Peptides held at Santa Monica, California, 1970: *Intra-Sci. Chem. Reports*, 1971, **5**, issues 3 and 4 (not available at the time of writing: see vol. 5 of this Report for reference to individual papers).

⁹ Abstracts of a Belgian-German Joint Biochemical Meeting on Peptides and Proteins held at Liège, Belgium, 1971: *Z. physiol. Chem.*, 1971, **352**, 1.

¹⁰ Abstracts of papers presented at a Colloquium on Polypeptide Hormones—Structure and Function: *Biochem. J.*, 1971, **125**, 49P.

^{10a} M. Oya and R. Katakai, *Yuki Gosei Kagaku Kyokai Shi*, 1971, **29**, 751 (*Chem. Abs.*, 1971, **75**, 141 129j).

^{10b} B. Dugonjic and D. Kolbah, *Tehnika (Belgrade)*, 1970, **25**, 2373 (*Chem. Abs.*, 1971, **74**, 142 311d).

^{10c} H. Yajima, *Yuki Gosei Kagaku Kyokai Shi*, 1971, **29**, 27 (*Chem. Abs.*, 1971, **75**, 6260e).

^{10d} T. Wieland, ref. 7, p. 3.


^{10e} B. J. Johnson, *Ann. Reports Medicin. Chem.*, 1969 (publ. 1970), 307.

^{10f} R. Geiger, *Angew. Chem. Internat. Edn.*, 1971, **10**, 152.

^{10g} T. Kato, H. Aoyagi, M. Waki, N. Mitsuyasu, and N. Izumiya, *Tampakushitsu Kakusan Koso*, 1971, **16**, 56, 139, 221, 293 (*Chem. Abs.*, 1971, **74**, 142 316j, **75**, 88 911e, 88 912f, 88 913g).


¹¹ E. Guibé-Jampel and M. Wakselman, *Chem. Comm.*, 1971, 267.

$$\left[\text{Bu}^t\text{O}-\text{C}(=\text{O})-\text{N}^+(\text{C}_6\text{H}_4\text{NMe}_2) \longleftrightarrow \text{Bu}^t\text{O}-\text{C}(=\text{O})-\text{N}(\text{C}_6\text{H}_4\text{NMe}_2^+) \right] \text{Cl}^- \quad (\text{I})$$



Scheme 2

The selective removal of *N*-*t*-butoxycarbonyl protecting groups in the presence of *N*-benzyloxycarbonyl groups can lead to partial cleavage of the *N*-benzyloxycarbonyl groups when conventional deblocking agents such as trifluoroacetic acid or hydrogen chloride in organic solvents are used (see ref. 16 for literature documentation). A comparative study of the efficacy of selective removal of such groups using a series of reagents¹⁶ has revealed that the required selective cleavage is best achieved with either 70% aqueous trifluoroacetic acid or boron trifluoride diethyl etherate in the presence of glacial acetic acid.¹⁷ In the case of the latter reagent at least equivalent molar quantities of the boron trifluoride reagent are required to remove *N*-*t*-butoxycarbonyl groups, whereas only catalytic amounts of the reagent are required to remove *t*-butyl ester protecting groups. Both the reagents mentioned cause slow cleavage of benzyl ester groups (particularly of γ -benzylglutamic acid derivatives). The boron trifluoride method is particularly suited to the removal of *N*-*t*-butoxycarbonyl groups from cysteine peptides which possess acid-labile *S*-protecting groups such as *S*-trityl^{16, 17} or *S*-diphenylmethyl,¹⁷ both of which remain intact during the treatment. Hydroxylic side-chains require protection if the boron trifluoride method is to be applied, otherwise partial acetylation is likely to occur.¹⁶ Mercaptoethanesulphonic acid (5) has been recommended as a



suitable reagent for the selective removal of *N*-*t*-butoxycarbonyl groups in the presence of *N*-benzyloxycarbonyl groups.¹⁸ A moderate molar excess of the reagent in glacial acetic acid causes the complete cleavage of *N*-*t*-butoxycarbonyl groups within a few minutes at room temperature, without any detectable cleavage of the side-chain protecting groups of ϵ -benzyloxycarbonyl-lysine or of γ -benzyl glutamate. A paper has appeared on the selective removal of an *N*-*t*-butoxycarbonyl group in the presence of a sterically hindered *t*-butyl ester.¹⁹



¹⁶ E. Schnabel, H. Klostermeyer, and H. Berndt, *Annalen*, 1971, **749**, 90.

¹⁷ R. G. Hiskey, L. M. Beacham, tert., V. G. Matl, J. N. Smith, E. B. Williams, jun., A. M. Thomas, and E. T. Wolters, *J. Org. Chem.*, 1971, **36**, 488.

¹⁸ A. Loffet and C. Dremier, *Experientia*, 1971, **27**, 1003.


¹⁹ A. Michalik and B. Liberek, *Zeszyty Nauk., Mat., Fiz., Chem.*, 1970, **10**, 157 (*Chem. Abs.*, 1971, **74**, 134 155).

The 2-(*p*-biphenyl)isopropoxycarbonyl amino-protecting group is usually introduced by means of the action of 2-(*p*-biphenyl)isopropoxycarbonyl azide (6) or 2-(*p*-biphenyl)isopropyl phenyl carbonate (7; R = H) on the benzyltrimethylammonium salt of an amino-acid in absolute



R = H, CO₂Me, COMe, or Ph

DMF. Three modified 2-(*p*-biphenyl)isopropyl phenyl carbonates have been prepared²⁰ in which the phenyl moiety is substituted in the *p*-position by the electron-withdrawing substituents methoxycarbonyl (7; R = CO₂Me), acetyl (7; R = COMe), or phenyl (7; R = Ph). These compounds were synthesized by a method analogous to that used for the preparation of the parent phenyl mixed carbonate (Scheme 3). They are




Conditions: i, C₆H₅·NMe₃; ii, C₆H₅N

Scheme 3

crystalline compounds, recrystallize well, and can be used to prepare 2-(*p*-biphenyl)isopropoxycarbonyl amino-acids, under the anhydrous conditions mentioned above, in good yields. They are also more thermally stable than the parent compound and can be kept at room temperature for several months without appreciable decomposition. 2-(*p*-Biphenyl)-isopropoxycarbonyl fluoride (8) has been prepared (Scheme 4), and although

²⁰ E. Schnabel, G. Schmidt, and E. Klauke, *Annalen*, 1971, **743**, 69.




Scheme 4

it is only stable for a few weeks at -70°C , it can be used to acylate amino-acids in aqueous organic solvents between 0 and -10°C . A wide range of amino-acid derivatives was prepared with good yields.²⁰

Citric acid, the reagent usually employed for acidifying aqueous solutions containing acid-labile amino-acid and peptide derivatives prior to extraction, can cause difficulties because of its solubility in the organic phase. This difficulty can be overcome by replacing the citric acid by an inorganic acid of comparable acidity, namely potassium hydrogen sulphate.²¹

The *N*-*o*-nitrophenylsulphenyl amino-protecting group is usually removed by treatment of the protected peptide with hydrogen chloride in ethyl acetate, or with thiols. Another reagent has been added to the latter category: Cleland's reagent [*threo*-2,3-dihydroxybutane-1,4-dithiol (9)]




removes the *o*-nitrophenylsulphenyl group quantitatively from *o*-nitrophenylsulphenylalanine in two hours at pH 8–9 when two equivalents of the reagent are used.²²

A method has been developed for the trifluoroacetylation of amino-acids and peptides under neutral conditions.²³ Trifluoroacetyl derivatives are of importance in peptide chemistry, since they form the basis of two methods of monitoring racemization tests, *viz.* gas-liquid chromatography and ^{19}F n.m.r. spectroscopy. The acyl group can be introduced by reaction of an excess of trichlorotrifluoroacetone in dimethyl sulphoxide with the amino-component (Scheme 5). The yields of the acylamino-acids obtained were moderate, but poor yields of two acyldipeptides were obtained. Two optically active amino-acids gave derivatives whose optical rotation values

²¹ R. Spangenberg, P. Thamm, and E. Wunsch, *Z. physiol. Chem.*, 1971, **352**, 655.

²² K. P. Polzhofer and K. H. Ney, *Tetrahedron*, 1971, **27**, 1997.


²³ C. A. Panetta and T. G. Casanova, *J. Org. Chem.*, 1970, **35**, 4275.



Scheme 5

were comparable to the literature values. Clearly this study is preliminary in nature and the usefulness of this method will be evaluated later when attempts have been made to optimize yields.



The removal of *N*-chloroacetyl protecting groups from amino-acids and peptides using thiourea often proceeds in unsatisfactory yield owing to secondary reactions. The nature of these side-reactions has been studied in the case of methyl *N*-chloroacetyl-L-valinate (10). It was shown that the 2-iminothiazolidinone (11), formed in the primary reaction, undergoes further reaction with the liberated amino-ester (Scheme 6). Steglich and



Scheme 6


Batz²⁴ therefore advocate the use of the *NN*-disubstituted thiourea 1-piperidinthiocarboxamide (12). The *N*-chloroacetyl residue can be removed quantitatively after boiling for several hours in ethanol with (12), the amine and 2-piperidinothiazolin-4-one (13) being produced without interference from side-reactions. A number of optically pure materials

²⁴ W. Steglich and H. G. Batz, *Angew. Chem. Internat. Edn.*, 1971, **10**, 75.



were prepared in good yield. The utility of the *N*-chloroacetyl group in peptide synthesis has been extended by showing that the dipeptide derivative obtained from *N*-chloroacetyl-L-valine and L-valine *t*-butyl ester by the dicyclohexylcarbodi-imide-*N*-hydroxysuccinimide method showed no racemization in the Weygand test after removal of the *N*-chloroacetyl group with (12) and conversion into the trifluoroacetyldipeptide methyl ester. Furthermore, the *N*-chloroacetyl group has been used to protect the ω -amino-function of ornithine in a synthesis which utilized *N*-trifluoroacetyl for α -protection. The former group can be removed selectively in the presence of the latter by using reagent (12), whereas the latter group can be removed selectively by treatment with sodium borohydride in ethanol.

An alternative to the use of *N*-carbethoxyphthalimide for the introduction of *N*-phthaloyl groups has been devised. *o*-Methoxycarbonylbenzoyl chloride (14) reacts readily with amino-esters in an anhydrous medium giving excellent yields of optically pure phthaloylated derivatives, presumably *via* an intermediate *o*-methoxycarbonylbenzoyl amino-acid ester (15) (Scheme 7).²⁵




Scheme 7

Cathodic reduction has been applied for the cleavage of *N*-tosyl groups²⁶ from amino-acids and peptides. The *N*-tosyl substrate is electrolysed in methanol or aqueous methanol containing two equivalents of sodium hydroxide in a cathode compartment with a lead (or porous zinc) electrode.

²⁵ D. N. Reinhoudt, D. A. Hoogwater, and H. C. Beyerman, ref. 7, p. 7.

²⁶ K. Okamura, T. Iwasaki, M. Matsuoka, and K. Matsumoto, *Chem. and Ind.*, 1971, 929.

The anode compartment of the cell, which is separated from the cathode compartment by a membrane, contains hydrochloric acid with a carbon electrode. A number of *N*-tosyl amino-acids and peptides gave very good yields of cleaved material which were optically pure, as judged by optical rotation. In addition it was shown that the selective cleavage of *N*-tosyl groups in the presence of *N*-benzyloxycarbonyl, *t*-amylloxycarbonyl, *t*-butoxycarbonyl, and *S*-benzyl groups is possible by this method. Since toluene-*p*-sulphinic acid was isolated after electrolysis of an *N*-tosyl derivate, it was assumed that the cathodic reduction proceeds *via* a two-electron change resulting in S—N bond cleavage (Scheme 8).²⁶



Scheme 8

The application of the *N*-trityl protecting group for industrial peptide synthesis has recently been examined.²⁷ The direct preparation of *N*-trityl amino-acids is claimed to proceed in good yield when amino-acid derivatives are treated with two equivalents of trityl chloride in an aprotic solvent in the presence of triethylamine.²⁷

New Methods of Amino-group Protection. *t*-Butoxycarbonyl groups are outstandingly useful for amino-group protection. In recent years the trend has been to produce modified *t*-butylurethanes, in which one of the methyl substituents has been replaced by a group capable of stabilizing the incipient carbonium ion still further, thus resulting in increased acid-lability of the protecting group. Recent investigations²⁸⁻³⁰ have been concerned with the effect of replacing one of the methyl groups by substituents which are highly electronegative. Such groups will destabilize the incipient carbonium ion but by the same token render the acylating agents (*e.g.* the chloroformates) more stable.

Carpino and his colleagues studied²⁸ several α -halogeno-*t*-butoxycarbonyl derivatives with a view to their eventual conversion into *t*-butoxycarbonyl


²⁷ T. Tamaki and S. Kudo, *Yuki Gosei Kagaku Kyokai Shi*, 1971, **29**, 599 (*Chem. Abs.*, 1971, **75**, 98 808r).

²⁸ L. A. Carpino, K. N. Parameswaran, R. K. Kirkley, J. W. Spiewak, and E. S. Schmitz, *J. Org. Chem.*, 1970, **35**, 3291.

²⁹ G. L. Southard, B. R. Zaborowsky, and J. M. Pettee, *J. Amer. Chem. Soc.*, 1971, **93**, 3302.


³⁰ E. Wünsch and R. Spangenberg, *Chem. Ber.*, 1971, **104**, 2427.

derivatives. The stable α -bromo-*t*-butyl chloroformate (16) was prepared, and although simple amines reacted with it to give high yields of the corresponding urethanes (17), amino-acids or amino-esters failed to react normally. Instead of the expected urethane the amine hydrobromide (18) and/or the urea derivative (19) were obtained (Scheme 9). Subsequent



Scheme 9


experiments showed that the amine hydrobromide probably arose by 'self-cleavage' of the expected urethane (Scheme 10). Hydrogenation of the simple model α -bromo-*t*-butylurethanes over a palladium-carbon catalyst in methanol solution in the presence of ammonium acetate gave only moderate yields of the corresponding *t*-butoxycarbonyl derivatives. Thus




Scheme 10

the 'self-cleavage' reaction and the moderate yields of simple *t*-butoxycarbonyl derivatives obtained by reduction make this interesting method impractical for the introduction of the *t*-butoxycarbonyl group.


The use of the 1,1-dimethyl-2-propynyloxycarbonyl group (20) for amino-group protection has been investigated in a preliminary fashion.^{28, 29} 1,1-Dimethyl-2-propynyloxycarbonyl chloride (21) was prepared from 2-methyl-3-butyn-2-ol (22) and phosgene (Scheme 11) in low yield, but although it is distillable at water-pump pressure it darkens on storage.²⁸






Scheme 11


Preparation of 1,1-dimethyl-2-propynyl 2,4,5-trichlorophenyl carbonate (23) has been mentioned²⁹ but without any experimental description. The carbanilate (24) was prepared²⁸ from the chloroformate (21) and aniline: catalytic reduction gave the corresponding t-amyloxycarbonyl derivative³¹ (25) (Scheme 12). In a preliminary report²⁹ it has been shown, however,



that the catalytic hydrogenolysis of 1,1-dimethyl-2-propynyloxycarbonyl-amino-protected peptides [*e.g.* (26)] which contain sulphur proceeds with cleavage of the *N*-protecting group (Scheme 13). Presumably the partially poisoned catalyst only allows reduction to the tertiary allylic derivative,



Scheme 12





Scheme 13

which becomes susceptible to allylic hydrogenolysis. The full paper of this study is awaited with interest so that the potential of this new protecting group can be evaluated.




The *N*-(cyano-t-butoxycarbonyl) group (27) has been introduced for the protection of amino-functions. Amino-acids protected in this way are

³¹ N. Schachat and J. J. Bagnell, jun., *J. Org. Chem.*, 1963, **28**, 991.



obtained by the action of crude cyano-*t*-butoxycarbonyl chloride (28) under Schotten-Baumann conditions.³⁰ It was demonstrated that a cyano-*t*-butoxycarbonyl amino-acid could be coupled with a suitable amino-component using the dicyclohexylcarbodi-imide-*N*-hydroxysuccinimide procedure. The new protecting group can be cleaved with weakly basic reagents (aqueous potassium carbonate or triethylamine at pH 10) *via* β -elimination, but is relatively stable in the presence of anhydrous tri-fluoroacetic acid. Glycyl-*L*-tryptophan (free peptide) prepared using this method of protection possessed the same optical rotation as a specimen prepared by a standard route.³⁰

Sakakibara and his co-workers have carried out a preliminary study of the efficacy of the di-isopropylmethoxycarbonyl group (29) for protecting the ϵ -amino-function of lysine.³² Both di-isopropylmethyl chloroformate




(30) and azidoformate (31) were prepared and utilized to form ϵ -di-isopropylmethoxycarbonyl-lysine *via* its copper complex, and the resulting protected amino-acid was used in peptide synthesis. The protecting group was shown to be considerably more stable to hydrogen chloride in acetic acid than is an ϵ -benzyloxycarbonyl group, but it could be removed completely with anhydrous hydrogen fluoride in the presence of anisole at 20 °C for 1 h. Its use is therefore recommended in cases where there would otherwise be a risk of partial cleavage of an *N*- ϵ -benzyloxycarbonyl group.³²

A further preliminary report has appeared on the use of the photochemically labile 6-nitroveratryloxycarbonyl group³³ for amino-group protection. This group can be introduced with 6-nitroveratryl chloroformate (32), which is prepared according to Scheme 14. Irradiation of 6-nitroveratryloxycarbonyl derivatives at 350 nm brings about an intramolecular redox reaction, which results in the liberation of carbon dioxide, 6-nitrosoveratraldehyde, and the free amino-group (Scheme 15). The

³² S. Sakakibara, T. Fukuda, Y. Kishida, and I. Honda, *Bull. Chem. Soc. Japan*, 1970, **43**, 3322.


³³ A. Patchornik, B. Amit, and R. B. Woodward, ref. 7, p. 12.



Conditions: i, HNO_3 ; ii, NaBH_4 ; iii, COCl_2

Scheme 14


yields of free amino-acids and peptides can be made practically quantitative by carrying out the photoreaction in the presence of strong acids or aldehyde reagents such as semicarbazide hydrochloride. The 6-nitroveratryloxy-carbonyl group can be removed readily from photolabile derivatives of tryptophan providing that wavelengths below 320 nm are filtered out. This method of removal is stated to be compatible with protection by benzyl-oxycarbonyl, *t*-butoxycarbonyl, trifluoroacetyl, tosyl, and benzyl groups,



Scheme 15


while *o*-nitrophenylsulphenyl and triphenylmethyl groups are sensitive to irradiation. No racemization of optically active derivatives was observed.

A further preliminary study of 2-methyl-2-*o*-nitrophenoxypropionyl-protected amino-acids (see vol. 2 of these Reports, p. 150) revealed that the group is easily removed by hydrogenolysis (Scheme 16).³⁴ Peptide-bond



Scheme 16


formation with (33) using the acid chloride method proceeds with complete racemization, whereas coupling mediated by mixed anhydrides or dicyclohexylcarbodi-imide is claimed to lead to optically pure products. A related pair of protecting groups which are removable by neighbouring-group participation are α -methyl- α -(4,5-dimethyl-2-phenazophenoxy)propionyl (34; $\text{R}^1 = \text{R}^2 = \text{Me}$) and α -methyl- α -(4-methyl-2-phenazophenoxy)propionyl (34; $\text{R}^1 = \text{H}$, $\text{R}^2 = \text{Me}$). These groups are introduced by



coupling the corresponding acids (35) with amino-esters using 'EEDQ'—*i.e.* 2-ethoxy-*N*-ethoxycarbonyl-1,2-dihydroquinoline (Scheme 17). The group is removed by converting the phenylazo-moiety into a nucleophilic reduction product using potassium borohydride and palladium on carbon. Acidification of the reaction mixture causes cleavage of the amide bond, with concomitant cyclization of the protecting moiety to a 3,4-dihydro-2,2-dimethyl-2*H*-1,4-benzoxazin-3-one (36). The optical stability of the protected derivatives has not been investigated, or their usefulness in peptide synthesis evaluated.³⁵ Although this kind of protecting group is chemically ingenious, the multiple possibilities for side-reactions and the predictable optical lability of the acids (33) during coupling combine to make any practical application in peptide chemistry most unlikely.

³⁴ F. Cuiban, *Tetrahedron Letters*, 1971, 2471.

³⁵ C. A. Panetta and Altaf-Ur-Rahman, *J. Org. Chem.*, 1971, 36, 2250.



Conditions: i, KBH_4 -Pd/C; ii, HCl




Scheme 17

The observation that peptide synthesis with *N*-acetoacetyl-amino-acid derivatives proceeds, in certain circumstances (*e.g.* using the carbodi-imide method), to give optically pure products has been rationalized by assuming that the carboxy-component is converted into a 2-acetonilidenoxazolidin-5-one (37)^{36, 37} which couples more rapidly with nucleophiles than does the corresponding oxazolinone. This tentative conclusion was reached on the basis of the spectroscopic properties of the compounds resulting from the treatment of *N*-acetoacetyl-amino-acids with dicyclohexylcarbodi-imide.

³⁶ C. Di Bello, F. Filira, and F. D'Angeli, ref. 7, p. 35.



³⁷ C. Di Bello, F. Filira, and F. D'Angeli, *J. Org. Chem.*, 1971, **36**, 1818.

Derivatives such as (37) undergo reaction with nucleophiles to yield optically pure products, and comparative qualitative rate measurements showed that 2-acetonilyden-4-isobutyloxazolidin-5-one (37; R = Bu¹) couples with amines more rapidly than does 4-isobutyl-2-phenyl-2-oxazolin-5-one (38).



An improved method for the synthesis of amino-acids protected with β -dicarbonyl compounds has appeared.^{38, 39} The amino-acid, in aqueous alcohol containing dicyclohexylamine, is treated with benzoylacetone to yield the crystalline *N*-(2-benzoyl-1-methylvinyl)amino-acid dicyclohexylammonium salt (39). The preparation of a number of active esters of β -dicarbonyl *N*-protected amino-acids has been described.⁴⁰

Protection of Carboxy-groups. The utility of the piperonyl group (40) for carboxy-group protection has been investigated.⁴¹ A limited number of




³⁸ G. L. Southard, G. S. Brooke, and J. M. Pettee, *Tetrahedron*, 1971, **27**, 1359.

³⁹ A. Balog, D. Breazu, E. Vargha, F. Gonczy, and L. Beu, *Rev. Roumaine Chim.*, 1970, **15**, 1375 (*Chem. Abs.*, 1971, **75**, 6264j).

⁴⁰ A. Balog, E. Vargha, D. Breazu, L. Beu, and G. Gonczy, *Rev. Roumaine Chim.*, 1970, **15**, 1391 (*Chem. Abs.*, 1971, **75**, 6286t).

⁴¹ F. H. C. Stewart, *Austral. J. Chem.*, 1971, **24**, 2193.

piperonyl esters were prepared by treating the *N*-protected amino-acid with piperonyl chloride (41) in the presence of triethylamine and subsequently removing the *N*-protecting group (Scheme 18). A number of




Conditions: i, (41)-NEt₃; ii, HCl in MeOH or dioxan

Scheme 18

benzyloxycarbonyldipeptide piperonyl esters were prepared by the *p*-nitrophenyl ester method, and their conversion to known free dipeptides enabled the absence of racemization during these synthetic steps to be inferred. The new ester group is removable in the presence of benzyloxycarbonyl by brief treatment with trifluoroacetic acid, or removable together with benzyloxycarbonyl by treatment with 2M hydrogen bromide in acetic acid.

The preparation of further amino-acid *p*-methoxybenzyl ester hydrochlorides, and their use in peptide synthesis, has been reported.^{42, 43} The derivatives of glycine, L-glutamine, L-asparagine, and *S*-benzyl-L-cysteine were prepared *via* the corresponding *o*-nitrophenylsulphenyl derivatives,⁴² whereas the esters of the imino-acids sarcosine, L-proline, and L-4-hydroxyproline were synthesized using the corresponding *N*-nitroso-derivatives.⁴³ However, in the sarcosine series some cleavage of the ester moiety was observed when the nitroso-group was removed by acidolysis.

An improved synthesis of L-histidine benzyl ester from *t*-butoxycarbonyl-histidine in 66% yield (Scheme 19) has been reported.⁴⁴ Another diazo-



Conditions: i, Ph·CHN₂; ii, 4M-HCl-dioxan; iii, K₂CO₃


Scheme 19

⁴² J. A. Maclaren, *Austral. J. Chem.*, 1971, **24**, 1695.

⁴³ F. H. C. Stewart, *Austral. J. Chem.*, 1971, **24**, 1749.

⁴⁴ A. M. Felix and D. P. Winter, *Org. Prep. Proced.*, 1970, **2**, 255.

alkane, namely 1-diazo-2,2-dimethylpropane (42) has been used as a reagent to prepare t-amyl esters of peptide acids.⁴⁵ As shown in Scheme 20, the diazo-alkane, on protonation, gives a neopentyl carbonium ion, which rearranges to the t-amyl carbonium ion, thus giving the ester mentioned.



Scheme 20

The resulting esters are stable to hydrazinolysis but are cleaved by short exposure to hydrogen bromide in acetic acid. C-Terminal arginine peptides protected as t-amyl esters are susceptible to tryptic hydrolysis.

In the picolyl ester method of peptide synthesis the crude product was originally separated from co-products and by-products, either by extraction into aqueous citric acid, or by adsorption on sulphoethyl-Sephadex (see previous volumes of these Reports). Full details of a synthesis of bradykinin (in which the citric acid method was used: see ref. 297) and of [5-valine]-angiotensin II (exemplifying the sulphoethyl-Sephadex technique: see ref. 423) have now been published. The use of the macroreticular sulphonic acid resin Amberlyst-15 is now recommended for the isolation stage,^{46, 47} since it can be used in anhydrous organic solvents. In a typical procedure the coupling solution is exhaustively cycled through the Amberlyst column, and the product is subsequently eluted with DMF containing pyridine. In order to overcome the reluctance of some protected peptide picolyl esters, with lipophilic side-chains, to extract into an acidic aqueous phase,


⁴⁵ C. F. Hayward and R. E. Offord, ref. 7, p. 116.

⁴⁶ J. Burton and G. T. Young, *Israel J. Chem.*, 1971, 9, 201.

⁴⁷ J. Burton, G. A. Fletcher, and G. T. Young, *Chem. Comm.*, 1971, 1057.


the additional use of the picolyl ester to protect carboxy-side-chains has been recommended.

The use of *N*-protected hydrazine derivatives to protect carboxy-groups enables the ready preparation of peptide hydrazides which might otherwise be difficult to obtain by direct hydrazinolysis of the corresponding peptide alkyl esters. For instance, the hydrazinolysis of peptide (43) leads to a product (44) which contains two hydrazide groupings (Scheme 21). A new



Scheme 21

protected hydrazine has been described, namely trichloroethoxycarbonylhydrazine (45),⁴⁸ which is prepared either directly from the corresponding trichloroethoxycarbonyl chloride (46) and hydrazine or indirectly *via* hydrazinolysis of trichloroethyl *p*-nitrophenyl carbonate (47) (see Scheme 22). Trichloroethoxycarbonyl hydrazides are prepared by coupling



Conditions: i, $\text{HO}-\text{C}_6\text{H}_4-\text{NO}_2$ $-\text{NEt}_3$; ii, $\text{H}_2\text{N}\cdot\text{NH}_2$



Scheme 22

acylamino-acids with (45) using dicyclohexylcarbodi-imide or the mixed-anhydride method. Conversion to the corresponding hydrazides is by means of zinc dust in acetic acid, which does not disturb other commonly used protecting groups [*e.g.* (48)—(50) and (49)—(51) in Scheme 23]. No optical rotations are quoted in the work just reported.

A paper has appeared dealing with the conversion of amino-acids into the corresponding ethyl esters using azeotropic distillation.⁴⁹

⁴⁸ H. Yajima and Y. Kiso, *Chem. and Pharm. Bull. (Japan)*, 1971, **19**, 420.




⁴⁹ M. Dymocky, E. F. Mellon, and J. Naghschi, *Analyt. Biochem.*, 1971, **41**, 487.



Conditions: i, Zn dust-MeCO₂H

Scheme 23



Protection of Hydroxy-groups. Side-chain hydroxy-functions are amenable to protection with the t-butoxycarbonyl group,⁵⁰ although the conditions for the removal of such a group have not been defined adequately. *N*-Mono-t-butoxycarbonyl derivatives of serine and threonine can be obtained in good yield by treating the amino-acid with the stoichiometric amount of t-butoxycarbonyl fluoride at pH 8.0, whereas the use of excess acylating agent, particularly at higher pH, yields in addition some *NO*-bis-t-butoxycarbonyl derivatives [(52), (53)] which can be obtained in a pure state by



counter-current distribution. When this acylation is carried out with serine in triethylamine the dehydro-alanine derivative (54) is the major product.

The partially resolved mixture of enantiomers obtained from the treatment of *N*-formyl-*O*-benzyl-*DL*-serine with brucine can be further separated by selective solubilization in ether and t-butyl alcohol.⁵¹ This provides an economic route to *O*-benzyl-*L*-serine.

Protection of Thiol Groups and Synthesis of Cystine Peptides. The t-butoxycarbonyl group can be used for masking the side-chain thiol function of cysteine. Treatment of cysteine with t-butoxycarbonyl fluoride at pH 8,⁵⁰ or with t-butoxycarbonyl chloride in the presence of triethylamine,⁵² yields *NS*-bis-t-butoxycarbonyl-*L*-cysteine (55). Acylation of cysteine with




⁵⁰ E. Schnabel, J. Stoltefuss, H. A. Offe, and E. Klauke, *Annalen*, 1971, **743**, 57.

⁵¹ A. S. Dutta and J. S. Morley, *Chem. Comm.*, 1971, 883.

⁵² M. Muraki and T. Mizoguchi, *Chem. and Pharm. Bull. (Japan)*, 1971, **19**, 1708.

t-butoxycarbonyl azide, on the other hand, is reported to yield mainly *NN'*-bis-t-butoxycarbonyl-L-cystine (56)⁵² with a little (55). The *N*-protecting group of (55) could be removed by the brief action of 2.8M hydrogen chloride in ethyl acetate,⁵² and the *S*-protecting group by treatment with iodine, thiocyanate, or heavy metal ions,⁵⁰ or by prolonged treatment with 2M sodium hydroxide solution.^{50, 52} Investigations of the differential acid-lability of the *N*- and *S*-protecting groups of (57) showed that the selectivity of acidolytic *N*-deprotection was not complete, although it was sufficient for use in a synthesis of glutathione (Scheme 24).⁵² Con-



Conditions: i, DCCI; ii, 2.8M-HCl-MeCO₂Et; iii, mixed anhydride; iv, 0.33M-NaOH; v, 1.4M-HCl-MeCO₂H

Scheme 24


version of (55) into (56)⁵² by alkaline *S*-deprotection followed by iodine oxidation gave a product with an optical rotation some 14% lower than previously recorded figures, which seems ominous in view of the known optical lability of cysteine derivatives.

The *S*-acetamidomethyl protecting group is removable by means of mercury(II) salts at pH 4. It is also possible to form cystine peptides directly from *S*-acetamidomethylcysteine derivatives by a simple procedure involving oxidation with iodine.⁵³ This technique has been illustrated with the synthesis of *cyclo*-L-cystine (Scheme 25).

The *t*-butylthio-group has been introduced for masking thiol functions.⁵⁴ Some derivatives were prepared by treating cystine or *NN'*-bis-(*t*-butoxycarbonyl)cystine with *t*-butylmercaptan in basic solution in the presence

⁵³ B. Kamber, *Helv. Chim. Acta*, 1971, **54**, 927.


⁵⁴ E. Wünsch and R. Spangenberg, ref. 7, p. 30.



Conditions: i, DCCl; ii, I_2 -MeOH; iii, $\text{H} \cdot \text{CO}_2\text{H}$ and cyclization by heating at 45°C


Scheme 25

of oxygen (Scheme 26), or by treating *N*-protected cysteine with *t*-butylsulphenylthiocyanate (59) in the presence of a tertiary base (Scheme 27). The *S*-*t*-butylthio protecting group can be removed by oxidative sulphito-lysis followed by reduction; alternatively Cleland's reagent (9) can be used



Conditions: i, $\text{Bu}^t\text{-SH}$ -base; ii, O_2 .


Scheme 26



Conditions: i, $\text{Bu}^t\text{-S-SCN}$ (59)-*N*-methylmorpholine

Scheme 27


directly (Scheme 28). A number of derivatives (60) with various *S*-alkyl-type protecting groups have been evaluated in solid-phase peptide synthesis.⁵⁵ The *S*-protecting groups shown in (60) are removable under




Conditions: i, HSO_3^- ; ii, H_2S or NaBH_4 ; iii, Cleland's reagent

Scheme 28

the mild conditions of oxidative sulphytolysis or by mercaptoethanol treatment. Thiol-disulphide exchange reactions of *S*-alkylthiocysteine derivatives with reduced glutathione (58) have also been studied,⁵⁶ and a number of solid-phase syntheses of insulin A-chain analogues using these *S*-alkylthio protecting groups have been described.⁵⁷



A new method has been described for the formation of simple unsymmetrical disulphides, based on the reaction of sulphenyl thiolcarbonates (61) with thiols (Scheme 29).⁵⁸ The main advantages of this method are that the reagents (61) are stable and easily prepared and do not appear to undergo side-reactions with other functional groups—*e.g.*, the amino-group




Scheme 29

⁵⁵ U. Weber and P. Hartter, *Z. physiol. Chem.*, 1970, **351**, 1384.


⁵⁶ U. Weber, P. Hartter, and L. Flohe, *Z. physiol. Chem.*, 1970, **351**, 1389.

⁵⁷ U. Weber, K. H. Herzog, H. Grossmann, P. Hartter, and G. Weitzel, *Z. physiol. Chem.*, 1971, **352**, 419.

⁵⁸ S. J. Brois, J. F. Pilot, and H. W. Barnum, *J. Amer. Chem. Soc.*, 1970, **92**, 7629.






in (62). Nevertheless, they are highly reactive towards thiols, and highly selective in that reaction. In some cases formation of disulphide is catalysed by trace amounts of tertiary amine. The process can be written as shown in Scheme 30 or, alternatively, the synchronous collapse of a six-membered



Scheme 30


cyclic transition state may be involved. The application of this procedure to peptides is awaited with interest, particularly on account of the inertness of sulphenyl thiolcarbonates towards amino-groups.

A series of L-cysteinyl-polyglycyl-L-cysteine peptides (63), generated by the action of sodium in liquid ammonia on the fully blocked peptides (64),




were autoxidized in dilute aqueous solution at pH 8.5 and provided a series of disulphides of varying complexity.⁵⁹ The lower members of the series gave rise to mixtures containing varying proportions of cyclic monomer (65) and antiparallel dimer (66). The hexapeptide (63; $n = 4$) and higher members, in contrast, gave predominantly the monomeric cyclic disulphides. The amounts of these monomers formed agree quite well with those predicted by a simple statistical theory,⁵⁹ indicating that the nature of the

⁵⁹ P. M. Hardy, B. Ridge, H. N. Rydon, and F. O. dos S. P. Serrão, *J. Chem. Soc. (C)*, 1971, 1722.



Scheme 31





Conditions: i, $\text{AgNO}_3\text{-C}_6\text{H}_5\text{N-DMF}$; ii, H_2S ; iii, I_2 ; iv, $(\text{SCN})_2\text{-CF}_3\cdot\text{CO}_2\text{H-CH}_3\cdot\text{CO}_2\text{H}$; v, $\text{BF}_3\text{-CH}_3\cdot\text{CO}_2\text{H}$; vi, Δ , DMF

Scheme 32

oxidation products is controlled mainly by the probability of encounter of the two thiol groups when the two sulphur atoms are separated by three or more glycine residues. No evidence for the formation of parallel cyclic dimers (67) was obtained in this work. A general route to such compounds involves the synthesis of bis-cysteine peptides with their thiol groups differentially protected (Scheme 31). Selective removal of A from (68) enables the symmetrical disulphide (69) to be formed; this is followed by selective removal of B and subsequent ring closure to the cyclic bis-cysteine peptide (70). A number of such peptides have been prepared using *S*-trityl or *S*-benzoyl groups for A-protection (Scheme 31) and *S*-benzhydryl for B-protection.⁶⁰ A representative example is shown in Scheme 32.^{60, 61} The striking observations was made that cyclic bis-cystine peptides [*e.g.* (71)] revert to the monomeric form (72) on heating in DMF, the rearrangement being base-catalysed.⁶⁰

Protection of Histidine Side-chains. The *t*-butoxycarbonyl group has also been used for imidazole side-chain protection. The introduction of the group into histidine by acylation with *t*-butoxycarbonyl azide⁶² or fluoride⁵⁰ to yield (73) must be carried out at carefully controlled pH: if the pH is too high concomitant hydrolysis of the newly formed acyl-imidazole occurs.⁶³ Earlier studies of the use of the *N*^{im}-*t*-butoxycarbonyl



group indicated that although the reduction in the basicity of the imidazole ring was satisfactory, some derivatives such as (74) lacked stability,⁶⁴ in addition to being labile to reagents such as hydrazine and methanolic ammonia.⁵⁰ A re-evaluation of the situation showed that although hydrogen bromide in trifluoroacetic or acetic acid, or hydrogen fluoride, cleaves (73) to give free histidine, selective removal of the *N*^a-protecting group is possible using 2M hydrogen chloride in dioxan.⁶² The protecting group has been further tested in a synthesis of poly-L-histidine (Scheme 33).⁶²

A convenient preparation of *N*^{im}-adamantyloxycarbonylhistidine has been reported (Scheme 34).⁶⁵ An application of the *N*^{im}-tosyl protecting group in a solid-phase synthesis of [5-isoleucine]-angiotensin II has been described.⁶⁶ The synthesis employed the standard Merrifield procedure in

⁶⁰ R. G. Hiskey, G. W. Davies, M. E. Safdy, T. Inui, R. A. Upham, and W. C. Jones, jun., *J. Org. Chem.*, 1970, **35**, 4148.

⁶¹ R. G. Hiskey and J. B. Adams, jun., *J. Org. Chem.*, 1966, **31**, 2178.


⁶² M. Fridkin and H. J. Goren, *Canad. J. Chem.*, 1971, **49**, 1578.

⁶³ G. Losse and U. Krychowski, *J. prakt. Chem.*, 1970, **312**, 1097.

⁶⁴ B. O. Handford, T. A. Hylton, K.-T. Wang, and B. Weinstein, *J. Org. Chem.*, 1968, **33**, 4251.


⁶⁵ M. A. Tilak, R. Russell, and M. L. Hendricks, *Org. Prep. Proced.*, 1971, **3**, 17.

⁶⁶ T. Fujii and S. Sakakibara, *Bull. Chem. Soc. Japan*, 1970, **43**, 3954.



Conditions: i, SOCl_2 ; ii, Ag_2O ; iii, NEt_3 ; iv, $\text{HBr-CH}_3\cdot\text{CO}_2\text{H}$


Scheme 33




Conditions: i, Adoc-Cl ; ii, $\text{H}_2\text{-Pd/C}$

Scheme 34

which the histidine residue was introduced as (75). The naked peptide was liberated from the resin by the hydrogen fluoride procedure and was obtained pure, possessing full hypertensive activity, after Dowex-1 chromatography.



Some new histidine derivatives protected in the side-chain by aralkyl groups have been prepared (Scheme 35),⁶³ and a comparative study of the lability of these and other N^{im} -substituted compounds (N^{im} -2,4-dinitrophenyl, N^{im} -picryl, N^{im} -benzyloxycarbonyl, and N^{im} -piperidinocarbonyl)




Conditions: i, Boc-N_3 , pH 10; ii, Trt-Cl or Bzh-Br ; iii, NaOH ; iv, HCl-MeOH

Scheme 35

to various conditions has been made, with a view to using the compounds in solid-phase work.⁶⁷


The thiolysis⁶⁸ of 2,4-dinitrophenylimidazoles (see vol. 2 of these Reports, p. 153) has been applied in classical preparations of some simple histidine-containing dipeptides (Scheme 36).⁶⁹ The rate of thiolysis of



Conditions: i, Dnp-F; ii, HONSu- DCCI ; iii, $\text{H-A}_1\text{-OR}$; iv, $\text{HS}\cdot\text{CH}_2\cdot\text{CH}_2\cdot\text{OH}$; v, $\text{HBr}\cdot\text{CH}_3\cdot\text{CO}_2\text{H}$; vi, $\text{Z-A}_1\text{-ONSu}$

Scheme 36

N^{im}-dinitrophenyl derivatives is sensitive to pH, to the amount of thiol used in excess, and to the solvent. Accordingly it is desirable to establish the optimum conditions for removal in each particular case. This is simplified by the development⁶⁹ of a spectrophotometric method for following the course of the reaction. In order to ensure a rapid release of histidine from its protecting moiety, and consequent diminution of side-reactions, it is recommended⁶⁹ to use a thousand-fold excess of mercaptoethanol or mercaptoacetic acid at pH 7–8. The use of Cleland's reagent²² for the same purpose has been described. The *N*-carboxy-anhydride of *N*^{im}-dinitrophenylhistidine (76) has been prepared, and used in a synthesis of




⁶⁷ G. Losse and U. Krychowski, *Tetrahedron Letters*, 1971, 4121.

⁶⁸ S. Shaltiel, *Biochem. Biophys. Res. Comm.*, 1967, **29**, 178.

⁶⁹ S. Shaltiel and M. Fridkin, *Biochemistry*, 1970, **9**, 5122.

poly-L-histidine⁷⁰ (see Section 2E below). It has been shown that in *N*^α-acetyl-*N*^{im}-2,4-dinitrophenylhistidine (77) nitrogen 3' of the imidazole ring bears the dinitrophenyl moiety.⁷¹ This result was obtained by carboxymethylating compound (77); after thiolysis and acid hydrolysis the resulting carboxymethyl derivative was shown to be identical in its chromatographic mobility with *N*¹-carboxymethylhistidine (78) (see Scheme 37). *N*^{im}-Di-




Conditions: i, $I \cdot CH_2 \cdot CO_2^-$, pH 5; ii, $HS \cdot CH_2 \cdot CH_2 \cdot OH$; iii, hydrolysis

Scheme 37

nitrophenylhistidine does not decompose under the standard conditions of protein hydrolysis: a paper⁷¹ on its quantitative determination on the amino-acid analyser has appeared.

Further reports on the use of (79) in solid-phase peptide synthesis comprise those concerning the tricosapeptide 124—146 of human haemoglobin β -chain,⁷² thyrotropin-releasing hormone,⁷³ and luteinizing-hormone releasing factor.⁷⁴



⁷⁰ M. Fridkin and S. Shaltiel, *Arch. Biochem. Biophys.*, 1971, **147**, 767.

⁷¹ P. Henkart, *J. Biol. Chem.*, 1971, **246**, 2711.

⁷² F. Chillemi, ref. 7, p. 84.

⁷³ P. Rivaille and G. Milhaud, *Helv. Chim. Acta*, 1971, **54**, 355.

⁷⁴ P. Rivaille, A. Robinson, M. Kamen, and G. Milhaud, *Helv. Chim. Acta*, 1971, **54**, 2772.

Final Deprotection. Methods for stripping a finished synthetic peptide of its protective groups after their work is done still leave much to be desired. Even syntheses which have been planned so that the mildest possible final deprotection is called for can run into difficulty: this was so in the case of calcitonin (see vol. 3 of these Reports, p. 253), where side-reactions were observed when the protecting groups (all of which were derived from *t*-butyl alcohol) were removed by brief treatment with cold concentrated hydrochloric acid. In more typical examples reagents of greater vigour are required for the last step. The use of anhydrous hydrogen fluoride for this purpose is the subject of a recent review by Sakakibara.⁷⁵ Experience with hydrogen fluoride has been very varied (see examples in Section 3), and it does not seem possible to generalize about its value: neither is it clear precisely what all the side-reactions induced by it are. Of older vintage is the use of sodium in liquid ammonia for final deprotection. Although this reagent has sometimes had quite disastrous results, in the past there was often no alternative for many syntheses, and the best that could be done was to minimize the side-reactions after extensive experimentation to locate the optimum conditions for each case. One of the main side-reactions is the cleavage of acyl-proline bonds (see ref. 76 for leading references to previous observations on this point). A recent study using model peptides suggests that Thr-Pro (insulin B27-B28) and Ser-Pro bonds are especially labile.⁷⁷ In a bovine (ovine, porcine) insulin B-chain synthesis reported during the year by Katsoyannis *et al.*,⁷⁸ cleavage of the Thr^{B27}-Pro^{B28} bond by sodium in ammonia was essentially quantitative, and in fact the reagent has been used⁷⁸ on a preparative scale to make de-(28-30)-B-chain.* It appears that this cleavage can be suppressed by carrying out the sodium-ammonia treatment in the presence of a large excess of sodamide,⁷⁶ and Katsoyannis and his collaborators were able to convert the human⁷⁹ and bovine (80)⁷⁶ protected B-chain derivatives to the corresponding deprotected B-chains (isolated as bis-*S*-sulphonates) in this way without fission of the threonylproline bond. This is clearly a finding of considerable potential usefulness, but the addition of sodamide may not prove a panacea for all the failings of sodium-ammonia since although no threonylproline cleavage was detected, both crude deprotected

⁷⁵ S. Sakakibara, in 'Chemistry and Biochemistry of Amino-acids, Peptides and Proteins', ed. B. Weinstein, vol. 1, p. 51.


⁷⁶ P. G. Katsoyannis, C. Zalut, A. Tometsko, M. Tilak, S. Johnson, and A. C. Trakatellis, *J. Amer. Chem. Soc.*, 1971, 93, 5871.

⁷⁷ A. Marglin, *Internat. J. Protein Res.*, 1972, 4, 47.

⁷⁸ P. G. Katsoyannis, C. Zalut, A. Harris, and R. J. Meyer, *Biochemistry*, 1971, 10, 3884.

⁷⁹ P. G. Katsoyannis, J. Ginos, C. Zalut, M. Tilak, S. Johnson, and A. C. Trakatellis, *J. Amer. Chem. Soc.*, 1971, 93, 5877.

* The des-(B28-B30)-bovine insulin (which also has a modified B-C-terminal group) derived from this degraded B chain was found to be fully active, and Katsoyannis *et al.* make the point that many earlier syntheses which used sodium-ammonia may have to be re-evaluated.



(80)

B-chain bis-*S*-sulphonates contained substantial amounts of at least two unidentified contaminants.

Katsoyannis *et al.* give full details⁷⁹ of the special glassware devised and employed by them for the convenient and controlled addition of sodium-ammonia solutions to their reaction mixtures.

Final deprotection of a protected (*N*^α-benzyloxycarbonyl, *O*-benzyl, ω-nitro-, and 4-picolyl ester groups) bradykinin by catalytic hydrogenolysis was accompanied by some reduction of the phenylalanine rings: this reduction could be made quantitative by using extended reaction times (see ref. 297).


Miscellaneous Matters relating to Protective Groups. A new simple quantitative method of reducing sulfoxides with sodium borohydride-cobalt chloride⁸⁰ has not as yet been applied to methionine sulfoxide derivatives. Methionine sulfoxide is quantitatively reduced by Cleland's reagent,²² which has been recommended as an antioxidant to protect methionine peptides during chromatography. A neutral side-product isolated from the acylation of glutamine with *t*-butoxycarbonyl fluoride has been identified as *N*-*t*-butoxycarbonyl-α-amino-glutarimide (Scheme 38).⁵⁰ When peptides containing both nitroarginine and phenylalanine are hydrolysed with hydrochloric acid, chlorinated phenylalanines are formed.⁸¹

It has been known for many years that exposure to alkali prolongs and potentiates the melanotropic activity of pituitary peptides (ref. 82 has introductory references on this topic). This effect has been attributed to racemization, which results in delayed proteolytic inactivation. A recently published⁸² detailed study provides further substantiation of this interpretation and concludes with the warning that 'The very significant levels of D-amino-acids formed after only 10 min of exposure of melanotropin to alkali should serve as a warning to peptide-synthetic chemists'. In fact the conditions used were 0.1M sodium hydroxide at 60 °C—hot alkali is

⁸⁰ D. W. Chasar, *J. Org. Chem.*, 1971, **36**, 613.

⁸¹ P. Moritz and R. Wade, *Analyt. Biochem.*, 1971, **41**, 446.


⁸² S. Lande and A. B. Lerner, *Biochim. Biophys. Acta*, 1971, **251**, 246.



Scheme 38

very rarely used in synthetic operations—but five minutes of such treatment were sufficient for 50% prolongation of melanotropic activity and 10% racemization of some residues. The caveat is clear, although vigorous alkaline deprotection steps are in any case already anathema to many of us because of the side-reactions which often result with complex peptide derivatives.

B. Formation of the Peptide Bond.—*Activated Esters.* In continuation of the study of amide bond formation assisted by intramolecular general base catalysis, which results in rapid racemization-free couplings, active esters





of 2-hydroxypyridine (81) and 2-mercaptopyridine (82) have been investigated.⁸³ Whereas the esters (83) were prepared using dicyclohexylcarbodi-imide in pyridine solution or in solvents containing two equivalents of pyridine⁸⁴ (in solvents such as acetonitrile or dichloromethane, *N*-acylureas were formed), the thioesters (84) could be prepared in ethyl acetate.⁸³ A wide range of *t*-butoxycarbonyl- and benzyloxycarbonyl-amino-acid pyridyl esters⁸⁴ and thioesters⁸³ were prepared (see Appendix B). Both types of ester are considerably more reactive towards nucleophiles than are the corresponding *p*-nitrophenyl esters or 4-pyridyl thioesters (85).^{83, 84} They react rapidly and exothermically even with hindered amino-esters to give very high yields of protected dipeptides. Both types

⁸³ K. Lloyd and G. T. Young, *J. Chem. Soc. (C)*, 1971, 2890.

⁸⁴ A. S. Dutta and J. S. Morley, *J. Chem. Soc. (C)*, 1971, 2896.

of ester react with alcohols, albeit rather slowly, and can be used for forming depsipeptides and *O*-acyl derivatives of serine, threonine, and tyrosine. In contrast to the usual solvent dependence for the aminolysis of esters such as those of *p*-nitrophenol, the rate of coupling for 2-pyridyl esters and 2-pyridyl thioesters increases^{83, 84} when the polarity of the medium is decreased. It appears that this type of solvent dependence may be characteristic of aminolyses which proceed by intramolecular general base catalysis. On account of this higher reactivity of the 2-pyridyl esters in non-polar solvents such as dichloromethane, their use in solid-phase peptide synthesis has been recommended, and this application has been evaluated by a synthesis of *SS'*-dibenzyl-oxytocinoic acid (86).⁸⁴ One 2-pyrimidinyl thioester (87) was also prepared: it behaved similarly to the corresponding 2-pyridyl ester.



A note has appeared on the marked catalysis of active ester couplings by the anhydrous sodium salt of 2-hydroxypyridine.⁸⁵ In various model systems the rate enhancement of aminolysis due to the salt, relative to the hydroxypyridine, is of the order of several hundreds. It is possible that these reactions proceed *via* nucleophilic catalysis in which either a pyridyl ester (83) or an *N*-acylpyridone is formed as a reactive intermediate.

Monoacyl derivatives of catechol also undergo aminolysis by an intramolecularly assisted mechanism: the use of these in sequential polypeptide synthesis is covered elsewhere in this chapter (Section 2E).


The preparation of 4-nitroguaiacyl esters of *N*-protected amino-acids (88) and their use in peptide synthesis has been described recently.⁸⁶

It was observed that 5-amino-3-methyl-4-nitroso-1-phenylpyrazole (89) reacts with acetic anhydride and yields, depending on the conditions used, either (90) or (91). The observation that ammonia converts (91) into (90)⁸⁷ (Scheme 39) formed the basis of an investigation of compounds related to (91) as new active esters. In the presence of dicyclohexylcarbodi-imide, (89) reacts with one or two moles of an *N*-protected amino-acid to yield (92) or


⁸⁵ N. Nakamizo, *Bull. Chem. Soc. Japan*, 1971, **44**, 2006.

⁸⁶ K. Bankowski and S. Drabarek, *Roczniki Chem.*, 1971, **45**, 1205.

⁸⁷ M. Guarneri and P. Giori, *Gazzetta*, 1969, **99**, 463.




(93) respectively.⁸⁸ Compounds such as (93) are stable, crystalline acylating agents which react rapidly at room temperature with amino-esters (Scheme 40): the yields of peptides were high and no racemization was detected in sensitive tests. The co-product (92) is readily removed from the crude peptide by extraction with aqueous sodium carbonate, and can be readily recovered by acidification. The rapidity of the coupling reaction and its



Conditions: i, $(\text{MeCO})_2\text{O}$, 45°C ; ii, $(\text{MeCO})_2\text{O}$, 60°C ; iii, NH_3

Scheme 39







Scheme 40

⁸⁸ M. Guarneri, P. Giori, and C. A. Benassi, *Tetrahedron Letters*, 1971, 665.

freedom from racemization suggest that the nitrogen atom of the 5-acylimino-group of (93) may be effecting intramolecular general base catalysis of the aminolysis reaction (94).

Other relevant papers have been concerned with applications of *O*-acyl-*N*-hydroxyureas (95)⁸⁹ and of *p*-(acetylsulphamoyl)phenyl esters (96)⁹⁰ in



peptide synthesis and with the preparation of cyanomethyl esters by treatment of *N*-protected amino-acid salts with (97).⁹¹

Coupling Methods involving Acyloxyphosphonium Salts. Simple amides can be prepared in high yield⁹² using the adduct of triphenylphosphine and carbon tetrachloride, which is transformed into a triphenylacyloxyphosphonium salt by treatment with the carboxyl component and then is treated


⁸⁹ D. Sarantakis, W. W. Light, A. R. Craig, and B. Weinstein, *Synthesis*, 1971, 328 (*Chem. Abs.*, 1971, **75**, 88 915j).

⁹⁰ G. Kupryszewski and F. Muzalewski, *Roczniki Chem.*, 1970, **44**, 2341 (*Chem. Abs.*, 1971, **75**, 49 555x).

⁹¹ M. Leplawy and J. Zabrocki, *Z. Chem.*, 1971, **11**, 16 (*Chem. Abs.*, 1971, **75**, 49 546v).

⁹² L. E. Barstow and V. J. Hruby, *J. Org. Chem.*, 1971, **36**, 1305.

with two equivalents of the amino-component (Scheme 41; $\text{:B} = \text{R}^3 \cdot \text{NH}_2$). Racemization can be minimized (to as little as 1—2% in the Young test)⁹ by using phosphines or amides of phosphorous or phosphoric acids of higher basicity than triphenylphosphine, namely hexamethylphosphorotriamide (98) or (99) (Scheme 41; $\text{:B} = N\text{-methylmorpholine}$).




Conditions: i, $\text{R}^2 \cdot \text{CO}_2\text{H}$; ii, :B ; iii, $\text{R}^3 \cdot \text{NH}_2$

Scheme 41

The above methods are reminiscent of the racemization-free condensation involving activated derivatives of hexamethylphosphorotriamide (see also vol. 2 of these Reports, p. 156). Dissolution of toluene-*p*-sulphonic



anhydride in an excess of hexamethylphosphorotriamide leads to the formation of an activated derivative (100).⁹⁴ Addition to this solution of a carboxylate salt generates (101), which readily undergoes aminolysis to form a peptide bond (Scheme 42). In the absence of chloride ion this





Conditions: i, Dry, room temperature, 15 min; ii, $\text{R}^2 \cdot \text{CO}_2^-$, 0 °C, 5—10 min; iii, $\text{R}^1 \cdot \text{NH}_2$

Scheme 42


⁹³ S. Yamada and Y. Takeuchi, *Tetrahedron Letters*, 1971, 3595.

⁹⁴ G. Gawne, G. W. Kenner, and R. C. Sheppard, ref. 7, p. 23.

method of peptide synthesis is largely racemization-free, which is ascribed to the low intrinsic activity of the resonance-stabilized intermediate (101). Aminolysis (but not oxazolinone formation) may be catalysed by anchimeric assistance (102) of the dimethylamino-groups or by initial attack at the



phosphorus atom (Scheme 43). Some tentative support for the latter possibility arises from the observation that coupling involving proline or sarcosine as amino-component leads to the production of some dimethylamide of the carboxyl component.




Scheme 43

The method of peptide synthesis using triphenyl phosphite and imidazole has been studied from a mechanistic point of view.⁹⁵ Conductivity studies are interpreted to indicate that triphenyl phosphite and imidazole interact with the formation of a compound containing a phosphorus–nitrogen bond. The postulated intermediate (103), prepared from diphenylphosphorochloridite and imidazole (Scheme 44), was shown to be reactive to aminolysis, although it was not characterized on account of its lack of stability. It is probable that the coupling proceeds *via* an acylimidazole, since in the absence of amino-component a phenyl ester results.


An acyloxyphosphonium salt is probably involved in the ‘oxidation–reduction condensation’ method of amide-bond synthesis (see vol. 1 of these Reports, p. 190). The observation that sulphenamides are attacked

⁹⁵ Yu. V. Mitin and O. V. Glinskaya, *J. Gen. Chem. (U.S.S.R.)*, 1971, **41**, 1152.



Scheme 46


but also to activate the sulphur–nitrogen bond of the sulphenamide to nucleophilic attack (Scheme 46). The coupling proceeds in high yield but is a victim of racemization which, however, can be reduced in the presence of acidic additives (such as *N*-hydroxysuccinimide) which take over the role of activating the sulphur–nitrogen bond by protonation. The most favourable conditions elaborated (Scheme 47) gave benzoyl-L-leucylglycine ethyl ester with 74% optical purity.⁹⁶



Scheme 47


A more generally applicable variation of the method of 'oxidation–reduction condensation' involves the coupling of an *N*-protected amino-acid and an amino-acid ester mediated by a disulphide as oxidant and triphenylphosphine as reductant in the presence of mercury(II) chloride (Scheme 48).⁹⁷ The Young test revealed that this procedure leads to extensive racemization. In order to suppress this, the tertiary base was replaced by various organic mercury(II) compounds. Salts of acids with stable anions such as 2,4-dinitrophenol, which presumably react with the acyloxyphosphonium mercaptide (104) producing the metal mercaptide and another acyloxyphosphonium salt (105) as shown in Scheme 49, reduce racemization in proportion to the increasing stability of the anion. (Benzoyl-L-leucylglycine ethyl ester prepared by this variation had an optical purity of 46%.) If the additive is di-*p*-anisylmercury then the mercaptan produced after the coupling step is scavenged, obviating anion formation and thereby reducing the risk of racemization (Scheme 50). In the usual non-polar coupling

⁹⁷ R. Matsueda, H. Maruyama, M. Ueki, and T. Mukaiyama, *Bull. Chem. Soc. Japan*, 1971, **44**, 1373.




solvents, the latter procedure gives benzoyl-L-leucylglycine ethyl ester with an optical purity of 90%.

If this method of amide-bond formation were to be applied to the solid-phase method of synthesis, mercaptan scavengers would be required



which give rise to soluble mercaptides. Possible compounds are olefins such as 2,3-dihydropyran, sulphenate esters, and 2,2'-bipyridyl disulphide.⁹⁸ The optical purity of the Young peptide when prepared by the solution technique using the last compound was 92%.⁹⁷ This whole series of






⁹⁸ T. Mukaiyama, R. Matsueda, and H. Maruyama, *Bull. Chem. Soc. Japan*, 1970, **43**, 1271.

highly ingenious methods of 'oxidation-reduction' coupling clearly requires further study: it might well be that the use of a phosphorus-containing compound of higher basicity than triphenylphosphine might render racemization negligible.

A related method of peptide synthesis involves the interaction of an arylsulphenyl amino-acid, a carboxyl component, and triethyl phosphite in a non-chlorinated hydrocarbon solvent. The reaction proceeds under mild conditions in moderate yield but difficulties are experienced with asparagine and glutamine peptides. The method is claimed to be free of racemization by the Anderson and Young tests.⁹⁹

N-Carboxy-anhydrides and *N*-Thiocarboxy-anhydrides. The use of amino-acid *N*-carboxy-anhydrides and *N*-thiocarboxy-anhydrides in the controlled stepwise synthesis of peptides in aqueous media, without the isolation of each individual peptide, is outlined in Volume 1 of these Reports, p. 196. The syntheses of the novel *N*-carboxy-anhydrides¹⁰⁰ and *N*-thiocarboxy-anhydrides¹⁰¹ used in this work have now been reported together with their evaluation in coupling reactions. The direct phosgenation of aspartic acid has been modified to give the corresponding Leuchs' anhydride (106) in the crystalline state, albeit in low yield, uncontaminated with compound (107). With ammonia (106) gives only isoasparagine, and in model coupling





reactions it gives only α -linked peptides.¹⁰⁰ The *N*-carboxy-anhydrides of asparagine (108; $n = 1$) and glutamine (108; $n = 2$) are obtained in the crystalline state by the action of phosphorus tribromide on the corresponding benzyloxycarbonylamino-acids. Whereas the glutamine anhydride affords α -glutamyl peptides without any evidence of rearrangement, the asparagine compound gives low yields of peptides, and the use of alternative reagents, such as *t*-butoxycarbonylasparagine succinimido-ester, is recommended.¹⁰⁰ An improved method is described for the preparation of the *N*-carboxy-anhydrides of serine (109; $R = H$) and threonine (109; $R = Me$) (the method has also been used for the Leuchs' anhydride of ϵ -*t*-butoxycarbonyl-L-lysine), which involves phosgenation of the silver salt of


⁹⁹ Yu. V. Mitin and G. P. Vlasov, *J. Gen. Chem. (U.S.S.R.)*, 1971, **41**, 419.

¹⁰⁰ R. Hirschmann, H. Schwam, R. G. Strachan, E. F. Schoenewaldt, H. Barkemeyer, S. M. Miller, J. B. Conn, V. Garsky, D. F. Veber, and R. G. Denkwalter, *J. Amer. Chem. Soc.*, 1971, **93**, 2746.

¹⁰¹ R. S. Dewey, E. F. Schoenewaldt, H. Joshua, W. J. Paleveda, jun., H. Schwam, H. Barkemeyer, B. H. Arison, D. F. Veber, R. G. Strachan, J. Milkowski, R. G. Denkwalter, and R. Hirschmann, *J. Org. Chem.*, 1971, **36**, 49.




the corresponding amino-acid. Side-reactions can be avoided in the coupling of the serine and threonine derivatives if they are first converted into their *O*-trimethylsilyl derivatives (110; R = H or Me respectively), the *O*-protecting group being removed during the coupling reaction.¹⁰⁰ The direct preparation of (110; R = Me; DL) has been reported, using a new general method for forming *N*-carboxy-anhydrides, in which an *N*-silyloxy-carbonylamino-acid trimethylsilyl ester is treated with phosgene.¹⁰² In order to overcome side-reactions consequent upon the general insolubility of the Leuchs' anhydride of tyrosine (111) in aqueous coupling media, the phenolic group is protected as the tetrahydropyranyl ether (112) as shown in Scheme 51: the diastereoisomer with the lower negative optical rotation



Conditions: i, dihydropyran-Tos·Cl


Scheme 51

was used for peptide synthesis on account of its more favourable solubility. The protecting tetrahydropyranyl group is cleanly removed when the coupling solution is acidified to bring about decarboxylation of the carbamate.¹⁰⁰ The recently reported *O*-trimethylsilyl-L-tyrosine *N*-carboxy-anhydride (113)¹⁰² might well become the reagent of choice for the introduction of tyrosyl residues by this method. The action of phosphorus tribromide on benzyloxycarbonylarginine yields a yellow tar containing *ca.* 50% of the desired *N*-carboxy-anhydride; despite this contamination the




¹⁰² H. R. Kricheldorf, *Chem. Ber.*, 1971, **104**, 87.

tar can be used successfully in peptide synthesis providing its anhydride content is known.¹⁰⁰ A similar method is used to prepare the crystalline hydrobromide salt of histidine *N*-carboxy-anhydride (114; X = O). This material could not be used successfully in repetitive peptide synthesis since the major product was an imidazo-tetrahydropyrimidinone (115; X = O), formed as shown in Scheme 52.¹⁰⁰



Scheme 52


The method of choice for the preparation of *N*-thiocarboxyamino-acid anhydrides (116) of high optical purity involves the cyclization of *N*-(alkoxythiocarbonyl) amino-acids (117) with phosphorus tribromide (Scheme 53).¹⁰¹ Alternatively, the required anhydrides (116) can be



Conditions: i, KOH; ii, PBr₃; iii, HBr

Scheme 53


prepared by cyclization of amino-acid thiocarbamates (118) with phosphorus pentachloride (Scheme 54), or by the reaction of an amino-thio-acid with phosgene, but in general lower yields are obtained with these methods.¹⁰¹ In general the *N*-thiocarboxy-anhydrides have an optical purity better than 98%, as revealed by hydrolysis to the corresponding amino-acid.



Conditions: i, KOH; ii, PCl₅; iii, H₂S

Scheme 54

In repetitive peptide synthesis the *N*-thiocarboxy-anhydrides in general give higher yields than do the corresponding *N*-carboxy-anhydrides, and on account of the greater stability of the thiocarbamate (119) produced, the coupling reaction is carried out at lower pH (Scheme 55) although side-



Conditions: i, NH₂·CHR²·CO₂⁻, pH 9, 0 °C; ii, H⁺

Scheme 55

products are still observed. In contrast to the *N*-carboxy-anhydride of histidine, the *N*-thiocarboxy-anhydride can be used successfully for peptide synthesis provided the reagent is used in excess.¹⁰¹ The *N*-thiocarboxy-anhydrides of glycine and alanine give significantly higher yields of product than do the corresponding *N*-carboxy-anhydrides.

Unfortunately, in contrast to the *N*-carboxy-anhydrides which give optically pure products, the *N*-thiocarboxy-anhydrides give products containing significant amounts of epimer. The optical purity of a series of products was measured by ^1H n.m.r. spectroscopy using the ^{13}C satellites as internal standards, or by hydrogen-isotope exchange, which showed the presence of 1–20% of the epimeric peptide.¹⁰¹

The controlled repetitive method of peptide synthesis using *N*-carboxy-anhydrides has been modified by carrying out the coupling reaction in a two-phase solvent system (acetonitrile–water, 60 : 50, v/v) containing sodium carbonate at an apparent pH of 11.6 (careful control of pH is unnecessary) at -15°C ; raising the temperature to 40°C enables the resulting carbamate to be decomposed, thus revealing a new amino-group for further chain elongation. The coupling reaction probably occurs at the solvent interface, the *N*-carboxy-anhydride being protected by the organic phase against side-reactions such as hydrolysis and polymerization. Furthermore, over-reaction is reduced since the carbamate produced appears to be stabilized in the mixed solvent system.¹⁰³

A paper has appeared on the use of *N*-carboxy-anhydrides in the synthesis of oligopeptides containing ϵ -benzyloxycarbonyl-lysine,¹⁰⁴ and a study of the mechanism of Leuchs' anhydride formation from *N*-benzyloxycarbonyl-amino-acids has been reported.¹⁰⁵

Other Methods. A symposium paper has appeared on the use of 1-hydroxy-benzotriazole as an additive in dicyclohexylcarbodi-imide-mediated couplings.¹⁰⁶ A report has now appeared on the evaluation of acyloxysilanes as acylating reagents (see vol. 2 of these Reports, p. 157) for peptide synthesis.¹⁰⁷ Carboxyl components are readily converted into the corresponding tetra-acyloxysilanes on treatment with silicon tetrachloride, and these react with amino-components to give moderate yields of simple dipeptides. These dipeptides were shown to be extensively racemized, and furthermore the benzyloxycarbonyl group is not compatible with this method of coupling since it undergoes cleavage.

A novel method has been developed for the insertion of amino-acid residues into peptides *via* the *N*-trimethylsilyl derivatives.¹⁰⁸ The reaction sequence is outlined in Scheme 56. Unambiguous synthesis of the product (120) showed that no significant degree of racemization had occurred in the course of the insertion process.

¹⁰³ Y. Iwakura, K. Uno, M. Oya, and R. Katakai, *Biopolymers*, 1971, 9, 1419.


¹⁰⁴ T. D. Skalaban, I. M. Nazimov, S. S. Pankova, E. N. Zvonkova, R. P. Evstigneeva, and N. A. Preobrazhenskii, *Zhur. org. Khim.*, 1971, 7, 47 (*Chem. Abs.*, 1971, 74, 100 403e).

¹⁰⁵ I. Z. Siemion and D. Konopinska, *Roczniki Chem.*, 1970, 44, 785 (*Chem. Abs.*, 1971, 74, 23 116j).

¹⁰⁶ W. König and R. Geiger, ref. 7, p. 17.

¹⁰⁷ T. H. Chan and L. T. L. Wong, *J. Org. Chem.*, 1971, 36, 850.

¹⁰⁸ J. S. Davies, C. H. Hassall, and K. H. Hopkins, *Chem. Comm.*, 1971, 1118.



Conditions: i, $\text{Me}_3\text{SiCl}\cdot\text{NEt}_3$; ii, Z-Ala-Cl ; iii, $\text{H}_2\text{-Pd/C}$

Scheme 56

A monograph¹⁰⁹ entitled 'Isonitrile Chemistry', which contains a chapter on the application of four-component condensations to peptide syntheses, has appeared. The formation of peptides from glycine in the presence of trimetaphosphate has been studied.¹¹⁰ Calculations of the relative statistical distribution of peptides in stepwise synthesis (as a function of a constant coupling yield at each step) have been tabulated.^{110a}

C. Racemization.—The results of racemization tests on various new coupling methods have been mentioned in the previous section.

The azide method of coupling, which has been shown previously to engender racemization when a vast excess of triethylamine is present, has now been shown to cause slight racemization even when the added base is not present in excess.¹¹¹ In the preparation of (121) by a 2 + 2 azide



(121)

coupling, triethylamine in amount equivalent to the hydrogen chloride present led to a peptide product of 90–95% optical purity; *N*-methylmorpholine led to 90–95% optical purity, and di-isopropylethylamine led to 97–98% optical purity. A number of examples were cited which

¹⁰⁹ G. Gokel, P. Hoffman, H. Kleimann, H. Klusacek, G. Luedke, D. Marquarding, and I. Ugi, in 'Isonitrile Chemistry', ed. I. Ugi, Academic Press, New York, 1971, p. 201.

¹¹⁰ N. M. Chung, R. Lohrmann, L. E. Orgel, and J. Rabinowitz, *Tetrahedron*, 1971, 27, 1205.

^{110a} J. M. A. Baas, H. C. Beyerman, B. van de Graaf, and E. W. B. de Leer, ref. 7, p. 173.

¹¹¹ P. Sieber, M. Brugger, and W. Rittel, ref. 7, p. 60.

indicate the importance of carefully selecting the conditions to be used in a prospective azide synthesis.

A discussion has appeared on the base strengths of a series of tertiary amines in various organic solvents (measured spectrophotometrically using 2,4-dinitrophenol as indicator) and their relationships to the racemization problem.¹¹² A kinetic study of the rate of racemization and the rate of deuterium exchange of *N*-benzyloxycarbonyl-*S*-benzyl-L-cysteine pentachlorophenyl ester in non-polar solvent in the presence of triethylamine and monodeuteriomethanol indicates that base-catalysed α -hydrogen abstraction proceeds *via* isoracemization.¹¹³ Preliminary kinetic data indicate that the base-catalysed racemization of *N*-benzyloxycarbonyl-L-phenylalanine pentachlorophenyl ester also proceeds *via* isoracemization.¹¹³

The Izumiya racemization test involves the determination of the amount of glycyl-D-alanyl-L-leucine in glycyl-L-alanyl-L-leucine by use of an amino-acid analyser. A simplified procedure has been described for the separation of these two peptides by ion-exchange chromatography on resin-coated chromatoplates.¹¹⁴ A review has appeared on the use of gas-liquid chromatography in the determination of the optical purity of amino-acids and peptides.¹¹⁵ A section of this review deals with the chromatographic resolution of diastereoisomeric peptides. The kinetics of the acid-catalysed reaction of DL-alanine ethyl ester with 2-phenyl-4,4-dimethyl-2-oxazolin-5-one have been studied.¹¹⁶

Treatment of α -melanotropin with hot alkali causes considerable racemization of some residues⁸² (see p. 339).

The effects of substituents in the ester aromatic nucleus of benzoyl-L-leucine phenyl ester on the rates of racemization by triethylamine and coupling with benzylamine have been investigated.^{116a}

When determining the stereochemical purity of a peptide by acid hydrolysis and subsequent analysis of the hydrolysate, it is important to be able to correct for the racemization actually occurring during the hydrolysis. A new method for doing this is based on the use of tritiated hydrochloric acid for hydrolysis and measurement of the incorporation of radioactivity into each amino-acid by monitoring the effluent from an amino-acid analyser with a flow-cell scintillation counter.¹¹⁷

D. Repetitive Methods of Peptide Synthesis.—Brief reports of investigations of macroreticular resins as solid-phase supports have appeared.^{118, 119}

¹¹² A. W. Williams and G. T. Young, ref. 7, p. 52.

¹¹³ J. Kovacs, H. Cortegiano, R. E. Cover, and G. L. Mayers, *J. Amer. Chem. Soc.*, 1971, **93**, 1541.

¹¹⁴ T. Devenyi, *Acta Biochim. Biophys.*, 1970, **5**, 441 (*Chem. Abs.*, 1971, **75**, 36 657g).

¹¹⁵ J. W. Westley in 'Chemistry and Biochemistry of Amino-acids, Peptides and Proteins', ed. B. Weinstein, Marcel Dekker, New York, 1971, vol. 1, p. 1.

¹¹⁶ H. Rodriguez, C. Chuaqui, S. Atala, and A. Márquez, *Tetrahedron*, 1971, **27**, 2425.



^{116a} J. Morawiec, D. Konopinska, and I. Z. Siemion, *Roczniki Chem.*, 1971, **45**, 771 (*Chem. Abs.*, 1971, **75**, 98 786g).

¹¹⁷ J. M. Manning, *J. Amer. Chem. Soc.*, 1970, **92**, 7449.


¹¹⁸ M. A. Tilak and S. C. Hollinden, *Org. Prep. Proced.*, 1971, **3**, 183 (*Chem. Abs.*, 1971, **75**, 141 164s).

¹¹⁹ S. Sano, R. Tokunaga, and K. A. Kun, *Biochim. Biophys. Acta*, 1971, **244**, 201.

Polymeric supports linked to the peptide through benzhydryl ester (122)^{120, 121} offer the advantage that the final separation from the polymer requires milder acidolysis than does the Merrifield resin: very acid-labile α -amino-protecting groups are of course required for use in conjunction with (122), and the enamine type has been used.¹²¹ The safety-catch principle has been incorporated into the design of the new polymeric support (123). The peptide-polymer link is completely acid stable, and nucleophilic



attack at the acylsulphonamide carbonyl group is prevented by the facile ionization of the N—H group. *N*-Methylation (with diazomethane), however, eliminates this inhibitory effect and the peptide-polymer link is then easily cleaved with alkali, ammonia, or hydrazine: the preliminary report describes the use of this support for synthesis of several oligopeptide derivatives which were suitable for further elaboration by classical means.¹²² Some limitations were noted—including slight racemization of *C*-terminal residues—but with further development the method could become very useful. It has been suggested that the scope of solid phase peptide synthesis could be extended by using side-chain functionalities for attachment to the polymer, and the idea has been illustrated by a synthesis of lysine vasopressin by an essentially stepwise solid-phase procedure but starting from (124),



which was obtained *via* the corresponding polymeric chloroformate.¹²³ A symposium paper on the use of *t*-alkoxycarbonylhydrazide- (see vol. 2 of these Reports, p. 162) and *t*-alkyl alcohol-resins for the preparation of protected fragments has been published.¹²⁴

The idea of using a soluble polymeric carrier so that coupling steps can be performed in homogeneous solution has been revived. In its first form

¹²⁰ G. L. Southard, G. S. Brooke, and J. M. Pettee, *Tetrahedron*, 1971, **27**, 2701.

¹²¹ G. L. Southard, G. S. Brooke, and J. M. Pettee, ref. 7, p. 95.


¹²² G. W. Kenner, J. R. McDermott, and R. C. Sheppard, *Chem. Comm.*, 1971, 636.

¹²³ J. Meienhofer and A. Trzeciak, *Proc. Nat. Acad. Sci., U.S.A.*, 1971, **68**, 1006.

¹²⁴ S. S. Wang and R. B. Merrifield, ref. 7, p. 74.

(see vol. 1 of these Reports, p. 164) this approach involved the separation of excess reagents *etc.* by washing the peptide-polymer conjugate with solvents which did not dissolve it: in the modified method which has been briefly described, polyethylene glycol is the polymeric carrier and ultrafiltration is used for this step.¹²⁵

Many pharmacologically active polypeptides possess a C-terminal amide group. The obvious means of constructing this feature in a solid-phase synthesis involving a Merrifield resin is to use ammonolysis for scission of the peptide-resin ester link. This is fine if the C-terminal residue is glycine, as in oxytocin, where the method has been used with considerable success. Hindered C-terminal residues cause difficulty, although the C-terminal hexapeptide amide (125) of secretin, which has C-terminal valine, has been obtained using forcing ammonolysis conditions (Scheme 57; $n = 1$ or 6).^{126, 127} In one of these examples (Scheme 57; $n = 6$)¹²⁷ a modified



Conditions: NH_3 -DMF (50 : 50 by vol.) at room temperature

Scheme 57


support was used: here the steric hindrance is presumably further reduced by greater distance between the site of ammonolysis and the polymeric web. An alternative approach to the solid-phase synthesis of C-terminal amides is to use a support which itself embodies an amide as the connecting functionality, removal from the carrier being accomplished by cleavage between the amide nitrogen and the polymer. Such is the principle of supports (126) derived from benzhydrylamine, which have recently proved useful in syntheses of Substance P and the luteinizing-hormone releasing factor (see Sections 3G and 3B, respectively).

Methods for the attachment of the first residue to Merrifield resins have received some attention. The most commonly used procedure has been refluxing the chloromethylated resin with the t-butoxycarbonyl derivative of the first residue in a solvent such as ethanol containing triethylamine. Some of the reactive groups on the resin become quaternized as a side-

¹²⁵ M. Mutter, H. Hagenmaier, and E. Bayer, *Angew. Chem. Internat. Edn.*, 1971, **10**, 811.



¹²⁶ W. Parr, C. Yang, and G. Holzer, *Tetrahedron Letters*, 1972, 101.

¹²⁷ E. Bayer, E. Breitmaier, G. Jung, and W. Parr, *Z. physiol. Chem.*, 1971, **352**, 759.



reaction—this can be avoided by using instead the tetramethylammonium salt of the t-butoxycarbonylamino-acid.¹²⁸ Treatment of the chloromethylated support with the t-butoxycarbonylamino-acid and methylamine in DMF at room temperature has been recommended as a mild procedure: this modification is suitable for use with t-butoxycarbonylasparagine, which is subject to side-reactions in the conventional technique.¹²⁹

The problem of 'failure' and 'error' sequences in solid-phase products has been further considered by Bayer and his colleagues¹³⁰ who have developed¹³¹ a sensitive method for detecting error sequences, based on ¹⁹F n.m.r. spectroscopy after trifluoroacetylation of the solid-phase product: the ¹⁹F shift in trifluoroacetylpeptides is very sensitive to the nature of the modified residue, so that contaminants with the wrong *N*-terminus are easily detected. Non-quantitative coupling has usually been blamed for the presence of failure and error sequences in solid-phase products, but this may not be the whole truth since incomplete deprotection has been identified as the difficulty in some cases,¹³² and irreversible blocking of *N*-termini by impurities in methylene chloride has also been recognized.¹³³ Treatment with (127) after each coupling step has been recommended: this facilitates removal of the products of incomplete coupling at the end of the synthesis since these are converted by (127) into strongly acidic derivatives (128)—*cf.* the use of 3-nitrophthalic anhydride (see vol. 2 of these Reports, p. 163).



¹²⁸ A. Loffet, *Internat. J. Protein Res.*, 1971, 3, 297.

¹²⁹ A. Marglin, *Tetrahedron Letters*, 1971, 3145.

¹³⁰ E. Bayer, H. Hagenmaier, G. Jung, W. Parr, H. Eckstein, P. Hunzicker, and R. E. Sievers, *ref. 7*, p. 65.

¹³¹ E. Bayer, P. Hunziker, M. Mutter, R. E. Sievers, and R. Uhmman, *J. Amer. Chem. Soc.*, 1972, 94, 265.

¹³² F. C.-H. Chou, R. K. Chaivla, R. F. Kibler, and R. Shapira, *J. Amer. Chem. Soc.*, 1971, 93, 267.

¹³³ K. Brunfeldt and T. Christensen, *F.E.B.S. Letters*, 1972, 19, 345.

Other relevant papers include studies of the use of symmetrical anhydrides,¹³⁴ succinimido-esters,¹³⁵ triazole with active esters,¹³⁶ and 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ('EEDQ')¹³⁷ for coupling in solid-phase work, alcoholysis of the peptide resin ester link,¹³⁸ comparisons of the utility of different *N*-protecting groups,¹³⁹ of rates of coupling obtained using different resins,^{140, 141} and of the reactivities of different *t*-butoxycarbonylamino-acids in solid-phase coupling,¹⁴² process control,^{143–145} a model system suitable for screening modified techniques,¹⁴⁶ and apparatus and instrumentation for automated solid-phase synthesis.^{147–149}

Other repetitive methods have been dealt with elsewhere—the use of *N*-carboxy-anhydrides in the section on formation of the peptide bond and the use of picolyl esters in the section on carboxy-group protection.

E. Synthesis of Polymeric Models for Studies in Protein Chemistry.—Polyamino-acids. By oversight, reference to an important book¹⁵⁰ which contains useful detailed chapters on the kinetics and mechanism of *N*-carboxy-anhydride polymerization was omitted from earlier volumes of these Reports.

The usefulness of the 2,4-dinitrophenyl protecting group for histidine side-chains has been further demonstrated by its employment in a synthesis of poly-L-histidine (Scheme 58):⁷⁰ a synthesis of poly-L-histidine which uses *N*^{im}-*t*-butoxycarbonyl protection has been discussed elsewhere (Scheme 33).

A synthesis of poly-(α -ethyl aspartate) has been described,¹⁵¹ and poly-DL-serine has been obtained *via* serine azide hydrobromide.¹⁵²

¹³⁴ T. Wieland, C. Birr, and F. Flor, *Angew. Chem. Internat. Edn.*, 1971, **10**, 336.

¹³⁵ A. Orlowska and S. Drabarek, *Roczniki Chem.*, 1971, **45**, 339 (*Chem. Abs.*, 1971, **75**, 64 246r).

¹³⁶ U. Ragnarsson, G. Lindeberg, and S. Karlsson, *Acta Chem. Scand.*, 1970, **24**, 3079.

¹³⁷ H. Yajima and H. Kawatani, *Chem. and Pharm. Bull. (Japan)*, 1971, **19**, 1905.

¹³⁸ H. C. Beyerman, H. Hindricks, J. Hirt, and E. W. B. de Leer, ref. 7, p. 87.

¹³⁹ U. Ragnarsson, S. Karlsson, and G. Lindeberg, *Acta Chem. Scand.*, 1970, **24**, 2821.

¹⁴⁰ J. J. Maher, M. E. Furey, and L. J. Greenberg, *Tetrahedron Letters*, 1971, 27.

¹⁴¹ A. Losse, *Tetrahedron Letters*, 1971, 4989.

¹⁴² U. Ragnarsson, S. Karlsson, and B. Sandberg, *Acta Chem. Scand.*, 1971, **25**, 1487.

¹⁴³ H. C. Beyerman and H. Hindricks, ref. 7, p. 145.

¹⁴⁴ B. Mehlis, W. Fischer, and H. Niedrich, ref. 7, p. 146.

¹⁴⁵ K. Brunfeldt, P. Roepstorff, and J. Thomsen, ref. 7, p. 148.

¹⁴⁶ L. C. Dorman, L. D. Markley, and D. A. Mapes, *Analyt. Biochem.*, 1971, **39**, 492.

¹⁴⁷ C. Birr and W. Lochinger, *Synthesis*, 1971, 319.


¹⁴⁸ A. M. Tometsko, J. H. Garden, sec., and J. Tschio, *Rev. Sci. Instr.*, 1971, **42**, 331.

¹⁴⁹ R. Boni, G. M. Bonara, L. Ciceri, A. Gambini, A. Scatturin, and E. Scoffone, *Chimica e Industria*, 1971, **53**, 10 (*Chem. Abs.*, 1971, **75**, 62 842r).

¹⁵⁰ M. Szwarc, 'Carbanions, Living Polymers, and Electron Transfer Processes', Interscience, New York, 1968.

¹⁵¹ S. E. Moschopedis and C. Mumford, *Canad. J. Chem.*, 1971, **49**, 2158.

¹⁵² W. J. Bailey, N. Kawabata, and R. C. Capozza, 'Kinetics and Mechanisms of Polymerizations', International Symposium on Macromolecular Chemical Preparation, 1969, vol. 1, p. 195 (*Chem. Abs.*, 1971, **75**, 49 558a).




Conditions: i, SOCl_2 ; ii, Ag_2O followed by filtration then Et_3N -dioxan; iii, $\text{HS}\cdot\text{CH}_2\cdot\text{CH}_2\cdot\text{OH}$ -DMF

Scheme 58

Sequential Polypeptides. The active-ester method of polymerization now enjoys exclusive application in sequential polypeptide synthesis: various active esters have been recommended for this purpose from time to time, but the succinimido-ester now seems the most favoured.¹⁵³⁻¹⁵⁷

A detailed paper describing the preliminary work on the catechol ester method of polymerization (see vol. 2 of these Reports, p. 71) has appeared.¹⁵⁸ Difficulties with the hydrogenolytic deprotection and activation of benzyl-oxy-carbonylpeptide 2-benzyloxyphenyl esters have been traced to sulphur-containing catalyst poisons derived from reagents used in their preparation. Rigorous avoidance of such reagents has solved this problem and enabled the extension of the method to the synthesis of sequential polypeptides with side-chains protected by means of *t*-butyl alcohol-derived substituents¹⁵⁹ (*e.g.* Scheme 59). An alternative modification devised by Trudelle¹⁶⁰ has been illustrated by the homopolytripeptide synthesis shown in Scheme 60,



Conditions: i, $\text{H}_2/\text{Pd-AcOH}$; ii, $\text{Et}_3\text{N-Me}_2\text{SO}$; iii, 90% aq. $\text{CF}_3\cdot\text{CO}_2\text{H}$

Scheme 59

which incidentally provides some further evidence for the freedom of catechol ester polymerizations from racemization, since the specific rotation of the polymer obtained was the same as that yielded by the appropriate *N*-carboxy-anhydride.

¹⁵³ G. P. Lorenzi, B. B. Doyle, and E. R. Blout, *Biochemistry*, 1971, **10**, 3046.

¹⁵⁴ P. M. Hardy, J. C. Haylock, D. I. Marlborough, H. N. Rydon, H. T. Storey, and R. C. Thompson, *Macromolecules*, 1971, **4**, 435.

¹⁵⁵ J. Ramachandran, A. Berger, and E. Katchalski, *Biopolymers*, 1971, **10**, 1829.


¹⁵⁶ B. Schechter, I. Schechter, J. Ramachandran, A. Conway-Jacobs, and M. Sela, *European J. Biochem.*, 1971, **20**, 301.

¹⁵⁷ A. Yaron, N. Turkeltaub, and A. Berger, *Israel J. Chem.*, 1970, **8** (suppl.), 180p.

¹⁵⁸ R. D. Cowell and J. H. Jones, *J. Chem. Soc. (C)*, 1971, 1082.

¹⁵⁹ R. D. Cowell and J. H. Jones, *Chem. Comm.*, 1971, 1009.

¹⁶⁰ Y. Trudelle, *Chem. Comm.*, 1971, 639.



Conditions: i, Zn-AcOH; ii, $\text{CF}_3\cdot\text{CO}_2\text{H}$; iii, $\text{Et}_3\text{N-DMF}$

Scheme 60

A complete list of the sequential polypeptides synthesized this year is to be found in Appendix A, part B.

F. Synthetic Operations with Peptides of Biological Origin.—As before, we confine ourselves here to work involving the controlled formation of new peptide bonds.

With Naked Natural Peptides. Further discussion of the extension of porcine β -MSH to $[\text{Lys}^{10}]$ -human β -MSH by reaction with a protected tetrapeptide azide (see vol. 3 of these Reports, p. 251) has been given at a symposium.¹⁶¹ This particular case was complicated by the fact that porcine β -MSH contains two lysine residues and therefore three nucleophilic sites, so that a large number of coupling products were possible. The substantial pK_a difference between α - and ϵ -amino-groups encouraged the authors to attempt to direct coupling towards the α -amino-function by working at a pH such that most of the ϵ -amino-substituents were removed from the sphere of action by protonation. A complex mixture of mono- and poly-acyl derivatives was nevertheless obtained, but it fortunately proved possible to resolve this mixture on carboxymethylcellulose. The direct use of protein-degradation products in synthetic operations is much less complicated when there is no ambiguity about the point of attack. Such is the case when insulin A-chain tetra-S-sulphonate is involved as the nucleophilic partner in coupling, and a number of A-chain analogues extended at the *N*-terminus have been obtained in this way.¹⁶²⁻¹⁶⁵ Acylamino-acid active esters or protected peptide azides were most commonly used as carboxyl components in solvents such as DMF-water. In one example,¹⁶³ however, an *N*-carboxy-anhydride was used, so that fully aqueous media were

¹⁶¹ S. Lande and J. Burton, ref. 7, p. 109.


¹⁶² M. Weinert, D. Brandenburg, and H. Zahn, *Z. physiol. Chem.*, 1969, **350**, 1556.

¹⁶³ M. Weinert, K. Kircher, D. Brandenburg, and H. Zahn, *Z. physiol. Chem.*, 1971, **352**, 719.

¹⁶⁴ V. K. Naithani and M. Weinert, unpublished work quoted in ref. 163.

¹⁶⁵ Y. Shimonishi, *Bull. Chem. Soc. Japan*, 1970, **43**, 3251.

appropriate (Scheme 61). Ion-exchange chromatography was of course necessary to separate the desired product from un- and over-reacted peptide, but this proved straightforward and the modified bovine A-chain obtained eventually yielded a crystalline bovine insulin analogue, after



Conditions: i, coupling at pH 10 followed by decarboxylation at pH 3, followed by ion-exchange chromatography; ii, reduction and oxidation in the presence of B-chain bis-S-sulphonate followed by gel chromatography and crystallization

Scheme 61

reduction and oxidation together with natural bovine B-chain bis-S-sulphonate.


With Partially Blocked Peptides. It has been shown in the case of insulin¹⁶⁶ and of porcine β -MSH¹⁶⁷ that *t*-butoxycarbonylazide can be used for partial protection. Porcine β -MSH apparently reacts with this reagent at pH 10.5 or in water-pyridine-triethylamine (10 : 10 : 1) most rapidly at the ϵ -amino-groups, the differentiation presumably being simply a matter of relative nucleophilicity.¹⁶⁷ Insulin reacts with the same acylating agent in DMF-aqueous sodium bicarbonate to give the $\alpha(\text{A1}), \epsilon(\text{B29})$ bis-*t*-butoxycarbonyl derivative as the major product. Here the differentiation between the two α -amino-groups, which are presumably of comparable intrinsic nucleophilicity, is probably steric in origin, and this suggestion is borne out by the fact that the less hindered acylating agent methyl succinimido-carbonate gives a triacylinsulin (*cf.* recent studies¹⁶⁸ on the reaction of insulin with succinimido acetate). The bis-*t*-butoxycarbonylinsulin obtained

¹⁶⁶ R. Geiger, H.-H. Schöne, and W. Pfaff, *Z. physiol. Chem.*, 1971, **352**, 1487.

¹⁶⁷ S. Lande, *J. Org. Chem.*, 1971, **36**, 1267.

¹⁶⁸ D. G. Lindsay and S. Shall, *Biochem. J.*, 1971, **121**, 737.

has only one nucleophilic point, and the stage is therefore set for the preparation of semisynthetic insulins extended from the B-N-terminus. No realization of this possibility has been described yet, but the principle has been used in an ingenious sequence of reactions leading from insulin to a specifically iodinated derivative (Scheme 62).^{169, 170}



Conditions: i, $\text{Boc-N}_3\text{-DMF-aq.NaHCO}_3$; ii, PhNCS ; iii, $\text{CF}_3\text{-CO}_2\text{H}$; iv, $\text{Boc-N}_3\text{-DMF-aq.NaHCO}_3$; v, $\text{Boc-Phe(p-I)-OTcp-Me}_2\text{SO-N-methylmorpholine}$; vi, $\text{CF}_3\text{-CO}_2\text{H}$

Scheme 62

Anfinsen and his colleagues have outlined some of their plans for the resynthesis of fragment (6—48) of staphylococcal nuclease from its tryptic peptides (as a preliminary to a programme of study on semisynthetic analogues). They are considering the use of a water-soluble carbodi-imide for coupling, and have reported exploratory relevant experiments with a model system.¹⁷¹

3 Syntheses Achieved and Structure-Activity Correlations

As in previous volumes, we make apology for the fact that the discussion in this chapter is highly selective: the Reader is referred to Appendix A for a comprehensive list of syntheses described during the year.

¹⁶⁹ R. Geiger, *Z. physiol. Chem.*, 1971, **352**, 7.

¹⁷⁰ G. Krail, D. Brandenburg, H. Zahn, and R. Geiger, *Z. physiol. Chem.*, 1971, **352**, 1595.

¹⁷¹ N. Izumiya, K. Noda, and C. B. Anfinsen, *Arch. Biochem. Biophys.*, 1971, **144**, 237.

A large number of books, reviews, and conference proceedings dealing with various aspects of polypeptide hormone chemistry and pharmacology have come to our notice, although our list is no doubt still incomplete, as it is difficult to keep systematic track of this kind of literature. Subjects covered include: methods of peptide hormone assay,¹⁷² adrenocorticotropin,^{173, 174} angiotensin,¹⁷⁵⁻¹⁷⁷ bradykinin and other kinin hormones,^{178, 179} calcitonin,¹⁸⁰ gastrointestinal hormones,¹⁸¹ growth hormone,¹⁷⁴ hypothalamic releasing factors,^{174, 182-185} insect venoms,² insulin,^{174, 186} lipotropin,¹⁷⁴ neurohypophyseal hormones,¹⁸⁷ peptide hormones and the brain,¹⁸⁸ prolactin,¹⁷⁴ snake venoms,¹⁸⁹ Substance P,¹⁹⁰ and vasopressin.¹⁹¹

There has been a great deal of work recently on the involvement of cyclic adenosine monophosphate as a 'second messenger' in the mediation

¹⁷² H. van Cauwenberge and P. Franchimont, 'Assay of Protein and Polypeptide Hormones', Pergamon Press, Oxford, 1970.

¹⁷³ L. D. Garren, G. N. Gill, H. Masui, and G. M. Walton, *Recent Progr. Hormone Res.*, 1971, **27**, 433.

¹⁷⁴ Proceedings of the Fourth Congress of the Hungarian Society of Endocrinology and Metabolism held in Budapest, 1969: 'Polypeptide Hormones', ed. E. Goth and J. Fövényi, Akademiai Kiado, Budapest, 1971.

¹⁷⁵ G. W. Boyd and W. S. Peart, *Adv. Metabolic Disorders*, 1971, **5**, 77.

¹⁷⁶ J. W. Fisher, 'Kidney Hormones', Academic Press, 1971.

¹⁷⁷ F. Gross in 'Pharmacology of Naturally Occurring Polypeptides and Lipid-soluble Acids', ed. J. M. Walker, Pergamon Press, Oxford, 1971, vol. 1, p. 73.

¹⁷⁸ M. Rocha e Silva, 'Kinin Hormones', Charles C. Thomas, Springfield, Illinois, 1970.

¹⁷⁹ 'Bradykinin, Kallidin and Kallikrein', ed. E. G. Erdős, Springer Verlag, Berlin, 1970.

¹⁸⁰ Proceedings of the Second International Symposium on Calcitonin held in London, 1969: 'Calcitonin 1969', ed. S. Taylor and G. Foster, William Heinemann Medical Books, London, 1970.

¹⁸¹ Proceedings of a Symposium held at Kingston, Ontario, 1969: 'The Exocrine Pancreas', ed. I. T. Beck and D. G. Sinclair, Churchill, London, 1971.

¹⁸² R. Guillemín, *Adv. Metabolic Disorders*, 1971, **5**, 1; A. V. Schally and A. J. Kastin, *Adv. Steroid Biochem. and Pharmacol.*, 1970, **2**, 41.

¹⁸³ Proceedings of a conference on the Bioassay and Chemistry of the Hypophysiotropic Hormones of the Hypothalamus held at Tucson, Arizona 1969: 'Hypophysiotropic Hormones of the Hypothalamus: Assay and Chemistry', ed. J. Meites, Williams and Wilkins, Baltimore, 1970.

¹⁸⁴ 'Neurochemical Aspects of Hypothalamic Function', ed. L. Martini and J. Meites. Academic Press, London, 1971 (Proceedings of a Symposium held in Milan, Italy, 1969, during the 2nd Meeting of the International Society for Neurochemistry).

¹⁸⁵ 'The Hypothalamus', ed. L. Martini, M. Motta, and F. Fraschini, Academic Press, London, 1971 (Proceedings of the Workshop Conference on the Integration of Endocrine and Non-endocrine Mechanisms in the Hypothalamus held in Stresa, Italy, 1969).

¹⁸⁶ G. M. Grodsky, *Vitamins and Hormones*, 1970, **28**, 37.

¹⁸⁷ 'Pharmacology of the Endocrine System and Related Drugs: The Neurohypophysis', ed. H. Heller and B. T. Pickering, Pergamon Press, Oxford, 1970.

¹⁸⁸ Proceedings of a Conference on the Pituitary-Adrenal Axis and the Nervous System held at Vierhouten, The Netherlands, 1969: 'Pituitary Adrenal and the Brain', ed. D. de Weid and J. A. W. M. Weijnen, Elsevier, Amsterdam, 1970.

¹⁸⁹ S. B. Henriques and O. B. Henriques, in 'Pharmacology and Toxicology of Naturally Occurring Toxins', ed. H. Raskova, Pergamon Press, Oxford, 1971, vol. I, part II.

¹⁹⁰ F. Lembeck and G. Zetter, in 'Pharmacology of Naturally Occurring Polypeptides and Lipid Soluble Acids', ed. J. M. Walker, Pergamon Press, Oxford, 1971, vol. I, p. 29.

¹⁹¹ N. A. Thorn, *Adv. Metabolic Disorders*, 1970, **4**, 40.

of the effects of peptide hormones, and a book on the subject is therefore very welcome.¹⁹²

Biologists have been warned¹⁹³ that when synthetic peptides are used in quantitative work, 100% purity should not be assumed without supporting evidence: account must be taken of erroneous sequences if present, as well as of solvent and salt content.

A. Calcitonin.—A second synthesis of human calcitonin has been outlined at a symposium:¹⁹⁴ the synthesis of salmon calcitonin published¹⁹⁵ in 1969 was discussed¹⁹⁶ at the same symposium. The intriguing thing about the salmon hormone is that in the rat and in man it is very much more potent than calcitonins of mammalian origin.¹⁹⁷ Evidence has recently been presented¹⁹⁸ to support the view that much of this high potency is due to slow inactivation: infused salmon calcitonin disappears from the circulation of the anaesthetized dog more slowly than does porcine calcitonin. Such resistance to inactivation is, perhaps, not surprising—the salmon hormone is grossly different in amino-acid sequence from the mammalian calcitonins, although it has the same chain length and also incorporates a heptapeptide disulphide loop. An anonymous sage¹⁹⁹ has seen fit to enunciate a 'new concept' based on this finding. The 'new concept' is that 'the activity of a peptide hormone is dependent not only on those amino-acids which confer biological activity but also possibly on other amino-acids which affect its rate of destruction'. It has, of course, long been known that the deliberate introduction into a peptide hormone of structural features which can be expected to delay enzymatic inactivation often gives analogues with high apparent activity. This principle has been especially fruitful in the field of corticotropin analogues, a recent example²⁰⁰ being provided by [1- β -alanine, 17-lysine]- β -corticotropin-(1—17)-heptadecapeptide-4-amino-n-butylamide which was designed to be resistant to amino- and carboxypeptidases and was found to be more potent than the natural hormone despite its shorter chain length.

The results of a clinical trial of synthetic human calcitonin in five cases of Paget's disease have been published.²⁰¹ Paget's disease is a common

¹⁹² G. A. Robison, R. W. Butcher, and E. W. Sutherland, 'Cyclic AMP', Academic Press, New York, 1971.

¹⁹³ J. R. Vane, *Nature*, 1971, **230**, 382; D. R. Bangham, D. H. Calam, J. A. Parsons, and C. J. Robinson, *Nature*, 1971, **232**, 631.

¹⁹⁴ H. M. Greven and L. J. W. M. Tax, ref. 7, p. 38.

¹⁹⁵ St. Guttman, J. Pless, R. L. Huguenin, E. Sandrin, H. Bossert, and K. Zehnder, *Helv. Chim. Acta*, 1969, **52**, 1789.

¹⁹⁶ St. Guttman, J. Pless, R. L. Huguenin, E. Sandrin, H. Bossert, and K. Zehnder, ref. 7, p. 54.

¹⁹⁷ H. T. Keutmann, J. A. Parsons, J. T. Potts, jun., and R. T. Schlueter, *J. Biol. Chem.*, 1970, **245**, 1491.

¹⁹⁸ J. F. Habener, F. R. Singer, L. J. Deftos, R. M. Neer, and J. T. Potts, jun., *Nature New Biol.*, 1971, **232**, 91.

¹⁹⁹ *Nature*, 1971, **232**, 156.

²⁰⁰ R. Geiger, *Annalen*, 1971, **750**, 165.


²⁰¹ N. J. Y. Woodhouse, P. Bordier, M. Fisher, G. F. Joplin, M. Reiner, D. N. Kalu, G. V. Foster, and I. MacIntyre, *Lancet*, 1971 (I), 1139.

metabolic disorder characterized by very rapid bone formation and resorption in which the bones become weak and painful. Administration of synthetic calcitonin over a period of a year to the five patients restored biochemical normality and relieved the pain in all cases. In normal dogs, however, the administration of calcitonin is without long-term effect on strontium-85 (the deposition and release of which is very similar to that of calcium) whole-body retention²⁰² so that calcitonin may prove a disappointment as far as the treatment of bone-loss disease (osteoporosis) is concerned.

B. Hypothalamic Releasing Factors.—Activity continues to increase in this area following the outstanding recent success with thyroid-stimulating hormone releasing factor. Indeed the rate of publication is such that we recognize that much of the following section will be out of date (or be shown to be clearly wrong in some cases, perhaps) by the time it reaches the eyes of the Reader.

The prospects for diagnostic and therapeutic applications for synthetic hypothalamic releasing factors have been surveyed briefly.²⁰³

Growth-hormone Releasing Factor. Schally and his group have isolated a peptide from porcine hypothalami which has growth-hormone releasing factor (GH-RF) activity and they have assigned to it the structure (129).²⁰⁴ This sequence has been synthesized by Denkwalter, Hirschmann, and their team,²⁰⁵ together with the 9-glutamine analogue (130), since there was some



(129)



(130)

doubt about residue 9. The observation that (129) and (130) are very similar to the *N*-terminal sequence of porcine haemoglobin β -chain raises the possibility that haemoglobin may be the natural prohormone for growth-hormone releasing factor: the synthesis of the *N*-terminal decapeptide of human haemoglobin β -chain was therefore also performed. The syntheses were performed by azide condensations of fragments, a combination of *N*-carboxy-anhydride, succinimido-ester, and solid-phase

²⁰² J. J. B. Anderson, M. W. Balk, W. C. Crackel, M. K. Austin, E. C. Bollmeier, and R. Slusher, *Nature New Biol.*, 1971, **232**, 93.

²⁰³ Editorial, *Brit. Med. J.*, 1972, **1**, 65.

²⁰⁴ A. V. Schally, Y. Baba, R. M. G. Nair, and C. D. Bennett, *J. Biol. Chem.*, in the press (cited in ref. 205, but not available at the time of writing).

²⁰⁵ D. F. Veber, C. D. Bennett, J. D. Milkowski, G. Gal, R. G. Denkwalter, and R. Hirschmann, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 235.

procedures being used for the preparation of the partial sequences. Unfortunately, details of the biological studies of these materials are not available at the time of writing, apart from the brief mention²⁰⁵ that (129) is inactive, perhaps confirming suspicions that residue 9 is glutamine, and not glutamic acid.

Luteinizing-hormone Releasing Factor and Follicle-stimulating Hormone Releasing Factor. A peptide with both luteinizing-hormone releasing factor (LH-RF) and follicle-stimulating hormone releasing factor (FSH-RF) activities has been isolated by Schally and his colleagues from porcine hypothalamic extracts:²⁰⁶⁻²¹⁰ the two activities could not be separated, and so may reside in the same substance, but it should be noted that there may in fact be more than one peptide with LH-RF activity in porcine hypothalami since concurrent work by Geiger and his co-workers²¹¹ has given two chromatographically well-separated preparations with this activity. The material isolated in Schally's laboratory was shown by degradation^{212, 213}—using extremely small amounts of material at first but more substantial amounts after improvements²⁰⁹ in the isolation procedures—to have the sequence (131). Since such small amounts of material were



(131)

initially available, the sequential analysis was not completely free of ambiguity and a solid-phase synthesis was therefore performed. A conventional strategy followed by ammonolysis from the resin, hydrogen fluoride deprotection, counter-current distribution, and finally carboxymethylcellulose chromatography gave a synthetic peptide with chromatographic and electrophoretic properties identical to the material of porcine origin.²¹⁴ The LH-RF activity of the synthetic preparation was somewhat greater than that of the natural substance, whereas the FSH-RF activity was about the same, but the natural material used for comparison was

²⁰⁶ A. V. Schally, Y. Baba, A. Arimura, T. W. Redding, and W. F. White, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 50.

²⁰⁷ A. V. Schally, A. Arimura, Y. Baba, R. M. G. Nair, H. Matsuo, T. W. Redding, and L. Debeljuk, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 393.

²⁰⁸ A. V. Schally, A. Arimura, A. J. Kastin, H. Matsuo, Y. Baba, T. W. Redding, R. M. G. Nair, and L. Debeljuk, *Science*, 1971, **173**, 1036 (Summary paper).

²⁰⁹ A. V. Schally, R. M. G. Nair, T. W. Redding, and A. Arimura, *J. Biol. Chem.*, 1971, **246**, 7230.

²¹⁰ Y. Baba, A. Arimura, and A. V. Schally, *J. Biol. Chem.*, 1971, **246**, 7581.

²¹¹ R. Geiger, W. König, H. Wissmann, K. Geisen, and F. Enzmann, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 767.

²¹² H. Matsuo, Y. Baba, R. M. G. Nair, A. Arimura, and A. V. Schally, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 1334.

²¹³ Y. Baba, H. Matsuo, and A. V. Schally, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 459.

²¹⁴ H. Matsuo, A. Arimura, R. M. G. Nair, and A. V. Schally, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 822.

impure, comprising only *ca.* 70% amino-acids by weight. Geiger and his colleagues have also synthesized²¹¹ the sequence (131) using a strategy based on fragment condensation, mainly by the dicyclohexylcarbodi-imide-hydroxybenzotriazole technique developed in their laboratory: other points of interest are the use of 4,4'-dimethoxybenzhydryl and bis-benzyloxy-carbonyl protection in the early stages for amide and guanidino-side-chains respectively, and the final purification by partition chromatography on Sephadex LH-20. Experienced workers will recognize the sequence (131) as a demanding exercise for unambiguous synthesis and will await full experimental detail with interest. The material synthesized by Geiger and his collaborators was shown by them to be chromatographically indistinguishable from one of the two different preparations with LH-RF activity obtained by them from porcine hypothalami: this synthetic material had LH-RF activity at nanogram levels, but no mention of examination for FSH-RF activity was made in the preliminary report.

A second solid-phase synthesis of (131) has been described by Rivaille and his colleagues:⁷⁴ their synthesis is of special interest because of the use of a benzhydrylamine-type²¹⁵ resin support (126)* so that acidolysis after assembly of the peptide chain gave the required peptide amide directly. After scission from the resin, thiolysis was used to remove the 2,4-dinitro-phenyl group which had been employed for protection of histidine, and, after purification by gel filtration, the product was homogeneous by electrophoretic and chromatographic criteria. The peptide thus obtained had greater LH-RF activity in normal man than was found²¹⁶ by Schally for the purified material of porcine origin: the FSH-RF activity of the synthetic peptide was on the other hand feeble.

Folkers and his colleagues were also engaged in the race for LH-RF but apparently in the first instance decided not to use the 'purify, isolate, analyse, and synthesize' tactics being simultaneously employed by Schally *et al.*, Geiger *et al.*, and Guillemain *et al.* Folkers' group based their approach on inactivation experiments using partially purified hypothalamic extracts with LH-RF activity. Investigations with specific enzymes and reagents^{217, 218} suggested the following vital characteristics: a pyroglutamic acid *N*-terminal, an amide *C*-terminal, and the presence of tryptophan, tyrosine, and arginine residues. Since no other features could be shown to be essential by inactivation experiments it was reasoned that the releasing factor—or an active segment thereof—might comprise these amino-acids alone. All six possible tetrapeptide amides composed of pyroglutamic acid,

²¹⁵ P. G. Pietta and G. R. Marshall, *Chem. Comm.*, 1970, 650.

²¹⁶ A. J. Kastin, A. V. Schally, C. Gual, A. R. Midgley, jun., M. C. Miller, tert., and A. Cabeza, *J. Clin. Investigation*, 1971, **50**, 1551.

²¹⁷ Y. Baba, A. Arimura, and A. V. Schally, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 483.

²¹⁸ C. Bogentoft, B. L. Currie, H. Sievertsson, J.-K. Chang, K. Folkers, and C. Y. Bowers, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 403.

* Potential users of this type of resin will be interested to note that experimental detail of its preparation and use are given by Rivaille *et al.*⁷⁴

arginine, tyrosine, and tryptophan were therefore synthesized.^{219, 220} Only one (132) of the synthetic peptides had any activity but this singleton was relatively potent in assays for LH-RF, although no FSH-RF activity was detected, showing that the two actions are separable. Folkers and his co-workers recognized that (132) was not potent enough to be the natural



(132)

factor but suggested from their results that all or part of the sequence of (132) might appear in natural LH-RF. As far as the material isolated, analysed, and synthesized by Schally's group is concerned, Folkers' suggestion is clearly wrong since the relationship between (132) and (131) is highly tenuous, being confined to identical termini and limited similarity in functional side-chain composition. The possibility remains, however, that (132) may prove similar to the second substance in porcine hypothalami with LH-RF activity which was mentioned²²¹ in passing by Geiger and his colleagues. The finding that a relatively simple tetrapeptide derivative has LH-RF activity is of course of enormous potential clinical importance, and the demonstration that some gross structural changes are not necessarily inconsistent with the retention of LH-RF activity has probably already initiated the synthesis and screening of many analogues. The apparent insensitivity of LH-RF activity to structural change shown by this example also warns that caution must be exercised in 'proving' structures by synthesis in this area, especially if the solid-phase method is used for this purpose.

Ovine²²¹ and bovine²¹⁸ hypothalami yield LH-releasing factors which are very similar to and probably identical to that found in the pig.

The evidence²⁰⁸ may seem persuasive that LH-RF and FSH-RF are identical, having the sequence (131). The security of this identification, however, remains to be fully tested. The notion that LH-RF and FSH-RF are identical goes against the simpler, and thus far tacitly accepted, hypothesis of one hypothalamic releasing factor for each pituitary hormone, although the generality of this hypothesis has very recently had doubt cast upon it from another direction by the demonstration²²² that TRF may also function as a releasing factor for prolactin. The report²¹¹ that porcine hypothalami in fact contain at least two substances with LH-RF activity

²¹⁹ C. Y. Bowers, J.-K. Chang, H. Sievertsson, C. Bogentoft, B. L. Currie, and K. Folkers, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 414.

²²⁰ J.-K. Chang, H. Sievertsson, C. Bogentoft, B. L. Currie, K. Folkers, and C. Y. Bowers, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 409.

²²¹ M. Amoss, R. Burgus, R. Blackwell, W. Vale, R. Fellows, and R. Guillemin, *Biochem. Biophys. Res. Comm.*, 1971, **44**, 205.

²²² C. Y. Bowers, H. C. Friesen, P. Hwang, H. J. Guyda, and K. Folkers, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1033.


is perhaps consistent with the control of LH and FSH release by a pair of peptides, one or both of which have some of the activity of the other.

Melanocyte-stimulating Hormone Release. It has been known for several years that the release of melanocyte-stimulating hormone (MSH) is under the predominant control of the hypothalamus, mediated by an MSH-release-inhibiting factor (MSH-RIF). It has recently been shown that this factor can be generated by the incubation of oxytocin with microsomal preparations from the stalk medium eminence of rats.²²³ Further investigations demonstrated that prolyl-leucylglycinamide (133) is formed from



(133)

oxytocin under these conditions, and Walter and his associates showed that a synthetic sample of this tripeptide did indeed possess MSH-RIF activity. The identification of the natural factor with (133) seems to be confirmed by concurrent work culminating in its isolation²²⁴ from bovine hypothalami by Schally and his colleagues, but it should be noted that although bovine hypothalami do contain a potent MSH-RIF of structure (133) they also contain another potent material with this activity,²²⁴ the structure of which has not yet been reported. In passing we note that also (133) has been found²²⁵ to potentiate the behavioural effects of dopamine—an effect apparently not mediated by MSH because hypophysectomized mice reacted essentially as intact animals. Despite the apparently mutually corroborating reports from the groups of Walter and Schally that (133) has high MSH-RIF activity, Hruby *et al.*²²⁶ report that in their hands pure synthetic (133) has no detectable MSH-RIF activity in rat or frog tissue. Hruby's group were however able to show that a synthetic peptide corresponding to the cyclic portion of oxytocin—'tocinoic acid' (134)—had



(134)

MSH-RIF activity in a rat pituitary assay at less than nanogram levels. The confusion may be in part due to the use of different assays and species in different laboratories: recent indications²²⁶ are that there may be some species specificity for MSH-RF.

²²³ M. E. Celis, S. Taleisnik, and R. Walter, *Proc. Nat. Acad. Sci., U.S.A.*, 1971, **68**, 1428.

²²⁴ R. M. G. Nair, A. J. Kastin, and A. V. Schally, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 1376.

²²⁵ N. P. Plotnikoff, A. J. Kastin, M. S. Anderson, and A. V. Schally, *Life Sci., Part I: Physiol. and Pharmacol.*, 1971, **10**, 1279.

²²⁶ Sister A. Bower, MacE. Hadley, and V. J. Hruby, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 1185.

Although MSH release is under the predominant control of a release-inhibiting factor, a releasing factor (MSH-RF) has also been demonstrated: a metabolite of oxytocin was again suspected and the synthetic pentapeptide (135) was shown²²⁷ to have MSH-RF activity, although identification of (135) with the natural factor is for the time being only compelling conjecture.

Assuming for the moment that the identification of MSH-RF as (135) is correct and making the further simplifying assumption that (133) or (134)



(135)

is the only MSH-RIF, the situation appears to be that the release of the peptide hormone MSH is controlled by two other peptides MSH-RF and MSH-RIF, each of which is formed by enzymic degradation of another peptide hormone. This is complicated enough, but there is yet more: pituitary MSH levels in the female rat are dependent on the oestrous cycle, possibly because the enzymic activity which generates MSH-RF fluctuates (that which generates MSH-RIF is apparently²²³ constant)—presumably at the nod of yet another hormone.

Thyroid-stimulating Hormone Releasing Factor. The solution of the structure (136) of thyroid-stimulating hormone releasing factor (TSH-RF) and



(136)

preliminary related synthetic work were discussed in last year's Report. A considerable number of further syntheses of the hormone itself have been described in detail this year,^{73, 228-232} and additional work on analogues has also appeared.^{233, 234}

Endocrinologists have been quick to seize the opportunity offered by the availability of pure TSH-RF in quantity, and numerous biological studies using the synthetic material have already been published. Discussion of these is outside the scope of this Report but we note some of special interest, including the demonstration that normal women are more sensitive

²²⁷ M. E. Celis, S. Taleisnik, and R. Walter, *Biochem. Biophys. Res. Comm.*, 1971, **45**, 564.

²²⁸ A. C. Beyerman, P. Kranenburg, and J. L. M. Syrier, *Rec. Trav. chim.*, 1971, **90**, 791.

²²⁹ J.-K. Chang, H. Sievertsson, C. Bogentoft, B. Currie, and K. Folkers, *J. Medicin. Chem.*, 1971, **14**, 481.

²³⁰ J. Bøler, J.-K. Chang, F. Enzmann, and K. Folkers, *J. Medicin. Chem.*, 1971, **14**, 475.

²³¹ K. Inouye, N. Namba, and H. Otsuka, *Bull. Chem. Soc. Japan*, 1971, **44**, 1689.

²³² F. Enzmann, J. Bøler, K. Folkers, C. Y. Bowers, and A. V. Schally, *J. Medicin. Chem.*, 1971, **14**, 469.

²³³ D. Gillesen, F. Piva, H. Steiner, and R. O. Studer, *Helv. Chim. Acta*, 1971, **54**, 1335.

²³⁴ J.-K. Chang, H. Sievertsson, B. Currie, K. Folkers, and C. Y. Bowers, *J. Medicin. Chem.*, 1971, **14**, 484.

to TSH-RF than are normal men,²³⁵ the finding²²² that TSH-RF also has prolactin-releasing activity, investigations of the metabolic fate of radioactive TSH-RF,²³⁶ and experiments²³⁷ on the infusion of TSH-RF into the anterior pituitary by way of the blood vessels which connect it to the hypothalamus: since this is a very efficient way of inducing TSH-release, direct support is provided for the idea that the releasing factor is formed in the hypothalamus and is carried to its site of action by the blood.

C. Oxytocin.—Oxytocin continues to be the subject of relentlessly patient synthetic alteration. Among the many new analogues reported this year (see Appendix A) are two which pose a conundrum: deamino-[4-threonine]-oxytocin and deamino-[4-threonine]-mesotocin.²³⁸ [4-Threonine]-oxytocin has higher oxytocin-like activity than the parent hormone (see vol. 3 of these Reports, ch. 3, section 3E) and [4-threonine]-mesotocin is similar: since it is well known that removal of the amino-group from oxytocin enhances apparent biological activity, analogues in which both of these features were simultaneously present were investigated. The problem is that the deamino-[4-threonine] analogues were found to have low activity.

Elegant n.m.r. investigations²³⁹⁻²⁴² have led to a detailed proposal²⁴¹ for the conformation of oxytocin in solution. The essence of the proposal is that the cyclic part of the hormone contains a β -turn, and that the acyclic tail turns back to form a second β -turn. The compact folded molecule has one essentially hydrophobic side, lacking in notable chemical features, which is postulated to be involved in hormone-receptor binding: since most of the functionality present protrudes from the other side it is presumed that this is the side involved in the initiation of the biochemical events which eventually lead to the observed pharmacological effects. Many of the biological results obtained with synthetic modifications of oxytocin can be rationalized in terms of this conformation.^{242, 243} For example, asparagine-5 occupies a central role in conformational stabilization since its N—H is involved in the formation of the ring β -turn, its C=O can hydrogen bond to the N—H of the tyrosine residue, and its side-chain stabilizes the folding back of the tail. The fact that 5-substituted analogues of oxytocin all have very low activities is therefore easily explained. The evidence for the hydrogen bond between the C=O of asparagine and the

²³⁵ C. Y. Bowers, A. V. Schally, A. Kastin, A. Arimura, D. S. Schalch, G. Gual, E. Castineda, and K. Folkers, *J. Medicin. Chem.*, 1971, **14**, 477.

²³⁶ T. W. Redding and A. V. Schally, *Endocrinology*, 1971, **89**, 1075.

²³⁷ J. C. Porter, W. Vale, R. Burgus, R. S. Mical, and R. Guillemin, *Endocrinology*, 1971, **89**, 1054.

²³⁸ M. Manning, E. J. Coy, and W. H. Sawyer, *Experientia*, 1971, **27**, 1372.

²³⁹ L. F. Johnson, I. L. Schwartz, and R. Walter, *Proc. Nat. Acad. Sci., U.S.A.*, 1969, **64**, 1269.

²⁴⁰ D. W. Urry, M. Ohnishi, and R. Walter, *Proc. Nat. Acad. Sci., U.S.A.*, 1970, **66**, 111.

²⁴¹ D. W. Urry and R. Walter, *Proc. Nat. Acad. Sci., U.S.A.*, 1971, **68**, 956.


²⁴² R. Walter in 'Structure-Activity Relationships of Protein and Polypeptide Hormones', ed. M. Margoulis and F. C. Greenwood, *Excerpta Medica*, 1971, p. 181.

²⁴³ R. Walter, I. L. Schwartz, J. H. Darnell, and D. W. Urry, *Proc. Nat. Acad. Sci., U.S.A.*, 1971, **68**, 1355.

N—H of tyrosine is in fact a little uncertain in oxytocin itself but is unambiguous in the case of the deamino-analogue. It appears that this second transannular hydrogen bond is stronger in deamino-oxytocin than in the natural hormone: the higher potency of the former therefore finds a possible explanation in its greater conformational rigidity. Many other synthetic analogue activities can be similarly explained, and it is clear that this work is a fundamentally important step towards the understanding of peptide hormone action at the molecular level. Similar studies on lysine-vasopressin are also at a refined stage,^{242, 244, 245} but whether conformational analysis will throw useful light on structure-action relations in other peptide hormones remains to be seen. The majority of the known peptide hormones are, unlike the neurohypophyseal group, acyclic and therefore presumably more conformationally mobile, possibly adopting their active conformations only on interaction with their receptors.

Synthetic analogues of oxytocin have been much used in studies of its *in vivo* inactivation: recent work^{246–248} provides further support for the contention that the major initial step of the enzymic inactivation is proteolysis in the acyclic appendage. The recent demonstration that one definite and one possible oxytocin metabolite have potent pharmacological properties quite different from those of oxytocin itself (see p. 370) will no doubt stimulate systematic screening of peptide hormone partial sequences for various activities other than those of the parent.

D. Ribonuclease T₁.—Further discussion of the synthetic work in progress on ribonuclease T₁ has appeared,²⁴⁹ and full details of the synthesis of a protected peptide (137) comprising residues (12—47) have been published.²⁵⁰ The synthesis is outlined, in highly abbreviated form, in Scheme 63. Each



²⁴⁴ P. H. von Dreele, A. I. Brewster, H. A. Scheraga, M. F. Ferger, and V. du Vigneaud, *Proc. Nat. Acad. Sci., U.S.A.*, 1971, **68**, 1028.

²⁴⁵ P. H. von Dreele, A. I. Brewster, F. A. Bovey, H. A. Scheraga, M. F. Ferger, and V. du Vigneaud, *Proc. Nat. Acad. Sci., U.S.A.*, 1971, **68**, 3088.


²⁴⁶ R. Walter and H. Shlank, *Endocrinology*, 1971, **89**, 990.

²⁴⁷ M. Loida, J. D. Glass, I. L. Schwartz, and R. Walter, *Endocrinology*, 1970, **88**, 633.

²⁴⁸ R. Walter, H. Shlank, J. D. Glass, I. L. Schwartz, and T. D. Kerenyi, *Science*, 1971, **173**, 827.

²⁴⁹ K. Hofmann, ref. 7, p. 130.

²⁵⁰ J. Beacham, G. Dupuis, F. M. Finn, H. T. Storey, C. Yanaihara, N. Yanaihara, and K. Hofmann, *J. Amer. Chem. Soc.*, 1971, **93**, 5526.



(137)

Conditions: i, $\text{CF}_3\text{CO}_2\text{H}$, then $\text{HCl-DMF-Bu}^t\text{ONO}$, -10°C ; ii, Pd-H_2 ; iii, $\text{Et}_3\text{N-DMF}$, -25°C

Scheme 63

of the three protected peptide *t*-butoxycarbonylhydrazides B, C, and D were prepared by essentially stepwise procedures, mostly using trichlorophenyl or succinimido esters: acylamino-acid or acyldipeptide azides were used for the incorporation of (unprotected) hydroxyamino-acid residues. The synthesis of fragment B, which contains five unprotected hydroxyside-chains and a glutamine residue, gave rise to solubility problems, and two of the hydrogenation steps were (successfully) performed in rather dilute solution in DMF at 70 °C. The protected hydrazides were purified as thoroughly as possible and were carefully examined for impurities: fragment C was obtained in high quality without special purification procedures, but the crude fragment D contained numerous impurities (some of which were possibly *O*-acyltyrosine derivatives) and partition chromatography was necessary for purification. It should be noted that the amino-acid analysis of the crude fragment D was 'good' and Hofmann and his colleagues stress that 'Amino-acid analysis in agreement with theory is a necessary, but not sufficient, criterion of purity'. Fragment B was too insoluble for sophisticated purification, but its state of purity was assessed by examination of deprotected derivatives.

The three fragments were condensed together in the order indicated by B + (C + D), using for each coupling Honzl-Rudinger azide reaction conditions, after exposure of the carboxyl component hydrazide by trifluoroacetic acid treatment and deprotection of the nucleophile by hydrogenolysis. The partially protected B-C-D product had numerous free side-chain carboxy-groups and could therefore be purified by ion-exchange chromatography. Hofmann *et al.* discuss suitable purity criteria for such fragment condensation products at some length, and point out that purity can be assessed reliably from the amino-acid analysis if attention is focused on 'diagnostic' residues which (a) are stable to acid hydrolysis and (b) are unique to one of the compounds involved in the fragment conjunction. If both partners in a fragment condensation contain a 'diagnostic' residue then the ratio between the diagnostic residues found on amino-acid analysis of the product provides a means of detecting contamination by either of the coupling components.* On this criterion and thin layer chromatography in two systems the partially protected B-C-D fragment appeared to be homogeneous.

E. Solid-phase Synthesis of High Molecular Weight Polypeptides.—The solid-phase approach is now firmly established as a satisfactory method for the rapid synthesis of oligopeptides of up to, say, 10–15 residues which can usually be purified with reasonable ease and be shown to be homogeneous by reliable criteria. This is far from true of the application of the

* Such an approach would obviously not detect coincidental contamination by equimolecular proportions of each component, and would give rise to misleading conclusions if both were present. In any case, contamination by peptides of very different size and composition is unlikely to present an intractable problem for detection or separation: much more serious is the problem of detecting contamination by slightly defective or damaged sequences of similar molecular weight and composition.

method to peptides and proteins of higher molecular weight. The principal limitations are, of course, (i) the presence in the synthetic product of 'error' and 'failure' sequences attributable to incomplete coupling, (ii) the presence of defects due to damage in the final stages by vigorous reagents, (iii) the inability of available methods to cope with the resolution of the complex mixtures produced, and (iv) the inadequacy of conventional purity criteria to differentiate reliably between very closely related macromolecules. However, some of these difficulties—especially (ii) and (iv)—also apply in varying measure to 'classical' syntheses of high molecular weight polypeptides and it is at this stage by no means clear that such approaches will be any more successful for protein synthesis than the solid-phase method.

Despite the difficulties, the year under review has seen several publications on applications of solid-phase synthesis to high molecular weight polypeptides: these are briefly discussed in alphabetical order below.

Acyl Carrier Protein. The acyl carrier protein (ACP) of *E. coli* is a 77-residue single-chain protein with a 4'-phosphopantetheine prosthetic group. No cysteine or tryptophan is present and the three residues at the C-terminus are not required for biological activity. Since the prosthetic group can be added to the apoprotein by means of an ACP synthetase which is specific for the purpose, residues 1—74 of ACP seemed a suitable simple objective for further evaluation of the use of the solid-phase method for protein synthesis. Preliminary reports of such a synthesis have appeared.²⁵¹ The procedure and tactics employed for assembling the peptide chain on the resin were essentially conventional. Removal of the peptide from the resin by means of hydrogen fluoride was not feasible as this reagent was found to cause complete inactivation of natural ACP apoprotein. Furthermore, 'it was observed that HF or HF-TFA mixtures gave incomplete removal of protecting groups', although the side-chain protection employed (benzyl esters and ethers; ϵ -benzyloxycarbonyl groups and ω -nitro-groups) was such that their removal by hydrogen fluoride would have been anticipated. Hydrogen bromide in trifluoroacetic acid (anisole and methionine as scavengers) was in fact used for scission of the peptide-resin link and the partially deprotected peptide was subjected to gel filtration, when some 5% of the applied material emerged in the expected position. Completion of the deprotection by hydrogenolysis, enzymatic introduction of the prosthetic group, and ion-exchange chromatography gave material which co-chromatographed with and was immunologically indistinguishable from natural ACP which had been deprived of its C-terminal tripeptide sequence. The synthetic material had some 30% biological activity when compared with the natural material. Since the activity of the natural material falls to 40% when it is similarly subjected to the conditions used for the deprotection and removal of the synthetic

²⁵¹ W. S. Hancock, D. J. Prescott, W. L. Nulty, J. Weintraub, P. R. Vagelos, and G. R. Marshall, *J. Amer. Chem. Soc.*, 1971, **93**, 1799; *Fed. Proc.*, 1971, **30**, 1273 Abs.

peptide from the resin, it would appear that the prospect for obtaining synthetic ACP of high activity by solid-phase synthesis is good if modifications involving less violent final steps prove applicable.

Basic Pancreatic Trypsin Inhibitor. Preliminary results of a solid-phase synthesis of bovine pancreatic trypsin inhibitor (58 residues, single chain, three disulphide bridges, nil tryptophan) have appeared.²⁵² Since it was found that the natural inhibitor could be recovered from solution in hydrogen fluoride without loss of activity,* this reagent (with anisole as scavenger) was used for deprotection and cleavage from the resin. Conversion to the *S*-sulphonate and gel filtration gave material which eluted at the same position as, and which was electrophoretically indistinguishable from, the hexa-*S*-sulphonate obtained from the natural peptide. Reduction of the synthetic *S*-sulphonate, further gel filtration and air oxidation gave a substance which had in two different assays *ca.* 30% of the trypsin-inhibitory activity of the natural inhibitor. Subjection of the natural inhibitor to the same reduction and reoxidation procedures regenerated only 40% of the activity. It might appear, therefore, that the solid-phase part of this experiment was reasonably satisfactory, and that the chance of ultimate success is fair if the purification can be improved (affinity chromatography is an obvious possibility). Unfortunately, trypsin-inhibitory activity is not an acceptable criterion of success, since the naturally occurring proteinase inhibitors are structurally rather diverse: it is possible, and some may think likely, that error and failure sequences may have some activity.

Human Growth Hormone. In 1969,²⁵³ Li and his group reported a complete primary structure for human growth hormone comprising 188 residues in a single chain with two disulphide bridges and one tryptophan residue. A solid-phase synthesis of this sequence has now been outlined by Li and Yamashiro.²⁵⁴ The assembly of the protected peptide on the resin followed the usual pattern, with some special features including the introduction of histidine residues using bis-*t*-butoxycarbonylhistidine and the protection of the tryptophan residue from oxidative degradation during acid-treatment steps by the addition of 2,5-dithiothreitol. Cleavage from the resin by means of hydrogen fluoride (anisole as scavenger), gel filtration, sodium-ammonia treatment, air oxidation, and further gel filtration gave material eluting 'as a single peak with a maximum close to the position of native human growth hormone'. The polymer thus prepared had *ca.* 10% growth-promoting activity, whereas the natural hormone which had been similarly abused by hydrogen fluoride and sodium in ammonia had *ca.* 35%

²⁵² K. Noda, S. Terada, N. Mitsuyasu, M. Waki, T. Kato, and N. Izumiya, *Naturwiss.*, 1971, **58**, 147.

²⁵³ C. H. Li, J. S. Dixon, and W. K. Liu, *Arch. Biochem. Biophys.*, 1969, **133**, 70.

²⁵⁴ C. H. Li and D. Yamashiro, *J. Amer. Chem. Soc.*, 1970, **92**, 7608.

* Quantitative recovery of activity was reported, which seems a little surprising: perhaps the relatively rigid structure which is presumably imposed by three disulphide bridges confers insensitivity to HF.

growth-promoting activity. Immunological testing was encouraging, since rabbit antiserum to human growth hormone did react with the synthetic preparation.

Shortly after the publication of this work, however, the sequence which had been the synthetic objective was shown to be grossly erroneous in several respects, the most serious being the mislocation of a 15-residue sequence incorporating the single tryptophan residue which in fact occupies position 85, not position 25.²⁵⁵⁻²⁵⁷ The synthetic product obtained by Li and Yamashiro,²⁵⁴ although possessing some biological activity, therefore could not have contained any material at all with the sequence of the natural hormone.

This abortive synthetic excursion is clearly a cautionary tale. In the first place the outlook for the eventual synthesis of growth hormone by this strategy is poor if experience with the erroneous sequence is any guide. More important, however, are the general warnings which arise. It is clear that greater caution than has hitherto been customary must be used in interpreting the results of biological activity determinations on solid-phase products: this example shows very clearly that the mere demonstration of some activity is only a necessary but not a sufficient criterion for synthetic success and does not necessarily provide good corroboration for a proposed structure. This point receives further emphasis from related work involving the solid-phase synthesis of some biologically active peptides obtained by limited proteolysis of growth hormone. The sections 1—21,²⁵⁸ 81—121,²⁵⁹ 122—153,²⁵⁹ and 164—188²⁵⁸ of Li's erroneous sequence were prepared and all were biologically active despite the fact that all four segments have subsequently been shown to contain sequence errors. It is also apparent from this work that immunological criteria are wholly unsatisfactory for establishing the success of a solid-phase synthesis. Antibodies to a native protein can be expected to react with another polypeptide if the antigenic determinant is present: an antigenic determinant can be quite a small part of a native macromolecule and it would be surprising indeed if an attempted solid-phase synthesis produced material containing none of the necessary determinants at all.

Lysozyme. Two brief abstracts²⁶⁰ reporting a solid-phase attempt at egg-white lysozyme (129 residues, four disulphide bridges, and six tryptophan residues) are available. The relatively high tryptophan content and the known lability of lysozyme to hydrogen fluoride make this an especially

²⁵⁵ H. D. Niall, *Nature New Biol.*, 1971, **230**, 90.

²⁵⁶ H. D. Niall, M. L. Hogan, R. Sauer, I. Y. Rosenblum, and F. C. Greenwood, *Proc. Nat. Acad. Sci., U.S.A.*, 1971, **68**, 866.

²⁵⁷ C. H. Li and J. S. Dixon, *Arch. Biochem. Biophys.*, 1971, **146**, 233.

²⁵⁸ J. Bornstein, J. McD. Armstrong, F. Ng, B. M. Paddle, and L. Misconi, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 252.

²⁵⁹ F. Chillemi and A. Pecile, *Experientia*, 1971, **27**, 385.

²⁶⁰ J. J. Sharp, A. B. Robinson, and M. D. Kamen, *Fed. Proc.*, 1971, **30**, 1273 Abs.; L. E. Barstow, V. J. Hruby, A. B. Robinson, J. A. Rupley, J. J. Sharp, and T. Shimoda, *Fed. Proc.*, 1971, **30**, 1274 Abs.

difficult case for the present state of the art. Material with low lysozyme activity has been obtained, although the incorporation of tryptophan (several residues of which are involved in the catalytic process) was poor. A full evaluation must obviously await further work and the publication of experimental detail.

Parathyroid Hormone. Bovine parathyroid hormone is a single-chain polypeptide of 84 residues, but partial hydrolysis with dilute acid gives smaller peptides which retain high hormonal activity. A solid-phase synthesis of the biologically active *N*-terminal 1—34-tetratriacontapeptide (no disulphide bridges, one tryptophan residue) has recently been described.²⁶¹ The insoluble support used was a chloromethylated graft co-polymer of styrene and trifluorochloroethylene—no details are given of this new type of support for which ‘unique advantages’ are claimed, but publication of these elsewhere was promised. Otherwise the synthesis was mostly along well established lines: 2,4-dinitrophenyl protection was used for histidine side-chains and trifluoroacetylation for lysine ϵ -amino-functions. Mercapto-ethanol was added at all acidic deprotection steps after addition of the tryptophan residue. The imidazole dinitrophenyl groups were removed by means of thiophenol before further partial deprotection and scission from the resin with hydrogen fluoride (anisole as scavenger): the trifluoroacetyl groups were removed with 1M piperidine—8M urea. Exposure of the native hormone to these deprotection conditions causes ‘significant loss of biological activity’. Gel filtration followed by carboxymethylcellulose chromatography gave synthetic peptide which had essentially the expected amino-acid composition with the exception of histidine, the low content of which was attributed to incomplete deprotection. The biological activity of this material *in vitro* was somewhat greater than that of the fragments from partial hydrolysis of the native hormone. It seems that the *N*-terminal region of the hormone is the region responsible for biological activity—the synthetic work so far reported indicates that the *N*-terminal 34 residues are sufficient, but briefly mentioned unpublished work suggests that even shorter segments of this part of the molecule are enough. What then is the function of the remaining two-thirds or so of the natural hormone? A possible answer to this question is provided by the observation that the *in vitro* activity (relative to that of the whole natural hormone) of the synthetic 1—34 fragment was found to be considerably greater than the *in vivo* activity, suggesting that the function of the remainder of the native hormone is to retard metabolic inactivation in some fashion.

Ribonuclease A. Gutte and Merrifield have now described²⁶² in great detail the solid-phase synthesis of bovine pancreatic ribonuclease A which was briefly reported by them early in 1970 (see vol. 1 of these Reports).

²⁶¹ J. T. Potts, jun., G. W. Tregear, H. T. Keutmann, H. D. Niall, R. Sauer, L. J. Deftos, B. F. Dawson, M. L. Hogan, and G. D. Aurbach, *Proc. Nat. Acad. Sci., U.S.A.*, 1971, **68**, 63.

²⁶² B. Gutte and R. B. Merrifield, *J. Biol. Chem.*, 1971, **246**, 1922.

The purification has been much improved since the preliminary report, the crucial step being limited tryptic digestion of the synthetic protein. Natural ribonuclease is resistant to trypsin, but it was reasoned that defective sequences might have conformations which would not protect them from proteolysis. In the event this proved to be the case, since the specific activity of the synthetic enzyme increased 7.6-fold to *ca.* 60% on treatment with trypsin.* Fractional precipitation with ammonium sulphate after trypsin treatment gave material with a specific activity of 78% which was indistinguishable from the native enzyme by chromatographic and electrophoretic criteria. The amino-acid content, substrate specificity, and Michaelis constant of the natural and synthetic proteins were also in essential agreement, as were the peptide maps they gave after performic acid oxidation and tryptic digestion, and in addition to all this it was shown that rabbit bovine pancreatic ribonuclease antibodies neutralized the two enzymes with equal effectiveness.

Unfortunately, ribonuclease is obviously a special case in that it withstands chemical maltreatment well and regains its active structure after reduction and reoxidation. It follows that the kind of approach used in this first example will not prove so successful in less amenable cases. Even when the strategy seems feasible, the value of further excursions of this kind seems questionable, since it appears that currently used criteria of purity are quite inadequate for assessing the homogeneity of solid-phase products. This is well illustrated by the experience of Li's laboratory with growth hormone (see above), but perhaps even better by the very rigorous comparison made between their product and the native enzyme by Gutte and Merrifield. Their material is obviously impure, although it cannot be said whether the proportion of material with correct structure is greater or less than the apparent 78%—erroneous or damaged sequences might be inhibitory or active. Despite this evident contamination, a most careful comparison with the natural protein revealed a single spot on a peptide map as the sole significant difference. It seems then that further advances in practicable methods suitable for investigating the composition of solid-phase products are sorely needed. Until such time as these desiderata are attained it seems certain that the use of experiments on solid-phase products in protein chemistry will be unacceptable except in instances such as a demonstration that a solid-phase synthesis of a partial sequence of a protein gives active material, from which it can be unambiguously deduced that the omitted portion is inessential. Gutte and Merrifield have provided one such example. Samples were withdrawn from their ribonuclease synthesis after the addition of 99 and 104 residues, giving de-(21—25)-S-protein and S-protein respectively. Reduction and reoxidation of these

* This treatment also increased the total number of apparent units of enzymic activity, strongly suggesting the presence of erroneous sequences with inhibitory properties—yet another indication of the caution required in evaluating the biological activity of solid-phase products.

materials in the presence of natural or synthetic S-peptide gave ribonuclease S and de-(21—25)-ribonuclease S of approximately equal enzymatic activity. Even if the synthetic de-(21—25)-ribonuclease was grossly impure, it can still be confidently concluded that the sequence (21—25) is not required for biological activity since the entire sequence is an inconceivable contaminant.

Further discussion of the Merck group's semiclassical synthesis of ribonuclease S has appeared ²⁶³—the highest specific activity mentioned in print to date is 40% ²⁶⁴ but no full experimental detail has yet been published.

Staphylococcal Nuclease. The work of Anfinsen's group on nuclease-T (see vol. 2, p. 177 and vol. 3, p. 257) and synthetic analogues of it continues. ²⁶⁵⁻²⁶⁷ The application of diverse purification techniques has culminated ²⁶⁵ in the isolation of semisynthetic nuclease-T with a specific activity of about 90% and other properties showing the 'essential identity' of the semisynthetic preparation with that obtained from the natural enzyme. A series of single-replacement analogues of P₂ with substitutions for aspartic acid-21, arginine-35, aspartic acid-40, and glutamic acid-43 have now been synthesized. ²⁶⁶ Results with these peptides confirm crystallographic evidence that the residues named are in the active site, since capacity to activate P₃ and produce nuclease-T activity was abolished in most of the analogues, although those which were conservative with respect to charge type were still able to bind to P₃ (see the Table).

Table^a *Synthetic analogues of fragment P₂ of staphylococcal nuclease*

Peptide	Does the peptide bind to P ₃ ?	Does the peptide activate P ₃ ?
[Glu ²¹](6—47)-P ₂	Yes	No
[Asn ²¹](6—47)-P ₂	No	No
[Lys ³⁵](6—47)-P ₂	Yes	No
[Cit ³⁵](6—47)-P ₂	No	No
[Glu ⁴⁰](6—47)-P ₂	Yes	No
[Asn ⁴⁰](6—47)-P ₂	Yes	Slightly ^b
[Asp ⁴³](6—47)-P ₂	Yes	No

^a This Table is a continuation of Table 3, vol. 3, p. 259.

^b As far as could be ascertained, the low activity of this analogue was intrinsic and not attributable to partial deamidation at residue 40.

An enzymically active complex is also formed on mixing the cyanogen bromide (99—149) and tryptic (1—126) fragments, which are separately inactive. This complex has a duplicated sequence between residues 99 and 126: the redundant portion appears to lie in the (99—149) component since on treatment of the active complex with trypsin in the presence of calcium

²⁶³ R. Hirschmann, ref. 7, p. 138.

²⁶⁴ R. Hirschmann and R. G. Denkewalter, *Naturwiss.*, 1970, **57**, 145.


²⁶⁵ I. M. Chaiken, *J. Biol. Chem.*, 1971, **246**, 2948.

²⁶⁶ I. M. Chaiken and C. B. Anfinsen, *J. Biol. Chem.*, 1971, **246**, 2285.

²⁶⁷ C. B. Anfinsen, D. A. Ontjes, and J. M. Chaiken, ref. 7, p. 130.

ions and 3',5'-thymidine phosphate (which protect native nuclease from tryptic degradation) only the (99—149) partner was attacked.²⁶⁸ The first solid-phase synthetic explorations by means of modifications of the (99—149)-fragment of this system have been described.²⁶⁹ Essentially the same procedures as used for P₂ and its analogues were employed, and as in their previous work, Anfinsen and his colleagues recognize the shortcomings of the solid-phase method and therefore confine themselves to seeking answers to questions which 'are essentially of the "yes-or-no" variety'. It appears that the (99—149)-fragment can be truncated by up to eighteen residues at its *N*-terminal end and by several residues at the other without destruction of the capacity to form an active complex on admixture with (1—126) from the natural protein. Also, the single tryptophan at position 140 can be replaced by phenylalanine without loss of enzymic activity.

F. Scotophobin.—It was reported in 1968 that extracts of the brains of rats which had been trained to avoid the dark could be used to induce the same behaviour in naive mice.²⁷⁰ Evidence was obtained at that time indicating that the active principle was an oligopeptide, and this has now been confirmed²⁷¹ by its isolation ('scotophobin').* Brain material from 4000 trained rats yielded tiny amounts of the active peptide, which could not be detected in extracts obtained from untrained animals. Insufficient material for complete conventional wet sequence analysis was obtained, but fortunately amino-acid analysis, enzymic digestion, *N*-terminal analysis, and pyrolysis of a derivative on the mass-spectrometer probe gave sufficient information for its tentative formulation as a pentadecapeptide amide, but there was at that stage still ambiguity concerning the position and number of amide side-chains.^{271, 272} Some of the possible sequences were therefore synthesized,^{273, 274} and after elimination of two which were inactive, the sequence (138) was confirmed by a solid-phase preparation²⁷³ of this structure, which gave material active in the behavioural bioassay.



(138)

²⁶⁸ H. Taniuchi and C. B. Anfinsen, *J. Biol. Chem.*, 1971, **246**, 2291.

²⁶⁹ I. Parikh, L. Corley, and C. B. Anfinsen, *J. Biol. Chem.*, 1971, **246**, 7392.

²⁷⁰ G. Ungar, L. Galvan, and R. H. Clark, *Nature*, 1968, **217**, 1261.

²⁷¹ G. Ungar, D. M. Desiderio, and W. Parr, *Nature*, 1972, **238**, 198.

^{271a} W. W. Stewart, *Nature*, 1972, **238**, 202.

²⁷² D. M. Desiderio, G. Ungar, and P. A. White, *Chem. Comm.*, 1971, 432.


²⁷³ W. Parr and G. Holzer, *Z. physiol. Chem.*, 1971, **352**, 1043.

²⁷⁴ A. Ali, J. H. R. Faesel, D. Sarantakis, D. Stevenson, and B. Weinstein, *Experientia*, 1971, **27**, 1138.

* It is hardly surprising that the suggestion that acquired information could be chemically transferred met with considerable scepticism. The much delayed long paper²⁷¹ on this work will not end the controversy, because it is accompanied^{271a} by a detailed hypercritical dissection of practically every aspect.

G. Substance P.—Substance P, as its positively alchemical name suggests, has long been something of a mystery.¹⁹⁰ Forty years ago Gaddum found that a dried powder (P for Powder) obtained from, *inter alia*, brain extracts contained a substance with a wide range of pharmacological properties, including the ability to cause transient hypotension and stimulate salivary secretion on intravenous injection, and also to bring about contraction of smooth muscle preparations. Substance P is very widely distributed and has been the subject of much inconclusive research. The vague idea that it has some sort of generalized neural function seems to have established itself, but real progress in the area has been severely hampered by ignorance of the structure and the uncertainties which must necessarily accompany experiments using partially purified extracts.

The stage is now set for some of the long-standing questions about substance P to be answered since it has been isolated.²⁷⁵ Its sequence (139)



(139)

has been determined²⁷⁶ and a solid-phase synthesis has been briefly outlined.²⁷⁷ The synthesis was performed on a benzhydrylamine-type support (126) (*cf.* ref. 74). After purification the synthetic material was indistinguishable from natural substance P by chromatographic and electrophoretic criteria, and in four different bioassays the natural and synthetic substances P were equipotent.

4 Appendix A. A List of Syntheses Reported during 1971

A. Naturally Occurring Peptides, Proteins, Analogues, and Partial Sequences.—All syntheses are listed under the natural substance to which they are relevant.

Peptide	Ref.
Acyl carrier protein	
<i>E. coli</i> acyl carrier protein (see p. 376)	251
Adrenocorticotropins	
β-Corticotropin <i>N</i> -terminal decapeptide, with a ¹⁴ C label in the glycine residue	277a
[Orn ^{15,16,17,18}]-β-corticotropin-(1—18)-octadecapeptide amide	277b
[D-Ser ¹ , Orn ^{15,16,17,18}]-β-corticotropin-(1—18)-octadecapeptide amide	277b
[Orn ^{11,15,16,17,18}]-β-corticotropin-(1—18)-octadecapeptide amide	277b
[D-Ser ¹ , Orn ^{11,15,16,17,18}]-β-corticotropin-(1—18)-octadecapeptide amide	277b
[β-Ala ¹ , Lys ¹⁷]-β-corticotropin-(1—17)-heptadecapeptide-4-amino-n-butylamide	200

²⁷⁵ M. M. Chang and S. E. Leeman, *J. Biol. Chem.*, 1970, **245**, 4784.

²⁷⁶ M. M. Chang, S. E. Leeman, and H. D. Niall, *Nature New Biol.*, 1971, **232**, 86.

²⁷⁷ G. W. Tregear, H. D. Niall, J. T. Potts, jun., S. E. Leeman, and M. M. Chang, *Nature New Biol.*, 1971, **232**, 87.

^{277a} K. Medzihradszky, H. S. Varga, S. Fittkau, and I. Marquardt, *Acta Chim. Acad. Sci. Hung.*, 1970, **65**, 449 (*Chem. Abs.*, 1971, **74**, 13 416t).

^{277b} G. I. Tesser and J. T. Burs, *Rec. Trav. chim.*, 1971, **90**, 444.

Peptide	Ref.
[Lys(Dns) ²¹]- β -corticotropin-(1—24)-tetracosapeptide	277c
[D-Ser ¹ ,Lys ^{17,18}]- β -corticotropin-(1—19)-nonadecapeptide and a series of C-terminal amide and ester derivatives thereof	278
[Leu ⁷]- β -corticotropin-(1—24)-tetracosapeptide	279
[MeTrp ⁹]- β -corticotropin-(1—24)-tetracosapeptide	279
[Aib ¹]- β -corticotropin-(1—18)-octadecapeptide amide	280
[β -Ala ¹]- β -corticotropin-(1—18)-octadecapeptide amide	280
β -Corticotropin-(6—24)-nonadecapeptide	281
β -Corticotropin-(4—23)-, -(5—23)-, and -(7—23)-peptide amides	281
Ovine β -corticotropin-(19—26)-heptapeptide	137
Angiotensin	
[Val ⁵]-angiotensin II	124; see also ref. 423
[Val ⁵ ,MeAla ⁷]-angiotensin II	282
Derivatives of [Gly ² ,Val ⁵]-angiotensin II	283
Tetraglycyl-[Val ⁵]-angiotensin II-(5—8)-tetrapeptide	284
Diglycyl-[Ile ⁶]-angiotensin II-(3—8)-hexapeptide	285
[Ile ⁶]-angiotensin II	66
An extensive series of des-Asp ¹ -[Ile ⁵]-angiotensin II analogues; no synthetic details—biological activities only	286
A series of analogues of [Asn ¹ ,Ile ⁶]-angiotensin II with different alkyl side-chains on residue number 5 to investigate the importance of steric factors at this position	287
Other derivatives and analogues	288—291
Angiotensin-converting enzyme inhibitors	292
Angiotensinogen	
A series of analogues of the sequence around the renin-labile bond of angiotensinogen, some of which were inhibitory towards the angiotensin-renin system	293

^{277c} R. Schwyzer and P. W. Schiller, *Helv. Chim. Acta.*, 1971, **54**, 897.

²⁷⁸ M. Brugger, *Helv. Chim. Acta*, 1971, **54**, 1261.

²⁷⁹ M. Fujino, C. Hatanaka, O. Nishimura, and S. Shinagawa, *Chem. and Pharm. Bull. (Japan)*, 1971, **19**, 1075.

²⁸⁰ K. Inouye, K. Watanabe, K. Namba, and H. Otsuka, *Bull. Chem. Soc. Japan*, 1970, **43**, 3873.

²⁸¹ M. Fujino, C. Hatanaka, and O. Nishimura, *Chem. and Pharm. Bull. (Japan)*, 1971, **19**, 1066.

²⁸² R. H. Andreatta and H. A. Scheraga, *J. Medicin. Chem.*, 1971, **14**, 489.

²⁸³ A. Pavars, G. Cipens, and Z. Auna, *Latv. P.S.R. Zinat. Akad. Vestis, Kim. Ser.*, 1970, 737 (*Chem. Abs.*, 1971, **74**, 142 332m).

²⁸⁴ A. Pavars and G. Cipens, *Zhur. obshchei Khim.*, 1971, **41**, 467 (*Chem. Abs.*, 1971, **75**, 36 638b).

²⁸⁵ S. A. Khan and K. M. Sivanandaiah, *Indian J. Chem.*, 1971, **9**, 184 (*Chem. Abs.*, 1971, **75**, 6314a).

²⁸⁶ J. S. de Graaf, A. C. A. Jansen, K. E. T. Kerling, C. Schattenkerk, and E. Havinga, *Rec. Trav. chim.*, 1971, **90**, 301.

²⁸⁷ E. C. Jorgensen, S. R. Rapaka, G. C. Windridge, and T. C. Lee, *J. Medicin. Chem.*, 1971, **14**, 899, 904.

²⁸⁸ P. Ya. Romanovskii, G. Cipens, and Z. Auna, *Latv. P.S.R. Zinat. Akad. Vestis, Kim. Ser.*, 1971, 503 (*Chem. Abs.*, 1971, **75**, 118 597).

²⁸⁹ J. A. Skorcz, *J. Medicin. Chem.*, 1971, **14**, 775.

²⁹⁰ R. J. Weinkam and E. C. Jorgensen, *J. Amer. Chem. Soc.*, 1971, **93**, 7033.

²⁹¹ R. Paruszewski, *Roczniki Chem.*, 1971, **45**, 289 (*Chem. Abs.*, 1971, **75**, 64 244).

²⁹² M. A. Ondetti, N. J. Williams, E. F. Sabo, J. Pluscec, E. R. Weaver, and O. Kocy, *Biochemistry*, 1971, **10**, 4033.

²⁹³ K. Shigezane, M. Muraki, T. Morikawa, and T. Mizoguchi, *Yakugaku Zasshi*, 1971, **91**, 987 (*Chem. Abs.*, 1971, **75**, 141 149r).

<i>Peptide Synthesis</i>	385
<i>Peptide</i>	<i>Ref.</i>
Bombesin	294
Bradykinin	295—297
[3 and 4-(<i>N</i> -2-aminoethylglycine)]-bradykinin; <i>i.e.</i> the derivative of [Gly ³]-bradykinin in which the carbonyl group of the peptide bond between Gly ³ and Gly ⁴ is reduced to a methylene group	298
1-Deamino-bradykinin	296
9-Decarboxy-bradykinin	296
1-Deamino, 9-decarboxy-bradykinin	296
[Har ¹]-, [Har ⁹]-, and [Har ^{1,9}]-bradykinins	295
[5- <i>threo</i> - β -phenylserine]-, [8- <i>threo</i> - β -phenylserine]-, and [5,8- <i>threo</i> - β -phenylserine]-bradykinins	299
[5- <i>erythro</i> - β -phenylserine]-, [8- <i>erythro</i> - β -phenylserine]-, and [5,8- <i>erythro</i> - β -phenylserine]-bradykinins	300
[5- β -(2-thienyl)alanine]-, [8- β -(2-thienyl)alanine]-, and [5,8- β -(2-thienyl)alanine]-bradykinins	301
[5,8- β -cyclohexylalanine]-bradykinin	297
Bradykinin-potentiating peptides	302
Caerulin	
Analogues	303, 303a
Calcitonin	
The human hormone	194
The salmon hormone	196
Cobrotoxin	
A partially protected hexapeptide fragment	304
Cytochromes	
Partially protected oligopeptides related to various cytochromes	305—309

²⁹⁴ L. Bernardi, R. De Castiglione, O. Goffredo, and F. Angelucci, *Experientia*, 1971, **27**, 873.

²⁹⁵ H. Arold and D. Stibenz, *J. prakt. Chem.*, 1970, **312**, 1161.

²⁹⁶ W. H. Johnson, H. D. Law, and R. O. Studer, *J. Chem. Soc. (C)*, 1971, 748.

²⁹⁷ D. J. Schafer, G. T. Young, D. F. Elliot, and R. Wade, *J. Chem. Soc. (C)*, 1971, 46.

²⁹⁸ E. Atherton, H. D. Law, S. Moore, D. F. Elliot, and R. Wade, *J. Chem. Soc. (C)*, 1971, 3393.

²⁹⁹ H. Arold and S. Reissmann, *J. prakt. Chem.*, 1970, **312**, 1130.

³⁰⁰ H. Arold and H. Feist, *J. prakt. Chem.*, 1970, **312**, 1145.

³⁰¹ F. W. Dunn and J. M. Stewart, *J. Medicin. Chem.*, 1971, **14**, 779.

³⁰² H. Kato and T. Suzuki, *Biochemistry*, 1971, **10**, 972.

³⁰³ A. Anastasi, L. Bernardi, G. Bosisio, R. de Castiglione, O. Goffredo, G. Bertaccini, and V. Erspamer, ref. 7, p. 328.

^{303a} A. Agosti, I. Orlandini, and R. de Castiglione, *Experientia*, 1971, **27**, 412.

³⁰⁴ K. Noda, S. Terada, N. Mitsuyasu, M. Waki, T. Kato, and N. Izumiya, *Mem. Fac. Sci. Kyushi Univ. Ser. C*, 1970, **7**, 189 (*Chem. Abs.*, 1971, **75**, 6297x).

³⁰⁵ N. L. Alarkon, S. D. L'vova, and R. P. Evstigneeva, *Khim. prirod. Soedinenii*, 1971, **7**, 474 (*Chem. Abs.*, 1971, **75**, 141 153n).

³⁰⁶ V. M. Kozhukhovskaya, S. D. L'vova, and R. P. Evstigneeva, *Khim. prirod. Soedinenii*, 1970, **6**, 599 (*Chem. Abs.*, 1971, **74**, 126 047s).

³⁰⁷ S. D. L'vova, I. N. Sologubovskaya, and R. P. Evstigneeva, *Zhur. obshchei Khim.*, 1971, **41**, 216 (*Chem. Abs.*, 1971, **75**, 20 978b).

³⁰⁸ S. D. L'vova, V. M. Kozhukhovskaya, T. A. Volkova, and R. P. Evstigneeva, *Zhur. obshchei Khim.*, 1971, **41**, 1393 (*Chem. Abs.*, 1971, **75**, 88 936s).

³⁰⁹ S. D. L'vova, V. M. Kozhukhovskaya, M. N. Averin, and T. P. Evstigneeva, *Khim. prirod. Soedinenii*, 1971, **7**, 466 (*Chem. Abs.*, 1971, **75**, 152 065m).

	Peptide	Ref.
Eledoisin		
Analogues		310—312
Follicle-stimulating hormone releasing factor: see luteinizing-hormone releasing factor (?)		
Ferredoxin		
Clostridal ferredoxin-(7—11)-pentapeptide and the analogue in which Cys ⁸ and Cys ¹¹ are both replaced by Ser		313
Gastrin		
The C-terminal tetrapeptide and derivatives thereof		314—317
Glucagon		
Glucagon-(18—29)-dodecapeptide; passing mention		121
Glutathione		27, 52
Gramicidin S		
Linear decapeptide analogues		318, 319
Growth hormone		
Peptides and protected peptide fragments synthesized on the basis of the sequence since shown to be in error		254, 258, 259, 320, 321
Growth-hormone releasing factor (GH-RF: see p. 366)		
A decapeptide with the proposed sequence of porcine GH-RF		205
Haemoglobin		
Partial sequences of human haemoglobin β -chain		72, 205, 322—324
Insulin		
Ovine insulin A-chain, [Ala ¹²]-A-chain, [Glu ⁵ ,Ala ^{12,18,21}]-A-chain, and the formation of semisynthetic insulin analogues from these		57
A-arginyl bovine insulin (crystalline) from combination of modified natural A-chain with natural B-chain		163
An extensive series of analogues and partial sequences of bovine insulin designed to investigate the importance of arginine-B22		325, 326

³¹⁰ H. Niedrich, C. Berseck, and P. Oehme, ref. 7, p. 370.

³¹¹ G. F. Zhukova, G. A. Ravdel, and L. A. Shchukina, *Zhur. obshchei Khim.*, 1970, **40**, 2573 (*Chem. Abs.*, 1971, **74**, 76 647q).

³¹² R. Grupe and H. Niedrich, *J. prakt. Chem.*, 1970, **312**, 1087.

³¹³ H. Yajima, N. Shirai, and Y. Kiso, *Chem. and Pharm. Bull. (Japan)*, 1971, **19**, 1900.

³¹⁴ V. Vilka and G. Cipens, *Khim. prirod. Soedinenii*, 1971, **7**, 498 (*Chem. Abs.*, 1971, **75**, 141 161p).

³¹⁵ C. R. Sachatello, J. Sedwick, C. L. Moriarty, O. Grahl-Nielsen, and G. L. Tritsch, *Endocrinology*, 1971, **88**, 1300.

³¹⁶ M. Portelli, G. Renzi, and G. Borin, *Farmaco, Ed. Sci.*, 1971, **26**, 322 (*Chem. Abs.*, 1971, **75**, 209 832).

³¹⁷ O. V. Smirnov, L. K. Poleyeva, and G. Cipens, *Khim. prirod. Soedinenii*, 1971, **7**, 94 (*Chem. Abs.*, 1971, **75**, 20 982y).

³¹⁸ S. Makisumi, S. Matsuura, M. Waki, and N. Izumiya, *Bull. Chem. Soc. Japan*, 1971, **44**, 210.

³¹⁹ S. Makisumi, M. Waki, and N. Izumiya, *Bull. Chem. Soc. Japan*, 1971, **44**, 143.

³²⁰ C. H. Li and D. Chung, *Internat. J. Protein Res.*, 1971, **3**, 73; W. Datino and C. H. Li, *ibid.*, p. 81, 99; K. Kovacs, Y. Kovacs-Petres, and C. H. Li, *ibid.*, p. 93.

³²¹ K.-T. Wang and C. H. Li, *J. Org. Chem.*, 1971, **36**, 2419.

³²² V. P. Chernyshev, E. I. Filippovich, and R. P. Evstigneeva, *Zhur. obshchei Khim.*, 1971, **41**, 1620, 1623 (*Chem. Abs.*, 1971, **75**, 130 115a, 130 116b).

³²³ P. G. Pietta and P. Cavallo, *Gazzetta*, 1970, **100**, 863.

³²⁴ V. P. Chernyshev, E. I. Filippovich, R. P. Evstigneeva, and N. A. Preobrazhenskii, *Zhur. obshchei Khim.*, 1970, **40**, 2478 (*Chem. Abs.*, 1971, **75**, 20 985b).

³²⁵ G. Weitzel, K. Eisele, H. Gugliemi, W. Stock, and R. Renner, *Z. physiol. Chem.*, 1971, **352**, 1735.

³²⁶ G. Weitzel, U. Weber, J. Martin, and K. Eisele, *Z. physiol. Chem.*, 1971, **352**, 1005.

<i>Peptide Synthesis</i>	387
<i>Peptide</i>	<i>Ref.</i>
[B1- <i>p</i> -iodophenylalanine]-bovine insulin prepared semisynthetically from an appropriately protected des-Phe ^{B1} -insulin	170
Insulin B-chain protected fragments, including symmetrical cystine derivatives	16, 32, 327—334, 334a
Des-(B28—B30)-bovine and porcine (human) insulins; resynthesis with materials from natural sources	78
Ovine (bovine, porcine) insulin B chain <i>S</i> -sulphonate	76
Human insulin B chain <i>S</i> -sulphonate	79
A series of fragments incorporating the A20—B19 disulphide bridge	331
Lysozyme (see p. 378)	260
[Ala ⁷⁰]-Lysozyme-(64—82)-nonadecapeptide	335
Lysozyme: protected <i>N</i> -terminal sequences	88, 336, 337
Lipotropin	
Ovine β -lipotropin-(73—78)-hexapeptide	338
Luteinizing-hormone releasing factor (LH-RF: see p. 367)	
The decapeptide with the sequence proposed for LH-RF/FSH-RF	74, 211, 214
A series of pyroglutamyltri- and tetra-peptide amides, one of which (Glp-Tyr-Arg-Trp-NH ₂) had LH-RF activity	220
Melanocyte stimulating hormones	
α -MSH	339
Semisynthetic [Lys ¹⁰]-human β -MSH	161
Melittin	
Melittin-(1—8)-, -(7—17)-, -(1—17)-, and -(14—17)-peptides	340
Melittins I and II (also some partial sequences)	341
Formyl melittins I and II	342
Comparison of natural and synthetic melittins	343
³²⁷ P. G. Katsoyannis, J. Ginos, and M. Tilak, <i>J. Amer. Chem. Soc.</i> , 1971, 93 , 5866.	
³²⁸ P. G. Katsoyannis, M. Tilak, J. Ginos, and K. Suzuki, <i>J. Amer. Chem. Soc.</i> , 1971, 93 , 5862.	
³²⁹ P. G. Katsoyannis, M. Tilak, and K. Fukuda, <i>J. Amer. Chem. Soc.</i> , 1971, 93 , 5857.	
³³⁰ H. R. Bosshard, <i>Helv. Chim. Acta</i> , 1971, 54 , 951.	
³³¹ B. Kamber, <i>Helv. Chim. Acta</i> , 1971, 54 , 398.	
³³² R. G. Vdovina, A. K. Gracheva, M. G. Poznyak, and Yu. P. Shvachin, <i>Zhur. obshchei Khim.</i> , 1971, 41 , 239 (<i>Chem. Abs.</i> , 1971, 75 , 20 975y).	
³³³ M. I. Titov, L. I. Leont'eva, and Zh. D. Bepalova, <i>Zhur. obshchei Khim.</i> , 1971, 41 , 224 (<i>Chem. Abs.</i> , 1971, 75 , 20 989f).	
³³⁴ M. I. Titov, Zh. D. Bepalova, and L. I. Leont'eva, <i>Zhur. obshchei Khim.</i> , 1971, 41 , 928 (<i>Chem. Abs.</i> , 1971, 75 , 64 262t).	
^{334a} M. I. Titov and Z. A. Ardemasova, <i>Zhur. obshchei Khim.</i> , 1971, 41 , 1403 (<i>Chem. Abs.</i> , 1971, 75 , 98 811m).	
³³⁵ R. Arnon, E. Maron, M. Sela, and C. B. Anfinsen, <i>Proc. Nat. Acad. Sci., U.S.A.</i> , 1971, 68 , 1450.	
³³⁶ M. Guarneri, C. A. Benassi, R. Tomatis, A. Guggi, R. Ferroni, and R. Rocchi, <i>Gazzetta</i> , 1971, 101 , 363.	
³³⁷ M. Guaneri, C. A. Benassi, R. Ferroni, A. Guggi, R. Tomatis, and R. Rocchi, <i>Gazzetta</i> , 1971, 101 , 375.	
³³⁸ A. Loffett and J. Close, ref. 7, p. 92.	
³³⁹ J. Blake and C. H. Li, <i>Internat. J. Protein Res.</i> , 1971, 3 , 185.	
³⁴⁰ L. C. Dorman and L. D. Markley, <i>J. Medicin. Chem.</i> , 1971, 14 , 5.	
³⁴¹ E. Schroder, K. Lübke, M. Lehmann, and I. Beetz, <i>Experientia</i> , 1971, 27 , 764.	
³⁴² K. Lübke, S. Matthes, and G. Kloss, <i>Experientia</i> , 1971, 27 , 765.	
³⁴³ E. Habermann and G. Zeuner, <i>Naunyn-Schmiedebergs Arch. Pharmacol.</i> , 1971, 270 , 1 (<i>Chem. Abs.</i> , 1971, 75 , 49 574c).	

Peptide	Ref.
Oxytocin	84, 343a
Oxytocin with a ^{14}C label in the glycine residue	344
[1-(1-2-hydroxy-3-mercaptopropionic acid)]-oxytocin	345
1-Deamino-[Thr ⁴]-oxytocin	238
1-Deamino-[Thr ⁴ ,Ile ⁸]-oxytocin; <i>i.e.</i> 1-Deamino-[Thr ⁴]-mesotocin	238
Oxytocin-(1—5)-pentapeptide	227
Analogues of 1-deamino-oxytocin in which the disulphide link is replaced by a single sulphur atom or by a methylene group	346
1-Deamino-carba ¹ -oxytocin	347
1-Deamino-carba ⁶ -oxytocin	348
1-Deamino-dicarba-oxytocin	348
<i>N</i> -Acetyl-[Tyr(Me) ²]-oxytocin	349
[Phe(<i>p</i> -NO ₂) ²]-oxytocin	350
[Tyr(3-NO ₂) ²]-oxytocin	350
[D-Tyr(3-NO ₂) ²]-oxytocin	350
[Arg ⁸]-oxytocin; <i>i.e.</i> [Arg ⁸]-vasotocin	351
[Arg ⁸]-oxytocinoic acid; <i>i.e.</i> [Arg ⁸]-vasotocinoic acid	351
1-Deamino-[Arg ⁸]-oxytocin; <i>i.e.</i> 1-deamino-[Arg ⁸]-vasotocin	351
1-Deamino-[Lys ⁸]-oxytocin; <i>i.e.</i> 1-deamino-[Lys ⁸]-vasotocin	352
[Leu ^{2,4}]-oxytocin	353
[Pro ⁴]-oxytocin	354
[Pro ⁴ ,Ile ⁸]-oxytocin; <i>i.e.</i> [Pro ⁴]-mesotocin	354
[Pro ⁴ ,Gln ⁸]-oxytocin; <i>i.e.</i> [Pro ⁴]-glumitocin	354
[Lys ⁴ ,Ile ⁸]-oxytocin; <i>i.e.</i> [Lys ⁴]-mesotocin	354
<i>S</i> -Benzyl-oxytocin <i>C</i> -terminal tetrapeptide	84
Oxytocin-(1—6)-hexapeptide; <i>i.e.</i> tocinoic acid	226, 354a
Oxytocin-(1—6)-hexapeptide amide; <i>i.e.</i> tocinamide	355
1-Deamino-oxytocin-(1—6)-hexapeptide amide; <i>i.e.</i> 1-deamino-tocinamide	355
[1-(3-Methyl,3-mercaptopbutyric acid)]-oxytocin; <i>i.e.</i> '[1-deamino-penicillamine]-oxytocin': deuteriated in position 1	356
Parathyroid hormone	
Bovine parathyroid hormone-(1—34)-tetratricontapeptide	261

^{343a} O. S. Papsuevich and G. Cipens, *Zhur. obshchei Khim.*, 1970, **40**, 2768 (*Chem. Abs.*, 1971, **74**, 76 646p).

³⁴⁴ R. Walter and R. T. Havran, *Experientia*, 1971, **27**, 645.

³⁴⁵ D. B. Hope and M. Wälti, *Biochem. J.*, 1971, **125**, 909.

³⁴⁶ K. Jošt and F. Šorm, *Coll. Czech. Chem. Comm.*, 1971, **36**, 2795.

³⁴⁷ K. Jošt, *Coll. Czech. Chem. Comm.*, 1971, **36**, 218.

³⁴⁸ K. Jošt and F. Šorm, *Coll. Czech. Chem. Comm.*, 1971, **36**, 234.

³⁴⁹ K. Jošt and F. Šorm, *Coll. Czech. Chem. Comm.*, 1971, **36**, 297.

³⁵⁰ Z. Auna, O. A. Kaurov, V. F. Martynov, and V. B. Morozov, *Zhur. obshchei Khim.*, 1971, **41**, 674 (*Chem. Abs.*, 1971, **75**, 49 560v).

³⁵¹ R. T. Havran, C. Meyer, I. L. Schwartz, and R. Walter, *ref. 7*, p. 161.

³⁵² M. Rimpler, *Annalen*, 1971, **745**, 8.

³⁵³ V. J. Hruby and W. Y. Chan, *J. Medicin. Chem.*, 1971, **14**, 1050.

³⁵⁴ M. Manning, J. W. M. Baxter, C. T. Wu, V. Smart-Abbey, K. Morton, E. J. Coy, and W. H. Sawyer, *J. Medicin. Chem.*, 1971, **14**, 1143.

^{354a} O. A. Kaurov, V. F. Martynov, Yu. V. Natochin, O. A. Popernatskii, and E. I. Shakhmatova, *Zhur. obshchei Khim.*, 1971, **41**, 213 (*Chem. Abs.*, 1971, **75**, 36 643z).

³⁵⁵ V. J. Hruby, M. F. Ferger, and V. du Vigneaud, *J. Amer. Chem. Soc.*, 1971, **93**, 5539.

³⁵⁶ V. du Vigneaud, J. D. Meador, M. F. Ferger, G. A. Allen, and A. T. Blomquist, *Bioorg. Chem.* 1971, **1**, 123.

<i>Peptide Synthesis</i>	389
<i>Peptide</i>	<i>Ref.</i>
Proinsulin	
Prolylprolyl- <i>N</i> - ϵ -benzyloxycarbonyl-lysyl- <i>N</i> - ω -nitroarginyl-bovine insulin A-chain; <i>i.e.</i> a partial proinsulin sequence obtained by semisynthetic means	165
Ribonuclease	
Ribonuclease T ₁ ; further discussion of progress	249
Ribonuclease T ₁ ; details for the 12—47 fragment	250
Ribonuclease S'; further discussion	263, 264
Ribonuclease A; full details	262
Ribonuclease <i>N</i> -terminal eicosapeptide (S peptide)	
[Ser ¹³]-S-peptide-(1—14)-tetradecapeptide	357
[12- β -(pyrazol-3-yl)-alanine]-S-peptide-(2—14)- and -(3—14)-peptides	357
[Nle ¹³]-S-peptide-(1—14)-, -(2—14)-, and -(3—14)-peptides	357
[Nle ⁷]-S-peptide-(1—14)-tetradecapeptide	357
[Nle ^{7,13}]-S-peptide-(1—14)-tetradecapeptide	357
[Cpg ⁸ , Orn ¹⁰]-S-peptide*	358
Rubredoxin	
Rubredoxin: protected <i>N</i> -terminal decapeptide	359
Scotophobin (see p. 382)	126, 271, 273
Analogues	273, 274
Secretin	
Secretin <i>C</i> -terminal hexapeptide amide	126, 127
[Orn ^{12,14,18,21}]-Secretin	360
Partially protected secretin-(18—27)-, -(12—27)- and -(7—11)-peptides	361—363
Staphylococcal nuclease	
Analogues of staphylococcal nuclease-(6—48)-peptide (P ₂)	266, 267
Analogues and partial sequences of staphylococcal nuclease-(99—149)-peptide	269
Substance P	277
Thyroid-stimulating hormone releasing factor (TSH-RF)	73, 228—232
Tritiated TSH-RF	364
Numerous analogues of TSH-RF	233, 234
Tobacco mosaic virus (TMV) coat protein	
TMV coat protein: (98—102)-partially protected pentapeptide	365
Trypsin inhibitor	
Bovine basic pancreatic trypsin inhibitor (see p. 377)	252
Vasopressin	
Lysine-vasopressin	123
Lysine- and arginine-vasopressins with ¹⁴ C labels in their glycine residues	344

⁸⁸⁷ K. Hofmann, R. Andreatta, F. M. Finn, J. Montibeller, G. Porcelli, and A. J. Quattrone, *Bioorg. Chem.*, 1971, **1**, 66.

⁸⁸⁸ G. Borin, F. Marchiori, R. Rocchi, L. Moroder, and E. Scoffone, *Gazzetta*, 1971, **101**, 426.

⁸⁸⁹ A. Ali and B. Weinstein, *J. Org. Chem.*, 1971, **36**, 3022.

⁸⁹⁰ M. J. Smithers, ref. 7, p. 44.

⁸⁹¹ E. Wünsch and P. Thamm, *Chem. Ber.*, 1971, **104**, 2454.

⁸⁹² E. Wünsch, G. Wendlberger, and P. Thamm, *Chem. Ber.*, 1971, **104**, 2445.

⁸⁹³ E. Wünsch, G. Wendlberger, and A. Högel, *Chem. Ber.*, 1971, **104**, 2430.

⁸⁹⁴ T. W. Redding and A. V. Schally, *Internat. J. Appl. Radiation Isotopes*, 1970, **21**, 742.

⁸⁹⁵ K. Brunfeldt and J. Halström, *Acta Chem. Scand.*, 1970, **24**, 3013.

* Cpg = α -cyclopentylglycine.

Peptide	Ref.
1-Deamino-[Ile ³]-lysine-vasopressin; <i>i.e.</i> 1-deamino-[Lys ⁸]-vasotocin	352
[Hly ⁸]-vasopressin*	366
Arginine-vasopressin	367—369
Arginine-vasopressinoic acid	368
[Ile ³]-arginine-vasopressin; <i>i.e.</i> [Arg ⁸]-vasotocin	351
[Ile ³]-arginine-vasopressinoic acid; <i>i.e.</i> [Arg ⁸]-vasotocinoic acid	351
1-Deamino-[Ile ³]-arginine-vasopressin; <i>i.e.</i> 1-deamino-[Arg ⁸]-vasotocin	351
A partially protected nonapeptide amide with the sequence of arginine vasopressin	370
[Gln ⁸]-vasopressin	370a

B. Sequential Polypeptides

poly-[D-Glu(OBzl)-Glu(OBzl)]	371
poly-[Glu(OBu ^b)-D-Glu(OBu ^b)]	154
poly-[Glu(OBzl)-D-Glu(OBzl)]	154
poly-[D-Glu(OBzl)-Leu]	154
poly-(Ala-Gly)	372
poly-(Ala-Ala-Gly)	372
poly-(Ala-Gly-Gly)	372
poly-(Ala-Gly-Gly-Gly)	372
poly-(Ala-Gly-Lys)	373
poly-(Lys-Gly-Ala)	373
poly-(Lys-Ala-Ala)	157, 159
poly-(Gly-Lys-Gly)	374
poly-(Gly-Gly-Lys)	375
poly-(Lys-Lys-Gly)	374
poly-(Ala-Pro-Gly)	153
poly-(Gly-Pro-Ala)	158
poly-(Gly-Pro-Pro)	376
poly-(Pro-Ser-Gly)	377

³⁶⁶ M. Bodanszky and G. Lindeberg, *J. Medicin. Chem.*, 1971, **14**, 1197.

³⁶⁷ K. Lübke, ref. 7, p. 154.

³⁶⁸ J. Meienhofer, A. Trzeciak, T. Dousa, O. Hechter, R. T. Havran, I. L. Schwartz, and R. Walter, ref. 7, p. 157.

³⁶⁹ J. Meienhofer, A. Trzeciak, R. T. Havran, and R. Walter, *J. Amer. Chem. Soc.*, 1970, **92**, 7199.

³⁷⁰ H. Wissmann and R. Geiger, *Angew. Chem. Internat. Edn.*, 1970, **9**, 908.

^{370a} O. S. Papsuevich, G. Cipens, and A. Krikis, *Khim. prirod. Soedinenii*, 1971, **7**, 543 (*Chem. Abs.*, 1971, **75**, 141 152m).

³⁷¹ F. Heitz and G. Spach, *Macromolecules*, 1971, **4**, 429.

³⁷² A. Brack and G. Spach, *Compt. rend.*, 1970, **271**, C, 916.

³⁷³ T. P. Chuvaeva, L. V. Morozova, V. A. Shibnev, and K. T. Poroshin, *Doklady Akad. Nauk Tadzh. S.S.R.*, 1970, **13**(9), 28 (*Chem. Abs.*, 1971, **74**, 142 333n).

³⁷⁴ A. V. Zakirov and V. G. Debabov, *Khim. prirod. Soedinenii*, 1970, **6**, 459 (*Chem. Abs.*, 1971, **75**, 20 967x).

³⁷⁵ V. K. Burichenko, V. G. Ovchinnikova, R. R. Dakhte, and K. T. Poroshin, *Doklady Akad. Nauk Tadzh. S.S.R.*, 1971, **14**(3), 30 (*Chem. Abs.*, 1971, **75**, 88 941q).

³⁷⁶ V. A. Shibnev, M. P. Finogenova, and K. T. Poroshin, *Doklady Akad. Nauk S.S.S.R.*, 1971, **198**, 862 (*Chem. Abs.*, 1971, **75**, 49 552u).

³⁷⁷ V. A. Shibnev, Sh. Kh. Khahkov, M. P. Finogenova, and K. T. Poroshin, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1970, 2822 (*Chem. Abs.*, 1971, **75**, 6303w).

* Hly = homolysine.

Peptide	Ref.
poly-[Tyr(Me)-Glu-Ala-Gly]-[1- ¹⁴ C]Gly-OEt	378
poly-(Glu-Tyr-Ala-Gly)-[1- ¹⁴ C]Gly-OEt	379
poly-(Tyr-Glu-Gly-Gly)-Gly-OMe	380
poly-(Phe-Glu-Ala-Gly)-Gly-OMe	381
poly-(Phe-Glu-Ala-Gly)-[1- ¹⁴ C]Gly-OEt	382
poly-(Tyr-Ala-Glu)	155, 156
Miscellaneous sequential polypeptides, intermediates in sequential polypeptide synthesis, etc.	158, 383—389
Repeating-sequence oligomers	
Derivatives of H-(Gly-Pro-Pro) _n -OH (<i>n</i> = 2—6)	390
Derivatives of H-(Ala-Pro-Gly) _n -OH (<i>n</i> = 2—6)	153

C. Miscellaneous Peptides

Leu-Ala-Gly-Val	36, 135, 146
Leu ₅ -Ala	391
Gly-Leu-Phe-Gly	119
Ala-Gly ₂ -Leu-Phe-Gly	119
Phe-Arg-Leu-Asp	171
Ile-Ala-Val-Gly	125
Chromophoric acyloligopeptide substrates for various proteolytic enzymes	392
A series of oligopeptide thrombin substrates	393, 394
Oligopeptide procollagen hydroxylase substrates	395

³⁷⁸ B. J. Johnson, *J. Medicin. Chem.*, 1971, **14**, 640.

³⁷⁹ B. J. Johnson, *J. Medicin. Chem.*, 1971, **14**, 488.

³⁸⁰ B. J. Johnson and E. G. Trask, *J. Medicin. Chem.*, 1971, **14**, 251.

³⁸¹ B. J. Johnson and F. Chen, *J. Pharm. Sci.*, 1971, **60**, 330.

³⁸² B. J. Johnson and C. Cheng, *J. Medicin. Chem.*, 1971, **14**, 1238.

³⁸³ V. A. Shibnev, T. P. Chuvaeva, Sh. Kh. Khahkov, and K. T. Poroshin, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1970, 2566 (*Chem. Abs.*, 1971, **75**, 6310w).

³⁸⁴ V. A. Shibnev, L. I. Mar'yash, V. S. Grechishko, and K. T. Poroshin, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1970, 2820 (*Chem. Abs.*, 1971, **75**, 6304x).

³⁸⁵ J. Sperling and D. Elad, *J. Amer. Chem. Soc.*, 1971, **93**, 967.

³⁸⁶ K. T. Poroshin, V. K. Burichenko, L. I. Mar'yash, and V. A. Shibnev, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1971, 1276 (*Chem. Abs.*, 1971, **75**, 77 253r).

³⁸⁷ A. B. Zegel'man, I. M. Savranskaya, G. D. Bozhkova, and K. T. Poroshin, *Doklady Akad. Nauk Tadzh. S.S.R.*, 1970, **13**(12), 28 (*Chem. Abs.*, 1971, **75**, 77 266x).

³⁸⁸ A. B. Zegel'man, T. Yu. Yusupov, G. N. Demyanik, Z. Sharifova, and K. T. Poroshin, *Doklady Akad. Nauk Tadzh. S.S.R.*, 1971, **14**(4), 31 (*Chem. Abs.*, 1971, **75**, 88 933p).

³⁸⁹ V. K. Burichenko, N. I. Koryakina, and K. T. Poroshin, *Doklady Akad. Nauk Tadzh. S.S.R.*, 1971, **14**(5), 16 (*Chem. Abs.*, 1971, **75**, 130 100s).

³⁹⁰ V. A. Shibnev, K. T. Poroshin, and V. S. Grechishko, *Doklady Akad. Nauk S.S.S.R.*, 1971, **198**, 608 (*Chem. Abs.*, 1971, **75**, 64 247s).

³⁹¹ A. M. Tometsko, J. Tischnio, and J. Garden, sec., *J. Pharm. Sci.*, 1970, **59**, 1655 (*Chem. Abs.*, 1971, **74**, 13 419w).

³⁹² E. Wünsch, G. Schönsteiner-Altmann, and E. Jäger, *Z. physiol. Chem.*, 1971, **352**, 1424; E. Wünsch, A. Högel, and E. Jäger, *ibid.*, p. 1553; E. Wünsch, E. Jäger and G. Schönsteiner-Altmann, *ibid.*, p. 1560, 1568.

³⁹³ R. K. H. Liem, R. H. Andreatta, and H. A. Scheraga, *Arch. Biochem. Biophys.*, 1971, **147**, 201.

³⁹⁴ R. H. Andreatta, R. K. H. Liem, and H. A. Scheraga, *Proc. Nat. Acad. Sci., U.S.A.*, 1971, **68**, 253.

³⁹⁵ Y. Kikuchi, D. Fujimoto, and N. Tamiya, *Biochem. J.*, 1971, **124**, 695.

Peptide	Ref.
A series of oligopeptide pepsin substrates, each containing a residue of <i>p</i> -nitrophenylalanine	396
A decapeptide antamanide precursor containing a residue of <i>p</i> -azidophenylalanine	397
A series of oligolysines and their mono- ϵ -Dnp derivatives	398
Lysine oligomers	399
A series of <i>t</i> -butoxycarbonyl-oligo-isoleucine methyl esters	400, 401
Arginine oligomers	402
γ -Glutamyl peptides	403, 403a
Peptides containing arginine	404
Peptides containing β -cyanoalanine	405
Peptides containing ϵ -benzyloxycarbonyl-lysine	104
Peptides containing histidine	406
Peptides containing serine and glutamine	407
Peptides containing ornithine and proline	408
Peptides containing alanine and glutamic acid	409
Peptides containing β -lysine	410, 411
Peptides containing hydroxyproline	412, 413
Peptides containing 2-amino-3-sulphamoylpropionic acid	414

³⁹⁶ K. Medzihradszky and J. S. Fruton, ref. 7, p. 285.

³⁹⁷ T. Wieland, A. von Dungen, and C. Birr, *Annalen*, 1971, **752**, 109.

³⁹⁸ Y. Stupp, W. E. Paul, and B. Benacerraf, *Immunology*, 1971, **21**, 575.

³⁹⁹ G. P. Vlasov, V. R. Glushenkova, and T. N. Prokopyuk, *Zhur. obshchei Khim.*, 1971, **41**, 430 (*Chem. Abs.*, 1971, **75**, 20 969z).

⁴⁰⁰ U. Widmer and G. P. Lorenzi, *Chimia (Switz.)*, 1971, **25**, 236.

⁴⁰¹ C. Toniolo, *Biopolymers*, 1971, **10**, 1709.

⁴⁰² K. T. Poroshin, V. K. Burichenko, and G. F. Kasymova, *Doklady Akad. Nauk Tadzh. S.S.R.*, 1970, **13**(8), 23 (*Chem. Abs.*, 1971, **75**, 20 965v).

⁴⁰³ J. Meienhofer, P. M. Jacobs, H. A. Godwin, and I. H. Rosenberg, *J. Org. Chem.*, 1970, **35**, 4137.

^{403a} D. E. Nitecki and J. W. Goodman, in 'Chemistry and Biochemistry of Amino-acids, Peptides, and Proteins', ed. B. Weinstein, vol. 1, p. 87.

⁴⁰⁴ E. I. Vinogradova, Yu. B. Alakhov, V. M. Liplin, N. A. Aldanova, M. Yu. Feigina, Yu. B. Shvetsov, and L. A. Fonina, *Zhur. obshchei Khim.*, 1970, **40**, 1385 (*Chem. Abs.*, 1971, **74**, 54 165d).

⁴⁰⁵ A. Michalik and B. Liberek, *Zeszyty Nauk., Mat., Fiz., Chem.*, 1970, **10**, 163 (*Chem. Abs.*, 1971, **74**, 13 418v).

⁴⁰⁶ V. P. Chernyshev, E. I. Filippovich, R. P. Evstigneeva, and N. A. Preobiazhenskii, *Zhur. obshchei Khim.*, 1970, **40**, 1646 (*Chem. Abs.*, 1971, **75**, 6298y).

⁴⁰⁷ N. A. Poddubnaya, G. N. Balandina, and O. A. Tambieva, *Zhur. obshchei Khim.*, 1971, **41**, 436 (*Chem. Abs.*, 1971, **75**, 20 967y).

⁴⁰⁸ N. A. Poddubnaya and N. Ya. Krasnobrizhii, *Zhur. obshchei Khim.*, 1971, **41**, 441 (*Chem. Abs.*, 1971, **75**, 36 639c).

⁴⁰⁹ C. Daicovicium, A. Balog, D. Breazu, L. Beu, and F. Gonczy, *Rev. Roumaine Chim.*, 1971, **16**, 751 (*Chem. Abs.*, 1971, **75**, 64 255t).

⁴¹⁰ L. I. Rostovtseva, E. A. Markelova, A. A. Kiryushkin, and A. S. Khokhlov, *Zhur. obshchei Khim.*, 1971, **41**, 1604; L. I. Rostovtseva, A. A. Kiryushkin, and A. S. Khokhlov, *Zhur. obshchei Khim.*, 1971, **41**, 1611 (*Chem. Abs.*, 1971, **75**, 130 099y, 130 117c).

⁴¹¹ L. I. Rostovtseva, A. A. Kiryushkin, and A. S. Khokhlov, *Zhur. obshchei Khim.*, 1971, **41**, 1380 (*Chem. Abs.*, 1971, **75**, 88 923k).

⁴¹² F. H. C. Stewart, *Austral. J. Chem.*, 1971, **24**, 1277.

⁴¹³ K. T. Poroshin, Sh. Kh. Khalikov, G. A. Pesina, and V. A. Shibnev, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1970, 1823 (*Chem. Abs.*, 1971, **75**, 6287u).

⁴¹⁴ B. Aleksiev, P. Nisanjan, S. Stoev, and V. Doseva, *Z. physiol. Chem.*, 1971, **352**, 1411.

Peptide	Ref.
Peptides containing a histidine analogue which incorporates a spin label	290
Peptides with tetrazole analogues at the C-termini	415, 416
Peptides containing <i>N</i> -(2-carboxamidoethyl)glycine	417, 418
Peptides containing <i>N</i> -(2-aminoethyl)glycine	298
Aza peptides	310, 312
Oxazoline peptides	415
Selenium-containing peptides	419
ϵ -(α -glutamyl)-, ϵ (γ -glutamyl)-, and ϵ (β -aspartyl)-lysine	420
Bis-cystine peptides	60
A series of cysteinyl-polyglycyl-cysteines	59
Antimitotic dipeptides	421
Three pentapeptides and a nonapeptide of unspecified relevance	422

5 Appendix B. A List of Some Useful New Synthetic Intermediates Described during 1971

As before, we warn that this list is selective and subjective. Compounds were taken to be new on the authority (whether explicit or implied) of the workers who described them: they are crystalline unless otherwise stated. One or two especially important intermediates which have been reported before have nevertheless been included in order to draw attention to some new point which we thought pertinent.

In this appendix, substitution into an aromatic protecting group is indicated by placing the substituent in brackets immediately after the symbol for the protecting group, *e.g.* Bzl(OMe) = methoxybenzyl.

Compound	Ref.
α -Aminobutyric acid (Abu)	
Abu-NH ₂ ,HCl	234
α -Aminoisobutyric acid (Aib)	
Boc-Aib	280
α -Amino- β -ethylvaleric acid (Aev)	
Boc-Aev	287
α -Aminopimelic acid (Apm)	
Apm(OMe),HCl	346
Z-Apm(OMe),Dcha	346
Nps-Apm(OMe),Dcha	346
Alanine	
Ala-NH ₂ ,HCl	234
Bpoc-Ala,Dcha	20
Z-Ala-SPy	83
Boc-Ala-SPy	83
Boc-Ala-OPy	84

⁴¹⁵ J. S. Morley, ref. 7, p. 361.

⁴¹⁶ Z. Grzonka, E. Rekowska, and B. Liberek, *Tetrahedron*, 1971, 27, 2317.

⁴¹⁷ F. H. C. Stewart, *Austral. J. Chem.*, 1971, 24, 1267.

⁴¹⁸ F. H. C. Stewart, *Austral. J. Chem.*, 1971, 24, 1743.

⁴¹⁹ D. Theodoropoulos, ref. 7, p. 367.

⁴²⁰ J. B. Caldwell, L. A. Holt, and B. Milligan, *Austral. J. Chem.*, 1971, 24, 435.

⁴²¹ A. Jean and J. Anatol, *Bull. Soc. chim. France*, 1970, 3698.

⁴²² F. Sipos and D. W. Gaston, *Synthesis*, 1971, 321.

<i>Compound</i>	<i>Ref.</i>
β -Alanine	
Z- β -Ala-SPy	83
Arginine	
Arg <i>N</i> -carboxy-anhydride, HBr; impure but usable	100
Aoc-Arg(Tos)	66
Nps-Arg(NO ₂)-ODnp	336
Nps-Arg(NO ₂), Dcha	336
Nps-Arg(NO ₂)-OPcp	337
Asparagine	
Asn <i>N</i> -carboxy-anhydride	100
Asn-OBzl(OMe), HCl	42
Asn-OBu ^t	331
Bpoc-Asn: m.p. 40 °C higher than in a previous report	20
Boc-Asn-ONp: purification by counter-current distribution	50
Boc-Asn-OPy	84
Boc-Asn-SPy	83
Z-Asn-OTcp	250
Aspartic acid	
Asp <i>N</i> -carboxy-anhydride	100
Asp(OPic)-OPic, 3HBr	423
Boc-Asp(OPic)	423
Z-Asp(OPic)	423
Z-Asp(OPic)-OTcp	423
Z-Asp(Bzl)-OPy	84
α -Cyclohexylglycine (Chg)	
Boc-Chg	287
α -Cyclopentylglycine (Cpg)	
Boc-Cpg	287
Cysteine	
Boc-Cys(Trt), Dcha	17
Boc-Cys(Trt)-ONp	16
Z-Cys(Trt); crystallization and physical constants of free acid	60
Cys(SBu ^t)	54
Boc-Cys(SBu ^t)	54
Nps-Cys(SBu ^t), Dcha	54
Boc-Cys(Boc); useful detailed description	424
Boc-Cys(Boc)-ONSu	50
Cys(Boc), HCl	52
Cys(Acm)-OMe, HCl	53
Boc-Cys(Bzl), Dcha	17
Boc-Cys(Bzl)-ONSu: no characterization—used crude	17
Cys(Bzl)-OBzl(OMe), HCl	42
Z(OMe)-Cys(Bzl)-ONp	313
Cys(Bzl)-Bzl(NO ₂), TosOH	355
Boc-Cys(Bzl)-OPy	84
Boc-Cys(Bzl)-SPy	83
Boc-Cys[Bzl(OMe)], Dcha	359
Nps-Cys[Bzl(OMe)], Dcha	336
Nps-Cys[Bzl(OMe)]-ONp	336

⁴²³ R. Garner and G. T. Young, *J. Chem. Soc. (C)*, 1971, 50.

⁴²⁴ J. J. Ferraro, *Biochem. Prep.*, 1971, 13, 39.

Compound	Ref.
Cystine	
Z-Cys,Dcha	
Z-Cys,Dcha	249
Boc-Cys	
Boc-Cys	52
Glutamic acid	
Boc-Glu(OPic)	423
Z-Glu(OPic)	423
Glu(OPic)-OPic,3HBr	423
Boc-Glu(OBu ^t)-ONSu	357
Nps-Glu(OBzl)-ONp	336
Boc-Glu(OBzl)-OPy	84
Boc-Glu(OBzl)-SPy	83
Z-Glu(ONSu)-OBu ^t	403
Glutamine	
Gln <i>N</i> -carboxy-anhydride	100
Gln-OBzl(OMe),HCl	42
Gln-NH·NH·Boc	250
Bpoc-Gln,Cha	20
Boc-Gln-SPy	83
Boc-Gln-OPy	84
Z-Gln-ONSu	250
Glycine	
Gly-OBzl(OMe),HCl	42
Gly-NH·NH·Z,HCl	294
Z-Gly-SPy	83
Boc-Gly-SPy	83
Boc-Gly-OPy	84
Histidine	
His <i>N</i> -carboxy-anhydride,HBr	100
His <i>N</i> -thiocarboxy-anhydride,HBr	101
His-OBzl,2HCl; improved procedure	44
Boc-His; alternative route	262
Boc-His(Z)	63
Z-His(Z); useful detailed description	425
Boc-His(Trt)	63, 67
His(Trt)-OMe,HCl	63
His(Trt),picrate	63
Boc-His(Bzh)	63, 67
His(Bzh)-OMe,HCl	63
His(Bzh),picrate	63
Z-His(Adoc)	65
Z-His(Boc); amorphous	62
His(Boc) <i>N</i> -carboxy-anhydride hydrochloride	62
His(Boc),2HCl	62
Boc-His(Boc),Dcha	254
Z-His(Dnp)	69
Z-His(Dnp)-ONSu	69
His(Dnp),2HBr	69

⁴²⁵ A. A. Wieland, R. J. Albers, and D. F. DeTar, *Biochem. Prep.*, 1971, 13, 28.

Compound	Ref.
His(Dnp) <i>N</i> -carboxy-anhydride hydrochloride	70
Boc-His(Piperidinocarbonyl)	67
Homoarginine	
Har(NO ₂)-OMe,HCl	295
Har(NO ₂)-OBzl(NO ₂),HBr	295
Z-Har(NO ₂)	295
Boc-Har(NO ₂); crystalline	295
Nps-Har(NO ₂),Dcha	295
Z-Har(NO ₂)-ONp	295
Homolysine (Hly)	
Hly(Tos)	366
Z-Hly(Tos); oil	366
Z-Hly(Tos)-ONp	366
4-Hydroxyproline (4Hyp)	
A series of potentially useful <i>N</i> -nitroso-4Hyp derivatives (active esters, <i>etc.</i>)	412
4Hyp-OBzl(NO ₂),HCl	412
4Hyp-OBzl(OMe),HCl	43
4Hyp-NH ₂ ,HCl	412
Isoleucine	
Nps-Ile-ONSu	347
<i>allo</i> -Isoleucine	
Boc- <i>alle</i> ,Dcha	287
Lysine	
Boc-Lys(Z)-OPcp	373
Lys(Z)-OPcp,HCl	373
Lys[Z(Cl)]	16, 32
Boc-Lys[Z(Cl)]	16
Boc-Lys[Z(Cl)]-ONp	16
Boc-Lys[Z(NO ₂)]-ONp	16
Lys(Boc) <i>N</i> -carboxy-anhydride	100
D-Lys(Boc)	50
Boc-Lys(Boc)-ONSu	165
Boc-Lys(Tos)-ONSu	321
Z-Lys(Dns); amorphous	277c
Nps-Lys(Dnp),Dcha	398
ε-di-isopropylmethoxycarbonyl-lysine	32
Methionine	
Boc-Met,Dcha	280
Boc-Met-ONp	280
Boc-Met-OPcp	337
Boc-Met-SPy	83
Boc-Met-OPy	84
Z-Met-SPy	83
Norleucine	
Boc-Nle-ONSu	357
Z-Nle-ONSu	357
Ornithine	
Orn[Z(NO ₂)]	426
Z(OMe)-Orn[Z(NO ₂)],Dcha	426
Z(OMe)-Orn[Z(NO ₂)]	426

⁴²⁶ M. Ohno, K. Kuramizu, H. Ogawa, and N. Izumiya, *J. Amer. Chem. Soc.*, 1971, **93**, 5251.

<i>Peptide Synthesis</i>	<i>Compound</i>	<i>Ref.</i>
	Orn(Z)-OMe,HCl	427
	Z-Orn(Boc)-OMe	277b
Phenylalanine		
	Bpoc-Phe,Dcha	20
	Boc-Phe-SPy	83
	Boc-Phe-OPy	84
Phenylalanine, substituted in the ring		
	Boc-Phe(<i>p</i> -I)-OTcp	170
	Boc-Phe(<i>p</i> -NO ₂)	428
	Boc-Phe(<i>p</i> -N ₃)*	397, 428
	Boc-Phe(<i>p</i> -N ₃)-ONp	428
	Boc-Phe(<i>p</i> -N ₃)-ONSu	428
β -Phenylserine, <i>erythro</i>		
	<i>Erythro</i> - β -phenylserine-OMe,HCl	300
	<i>Z-erythro</i> - β -phenylserine	300
	Boc- <i>erythro</i> - β -phenylserine	300
β -Phenylserine, <i>threo</i>		
	<i>Z-threo</i> - β -phenylserine	299
	<i>Threo</i> - β -phenylserine-NH·NH·Boc	299
Proline		
	Pro-OBzl(OMe),HCl	43
	Boc-Pro-SPy	84
Sarcosine		
	Sar-OBzl(OMe),HCl	43
Serine		
	Ser(Tms) <i>N</i> -carboxy-anhydride†	100
	Bpoc-Ser	20
	Bpoc-Ser(Bu [†]),Dcha	20
	Ser(Bzl): the resolution step improved in a large-scale preparation	51
	Boc-Ser(Bzl),Cha	427
	Boc-Ser(Bzl)-SPy	83
β -(2-Thienyl)alanine (Tha)		
	Boc-Tha	301
Threonine		
	Thr(Tms) <i>N</i> -carboxy-anhydride†	100
	Thr-NH ₂ ,HCl	234
	Thr-OBzl,HCl	16
	Boc-Thr-OBzl: oil	16
	Bpoc-Thr,Cha	20
Tryptophan		
	Boc-Trp-SPy	83
	Boc-Trp-OPy	84
Tyrosine		
	Tyr(Thp) <i>N</i> -carboxy-anhydride‡	100
	Z-Tyr(Z)-ONSu	156

⁴²⁷ M. Iwai, K. Nakajima, A. Uno, S. Hase, I. Takeuchi, and K. Okawa, *Bull. Chem. Soc. Japan*, 1970, **43**, 3246.

⁴²⁸ R. Schwyzler and M. Caviezel, *Helv. Chim. Acta*, 1971, **54**, 1395.

* This derivative can be used in the synthesis of peptides which contain *p*-azidophenylalanine (a potential photoaffinity label) by the solid-phase method without any special precautions or procedures.

† Tms = Me₃Si.

‡ Thp = tetrahydropyranyl.

Compound	Ref.
Boc-Tyr(Bu ^t)-OMe	347
Boc-Tyr(Bu ^t),Dcha	347
Boc-Tyr(Bu ^t)-ONSu	347
Boc-Tyr(Bzl)-ONp	280
Boc-Tyr(Bzl)-SPy	83
Boc-Tyr(Bzl)-ONSu	155
Valine	
Val-NH ₂ ,HBr	363
Boc-Val-ONp; previously described as an oil	16
Bpoc-Val,Dcha	20
Z(OMe)-Val-ONp	313
Boc-Val-SPy	83
Miscellaneous derivatives	
Tetrazole analogues of some benzyloxycarbonylamino-acids	415, 429
A number of useful <i>N</i> -thiocarboxy-anhydrides	101
A series of <i>N</i> -(2-benzoyl-1-methylvinyl)amino-acid derivatives	121, 38

⁴²⁹ Z. Grzonka and B. Liberek, *Tetrahedron*, 1971, **27**, 1783.

4

Peptides with Structural Features Not Typical of Proteins

BY J. S. DAVIES

1 Introduction

The aim this year has been to cover papers on this subject whose titles appeared in the 1971 volume of *Chemical Titles*. The coverage was augmented by scanning, over the same period, the sections on General Biochemistry, Microbial Biochemistry, and Synthesis of Amino-acids, Peptides, and Proteins in *Chemical Abstracts*. Although as many papers were retrieved as for Volume 3, fewer novel structures for peptide antibiotics were characterized sufficiently well for coverage in this compilation. Instead it has been a year dominated by the application of theoretical and spectroscopic techniques for the determination of the conformation of cyclic peptides and depsipeptides. Only a few years ago the dioxopiperazines presented almost the ultimate as models for such investigations of cyclic structures, but now cyclic nonapeptides and even larger structures such as alamethicin are undergoing detailed conformational analysis. However, the dioxopiperazines have not escaped detailed analysis and a number of interesting papers have appeared on their conformation. The occurrence of the epidithiadioxopiperazine ring system in a number of naturally occurring antibiotics has stimulated interest in the synthesis of these compounds, and although the methods reported for the synthesis of cyclic peptides in general have not produced novel approaches this year, it has been an active field with many important papers.

Of the new structures that have been reported a substantial number contain dehydroamino-acids, which could well be of biosynthetic significance, none less so than in the formation of the very interesting structure of nisin.



Less work than usual has appeared on the glycopeptide aspects of bacterial cell walls but this has been balanced by the increased number of glycosidic-asparaginyl linkages found in glycopeptides and glycoproteins from other sources. Epimerization, the conversion of penicillins into cephalosporins, and the formation of non-fused β -lactam derivatives dominate the interest in the penicillin-cephalosporin field. The synthesis of β -lactam derivatives without the fused thiazolidine ring could well be the beginning of interesting possibilities for the future. The first synthesis of a cyclol *via* an amide-amide interaction and the isolation of a naturally

occurring hydrazino-peptide for the first time were also achieved during the year.

A comprehensive account of the earlier work on the isolation and chemistry of peptide antibiotics has appeared¹ but the review unfortunately contains very few papers published during the past five years. Most of the papers presented² at an antibiotics symposium in Quebec, Canada (May 1971), are very relevant to the subjects covered in this chapter. Recent developments in the biosynthesis³ and synthesis⁴ of peptide antibiotics have been reviewed and the significant contributions to cyclopeptide and cyclodepsipeptide chemistry made by the group led by the late Professor Shemyakin during the last decade have been recorded.⁵ A comprehensive account of the chemistry and biochemistry of the mycobactins has also appeared.⁶

2 Cyclic Peptides

The application of various methods for determining conformation continues to dominate the interest in model cyclic peptides. Recent studies on the theoretical determination of the conformation of cyclic oligopeptides have been briefly discussed⁷ as part of a more general review and the conformation of cyclic oligopeptides containing sarcosine has been discussed in a symposium lecture.⁸ Circular dichroism (c.d.) studies⁹ carried out on a series of cyclo- γ -oligoglutamic acids (1; $n = 2, 3$, or 4; $R = H$ or Bu^t) show that the preferred conformation for the cyclodipeptides ($n = 2$) can be represented by structure (2) with both amide groups *trans*, and with



no indication of intramolecular hydrogen bonds. In the cyclo-tri- and -tetra-peptides there is more flexibility in the ring conformation but some cyclodipeptide character is still present. N.m.r. studies¹⁰ at 220 MHz on *cyclo*-(Pro₃-) and derivatives have confirmed a previously calculated

¹ S. Sengupta, A. B. Banerjee, S. K. Majumder, and S. K. Bose, *J. Sci. Ind. Res., India*, 1970, **29**, 451.

² *Pure Appl. Chem.*, 1971, **28**, No. 4.

³ D. Perlman and M. Bodanszky, *Ann. Rev. Biochem.*, 1971, **40**, 449; E. Katz, Ref. 2, p. 551.

⁴ N. Izumiya, S. Matsuura, and K. Kuromizu, *J. Synthetic Org. Chem., Japan*, 1971, **29**, 1032.

⁵ M. M. Shemyakin, *Pure Appl. Chem.*, 1971, **25**, 211.

⁶ G. A. Snow, *Bacteriol. Rev.*, 1970, **34**, 99.

⁷ H. A. Scheraga, *Chem. Rev.*, 1971, **72**, 195.


⁸ J. Dale, *Pure Appl. Chem.*, 1971, **25**, 469.

⁹ M. Kajtar, M. Hallosi, and G. Snatzke, *Tetrahedron*, 1971, **27**, 5659.

¹⁰ C. M. Deber, D. A. Torchia, and E. R. Blout, *J. Amer. Chem. Soc.*, 1971, **93**, 4893.

Karplus-type analysis in that the conformation due to the planar *cis* peptide bonds requires the nitrogen atom to be out of the plane of the pyrrolidine carbon atoms in each proline residue.

Refinements to the conformations of a series of cyclohexapeptides previously investigated using n.m.r. spectroscopy have been deduced from c.d. studies.¹¹ It has been proposed that the conformation of *cyclo*-(Gly₅-Leu-) is an equilibrium between two forms, one of which is preferred in *cyclo*-(Gly₂-Leu-)₂. In *cyclo*-(Gly₆-Tyr-) and *cyclo*-(Gly₂-Tyr-Gly₂-His)- enhanced amide c.d. has been explained in terms of a coupling between both the tyrosyl and histidiny chromophores and the amide bonds. N.m.r., i.r., and c.d. techniques have been applied in studies on cyclohexapeptides containing all possible combinations of L-alanyl and glycyl residues¹² and to all the diastereomeric cyclohexa-alanyls.¹³ All the cyclohexapeptides revealed two groups of N—H signals: at 7.3—8.0 p.p.m. (two protons) and at 7.9—8.6 p.p.m. (four protons). The former has been assigned to protons involved in intramolecular transannular hydrogen-bonding as shown in (3)



(pleated sheet conformation) but complete randomness in the residues involved in hydrogen-bonding was revealed in the studies. Analysis of the coupling constants supports a structure for *cyclo*-(Gly-Ala₅-) as shown in Figure 1, with pseudo-axial methyl groups in positions 1, 3, 4, and 6. Changes in the polarity of the solvent¹³ do not drastically affect the conformations of cyclohexa-alanils. The solution conformations of *cyclo*-(Pro-Ser-Gly-Pro-Ser-Gly-) and its retro-isomers *cyclo*-(Ser-Pro-Gly-Ser-Pro-Gly-) have been investigated (220 MHz n.m.r.)^{14, 15} and each

¹¹ S. M. Ziegler and C. A. Bush, *Biochemistry*, 1971, **10**, 1330.

¹² S. L. Portnova, V. V. Shilin, T. A. Balashova, J. Biernat, V. F. Bystrov, V. T. Ivanov, Yu. A. Ovchinnikov, *Tetrahedron Letters*, 1971, 3085; *Khim. prirod. Soedinenii*, 1971, 7, 323, 339; V. T. Ivanov, G. A. Kogan, E. A. Meshcheryakova, V. V. Shilin, and Yu. A. Ovchinnikov, *ibid.*, p. 309.

¹⁹ V. T. Ivanov, L. B. Senyavina, E. S. Efremov, V. V. Shilin, and Yu. A. Ovchinnikov, *Khim. prirod. Soedinenii*, 1971, 7, 347; V. T. Ivanov, V. V. Shilin, G. A. Kogan, E. N. Meshcheryakova, L. B. Senyavina, E. S. Efremov, and Yu. A. Ovchinnikov, *Tetrahedron Letters*, 1971, 2841.

¹⁴ D. A. Torchia, A. di Corato, S. C. K. Wong, C. M. Deber, and E. R. Blout, *J. Amer. Chem. Soc.*, 1972, **94**, 609.

¹⁵ D. A. Torchia, S. C. K. Wong, C. M. Deber, and E. R. Blout, *J. Amer. Chem. Soc.*, 1972, **94**, 616.

shows two sets of resonances, indicating that the cyclic peptides rapidly interconvert between two conformations. Both conformations of the former cyclic peptide contain two glycyl-glycyl hydrogen bonds and two *trans* Gly-Pro peptide bonds, whereas in the retro-isomer the hydrogen bonds occur between the two seryl residues but with all peptide bonds *trans*. Changes in solvent affect the relative population of the conformations, *e.g.* in $[^2\text{H}_6]\text{DMSO}$ the major conformation for the retro-isomer contains no intramolecular hydrogen bonds and has both Ser-Pro peptide bonds in the *cis* conformation.





Figure 1

(Reproduced by permission from *Tetrahedron Letters*, 1971, 3085)

A detailed examination¹⁶ of evolidine, *cyclo*-(Ser-Phe-Leu-Pro-Val-Asn-Leu-), again using 220 MHz n.m.r. spectroscopy, favours a conformation represented by (4) for the cycloheptapeptide. The temperature




dependence of the chemical shifts of DMSO solutions shows that the peptide protons of the asparaginyl and phenylalanyl residues are shielded

¹⁶ K. D. Kopple, *Biopolymers*, 1971, 10, 1139.

from the solvent. This case gives a timely note of warning against complete reliance on evidence from slow deuterium-exchange rates as a means of identifying internal hydrogen bonds, since only small changes in conformation would be required to make internal bonds exchange with solvent. In contrast to the cyclic peptides just described, a detailed study¹⁷ of the all-L-cyclolinopeptide A, *cyclo*-(Leu-Ile-Ile-Leu-Val-Pro-Pro-Phe-Phe-), suggests that although four types of conformation are probable in solution (DMSO) none appears to possess intramolecular hydrogen-bonding, although two types of protons (five exposed and two internal) are implied from exchange reactions. The deductions for the cyclolinopeptide therefore appear to be in complete contrast to one of the proposals made for the conformation of antamanide (see later), a closely related case.

A pulse radiolysis study of cyclic peptides in solution has been reported.¹⁸

A. 2,5-Dioxopiperazines.—As in the case of the larger cyclic peptides, conformational aspects amount to an important part of the year's output of papers on dioxopiperazines. N.m.r. studies¹⁹ have shown that the dioxopiperazine ring in *cyclo*-(Ala-Gly-) and *cyclo*-(Aib*-Gly-) is planar but that *cyclo*-(Pro-Gly-) exists as a boat conformation (5) which reverts to a planar ring system (6) in trifluoroacetic or deuteriotrifluoroacetic acids. In *cyclo*-(L-Pro-L-Pro-) the dioxopiperazine ring again reverts to the stable boat conformation as in (5) but in *cyclo*-(L-Pro-D-Pro-) the stable conformation is similar to (6). These deductions are also borne out in an *X*-ray



study²⁰ of *cyclo*-(L-Pro-L-Leu-) which shows that the molecule has a folded conformation with a dihedral angle of 143° between the two planar peptide units, with the leucyl side-chain fully extended. In this molecule the C^β-atom of the proline ring is out of the plane of the other four.

Calculation of optimum conformations together with ¹H n.m.r. and o.r.d. data favour²¹ a non-planar conformation for *cyclo*-(L-Val-L-Val-) and a planar ring for the LD isomer.

¹⁷ F. Naider, E. Benedetti, and M. Goodman, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 1195; A. I. Brewster and F. A. Bovey, *ibid.*, p. 1199; A. E. Tonelli, *ibid.*, p. 1203.

¹⁸ E. Hayon and M. Simic, *J. Amer. Chem. Soc.*, 1971, **93**, 6781.




¹⁹ I. Z. Siemion, *Annalen*, 1971, **748**, 88.

²⁰ I. L. Karle, *J. Amer. Chem. Soc.*, 1972, **94**, 81.

²¹ E. M. Popov, V. Z. Portnova, V. Z. Pletnev, V. T. Ivanov, P. V. Kostetskii, and Yu. A. Ovchinnikov, *Zhur. obshchei Khim.*, 1971, **41**, 420.

* Aib = α-aminoisobutyric acid.

Previously reported n.m.r. studies on *cyclo*-(Gly-L-Tyr-) have been substantiated in a single-crystal X-ray study,²² which shows that there is some buckling of the ring system towards a boat conformation with the aromatic ring above the dioxopiperazine ring as in (7). Quantum-mechanical calculations²³ support these results and also predict that the dioxopiperazine ring containing the side-chain methyl groups of valine would have the valine methyls stacked over the ring system. This stacking of side-chains above the ring is also favoured in the results obtained from a 220 MHz n.m.r. study²⁴ of *cyclo*-(L-His-L-Ser) (8) and *cyclo*-(L-Asp-L-His-) (9). *Cyclo*-(L-His-L-His) resembles²⁴ the cyclic anhydride of tyro-



sine, suggesting that the imidazole rings are sharing the space over the dioxopiperazine ring. Minimum energy conformations derived from consistent force-field calculations²⁵ show that *cyclo*-(Gly-Gly-) and *cyclo*-(Ala-Ala-) have flexible structures with shallow non-planar conformations in the free state which average out to appear as planar except at low temperatures.

The occurrence of the epidithiadioxopiperazine ring system in the antibiotics gliotoxin, sporidesmin, aranotin, chaetocin, and, more recently, in verticillin A (see below) has initiated a number of approaches to the synthesis of this novel ring system. The direct introduction of the sulphur functions into the dioxopiperazine ring can be achieved²⁶ using a nucleophilic substitution reaction as outlined in Scheme 1. The reaction of 3,6-diethoxycarbonyl-2,5-dioxopiperazine with sulphur chloride S_2Cl_2 and


²² L. E. Webb and C.-F. Lin, *J. Amer. Chem. Soc.*, 1971, **93**, 3818.

²³ J. Cailliet, B. Pullman, and B. Maigret, *Biopolymers*, 1971, **10**, 221.

²⁴ Z. Kopple, K. D. Kopple, and C. A. Bush, *Tetrahedron Letters*, 1972, 483.

²⁵ S. Karplus and S. Lifson, *Biopolymers*, 1971, **10**, 1973.


²⁶ H. Poisel and U. Schmidt, *Angew. Chem. Internat. Edn.*, 1971, **10**, 130; *Chem. Ber.*, 1971, **104**, 1714.



Conditions: i, MeOH-MeS⁻ giving compound R = Me; ii, aqueous KI₃ starting from thiol R = H

Scheme 1

sodium hydride yields²⁷ a mixture of polysulphides (10; $n = 1, 2, 3$, or 4) but triphenylphosphine converts the tetrasulphide into the tri- and disulphides. This latter reagent has also been used²⁸ on compound (11; $n = 2$) and converts it into the monosulphide (11; $n = 1$). Degradative and spectroscopic evidence²⁹ on verticillin A is in agreement with structure (12) for this antibiotic, isolated from a *Verticillium* species. It is therefore similar to gliotoxin (13) and sporidesmin and is isomeric with chaetocin,



whose structure was recently determined by X-ray crystallography.³⁰ ¹⁴C-Labeling studies³¹ indicate that [3-¹⁴C]phenylalanine is a more efficient precursor of gliotoxin (13) than is *m*-[2-¹⁴C]tyrosine.

²⁷ T. Hino and T. Sato, *Tetrahedron Letters*, 1971, 3127.





²⁸ S. Safe and A. Taylor, *J. Chem. Soc. (C)*, 1971, 1189.

²⁹ H. Minato, M. Matsumoto, and T. Katayama, *Chem. Comm.*, 1971, 44.

³⁰ D. Hauser, H. P. Weber, and H. D. Sigg, *Helv. Chim. Acta*, 1970, 53, 1061.

³¹ D. R. Brannon, J. A. Mabe, B. B. Molloy, and W. A. Day, *Biochem. Biophys. Res. Comm.*, 1971, 43, 588.

Austamide, a toxic metabolite from *Aspergillus ustus*, has been shown³² to have the structure (14), and a minor component also extracted has been identified as (15) which is identical with the previously reported³³ deoxybrevianamide E. Ozonolysis and hydrolysis of echinulin (16) give L-aspartic acid, thus confirming that the echunin moiety in the molecule must have the L-configuration.³⁴ *cyclo*-L-Cystine (17) has been synthesized³⁵ for the first time by converting suitably protected *S*-acetamidomethyl-cysteine peptides into cystine by reaction with iodine.



Cyclization of the appropriate cystine dipeptide ester followed by the reduction of the disulphide links with mercaptoethanol has yielded³⁶ *cyclo*-(Cys-Ser-), *cyclo*-(Cys-Asp-), and *cyclo*-(Cys-Trp-). Kinetic studies using *p*-nitrophenyl acetate indicate that the thiol groups of the cysteines in these systems have a greater nucleophilic reactivity than is expected on the basis of pK_{S-H} values. An investigation of the kinetics of hydrolysis of a series of dioxopiperazine derivatives, (18)—(20), has been reported.³⁷ In hydrochloric acid solution at pH 1—2 the cycloserine dimer (18) rapidly establishes an equilibrium with cycloserine monomer.

³² P. S. Steyn, *Tetrahedron Letters*, 1971, 3331.


³³ A. J. Birch and J. J. Wright, *Tetrahedron*, 1970, **26**, 2329.

³⁴ R. Nakashima and G. P. Slater, *Tetrahedron Letters*, 1971, 2649.

³⁵ B. Kamber, *Helv. Chim. Acta*, 1971, **54**, 927.





³⁶ V. Rossbach, F. Schneider, and H. Wenck, *Z. Naturforsch.*, 1971, **26b**, 1144.

³⁷ C. H. Stammer and F. O. Lassen, *J. Org. Chem.*, 1971, **36**, 2631.

(18) R = CH₂OH(19) R = CH₂·ONH₂

(20) R = Me

Two rather unconventional and specialized methods for preparing dioxopiperazines have been reported. The triazine intermediate (21) rearranges³⁸ at temperatures above 20 °C to give a dioxopiperazine acetal which can be hydrolysed to (22). An ethanolic solution of (23), on saturation with dry ammonia, gives³⁹ the dioxopiperazine (24). In a more conventional manner, albeit an unlikely pathway, the dioxopiperazine (25) has been formed⁴⁰ by treating the *p*-nitrophenyl ester of benzyloxycarbonylglycylproline with sodium bicarbonate or sodium carbonate solution.




Various mechanisms have been proposed⁴¹ for the fragmentation of 3,6-dibenzyl-2,5-dioxopiperazines in the mass spectrometer and new polymers have been reported⁴² to be formed in the polymerization of 3,6-bifunctional-2,5-dioxopiperazines.

B. Gramicidins.—Interest continues in the conformation of gramicidin S with all the methods up to date confirming the well-established Hodgkin-Oughton-Schwyster model (Vol. 3, p. 282). Thus calculations⁴³ based on

³⁸ G. J. Kovacs and I. G. Csizmadia, *Tetrahedron Letters*, 1971, 2599.³⁹ C. Shin, M. Fujii, and J. Yoshimura, *Tetrahedron Letters*, 1971, 2499.⁴⁰ G. Lucente, G. Fiorentini, and D. Rossi, *Gazzetta*, 1971, 101, 109.⁴¹ K. Jankowski and L. Varfalvy, *Canad. J. Chem.*, 1971, 49, 1583.⁴² U. Haberthuer and H. G. Elias, *Makromol. Chem.*, 1971, 144, 183, 193, 213; V. Crescenzi, A. Ciana, V. Giancotti, E. Russo, L. Salvestrini, and L. Ciceri, *ibid.*, 1971, 141, 199.⁴³ P. De-Santis and A. M. Liquori, *Biopolymers*, 1971, 10, 699.

available experimental evidence and computed c.d. properties⁴⁴ are again in agreement with a conformation containing four hydrogen bonds and a dyad axis relating the chemically equivalent halves of the molecule. Analogues of gramicidin S, namely [Cys^{2,2'}]gramicidin S (26) and [(S-acetamidomethyl-Cys)^{2,2'}] gramicidin S have been used to study⁴⁵ the chirality of the cystine disulphide group. The shielding of the valine peptide protons in (26) (from 7.20 to 7.00 p.p.m.) has been interpreted as



(26)

support for the *P*-helical chirality for the sulphur bridge. Attempts to correlate conformation with biological activity in gramicidin S analogues have also been reported.⁴⁶ A detailed o.r.d. study⁴⁷ of the copper complexes of gramicidin S establishes that the δ -amino-groups of the ornithine residues participate in complex formation.

Very impressive results with high yields (48—57% overall) of biologically active material have been reported⁴⁸ in the solid-phase synthesis of gramicidin S using the azide method (85% yield) for cyclization between leucyl and D-phenylalanyl residues. Quantitative detachment of the linear protected decapeptide from the polymer was achieved by hydrazinolysis. [D-Ala^{4,4'}]Gramicidin S and [D-Ala⁴]cyclosemi-gramicidin S have been synthesized,⁴⁹ but only the former showed antibacterial activity, similar to that of gramicidin S. Thus the D-phenylalanine residues can be replaced without loss of activity. Linear decapeptide analogues with gramicidin S sequences and with a series of N- and C-terminal derivative groups have been synthesized.⁵⁰ Although o.r.d. measurements suggest that these linear peptides adopt certain conformational characteristics, their antibacterial activity does not match that of gramicidin S.

The elongation and cyclization of enzyme thioester-bound intermediates, recently proposed⁵¹ as a mechanism for the biosynthesis of gramicidin S, included a hypothetical termination reaction involving an antiparallel doubling reaction between two carboxy-activated pentapeptide units. An

⁴⁴ P. M. Bayley, *Biochem. J.*, 1971, **125**, 90P.

⁴⁵ U. Ludescher and R. Schwyzer, *Helv. Chim. Acta*, 1971, **54**, 1637.

⁴⁶ T. Kato, M. Waki, S. Matsuura, and N. Izumiya, *J. Biochem. (Japan)*, 1970, **68**, 751.

⁴⁷ N. A. Poddubnaya and N. Y. Krasnobrizhii, *Zhur. obshchei Khim.*, 1971, **41**, 46.

⁴⁸ M. Ohno, K. Kuromizu, H. Ogawa, and N. Izumiya, *J. Amer. Chem. Soc.*, 1971, **93**, 5251.

⁴⁹ S. Lee, R. Ohkawa, and N. Izumiya, *Bull. Chem. Soc. Japan*, 1971, **44**, 158.

⁵⁰ S. Makisumi, M. Waki, and N. Izumiya, *Bull. Chem. Soc. Japan*, 1971, **44**, 143; S. Makisumi, S. Matsuura, M. Waki, and N. Izumiya, *ibid.*, h. 210.

⁵¹ W. Gevers, H. Kleinkauf, and F. Lipmann, *Proc. Nat. Acad. Sci. U.S.A.*, 1969, **63**, 1335; R. Roskoski, G. Ryan, H. Kleinkauf, W. Gevers, and F. Lipmann, *Arch. Biochem. Biophys.*, 1971, **143**, 485.

alternative mechanism now proposed⁵² suggests that the two pentapeptide chains attached to the same enzyme cyclize *via* an intra- rather than an inter-molecular reaction. ¹⁴C-Labeling studies⁵³ have confirmed the role of pantotheine as a transmitter of the growing peptide chain to thioester-linked amino-acids in both gramicidin S and tyrocidin biosynthesis, as summarized in Figure 2. A close link is therefore established between the biosynthesis of these compounds and Lynen's theory for fatty-acid biosynthesis.




Figure 2 A schematic representation of transpeptidation and transthioleation (Reproduced by permission from *Science*, 1971, 173, 875)

Studies on the interaction of gramicidin S (and polymyxin B) with membranes,⁵⁴ and on the production of gramicidin S in batch and continuous culture,⁵⁵ have been reported.

A series of helical structures have been proposed⁵⁶ for gramicidin A (27), which has alternating D and L residues. Because of the alternating directions of the carbonyl groups, head-to-head hydrogen-bonded dimers can be formed with the capacity to function as transmembrane channels.

⁵² E. Stoll, O. Froyshov, H. Holm, T. L. Zimmer, and S. G. Laland, *F.E.B.S. Letters*, 1970, 11, 348.

⁵³ H. Kleinkauf, R. Roskoski, and F. Lipmann, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, 68, 2069; F. Lipmann, *Science*, 1971, 173, 875.

⁵⁴ W. Pache, D. Chapman, and R. Hillaby, *Biochim. Biophys. Acta*, 1972, 255, 358.

⁵⁵ H. W. Blanch and P. L. Rogers, *Biotechnol. and Bioeng.*, 1971, 13, 843.

⁵⁶ D. W. Urry, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, 68, 672; D. W. Urry, M. C. Goodall, J. D. Glickson, and D. F. Mayers, *ibid.*, p. 1908.

in solution. Tonelli *et al.*,⁶² using 220 MHz n.m.r., c.d., and a theoretical treatment, claim that the conformation of antamanide is not stabilized by intramolecular hydrogen-bonding and that it possesses considerable symmetry, with a polar face (carbonyl groups capable of complexing with metal cations) on one side of the plane of the ring and a non-polar face on the other. Ivanov *et al.*⁶³ using 100 MHz n.m.r. with i.r. and o.r.d. data, have deduced that all N—H bonds participate in intramolecular hydrogen-bonding, and an n.m.r. examination of the Na⁺ complex of antamanide⁶³ implies that the 'bracelet' form, similar to that of valinomycin complexes, is present in solution. Obviously more work is needed, and the answer may lie with X-ray crystallography; already a report on the crystallization and preliminary crystal data has been published.⁶⁴

A number of antamanide analogues have been synthesized, in order to discover which residues are required for antibiotic activity against phalloidin (details of the cyclization step in each case are summarized in Table 1). Studies⁶⁵ on ten analogues possessing structural variants at positions 1 and 4 have shown that there is a requirement for amino-acids containing lipophilic side-chains in these positions, in order to retain antitoxic properties. Only [L-Abu⁴]antamanide in a series⁶⁶ of synthetic α -amino-butyric acid-containing analogues shows activity comparable to that of antamanide. *p*-Azidophenylalanine, tyrosine, *O*-methyltyrosine, and *O*-benzyltyrosine have in turn been incorporated^{67, 68} into position 6 of antamanide. The first three analogues showed antitoxic activity but the *O*-benzyl analogue was ineffective. Antitoxic properties are also characteristic of [Phe⁴, Val⁶]antamanide, which is an interesting analogue since it possesses *C*₂ symmetry.⁶⁹ Most of the linear precursors of the cyclic decapeptides discussed above were synthesized using the automated solid-phase method. A new reactor for such a synthesis has also been tested in the synthesis of antamanide.⁷⁰ Other syntheses of antamanide, retro-antamanide, and perhydroantamanide have also been reported,⁷¹ but details were not available in time for this review.

A synthesis of norphalloin (29) has been reported⁷² and it involves two cyclization steps. The first cyclization at position A, using the anhydride

⁶² A. E. Tonelli, D. J. Patel, M. Goodman, F. Naider, H. Faulstich, and Th. Wieland, *Biochemistry*, 1971, **10**, 3211.

⁶³ V. T. Ivanov, A. I. Miroshnikov, N. D. Abdullaev, L. B. Senyavina, S. E. Arkhipova, N. N. Uvarova, K. K. Khaliluna, V. F. Bystrov, and Yu. A. Ovchinnikov, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 654.

⁶⁴ W. Littke, *Tetrahedron Letters*, 1971, 4247.

⁶⁵ Th. Wieland, L. Lapatsanis, J. Faesel, and W. Konz, *Annalen*, 1971, **747**, 194.

⁶⁶ Th. Wieland, C. Birr, and A. von Dungen, *Annalen*, 1971, **747**, 207.

⁶⁷ Th. Wieland, A. von Dungen, and C. Birr, *Annalen*, 1971, **752**, 109.


⁶⁸ Th. Wieland and C. Rietzel, *Annalen*, 1971, **754**, 107.

⁶⁹ Th. Wieland, A. von Dungen, and C. Birr, *F.E.B.S. Letters*, 1971, **14**, 299.

⁷⁰ C. Birr and W. Lochinger, *Synthesis*, 1971, 319.


⁷¹ Yu. A. Ovchinnikov, V. T. Ivanov, A. I. Miroshnikov, K. K. Khaliluna, and N. N. Uvarova, *Khim. prirod. Soedinenii*, 1971, **7**, 469.

⁷² Th. Wieland, H. Faulstich, and F. Fahrenholz, *Annalen*, 1971, **743**, 77, 83.



method, yielded only 5% of the monocyclic compound, but using the same method for position B cyclization occurred in 25% yield.

F. Viomycin, Capreomycin, and Tuberactinomycin.—Differences of opinion still exist concerning the structure of viomycin. In one study⁷³ the structure (30) has been put forward for viomycin and a related structure (31)⁷⁴ for



(30) $R = R^1 = R^2 = OH$

(31) $R = R^1 = R^2 = NH_2$


(33) $R = H, R^1 = R^2 = OH$, but with sequence of residues-YYZX instead of XYZ shown in diagram

capreomycin IB. The structure of the chromophore in both cases has been proposed on the evidence that mild hydrolysis yields urea and a desurea derivative. Each desurea derivative re-formed the antibiotics in the presence of excess urea and dilute acid, thus giving strong support for the dehydroserine ureide unit as representing the chromophore. However, these deductions have been disputed⁷⁵ and another structure (32) for the

⁷³ B. W. Bycroft, D. Cameron, L. R. Croft, A. Hassanali-Walji, A. W. Johnson, and T. Webb, *Experientia*, 1971, **27**, 501.

⁷⁴ B. W. Bycroft, D. Cameron, L. R. Croft, A. Hassanali-Walji, A. W. Johnson, and T. Webb, *Nature*, 1971, **231**, 301.

⁷⁵ L. Lechowski, *Roczniki Chem.*, 1971, **45**, 581.




(32)

chromophore has been proposed. Nevertheless, *X*-ray data⁷⁶ on another related antibiotic, tuberactinomycin from *Streptomyces griseovorticillatus* var. *tuberacticus*, which also produces viomycin, confirm the dehydroserine ureide moiety for viomycin but lend support⁷⁶ to a totally different sequence for viomycin. The structure based on the *X*-ray results is represented by (33) for tuberactinomycin O, and from *X*-ray data viomycin appears to have a similar sequence.

Hydrogenated derivatives of viomycin and capreomycin have been reported⁷⁷ to have 30% and 43% respectively of the activity of the parent antibiotics. Detailed spectroscopic and degradative evidence⁷⁸ has been published for the structure of viomycin, an artefact found in viomycin hydrolysates. Capreomycin, a hydrogenation product of viomycin, and an epimer have been synthesized,⁷⁹ and the configuration of *cis*-3-guanidinoproline, the other hydrogenation product of viomycin, has been determined.⁸⁰

G. Nisin.—Information obtained from cyanogen bromide cleavage, and from enzymic and Edman degradation, supports⁸¹ the structure (34) for nisin. The structure, which contains a number of lanthionine residues, is



$\Delta\beta\text{MeAla}$ = β -methyl-dehydroalanine

ΔAla = dehydroalanine

Abu = α -aminobutyric acid

(34)

⁷⁶ H. Yoshioka, T. Aoki, H. Goko, K. Nakatsu, T. Noda, H. Sakakibara, T. Take, A. Nagata, J. Abe, T. Wakamiya, T. Shiba, and T. Kaneko, *Tetrahedron Letters*, 1971, 2043.

⁷⁷ J. R. Dyer, J. H. Carter, and P. J. van Wyk, *J. Medicin. Chem.*, 1971, **14**, 1120.


⁷⁸ G. Buchi and J. A. Raleigh, *J. Org. Chem.*, 1971, **36**, 873.

⁷⁹ B. W. Bycroft, D. Cameron, and A. W. Johnson, *J. Chem. Soc. (C)*, 1971, 3040.

⁸⁰ C. Gallina, C. Marta, C. Colombo, and A. Romeo, *Tetrahedron*, 1971, **27**, 4681.


⁸¹ E. Gross and J. L. Morell, *J. Amer. Chem. Soc.*, 1971, **93**, 4634.

the first discovered example of a pentacyclic heterodetic type peptide containing sulphur linkages. It is also interesting to note the presence of a number of $\alpha\beta$ -unsaturated amino-acids which could well be biosynthetically important. In contrast to many microbial peptides, nisin is probably biosynthesized *via* a ribosomal mechanism, since lanthionine peptide synthesis can be inhibited⁸² by chloroamphenicol, chlorotetracycline, and puromycin. Results using [¹⁴C]cysteine show⁸² that in addition to serine and threonine, cysteine also takes part in the biosynthesis of lanthionine as depicted in Scheme 2. Mass spectral properties of lanthionine



Scheme 2

derivatives have been reported⁸³ together with a novel synthesis of L-lanthionine (36) by selective desulphurization of a cystine derivative (35).



H. Other Cyclic Peptides.—Tentoxin, a metabolite of *Alternaria tenuis* Auct., has been tentatively shown⁸⁴ to have the structure (37) although the sequence and configuration is not completely defined. The results⁸⁵ from hypobromite oxidation, hydrazinolysis, and reduction support the structure (38) for mycobacillin, a peptide antibiotic isolated from cultures of *Bacillus subtilis* B₃. The solid-phase technique has been used extensively for the synthesis of linear protected lysine analogues of the cyclopeptide part of the polymyxins D,⁸⁶ M,⁸⁷ and E.⁸⁸

⁸² L. Ingram, *Biochim. Biophys. Acta*, 1970, **224**, 263.

⁸³ D. N. Harpp and J. G. Gleason, *J. Org. Chem.*, 1971, **36**, 73.



⁸⁴ W. L. Meyer, G. E. Templeton, C. I. Grable, C. W. Sigel, R. Jones, S. H. Woodhead, and C. Sauer, *Tetrahedron Letters*, 1971, 2357.

⁸⁵ S. Sengupta, A. B. Banerjee, and S. K. Bose, *Biochem. J.*, 1971, **121**, 839.

⁸⁶ M. A. Zevail and E. A. Morozova, *Vestnik. Moskov. Univ.*, 1971, **12**, 246.

⁸⁷ E. A. Morozova, M. A. Zevail, and G. F. Zhukova, *Zhur. obshchei Khim.*, 1970, **40**, 1376; E. A. Morozova and M. A. Zevail, *ibid.*, p. 1379.

⁸⁸ M. A. Zevail and E. A. Morozova, *Zhur. obshchei Khim.*, 1970, **40**, 2760.



I. Synthesis of Homodetic Cyclic Peptides.—Tables 1 and 2 summarize the details of the yields of cyclic peptides synthesized in 1971. It can be seen that the active ester and the dicyclohexylcarbodi-imide-hydroxysuccinimide methods for cyclization lead the list in popularity. However, the most impressive yield at the cyclization stage was achieved⁴⁸ by the azide

Table 1 *Syntheses of cyclic peptides achieved in 1971*
(Methods listed start from linear analogues unless otherwise stated)

Method for cyclization	Peptide	Bond formed in cyclization step	Yield (%)	Ref.
(i) <i>p</i> -nitrophenyl ester method				
	<i>cyclo</i> -(Pro ₃ -) and analogues	Pro-Pro	12	10
	<i>cyclo</i> -(Pro-Ser-Gly) ₂	Gly-Pro	16	14
	<i>cyclo</i> -(Ser-Pro-Gly) ₂	Gly-Ser ^a	4	15
	[Cys(Acm) ^{3,7}]-gramicidin S ^b	Pro-Val	?	45
	[D-Ala ^{4,4'}]-gramicidin S	Pro-Val	20	49
	<i>cyclo</i> -(Gly ₂ -L-Tyr) ₂	Gly-Tyr ^a	9	90
(ii) <i>DCCI-N</i> -hydroxysuccinimide				
	[Val ¹ , Ala ⁴]-antamanide	Phe-Phe	31	65
	[Ile ¹ , Val ⁴]-antamanide	Phe-Phe	48	65
	[Leu ¹ , Ala ⁴]-antamanide	Phe-Phe	46	65
	[Gly ¹ , Ala ⁴]-antamanide	Phe-Phe	49	65
	[Ala ¹ , Ala ⁴]-antamanide	Phe-Phe	45	65
	[Ala ¹ , Gly ⁴]-antamanide	Phe-Phe	49	65
	[Gly ¹ , Gly ⁴]-antamanide	Phe-Phe	47	65
	[Abu ¹]-antamanide	Phe-Phe	26	66
	[Abu ⁴]-antamanide	Phe-Phe	16	66
	[Abu ^{1,4}]-antamanide	Phe-Phe	8	66
	[Phe(<i>p</i> N ₃) ⁶]-antamanide	Pro-Ala	14	67
	[Tyr ⁶]-antamanide	Phe-Tyr	33	68
(iii) <i>Azide method</i>				
	[Orn(Z(OMe)) ^{2,2'}]-gramicidin S	Leu-Phe	85	48
	<i>cyclo</i> -(Gly ₂ -L-Tyr) ₂	Gly-Tyr ^a	6	90
	<i>cyclo</i> -(Gly ₂ -L-Tyr) ₂	Gly-Gly ^a	17	90
	<i>cyclo</i> -(Gly ₂ -L-Tyr) ₂	Tyr-Gly ^a	15	90
	<i>cyclo</i> -(Gly ₂ -L-Tyr) ₂	Tyr-Gly	20	90
	<i>cyclo</i> -(Gly ₂ -Phe) ₂	Phe-Gly ^a	25	90
	<i>cyclo</i> -(Gly-Cys(Bzl)-L-Leu) ₂	Leu-Gly	26	92
	<i>cyclo</i> -(Gly-Cys(Bzl)-L-Leu) ₂	Leu-Gly ^a	20	92
	<i>cyclo</i> -(Gly-Cys(Bzl)-D-Leu) ₂	Leu-Gly	43	92
	<i>cyclo</i> -(Gly-Cys(Bzl)-D-Leu) ₂	Leu-Gly ^a	16	92

Table 1 (cont.)


Method for cyclization	Peptide	Bond formed in cyclization step	Yield (%)	Ref.
(iv) <i>Mixed anhydride method</i>				
	[Ala ¹ , Val ⁴]-antamanide	Phe-Phe	20	65
	[Val ¹ , Phe ⁴]-antamanide	Phe-Phe	21	65
	[Phe ¹ , Phe ⁴]-antamanide	Phe-Phe	30	65
	[Val ¹ , Gly ⁴]-antamanide	Gly-Phe	20	65
	norphalloin (29) 1st stage	α Hyp-Cys	5	72
	2nd stage	Nva-Ala	27	72
(v) <i>Tcp ester method</i>				
	(see Table 2)			89
(vi) <i>o</i> -Phenylene chlorophosphite/imidazole				
	cyclopeptide (40)	Gly- β -Ala	40	91
	cyclopeptide (41)	Gly- β -Ala	60	91

^a By cyclodimerization of the corresponding monomeric sequences.^b Acn = acetamidomethyl.**Table 2** Cyclization of linear sarcosine tetrapeptides (pyridine at 115 °C)

1	2	3	4	% Yield of cyclic tetrapeptide	Cyclic dipeptide (% yield)
Sar—Sar—Sar—Sar-OTcp				43	—
Gly—Sar—Sar—Sar-OTcp				25	—
Sar—Gly—Sar—Gly-OTcp				40	—
Sar—Gly—Gly—Sar-OTcp				10	—
Sar—Sar—Gly—Gly-OTcp				—	{ <i>cyclo</i> -(Sar ₂ -) 25%
Gly—Sar—Sar—Gly-OTcp				—	{ <i>cyclo</i> -(Gly ₂ -) 10%
L-Ala—Sar—Sar—Sar-OTcp				25	—
Sar-D-Ala—Sar-L-Ala-OTcp				30	—
Sar-L-Ala-L-Ala—Sar-OTcp				10	—
Sar—Sar-L-Ala-L-Ala-OTcp				—	{ <i>cyclo</i> -(Sar ₂ -) 30%
					{ <i>cyclo</i> -(L-Ala ₂ -) 13%


method in the synthesis of a derivative of gramicidin S. Table 2 shows that several closely related linear tetrapeptides containing sarcosine do not cyclize under the same conditions but split⁸⁹ into cyclic dipeptides. Cyclic dipeptides are formed more readily if the amide bond joining residues 1 and 2 is of the *cis*-allowed type (obtained readily in sarcosine) whereas the 3 \rightarrow 4 amide group is of the *trans*-preferred type. Diagrammatically this is visualized as in structure (39) where the free amino end appears to be unable to reach the activated ester group. It has been suggested that a good yield of cyclic tetrapeptide is obtained whenever the linear peptide chain has a high probability of folding the same way as *cis,trans,cis,trans* sequence in the cyclic tetrapeptides.

⁸⁹ K. Titlestad, *Chem. Comm.*, 1971, 1527.



(39)

Studies⁹⁰ on the synthesis of *cyclo*-(Gly₂-L-Tyr-Gly₂-L-Tyr-) reveal that using the azide method the yields varied depending upon the position of the tyrosyl residue in the tripeptide precursor when a cyclodimerization method was used. Thus Tyr-Gly-Gly-N₃, Gly-Tyr-Gly-N₃, and Gly-Gly-Tyr-N₃ cyclodimerized in 6, 17, and 15% yield respectively. The best yield (20%) was obtained by the cyclization of the linear hexapeptide Gly₂-Tyr-Gly₂-Tyr-N₃ using the azide method. Treatment of the cyclic hexapeptide with chymotrypsin showed that the cyclic peptide was hydrolysed to Gly-Gly-Tyr after 6 h presumably *via* the linear hexapeptide analogue.

(40) X = H, Y = NH₂(41) X = CO₂Me, Y = H

Very good yields of the model cyclic tetrapeptides (40) and (41) have been obtained⁹¹ from the corresponding linear analogues using *o*-phenylenechlorophosphite-imidazole. Two analogous cyclohexapeptides, *cyclo*-[Gly-Cys(Bzl)-L-Leu-Gly-Cys(Bzl)-L-Leu-] and *cyclo*-[Gly-Cys(Bzl)-D-Leu-Gly-Cys(Bzl)-D-Leu-] have been prepared⁹² in 26% and 43% yield respectively from the *t*-butoxycarbonylhydrazide of the linear hexapeptide. The hydrazide without the *t*-butoxycarbonyl group attached gave a higher yield (55%) for the all-L compound, but lower yields were obtained when attempts were made to cyclodimerize from the corresponding tripeptides. Comparison of the c.d. spectrum of the all-L *S*-benzylcysteine peptide with that of an L-phenylalanine analogue showed that⁹² the peptide backbones must have similar conformations. However, the comparison does not hold for the *cyclo*-[Gly-Cys(Bzl)-D-Leu-Gly-Cys(Bzl)-D-Leu-], which may be explained by the fact that the phenyl ring of the *S*-benzyl group is further away than the phenylalanine ring from the peptide backbone thus giving no phenyl-amide interaction.

⁹⁰ M. Konishi, N. Yoshida, and N. Izumiya, *Bull. Chem. Soc. Japan*, 1971, **44**, 2801.⁹¹ C. H. Hassall, D. G. Sanger, and B. K. Handa, *J. Chem. Soc. (C)*, 1971, 2814.⁹² K. Bláha, I. Frič, Z. Bezpalova, and O. Kaurov, *Coll. Czech. Chem. Comm.*, 1970, **35**, 3557.

Until this year, strict adherence to the title of this chapter has kept oxytocin analogues with their disulphide links outside the bounds of the chapter. However, synthetic studies⁹³ on analogues of deamino-oxytocin with ring systems not containing a disulphide bond have provided the necessary conditions for coverage in the present context. Thus *cyclo*-[Tyr-Ile-Gln-Asn-Cys(CH₂·CH₂·CO)]-Pro-Leu-Gly-NH₂ with the cystine disulphide bridge replaced by a —CH₂—S— bridge and the methylene analogue *cyclo*-[Tyr-Ile-Gln-Asn-Apim*]-Pro-Leu-Gly-NH₂ were obtained in up to 60% yield by cyclization at the tyrosyl-cysteinyl bond (or analogue) using the *p*-nitrophenyl ester method or pyridine in DMF.

3 Dipeptides (Heterodetic Peptides)

A. Actinomycins.—Actinomycins C₁(D) selectively deuteriated in both the α - or β -peptide lactone rings and in the chromophore have been synthesized⁹⁴ and used to good effect in the assignment⁹⁵ of chemical shifts in the n.m.r. spectra of actinomycin C₁(D) and closely related analogues. Details of the conformation of the single pentapeptide lactone unit derived from this study (Vol. 3, p. 294) have been questioned⁹⁶ mainly in connection with the fact that the *N*-methyl group of sarcosine appears to be too near the proline ring. Apart from this detail there is good agreement between this conformation and that obtained from theoretical calculations⁹⁶ based on experimental data. This model has also been supported by X-ray crystallographic data⁹⁷ on a complex formed between 7-bromoactinomycin C₁(D) and deoxyguanosine which confirms the two-fold symmetry of the actinomycin molecule as shown in Figure 3. A strong hydrogen bond exists between neighbouring cyclic pentapeptide chains connecting the N—H bond of one D-valine residue with the carbonyl groups of the other D-valine. It has also been shown that hydrogen bonds play an important role in the association between the actinomycin and the guanine residues and the 1 : 2 stoichiometry of the complex is a direct consequence of the two-fold symmetry of the actinomycin. This appears to be a very interesting model for further work on actinomycin–DNA binding characteristics.

Pseudoactinomycin C₁ (42)⁹⁸ and a series of actinomycin derivatives⁹⁹ (43; R = H, OMe, Et, or Bu^t) have been synthesized. Yields of up to 30% in the cyclization step to form the lactone rings were achieved using *N*-acetylimidazole–acetyl chloride. In the derivatives (43) antibiotic activity was highest for R = H, but all substituents decreased the activity,

⁹³ K. Jost, *Coll. Czech. Chem. Comm.*, 1971, **36**, 218; K. Jost and F. Sorm, *ibid.*, p. 2795.

⁹⁴ H. Lackner, *Chem. Ber.*, 1971, **104**, 3653.

⁹⁵ H. Lackner, *Tetrahedron Letters*, 1971, 2221.

⁹⁶ P. De Santis, R. Rizzo, and G. Ughetto, *Tetrahedron Letters*, 1971, 4309.

⁹⁷ H. M. Sobell, S. C. Jain, T. D. Sakore, and C. E. Nordman, *Nature (New Biol.)*, 1971, **231**, 200.

⁹⁸ H. Brockmann and E. Schulze, *Tetrahedron Letters*, 1971, 1489.

⁹⁹ H. Brockmann and F. Seela, *Chem. Ber.*, 1971, **104**, 2751.

* Apim = α -aminopimelic acid.










Figure 3 Illustration of actinomycin–deoxyguanosine complex. An additional weak hydrogen bond (not shown) connects the guanine N(3) ring nitrogen with the N–H group in L-threonine residues

[Reproduced by permission from *Nature (New Biol.)*, 1971, 231, 200]

the extreme case being the 4,6-di-*t*-butyl compound with no activity. Model compounds (44),¹⁰⁰ (45), and (46),¹⁰¹ based on the phenoxazone chromophore of actinomycin, have been synthesized in order to study actinomycin–DNA interactions. Attempts to link (47; R = Cl) to the protected penta-depsipeptide (48) have been complicated by the formation of oligomers,


¹⁰⁰ M. T. Wu and R. E. Lyle, *J. Heterocyclic Chem.*, 1971, 8, 989.

¹⁰¹ F. Seela, *Z. Naturforsch.*, 1971, 26b, 875.



but an improved yield of the monomer can be obtained¹⁰² using the symmetrical anhydride generated by reaction with dicyclohexylcarbodiimide.

A series of actinomycins has been used¹⁰³ to ascertain the usefulness of a pyrolysis-gas chromatography analysis of dioxopiperazines as a method for determining peptide sequences. All adjacent pairs of amino-acids in the actinomycins, except those containing threonine, formed dioxopiperazines and the sequences (49) and (50) have been confirmed for actinomycin II and actinomycin Pip 2 respectively.



Actinomycin mono-lactone isolated¹⁰⁴ from *Streptomyces antibioticus* 3720 shows only 1% of the biological activity of actinomycin C₁(D). Addition of D- or L-isoleucine or L-*allo*-isoleucine to the culture medium of *S. antibioticus* or *S. chrysomallus* has led¹⁰⁵ to the synthesis of new actinomycins. Hydrolysates of all these actinomycins contained N-methyl-L-*allo*-isoleucine, which is another interesting example of the isomerization of amino-acids by micro-organisms.

¹⁰² J. Meienhofer, R. Cotton, and E. Atherton, *J. Org. Chem.*, 1971, **36**, 3746.

¹⁰³ A. B. Mauger, *Chem. Comm.*, 1971, 39.

¹⁰⁴ K. L. Perlman, J. Walker, and D. Perlman, *J. Antibiotics (Japan)*, 1971, **24**, 135.

¹⁰⁵ E. Katz, Y. Kawai, and J. Tsuboi, *Biochem. Biophys. Res. Comm.*, 1971, **43**, 1035.

B. Valinomycin.—The ion-complexing properties and conformation of this cyclic depsipeptide continue to be fields of active interest. In a very comprehensive application of model calculations,¹⁰⁶ the complexation of alkali- and alkaline-earth-metal cations by valinomycin has been compared with the macrotetrolide antibiotics and other compounds. The fluorescent probes 1-anilino-8-naphthalene and 2-*p*-toluidino-6-naphthalenesulphonates have also been used¹⁰⁷ to determine relative cation affinities in valinomycin, the order of affinity being $Rb^+ > K^+ > Cs^+$. In a conductometric study¹⁰⁸ of complex formation with both valinomycin and its analogues, only analogues which formed potassium ion complexes showed antibiotic activity.

Details of the combined use of i.r., n.m.r., o.r.d., and c.d. techniques which support the 'bracelet' type of conformation for valinomycin have now appeared¹⁰⁹ (Vol. 2, p. 200). This 'bracelet' model has also been confirmed in conformational energy calculations¹¹⁰ based on i.r. and n.m.r. studies. The most stable conformer exists with the methyl groups of the lactyl side-chain in the axial position with all the carbonyl groups pointing inwards. Valinomycin and its K^+ -complex have also been studied¹¹¹ using Fourier-transform ^{13}C n.m.r. Resonances of the carbonyls directly co-ordinating the K^+ -ion in valinomycin (and nonactin) shift downfield (4 p.p.m.) upon complex formation, but much smaller shifts (up- and down-field) appeared for carbons not involved in the binding site.

The linear sequence $H-(D\text{-Val-L-Lac-L-Val-D-Hyiv}^*)_3\text{-OH}$ of valinomycin has been synthesized¹¹² using three approaches: (a) in homogeneous phase, by stepwise lengthening of L-Val-D-Hyiv-OBzl with Boc-amino-acyl-hydroxy-acids (12% yield); (b) by solid-phase synthesis using the same unit (56% yield); (c) by a two-fold fragment condensation of D-Val-L-Lac-L-Val-D-Hyiv-O- Φ with Boc-D-Val-L-Lac-L-Val-D-Hyiv-OH (66% yield). Cyclization to form valinomycin was carried out using thionyl chloride, giving yields of up to 24%. Topochemical analogues¹¹³ of valinomycin and analogues differing in the number of amide and ester bonds have also been synthesized.¹¹⁴ Ester bonds in the *meso* analogues, cyclo-(D-Val-L-Hyiv-L-

¹⁰⁶ W. E. Morf and W. Simon, *Helv. Chim. Acta*, 1971, **54**, 2683.

¹⁰⁷ M. B. Feinstein and H. Felsenfeld, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 2037.

¹⁰⁸ I. M. Andreev, G. G. Malenkov, A. A. Shkrob, and M. M. Shemyakin, *Mol. Biol.*, 1971, **5**, 614.

¹⁰⁹ V. T. Ivanov, I. A. Laine, N. D. Abdullaev, V. Z. Pletnev, G. M. Lipkind, S. F. Arkhipova, L. B. Senyavina, E. N. Meshcheryakova, E. M. Popov, V. F. Bystrov, and Yu. A. Ovchinnikov, *Khim. prirod. Soedinenii*, 1971, **7**, 221.

¹¹⁰ D. F. Mayers and D. W. Urry, *J. Amer. Chem. Soc.*, 1972, **94**, 77.

¹¹¹ M. Ohnishi, M.-C. Fedarko, J. D. Baldeschwieler, and L. F. Johnson, *Biochem. Biophys. Res. Comm.*, 1972, **46**, 312.

¹¹² G. Losse and H. Klengel, *Tetrahedron*, 1971, **27**, 1423.


¹¹³ V. T. Ivanov, I. A. Laine, I. D. Ryabova, and Yu. A. Ovchinnikov, *Khim. prirod. Soedinenii*, 1970, **6**, 744.

¹¹⁴ L. A. Fonina, A. A. Sanasaryan, and E. I. Vinogradova, *Khim. prirod. Soedinenii*, 1971, **7**, 69.

* Hyiv = α -hydroxyisovaleric acid, Lac = lactic acid.


Ala-D-Hyiv-)₃, cyclo-(D-Ala-L-Hyiv-L-Ala-D-Hyiv-)₃, and cyclo-(D-Val-Glyc-L-Val-Glyc-*)₃ and eight diastereoisomers have been produced¹¹⁵ by forming mixed anhydrides with benzenesulphonyl chloride, whereas the amide bonds were formed from the acid chloride or by means of dicyclohexylcarbodi-imide and *N*-hydroxysuccinimide.

C. Other Naturally Occurring Depsipeptides.—I.r. and n.m.r. studies¹¹⁶ at 100 and 220 MHz on serratamolide derivatives suggest that the most likely conformation for the molecule is as shown in [51; R = (CH₂)₆Me] which contains 'free' N—H groups and intramolecularly bonded hydroxy-groups.



(51)

In an analogue of serratamolide in which two seryl groups have opposite configurations (*meso* form) and with the two hydroxy-groups protected as *t*-butyl ethers, a conformation similar to that proposed by Dale for cyclo-tetradecane has been proposed. Details of the elucidation of the structure of the macrocyclic lactone griselimycin (52) and a number of minor analogues (53), (54), and (55) have been reported.¹¹⁷



(52) X = Y = *trans*-4MePro, Q = Pro

(53) X = Y = Q = *trans*-4MePro

(54) X = Q = Pro, Y = *trans*-4MePro

(55) X = Y = Q = Pro

Purification of virginiamycin S has revealed¹¹⁸ three other minor components, probably formed by use of a mutant strain (or due to the modification of the growth medium) of *Streptomyces virginiae*. Virginiamycin S was found to be identical with osteogrycin B₁ (56) and virginiamycin S₃ was found to be identical with osteogrycin B₂ (57). The third,

¹¹⁵ L. A. Fonina, A. A. Sanasaryan, E. I. Vinogradova, and U. B. Shvetsov, *Khim. prirod. Soedinenii*, 1971, 7, 81.


¹¹⁶ C. H. Hassall, M. C. Moschidis, and W. A. Thomas, *J. Chem. Soc. (B)*, 1971, 1757.

¹¹⁷ B. Terlain and J. P. Thomas, *Bull. Soc. chim. France*, 1971, 2349, 2357, 2363.

¹¹⁸ H. Vanderhaeghe, G. Janssen, and F. Compennolle, *Tetrahedron Letters*, 1971, 2687.

* Glyc = glycollic acid.


virginiamycin S₂, was found to have structure (58). Ostreogrycin B₃, a minor component from cultures of *Streptomyces ostreogrisens*, has been given ¹¹⁹ the structure (59).



- (56) $R^1 = R^2 = \text{Me}$, $R^3 = R^4 = \text{H}$, $X = \text{O}$
 (57) $R^1 = \text{Et}$, $R^2 = \text{Me}$, $R^3 = \text{OH}$, $R^4 = \text{H}$, $X = \text{O}$
 (58) $R^1 = \text{Et}$, $R^2 = R^3 = R^4 = \text{H}$, $X = \text{H, OH}$
 (59) $R^1 = \text{Et}$, $R^2 = \text{Me}$, $R^3 = \text{OH}$, $R^4 = \text{NMe}_3$, $X = \text{O}$

Full details¹²⁰ of the mass spectrometric breakdown of the destruxins A and B have become available (see Vol. 3, p. 299, for typical structures).

The results of the Edman sequencing method give support¹²¹ to the structures (60) and (61) for the antibiotics A-128-OP and A-128-P respectively. The main structures of these compounds appear to differ from



telomycin only in the choice of the threonine residue used to make up the depsipeptide ring. Mild alkaline hydrolysis of A-128-OP converted the *O*-substituted threonine into β -methyldehydroalanine.¹²²

The origin of D-amino-acid residues in microbial peptides continues to be of interest but no satisfactory explanation has yet been obtained. Studies¹²³ on angolide cyclo-(L-Hyiv-L-Ile-L-Hyiv-D-Alle-) from the fungus *Pithomyces sacchari* show that if the organism is grown on a medium rich in valine then a mixture of (L-Val², D-Val⁴)-angolide together with

¹¹⁹ B. R. Cox, F. W. Eastwood, B. K. Shell, and Lord Todd, *Chem. Comm.*, 1970, 1623.

¹²⁰ A. Suzuki, N. Takahashi, and S. Tamura, *Org. Mass Spectrometry*, 1970, **4**, 175.

¹²¹ A. B. Silaev, G. S. Katrukha, Z. P. Trifonova, R. I. Li, and T. M. Melent'eva, *Khim. prirod. Soedinenii*, 1971, 7, 130.

¹²² I. G. Smirnova, A. B. Silaev, and G. S. Katrukha, *Khim. prirod. Soedinenii*, 1971, 7, 544.

¹²³ R. O. Okotore and D. W. Russell, *Experientia*, 1971, 15, 380.

homologues in which one isoleucine is replaced by valine are obtained. It has therefore been suggested, since exogeneous L-valine promotes the biosynthesis of L-Val²- and D-Val⁴-angolide in equal amounts, that the biosynthesis of angolide itself proceeds *via* an all-L cyclotetradepsipeptide with single D-residues being introduced by random inversion of one or other of two stereochemically equivalent L-amino-acid residues. ¹⁴C- Labelling studies¹²⁴ on L-N, β -dimethyl-leucine in the antibiotic etamycin have shown that the amino-acid is derived from L-leucine and that the N-methyl and β -methyl groups are derived from L-methionine.

A theoretical conformational analysis of the enniatins has been reported.¹²⁵

D. Miscellaneous.—The conformations of the substituted 2,5-dioxo-morpholines cyclo-(L-Ala-L-Lac-), cyclo-(L-Ala-D-Lac-), cyclo-(L-Val-L-Hyiv-), and cyclo-(L-Val-D-Hyiv-) have been analysed^{21, 126} using ¹H n.m.r., o.r.d., and a theoretical calculation, and they all have non-planar conformations. Cyclo-(L-Val-L-Hyiv-), with an LL configuration and bulky side-chains, has a ring-folding angle > 180° with a pseudo-equatorial arrangement of substituents. Optimum conformations of the cyclic tetradepsipeptides cyclo-(Gly-Glyc)₂ and cyclo-(MeAla-Lac)₂ with all possible sets of C α -configurations have been calculated.¹²⁷ The compounds have *cis*-amide and *trans*-ester groups and the optimum form of cyclo-(L-MeAla-D-Lac)₂ corresponds to the conformation previously reported in an X-ray study on cyclo-(D-Hyiv-L-Melle-)₂ (Vol. 2, p. 206). Conformational analyses have also been carried out¹²⁸ on various derivatives of O-acetyl-L-Lac-L-Ala and N-acetyl-L-Ala-L-Lac.

Synthesis of the LL or LD diastereoisomers of (62) has been achieved¹²⁹ using the triethylammonium salts of the benzyloxycarbonylamino-acid



(62) (R¹ = Prⁱ or CH₂·CHMe₂; R² = Me or Et)

derivative and the t-butyl ester of racemic α -bromopropionic acid or α -bromobutyric acid. The free depsipeptides were obtained on catalytic hydrogenolysis and the diastereoisomers were separated¹³⁰ using paper chromatography.

¹²⁴ J. E. Walker and D. Perlman, *Biotechnol. and Bioeng.*, 1971, 13, 371.

¹²⁵ E. M. Popov, V. Z. Pletnev, A. V. Evstratov, V. T. Ivanov, and Yu. A. Ovchinnikov, *Khim. prirod. Soedinenii*, 1970, 6, 616.

¹²⁶ E. M. Popov, V. Z. Pletnev, G. M. Lipkind, and S. F. Arkhipova, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1971, 33.

¹²⁷ V. Z. Pletnev and E. M. Popov, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1970, 991; *Biofizika*, 1971, 16, 407.

¹²⁸ E. M. Popov, V. Z. Pletnev, G. M. Lipkind, and S. F. Arkhipova, *Khim. prirod. Soedinenii*, 1971, 7, 191, 184.


¹²⁹ C. Wasielewski and M. Hoffmann, *Roczniki Chem.*, 1971, 45, 995.

¹³⁰ C. Wasielewski and M. Hoffmann, *Roczniki Chem.*, 1970, 44, 465.

4 Peptide-Carbohydrate Linkages (See also the Specialist Periodical Reports on Carbohydrate Chemistry)


A. Glycopeptides from Bacterial Cell Walls.—Fewer papers than usual have appeared on this subject this year. Biosynthetic aspects have been the subject of a review¹³¹ and a three-dimensional model of the bacterial cell wall has been proposed.¹³²

A number of peptides making up the various partial structures of the peptide (63) have been isolated¹³³ from autolysates of the vegetative cell



(63)

walls of *Bacillus subtilis*. The main difference between this glycopeptide and the ones from *E. coli* and *B. megaterium* is the presence of the diaminopimelyl amide residues and the absence of C-terminal D-alanine. Partial hydrolysis¹³⁴ of purified UDP-activated precursors of the peptidoglycan of *Arthrobacter* strain J.39 has given peptides in agreement with the unit structure (64). This is the first example in which a dicarboxylic



(64)

amino-acid [*i.e.* $\boxed{\text{L-Glu}}$ as indicated in (64)] occupies position 3: usually only diamino-acids are found there. Enzymic degradation¹³⁵ of cell walls of strains of *Aerococcus viridans* and *Gaffkya homari* reveal that the glycopeptides contain the peptide units L-Ala- γ -D-Glu-L-Lys-D-Ala and L-Ala-D-isoglutaminyl-L-Lys-D-Ala. Half of these peptide units occur as

¹³¹ F. C. Neuhaus, *Accounts Chem. Res.*, 1971, **4**, 297.

¹³² M. V. Kelemen and H. J. Rogers, *Proc. Nat. Acad. Sci. U.S.A.*, 1971, **68**, 992.


¹³³ A. D. Warth and J. L. Strominger, *Biochemistry*, 1971, **10**, 4349.

¹³⁴ B. Cziharz, K. H. Schleifer, and O. Kandler, *Biochemistry*, 1971, **10**, 3574.

¹³⁵ M. Nakel, J. M. Ghuysen, and O. Kandler, *Biochemistry*, 1971, **10**, 2170.

unlinked monomers whereas others form dimers *via* N^8 -(D-Ala)-L-lysyl linkages and constitute the first known examples of lysine-containing peptidoglycans of chemotype I (see Vol. 3, p. 302, for references defining chemotypes). L-Configurations have been assigned¹³⁶ to homoserine and diaminobutyric acid from mucopeptide precursor nucleotides and from the cell walls of some plant pathogenic corynebacteria. Chromatographically distinct fractions of the glycopeptide* GNAc-MurNAc-L-Ala-D-Glu-meso-Dpm-D-Ala have been isolated¹³⁷ from the murein of a venereal and intestinal strain of *Vibrio fetus* and were found to be identical. A simple elution system involving two (or three) buffer changes from pH 2.87 to 5.25 on a single-column amino-acid analyser has been used¹³⁸ in the analysis of all amino-acids and amino-sugars in some common cell-wall peptidoglycans.

B. Glycopeptides from Miscellaneous Sources.—The formation of trimethylsilyl derivatives of both amino-acids and carbohydrates from hydrolysates of known glycopeptides enable¹³⁹ g.l.c. analyses of both components to take place simultaneously. Preliminary reports¹⁴⁰ have appeared of a new type of carbohydrate-peptide linkage in the form of a link between the thiol group of cysteine and galactose as found in (galactosyl)-Cys-Glu-His-Ser-His-Asp-Gly-Ala isolated from human urine. The position of the carbohydrate-peptide link was inferred from the isolation of a galactosyl-cysteine from a leucine aminopeptidase digest. A similar type of glycopeptide has been found¹⁴¹ in human erythrocyte membrane. The novel glucosyl-cysteine linkage was again proved using leucine aminopeptidase digestion and this, together with the use of Dansyl-Edman technique, confirmed the structure to be (65). Tryptic digests¹⁴² of κ -type light chains



from human myeloma proteins have yielded the glycopeptide having the sequence Ala-Ser-Gln-Asn-Ile-Ser, corresponding to positions 25—31 in the protein chain, and another glycopeptide Phe-Ser-Gly-Ser-Gly-Ser-Gly-(Thr-Asp)-Phe-Thr-Leu-Asx-Ile-Ser-Arg, corresponding to positions 62—77. In both these peptides the carbohydrate link is probably attached to the asparagine residue.

Two large glycopeptides, one a unit containing 22 amino-acid residues with one carbohydrate link, and the other a unit with 65 amino-acid residues

¹³⁶ H. R. Perkins, *Biochem. J.*, 1971, **121**, 417.

¹³⁷ A. J. Winter, W. Katz, and H. H. Martin, *Biochim. Biophys. Acta*, 1971, **244**, 58.

¹³⁸ P. Guire, *Analyt. Biochem.*, 1971, **42**, 1.

¹³⁹ T. Bhatti and J. R. Clamp, *Biochim. Biophys. Acta*, 1971, **229**, 293.

¹⁴⁰ C. J. Lote and J. B. Weiss, *Biochem. J.*, 1971, **123**, 25P; *F.E.B.S. Letters*, 1971, **16**, 81.

¹⁴¹ J. B. Weiss, C. J. Lote, and H. Bobinski, *Nature (New Biol.)*, 1971, **234**, 25.

¹⁴² C. P. Milstein and C. Milstein, *Biochem. J.*, 1971, **121**, 211.

* GNAc = *N*-acetyl-D-glucosamine, MurNAc = *N*-acetylmuramic acid.

with four carbohydrate linkages, have been characterized¹⁴³ from the amino-terminus of α_1 -acid glycoprotein (human plasma globulin). All the carbohydrate units were found to be attached to asparagine residues with the carboxy-terminal sequences; -Asn-Ala-Thr, -Asn-Lys-Ser, -Asn-Lys-Thr, -Asn-Thr-Thr, -Asn-Gly-Thr. This is in accord with a previous theory¹⁴⁴ that in globular glycoproteins the carbohydrate-peptide linkage is usually found in the environment -Asn-X-(Ser or Thr)-. On the basis of the structures deduced¹⁴⁵ for five glycopeptides [(66)–(70)] from the constant sequence region of μ heavy chain of human immunoglobulin M, it is quite probable that the same theory holds. The same situation arises in the structures of the glycopeptides (71)–(73) isolated¹⁴⁶ from tryptic

(66) Phe-Ser-Trp-Lys-Tyr[Ser, Lys, Asx, Asx, Asx(Glycan)]

(67) Gly-Leu-Thr-Phe-Gln-Glx-Asx(Glycan)-Ala-Ser-Ser-Met

(68) Val-Lys-Thr-His-Thr-Asx(Glycan)

(69) Ile-Ser-Glx[Ser, His, Pro, Asx(Glycan)]

(70) Leu-Tyr-Asx(Glycan)-Val-Ser-Leu-Val-Met

(71) Gly-Ser-Asn(Glycan)-Val-Thr-Asp-Cys-Ser-Gly-Asp-Phe
 $\begin{array}{c} | \\ \text{O}_3\text{H} \end{array}$

(72) Asn(Glycan)-Lys-Ser-Asx₂(Thr, Asx, Pro, Cys(O₃H)Glx₂)-Ala-Gly-Tyr

(73) Gly-Ser-Asn(Glycan)-Val-Thr-Asp-Cys-Ser-Gly-Asp-Phe-Leu-Phe-Cys

hydrolysates of human transferrin. The carbohydrate linkage in a glycopeptide from taka-amylase A has been proved¹⁴⁷ to be GNAc-Asp-Ser with the sugar moiety β -anomeric. Two glycopeptides obtained from tryptic and pronase digests of fibroin of the silk worm *Bombyx mori* have both been found¹⁴⁸ to contain the Ser-Asn-(glucosaminyl)-Thr unit. Pronase digestion of phosvitin, the phosphoprotein from hens' egg yolk, has yielded¹⁴⁹ a glycopeptide having the sequence (74). Again all of the

Ser-Asn(Glycan)-Ser-Gly-Ser(P)₈-Arg-Ser-Val-Ser-His₂

(74)

carbohydrate part of the molecule is attached to the aspartic acid residue and an interesting feature is the eight phosphoserine residues in sequence.

Alkaline degradation studies¹⁵⁰ have revealed linkages between 2-acetamido-2-deoxygalactose and serine and threonine in the antigenic

¹⁴³ K. Schmid, M. Ishiguro, J. Emura, S. Isemura, H. Kaufmann, and T. Motoyama, *Biochem. Biophys. Res. Comm.*, 1971, **42**, 280.

¹⁴⁴ A. Neuberger and R. D. Marshall, in 'Carbohydrates and their Roles', ed. H. W. Schultz, R. F. Cain, and R. W. Woolstad, Avi, Westport, Conn., 1969.

¹⁴⁵ A. Shimizu, F. W. Putnam, C. Paul, J. R. Clamp, and I. Johnson, *Nature (New Biol.)*, 1971, **231**, 73.

¹⁴⁶ P. Charet and J. Montreuil, *Compt. rend.*, 1971, **273**, D, 533; P. Charet, G. Spil, and J. Montreuil, *ibid.*, p. 422.

¹⁴⁷ H. Yamaguchi, T. Ikenaka, and Y. Matsushima, *J. Biochem. (Japan)*, 1971, **70**, 587.


¹⁴⁸ H. Sinohara, Y. Asano, and A. Fukui, *Biochim. Biophys. Acta*, 1971, **237**, 273.

¹⁴⁹ R. Shainkin and G. E. Perlmann, *J. Biol. Chem.*, 1971, **246**, 2278.

¹⁵⁰ J. M. How and J. D. Higginbotham, *Carbohydrate Res.*, 1970, **14**, 335.

sulphated glycopeptide from chick allantoic fluid. Details have also been reported of glycopeptides isolated from both low- and high-density platelet plasma membranes¹⁵¹ and from enzymic digests¹⁵² of normal and ulcerated gastric mucosae of pig.

C. Studies on Model Glycopeptide Linkages.—Syntheses have been reported¹⁵³ for *N*-glycyl, *N*-L-alanyl, *N*-L-valyl, *N*-L-glutamyl, and *N*-L-seryl derivatives of 2-acetamido-2-deoxy- β -D-glucopyranosyl starting from the amino-sugar. Only the aspartyl derivative was hydrolysed by an amido hydrolase. First-order rate constants for the alkaline reductive cleavage of 4-*N*-(2-acetamido-2-deoxy- β -D-glucopyranosyl)-L-asparagine and 4-*N*-(β -D-glucopyranosyl)-L-asparagine have been reported¹⁵⁴ to be 6.44×10^{-3} and $5.97 \times 10^{-3} \text{ min}^{-1}$ respectively in 0.2M-NaOH at 100 °C. Approximately 50% of each compound was degraded to aspartic acid and reduced sugars. The mono- and di-saccharide derivatives (75) and (76) have been synthesized¹⁵⁵ as intermediates for glycopeptide synthesis. A number of *O*-glycosides of dipeptides containing β -hydroxyamino-acids as given in (77) have been prepared¹⁵⁶ by the reaction of the appropriate glycosidyl



amino-acid derivative with an amino-acid derivative in aqueous pyridine-dicyclohexylcarbodi-imide at -10°C .

D. Other Carbohydrate-linked Compounds.—*Streptomyces coelicolor* transforms¹⁵⁷ clindamycin (78) into a ribonucleotide derivative (79). A new metabolite, phosphoramidon, isolated from a strain of *Streptomyces*

¹⁵¹ A. J. Barber and G. A. Jamieson, *Biochemistry*, 1971, **10**, 4711.

¹⁵² G. Pallavicini, G. Cetta, A. Quaroni, and A. Castellani, *Experientia*, 1971, **27**, 895.

¹⁵³ D. E. Cowley, L. Hough, and C. M. Peach, *Carbohydrate Res.*, 1971, **19**, 231.


¹⁵⁴ B. M. Austen and R. D. Marshall, *Biochem. J.*, 1971, **124**, 14P.

¹⁵⁵ M. Spinola and R. W. Jeanloz, *Carbohydrate Res.*, 1970, **15**, 361.

¹⁵⁶ V. A. Derevitskaya, I. M. Rotenberg, and N. K. Kochetkov, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1971, 2092.


¹⁵⁷ A. D. Argoudelis and J. H. Coats, *J. Amer. Chem. Soc.*, 1971, **93**, 534.

tanashiensis, has been identified¹⁵⁸ as (80). Mild acid hydrolysis of phosphoramidon yields L-leucyl-L-tryptophan.



5 Peptides and Amino-acids Linked to Nucleosides and Nucleotides

Several 5'-N-aminoacyl-5'-amino-5'-deoxy- and 5'-amino-2',5'-dideoxy-9 β -D-ribofuranosyl purine nucleoside peptides have been synthesized.¹⁵⁹ These represent a new class of peptide nucleosides of interest in studies of the nucleoside peptides of DNA and RNA. Peptide bond formation was achieved using the active ester and carbodi-imide methods, giving the compounds (81)–(84). ¹H N.m.r. data indicate that the phenyl and



(81) R = PhCH₂, X = H.

(83) R = H, X = H,

(82) R = Me₂CH·CH₂, X = H


(84) R = H, X = NH₂·CH₂·CO

adenine rings are stacked over one another in (81). The imidazolidine of *N*-benzyloxycarbonyl-L-Leu-Gly-Trp reacts readily¹⁶⁰ with the four main types of natural ribonucleoside-5'-triphosphates to give both the 3'- or 2'-*O*-peptidyl isomers (85) and (86). The *O*-peptidyl bond appears to be more stable than an *O*-amino-acyl bond when attached to the ribonucleosides.

¹⁵⁸ S. Umezawa, K. Tatsuta, O. Izawa, and T. Tsuchiya, *Tetrahedron Letters*, 1972, 97.

¹⁵⁹ M. J. Robins, L. N. Simon, M. G. Stout, G. A. Ivanovics, M. P. Schweizer, R. J. Rousseau, and R. K. Robins, *J. Amer. Chem. Soc.*, 1971, 93, 1474.


¹⁶⁰ P. P. Purygin, A. A. Kraevskii, and B. P. Gottikh, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1970, 1369.



B = guanine or cytosine

(85) $R^1 = \text{Leu-Gly-Trp}$, $R^2 = \text{H}$ (86) $R^1 = \text{H}$, $R^2 = \text{Leu-Gly-Trp}$


The properties of phosphoramidate nucleotide peptide bonds formed from serine are significantly different from the properties of this bond in derivatives of simple amino-acids. Hydrolysis studies¹⁶¹ show that in acidic and alkaline media the reactions probably proceed according to the routes summarized in Scheme 3.



Scheme 3

¹⁶¹ E. P. Savel'ev, E. S. Gromova, Z. A. Zhabarova, and M. A. Prokofiev, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1970, 1817.

willardiine (87) have been synthesized¹⁶² using the mixed anhydride, active ester, and carbodi-imide methods for coupling. DL-Willardiyl-DL-willardiine was also prepared by these methods. Syntheses of β -pyridyl- α -alanine




(87)

peptides,¹⁶³ α -amino- ϵ -(6-chloro-9-purinyl)caproic acid,¹⁶⁴ *N*-[(6-diphenylmethylthio)purin-9-yl]-, and *N*-[(6-thiopurin-9-yl)]-acetylaminic acids¹⁶⁵ have been reported.

6 Peptide Alkaloids

A comprehensive review dealing with this subject has recently been published.¹⁶⁶

Another variation (88) on the *p*-alkoxystyrylamino-ring system has been identified,¹⁶⁷ using mass spectrometry, in the structure of scutianin B from *Scutia buxifolia* Reiss. A West Indian shrub, *Croton humilis* has yielded¹⁶⁸



(88)

¹⁶² M. Lidaks, R. Paegle, V. Straume, D. Snore, and Yu. P. Shvachkin, *Khim. geterotsikl. Soedinenii*, 1970, 1002; 1971, 404.

¹⁶³ B. L. Krainova, G. A. Agafonova, and E. S. Chapman, *Zhur. obshchei Khim.*, 1971, 41, 1617; G. A. Agafonova, N. E. Gerasimova, M. V. Guseva, B. L. Krainova, T. V. Petrova, V. E. Pozdnev, and E. S. Chapman, *ibid.*, 1970, 40, 2502.

¹⁶⁴ M. U. Lidak, Y. Y. Shluke, S. E. Poritere, and U. P. Shvachin, *Khim. geterotsikl. Soedinenii*, 1971, 427.


¹⁶⁵ E. D. Kaverzneva, V. V. Kiseleva, and L. I. Deeva, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1971, 2031.

¹⁶⁶ M. Pais and F.-X. Jarreau in 'Chemistry and Biochemistry of Amino-acids, Peptides, and Proteins', ed. B. Weinstein, Dekker, New York, 1971, vol. 1, p. 127.

¹⁶⁷ R. Tschesche, E. Ammermann, and H.-W. Fehlhaber, *Tetrahedron Letters*, 1971, 4405.


¹⁶⁸ J. P. Kutney, F. K. Klein, G. Knowles, and K. L. Stuart, *Tetrahedron Letters*, 1971, 3263; J. P. Kutney, F. K. Klein, G. Eigendorf, D. McNeill, and K. L. Stuart, *Tetrahedron Letters*, 1971, 4973.

a number of interesting peptidyl alkaloids (89)–(92). The α -glutamyl linkage in (89) and (90) was identified from the mass spectra and appears to be unique to this series. The glutarimide structures in (91) and (92) are also the first of this type to be isolated from higher plants.



7 Hydrazino Peptides

Negamycin, a new antibiotic isolated¹⁶⁹ from *Streptomyces purpeofuscus*, has been shown to have the structure (93). This novel structure has been confirmed by partial synthesis using the *N*-hydroxysuccinimide ester of di-*N*-Z- δ -*O*-tetrahydropyranyloxy- β -lysine with 1-methylhydrazine-acetic



acid, $\text{NH}_2 \cdot \text{NMe} \cdot \text{CH}_2 \cdot \text{CO}_2\text{H}$. Selective acylation of the N^α -(with the acetyl group) and N^β -(with the benzyloxycarbonyl group) positions in α -hydrazino- β -phenylpropionic acid ($\text{NH}_2\text{-Phe}$) has provided¹⁷⁰ useful derivatives for the synthesis of hydrazine-containing peptides, as for example in the hetero-sequence Ala-L-NH-Phe-Ile-Gly-Leu-Met-NH₂, an analogue of the sequence found in eledoisin.

8 Penicillins and Cephalosporins

Once again the coverage of these compounds has been selective rather than comprehensive with the main emphasis on reactions involving the amide portion of the molecules rather than the heterocyclic aspects of their structures. A comprehensive review of the recent developments in the chemistry of the penicillins and cephalosporins (coverage up to 1970) has been published,¹⁷¹ and the biochemistry and chemistry of the two series have been compared and contrasted in a symposium lecture.¹⁷²


¹⁶⁹ S. Kondo, S. Shibahara, S. Takahashi, K. Maeda, H. Umezawa, and M. Ohno, *J. Amer. Chem. Soc.*, 1971, **93**, 6305.

¹⁷⁰ R. Grupe and H. Niedrich, *J. prakt. Chem.*, 1970, **312**, 1087.

¹⁷¹ J. L. Lucke and G. Balavoine, *Bull. Soc. chim. France*, 1971, 2733.

¹⁷² E. P. Abraham, Ref. 2, p. 399.

Epimerization at the C-6 position having a phthalimido side-chain proceeds *via* an enolate intermediate,¹⁷³ but in the penicillins, in which there is a secondary amide group present in that position, epimerization has proved difficult (Vol. 3, p. 315). Last year a breakthrough was made in the use of *NO*-bis(trimethylsilyl)acetamide (BSA) to induce epimerization, and further success using this reagent has now been achieved.¹⁷⁴ A mixture of BSA and 1,5-diazobicyclo[4,3,0]non-5-ene (DBN) gives 75% epimerization using either the esters or free acids of phenoxymethyl- and benzylpenicillin. Equilibration¹⁷⁵ of penicillanic acid derivatives (94) and (95)




(94) R = phthalimido

(95) R = 2-hydroxy-1-naphthylidenimino

using DBN in methylene chloride at room temperature gives complete conversion of the former into the 6 α -isomer, but only 61% conversion in the latter case. It is therefore implied that the overwhelming thermodynamic preference for the α -isomer previously reported should not be assumed to apply to every penicillin derivative.

Attempts to substitute methyl groups in the 6-position of modified penicillins and the 7-position of cephalosporin have been accompanied by epimerization.¹⁷⁶ Alkylation of *N*-benzylidene-6-aminopenicillanic acid methyl ester with one equivalent of sodium hydride and excess of iodomethane gave a mixture of the 6-methyl epimers as shown in Scheme 4



Conditions: i, NaH-MeI; ii, acid hydrolysis

Scheme 4

¹⁷³ B. G. Ramsey and R. J. Stoodley, *Chem. Comm.*, 1971, 450.


¹⁷⁴ A. Vlietinck, E. Roets, P. Claes, and H. Vanderhaeghe, *Tetrahedron Letters*, 1972, 285.

¹⁷⁵ J. R. Jackson and R. J. Stoodley, *Chem. Comm.*, 1971, 647.

¹⁷⁶ E. H. W. Bohme, H. E. Applegate, B. Toeplitz, J. E. Dolfini, and J. Z. Gougoutas, *J. Amer. Chem. Soc.*, 1971, 93, 4324.

(R = Me). A similar reaction in the cephalosporin series gave a similar analogue. The methylated derivatives obtained were much less active than the unsubstituted analogues. In contrast, 6 α -methyl (and -ethyl) penicillin G sodium salt and the cephalosporin analogues show appreciable activity.¹⁷⁷ It appears that the free carboxy-group is a requisite for activity, and the fact that these methyl-substituted analogues do show activity might be some support for the hypothesis that penicillins and cephalosporins react by mimicking D-Ala-D-Ala in enzyme transpeptidase reactions.


Epimerization at the penicillin C-6 position has been prevented in a rather specialized procedure¹⁷⁸ for alkylating this position as shown in Scheme 5. This is an interesting example of a carbanion centre retaining



Conditions: i, NaH-Me₂N⁺CHO-benzene

Scheme 5

its configuration, which is probably the consequence of the adjacent geometry rather than being a general phenomenon. Benzyl 6-diazo-penicillinate (96) has been converted¹⁷⁹ into 6-acetyl- and 6-phenylacetyl-hydrazonopenicillanic acids using triphenylphosphine in wet ether followed by acetylation. Stereoselective borohydride reduction gave the β -isomer (97) which is effective against a penicillin-resistant strain of *Staph. aureus*. Isomerization of benzylpenicillin into benzylpenicillenic acid (98) has been shown to be catalysed strongly by imidazole.¹⁸⁰



(96) R = N₂, R¹ = Bzl
(97) R = R²CO·NH·NH, R¹ = Bzl

The economically important conversion of penicillins into cephalosporins continues to be a major field of research activity. Compounds such as (99) react¹⁸¹ with the strong base DBN (1,5-diazabicyclo[4,3,0]-non-5-ene) to give (100) as a mixture of C-6 epimers. Replacement of the


¹⁷⁷ R. A. Firestone, N. Schelechow, D. B. R. Johnson, and B. G. Christensen, *Tetrahedron Letters*, 1972, 375.

¹⁷⁸ G. V. Kaiser, C. W. Ashbrook, and J. E. Baldwin, *J. Amer. Chem. Soc.*, 1971, **93**, 2342.


¹⁷⁹ D. M. Brunwin and G. Lowe, *Chem. Comm.*, 1972, 192.

¹⁸⁰ H. Bundgaard, *Tetrahedron Letters*, 1971, 4613.

¹⁸¹ B. G. Ramsay and R. J. Stoodley, *J. Chem. Soc. (C)*, 1971, 3859, 3864.




(99)




(100)

phthalimido-group by a phenoxyamido-group eliminates epimerization. More detailed analysis of the rearrangement of penicillin sulphoxide esters to desacetoxyccephalosporins has been made¹⁸² as a result of the discovery of the oral effectiveness of cephalexin (101). Acid-catalysed ring expansion of the penicillin sulphoxides yields (102), a novel class of 3-(*S*)-hydroxy-3-



(101)



(102)

methylcepham derivatives, as intermediates in these rearrangements. Complete details have now been published¹⁸³ of the preparation and rearrangements of 6 β -phenylacetamido-penicillanic sulphoxides (103) into acetoxypenam and acetoxyccephams. Thiols react¹⁸⁴ with the sulphoxide (103) to give (104; X = SSR) which, on treatment with trimethylphosphine, gives the thiol (104; X = SR). Similar results have been obtained¹⁸⁵ by treating an *N*-tritylpenicillin derivative with iodomethane in the presence of sodium hydride when a selective cleavage of the thiazolidine ring takes place giving (105). Successful attempts at removing the isopentenyl residue, as *e.g.* in (104), using diazomethane followed by *t*-butoxide,¹⁸⁶ and also for (106)¹⁸⁷ using permanganate or osmium tetroxide, have been reported. These methods for producing non-fused β -lactam compounds provide very interesting possibilities for future developments. A rather remarkable methylthio-group migration giving (107) occurs on treating (106) with lead tetra-acetate.¹⁸⁷

¹⁸² R. R. Chauvette, P. A. Pennington, C. W. Ryan, R. D. G. Cooper, F. L. Jose, I. G. Wright, E. M. Van Heyningen, and G. W. Huffman, *J. Org. Chem.*, 1971, **36**, 1259; G. E. Gutowski, C. M. Daniels, and R. D. G. Cooper, *Tetrahedron Letters*, 1971, 3429; G. E. Gutowski, B. J. Foster, C. J. Daniels, L. D. Hatfield, and J. W. Fisher, *ibid.*, 1971, 3433.


¹⁸³ D. H. R. Barton, F. Comer, D. G. T. Greig, P. G. Sammes, C. M. Cooper, G. Hewitt, and W. G. E. Underwood, *J. Chem. Soc. (C)*, 1971, 3540.

¹⁸⁴ D. H. R. Barton, P. G. Sammes, M. V. Taylor, C. M. Cooper, G. Hewitt, B. E. Looker, and W. G. E. Underwood, *Chem. Comm.*, 1971, 1137.



¹⁸⁵ J. P. Clayton, J. H. C. Nayler, R. Southgate, and P. Tolliday, *Chem. Comm.*, 1971, 590.

¹⁸⁶ D. H. R. Barton, D. G. T. Greig, P. G. Sammes, and M. V. Taylor, *Chem. Comm.*, 1971, 845.


¹⁸⁷ E. G. Brain, A. J. Eglinton, J. H. C. Nayler, M. J. Pearson, and R. Southgate, *J.C.S. Chem. Comm.*, 1972, 229.



(103)


(104) $R^1 = \text{CH}_2 \cdot \text{CCl}_3$, $R^2 = \text{Ph} \cdot \text{CH}_2 \cdot \text{CO} \cdot \text{NH}$ (105) $R^1 = p\text{-MeO} \cdot \text{C}_6\text{H}_4 \cdot \text{CH}_2$, $R^2 = \text{Trt-NH}$, $X = \text{SMe}$ 

(106)



(107)

A preliminary report¹⁸⁸ has appeared on the synthesis of (+)-methyl-6-bromopenicillinate by a novel route using a mercury-induced carbene reaction. Analogues of the penicillins and cephalosporins have been synthesized¹⁸⁹ using the photolysis of the diazo-compound (108) as a key step in the reaction, but no antibacterial activity was found in the product.



(108)

The key step in the formation of semisynthetic penicillins, namely the removal of the phenylacetyl group in penicillin G, has been accomplished¹⁹⁰ by means of phosphorus pentachloride and *N*-methylmorpholine followed by methanol. The phosphorus reagent with butanol at low temperatures is also capable of selective cleavage¹⁹¹ of the amide bond in the silyl ester of benzylpenicillin. Semisynthetic penicillins and cephalosporins reported

¹⁸⁸ N. G. Johansson and B. Akermarck, *Tetrahedron Letters*, 1971, 4785.


¹⁸⁹ D. M. Brunwin, G. Lowe, and J. Parker, *J. Chem. Soc. (C)*, 1971, 3756; *Chem. Comm.*, 1971, 865.

¹⁹⁰ G. R. Fosker, K. D. Hardy, J. H. C. Nayler, P. Seggery, and E. R. Stove, *J. Chem. Soc. (C)*, 1971, 1917, 1920.


¹⁹¹ H. W. O. Weissenburger and M. G. Van der Hoeven, *Rec. Trav. chim.*, 1970, 89, 1081.

during the year include compounds derived from D-2-(1,4-cyclohexadienyl)-glycine,¹⁹² 3-methoxymethyl-7-acylaminocephalosporin and derivatives,¹⁹³ and 2-thiomethyl- and 2-thiomethylene-cephalosporins.¹⁹⁴

Successful attempts,¹⁹⁵ using Sephadex G-25, have been made to separate the polymers present in aqueous solutions of 6-aminopenicillanic acid, benzylpenicillin, ampicillin, and hetacillin. The evidence pointed to a general structure (109) for the polymers. Penicillin N and three new



cephalosporins (110)–(112) have been isolated¹⁹⁶ from *Streptomyces lipmanii* and *S. clavuligerus*. Compounds (110) and (112) exhibited greater



activity against Gram-negative organisms than does cephalosporin C. ¹³C N.m.r. spectroscopic analysis¹⁹⁷ of the sodium salt of cephalosporin C obtained from cultures of *Cephalosporium acremonium* fed with sodium [1-¹³C]- and [2-¹³C]-acetate revealed enhanced ¹³C-chemical shift intensities as shown in (113). Of particular importance is the distribution of labels in C-11, C-12, and C-13 in that it corresponds to the labelling expected for the formation of α-aminoadipic acid *via* the Krebs cycle.

¹⁹² J. E. Dolfini, H. E. Applegate, G. Bach, H. Basch, J. Bernstein, J. Schwartz, and F. L. Weisenborn, *J. Medicin. Chem.*, 1971, 14, 117.

¹⁹³ J. A. Webber, G. W. Huffman, R. E. Koehler, C. F. Murphy, C. W. Ryan, E. M. Van Heyningen, and R. T. Vasileff, *J. Medicin. Chem.*, 1971, 14, 113.

¹⁹⁴ G. V. Kaiser, C. W. Ashbrook, T. Goodson, I. G. Wright, and E. M. Van Heyningen, *J. Medicin. Chem.*, 1971, 14, 420, 426.

¹⁹⁵ H. Smith and A. C. Marshall, *Nature*, 1971, 232, 45.

¹⁹⁶ R. Nagarajan, L. D. Boeck, M. Gorman, R. L. Hamill, C. E. Higgins, M. M. Hoehn, W. M. Stark, and J. G. Whitney, *J. Amer. Chem. Soc.*, 1971, 93, 2308.

¹⁹⁷ N. Neuss, C. H. Nash, P. A. Lemke, and J. B. Grutzner, *J. Amer. Chem. Soc.*, 1971, 93, 2337.



(116)

A preliminary degradative study²⁰⁴ on the antibiotic complex S-520 from *Streptomyces diastaticus* shows that there is a mixture of peptides present which contains glycine, D-valine, ornithine and D-isoleucine, and L-threo- β -hydroxyglutamic acid, as well as previously unknown amino-acids. The




Figure 4

presence of D-isoleucine is interesting since it is only the second time that this isomer has been isolated from micro-organisms. Labelling studies²⁰⁵ have shown that indolmycin is formed from the precursors shown in Figure 4. A biosynthetic pathway, involving an intermediate on the route to melanin, has at last been elucidated²⁰⁶ for the bioconversion of tyrosine into the propylproline residue of lincomycin.

Homologues of D- and L-3-hydroxyacylhexapeptides have been prepared²⁰⁷ by the azide coupling of Gly-Ser-Val-Thr-Leu with D- or L-3-hydroxyacyl-leucine hydrazides, but none of the compounds was identical with viscosin. An analogue of bradykinin, containing *N*-(2-aminoethyl) glycine instead of prolyl-glycyl residues, has been synthesized²⁰⁸ but was

²⁰⁴ J. Shoji, S. Kozuki, M. Mayama, and N. Shimaoka, *J. Antibiotics (Japan)*, 1970, **23**, 429; J. Shoji and R. Sakazaki, *ibid.*, 1970, **23**, 432, 418.


²⁰⁵ U. Hornemann, L. H. Hurley, M. K. Speedie, and H. G. Floss, *J. Amer. Chem. Soc.*, 1971, **93**, 3028.

²⁰⁶ D. F. Witz, E. J. Hessler, and T. L. Miller, *Biochemistry*, 1971, **10**, 1128.

²⁰⁷ M. Hiramoto, K. Okada, S. Nagai, and H. Kawamoto, *Chem. and Pharm. Bull. (Japan)*, 1971, **19**, 1308.

²⁰⁸ E. Atherton, H. D. Law, S. Moore, D. F. Elliott, and R. Wade, *J. Chem. Soc. (C)*, 1971, 3393.

found to be inactive. Peptides of sarcolysin (117) with γ -aminobutyric acid and containing C- and N-terminal sarcolysin have been synthesized.²⁰⁹



The eleven peptide hydrogens in bacitracin A form²¹⁰ at least three distinct kinetic classes, including a single slow-exchanging proton—probably implying a single hydrogen bond in the macrocyclic ring.

²⁰⁹ A. A. B. Paylyukonis, K. I. Karpavichus, O. V. Kilkisheva, and I. L. Knunyants, *Izvest. Akad. Nauk S.S.S.R., Ser. khim.*, 1970, 161.

²¹⁰ R. E. Galardy, M. P. Printz, and L. C. Craig, *Biochemistry*, 1971, **10**, 2429.

5

Further Extracts from the Rules and Tentative Rules of the I.U.P.A.C.–I.U.B. Commission on Biochemical Nomenclature

In Volume 2, Chapter 5, we reprinted the following extracts from the I.U.P.A.C.–I.U.B. Recommendations relevant to amino-acids, peptides, and proteins:

Tentative Abbreviated Designation of Amino-acid Derivatives and Peptides; Tentative Rules for Naming Synthetic Modifications of Natural Peptides; Tentative Abbreviated Nomenclature of Synthetic Polypeptides (Polymerised Amino-acids). We reprint here the 1971 revision of the first-named recommendations, together with the new recommendations *Abbreviations and Symbols for the Description of the Conformation of Polypeptide Chains.*

I Symbols for Amino-Acid Derivatives and Peptides Recommendations (1971)

(Reprinted by permission from I.U.P.A.C. Information Bulletin, Appendices on Tentative Nomenclature, Symbols, Units, and Standards, No. 23, June 1972)

The revised Tentative Rules published by CBN in 1966 (1) were an attempt to achieve a broad systematization of various types of abbreviated notation already in use [e.g., Brand & Edsall (1947) *Annu. Rev. Biochem.*; *Report of the Committee on Abbreviations of the American Society of Biological Chemists*, 18 December 1959; *Report of the Committee on Nomenclature of the European Peptide Symposium* (1963) pp. 261–269, Pergamon Press, Oxford; ‘Tentative Rules for Abbreviations and Symbols of Chemical Names of Special Interest in Biological Chemistry’ (2)]. They sought to reconcile the needs of the protein chemist, i.e., indication of amino-acid sequences, with those of persons concerned more with the chemical reactions of proteins and the synthesis of polypeptides, i.e., the need for conveying more detailed chemical information in abbreviated form.

Recent progress in the field of peptide synthesis and in the chemical modification of proteins has made necessary a revision of these Tentative Rules. This revision has been aided by the work of an expert group consisting of J. S. Fruton, B. S. Hartley, R. R. Porter, J. Rudinger, R. Schwyzler and G. T. Young. They are greatly indebted to many colleagues, notably W. H. Stein, for helpful suggestions.

1. General Considerations

1.1

The symbols chosen are derived from the trivial names or chemical names of the amino acids and of chemicals reacting with amino acids and polypeptides. For the sake of clarity, brevity and listing in tables, the symbols for amino-acid residues have been, wherever possible, restricted to three letters, usually the first letters of the trivial names.

1.2

The symbols represent not only the names of the compounds but also their structural formulae.

1.3

The amino-acid symbols by themselves represent the amino acids. The use of the symbols to represent the free amino acids is *not* recommended in textual material, but such use may occasionally be desirable in tables, diagrams or figures. Residues of amino acids are represented by addition of hyphens in specific positions as indicated in Section 3.

1.4

Heteroatoms of amino-acid residues (e.g., O³ and S³ of serine and cysteine respectively, N⁶ of lysine, N² of glycine etc.) do not explicitly appear in the symbol; such features are understood to be encompassed by the abbreviation.

1.5

Amino-acid symbols denote the L configuration unless otherwise indicated by D or DL appearing before the symbol and separated from it by a hyphen. When it is desired to make the number of amino-acid residues appear more clearly, the hyphen between the configurational prefix and the symbol may be omitted (see 6.3.1.1 *et seq.*). (Note: The designation of an amino-acid residue as DL is inappropriate for compounds having another amino-acid residue with an asymmetrical centre.)

1.6

Structural formulae of complicated features may be used along with the abbreviated notation wherever necessary for clarity.

1.7

All symbols listed below are to be printed or typed as one capital letter followed by two lower-case letters, e.g., Gln, not GLN or gln or Gln or gln, regardless of position in a sentence or structure. However, when used for purposes other than to represent an amino-acid residue (e.g., to designate a genetic factor), three lower-case italic letters (i.e., *gln*) should be used.

2. Symbols for Amino Acids

2.1 Common amino acids

Alanine	Ala	Leucine	Leu
Arginine	Arg	Lysine	Lys
Asparagine	Asn ²	Methionine	Met
Aspartic acid	Asp	Phenylalanine	Phe
Cysteine	Cys	Proline	Pro
Glutamic acid	Glu	Serine	Ser
Glutamine	Gln ²	Threonine	Thr
Glycine	Gly	Tryptophan	Trp
Histidine	His		(not Try)
Isoleucine	Ile	Tyrosine	Tyr
		Valine	Val

² Asparagine and glutamine may also be denoted as Asp(NH₂) or Asp and Glu(NH₂)

or Glu, respectively, if necessary (as when the NH₂ is substituted, or its removal or modification is under discussion). See 4.2.

Glx may be used when the residue denoted could be 'glutamic acid or glutamine'; similarly, Asx for 'aspartic acid or asparagine'.

2.2 Less-common amino acids

Symbols for less-common amino acids should be defined in each publication in which they appear. The following principles and notations are recommended.

2.2.1 Hydroxyamino acids.

		Preferred alternatives	
5-Hydroxylysine	5Hyl	Lys(5OH) or	Lys 5 OH
3-Hydroxyproline	3Hyp	Pro(3OH) or	OH 3 Pro
4-Hydroxyproline	4Hyp	Pro(4OH) or	Pro 4 OH

2.2.2 *allo*-Amino acids.

<i>allo</i> -Isoleucine	<i>alle</i>		OH 5
<i>allo</i> -Hydroxylysine	<i>a</i> Hyl	<i>a</i> Lys(5OH) or <i>a</i> Lys	

2.2.3 'Nor' and 'homo' amino acids. 'Nor' (e.g., in norvaline) is not used in its accepted sense (denoting a lower homologue) but to change the trivial name of a branched-chain compound into that of a straight-chain compound (compare with 'iso', paragraph 2.1). 'Nor' should therefore be treated as part of the trivial name without special emphasis. 'Homo', used in the

sense of a higher homologue, may also be incorporated into the trivial name.

Norvaline	Nva	Homoserine	Hse
Norleucine	Nle	Homocysteine	Hcy

2.2.4 Higher unbranched amino acids. The functional prefix 'amino' is included in the symbol as the letter 'A', diamino as 'A₂'³. The trivial name of the parent acid is abbreviated to two letters. The word 'acid' ('-säure' etc.) is omitted from the symbol as carrying no significant information. Unless otherwise indicated, single groups are in the 2-position, two amino groups in the 2- and terminal positions (monocarboxylic acids) or 2- and 2'-positions (dicarboxylic acids). The location of amino groups in positions other than these is shown by appropriate prefixes.

Examples:

2-Aminobutyric acid	Abu
2-Aminoadipic acid	Aad
2-Aminopimelic acid	Apm
2,4-Diaminobutyric acid	A ₂ bu ³
2,2'-Diaminopimelic acid	A ₂ pm ³
2,3-Diaminopropionic acid	A ₂ pr ³ or Ala(3NH ₂)
	NH ₂
	or ³
	Ala (see 4.3)
β-Alanine	βAla
Ornithine (2,4-diaminovaleric acid)	Orn
6-Aminohexanoic acid	εAhx ⁴
3-Aminoadipic acid	βAad

³ The symbols for diamino compounds previously (1) utilized the letter 'D' for 'diamino'. However, the overuse of 'D' as the initial letter for many compounds beginning with 'di' (and of 'T' for 'tri' and 'tetra'), in addition to the fact that standard chemical symbolism utilizes subscript numerals for multipliers, leads to the proposal that diamino should be represented by A₂. This eliminates the ambiguity attached to 'D' and makes more clear the chemical relationship between the diamino and monoamino derivatives. It is in keeping with the increasing use of Me₂SO instead of DMSO and of Me₃Si- in place of TMS-, and with the earlier proposal of H₄ for tetrahydro (4).

⁴ Recommended in place of the previous (1) εAcp, in which 'cp' for caproic may be confused with capric and caprylic.

2.2.5 N²-Alkylated amino acids. N²-Alkylamino acids are becoming more and more common (e.g., in the large group of depsipeptides). This justifies special symbols.

Examples:

N-Methylglycine (sarcosine) (see 6.2)	MeGly or Sar
N-Methylisoleucine	Melle
N-Methylvaline etc.	MeVal etc.
N-Ethylglycine etc.	EtGly etc.

2.3 *Non-amino-acid residues linked to peptides*

For residues of muramic acid, sialic acid, neuraminic acid etc. linked to amino-acid residues, as in bacterial-cell-wall components, the symbols Mur, Sia, Neu etc. (preceded by Ac if *N*-acetylated) are recommended. The symbols for sugar residues (Glc, Gal etc.) (2) and nucleotides (Ado, Cyt etc.) (3) may also be used.

3. **Amino-Acid Residues**

The links between residues have frequently been shown by peptide chemists as full points (periods, dots: ·) and by carbohydrate chemists (generally) as short strokes (dashes, hyphens: -). At times, special symbols have been used (> or →) to show the direction of what is in all cases an unsymmetrical link (peptide or glycoside).

For consistency and ease of typing as well as economy in printing, the hyphen, representing the peptide bond, should be the standard connecting symbol (2).

The simple usage by which Gly-Gly-Gly stands for glycylglycylglycine appears to involve the employment of the same three letters (Gly) for three different residues or radicals (*b*), (*c*), (*d*) below. However, if the dashes or hyphens are considered as part of each symbol, we have four distinct forms, for the free amino acid and the three residues, viz.:


- | | | |
|-------------|---|---------------------|
| (a) Gly = | $\text{NH}_2\text{—CH}_2\text{—CO}_2\text{H}$ | the free amino acid |
| (b) Gly- = | $\text{NH}_2\text{—CH}_2\text{—CO—}$ | the left-hand unit |
| (c) -Gly- = | $\text{—NH—CH}_2\text{—CO—}$ | the middle unit |
| (d) -Gly = | $\text{—NH—CH}_2\text{—CO}_2\text{H}$ | the right-hand unit |

For peptides, a distinction may be made between the *peptide*, e.g., Gly-Glu (shown *without* dashes at the ends of the symbols), and the *sequence*, e.g., -Gly-Glu- (shown *with* dashes at the ends of the symbols).

3.1 *Lack of hydrogen on the 2-amino group*

The 2-amino group is understood to be at the left-hand side of the symbol when hyphens are used, and — in special cases — at the point of the arrow when arrows are used to indicate the direction of the peptide bond ($\text{—CO} \rightarrow \text{NH—}$, $\text{—NH} \leftarrow \text{CO—}$). (For substitution for 2-amino hydrogen, see 4.1.)


Examples:




3.2 Lack of hydroxyl on the 1-carboxyl group

The 1-carboxyl group is understood to be on the right-hand side of the symbol when hyphens are employed and — in such special cases as 6.3.1.3 — at the tail of the arrow when arrows are used to indicate the direction of the peptide bond ($-\text{CO} \rightarrow \text{NH}-$, $-\text{NH} \leftarrow \text{CO}-$).

Example:






It is generally convenient to use the same abbreviated formula for a polypeptide no matter what its state of ionization. To show that a peptide is acting as a cation or anion, the amino-terminal and carboxyl-terminal ends of the peptide are amplified with H and OH respectively (I); these may be modified to show the appropriate state of ionization (II or III).



3.3 Lack of hydrogen on amino, imino, guanidino, hydroxyl and thiol functions in the side chain





(For substitution in such positions, see 4.2.)



⁵ The prolonged and well-entrenched ambiguity in the nomenclature of the *N*-methyl-histidines (the chemist's N-1 being the biochemist's N-3 and vice versa) leads to the proposal that a new trivial system for designating these substances is necessary. It is therefore proposed that the imidazole N nearer the alanine residue be designated *pros* (symbol π) and the one farther *tele* (symbol τ), to give the following names and symbols:



prosmethylhistidine or *N* $^\pi$ -methylhistidine, His(π Me);
telemethylhistidine or *N* $^\tau$ -methylhistidine, His(τ Me).

See also 4.2, final example.



(Cystine would be: $\begin{array}{c} \text{Cys} \\ | \\ \text{Cys} \end{array}$, $\begin{array}{c} \text{Cys} \quad \text{Cys} \\ \text{Cys} \quad \text{Cys} \end{array}$, or $\begin{array}{c} \text{Cys} \quad \text{Cys} \\ \text{Cys} \quad \text{Cys} \end{array}$, not Cys-Cys)


3.4 Lack of hydroxyl on carboxyl groups in the side chain



3.5 Cyclic derivatives of amino acid residues

For the special cases of the residues derived from pyrrolid-2-one-5-carboxylic acid (also known as pyroglutamic acid) and from homoserine

lactone, the following are recommended:



4. Substituted Amino Acids

4.1 Substitution in the 2-amino and 1-carboxyl groups

This follows logically from 3.1 and 3.2. The following examples will make the usage clear. (See also 6.2.)

<i>N</i> -Acetylglycine	Ac-Gly
Glycine ethyl ester	Gly-OEt
<i>N</i> ² -Acetyllysine	Ac-Lys
Serine methyl ester	Ser-OMe
<i>O</i> ¹ -Ethyl <i>N</i> -acetylglutamate	Ac-Glu-OEt
Isoglutamine	Glu-NH ₂
<i>O</i> ¹ -Methyl hydrogen aspartate	Asp-OMe
<i>N</i> -Ethyl- <i>N</i> -methylglycine	Et-MeGly,
	$ \begin{array}{c} \text{Et} \\ \diagup \\ \text{Gly, Me} \end{array} $

4.2 Substitution in the side chain

Side-chain substituents may be portrayed above or below the amino-acid symbol (see 3.3 and 3.4), or by placing the symbol for the substituent in parentheses immediately after the amino-acid symbol.

The use of parentheses should be reserved for a *single* symbol denoting a side-chain substituent. When a more complex substituent is involved, it is recommended that the vertical stroke and the two-line abbreviation be used (5). In general, the one-line abbreviation should be used only when the structure of a substituted peptide is given in textual material.

<i>O</i> ¹ -Methyl hydrogen aspartate	$ \begin{array}{c} \text{OMe} \\ \\ \text{Asp or Asp or Asp(OMe)} \end{array} $
<i>O</i> ⁵ -Ethyl hydrogen <i>N</i> -acetylglutamate	$ \begin{array}{c} \text{OMe} \\ \\ \text{Ac-Glu(OEt)} \end{array} $
<i>N</i> ⁶ -Acetyllysine	$ \begin{array}{c} \text{Ac} \\ \\ \text{Lys or Lys or Lys(Ac)} \\ \\ \text{Ac} \end{array} $

<i>O</i> ³ -Acetylserine	$\begin{array}{c} \text{Ac} \\ \\ \text{Ser or Ser or Ser(Ac)} \\ \\ \text{Ac} \end{array}$
<i>O</i> ⁴ -Methyltyrosine	$\begin{array}{c} \text{Me} \\ \\ \text{Tyr or Tyr or Tyr(Me)} \\ \\ \text{Me} \end{array}$
<i>S</i> -Ethylcysteine	$\begin{array}{c} \text{Et} \\ \\ \text{Cys or Cys or Cys(Et)} \\ \\ \text{Et} \end{array}$
<i>S</i> -Sulfocysteine (<i>S</i> -cysteinesulfonic acid)	$\begin{array}{c} \text{SO}_3\text{H} \text{ or } \text{Cys} \\ \quad \quad \\ \text{Cys} \quad \quad \text{SO}_3\text{H or} \\ \text{Cys(SO}_3\text{H)} \end{array}$
Cysteinesulfinic acid	$\begin{array}{c} \text{OH} \text{ or } \text{Cys} \\ \quad \quad \\ \text{Cys} \quad \quad \text{OH or Cys(OH)} \end{array}$
Cysteinesulfenic acid	$\begin{array}{c} \text{O}_2\text{H} \text{ or } \text{Cys} \\ \quad \quad \\ \text{Cys} \quad \quad \text{OH}_2 \text{ or} \\ \text{Cys(O}_2\text{H)} \end{array}$
Cysteic acid (3-sulfoalanine)	$\begin{array}{c} \text{O}_3\text{H} \text{ or } \text{Cys} \\ \quad \quad \\ \text{Cys} \quad \quad \text{O}_3\text{H or} \\ \text{Cys(O}_3\text{H)} \end{array}$
<i>S</i> -Cyanocysteine	$\begin{array}{c} \text{CN} \text{ or } \text{Cys} \\ \quad \quad \\ \text{Cys} \quad \quad \text{CN or Cys(CN)} \end{array}$
Methionine sulfoxide	$\begin{array}{c} \text{O} \\ \\ \text{Met or Met or Met(O)} \\ \\ \text{O} \end{array}$
Methionine sulfone	$\begin{array}{c} \text{O}_2 \\ \\ \text{Met or Met or Met(O}_2\text{)} \\ \\ \text{O}_2 \end{array}$
<i>O</i> ³ -Phosphoserine (phosphoserine)	$\begin{array}{c} \text{P} \\ \\ \text{Ser or Ser or Ser(P)} \\ \\ \text{P} \end{array}$
<i>N</i> ⁷ -Methylhistidine ⁵ (see 3.3) (<i>telemethyl</i> - histidine)	$\begin{array}{c} \text{Me} \\ \tau \\ \text{His or His or His}(\tau\text{Me}) \\ \tau \\ \text{Me} \end{array}$

similarly for *N*^τ-substitution (*prosmethylhistidine*).

4.3 Substitution on carbon side chain

This may use the same convention as in 4.2, with the addition of locant numerals where necessary, e.g.:

3-Nitrotyrosine	$\begin{array}{c} \text{NO}_2 \\ \\ \text{Tyr or Tyr or Tyr (3NO}_2\text{)} \\ \\ \text{NO}_2 \end{array}$
2,3-Diaminopropionic acid (see 2.2.4) (3-aminoalanine)	$\begin{array}{c} \text{NH}_2 \quad \text{Ala} \\ \quad \text{or } \\ \text{Ala} \quad \text{NH}_2 \\ \text{Ala(3NH}_2\text{)} \end{array}$
Di-iodotyrosine	Tyr(I ₂)

5. Symbols for Substituents

Groups substituted for hydrogen or for hydroxyl may be indicated either by their structural formulae or by symbols or by combinations of both, e.g.:

Benzoylglycine (hippuric acid)	-CO-Gly* or C ₆ H ₅ CO-Gly or °Bz-Gly or PhCO-Gly
Glycine methyl ester	Gly-OCH ₃ or Gly-OMe
Trifluoroacetyl glycine	CF ₃ CO-Gly

Suggestions for symbols designating substituent (or protecting) groups common in polypeptide and protein chemistry follow.

5.1 *N*-Substituents (protecting groups) of the urethane type

Benzoyloxycarbonyl-	Z- or Cbz-
<i>p</i> -Nitrobenzyloxycarbonyl-	Z(NO ₂)-
<i>p</i> -Bromobenzyloxycarbonyl-	Z(Br)-
<i>p</i> -Methoxybenzyloxycarbonyl-	Z(OMe)-
<i>p</i> -Methoxyphenylazobenzyloxycarbonyl-	Mz-
<i>p</i> -Phenylazobenzyloxycarbonyl-	Pz-
<i>t</i> -Butoxycarbonyl-	Boc- or Bu'OCO-
Cyclopentyloxycarbonyl-	Poc- or cPeOCO-

5.2 Other *N*-substituents

Acetyl-	Ac-
Benzoyl- (C ₆ H ₅ —CO—)	PhCO- or Bz-
Benzyl- (C ₆ H ₅ —CH ₂ —)	PhCH ₂ - or °Bzl
Benzylthiomethyl-	PhSCH ₂ - or Btm-†
Carbamoyl-	NH ₂ CO- (preferred to Cbm)
1-Carboxy-2-nitrophenyl-5-thio-	°Nbs-

* Bz- is the symbol generally used for *benzoyl* in organic chemistry. It should not be used for *benzyl* (C₆H₅CH₂- or PhCH₂-), for which the symbol is Bzl-. However, PhCH₂- is unambiguous.

† See Comment following 5.3.

* *Senior Reporter's note:* In this formulation the phenyl group was to be repeated by its structural formulae.

† *Senior Reporter's note:* Benzylthiomethyl is PhCH₂-SCH₂-. It is used as an S-, not N-substituent. Section 5.2 includes groups used for O- and S-protein.

3-Carboxypropionyl- (HO ₂ C—CH ₂ —CH ₂ —CO—) ⁸	Suc-
Dansyl- (5-dimethylaminonaphthalene- 1-sulfonyl)	Dns-
Dinitrophenyl-	⁹ N ₂ ph- or Dnp
Formyl-	HCO- or CHO-
<i>p</i> -Iodophenylsulfonyl- (pipsyl)	Ips
Maleoyl- (—OC—CH=CH—CO—)	-Mal- or Mal <
Maleyl- (HO ₂ C—CH=CH—CO—)	Mal-
Methylthiocarbamoyl- ¹⁰	MeNHCS- or ¹⁰ Mtc-
<i>o</i> -Nitrophenylthio-	Nps-
Phenylthiocarbamoyl- ¹⁰	PhNHCS- or ¹⁰ Ptc
Phthaloyl-	-Pht- or Pht <
Phthalyl-	Pht-
Succinyl- ¹¹ (—OC—CH ₂ —CH ₂ —CO—)	-Suc- or Suc <
Tetrahydropyranyl-	H ₄ pyran- (preferred to Thp ⁹)
Tosyl- (<i>p</i> -tolylsulfonyl)	Tos-
Trifluoroacetyl-	⁹ CF ₃ CO-
Trityl- (triphenylmethyl)	Ph ₃ C- or Trt-

5.3 Substituents at carboxyl group

Benzyloxy- (benzyl ester)	-OCH ₂ Ph or -OBzl
Cyanomethoxy-	-OCH ₂ CN
Diphenylmethoxy- (benzhydryl ester)	-OCHPh ₂ or -OBzh
Ethoxy- (ethyl ester)	-OEt
Methoxy- (methyl ester)	-OMe
<i>p</i> -Nitrophenoxy- (<i>p</i> -nitrophenyl ester)	-ONp
<i>p</i> -Nitrophenylthio-	-SNp
Phenylthio- (phenylthiol ester)	-SPh
1-Piperidino-oxy-	-OPip
8-Quinolylxy-	-OQu
Succinimido-oxy-	-ONSu
<i>t</i> -Butoxy- (<i>t</i> -butyl ester)	-OBu ^t

⁸ Not succinyl, although it is the univalent radical of succinic acid. See succinyl and footnote 11.

⁹ The use of 'D' for 'di' and 'T' for 'tri' or 'tetra' (and 'DH' and 'TH' for 'dihydro' and 'tetrahydro' respectively) is discouraged. Recognized symbols and subscripts are recommended. See also footnote 3.

¹⁰ The symbol Pth has been used to denote a phenylthiohydantoin (e.g., Pth-Leu). Since this incorrectly implies the substitution of an amino acid by a 'phenylthiohydantoyl' group, it is suggested that the abbreviated symbol for such compounds be of the type CS-Leu-NPh or PhNCS-Leu (or Leu > PhNCS in textual material).

¹¹ Not succinoyl (6).

Comment

Many reagents used in peptide and protein chemistry for the modification (protection) of amino, carboxyl and side-chain groups in amino-acid residues have been designated by a variety of acronymic abbreviations, too numerous to be listed here. Extensive and indiscriminate use of such abbreviations is discouraged, especially where the accepted trivial name of

a reagent is short enough, e.g., tosyl chloride, bromosuccinimide, trityl chloride, dansyl chloride etc., or may be formulated in terms of the group transferred, e.g., $^9\text{N}_2\text{ph-F}$ instead of FDNB for 1-fluoro-2,4-dinitrobenzene, Dns-Cl or dansyl-Cl in place of DNS, $^9\text{Nbs}_2$ in place of DTNB for 5,5'-dithiobis-(2-nitrobenzoic acid) (Ellman's reagent), $(\text{Pr}^i\text{O})_2\text{PO-F}$, $\text{Pr}^i_2\text{P-F}$, $i\text{Pr}_2\text{P-F}$, or $\text{Dip-F}^{3,9}$ instead of DFP for di-isopropylfluorophosphate. Other commonly used substances that may be expressed more clearly in terms of symbols are MalNet (instead of NEM) for *N*-ethylmaleimide, Tos-PheCH₂Cl (instead of TPCK) for L-1-tosyl-amido-2-phenylethyl chloromethyl ketone, Tos-Arg-OMe (instead of TAME) for tosyl-L-arginine methyl ester, Me₃Si- (instead of TMS-) for trimethylsilyl, CF₃CO- (instead of TFA) for trifluoroacetyl (see 5.2), H₄furan (instead of THF) etc. (See also footnotes 3 and 9.)

Some additional symbolic terms for substituents (and reagents), as examples, are:

2-Aminomethyl-	-(CH ₂) ₂ NH ₂ (preferred to Aet)
Carbamoylmethyl-	-CH ₂ CONH ₂ (preferred to Cam)
Carboxymethyl-	-CH ₂ CO ₂ H (preferred to Cm)
Chloroethylamine	Cl(CH ₂) ₂ NH ₂
Ethyleneimine	(CH ₂) ₂ NH
Chloroacetamide	ClCH ₂ CONH ₂
Chloroacetic acid	ClCH ₂ CO ₂ H
<i>p</i> -Carboxyphenylmercuri-	-HgBzOH
<i>p</i> -Chloromercuribenzoate	<i>p</i> Cl-HgBzO ⁻
Diazoacetyl-	N ₂ CHCO-
Hydroxyethyl-	-(CH ₂) ₂ OH
Ethylene oxide	(CH ₂) ₂ O

6. Polypeptides

6.1 Polypeptide chains (5)

Polypeptides may be dealt with in the same manner as substituted amino acids, e.g.:


Glycylglycine	Gly-Gly
<i>N</i> -α-Glutamylglycine	Glu-Gly
<i>N</i> -γ-Glutamylglycine	or

or Gly or Glu(Gly)


Glutathione	or
	or Cys-Gly or Glu(Cys-Gly)

(Note that Glu would represent the corresponding thiol ester with a
 \downarrow
 Cys-Gly


bond between the γ -carboxyl of glutamic acid and the thiol group of cysteine.)



The presence of free, substituted, or ionized functional groups can be represented (or stressed) as follows:



6.2 Peptides substituted at N^2 (see 4.1)



6.3 Cyclic polypeptides

6.3.1 Homodetic cyclic polypeptides (the ring consists of amino-acid residues in peptide linkage only). Three representations are possible:

6.3.1.1 The sequence is formulated in the usual manner but placed in parentheses and preceded by (an italic) *cyclo*.

Example:


Gramicidin S

cyclo(-Val-Orn-Leu-D-Phe-Pro-Val-Orn-Leu-D-Phe-Pro-)


or (see 1.5, sentence 2)

cyclo(-Val-Orn-Leu-DPhe-Pro-Val-Orn-Leu-DPhe-Pro-)


6.3.1.2 The terminal residues may be written on one line, as in 6.3.1.1, but joined by a lengthened bond. Using the same example in the two forms (see 1.5):



or




6.3.1.3 The residues are written on more than one line, in which case the CO → NH direction must be indicated by arrows, thus (in the optional manner of 1.5):




6.3.2 *Heterodetic cyclic polypeptides (the ring consists of other residues in addition to amino-acid residues in peptide linkage)*. These follow logically from the formulation of substituted amino acids.

Examples:

Oxytocin



Cyclic ester of threonylglycylglycylglycine



References

- (1) Abbreviated Designation of Amino Acid Derivatives and Peptides: *J. Biol. Chem.* (1966) **241**, 2491; *Biochemistry* (1966) **5**, 2485; *Biochim. Biophys. Acta* (1966) **121**, 1; *Biochem. J.* (1967) **102**, 23; *Arch. Biochem. Biophys.* (1967) **121**, 1; *Eur. J. Biochem.* (1967) **1**, 375; *Hoppe-Seyler's Z. Physiol. Chem.* (1967) **348**, 256; *Bull. Soc. Chim. Biol.* (1967) **49**, 121; *Molek. Biol.* (1968) **2**, 282
- (2) Abbreviations and Symbols for Chemical Names of Special Interest in Biological Chemistry (Section 5 revised by 3 below): *J. Biol. Chem.* (1966) **241**, 527; *Biochemistry* (1966) **5**, 1445; *Biochem. J.* (1966) **101**, 1; *Virology* (1966) **29**, 480; *Arch. Biochem. Biophys.* (1966) **115**, 1; *Eur. J. Biochem.* (1967) **1**, 259; *Hoppe-Seyler's Z. Physiol. Chem.* (1967) **348**, 245; *Bull. Soc. Chim. Biol.* (1968) **50**, 3; *Molek. Biol.* (1967) **1**, 872
- (3) Abbreviations and Symbols for Nucleic acid, Polynucleotides and the Constituents: *Biochem. J.* (1970) **120**, 449; *Biochemistry* (1970) **9**, 4022; *Eur. J. Biochem.* (1970) **15**, 203; *J. Biol. Chem.* (1970) **245**, 5171; *Hoppe-Seyler's Z. Physiol. Chem.* (1970) **351**, 1055; *J. Mol. Biol.* (1971) **55**, 299; in the press elsewhere
- (4) Nomenclature of Vitamins, Coenzymes and Related Compounds: Trivial Names of Miscellaneous Compounds of Importance in Biochemistry, Nomenclature of Quinones with Isoprenoid Side Chains, Nomenclature and Symbols for Folic Acid and Related

- Compounds, Nomenclature of Corrinoids: *Arch. Biochem. Biophys.* (1967) **118**, 505; *Biochem. J.* (1967) **102**, 15; *Biochim. Biophys. Acta* (1965) **107**, 1; (1966) **117**, 285; *Eur. J. Biochem.* (1967) **2**, 1; *J. Biol. Chem.* (1966) **241**, 2987; *Bull. Soc. Chim. Biol.* (1967) **49**, 331; *Hoppe-Seyler's Z. Physiol. Chem.* (1967) **348**, 266
- (5) Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids): *Biopolymers* (1969) **8**, 161; *Arch. Biochem. Biophys.* (1968) **123**, 633; *Biochem. J.* (1968) **106**, 577; *Biochemistry* (1968) **7**, 483; *Biochim. Biophys. Acta* (1968) **168**, 1; *Eur. J. Biochem.* (1968) **3**, 129; *J. Biol. Chem.* (1968) **243**, 2451; *Bull. Soc. Chim. Biol.* (1969) **51**, 205; *Hoppe-Seyler's Z. Physiol. Chem.* (1969) **349**, 1013 (Revision in the press)
- (6) IUPAC: Nomenclature of Organic Chemistry (Definitive Rules for Section C), Rule C-404 and Table VI: *Pure Appl. Chem.* (1965) **11**, nos. 1-2

II Abbreviations and Symbols for the Description of the Conformation of Polypeptide Chains

(Reprinted by permission from I.U.P.A.C. Information Bulletin, Appendices on Tentative Nomenclature, Symbols, Units, and Standards, No. 10, February 1971)

Preamble

These Rules are based on *A proposal of standard conventions and nomenclature for the description of polypeptide conformation* (Edsall *et al.*, 1966*a,b,c*), and have been prepared by a Subcommission set up by the I.U.P.A.C.-I.U.B. Commission on Biochemical Nomenclature in 1966. The original proposals have been modified so as to bring them as far as possible into line with the system of nomenclature current in the fields of organic and polymer chemistry.


Two Recommendations are appended to the Rules, the first dealing with the terms configuration and conformation, and the second with primary, secondary and tertiary structure. These are formulated as recommendations rather than rules, because there is at present no general agreement about their definition.

Note: Two alternative notations are recommended throughout. That with superscripts and subscripts may be used when it is unlikely to cause confusion, e.g. in printed or manuscript material; that without is to be used where superscripts or subscripts may cause confusion, or are technically difficult or impossible, e.g. in computer outputs. In the latter connexion the following Roman equivalents of Greek letters are recommended:


α	A	τ	T
β	B	ν	U
γ	G	ϕ	F
δ	D	χ	X
ϵ	E	ψ	Q
ζ	Z	ω	W
η	H		

Rule 1. General Principles of Notation

1.1. *Designation of atoms.* The atoms of the main chain are denoted thus:




Where confusion might arise, the following additional symbolism may be used:



1.2. *Amino-acid residues*, —NH—CHR—CO— , are numbered sequentially from the amino-terminus to the carboxyl-terminus of the chain, the residue number being denoted i .

Example: C^α of the i th residue is written C_i^α or $\text{C}\alpha(i)$.

1.3. *Peptide units*. For some purposes it is more convenient to group together the atoms —CHR—CO—NH— . These groups are described as “peptide units”, and the peptide unit number, like the residue number, is denoted i . It will be noted that the two numbers are identical for all atoms except NH; generally there will be no confusion, because a single document will use either “residues” alone, or “peptide units” alone, but in the latter case explicit reference must be made to this usage at the beginning. If confusion might arise, the symbols N_i^* and H_i^* are to be used for these atoms in the i th peptide unit, which are N_i and H_i in the i th residue (so that $\text{N}_i^* = \text{N}_{i+1}$).



Residue notation	N_2	C_2^α	C_2	N_3
Peptide unit notation	N_1^*	C_2^α	C_2	N_2^*

Notes: (i) Residue notation is used throughout these Rules.

(ii) Whether “residues” or “peptide units” are being used, ϕ_i and ψ_i always refer to torsion angles about bonds of the same C_i^α .

1.4. *Bond lengths*. If a bond A—B be denoted $\text{A}_i\text{—B}_j$ or A_i (see Rules 3.1, 4.5), the bond length is written $b(\text{A}_i, \text{B}_j)$ (or $b(\text{A}_i, \text{B}_j)$), or b_i^{A} (or $b\text{A}(i)$). An abbreviated notation for use in side chains is indicated in Rule 4.5.

Note: The symbol previously recommended for bond length was l . This symbol is no longer recommended, partly because it is easily confused with 1 in many type fonts, and partly because it is also used for vibration amplitude in electron diffraction and spectroscopy.

1.5. *Bond angles*. The bond angle included between three atoms $\text{A}_i\text{—B}_j\text{—C}_k$ is written $\tau(\text{A}_i, \text{B}_j, \text{C}_k)$, which may be abbreviated, if there is no ambiguity, to $\tau(\text{B}_j)$ or τ_j^{B} or $\tau\text{B}(j)$.

1.6. *Torsion angles*. If a system of four atoms A—B—C—D is projected on to a plane normal to bond B—C , the angle between the projection of

A—B and the projection of C—D is described as the *torsion angle*[†] of A and D about bond B—C; this angle may also be described as the angle between the plane containing A, B and C, and the plane containing B, C and D. The torsion angle is written in full as $\theta(A_i, B_j, C_k, D_l)$, which may be abbreviated, if there is no ambiguity, to $\theta(B_j, C_k)$, $\theta(B_j)$ or θ_j^B , etc. In




FIG. 1. Newman and perspective projections illustrating positive and negative torsion angles. Note that a right-handed turn of the bond to the front atom about the central bond gives a positive value of θ from whichever end the system is viewed.

Notes: (i) Angles are measured in the range $-180^\circ < \theta \leq +180^\circ$, rather than from 0° to 360° , so that the relationship between enantiomeric configurations or conformations can be readily appreciated.

(ii) The symbols actually used to describe the various torsion angles important in polypeptides are ϕ , ψ , ω , ν and χ (see Rules 3.2, 4.5.2). In the above, θ is used simply as an illustrative generic symbol covering all these.

the eclipsed conformation in which the projections of A—B and C—D coincide, θ is given the value 0° (synplanar conformation). A torsion angle is considered positive ($+\theta$) or negative ($-\theta$) according as, when the system is viewed along the central bond in the direction $B \rightarrow C$ (or $C \rightarrow B$), the bond to the front atom A (or D) requires to be rotated to the right or to the left, respectively, in order that it may eclipse the bond to the rear atom D (or A); note that it is immaterial whether the system be viewed from one end or the other. These relationships are illustrated in Figure 1.

[†] The terms *dihedral angle* and *internal rotation angle* are also used to describe this angle, and may be regarded as alternatives to *torsion angle*, though the latter has been used throughout these Rules.

Rule 2. The Sequence Rule, and Choice of Torsion Angle


2.1. The Rules here enunciated for use in the field of synthetic polypeptides and proteins are in general harmony with the Sequence Rule of Cahn, Ingold & Prelog†, with the exceptions of Rules 2.1.1 and 2.2.2 (Cases II and III), and later Rules dependent upon these. The Sequence Rule was formulated as a universal and unambiguous means of designating the "handedness" or chirality of an element of asymmetry. It includes Subrules for the purpose of arranging atoms or groups in an order of precedence or preference, and this system may conveniently be used in the description of steric relationships across single bonds (see Klyne & Prelog, 1960). Here its function is to determine the priority or precedence of different atoms or groups attached to the same atom. However, Rule 2.1.1 below overrides the precedences of the Sequence Subrules, providing a new 'local' (specialist) system for use with the general Sequence Rule‡. After application of Rule 2.1.1, the normal procedure of the Sequence Rule is applied, but modified by Rule 2.2.2; in this connexion the only parts of the Sequence Rule required are given in Rules 2.1.2 to 2.1.5.

2.1.1. The main chain is given formal priority over branches, notwithstanding any conflict with the following rules. Thus the main chain has precedence at C α over the side chain, and at C' over O'.

Note: This rule has not yet been formally accepted except in the present context.

2.1.2. The order of (decreasing) priority is the order of (decreasing) atomic number.


Example: in



the order of priority is Br, Cl, CH₃, H.


2.1.3. If two atoms attached to the central atom are the same, the ligands attached to these two atoms are used to determine the priority.

Examples: (i) in



the order is Cl, (CH₂-CH₃), CH₃, H. (C^xH₂-CH₃ takes precedence over C^yH₃ because C^x is bonded to C, H, H and C^y to H, H, H.)

(ii) in




† See Cahn, Ingold & Prelog (1966*a,b,c*), IUPAC Tentative Rules for the Nomenclature of Organic Chemistry, Section E, IUPAC Information Bulletin no. 35, pp. 36-80 (1969). Earlier papers: Cahn & Ingold (1951), Cahn, Ingold & Prelog (1956). For a partial, simplified account see Cahn (1964) and Eliel (1962).

‡ Other local systems are available analogously for steroids, carbohydrates and cyclitols, where the Sequence Rule is applied when the local system does not suffice.

the order is OH, CH₂Cl, CH₂OH, H.

(iii) in



the order is OH, CH(CH₃)₂, CH₂-CH₃, H.


2.1.4. A double bond is formally treated as though it were split. Thus > C=O is treated as > C-O.



Example: in CH₃-CO-OH the order is =O, -OH, CH₃.

2.1.5. If two ligands are distinguished only by having different masses (e.g. deuterium and hydrogen), the heavier takes precedence.

Example: in




the order is Br, CH₃, D, H.

Note: This rule is to be used only if the two previous rules do not give a decision.

2.2. Choice of torsion angle and numbering of branches (tetrahedral configurations)

2.2.1. If, in a compound



the Sequence Rule gives the priorities A > P, Q and D > E > F, then the *Principal Torsion Angle* θ is that measured by reference to the atoms A-B-C-D as in Rule 1.6 above.

The branches beginning at C are numbered C₁-D, C₂-E and C₃-F.

2.2.2. If two branches are identical, and the third is different (or non-existent), they are numbered in a clockwise sense when viewed in the direction B → C, as follows (see Fig. 2).

Case I. D > E = E. D has the highest priority and is given the smallest number (1).

Case II. D = D > E. E has the lowest priority and is given the largest number (3).

Case III. D = D, numbered 1 and 2 (E non-existent).

In each case the Principal Torsion Angle is measured between A-B and branch 1.




FIG. 2. Tetrahedral configurations. Case I: $D > E = E$. Case II: $D = D > E$. Case III: $D = D$ (E non-existent).

Notes: (i) The rule given in Case II differs from Conformational Selection Rule (b) of the Sequence Rule (see Cahn *et al.*, 1966a, p. 406), according to which if an identity among the groups of a set leaves one group unique, the unique group is fiducial. The reason for the difference is that the Sequence Rule would define Principal Torsion Angle in terms of a hydrogen atom whenever a single such atom formed part of the set; in the X-ray technique, nearly always used to establish structures of the type under discussion, hydrogen atoms are usually unobservable, and even at the best cannot be located accurately, so that the position of one used to define a Principal Torsion Angle could only be established by calculation based on (perhaps unjustified) assumptions about the bond angles concerned. These considerations apply with even more force to Case III, where one branch is non-existent: the "phantom atom" of zero atomic number would be given highest priority because it is unique.


(ii) in case III the clockwise passage from CD^1 to CD^2 shall be by the shorter of the two possible routes.

2.2.3. If all three branches are identical, that giving the smallest positive or negative value of the Principal Torsion Angle is normally† assigned the highest priority and the lowest number (1) (see Fig. 3, IV, V); if two branches have torsion angles respectively $+60^\circ$ and -60° , the former is chosen (see Fig. 3, VI). The others are numbered in a clockwise sense when viewed in the direction $B \rightarrow C$.

Note: Rule 2.2.3 introduces a new principle, not invoked in 2.2.1 or 2.2.2, that the precedence depends on the conformation. This must necessarily be done since in this case the branches are distinguishable only in this respect. (The same applies to Rule 2.3.2 below.)

2.3. Choice of torsion angle and numbering of branches (planar trigonal configurations)

2.3.1. If, in a compound



such that B, C, D and E are coplanar, or nearly so, the Sequence Rule gives the priorities $A > P, Q$ and $D > E$, then the Principal Torsion

† The qualification "normally" is added to avoid the need to renumber the branches if by chance the rule would demand this in consequence of a movement during refinement of a structure. In this or similar cases the symbolism should remain unchanged.

Angle is that measured by reference to atoms A—B—C—D as in Rule 1.6 above.

The branches beginning at C are numbered C₁—D, C₂—E.




FIG. 3. Tetrahedral configurations. Three identical branches; IV, general case, θ positive; V, general case, θ negative; VI, $\theta = +60^\circ$.




FIG. 4. Planar trigonal configurations. Identical branches; VII, θ positive, VIII, θ negative, IX, $\theta = +90^\circ$.

2.3.2. If the branches are identical, that giving the smaller positive or negative value of the Principal Torsion Angle is normally assigned the highest priority and the lowest number (1); if the two branches have torsion angles respectively $+90^\circ$ and -90° , the former is chosen (see Fig. 4).

Rule 3. The Main Chain (or Polypeptide Backbone)

3.1. *Designation of bonds.* Bonds between main-chain atoms are denoted by the symbols of the two atoms terminating them, e.g. $N_i-C_i^\alpha$, $C_i^\alpha-C_i$, C_i-N_{i+1} , C_i-O_i , N_i-H_i . Abbreviated symbols should not be used. Bond lengths are written $b(C_i, N_{i+1})$, etc.

3.2. Torsion angles

3.2.1. The Principal Torsion Angle describing rotation about $N-C^\alpha$ is denoted by ϕ , that describing rotation about $C^\alpha-C$ is denoted by ψ , and that describing rotation about $C-N$ is denoted by ω . The symbols ϕ_i , ψ_i and ω_i are used to denote torsion angle of bonds within the i th residue in the case of ϕ and ψ , and between the i th and $(i+1)$ th

residues in the case of ω ; specifically, ϕ_i refers to the torsion angle of the sequence of atoms C_{i-1} , N_i , C_i^α , C_i ; ψ_i to the sequence N_i , C_i^α , C_i , N_{i+1} ; and ω_i to the sequence C_i^α , C_i , N_{i+1} , C_{i+1}^α (see Fig. 5). In accordance with Rules 1.6 and 2.1.1, these torsion angles are ascribed zero values for eclipsed conformations of the main-chain atoms N, C^α and C, that is, for the so-called *cis*-conformations (see Table 1).




FIG. 5. Perspective drawing of a section of polypeptide chain representing two peptide units. The limits of a *residue* are indicated by dashed lines, and recommended notations for atoms and torsion angles are indicated. The chain is shown in a fully extended conformation ($\phi_i = \psi_i = \omega_i = +180^\circ$), and the residue illustrated is L-.

Notes: (i) This convention differs from that proposed by Edsall *et al.* (1966*a,b,c*). The new designation of angles may be derived from the old by adding 180° to, or subtracting 180° from, the latter. (This statement is precisely correct only if the peptide bond is exactly planar, which is not generally the case in experimentally determined structures.)

(ii) Owing to the partial double-bond character of $\text{CO} \cdots \text{NH}$, it is normally possible for ω to assume values only in the neighbourhood of 0° or 180° . $\omega \sim 180^\circ$ is the value which is generally found (i.e. the *trans*-conformation).

(iii) A "fully-extended" polypeptide chain is characterized by $\phi = \psi = \omega = +180^\circ$. The case of $\phi = \psi = 0^\circ$ would involve the relations indicated in Table 1.

(iv) Table 2 gives values of ϕ and ψ for various well-known regular structures. It is noteworthy that a right-handed α -helix has negative torsion angles.

(v) Figure 6 is a typical conformational map ($\phi - \psi$ plot) using the Rules enunciated above.

3.2.2. There may occasionally be a need to consider torsion angles differing from zero for the sequences of atoms $\text{O}=\text{C}-\text{N}-\text{C}^\alpha$ and $\text{C}^\alpha-\text{C}-\text{N}-\text{H}$, in cases where $\text{C}=\text{O}$ or $\text{N}-\text{H}$ lies out of the peptide plane. These angles may be represented ν^0 and ν^{H} (Greek *upsilon*).

TABLE 1
Main-chain torsion angles for various conformations in peptides
of L-amino acids

ϕ	Rotation about $\text{N}-\text{C}^\alpha$	ψ	Rotation about $\text{C}^\alpha-\text{C}$
0°	$\text{C}^\alpha-\text{C}$ <i>trans</i>	0°	$\text{C}^\alpha-\text{N}$ <i>trans</i>
$+60^\circ$	$\text{C}^\alpha-\text{H}$ <i>cis</i>	$+60^\circ$	$\text{C}^\alpha-\text{R}$ <i>cis</i>
$+120^\circ$	$\text{C}^\alpha-\text{R}$ <i>trans</i>	$+120^\circ$	$\text{C}^\alpha-\text{H}$ <i>trans</i>
$+180^\circ$	$\text{C}^\alpha-\text{C}$ <i>cis</i>	$+180^\circ$	$\text{C}^\alpha-\text{N}$ <i>cis</i>
-120°	$\text{C}^\alpha-\text{H}$ <i>trans</i>	-120°	$\text{C}^\alpha-\text{R}$ <i>trans</i>
-60°	$\text{C}^\alpha-\text{R}$ <i>cis</i>	-60°	$\text{C}^\alpha-\text{H}$ <i>cis</i>

Notes: (i) *Trans* to N_i-H_i is the same as *cis* to $\text{N}_i-\text{C}_{i-1}$; *trans* to C_i-O_i is the same as *cis* to $\text{C}_i-\text{N}_{i+1}$ (see Fig. 5).

(ii) For the description of D-amino acids, interchange $\text{C}^\alpha-\text{H}$ and $\text{C}^\alpha-\text{R}$ in the Table.

TABLE 2
Approximate torsion angles for some regular structures

	ϕ (deg.)	ψ (deg.)	ω (deg.)	Reference
Right-handed α -helix (α -poly(L-alanine))	- 57	- 47	+ 180	Arnott & Dover (1967)
Left-handed α -helix	+ 57	+ 47	+ 180	Arnott & Dover (1967)
Parallel-chain pleated sheet	- 119	+ 113	+ 180	Schellman & Schellman (1964)
Antiparallel-chain pleated sheet (β -poly(L-alanine))	- 139	+ 135	- 178	Arnott, Dover & Elliott (1967)
Polyglycine II	- 80	+ 150	+ 180	Ramachandran, Sasisekharan & Ramakrishnan (1966)
Collagen	- 51, - 76, - 45	+ 153, + 127, + 148	+ 180	Yonath & Traub (1969)
Poly(L-proline) I	- 83	+ 158	0	Ramachandran & Sasisekharan (1968), calculated from Traub & Schmuclli (1963)
Poly(L-proline) II	- 78	+ 149	+ 180	Arnott & Dover (1968)

(Note: for a fully extended chain $\phi = \psi = \omega = + 180^\circ$.)

3.3 Chain terminations

3.3.1. If the terminal amino group of the chain is protonated, the three hydrogen atoms are denoted H_1^+ , H_2^+ and H_3^+ ; the hydrogen atom giving the smallest (positive or negative) value of the Principal Torsion Angle $H-N-C^\alpha-C$ is denoted H_1^+ and the others are numbered in





FIG. 6. Typical conformational map (Ramachandran, Ramakrishnan & Sasisekharan, 1963) transposed into the standard conventions.

Note: This diagram is identical with that of Edsall *et al.* (1966*a,b,c*), except that the origin is now at the centre, instead of at the lower left-hand corner. The solid lines enclose the freely allowed values of ϕ and ψ for an alanine residue in a polypeptide; the dotted lines enclose "outer limit" values based on the shortest known van der Waals radii in related structures. Analogous diagrams for other residues, and for slightly different assumptions, are given by Ramachandran & Sasisekharan (1968; note that these authors used the earlier convention with the origin at the corner).

a clockwise sense when viewed in the direction $C^\alpha \rightarrow N$. The corresponding torsion angles are denoted ϕ_1^+ , ϕ_2^+ and ϕ_3^+ . If the terminal amino group is not protonated, the hydrogen atoms are denoted H_1^- and H_2^- in accordance with Rule 2.2.2, and the corresponding torsion angles ϕ_1^- and ϕ_2^- .

3.3.2. At the carboxyl-terminus of the chain ($i = T$) the double-bonded oxygen is written as O' and the other oxygen as O'' , thus




The torsion angles about the $C^\alpha-C$ bond are written ψ_1^+ and ψ_2^+ (or $\psi_1(T)$, $\psi_2(T)$); the torsion angle about the $C-O''$ bonds, defining the orientation of the hydrogen atom of the

hydroxyl group relative to C^α , is written θ_T^G (or $\theta C(T)$). If the terminal carboxyl group is ionized, the oxygen atoms are denoted O' and O'' , the precedence being determined by Rule 2.3.2, and the torsion angles are written as before.


Note: Instead of O' and O'' the alternative notations O^1 and O^2 may be used. ψ_T may be used instead of ψ_T^1 , in conformity with the convention for the middle of the chain, so long as confusion does not arise.

3.3.3. *Substituted terminal groups.* Natural extensions of the above rules may be devised, e.g.:


(i) *N-formyl group*



(ii) *N-acetyl group*



(iii) *C-amido group*



Rule 4. Side Chains

4.1. Atoms are lettered, or lettered and numbered, from C^α , and bonds are numbered from C^α , working outwards away from the main chain.

4.2. *Designation of atoms other than hydrogen.* Atoms other than hydrogen are designated in the usual way by Greek letters, β , γ , δ , etc. C_i^β (or $C\beta(i)$), N_i^ζ (or $N\zeta(i)$).

Note: The notations for the amino acids normally occurring in proteins are given in Table 3.

TABLE 3

Symbols for atoms and bonds in the side chains of the commonly occurring L-amino acids

(a) Unbranched side chains

Alanine	$C^\alpha-C^\beta$ 1
Serine	$C^\alpha-C^\beta-O^\gamma$ 1 2
Cysteine	$C^\alpha-C^\beta-S^\gamma$ 1 2
Cystine	$C_{1_i}^\alpha-C_{2_i}^\beta-S_{3_i}^\gamma-S_{2_k}^\gamma-C_{1_k}^\beta-C_{2_k}^\alpha$ 1 _i 2 _i 3 _i 2 _k 1 _k
Methionine	$C^\alpha-C^\beta-C^\gamma-S^\delta-C^\epsilon$ 1 2 3 4
Lysine	$C^\alpha-C^\beta-C^\gamma-C^\delta-C^\epsilon-N^\zeta$ 1 2 3 4 5

TABLE 3—continued

(b) Branched side chains






TABLE 3—continued

(c) Cyclic side chains


Proline




Hydroxyproline




Histidine




Phenylalanine



Tyrosine



Tryptophan




4.3. *Designation of branches.* If a side chain is branched, the branches are numbered 1 and 2, the order being determined:

- (i) in cases where the branches are different, by application of Rule 2.2.1 or 2.3.1,

- (ii) in cases where two branches are identical (e.g. in valine, phenylalanine), by the application of Rule 2.2.2 (valine) or 2.3.2 (phenylalanine).

Non-hydrogen atoms in different branches are designated by the Greek letter indicating their degree of remoteness from C^α and by the number of their branch (see Rules 2.2 and 2.3); e.g. in valine C_i^γ and C_j^γ (or $C_{\gamma 1(i)}$, $C_{\gamma 2(j)}$). The branch number need not be indicated where no ambiguity results: e.g. in threonine O^γ and C^γ instead of $O^{\gamma 1}$ and $C^{\gamma 2}$, hydroxyproline O^δ , C^δ instead of $O^{\delta 1}$, $C^{\delta 2}$, and in histidine C^δ , N^ϵ , etc. instead of $C^{\delta 2}$, $N^{\epsilon 2}$. For asparagine or glutamine, in cases where nitrogen and oxygen in the amide group have not yet been distinguished, these atoms may be written $(NO)^{\delta 1}$, $(NO)^{\delta 2}$, or $(NO)^{\epsilon 1}$, $(NO)^{\epsilon 2}$, the indices 1 and 2 being determined by Rule 2.3.2.

4.4. *Designation of hydrogen atoms.* Hydrogen atoms are designated by the Greek letter and/or number of the atom to which they are attached; e.g. in valine H_i^β (or $H\beta(i)$). Where three hydrogen atoms are attached to a single non-hydrogen atom, they are designated 1, 2 and 3; in the situation




value of the Principal Torsion Angle is designated 1, and the others are numbered in a clockwise sense when viewed in the direction $B \rightarrow C$ (see Rule 2.2.3, which also covers the case where $\theta = \pm 60^\circ$). E.g. in valine $H_i^{\gamma 1}$, $H_i^{\gamma 2}$, $H_i^{\gamma 3}$ and $H_i^{\gamma 21}$, $H_i^{\gamma 22}$, $H_i^{\gamma 23}$ (or $H_{\gamma 11(i)}$, etc.). Where only two hydrogen atoms are present, they are designated in accordance with Rule 2.2.2, case I for $-\text{CH}_2-\text{R}$ and case III for $-\text{NH}_2$.

4.5. *Designation of bonds and torsion angles* (see Table 3)

4.5.1. Bonds are designated by means of the two atoms terminating them, e.g. $C_i^\alpha-C_i^\beta$, $N_i^\gamma-H_i^{\epsilon 2}$, or, if no ambiguity results, by the symbol of the first atom of the bond, e.g. C_i^α , C_i^γ . In superscripts, the bond may be denoted either by α ; β ; $\gamma 1$; $\gamma 2$ etc. or by, 1; 2; 3,1; 3,2; etc. Bond lengths are denoted $b(C_i^\alpha, C_i^\beta)$, bC_i^α , b_1^α , $b_1^{\beta 1}$ etc.

4.5.2. Torsion angles are denoted by χ , and are specified by two (or



indicating the bond B—C about which the angle is measured, and the last indicating whether the angle is measured relative to D, E or F. The Principal Torsion Angle is defined by Rule 2.2.1, and if there is no ambiguity the last superscript may be omitted in referring to it.

Thus, in valine, $\chi_i^{\beta 1}$ and $\chi_i^{\beta 2}$ refer to the torsion angles specifying atoms C_i^γ and C_i^δ ; in leucine $\chi_i^{\beta 1,1}$, $\chi_i^{\beta 1,2}$ and $\chi_i^{\beta 1,3}$ refer to the torsion

angles specifying the three hydrogen atoms attached to $C^{\delta 1}$. If there is no ambiguity the Principal Torsion Angles may be referred to, in valine and leucine, as χ_i^1 and $\chi_i^{3,1}$, respectively. Corresponding notations without subscripts are $\chi 2,1(i)$, $\chi 2(i)$; $\chi 3,1,1(i)$, $\chi 3,1(i)$.


Note: By the Sequence Rule, when $\chi_1 = 0$, C^γ (or $C^{\gamma 1}$) is in the eclipsed position relative to N.

Rule 5. Hydrogen Bonds

5.1. *Polarity of hydrogen bonds.* In specifying a hydrogen bond as directed from residue i to residue k (or from atom X_i to atom Y_k), the direction $X-H$ to $:Y$ is implied; i.e. the atom covalently linked to the hydrogen atom is mentioned first.

Example: in the α -helix, the $N-H$ of residue i is hydrogen-bonded to the $O=C$ of residue $(i - 4)$. Therefore, the α -helix is described as having i to $(i - 4)$, or $(5 - 1)$, hydrogen-bonding.

5.2. *Dimensions of hydrogen bonds.* Dimensions may be denoted by natural extensions of the nomenclature given above. For example, in



the following symbols might be used:

$b(H_i, O_k)$, $\tau(N_i, H_i, O_k)$, $\tau(H_i, O_k, C_k)$, $\theta(H_i, O_k)$, $\theta_i(N, H)$, $\theta_k(C, O)$.

Rule 6. Helical Segments

A regular helix is strictly of infinite length, with all ϕ 's identical and all ψ 's identical. A helical *segment* of polypeptide chain may be defined *either* in terms of ϕ and ψ , *or* in terms of symmetry and hydrogen-bond arrangement.

6.1. In the description of helices or helical segments, the following symbols should be used:

n = number of residues per turn;

h = unit height (translation per residue along the helix axis);

$t = 360^\circ/n$ = unit twist (angle of rotation per residue about the helix axis).

6.2. *Definition in terms of ϕ and ψ .* Under this definition a helical segment is referred to as a (ϕ, ψ) helix; thus a right-handed α -helix would be a $(-57^\circ, -47^\circ)$ helix. The *first* and *last* residues of the helical segment are taken to be the first and last residues which have ϕ and ψ values equal to those defining the helix, within limits which should be defined in the context. No account is taken of hydrogen-bonding arrangements.

6.3. *Definition in terms of symmetry and hydrogen-bond arrangement.* A helix is referred to as an n_r helix,

where n = number of residues per turn;

r = number of atoms in ring formed by a hydrogen bond and the segment of main chain connecting its extremities.

Thus an α -helix would be 3.6_{13} . The *first* helical residue is taken as the first whose CO group is *regularly* bonded to NH along the helix (in the case of an α -helix, to the NH of the fifth residue); the *last* helical residue is the last whose NH is *regularly* hydrogen-bonded to CO along the helix (in the case of an α -helix, to the CO of the residue last but four). Irregular hydrogen-bonding arrangements are not considered to form part of the helix.

Notes: (i) A helical segment defined by Rule 6.2 may, but need not necessarily, be two residues shorter than the same segment defined by Rule 6.3.

(ii) These rules prescribe no definitions for irregular helical segments.

APPENDIX

Recommendation A. Conformation and Configuration

There is at present no agreed definition of these two terms for general stereochemical usage.

In polypeptide chemistry, the term "conformation" should be used, in conformity with current usage, to describe different spatial arrangements of atoms produced by rotation about covalent bonds; a change in conformation does not involve the breaking of chemical bonds (except hydrogen bonds) or changes in *chirality* (see Cahn, Ingold & Prelog, 1966*a,b,c*).

On the other hand, in polypeptide chemistry the term "configuration" is currently used to describe spatial arrangements of atoms whose inter-conversion requires the formal breaking and making of covalent bonds (*Note:* this usage takes no account of the breaking or making of hydrogen bonds). For a more extensive discussion see IUPAC Tentative Rules for the Nomenclature of Organic Chemistry, Section E, Fundamental Stereochemistry, *IUPAC Information Bull. no. 35* (1969), pp. 71–80.

Recommendation B. Definitions of Primary, Secondary, Tertiary and Quaternary Structure

These concepts, originally introduced by Linderstrøm-Lang (1952)[†], cannot be defined with precision, but the definitions given below may be helpful.

B.1. The *primary structure* of a segment of polypeptide chain or of a protein is the amino-acid sequence of the polypeptide chain(s), without regard to spatial arrangement (apart from configuration at the α -carbon atom).

Note: This definition does not include the positions of disulphide bonds, and is therefore not identical with "covalent structure".

[†] The use of the terms "primary, secondary, tertiary and quaternary structure" has been criticized as being imprecise by Wetlaufer (1961). He has proposed an alternative terminology.

B.2. The *secondary structure* of a segment of polypeptide chain is the local spatial arrangement of its main-chain atoms without regard to the conformation of its side chains or to its relationship with other segments.

B.3. The *tertiary structure* of a protein molecule, or of a subunit of a protein molecule, is the arrangement of all its atoms in space, without regard to its relationship with neighbouring molecules or subunits.

B.4. The *quaternary structure* of a protein molecule is the arrangement of its subunits in space and the ensemble of its intersubunit contacts and interactions, without regard to the internal geometry of the subunits.

Note: A protein molecule not made up of at least potentially separable subunits (not connected by covalent bonds) possesses no quaternary structure. Examples of proteins without quaternary structure are ribonuclease (1 chain) and chymotrypsin (3 chains).

REFERENCES

- Arnott, S. & Dover, S. D. (1967). *J. Mol. Biol.* **30**, 209.
Arnott, S. & Dover, S. D. (1968). *Acta Cryst. B*, **24**, 599.
Arnott, S., Dover, S. D. & Elliott, A. (1967). *J. Mol. Biol.* **30**, 201.
Cahn, R. S. (1964). *J. Chem. Educ.* **41**, 116.
Cahn, R. S. & Ingold, C. K. (1951). *J. Chem. Soc.* p. 612.
Cahn, R. S., Ingold, C. K. & Prelog, V. (1956). *Experientia*, **12**, 81.
Cahn, R. S., Ingold, C. K. & Prelog, V. (1966a). *Angew. Chem. intern. Edit.* **5**, 385.
Cahn, R. S., Ingold, C. K. & Prelog, V. (1966b). *Angew. Chem. intern. Edit.* **5**, 511.
Cahn, R. S., Ingold, C. K. & Prelog, V. (1966c). *Angew. Chem.* **78**, 413.
Edsall, J. T., Flory, P. J., Kendrew, J. C., Liguori, A. M., Némethy, G., Ramachandran, G. N. & Scheraga, H. A. (1966a). *J. Biol. Chem.* **241**, 1004.
Edsall, J. T., Flory, P. J., Kendrew, J. C., Liguori, A. M., Némethy, G., Ramachandran, G. N. & Scheraga, H. A. (1966b). *Biopolymers*, **4**, 130.
Edsall, J. T., Flory, P. J., Kendrew, J. C., Liguori, A. M., Némethy, G., Ramachandran, G. N. & Scheraga, H. A. (1966c). *J. Mol. Biol.* **15**, 339.
Eliel, E. L. (1962). *Stereochemistry of Carbon Compounds*, pp. 92–4. New York: McGraw Hill.
IUPAC Information Bulletin. (1969). No. 35, pp. 36–80.
Klyne, W. & Prelog, V. (1960). *Experientia*, **16**, 521.
Linderstrøm-Lang, K. (1952). *Proteins and Enzymes, Lane Memorial Lectures*, p. 54. Stanford, Calif.: Stanford University Press.
Ramachandran, G. N., Ramakrishnan, C. & Sasisekharan, V. (1963). *J. Mol. Biol.* **7**, 95.
Ramachandran, G. N. & Sasisekharan, V. (1968). *Advanc. Protein Chem.* **23**, 283.
Ramachandran, G. N., Sasisekharan, V. & Ramakrishnan, C. (1966). *Biochim. biophys. Acta*, **112**, 168.
Schellman, J. A. & Schellman, C. (1964). In *The Proteins*, ed. by H. Neurath, vol. 2, p. 1. New York: Academic Press.
Traub, W. & Schmueli, U. (1963). In *Aspects of Protein Structure*, ed. by G. N. Ramachandran, p. 81. London: Academic Press.
Wetlaufer, D. B. (1961). *Nature*, **190**, 1113.
Yonath, A. & Traub, W. (1969). *J. Mol. Biol.* **43**, 461.

Author Index

- Aanning, H. L., 285
 Abdulaev, N. G., 118
 Abdullaev, N. D., 411, 421
 Abe, J., 179, 413
 Abe, T., 172
 Abel, C. A., 151, 154
 Abermark, B., 436
 Abernethy, J. L., 16
 Aboderin, A. A., 96, 237
 Abraham, E. P., 432
 Abraham, S., 303
 Abrash, L., 285
 Aburatuni, M., 7
 Acampora, M., 262
 Acher, R., 100, 141
 Achiwa, K., 20, 259
 Achter, E. K., 109
 Ackerman, R. J., 34
 Ackers, G. K., 289, 293
 Acre, D., 171
 Acton, R. T., 148
 Adachi, K., 30
 Adams, E. T., jun., 287
 Adams, J. B., jun., 334
 Adams, M. J., 112, 199
 Adams, P., 289
 Adams, R. W., 90
 Adamson, J., 144
 Adickes, H. W., 438
 Adler, A. J., 282
 Adman, E., 245
 Aebersold, D., 255
 Agadzhanian, Ts. E., 40
 Agafonova, G. A., 431
 Agarwal, S. P., 91
 Aggarwal, S. J., 138
 Agosta, A., 385
 Ahmad, V. U., 3
 Ainsworth, C. F., 214, 219
 Air, G. M., 141
 Akagi, J. M., 136
 Akazawa, S., 2
 Akervall, K., 182, 222
 Akeson, A., 199
 Akgün, A., 92
 Akimoto, T., 21
 Aktipis, S., 257
 Alakhov, Yu. B., 392
 Alarkon, N. L., 385
 Albano, E., 16
 Albers, J. J., 55
 Albers, R. J., 395
 Albert, A., 29, 238, 278
 Aldanova, N. A., 41, 118, 392
 Alden, R. A., 184, 187, 205
 Aldridge, J., 70
 Alekseeva, L. V., 12
 Aleksiev, B., 392
 Alexander, B., 46
 Alexander, C., 157
 Ali, A., 382, 389
 Allan, D., 162
 Allard, D., 125
 Allen, G. A., 388
 Allen, L. M., 113
 Allerhand, A., 248
 Allewell, N. M., 191
 Aloj, S. M., 268, 270
 Al-Saghab, A. F., 22
 Altaf-Ur-Rahman, 322
 Altekhar, W. W., 116
 Ambler, R. P., 39, 135
 Amiconi, G., 147, 302, 305
 Amirkhanyan, M. M., 105
 Amit, B., 320
 Ammermann, E., 431
 Amos, L. A., 222
 Amoss, M., 81, 369
 Amzel, L. M., 220
 Anand, N., 261
 Anastasi, A., 83, 385
 Anatol, J., 393
 Anders, E., 7
 Anders, R., 112
 Andersen, B., 104
 Andersen, M. E., 306, 307
 Anderson, C. G., 84
 Anderson, J. A., 70
 Anderson, J. J. B., 366
 Anderson, J. M., 223, 263
 Anderson, M. E., 295
 Anderson, M. S., 370
 Anderson, N. M., 305
 Anderson, P. J., 114
 Anderson, P. M., 168
 Anderson, R. D., 207
 Anderson, S. R., 243, 277, 304
 Anderson, W. B., 299
 Andersson, B. A., 21
 Andersson, L. O., 165, 238
 Ando, T., 172
 Andreatta, R. H., 44, 384, 389, 391
 Andrew, I. M., 421
 Andrews, E. P., 158, 159
 Andreyeva, N. S., 195, 198
 Andria, G., 117
 Andries, J. C., 223
 Anfinsen, C. B., 56, 108, 116, 117, 156, 225, 242, 281, 363, 381, 382, 387
 Angeletti, R. H., 88, 132
 Angelucci, F., 385
 Annan, W. D., 75
 Anselme, J. P., 311
 Anthony, J. S., 286
 Antkowiak, D. H., 299
 Antonini, E., 143, 147, 294, 302, 305
 Antonini, J., 105
 Antonoff, R. S., 36
 Aoe, H., 237
 Aoki, K., 178
 Aoki, T., 179, 413
 Aoyagi, H., 310
 Apgar, P. A., 207
 Appella, E., 150, 151, 154
 Applegate, H. E., 433, 437
 Applequist, J., 247
 Araya, A., 142
 Ard, J. S., 252
 Argos, P., 205
 Argoudelis, A. D., 428
 Arian, S., 240
 Arimura, A., 81, 367, 372
 Arison, B. H., 349
 Ariyoshi, Y., 21, 30
 Arkhipova, S. F., 411, 421, 424
 Armstrong, J. McD., 378
 Arnberg, H., 84
 Arndt, D. J., 146
 Arnheim, N., 108
 Arnold, W. J., 132
 Arnon, D. I., 136
 Arnon, R., 108, 387
 Arnone, A., 116, 192
 Arnott, S., 471
 Arold, H., 385
 Arrio, B., 264
 Arrio-Dupont, M., 119, 239
 Asaba, K., 281
 Asakura, T., 230, 231
 Asano, Y., 427
 Ashbrook, C. W., 434, 437
 Ashby, C. D., 307
 Ashida, T., 128, 178
 Ashoor, S. H., 47
 Ashton, F. E., 55
 Ashton, H., 248
 Ashton, K., 132, 299
 Ashworth, R. B., 121
 Askonas, B. A., 156
 Asquith, R. S., 28, 74
 Atala, S., 355
 Atassi, M. Z., 24, 45, 109, 143, 167, 273, 281
 Atherton, E., 385, 420, 439
 Atkin, G. E., 34
 Atkinson, A., 132

- Atkinson, D. E., 289, 299
 Atto, A. T., 22
 Aubry, A., 17
 Aue, W. A., 1
 Augusteyn, R. C., 73
 Auna, Z., 384, 388
 Aune, J. P., 7
 Aune, K. C., 304
 Aurbach, G. D., 82, 379
 Austen, B. M., 428
 Austin, M. K., 366
 Autkowiak, D. H., 132
 Averin, M. N., 385
 Avey, H. P., 220
 Avi-dor, Y., 237
 Avigad, G., 258
 Avignon, M., 250
 Aviram, I., 133
 Avrameas, S., 47
 Avramovic-Zikic, O., 167
 Axén, R., 46
 Axenrod, T., 42
 Azari, P., 71
 Azuma, T., 171

 Baba, Y., 81, 82, 366, 367, 368
 Bach, G., 437
 Baddiel, C. B., 253
 Badley, R. A., 241
 Baggott, J. P., 241
 Bagnell, J. J., jun., 319
 Bahadar, K., 2
 Bahl, O. P., 78
 Bailey, A. J., 63, 64
 Bailey, W. J., 359
 Baily, E. D., 258
 Bakardjieva, A., 143
 Bakay, B., 55
 Balandina, G. N., 392
 Balashova, T. A., 401
 Balavoine, G., 432
 Baldassare, J. J., 249
 Baldeschwieler, J. D., 247, 421
 Baldesten, A., 113
 Baldwin, G. S., 86
 Baldwin, J. E., 434
 Bales, B. L., 235
 Balis, M. E., 31
 Balk, M. W., 366
 Ballantyne, D. L., 37
 Balog, A., 324, 392
 Balhasar, W., 110, 232
 Balyulis, R. A., 105
 Banaszak, L. J., 198, 201
 Bando, M., 44
 Bando, S., 178
 Banerjee, A. B., 400, 414
 Banerjee, R., 274
 Banerjee, S. K., 96
 Bangham, D. R., 365
 Bankowski, K., 341
 Banks, B. E. C., 123, 132
 Banner, D. W., 195
 Bannister, W., 276
 Barandum, S., 148
 Barat, E., 82
 Baratova, L. A., 37, 104
 Baratti, J., 95
 Barber, A. J., 428
 Barel, A. O., 109
 Bargerion, C. R., 244
 Barkemeyer, H., 349
 Barker, R., 59
 Barker, S. A., 172
 Barlow, G. H., 98
 Barnard, E. A., 163, 262
 Barnes, E. M., 136
 Barnes, L. D., 289, 299
 Barnes, M. J., 65
 Barnett, W., 301
 Barnikol, H.-U., 149
 Barnum, H. W., 331
 Barooshian, A. V., 30
 Barra, D., 119
 Barran, L. R., 116
 Barrett, A. N., 182, 221
 Barrington-Leigh, J., 221
 Barry, C. D., 182
 Barskaya, T. F., 229
 Barstow, L. E., 343, 378
 Bartels, E., 163
 Bartelt, D. C., 100
 Barth, G., 257
 Barth, T., 16
 Barton, D. H. R., 435
 Barton, J. P., 28
 Barton, M. A., 18
 Barton, R. A., 122
 Basch, H., 437
 Baskova, I. P., 97
 Bass, J. M. A., 354
 Bates, L. S., 30
 Bati, J., 31
 Batke, J., 111
 Batooisingh, E., 2
 Battersby, A. R., 14
 Batz, H. G., 315
 Baur, M. E., 235
 Baxter, J. W. M., 388
 Bayer, E., 16, 18, 29, 246, 247, 357, 358
 Bayley, P. M., 260, 275, 285, 408, 410
 Beacham, J., 373
 Beacham, L. M., tert., 312
 Beard, J. M., 140
 Bearden, A. J., 245
 Bechtel, P. J., 61
 Becka, L. N., 220
 Becker, J. M., 175
 Becker, J. W., 214, 215
 Becker, M., 60
 Becker, R. R., 268
 Beechey, R. B., 161
 Beet, I., 387
 Behal, F. J., 132
 Behnke, W. D., 89, 279
 Beikirch, H., 122
 Beinert, H., 245
 Belchich, A. L., 16
 Belikov, V. M., 17
 Belitz, H. D., 102
 Belkhodja, O., 144
 Bell, E. A., 2
 Bell, J. D., 201
 Bellamy, G., 63
 Belleau, B., 163
 Belliveau, P. E., 31
 Bello, J., 118
 Belyanova, L. P., 37, 104
 Benacerraf, B., 392
 Benassi, C. A., 281, 342, 387
 Bender, M. L., 91, 92
 Bender, W. W., 159
 Benditt, E. P., 150
 Benedetti, E., 260, 403
 Bengtsson, U., 194, 222
 Benisek, W. F., 175
 Benjamini, M., 240
 Bennett, A., 7, 139
 Bennett, C. D., 82, 366
 Bennett, E. L., 241
 Bennett, J. C., 148, 172
 Bennett, H. P. J., 33
 Bennick, A., 233
 Bensiton, N. L., 11, 16
 Benson, A., 138
 Benson, A. M., 127
 Bensusan, H. B., 63
 Berg, H. C., 159
 Berger, A., 261, 262, 360
 Berger, E., 95
 Berger, R. L., 21
 Berggård, I., 150
 Berghäuser, J., 112
 Berglund, O., 113, 114
 Bergman, R., 46
 Bergsten, P.-C., 194
 Bergstrom, K., 29
 Berliner, L. J., 194, 234
 Berman, J. D., 57
 Bernardi, G., 267
 Bernardi, L., 385
 Berndt, H., 312
 Bernhard, S. A., 111, 128
 Bernier, I., 109
 Bernini, L. F., 144
 Berns, D. S., 138, 304
 Bernstein, H., 269
 Bernstein, J., 437
 Bernstein, M. D., 16
 Berridge, B. J., 34
 Berse, C., 9
 Berseck, C., 386
 Bertaccini, G., 385
 Berthon, J., 218, 299
 Bertland, A. U., 241
 Besspalova, Zh. D., 387
 Bessette, P., 9
 Best, J. S., 142
 Bethune, J. L., 132, 299
 Beu, L., 324, 392
 Beutler, E., 132
 Bevan, K., 7
 Bewley, T. A., 80, 268
 Beychok, S., 259, 268, 269, 271
 Beyer, H., 36
 Beyerman, H. C., 316, 354, 359, 371
 Bezkorovainy, A., 71
 Bezpalova, Z., 417
 Bhatnagar, G. M., 161
 Bhatti, T., 426
 Bickle, T. A., 53
 Bielański, W., jun., 50

- Bielka, H., 69
 Bier, C. J., 116, 192, 193
 Bierme, R., 144
 Biernat, J., 401
 Billa, S. P., 2
 Billups, C., 20, 267
 Binotti, L., 147
 Biondi, L., 25, 171
 Birch, A. J., 406
 Birchmeier, W., 168
 Birkett, D. J., 297
 Birktoft, J. J., 184
 Birnbaum, E. R., 270
 Birnbaumer, L., 60
 Birr, C., 359, 392, 411
 Birrell, G. B., 235
 Birshtein, B. K., 151, 153
 Birshtein, T. M., 254
 Bischofberger, H., 132
 Biscoglio, M. J., 80
 Biserte, G., 143
 Bjork, I., 132, 150, 277, 283, 299, 300
 Blackwell, R., 81, 369
 Blackwell, R. Q., 144
 Bláha, K., 21, 417
 Blagrove, R. J., 294
 Blair, T. T., 91
 Blake, C. C. F., 106, 193, 198, 218, 234, 299
 Blake, D. A., 10
 Blake, J., 387
 Blanch, H. W., 409
 Blanco, F. G., 229
 Bland, J. S., 25
 Blapp, B. V., 33
 Blasi, F., 270
 Blinova, G. G., 12
 Blinova, I. N., 438
 Bloch, K. J., 63, 154
 Bloembergen, N., 233
 Bloemendal, H., 50, 72, 73
 Bloemmen, J., 167
 Blombäck, B., 66
 Blombäck, M., 66
 Blomquist, A. T., 388
 Bloomer, A. C., 195
 Blout, E. R., 93, 224, 251, 252, 261, 263, 264, 360, 400, 401
 Blow, D. M., 177, 187
 Bloxside, J., 19
 Blumberg, P. M., 154
 Blumberg, S., 175
 Blume, K. G., 132
 Blumenfeld, O.-O., 66
 Blumenkrantz, N., 33
 Blundell, T. L., 177, 182, 215, 216
 Boas, J. F., 246
 Boatman, G., 53
 Bobinski, H., 426
 Bobodzhyanov, P. Kh., 235
 Bocchi, V., 25
 Bocchini, V., 60
 Boctor, F. N., 33
 Bodanszky, A., 3, 285
 Bodanszky, M., 3, 285, 390, 400
 Bode, W., 132
 Bodlaender, P., 96
 Bodwell, C. E., 61
 Boeck, L. D., 3, 437
 Boehm, S., 21
 Boeker, E. A., 119
 Bøler, J., 371
 Boelts, K. J., 307
 Boerma, F. W., 144
 Bogach, P. G., 28
 Bogentoft, C., 42, 81, 82, 368, 369, 371
 Boggs, L. E., 24
 Bogorad, L., 139
 Bohme, E. H. W., 433
 Bohrer, A. T., 55
 Boisseau, J., 30, 35
 Boiwe, R., 199
 Bol, J. F., 75
 Bollinger, F. W., 259
 Bollmeier, E. C., 366
 Bongiovanni, G., 34
 Boni, R., 359
 Bonner, J., 69
 Bonora, G. M., 25, 171, 359
 Boosman, A., 299
 Borch, R. F., 16
 Borchers, S. L., 44
 Borders, C. L., jun., 108
 Bordier, P., 365
 Borin, G., 386, 389
 Bornet, H., 242
 Bornstein, J., 378
 Bornstein, P., 63, 65
 Bose, S., 126
 Bose, S. K., 400, 414
 Bosisio, G., 385
 Bossa, F., 119
 Bossert, H., 365
 Bosshard, H. R., 77, 387
 Botes, D. P., 84
 Boublik, M., 249, 261
 Boucher, M. E., 77
 Boulter, D., 134, 135
 Boulton, F. E., 145
 Bovey, F. A., 247, 373, 403
 Bowen, T. J., 132, 301
 Bower, A., 370
 Bowers, C. Y., 81, 82, 368, 369, 371
 Bowers, W. F., 288
 Box, H. C., 27
 Boyd, G. W., 364
 Boyd, N. D., 169
 Boyer, P. D., 177
 Bozhkova, G. D., 391
 Braam, W. G. M., 70, 71
 Brack, A., 390
 Bradbury, E. M., 247, 249, 261
 Bradbury, J. H., 248
 Bradshaw, R. A., 88, 89, 112, 132, 155, 220
 Brady, A. H., 271
 Brady, P. R., 31
 Bränden, C. I., 199
 Braginski, J. E., 168
 Brahms, J., 257
 Brain, E. G., 435
 Branch, W. T., 268
 Brand, D. A., 225
 Brand, L., 236, 237
 Branden, C. I., 223
 Brandenburg, D., 361, 363
 Brandt, J., 165
 Brandt, W. F., 68
 Brandts, J. F., 224, 247
 Brannon, D. R., 405
 Brattin, W. J., jun., 111
 Bratu, V., 144
 Braun, M., 149
 Braun, P., 9
 Braunitzer, G., 37, 142
 Braunstein, A. E., 118
 Bray, R. C., 303
 Braymer, H. D., 132, 299
 Breazu, D., 324, 392
 Breckenridge, A., 280
 Brederode, F. Th., 75
 Breitmaier, E., 18, 247, 357
 Bresler, S. E., 91
 Breslow, E., 285
 Bretscher, M. S., 54, 159
 Bretzel, G., 69
 Brewer, H. B., jun., 21, 29, 37
 Brewer, J. M., 121
 Brewster, A. I., 247, 373, 403
 Brewster, K., 10
 Brice, B. A., 294
 Briceux-Grégoire, S., 54, 94
 Bridgen, J., 61
 Bridges, S. H., 156
 Bright, H. J., 47, 60
 Brignon, G., 75
 Brimacombe, R., 70
 Brimhall, B., 144
 Brinkhurst, R. O., 2
 Brocklehurst, J. R., 236
 Brocklehurst, K., 34, 46
 Brockmann, H., 418
 Brois, S. J., 331
 Bromer, W. W., 77
 Bronzert, T. J., 21, 29, 37
 Brooke, G. S., 324, 356
 Brooks, C. C., 29
 Brooks, J. C., 161, 304
 Broomfield, C. A., 233
 Brosemer, R. W., 110
 Brossmer, R., 78
 Brostoff, S., 86, 87
 Brostrom, M. A., 307
 Brovetto-Cruz, J., 80
 Brown, A. T., 110
 Browne, D. T., 173
 Brown, F. R., tert., 263
 Brown, J. E., 281
 Brown, J. H., 29
 Brown, J. R., 48
 Brown, W. D., 274
 Brown, W. E., 93
 Brown, W. V., 286
 Brugger, M., 354, 384
 Bruce, T. C., 169
 Brumbaugh, E. E., 293
 Brummel, M. C., 113, 142
 Brun, F., 241

- Brunfeldt, K., 39, 358, 359, 389
 Bruni, C. B., 127
 Brunori, M., 143, 147, 243, 302, 305
 Brunswick, D. J., 173
 Brunwin, D. M., 434, 436
 Bruschi, M., 135
 Bruzzesi, M. R., 294
 Bryan, A. M., 22
 Bryan, J., 62
 Bryant, R., 144
 Bryce, C. F. A., 50, 132, 299
 Bucci, E., 147, 305
 Bucci, M., 83
 Buchanan, B. B., 136
 Bucher, D. J., 274
 Budde, W. L., 43
 Budzinski, E. E., 27
 Budzynski, A. Z., 166, 266, 281
 Büchi, G., 5, 413
 Buehner, M., 199
 Bünzli, H. F., 77
 Bundgaard, H., 434
 Bunn, C. W., 182
 Bunn, H. F., 145
 Bunnenberg, E., 257
 Burford, G. D., 81
 Burde, N. L., 12
 Burgen, A. S. V., 247, 248
 Burgus, R., 42, 81, 369, 372
 Burichenko, V. K., 390, 391, 392
 Burley, R. W., 235
 Burnham, B. F., 132
 Burnett, P. R., 86, 88
 Burnett, R. M., 207
 Burns, D. J. W., 132, 299
 Burs, J. T., 383
 Burshtein, E. A., 242
 Burt, M. E., 53
 Burton, J., 326, 361
 Busch, H., 67
 Bush, C. A., 254, 260, 401, 404
 Bush, D. A., 109
 Bustin, M., 68, 106, 265
 Butcher, B. H., 10
 Butcher, R. W., 365
 Butler, P. J. G., 222, 302
 Butler, W. T., 64, 154
 Buttlare, D. H., 132
 Buxton, D. A., 10
 Bychova, V. E., 229
 Bycroft, B. W., 7, 412, 413
 Bye, E., 17
 Bystrov, V. F., 401, 411, 421, 438
 Caban, C. E., 115, 132, 299
 Cabeza, A., 368
 Caccam, J., 86
 Cahn, R. S., 471
 Caillet, J., 404
 Calam, D. H., 365
 Caldwell, J. B., 393
 Calkins, D., 307
 Callewaert, G. L., 123, 132
 Calvan, L., 382
 Calvin, M., 241, 264, 272
 Cameron, D., 7, 412, 413
 Cammack, R., 138, 244, 245, 276
 Campbell, I. D., 233
 Campbell, J. W., 195
 Campbell, W. P., 97
 Candido, E. P. M., 69
 Canfield, R. E., 106, 108
 Cann, J. R., 266, 295, 304
 Cantor, C. R., 254
 Capet-Antonini, F. C., 304
 Capetillo, S., 264
 Caplan, Y. H., 10
 Capon, B., 248
 Capony, J.-P., 62
 Capozza, R. C., 359
 Capra, J. D., 80, 149, 151
 Capuggi, G., 39
 Caputo, A., 305
 Carlbam, U., 194
 Carlsen, R. B., 78
 Carlson, C. W., 110
 Carlson, F. D., 294
 Carlson, K., 62
 Carlson, W. D., 191
 Carmack, M., 259
 Carnegie, P. R., 86
 Carpenter, B. G., 247
 Carpenter, F. H., 132, 299
 Carpino, L. A., 317
 Carraway, K. L., 160
 Carre, D. S., 46
 Carrel, S., 148
 Carrell, R. W., 144
 Carroll, D., 69, 281
 Carroll, R. J., 252
 Carson, J. F., 24
 Carta, S., 143
 Carter, C. W., 205
 Carter, J. H., 413
 Cartwright, T., 66
 Cary, P. D., 247, 249
 Casanova, T. G., 314
 Casassa, E. F., 301
 Casnati, G., 25
 Caspar, D. L. D., 220
 Cassim, J.-Y., 256
 Cassio, D., 127
 Cassman, M., 301
 Cassoly, R., 248, 274
 Castellani, A., 428
 Castineda, E., 372
 Cathou, R. E., 284
 Catsimpoalas, N., 55
 Cattell, K. J., 161
 Catterall, W. A., 161, 304
 Cavallo, P., 386
 Caviezel, M., 11, 260, 397
 Cavins, J. F., 30
 Cebra, J. J., 151, 153
 Cech, M., 69
 Čechová, D., 98
 Celis, M. E., 370, 371
 Cerletti, P., 113, 132
 Cerrini, S., 180, 438
 Cetta, G., 428
 Chadha, M. S., 21
 Chaiken, I. M., 117, 242, 247, 249, 381
 Chaivla, R. K., 358
 Chakrabarti, S. K., 237
 Chalkley, R., 52, 55, 142
 Champress, J. N., 224
 Chan, T. H., 353
 Chan, W. W.-C., 57
 Chan, W. Y., 388
 Chance, B., 230, 236
 Chanda, S. K., 67
 Chandrasekaran, R., 246
 Chandrasekharan, V., 257
 Chaney, M. O., 178
 Chang, C., 70
 Chang, C. C., 86
 Chang, F. N., 70
 Chang, H. W., 70
 Chang, J., 138
 Chang, J. K., 42, 81, 82, 368, 369, 371
 Chang, M. C., 83
 Chang, M. M., 383
 Chang, Y. H., 33
 Changeux, J. P., 59, 162
 Chao, L. P., 286
 Chao, W. R., 34
 Chapeville, F., 46
 Chapman, D., 409, 410
 Chapman, E. S., 431
 Charache, S., 249
 Charet, P., 427
 Charles, M., 123
 Charlwood, P. A., 289
 Charney, E., 258
 Chartrand, S. L., 283
 Chasar, D. W., 339
 Chaturvedi, N. C., 3
 Chaudhuri, D., 253
 Chauvet, J. P., 100, 141
 Chauvette, R. R., 435
 Chavin, S. I., 157
 Chen, A. K., 255
 Chen, C., 114, 115, 132
 Chen, F., 391
 Chen, R., 67
 Chen, R. F., 236, 242
 Chen, W. Y., 22
 Chen, Y.-H., 256
 Cheng, C., 391
 Cheng, K. W., 81
 Cheng, S. H., 24, 167
 Chepyzheva, M. A., 99
 Cherian, M. G., 55
 Chernitskii, E. A., 242
 Chernoff, A. I., 145
 Chernyshev, V. P., 386, 392
 Chersi, A., 151, 154
 Chervenka, C. H., 132
 Cheung, H. C., 238
 Chiancone, E., 287, 294, 305
 Chibata, I., 47
 Chicheportiche, R., 99, 264
 Chien, J. C. W., 247
 Chignell, C. F., 254, 280
 Chillemi, F., 337, 378
 Chilson, O., 299

- Chimiak, A., 9
 Chioccaro, F., 36
 Chirgadze, Yu. N., 257
 Chittenden, C. G., 34, 132, 299
 Chiu, T. H., 163
 Chiu, Y. N., 256
 Cho, S., 77
 Choi, Y. S., 148, 156
 Chopek, M., 235
 Chou, F. C.-H., 87, 358
 Chrambach, A., 51, 300
 Christen, P., 168, 170, 280
 Christensen, B. G., 434
 Christensen, P. A., 84
 Christensen, T., 358
 Christensen, T. B., 132
 Christian, S. T., 237
 Christman, A. A., 35
 Chua, K. E., 2
 Chuaqui, C., 355
 Chulkova, T. M., 98
 Chung, A. E., 168
 Chung, D., 80, 386
 Chung, N. M., 354
 Church, R. L., 63
 Churchich, J. E., 239
 Chuvavaeva, T. P., 390, 391
 Ciana, A., 407
 Ciceri, L., 359, 407
 Ciferri, A., 229
 Cipens, G., 384, 386, 388, 390
 Claes, P., 433
 Clamp, J. R., 151, 426, 427
 Clark, C. E., 112
 Clark, D. G., 162
 Clark, R. C., 71
 Clark, R. H., 382
 Clarke, M., 160
 Clarke, R., 239
 Clayton, J. P., 435
 Cleave, A. J., 294
 Clegg, J. B., 145
 Clem, L. W., 148
 Clemetson, K. J., 57
 Close, J., 387
 Closset, J., 79
 Coan, M. H., 94
 Coates, J. H., 287
 Coats, J. H., 428
 Cochran, D. W., 248
 Cody, V., 17
 Coffee, C. J., 112, 220
 Coggins, J. R., 11
 Cohen, C., 220, 221
 Cohen, G. H., 92, 184
 Cohen, J. S., 21, 242, 246, 247, 249
 Cohen, L. A., 11
 Cohen, L. H., 56, 67
 Cohen, R., 287
 Cohen, S., 149
 Cohen-Bazire, G., 139
 Cohn, M., 232
 Cole, P. W., 106
 Cole, R. D., 67, 68
 Coleman, N. F., 267
 Collier, R., 59
 Collier, R. J., 83
 Collins, K. O., 125
 Colman, J. E., 121
 Colman, P. M., 191, 194
 Colman, R. W., 166
 Colombo, C., 22, 413
 Coltrain, I. M., 66
 Colvin, H. J., jun., 132, 299
 Combelas, P., 253
 Comer, F., 435
 Commoner, B., 235
 Compernelle, F., 422
 Comyns, J., 16
 Cone, C., 2
 Cone, J. L., 116, 117
 Cone, R. E., 171
 Conio, G., 251
 Conn, J. B., 349
 Connell, G. E., 149, 283
 Conrad, R. H., 236
 Constable, B. J., 65
 Contaxis, C. C., 271, 296
 Conte, A., 47
 Conway, A., 232
 Conway-Jacobs, A., 106, 284, 360
 Cook, D. A., 228
 Cooke, D. W., 29
 Cooke, R., 235, 238
 Coon, M. J., 138, 165
 Cooper, A., 128, 201
 Cooper, C. M., 435
 Cooper, R. D. G., 435
 Cooperman, B. S., 173
 Corbin, J. D., 307
 Corbin, J. L., 62
 Cordy, A., 31
 Corley, L., 117, 382
 Cormick, G., 223
 Cormier, M. J., 124
 Cornell, J. S., 78
 Corradin, G., 133
 Corrado, A. P., 309
 Corran, P. H., 73
 Cortegiano, H., 355
 Cortijo, M., 229
 Cosani, A., 262
 Cotton, F. A., 116, 177, 192, 193
 Cotton, R., 420
 Cottrell, R. C., 123, 132
 Coulter, C. L., 182
 Counsell, R. E., 10
 Cournil, I., 119
 Cover, R. E., 355
 Cowell, R. D., 360
 Cowgill, R. W., 121, 239
 Cowley, D. E., 428
 Cox, B. R., 423
 Cox, D. J., 48, 293
 Cox, J. M., 306
 Cox, R. A., 70
 Coy, E. J., 372, 388
 Crackel, W. C., 366
 Craig, A. R., 343
 Craig, J. C., 258
 Craig, L. C., 410, 440
 Cramer, F., 133
 Crane-Robinson, C., 247, 249, 261
 Cranwell, P. A., 26
 Crawford, I. P., 120, 133
 Cremlyn, R. J. W., 22
 Cremona, T., 115
 Crescenzi, V., 263, 407
 Crichton, R. R., 50, 71, 132, 277, 299
 Croft, L. R., 73, 412
 Crombie, G., 2
 Cronin, J. R., 2
 Crook, E. M., 46
 Crowther, R. A., 222
 Cruickshank, W. H., 48
 Crumm, S., 80
 Crumpton, M. J., 162
 Cseh, G., 82
 Csizmadia, I. G., 407
 Cuatrecasas, P., 56, 59, 156
 Cuendet, P. A., 59
 Cuiban, F., 322
 Cultrera, R., 28
 Culvenor, C. C. J., 7
 Cunningham, B. A., 132
 Cunningham, L. W., 106
 Currie, B. L., 42, 81, 82, 368, 369, 371
 Cusanovich, M. A., 135
 Cusumano, C. L., 116
 Cutfield, J. F., 215
 Cutfield, S. M., 215
 Cziharz, B., 425
 Czombos, J., 34
 Dabev, D., 31
 Dabiowiak, J. C., 29
 Dahl, J. L., 161
 Dahn, H., 20
 Daicovicium, C., 392
 Dairman, W., 30, 34
 Dakhte, R. R., 390
 Dale, J., 400
 D'Alessio, G., 110, 132
 Dalgleish, D. G., 276
 Dalidowicz, J. E., 86
 Damany, H., 257
 Damerau, W., 27
 Damjanovich, S., 240
 Damoglou, A. P., 44
 Damus, P. S., 98
 Dang, T. P., 5
 D'Angeli, F., 323
 Danyan, M. T., 8
 Daniels, C. J., 435
 Daniels, C. M., 435
 D'Anna, J. A., 240
 Dannies, P. S., 132
 Darnall, D. W., 270
 Darnell, J. H., 372
 Darskus, R. L., 51, 75
 Dastoor, M. N., 201
 Datino, W., 386
 Datta, P., 133, 303
 Daurat, S. T., 80
 Dautrevaux, M., 143
 Davankov, V. A., 16
 Daves, G. B., 42
 Davidson, B., 281
 Davidson, B. E., 62, 109
 Davie, E. W., 59
 Davies, D. M., 31

- Davies, D. R., 92, 184, 218, 219
 Davies, G. W., 334
 Davies, J. S., 7, 353
 Davis, G. E., 300
 Davis, K. A., 113, 132, 299
 Davis, L. C., 173
 Davydova, G. A., 12
 Dawson, B. F., 82, 379
 Daxenbichler, M. E., 4, 438
 Day, V. W., 116, 192, 193
 Day, W. A., 405
 Deal, W., 163
 Dean, P. D. G., 59, 60
 Dearborn, D. G., 265
 Debabov, V. G., 390
 Debeljuk, L., 81, 367
 Deber, C. M., 400, 401
 De Bruin, S. H., 147
 Debrunner, P. G., 245
 de Castiglione, R., 385
 de Castro, J., 116
 Decker, K. A., 115, 302
 Declercq, J. P., 180
 Deen, R., 234
 Deeva, L. I., 431
 Defetos, L. J., 82, 365, 379
 Degens, E. T., 88
 de Graaf, J. S., 384
 de Groot, K., 73
 Degutis, J., 11
 Deibler, G. E., 87
 De Jong, W. W. W., 142, 144
 Dekker, C. A., 118
 Dekker, E. E., 116
 Dekker, K. A., 132, 299
 Dekkers, H. P. J. M., 258
 De Lange, R. J., 67, 72
 de Lauder, W. B., 239, 242
 Delaunay, J., 142
 Delbaere, L. T. J., 178
 de Leer, E. W. B., 354, 359
 Dellacha, J. M., 80
 De Lorenzo, F., 118
 Del Pulsinelli, P., 144, 212
 Demaille, J., 62
 De Marco, C., 12
 Demny, T. C., 3
 Demyanik, G. N., 391
 Denkwalter, R. G., 349, 366, 381
 Dennert, O., 122
 Denton, W. L., 169
 de Ochoa, O. E., 438
 Deranleu, D. A., 89
 Derevitskaya, V. A., 428
 Derosier, D. J., 122, 201
 der Terrossian, E., 125
 Desai, P., 10
 Desai, P. R., 283
 de Sangüesa, A. V. F., 80
 De Santis, P., 225, 407, 418
 Desbuquois, B., 59
 Desena, T., 265
 de Sese, Z. M. M., 80
 Deshcherevskii, V. I., 21
 Deshmukh, K., 65
 Desiderio, D. M., 40, 41, 42, 382
 Desmazeaud, M. J., 45
 Desnuelle, P., 94, 95, 123
 Desvages, G., 125
 De Tar, D. F., 395
 Devanathan, T., 136
 Devenyi, T., 31, 355
 Deverson, E. V., 149
 de Vijlder, J. J. M., 232
 De Vries, A. L., 76
 Dewey, R. S., 349
 Deyl, Z., 36
 Diamond, R., 182
 Diaz, F. J., 29, 31, 36
 Di Bello, C., 259, 323
 Dickerson, R. E., 128, 133, 184, 201, 203
 Dickinson, F. M., 237
 Dickson, G. H., 10
 Di Corato, A., 263, 401
 Diefenbach, H., 232
 Diezel, W., 132
 Dinamarea, M. L., 133
 Dinerstein, R. J., 235
 Dinius, L. L., 83
 Diniz, C. R., 309
 Dintzis, H. M., 71
 Diorio, A., 16
 di Prisco, G., 112
 Dirvianskyte, N., 11
 Di Sabato, G., 112
 Di Tullio, V., 163
 Dixit, S. N., 63
 Dixon, G. H., 69
 Dixon, H. B. F., 33, 118, 119
 Dixon, J. F., 161
 Dixon, J. S., 80, 377, 378
 Dixon, J. W., 92
 Djerassi, C., 257
 Dockier, A., 79
 Doddrell, D., 248
 Dodonova, N. Ya., 28
 Dodson, E. J., 177, 182, 215, 216
 Dodson, G. G., 177, 182, 215, 216
 Dörner, M., 78
 Doherty, R. F., 59
 Dolder, F., 148
 Dolfini, J. E., 433, 437
 Dolmans, M., 109
 Donald, E., 10
 Dong, R. Y., 19
 Doolittle, R. F., 66, 67
 Doonan, S., 123, 132
 Dorland, L., 40
 Dorman, L. C., 359, 387
 Dörner, F., 121, 169
 Dorrington, K. J., 254, 283, 284
 Doscher, M. S., 117
 Doseva, V., 392
 Dounce, A. L., 67
 Dousa, T., 390
 Douzou, P., 257
 Dover, S. D., 471
 Dowling, L. M., 38
 Doyle, B. B., 224, 252, 360
 Doyle, D., 132, 299
 Drabarek, S., 341, 359
 Drawert, F., 56
 Drazin, R., 83
 Dremier, C., 312
 Drenth, J., 106, 177, 184
 Drew, C. M., 1
 Dreyfus, J. C., 125
 Drickamer, H. G., 244
 Drinkwater, D. J., 8
 Driscoll, G. A., 113
 Drott, H. R., 230, 231
 Drucker, H., 44
 Drum, D. E., 279
 Drysdale, J. W., 55, 145
 D'Souza, L., 271
 Duax, W. L., 17
 Dubiski, S., 151
 Duce, E., 195
 Dufour, C., 123
 Dugonjic, B., 310
 Duguet, M., 141
 Duke, J., 235
 Dukler, S., 26
 Dulak, N. C., 161
 Dunford, H. B., 276
 Dunham, W. R., 245
 Dunlap, R. B., 133, 299
 Dunlop, P., 92
 Dunn, F. W., 385
 Dunn, T. F., 42
 Dunnill, P., 59
 Dupourque, D., 191
 Dupree, H. K., 148
 Dupuis, G., 373
 Durand, G., 47
 Durchschlag, H., 111
 Durgaprasad, G., 250
 Durham, A. C. H., 222
 Durst, H. D., 16
 Dus, K., 249
 Dutta, A. S., 328, 340
 Du Vigneaud, V., 247, 373, 388
 Dwek, R. A., 233, 248, 297
 Dyckes, D. F., 299
 Dyer, J. R., 413
 Dygert, M., 228
 Dymicky, M., 23, 327
 Dyson, R. D., 288
 Eagles, P. A. M., 195
 Eaker, D., 84, 122, 222
 Eaker, D. L., 238
 Earland, C., 74
 Earle, K. M., 17
 Easton, D. M., 51
 Eastwood, F. W., 423
 Eaton, S. S., 258
 Eaton, W. A., 257
 Ebert, W., 29
 Ebner, K. E., 108, 169
 Eby, D., 111
 Eckstein, H., 358
 Edelhoeh, H., 242, 268
 Edelman, G. M., 132, 214, 215, 237, 268
 Edelstein, S. J., 292, 296

- Edlund, B., 132
 Edmonds, D. T., 19
 Edmondson, D. E., 271
 Edmunson, A. B., 214, 219, 228
 Edsall, J. T., 471
 Edwards, B. F. P., 201
 Efremov, E. S., 401
 Efremov, G. D., 144
 Egami, F., 118
 Egelrud, T., 59
 Eglinton, A. J., 435
 Egorov, Ts. A., 118
 Eicher, H., 212
 Eidem, A., 12
 Eigendorf, G., 431
 Eilam-Rubin, G., 94
 Einstein, E. R., 286
 Eisele, B., 132
 Eisele, K., 77, 386
 Eisen, H. N., 155
 Eisenberg, D., 114, 128, 201
 Eisenberg, H., 301
 Elad, D., 391
 El-Bayoumi, M. A., 28
 Elberling, J. A., 12
 Elek, G., 235
 Elias, H. G., 407
 Eliel, E. L., 471
 Elkana, Y., 90
 Ellam, R. M., 22
 Elleman, T. C., 71, 74
 Ellfolk, N., 141
 Ellinger, G. M., 31, 36
 Elliott, A., 471
 Elliott, D. F., 33, 385, 439
 Ellis, J. P., jun., 30, 35
 Ellison, J. S., 113
 Elmore, D. T., 59, 90
 Elsen, H. N., 156
 Elvidge, J. A., 19
 Ely, K. R., 219
 Elzinga, M., 61, 62
 Emeis, C. A., 258
 Emmer, M., 299
 Emura, J., 427
 Endres, G. F., 304
 Eng, L. I. L., 144
 Engel, A. M., 46
 Engel, J., 262
 Engel, L. L., 132, 299
 Engel, P. C., 132
 Englard, S., 258
 Englesberg, E., 57
 Enzmann, F., 367, 371
 Epp, O., 98, 142, 213, 214, 219
 Epstein, E. H., 63
 Epstein, H. F., 242
 Erbe, R. W., 279
 Erickson, J. S., 59
 Ericsson, L. H., 150
 Eriksen, N., 150
 Eriksson, S., 57
 Erlanger, B. F., 97, 163
 Ernback, S., 46
 Erspamer, V., 83, 385
 Ettinger, M. J., 268
 Evans, D. R., 201
 Evans, E. A., 19
 Evans, E. E., 148
 Evans, H. J., 268
 Evans, M. T., 281
 Evans, P. R., 198
 Evstigneeva, R. P., 353, 385, 386, 392
 Evstratov, A. V., 424
 Eyl, A. W., jun., 96
 Eylar, E. H., 86, 87, 88, 286
 Eyring, H., 279
 Fabian, F., 31
 Fabre, L. F., 29
 Faesel, J., 411
 Faesel, J. H. R., 382
 Fahren, L. A., 132, 299
 Fahrenholz, J., 411
 Fahrney, D., 105
 Fairbanks, G., 160
 Fairweather, R., 49
 Fairwell, T., 21, 43
 Falderbaum, I., 112
 Fales, H. M., 21, 37, 42
 Falk, E., 31, 48
 Fan, C. C., 147
 Fanconi, B., 225
 Fanning, E. M., 37, 149
 Farely, J. G., 241
 Faris, B., 2
 Farmer, R. W., 29
 Fasman, G. D., 261, 262, 281, 282
 Fass, D. N., 97
 Fattoum, A., 170
 Fauchere, J. L., 11
 Faulstich, H., 246, 411
 Favilla, R., 240
 Fawcett, R. L., 108
 Fayet, M., 239
 Fearheller, W. R., 250
 Fedarko, M.-C., 247, 421
 Fedeli, W., 180, 438
 Feder, J., 103
 Fedoseev, V. A., 35
 Fee, J. A., 276
 Feeney, J., 247, 248
 Feeney, R. E., 76, 102, 175
 Fehlhaber, H.-W., 431
 Feibush, B., 29
 Feigina, M. Yu., 118, 392
 Feil, M., 249
 Feinberg, A. M., 8
 Feingold, D. A., 37
 Feinstein, G., 56, 59, 102
 Feinstein, M. B., 421
 Feist, H., 385
 Feit, H., 62
 Feitelson, J., 90, 240
 Feldbau, E., 93
 Feldberg, R. S., 133, 303
 Felix, A. M., 325
 Fellows, R., 81, 369
 Felsenfeld, H., 421
 Felsted, R. L., 95
 Fenton, J. W., 97, 155
 Ferdinand, W., 34
 Ferenczi, S., 31
 Ferger, M. F., 247, 373, 388
 Ferguson, J. B., 105
 Fermandjian, S., 218, 268
 Fernandez, H. N., 80
 Ferraro, A., 119
 Ferraro, J. J., 394
 Ferrell, R. E., 147
 Ferri, G., 110
 Ferro, D., 225
 Ferroni, R., 281, 387
 Fersht, A. R., 92
 Fesenko, E. E., 28
 Fessenden, R. W., 27
 Fiaud, J., 6
 Fielder, F., 98
 Fields, R., 33, 118
 Fiegelson, P., 289
 Fieggen, W., 50
 Filenko, A. M., 28
 Filippovich, E. I., 386, 392
 Filira, F., 259, 323
 Filmer, D. L., 287
 Fin, R. T., 239
 Finch, J. T., 222
 Finch, P. R., 86
 Fincher, E. H., 307
 Fine, R. E., 62
 Finer, E. G., 410
 Fink, E., 102
 Finkelstein, A. U., 228
 Finley, J. W., 31
 Finn, F. M., 373, 389
 Finnigan, J. A., 294
 Finnstrom, B., 28
 Finogenova, M. P., 390
 Finstad, J., 283
 Fiorentini, G., 407
 Firestone, R. A., 434
 Fischer, E. H., 119, 121
 Fischer, H., 28
 Fischer, W., 359
 Fish, W. W., 132, 299, 300
 Fisher, H. F., 112, 226
 Fisher, J. W., 364, 435
 Fisher, M., 365
 Fitch, W. M., 148
 Fittkau, S., 383
 Fitzak, B. A., 78
 Flaks, J. G., 70
 Flamm, U., 142
 Flanders, L. E., 132, 299
 Flashner, M., 165
 Flatz, G., 145
 Flavin, M., 273
 Fleischman, J. B., 154
 Fletcher, G. A., 326
 Flohé, L., 132, 331
 Flor, F., 359
 Florkin, M., 54, 94
 Flory, P. J., 225, 471
 Floss, H. G., 439
 Fluri, R., 120
 Folch-Pi, J., 286
 Foley, R., 168
 Folin, M., 173
 Folk, J. E., 168
 Folk, W. R., 133

- Folkers, K., 42, 81, 82, 368, 369, 371, 372
 Foltmann, B., 104
 Fondy, T. P., 113, 132
 Fonina, L. A., 392, 421, 422
 Foord, R., 294
 Forbes, W. F., 19
 Forcina, B. G., 110, 115
 Ford, G. C., 199
 Formanek, H., 98, 142, 213, 214
 Forrest, L., 65
 Forrey, A. W., 121
 Fosker, G. R., 436
 Fosset, M., 121
 Foster, B. J., 435
 Foster, G. V., 365
 Foster, J. F., 257, 270
 Foster, M. C., 7
 Foster, R. L., 248
 Fowden, L., 4, 19, 30
 Fox, I. H., 304
 Fox, R., 63
 Fox, S. W., 1
 Fraenkel-Conrat, H., 84
 Franchimont, P., 364
 Franěk, F., 153
 Frangione, B., 153, 154
 Frank, C. W., 244
 Franklin, E. C., 154
 Franklin, J. G., 96
 Franklin, R. M., 222, 223
 Franks, W. A., 201
 Franzblau, C., 2
 Franzel, R., 212
 Franzen, J. S., 168
 Fraser, P. S., 12
 Fraser, R. D. B., 223
 Frater, R., 166
 Frauendorfer, E., 17
 Fredrickson, D. S., 286
 Freedberg, W. B., 120, 270
 Freedman, M. H., 154, 247
 Freedman, R. B., 164
 Freer, S. T., 205
 Frei, R. W., 31
 Freisheim, J. H., 271
 Freund, T., 73
 Eric, I., 282, 417
 Fridborg, K., 194, 222
 Fridkin, M., 334, 336, 337
 Fridland, A., 133
 Fridovich, I., 132
 Friedberg, F., 126
 Frieden, C., 112, 287, 292
 Friedman, H. L., 235
 Friedman, M., 31, 34
 Friedman, S., 262
 Fries, D. C., 178
 Friesen, A. D., 55
 Friesen, H. G., 59, 81, 369
 Fritz, H., 102
 Fromageot, P., 218, 268
 Fromm, H. J., 132
 Frommel, D., 283
 Froyshov, O., 409
 Fruton, J. S., 103, 105, 171, 392
 Fry, K. T., 139
 Fuchi, I., 212
 Fuchs, S., 156
 Fudenberg, H. H., 148, 149, 151
 Fujii, M., 407
 Fujii, T., 334
 Fujimaki, M., 28
 Fujimoto, D., 391
 Fujimoto, Y., 8
 Fujino, M., 384
 Fujita, H., 287
 Fujiwaka, K., 410
 Fujiwara, N., 144
 Fujiwara, S., 31
 Fuku, A., 427
 Fukuda, K., 387
 Fukuda, T., 31, 320
 Fukui, Y., 163
 Fukumoto, J., 172
 Fukunaga, K., 132
 Fuller, G. M., 66
 Funamizu, M., 5, 8
 Fung, B. M., 249
 Fung, D. S., 117
 Furey, M. E., 359
 Furthmayr, H., 52
 Furutachi, N., 5
 Futagawa, S., 9
 Gabel, D., 242
 Gabriel, O., 51
 Gache, C., 123
 Gadegbeku, B., 265
 Gainer, H., 53
 Gal, G., 366
 Galarzy, R. E., 440
 Galiazzo, G., 173, 266
 Gallego, E., 111
 Gallina, C., 22, 413
 Gallop, P. M., 2, 66
 Gambini, A., 359
 Ganguly, M., 175
 Garan, H., 159
 Garbett, K., 245
 Garcia, J. B., jun., 35
 Garden, J. H., jun., 359, 391
 Gardini, G. P., 25
 Gardner, K. L., 74
 Garel, J. R., 242
 Garner, R., 394
 Garren, L. D., 307, 364
 Garrett, L. R., 103
 Garrigou-Lagrange, C., 250, 253
 Garsky, V., 349
 Garver, F. A., 149
 Gaston, D. W., 393
 Gatenby, A. D., 132
 Gates, R. E., 226
 Gathercol, L. J., 55
 Gauer, J., 132
 Gawne, G., 344
 Gawronski, T. H., 294
 Gehrke, C. W., 1, 29, 36
 Geiger, R., 310, 353, 362, 363, 365, 367, 390
 Geisen, K., 367
 Gennari, G., 172, 173
 Gerasimova, N. E., 431
 Gerding, J. J. T., 50, 73
 Gergely, J., 161, 235
 Gerhart, J. C., 289, 308
 Gershengorn, M. C., 31
 Gersonde, K., 137
 Gertler, A., 102, 103, 165, 166
 Geschwind, I. I., 80
 Gevers, W., 408
 Ghani, S. N., 225
 Ghose, A. C., 283
 Ghuysen, J. M., 425
 Giancontti, V., 263, 407
 Giardina, B., 147
 Giartosio, A., 119
 Gibbons, I. R., 62
 Gibbs, D. E., 34
 Gibbs, J. H., 261
 Gibson, D., 37, 149, 150
 Gibson, F., 132
 Gibson, J. F., 245
 Gibson, Q. H., 146, 248, 295, 296, 306, 307
 Giessner-Pretre, C., 246
 Gil-Av, E., 2, 29
 Gilbert, E. J., 42
 Gilbert, G. A., 287, 289, 291, 293
 Gilbert, L. M., 287, 289, 291
 Gilbert, P. F. C., 222
 Gill, D. M., 83
 Gill, G. N., 307, 364
 Gillespie, J. M., 75
 Gillessen, D., 371
 Gilman, J. G., 37
 Gilmour, M. V., 136
 Ginos, J., 338, 387
 Ginsberg, H. S., 223
 Giori, P., 341, 342
 Girshovich, A. S., 235
 Givol, D., 60, 153, 155, 156
 Gjessing, E. C., 95
 Glaser, J. A., 247
 Glaser, M., 284, 286
 Glass, J. D., 373
 Glazer, A. N., 139, 168
 Gleason, J. G., 414
 Glenner, G. G., 150
 Glickson, J. D., 247, 249, 284, 409
 Glinskaya, O. V., 345
 Glossmann, H., 132, 162
 Glover, G., 97
 Glushenkova, V. R., 392
 Glushko, V., 248
 Gó, M., 229
 Gó, N., 229
 Goaman, L. C. G., 306
 Gobyunov, A. I., 195, 198
 Godwin, H. A., 392
 Goffredo, O., 385
 Gohlke, J. R., 236, 237
 Gokel, G., 354
 Goko, H., 413
 Goko, T., 179
 Goldberg, A. I., 144
 Goldberger, R. F., 270
 Goldin, B. R., 112
 Goldman, H., 247

- Goldman, P., 21
 Goldman, R., 45
 Goldsack, D. E., 228
 Goldspink, D. F., 143
 Goldstein, D. J., 220
 Goldstein, L., 46
 Gonczyk, F., 392
 Gonczyk, G., 324
 Gonzalez, C., 307
 Gonzalez, G., 132, 299
 Good, R. A., 148, 149, 283
 Goodall, D., 111
 Goodall, M. C., 284, 409
 Goodflesh, R. M., 37
 Goodkin, P., 201
 Goodman, D., 55
 Goodman, J. W., 392
 Goodman, M., 246, 247, 251, 260, 261, 403, 411
 Goodson, T., 437
 Goolsby, S. P., 34
 Gordon, D. J., 255, 285
 Gordon, J. A., 50
 Gorecki, M., 170
 Goren, H. J., 334
 Gorlenko, V. A., 40
 Gorman, M., 3, 437
 Gotchel, B. V., 67
 Goto, K., 170
 Gottikh, B. P., 429
 Gottschalk, E., 133
 Gougoutas, J. Z., 433
 Gould, H. J., 53
 Graab, G., 8
 Grachev, M. A., 235
 Gracheva, A. K., 387
 Gracy, R. W., 122
 Graf, L., 82
 Grafius, M. A., 128
 Graham, J. E. S., 92
 Grahl-Nielsen, O., 386
 Gramppe, E., 45
 Grandjean, C. J., 70
 Grant, J. A., 149
 Grant, M. E., 66
 Gratecos, D., 94
 Gratzner, W. B., 51, 289
 Gravenmade, E. J. S., 269
 Gray, C. J., 172
 Gray, W. R., 41, 110
 Grazi, E., 269
 Grebenshchikov, Yu. B., 235
 Grechishko, V. S., 391
 Green, G. M., 47
 Green, J., 306
 Green, N. M., 157
 Green, S., 110
 Greenaway, P. J., 68
 Greenberg, D. J., 249
 Greenberg, L. J., 359
 Greene, L. J., 100
 Greenstein, J. P., 309
 Greenwood, C., 275
 Greenwood, F. C., 378
 Greer, J., 145, 209, 211, 212
 Gregory, E. M., 113
 Gregory, M. J., 169
 Greig, D. G. T., 435
 Grenoble, D. C., 244
 Greven, H. M., 365
 Grey, H. M., 148, 151, 154
 Griffith, O. H., 230, 235
 Griffith, R. K., 3
 Griffiths, G., 69
 Grishin, E. V., 118
 Grisolia, S., 68
 Grizzuti, K., 261, 270, 274
 Grodsky, G. M., 364
 Grohlich, D., 71
 Gromova, E. S., 20, 430
 Gronow, M., 69
 Grosclaude, F., 75
 Gross, E., 413
 Gross, F., 364
 Gross, J., 63, 64
 Gross, M., 168
 Grossmann, H., 331
 Groth, P., 17
 Groudinsky, O., 136
 Grouke, M. J., 261
 Grove, M. D., 4, 438
 Grunberger, D., 5
 Grupe, R., 386, 432
 Grutzner, J. B., 437
 Grzonka, Z., 393, 398
 Gual, C., 368, 372
 Guarneri, M., 281, 341, 342, 387
 Guermont, J. P., 14
 Guerrini, A. M., 115
 Guerriore, D., 143
 Gürtler, L., 134
 Guggenheim, S., 273
 Guggi, A., 281, 387
 Gugliemi, H., 386
 Guha, A., 114, 132
 Guibé-Jampel, E., 310
 Guidotti, G., 305
 Guilbault, G. G., 31
 Guilbert, B., 47
 Guilford, H., 59
 Guillemin, R., 42, 81, 364, 369, 372
 Guinand, S., 304
 Guire, P., 426
 Gundersen, L. E., 39
 Gunsalus, I. C., 245
 Gupta, R. K., 249
 Gurd, F. R. N., 248
 Gurtler, J., 29
 Guseva, M. V., 431
 Gut, V., 7
 Gutfreund, H., 195, 303
 Gutowski, G. E., 435
 Gutte, B., 117, 379
 Guttman, St., 365
 Guy, O., 100
 Guyda, H. J., 59, 369
 Guzzo, A. V., 228
 Gwynne, J. T., 286
 Haas, E., 90
 Habeeb, A. F. S. A., 45, 109, 172
 Habener, J. F., 365
 Haber, E., 57, 154
 Habermann, E., 387
 Haberthuer, U., 407
 Hachimori, Y., 123
 Hackert, M. L., 199
 Hackley, B. E., jun., 233
 Hadler, N. M., 156
 Hadley, MacE., 370
 Haendle, H., 102
 Haenisch, G., 100
 Hagel, P., 50
 Hagenmaier, H., 357, 358
 Haider, J., 269, 284
 Haimovich, J., 156
 Hainu, M., 136
 Håkanson, R., 49
 Halfman, C. J., 242, 304
 Hall, D. E., 113
 Hall, D. O., 138, 244, 245, 276
 Hallosi, M., 400
 Halper, J. P., 269
 Halpin, R. A., 161
 Halström, J., 389
 Halwer, M., 294
 Hamada, N., 30
 Hamaguchi, K., 86, 171, 267, 280
 Hamill, R. L., 437
 Hamilton, C. L., 230
 Hamilton, H. B., 144, 212
 Hamilton, P. B., 1
 Hammerstedt, R. H., 115, 132, 299, 302
 Hammes, G. G., 111, 286
 Hampton, A., 175
 Han, K., 143
 Hanafi, D. E., 31, 49
 Hanahan, D. J., 123
 Hancock, W. S., 376
 Handa, B. K., 417
 Handford, B. O., 334
 Handler, P., 3
 Handwerker, S., 80
 Haniu, M., 138
 Hanlon, S., 132
 Hanna, M. L., 280
 Hanson, K. R., 14
 Hapner, K. D., 34
 Happe, J. A., 249
 Harada, K., 1
 Harada, M., 150
 Harbury, H. A., 133
 Hardin, J. M., 68
 Harding, H. W. J., 74
 Harding, N. G. L., 59, 133, 299
 Hardman, D. F., 120
 Hardman, J. K., 120, 270
 Hardman, K. D., 214, 219
 Hardy, K. D., 436
 Hardy, P. M., 224, 251, 332, 360
 Hare, P. E., 1, 2
 Hargrave, P. A., 126
 Harmsen, B. J. M., 70, 71
 Harper, E., 63
 Harper, P. J., 175
 Harpp, D. N., 414
 Harrigan, P. J., 111
 Harrington, J. C., 97
 Harris, A., 338
 Harris, C. M., 143

- Harris, J. I., 109, 302
Harris, J. R., 160
Harris, J. U., 261
Harris, W. G., 30
Harrison, J. H., 113, 169
Harrison, R. G., 221
Harrison, S. C., 222, 223
Hart, F. A., 18
Hart, P. A., 254
Hartley, B. S., 164, 177
Hartman, F. C., 122, 175
Hartsuck, J. A., 88, 177
Hartter, P., 331
Haschemeyer, R. H., 53, 288, 289
Hase, S., 397
Hash, J. H., 109
Hashim, G., 86
Hashimoto, J., 118
Hasinoff, B. B., 167
Haslam, E., 15
Hass, G. M., 89
Hass, L. F., 115, 132, 299
Hassall, C. H., 5, 7, 353, 417, 422
Hassanali-Walji, A., 412
Hasselbach, W., 235
Hastings, J. W., 124, 302
Hatanaka, C., 384
Hatefi, Y., 113, 132, 299
Hatfield, L. D., 435
Hatfield, L. M., 96
Hatsuhiko, M., 259
Hauser, D., 405
Hauser, H., 410
Havinga, E., 384
Havir, E. A., 303
Havran, R. T., 388, 390
Hawkins, C. J., 259
Haworth, C., 31, 35
Haworth, R. D., 26
Hayaishi, O., 280
Hayashi, A., 144
Hayashi, K., 84, 86
Hayashi, T., 82
Hayashida, H., 45
Hayatsu, R., 7
Haylett, T., 74
Haylock, J. C., 251, 360
Hayman, S., 45
Hayon, E., 403
Hayward, C. F., 326
Hazen, E. E., jun., 116, 177, 192, 193
Heathcote, J. G., 31, 251
Hechter, O., 390
Hedley-Whyte, J., 274
Hegarty, M. P., 7
Heidelberger, C., 133
Heidemann, E., 63
Heider, H., 133
Heidner, E. G., 114, 201
Heilmann, H. D., 45
Heinrich, C. P., 133, 299
Heinrich, W., 63
Heinrikson, R. L., 127, 167
Heinz, F., 50
Heitz, F., 390
Heitz, J. R., 236, 237
Heldebrant, C. M., 97
Helene, C., 241
Helleiner, C. W., 55
Heller, J., 257
Helman, M., 60
Helmuth, J., 249
Hemminki, K., 55
Henderson, E. J., 132, 299
Henderson, R., 92, 182, 187
Hendlin, D., 3
Hendon, R. A., 84
Hendricks, M. L., 334
Hendrickson, W. A., 142, 178, 182, 214
Henkart, P., 36, 121, 337
Henkens, R. W., 280
Hennen, G., 78, 79
Henning, U., 122, 132
Henriques, O. B., 364
Henriques, S. B., 364
Henson, E., 66
Herbert, T. J., 294
Herbert, V. C., 235
Heremans, J. F., 132
Hermann, J., 106
Hermans, J., 225, 229
Hermier, J. H., 45
Hermudson, M. A., 88, 90, 94, 150
Herriott, J. R., 182
Hersh, L. B., 132, 299
Hersh, R. T., 132, 289
Herskovits, T. T., 96, 265, 280
Herwig, K. J., 132
Herzfeld, F., 132
Herzog, K. H., 331
Hess, B., 132
Hess, G. P., 88, 91, 187
Hess, M., 149, 150
Hessler, E. J., 439
Hetland, Ø., 132
Heustis, W. H., 248
Hewitt, G., 435
Hewitt, J. A., 307
Hexter, C. S., 93, 94
Hexum, T. D., 161
Heyningen, S. V., 299
Hibino, Y., 281
Higashi, F., 24
Higginbotham, J. D., 427
Higgins, C. E., 437
Highberger, J. H., 64
Hikoya, H., 24
Hildesheim, J., 175
Hilgenfeldt, U., 78
Hill, E., 201
Hill, R. L., 59, 109, 143, 147, 299, 300, 304
Hillaby, R., 409
Hiltschmann, N., 149, 150
Himes, R. H., 132, 136, 168
Hinazumi, H., 17
Hindennach, I., 70
Hindricks, H., 359
Hines, J., 51
Hino, T., 405
Hippe, E., 57
Hiramoto, M., 439
Hirano, J., 44
Hirata, F., 280
Hirose, T., 172
Hirota, K., 27
Hirsch-Kolb, H., 249
Hirschmann, R., 349, 366, 381
Hirt, J., 359
Hiskey, R. G., 312, 334
Hixson, S. S., 173
Hjerlén, S., 222
Ho, C., 248, 249
Ho, E. S., 307
Hoagland, V. D., jun., 288
Hochstrasser, K., 102
Hodgins, D. S., 126
Hodgkin, D. C., 177, 215, 216
Hodgson, G., 195
Högel, A., 389, 391
Högel-Betz, A., 91
Hoehn, M. M., 437
Hoenders, H. J., 72, 73
Hofer, H. W., 296
Hoff, A. J., 234
Hoffman, R., 227
Hoffmann, M., 424
Hoffmann, P., 354
Hofle, G., 9
Hofmann, E., 132
Hofmann, K., 373, 389
Hofmann, T., 92, 103, 105
Hogan, M. L., 378, 379
Hohnstedt, L. F., 23
Hokin, L. E., 161
Hol, W. G. T., 184
Hollander, C. S., 31
Hollenberg, P. F., 165
Holler, E., 241
Hollinden, S. C., 355
Holm, H., 409
Holmes, D., 143
Holmes, K. C., 182, 221
Holmes, L. G., 240
Holmgren, A., 113, 114
Holt, L. A., 75, 393
Holzer, G., 357, 382
Holzwarth, G., 285
Honda, I., 320
Honda, Y., 7
Hong, B.-S., 84
Hood, L., 148, 149
Hoogwater, D. A., 316
Hooker, T. M., jun., 267
Hooper, M., 22
Hope, D. B., 2, 81, 388
Hopkins, K. H., 353
Horbett, T. A., 94, 288
Horecker, B. L., 114, 115, 116, 132, 173
Horisberger, M., 109
Hornemann, U., 439
Horstmann, H. J., 134
Horton, B. F., 145
Horton, H. R., 89, 171
Horwitz, A., 230
Horwitz, J., 20, 257, 267
Hoskinson, R. M., 31
Hosokawa, K., 272

- Hough, L., 428
 Houston, L. L., 54
 How, J. M., 427
 Howard, I. K., 299
 Howard, P., 29
 Howells, D. J., 10
 Hrabanova, E., 31
 Hruby, V. J., 247, 343, 370, 378, 388
 Hsia, J. C., 233, 235
 Hsieh, W. T., 39
 Hsu, M. C., 255, 277
 Huang, R. C. C., 157
 Huang, T. S., 72
 Hubbell, W. L., 235
 Huber, R., 98, 142, 184, 213, 214, 219
 Huc, C., 172
 Huennekens, F. M., 133, 299
 Huestis, W. H., 117
 Huffman, G. W., 435, 437
 Hugli, T. E., 169
 Huguenin, R. L., 365
 Huisman, T. H. J., 144
 Hulme, E. C., 296
 Humphrey, R. L., 220
 Hunston, D. L., 303
 Huntsman, R. G., 145
 Hunzicker, P., 246, 358
 Hurley, L. H., 439
 Hursthouse, H. B., 180
 Hurwitz, E., 153, 156
 Husain, S. S., 105
 Huseby, N. E., 132
 Hussain, Q. Z., 153
 Huszar, G., 62
 Hutchet, M., 59
 Hutchinson, W. D., 305
 Hwang, L. H., 132
 Hwang, P., 369
 Hylton, T. A., 334

 Iancu, C., 63
 Ide, A., 10
 Idsvoog, P., 286
 Ife, R., 15
 Iio, T., 228, 251
 Iitaka, Y., 17, 178, 180
 Ikeda, K., 267
 Ikeda, S., 251, 262, 280
 Ikemoto, N., 161
 Ikenaka, T., 101, 427
 Ikutani, Y., 25
 Iles, G. H., 161
 Illiano, G., 59
 Imada, M., 109
 Imac, T., 280
 Imahori, K., 7, 278
 Imamura, A., 227
 Imhoff, J. M., 44
 Inada, Y., 44
 Inagaki, M., 7
 Inagami, T., 96, 106
 Inbar, D., 155
 Inesi, G., 161
 Ingold, C. K., 471
 Ingram, L., 414
 Ingrisch, H., 102
 Inoue, H., 95

 Inoue, M., 24
 Inouye, K., 371, 384
 Inouye, M., 54
 Insalaco, M. A., 311
 Inui, T., 9, 334
 Irias, J. J., 303
 Irie, M., 280
 Irons, L., 281
 Irreverre, F., 8
 Irwin, R., 239
 Isemura, S., 427
 Isemura, T., 263
 Isenberg, I., 282, 288
 Isersky, C., 150
 Ishi, S. I., 98
 Ishigami, M., 7
 Ishiguro, M., 427
 Ishii, S., 84, 280
 Ishikawa, K., 20, 259
 Ishizuka, H., 31
 Isshiki, G., 5
 Ito, N., 259
 Ito, T., 178
 Itoh, K., 225
 Iuchi, I., 144
 Ivanov, C., 24
 Ivanov, C. O., 24
 Ivanov, I. V., 272
 Ivanov, V. T., 401, 403, 411, 421, 424
 Ivanovics, G. A., 429
 Iverius, P.-H., 59
 Ivkova, M. N., 232
 Iwai, K., 82
 Iwai, M., 397
 Iwakura, Y., 353
 Iwanaga, S., 66, 84
 Iwasaki, M., 316
 Iwata, T., 278
 Iwatsubo, M., 271
 Izawa, O., 429
 Izui, K., 270
 Izumi, Y., 5, 24, 27
 Izumiya, N., 98, 285, 310, 363, 377, 385, 386, 396, 400, 408, 417

 Jack, A., 215
 Jackson, D. S., 65, 66
 Jackson, J. R., 433
 Jackson, L. E., 120
 Jackson, M., 3
 Jackson, R. L., 159
 Jackson, S. A., 151
 Jackson, T. A., 7
 Jacobs, D. J., 294
 Jacobs, P. M., 392
 Jacobson, R. A., 69
 Jacoby, H. M., 31, 36, 86
 Jacq, C., 132
 Jaeger, E., 41, 91, 391
 Jaenicke, R., 289
 Jaillet, H., 265
 Jain, S. C., 180, 418
 Jakeman, E., 294
 Jallon, J.-M., 271
 James, L. B., 30, 34
 Jameson, G. W., 59, 90
 Jamieson, G. A., 428
 Jamieson, J. C., 55

 Janda, H. G., 69
 Jandacek, R. J., 17
 Janetzko, R., 237
 Jankowski, K., 407
 Jansen, A. C. A., 384
 Jansen, E. F., 47
 Jansonius, J. N., 106, 177, 184, 191
 Janssen, G., 422
 Jarabak, J., 53
 Jarabak, R., 127
 Jarreau, F.-X., 431
 Jarup, L., 194
 Jaspars, E. M. J., 75
 Jaton, J. C., 154
 Jaumann, E., 102
 Jayaweera, S. A. A., 180
 Jean, A., 393
 Jeanloz, R. W., 428
 Jeck, R., 175
 Jeckel, D., 112
 Jeffrey, P. D., 287
 Jeffs, P. W., 3
 Jenkins, R. C. L., 287
 Jenkins, T., 146
 Jenness, R., 108
 Jennings, D. R., 258
 Jensen, L. H., 182, 206, 245
 Jentsch, J., 44
 Jiang, N. S., 132
 Jirgensons, B., 264, 383
 Jocius, I. B., 155
 Johannisen, H., 222
 Johansen, J. T., 89
 Johansson, B. G., 171
 Johansson, N. H., 436
 Johansson, S., 165
 Johns, E. W., 249
 Johns, S. R., 2
 Johnson, A. W., 7, 412, 413
 Johnson, B. J., 310, 391
 Johnson, C. E., 243, 244, 245
 Johnson, C. S., 235
 Johnson, E. M., 10
 Johnson, F. H., 299
 Johnson, I., 151, 427
 Johnson, L. D., 35
 Johnson, L. F., 247, 372, 421
 Johnson, L. N., 195, 234
 Johnson, P., 102, 103
 Johnson, S., 338
 Johnson, W. C., jun., 257, 282
 Johnson, W. H., 385
 Johnson, W. R., 22
 Johnston, D. B. R., 434
 Jolicoeur, C., 235
 Jollès, J., 32, 106
 Jollès, P., 32, 109
 Jolley, C. J., 167
 Jolley, M. E., 172
 Jonáková, V., 98
 Jonas, A., 242
 Jones, C. W., 81
 Jones, D. C., 121
 Jones, G., 11
 Jones, H. A., 270

- Jones, J. H., 49, 360
 Jones, J. R., 19
 Jones, M., 281
 Jones, R. T., 144, 249
 Jones, W. C., jun., 334
 Joplin, G. F., 365
 Jordan, J., 67
 Jorgensen, E. C., 19, 384
 Jori, G., 172, 173, 259, 266
 Jorpes, E. U., 285
 Jose, F. L., 435
 Joseph, D. R., 133
 Josephs, R., 112
 Joshi, V. C., 132
 Joshua, H., 349
 Josse, J., 110, 132
 Jošt, K., 388, 418
 Jost, P., 235
 Jouan, P., 30, 35
 Joubert, F. J., 71
 Joy, K. W., 112
 Joynson, M. A., 195
 Juckes, I. R. M., 47
 Jung, G., 18, 247, 357, 358
 Jurašek, L., 102
- Kafatos, F. C., 95
 Kagan, H. B., 5, 6
 Kagi, J. H. R., 278
 Kahn, P. C., 259
 Kainosho, M., 21
 Kaiser, G. V., 434, 437
 Kaiser, K. P., 102
 Kajtar, M., 400
 Kajurai, T., 21
 Kakimoto, Y., 2, 86
 Kakiuchi, K., 263
 Kakudo, M., 128, 178
 Kalb, A. J., 215
 Kallai, O. B., 128, 201, 203
 Kallen, R. G., 24
 Kallos, J., 175
 Kaltschmidt, E., 51, 69, 70
 Kalu, D. N., 365
 Kambe, M., 410
 Kamber, B., 24, 329, 387, 406
 Kamen, M. D., 135, 337, 378
 Kammerman, S., 106
 Kanaoka, Y., 280
 Kanarek, L., 108
 Kandel, J., 83
 Kandler, O., 425
 Kaneko, T., 6, 9, 179, 413
 Kang, A. H., 64
 Kang, J. C., 22
 Kannan, K. K., 194, 222
 Kao, O., 138, 304
 Kapadia, G., 51
 Kaplan, H., 48, 91, 164
 Karady, S., 10
 Karkhanis, Y. D., 124
 Karle, I. L., 8, 403
 Karle, J., 178
 Karle, J. M., 8
 Karlin, A., 163
 Karlsson, E., 84
 Karlsson, F. A., 150
 Karlsson, S., 359
- Karmanskaya, B. M., 12
 Karpavichus, K. I., 440
 Karpeisky, M. Y., 272
 Karplus, S., 404
 Kasai, K.-I., 98
 Kasai, M., 162
 Kasche, V., 46
 Kasper, C. B., 157
 Kassab, R., 125, 170
 Kassel, S., 9
 Kassell, B., 59, 95, 105
 Kastin, A. J., 364, 367, 370, 372
 Kasymova, G. F., 392
 Katakai, R., 310, 353
 Katayama, T., 405
 Katchalski, E., 45, 175, 242, 261, 262, 360
 Kato, G., 248
 Kato, H., 385
 Kato, T., 98, 285, 310, 377, 385, 408
 Katrukha, G. S., 423
 Katrukha, S. P., 35, 37
 Katsoyannis, P. G., 338, 387
 Katsuki, H., 270
 Katsura, H., 6, 9
 Katz, E., 420
 Katz, S., 301
 Katz, W., 426
 Kaufman, B. T., 59
 Kaufmann, H., 427
 Kaurov, O. A., 388, 417
 Kaverzneva, E. D., 431
 Kawabata, N., 359
 Kawai, Y., 420
 Kawamoto, H., 439
 Kawasaki, H., 72
 Kawatani, H., 311, 359
 Kay, J., 95, 105
 Kay, C. M., 132, 266, 268, 270
 Kay, L. M., 184
 Kazaryan, S. A., 41
 Ke, B., 276
 Keana, J. F. W., 25, 235
 Kearney, E. B., 113
 Keele, B. B., jun., 133
 Kegeles, G., 295, 297
 Keil, B., 44, 99
 Keil-Dlouhá, V., 44
 Keirns, J. J., 136
 Keith, A. D., 223, 235
 Kekwick, R. G. O., 66
 Kelemen, M. V., 425
 Keleti, T., 111, 235
 Kellett, G. L., 287, 288, 289, 296, 305
 Kelley, W. N., 132, 304
 Kelly, M. J., 288
 Kelly, P. G., 158
 Kelson, M. N., 30, 35
 Kendrick, P. J., 471
 Kenner, G. W., 344, 356
 Kenner, R. A., 96, 170, 237, 238
 Kenney, W., 113
 Kenney, W. C., 118
 Kent, P. W., 248
- Kenyon, G. L., 18
 Kerenyi, T. D., 373
 Kerling, K. E. T., 384
 Keresztes-Nagy, S., 127, 293, 301
 Keutmann, H. T., 82, 365, 379
 Khailova, L. S., 123
 Khalikov, Sh. Kh., 390, 391, 392
 Khaliluna, K. K., 411
 Khan, M. A., 3
 Khan, P. M., 144
 Khan, S. A., 384
 Khanagov, A. A., 249
 Khandwala, A. S., 157
 Khare, B. N., 7
 Khawas, B., 17, 178
 Khokhlov, A. S., 392
 Khomotov, R. M., 119, 272
 Khurs, E. N., 119
 Kibler, R. F., 87, 358
 Kierstan, M., 34
 Kies, M. W., 87
 Kikuchi, M., 45
 Kikuchi, Y., 391
 Killisheva, O. V., 440
 Killilea, S. D., 49, 139
 Kilmartin, J. V., 144, 145, 147, 212, 307
 Kim, S., 61
 Kim, W. J., 90
 Kim, Y. D., 264, 276
 Kinderlerer, J. L., 145
 King, C. A., 307
 King, L., 166
 King, N. L. R., 248
 King, R. W., 248
 King, T. E., 275, 276
 Kingdon, H. S., 127
 Kinoshita, H., 17
 Kirby, G. W., 14
 Kirby, S., 291
 Kircher, K., 361
 Kirk, K. L., 11
 Kirkley, R. K., 317
 Kirpichnikov, M. P., 119
 Kirschenbaum, D. M., 33
 Kirschner, K., 111
 Kirschner, M. W., 287, 288
 Kirtley, M. E., 111
 Kiryushkin, A. A., 40, 42, 118, 392, 410
 Kiselev, A. P., 118
 Kiselev, N. A., 121
 Kiseleva, V. V., 431
 Kishida, Y., 320
 Kiso, Y., 31, 48, 327, 386
 Kitagawa, T., 259
 Kitto, G. B., 113, 147
 Kivirikko, I. K., 65
 Klapper, D. G., 148
 Klapper, M. H., 301
 Klauke, E., 313, 328
 Klee, M. A., 281
 Kleimann, H., 354
 Klein, F. K., 431

- Klein, L., 55
 Kleinhau, H., 408, 409
 Klengel, H., 421
 Klenow, H., 127
 Klimov, A. I., 21
 Klingenburg, H., 122
 Kloss, P. A., 214
 Kloss, G., 387
 Klostermeyer, H., 312
 Klotz, I. M., 147, 245, 247,
 261, 301, 303
 Klüh, I., 79, 143
 Klug, A., 221, 222
 Klusacek, H., 354
 Klyne, W., 20, 471
 Knappe, J., 138
 Knight, C. A., 51, 300
 Knight, I. G., 161
 Knippers, R., 132
 Knopf, P. M., 156
 Knorr, R., 23
 Knorre, D. G., 235
 Knowles, G., 431
 Knunyants, I. L., 440
 Ko, A. S. C., 77
 Kobayashi, Y., 263
 Kobes, R. D., 116, 175,
 279
 Kobylka, D., 160
 Koch, G. L. E., 132
 Koch, R. T., 31
 Kochetkov, G. A., 279
 Kochetkov, N. K., 428
 Kocy, O., 83, 384
 Kodama, H., 5
 Kodicek, E., 65
 Köhler, H., 151, 154
 Koehler, R. E., 437
 Koekoek, R., 106, 112,
 177, 184, 199
 Koenig, S. H., 249
 König, W., 353, 367
 Koffenberger, J. E., jun.,
 77
 Koga, K., 22, 26, 27
 Kogan, G. A., 401
 Kohama, Y., 299
 Kohlhaw, G., 53, 59
 Kohn, L. D., 63
 Kohno, T., 127
 Koide, T., 101
 Kokhanov, Yu. V., 235
 Kolbah, D., 310
 Kolodny, E. H., 258
 Kolomitseva, G. Ya., 99
 Kon, H., 231
 Konarski, J. M., 250
 Kondo, S., 432
 Konev, S. V., 236
 Konigsberg, W., 76, 146
 Konishi, M., 417
 Kono, N., 303
 Konopinska, D., 353, 355
 Konschewski, H., 31
 Konz, W., 411
 Koppel, V., 31
 Koppers, A., 50
 Koppke, K. D., 246, 402,
 404
 Kopple, Z., 404
 Korn, E. D., 61
 Kornberg, A., 124
 Kornguth, S. E., 286
 Korshak, V. V., 16
 Korte, K., 27
 Koryakina, N. I., 391
 Korzhenko, V. P., 37, 104
 Kosharov, A. N., 30
 Koshland, D. E., jun., 232,
 303
 Kosman, D. J., 233
 Kossmann, K. T., 30
 Kostetiskii, P. V., 403
 Kotake, H., 17
 Kotaki, A., 272
 Kotelchuck, D., 228, 229
 Kotoku, I., 44
 Kotowycz, G., 272
 Kovacs, J., 355
 Kovacs, K., 386
 Kovacs-Petres, Y., 386
 Koves, G. J., 407
 Koyama, Y., 21
 Kozhevnikova, I. V., 410
 Kozhukhovskaya, V. M.,
 385
 Kozlova, N. M., 242
 Kozuki, S., 439
 Kraal, B., 75
 Kraevskii, A. A., 429
 Krahm, J., 101
 Krail, G., 363
 Krainova, B. L., 431
 Krakow, J. S., 34
 Krane, S. M., 63
 Kranenburg, P., 371
 Krans, H. M. J., 60
 Krapivinskii, G. B., 239
 Krasnobrizhii, N. Ya., 250,
 392, 408
 Kratky, O., 111
 Kraut, J., 177, 184, 187,
 205
 Krebs, E. G., 303, 307
 Krejcarek, G. E., 249
 Kremer, B., 49
 Kress, L. F., 98
 Kretsinger, R. H., 214, 220
 Kricheldorf, H. R., 350
 Krietsch, W. K. G., 122
 Krigbaum, W. R., 109
 Krijn, J., 241, 264
 Krikis, A., 390
 Krimm, S., 265
 Krinsky, M. M., 171
 Krivacic, J. R., 257, 269,
 285
 Krivis, A. F., 31
 Kronman, M. J., 240
 Krug, F., 59
 Krugh, T. R., 248
 Krull, L. H., 34
 Kruseman, J., 75
 Krutyakov, V. M., 91
 Krychowski, U., 334, 336
 Krzysik, B., 61
 Kuble, K. D., 31
 Kuchmy, B., 31
 Kuczenski, R., 273
 Kuczenski, R. T., 241
 Kudo, S., 317
 Kuehn, G. D., 289, 299
 Kühn, K., 63, 64
 Kügler, F. R., 109
 Kueppers, F., 102
 Küntzel, H., 132
 Kukla, D., 98, 184
 Kulbe, K. D., 37
 Kulka, R. G., 90, 94
 Kulkarni, P. G., 10
 Kulonea, K., 63
 Kumarev, V. P., 235
 Kun, K. A., 355
 Kunderd, A., 43
 Kuntz, I. D., 249
 Kuo, K., 29, 36
 Kupfer, S., 100
 Kupryszewski, G., 343
 Kurahashi, K., 410
 Kuriyama, K., 278
 Kurobe, M., 86
 Kuromizu, K., 396, 400,
 408
 Kurosky, A., 92
 Kuter, D. J., 53, 300
 Kutney, J. P., 431
 Kuznetsov, Yu. S., 105
 Kvenvolden, K. A., 1, 2
 Kwolek, W. F., 30
 Kyle, W. S. A., 90
 Kyte, J., 161
 Laasberg, L. H., 274
 Labaw, L. W., 218, 219
 Labie, D., 144
 Labouesse, B., 91, 242
 Lackner, H., 418
 Lai, C. Y., 114, 115, 132
 Laiken, N., 304
 Laiken, S. L., 410
 Laine, I. A., 421
 Laland, S. G., 409
 Lam, D. P., 21
 Lambert, M. A., 29, 31, 36
 Lamberton, J. A., 2
 Lamberts, B. L., 35
 Lambeth, D. O., 161, 304
 Lami, H., 28
 Lamm, M. E., 153
 Lampaiho, K., 63
 Lande, S., 339, 361, 362
 Landman, A., 59
 Landon, M., 111, 112
 Lane, R. S., 116
 Lang, G., 243, 244
 Lang, H. M., 105
 Langan, T. A., 68, 282
 Lange, P. M., 63
 Langenbach, R. J., 133
 Langley, T. J., 111
 Lanner, M., 80
 Lapanje, S., 264
 Lapatsanis, L., 411
 Lapière, C. M., 63
 Lapointe, N., 283
 Lardy, H. A., 161, 304
 Larsen, S., 193
 Larsson, P.-O., 59
 Laseter, J. L., 29
 Laskowski, M., 98, 99

- Lassen, F. O., 406
 Lasser, N., 90
 Lassman, G., 27
 Latovitzki, N., 269
 Latt, S. A., 279
 Lattman, E. E., 214
 Lau, F., 67
 Laurent, A., 218, 299
 Laursen, R. A., 38
 Laustriat, G., 28
 Lautenschleger, M. J., 30
 Lavie, D., 26
 Law, G. R., 118
 Law, H. D., 385, 439
 Law, J. H., 95
 Lawinger, C., 3
 Lawless, J. G., 1, 2, 21
 Lawson, P. J., 248, 259
 Lazdunski, M., 99, 264
 Lazer, L., 301
 Leaver, J. L., 68
 Leberman, R., 221, 302
 Lechowski, L., 412
 Leclercq, P. A., 40
 Ledderose, G., 150
 Lederer, F., 132, 133, 136
 Lee, B., 164, 183, 191, 226
 Lee, C. T., 132, 299
 Lee, C. Y., 84, 162
 Lee, F., 10
 Lee, J. J., 304
 Lee, P. K., 264
 Lee, R. T., 124
 Lee, S., 408
 Lee, T. C., 384
 Lee, W. E., 120
 Lee-Huang, S., 70, 132
 Leeman, S. E., 83, 383
 Le Gall, J., 135, 136
 Legressus, C., 218
 Lehmann, H., 143, 144, 145, 209, 387
 Lehmann, K., 47
 Lehrer, S. S., 242
 Leibold, W., 149
 Leibowitz, M. J., 70
 Leidy, J. G., 241, 264
 Leif, R. C., 51
 Leigh, J. S., jun., 230, 231, 232
 Leindenberger, F., 78
 Lembeck, F., 364
 Lemieux, R. U., 18
 Lemke, P. A., 437
 Lemaers, A., 63
 Lenard, J., 54
 Lennox, E. S., 156
 Lentz, P. J., jun., 199, 238
 Leon, A. E., 73
 Leon, M. A., 155, 299
 Leon, S. A., 55
 Léonis, J., 109
 Leont'eva, L. I., 387
 Lepawly, M., 343
 Le Quesne, M. E., 207
 Leriner, K., 36
 Lerman, S., 270
 Lerner, A. B., 339
 Lerner, F. Ya., 121
 Leroy, E., 28
 Leslie, J., 96
 Leslie, R. G. Q., 149
 Lessard, J. L., 147
 Letham, D. S., 11
 Lê-Thi-Lan, 172
 Leuzinger, W., 128
 Levanon, M., 150
 Levenbook, L., 133
 Levilliers, N., 264
 Levine, L., 132
 Levine, M., 205
 Levinthal, V. I., 235
 Levitzki, A., 303
 Levjant, M. I., 35
 Levy, C. C., 49
 Levy, R. I., 286
 Lew, K. K., 124, 302
 Lewin, S., 226
 Lewis, A. F., 283
 Lewis, P. N., 109, 133, 228, 229
 Lewis, U. J., 80
 Lezius, A. G., 59
 Li, C. H., 79, 80, 268, 377, 378, 386, 387
 Li, H. J., 282
 Li, L.-K., 73
 Li, R. I., 423
 Li, S. L., 143
 Li, T. K., 278
 Liao, T.-H., 78
 Liberek, B., 11, 312, 392, 393, 398
 Libertini, L. J., 235
 Lichenstein, H., 2
 Lidak, M. Y., 11, 431
 Liebe, S., 132
 Liehl, E., 262
 Liem, P. N., 14
 Liem, R. K. H., 44, 391
 Liener, I. E., 101
 Lifson, S., 404
 Light, A., 95, 96
 Light, W. W., 343
 Likhtenshtein, G. I., 235
 Liljas, A., 194
 Lillford, P. J., 111
 Lilly, M. D., 59
 Limbird, T. J., 108
 Lin, C. F., 404
 Lin, M. C., 265
 Lin, T.-Y., 88
 Lin, Y., 175
 Lindberg, U., 57, 59
 Lindeberg, G., 359, 390
 Linderberg, J., 260
 Linderstrom-Lang, K., 471
 Lindley, H., 44
 Lindop, C. R., 161
 Lindsay, D. G., 77, 362
 Lindsey, P., 265
 Lindstrom, T. R., 248, 249
 Lipkin, V. M., 118, 392
 Lipkind, G. M., 421, 424
 Lipmann, F., 307, 408, 409
 Lipner, H., 51
 Lipscomb, W. N., 88, 177, 201, 214
 Liquori, A. M., 225, 227, 228, 407
 Liquori, J. C., 471
 Listowsky, I., 258
 Litman, G. W., 149, 283
 Littke, W., 411
 Little, G., 34
 Little, G. H., 132
 Little, J. R., 156
 Little, M., 74
 Litvak, S., 46
 Liu, C. S., 144
 Liu, T. H., 59
 Liu, W., 98
 Liu, W.-H., 102
 Liu, W. K., 377
 Livett, B. G., 81
 Livingston, D. M., 90
 Liwschitz, Y., 9
 Lloyd, K., 340
 Lobachev, V. M., 257
 Lochinger, W., 359
 Lockhart, W. L., 165
 Lode, E. T., 138
 Löfqvist, B., 102
 Lövgren, S., 222
 Loewenstein, A., 28
 Loffet, A., 312, 358, 387
 Lohrmann, R., 354
 Loida, M., 373
 Longton, R. W., 35
 Longworth, J. W., 241
 Longworth, L. G., 292, 294
 Lontie, R., 167
 Looker, B. E., 435
 Lorenzi, G. P., 224, 252, 263, 360, 392
 Lorkin, P. A., 144, 145
 Losse, A., 359
 Losse, G., 334, 336, 421
 Lote, C. J., 426
 Lotz, B., 223
 Love, D. S., 303
 Love, W. E., 142, 214
 Lovell, F. M., 178, 228
 Lovenberg, W., 257
 Lovgren, S., 194
 Lovins, R. E., 21, 43
 Low, B. W., 178, 228
 Low, E. W., 215
 Lowe, A. G., 132
 Lowe, C. R., 59, 60
 Lowe, G., 434, 436
 Lowe, J. M., 169
 Lowe, M., 59
 Lowell, J. L., 30
 Lowry, S., 61, 221
 Lowry, P. J., 33
 Loxsom, F. M., 254
 Lu, Y., 275
 Lucas, R. M., 220
 Lucente, G., 407, 438
 Luchter, E., 50
 Lucke, J. L., 432
 Ludescher, U., 260, 408
 Ludwig, M. L., 207
 Lübke, F., 390

- Luebke, G., 354
 Lübke, K., 309, 387
 Luft, J. H., 303
 Lui, T. Y., 33
 Luisi, P. L., 240
 Luk, C. K., 238
 Lumley Jones, R., 227
 Lumper, L., 274
 Lundblad, R. L., 97, 169
 Lundqvist, H., 46
 Lunney, J., 51
 L'vova, S. D., 385
 Ly, M. G., 10
 Lyle, R. E., 419
 Lynch, L. J., 249
 Lynch, R. G., 155
 Lyons, J. M., 235

 Ma, L., 80
 Mabe, J. A., 405
 McCandy, E. L., 306
 MacColl, R., 138, 304
 McConnell, H. M., 230, 234, 235
 McCord, J. M., 132
 McCormick, D. B., 28, 240, 259
 McCubbin, W. D., 132, 268, 270
 McDonagh, J., 66
 McDonagh, R. P., 66
 McDonald, C. C., 249
 McDonald, I. R., 225
 McDermott, J. R., 356
 McElroy, R. G. C., 19
 McElroy, W. O., 124
 McFarland, B. G., 230
 McFarland, B. H., 161
 MacFarlane, P. H., 23
 McGee, J. O'D., 63
 MacGillivray, A. J., 69
 McGoodwin, E., 65
 Machicao, F., 67
 MacInnes, D. A., 294
 MacIntyre, I., 365
 McKehoe, J., 151
 Mackenzie, R. E., 259, 296
 McKerrow, J. H., 48
 McKneally, S. S., 87
 McKnight, S. D., 63
 McLachlan, A. D., 32, 103, 184
 McLain, G., 135
 McLaren, J. A., 325
 McLaughlin, A., 232
 McLaurin, W. D., 80
 MacLennan, D. H., 161, 162, 235
 McManus, I. R., 61
 McMarker, C., 33
 McMenamy, R. H., 71
 McMullen, A. I., 285, 410
 McMurray, C. H., 147, 195, 201
 McNeill, D., 431
 McPherson, A., jun., 199
 McPhie, P., 266
 MacQuarrie, R. A., 111
 MacRae, T. P., 223
 Maddy, A. H., 158

 Madsen, N. B., 167
 Maeda, G., 6
 Maeda, H., 34, 251, 262
 Maeda, K., 5, 432
 Maeda, Y., 244
 Maekawa, T., 144
 Mage, R. G., 151, 157
 Maghuin-Rogister, G., 78, 79
 Magnusson, S., 97
 Maguire, R. J., 276
 Maher, J. J., 359
 Mahlen, A., 299
 Maia, H. L., 18
 Maigret, B., 227, 404
 Mains, G., 103
 Mair, G. A., 234
 Maire, P., 218
 Maita, T., 76, 142, 146
 Maizel, J. V., 299
 Majumder, S. K., 400
 Makinen, M. W., 231
 Makino, S., 262
 Makisumi, S., 386, 408
 Malborough, D. I., 360
 Maldonado, P., 7
 Maleev, V. Ya., 253
 Maleknia, N., 142
 Malenkov, G. G., 421
 Malkin, R., 276
 Malstrom, B. G., 276
 Mamaril, F. P., 110
 Mandelkern, L., 263
 Mandlekow, E., 221
 Manian, A. A., 10
 Mann, K. G., 97
 Manning, J. M., 30, 35, 355
 Manning, M., 372, 388
 Manson, W., 75
 Mapes, D. A., 359
 Marchalonis, J. J., 171
 Marchesi, V. T., 158, 159
 Marchiori, F., 389
 Marciniszyn, J. P., jun., 105
 Mardashev, S. R., 119
 Marglin, A., 338, 358
 Margoliash, E., 77, 128, 201
 Margolies, M. N., 154
 Marina, M. A., 30, 31
 Marinetti, G. V., 158
 Marini, M. A., 21, 91, 92
 Marinucci, M., 143
 Markelova, E. A., 392
 Markert, C. L., 301
 Markland, F. S., 98
 Markley, L. D., 359, 387
 Markovich, D. S., 239
 Markussen, J., 77
 Marlborough, D. I., 251, 285, 410
 Maron, E., 108, 387
 Maroux, S., 95
 Marquarding, D., 354
 Marquardt, I., 383
 Marquardt, R. R., 115
 Marquez, A., 355
 Marraud, M., 17

 Marsden, J. C., 294
 Marsden, K. H., 249
 Marshall, A. C., 437
 Marshall, G. R., 368, 376
 Marshall, R. D., 427, 428
 Marshall, T. H., 92
 Marshall, V., 7
 Marta, C., 22, 413
 Martenson, R. E., 87
 Martin, C. J., 21, 91, 92
 Martin, G. R., 65
 Martin, H. H., 426
 Martin, J., 77, 386
 Martin, R. B., 259
 Martin, S. R., 98
 Martinez-Carrion, M., 273
 Martini, O. H. W., 53
 Martonosi, A., 161
 Martynov, V. F., 388
 Martz, W. W., 257
 Marumo, F., 178
 Marushige, K., 69
 Maruyama, H., 346, 347, 348
 Mar'yash, L. I., 391
 Marzotto, A., 25, 171
 Masaki, M., 25
 Mašková, H., 16
 Mason, H. S., 276
 Massa, A., 143
 Massey, V., 132, 138
 Masson, P. L., 132
 Masters, C. J., 304
 Masuda, Y., 251
 Masui, H., 364
 Matheja, J., 88
 Mathews, C. K., 59
 Mathews, T. S., 205
 Mathur, N. K., 23
 Matl, V. G., 312
 Matsubara, H., 138
 Matsuda, G., 142, 144
 Matsueda, G., 136, 138
 Matsueda, R., 347, 348
 Matsumoto, K., 316
 Matsumoto, M., 405
 Matsuo, H., 81, 367
 Matsuoka, M., 316
 Matsuoka, Y., 2
 Matsushima, A., 44
 Matsushima, Y., 427
 Matsura, S., 285, 386, 400, 408
 Matsura, T., 27
 Matsuzaki, T., 17, 180
 Matthes, S., 387
 Matthews, B. W., 191, 194
 Matthews, F. S., 195, 306
 Mattice, W. L., 263
 Matzura, H., 55
 Mauger, A. B., 420
 Mauk, A. G., 147
 Maurer, R., 120, 133
 May, L., 243, 244
 Mayama, M., 439
 Mayer, A., 212
 Mayers, D. F., 284, 409, 421
 Mayer, M., 237
 Mayers, G. L., 355

- Mayhew, S., 138
 Mayhew, S. G., 207
 Maylié, M. F., 123
 Maynard, J. R., 121
 Mazur, A., 55
 Mazza, F., 180, 438
 Meachum, Z. D., jun., 132, 299
 Meador, J. D., 388
 Means, G. E., 102, 166, 175
 Mebs, D., 84
 Medzihradsky, K., 383, 392
 Mee, J. M. L., 29
 Mehlhorn, R. J., 235
 Mehlis, B., 359
 Meienhofer, J., 98, 356, 390, 392, 420
 Meighen, E. A., 124, 299, 301, 302
 Meister, A., 53
 Meitner, P. A., 104, 105
 Meizenhofer, J., 34
 Melamed, M. D., 111, 149
 Melançon, S. B., 35
 Melbye, S. W., 132, 299
 Melchers, F., 125, 156
 Melent'eva, T. M., 423
 Mellon, E. F., 23, 327
 Mercer, W. D., 195
 Mercier, J. C., 75
 Mercola, D. A., 215
 Merkel, J. R., 45
 Merrifield, R. B., 117, 356, 379
 Mertz, E. T., 59
 Merzlov, V. P., 279
 Meshcheryakova, E. N., 401, 421
 Messer, W., 125
 Mestecky, J., 154
 Meth-Cohn, O., 23
 Metz, J., 29
 Metzger, H., 156, 169
 Metzger, J., 7
 Metzger, J. J., 153
 Metzler, D. E., 272
 Meulemans, R., 180
 Meurnier, J. C., 59
 Meyer, C., 388
 Meyer, P. D., 142
 Meyer, R. J., 338
 Meyer, T., 135
 Meyer, W. L., 414
 Mical, R. S., 372
 Michael, J., 14
 Michalik, A., 312, 392
 Michelitsch, B., 150
 Michl, J., 260
 Michman, M., 9
 Midgley, A. R., jun., 368
 Migita, S., 171
 Mihaesco, C., 154
 Mihaesco, E., 154
 Mihalyi, E., 238, 278
 Mikami, H., 31
 Milburn, G. H. W., 180
 Mildvan, A. S., 233
 Miledi, R., 162, 163
 Miles, D. W., 279
 Milevskaya, I. S., 254
 Milhaud, G., 337
 Milkowski, J. D., 349, 366
 Millar, D. B., 128
 Miller, A., 224
 Miller, A. K., 3
 Miller, D. D., 94, 288
 Miller, D. L., 175
 Miller, E. J., 63, 64
 Miller, J. C., 122
 Miller, J. E., 301
 Miller, K. D., 97
 Miller, M. A., 18
 Miller, M. C., tert., 368
 Miller, R. L., 65
 Miller, S. M., 349
 Miller, T. L., 439
 Miller, T. W., 3
 Miller, W. G., 225
 Milligan, B., 75, 393
 Millo, J. T., 250
 Milne, G. W. A., 21, 37, 42
 Milner, P. F., 145
 Milstein, C., 148, 149, 153, 426
 Milstein, C. P., 149, 426
 Milstien, J. B., 258
 Minaev, V. E., 250
 Minato, H., 405
 Mire, M., 287
 Miroshnikov, A. I., 411
 Misconi, L., 378
 Mitch, W. E., 49
 Mitchell, C. B., 144
 Mitchell, W. M., 106
 Mitin, Yu. V., 345, 349
 Mitra, T. K., 22
 Mitsui, T., 17
 Mitsui, Y., 191
 Mitsuma, T., 31
 Mitsuyasu, N., 98, 310, 377, 385
 Miyaji, T., 144, 212
 Miyatake, A., 119
 Mizoguchi, T., 328, 384
 Mizuhara, S., 5
 Mizumo, N. S., 12
 Mizutani, J., 28
 Mock, N. H., 248, 249
 Modyanov, N. N., 118
 Modzelski, J. E., 1
 Modzelski, V. E., 1
 Möhler, H., 115, 132, 299, 302
 Moffat, J. K., 146, 182, 212, 230, 295, 306
 Mohammad, M. A. J., 1
 Mole, L. E., 151
 Molea, G., 118
 Molinaro, M., 118
 Molinoff, P., 162
 Molloy, B. B., 405
 Momany, H., 228
 Mondino, A., 34
 Monsan, P., 47
 Montgomery, P. C., 284
 Montibeller, J., 389
 Montreuil, J., 427
 Moore, C. B., 1, 2
 Moore, G. L., 36
 Moore, S., 33, 439
 Morawiec, J., 355
 Morell, A., 148
 Morell, J. L., 413
 Morf, W. E., 421
 Morgan, F. J., 106
 Morgan, J., 70
 Morgat, J. L., 218, 268
 Morgenstern, A. P., 10
 Mori, T., 47
 Moriarty, C. L., 386
 Morihara, K., 45
 Morikawa, T., 384
 Morimoto, H., 144, 209
 Morimoto, K., 295
 Moring, I., 222
 Morita, M., 28
 Morita, Y., 244
 Moritz, P., 33, 339
 Moriyama, T., 132
 Morley, J. S., 328, 340, 393
 Moroder, L., 389
 Morozov, V. B., 388
 Morozov, Y. V., 119
 Morozova, E. A., 414
 Morozova, L. V., 390
 Morris, C. J. O. R., 49, 300
 Morris, H. R., 39
 Morris, P., 49, 300
 Morrisett, J. D., 233
 Morrison, J. D., 5
 Morrison, M., 159
 Mortenson, L. E., 132, 137, 299
 Mortimer, M. G., 132, 301
 Morton, K., 388
 Morton, L. F., 65
 Morton, R. B., 7
 Mosbach, K., 59
 Moscarello, M. A., 86, 286
 Moschetto, V., 143
 Moschidis, M. C., 422
 Moschopedis, S. E., 359
 Moser, P., 260
 Mosher, H. S., 5
 Moss, C. W., 29, 31, 36
 Moss, G. P., 18
 Mostad, A., 17, 178
 Motoyama, T., 71, 427
 Moxon, G. H., 251
 Muehlinghaus, J., 252
 Müller, B., 98
 Müller, H., 122
 Müller, P., 5
 Müller, P. K., 65
 Müller, W., 56
 Muench, K. H., 133
 Münck, E., 245
 Muir, L. W., 121
 Muirhead, H., 195, 306
 Mukaiyama, T., 346, 347, 348
 Müller-Eberhard, U., 274
 Mumford, C., 359
 Mumford, F. E., 139

- Munkres, K. D., 52
 Munro, A. J., 148
 Murachi, T., 170
 Muraishi, S., 21
 Murakami, K., 106
 Muraki, M., 328, 384
 Murano, G., 66
 Muraoka, Y., 5
 Murphy, A. J., 278
 Murphy, C. F., 437
 Murray, K., 68
 Murthy, N. S. R. K., 261
 Mutt, V., 285
 Mutter, M., 246, 357, 358
 Myer, Y. P., 262, 274, 275
 Myers, B., jun., 168
 Myers, J. S., 120
 Muzalewski, F., 343
- Nachbar, M. S., 163
 Nagai, M., 274
 Nagai, S., 439
 Nagai, T., 20
 Nagai, Y., 21, 37
 Nagamachi, T., 27
 Naganathan, P. S., 17
 Nagano, K., 178
 Nagarajan, N., 438
 Nagarajan, R., 260, 437
 Nagasaka, T., 24
 Nagasawa, H. T., 12
 Nagata, A., 179, 413
 Nagel, D., 8
 Nagel, R. L., 146
 Naghski, J., 23, 327
 Nagy, B., 1
 Nagy, L. A., 1
 Nahm, H. S., 78
 Nahorski, S. R., 31
 Naider, F., 246, 260, 261, 403
 Naik, V. R., 89
 Nair, R. M. G., 81, 82, 336, 367, 370
 Naithani, V. K., 361
 Nakagawa, Y., 105
 Nakahara, M., 9
 Nakai, K., 84, 86
 Nakai, S., 239
 Nakajima, K., 397
 Nakajima, T., 2
 Nakamizo, N., 341
 Nakamoto, H., 7
 Nakamura, A., 21
 Nakamura, Y., 264
 Nakanishi, K., 5, 8
 Nakano, E., 45
 Nakaparksin, S., 2
 Nakashima, R., 406
 Nakashima, Y., 142
 Nakatsu, K., 179, 413
 Nakaya, K., 264
 Nakayama, M., 6
 Nakayama, T., 133
 Nakazawa, A., 280
 Nakel, M., 425
 Nakos, G. N., 132, 137, 299
 Namba, K., 384
 Namba, N., 371
- Namiki, M., 28
 Naoi, N., 272
 Narita, K., 84, 133, 135
 Nash, C. H., 437
 Nason, A., 147
 Nassi, P., 39
 Nassif, R., 244
 Natchin, Yu. V., 388
 Nauta, W. Th., 10
 Nayler, J. H. C., 435, 436
 Naylor, J. F., 143
 Nazimov, I. M., 353
 Neel, J., 17
 Neer, R. M., 365
 Nees, S., 164
 Negi, T., 280
 Neill, J. D., 78
 Nelson, C. A., 52
 Nelson, N., 276
 Némethy, A. M., 471
 Nemethy, G., 304
 Neta, P., 27
 Neuberger, A., 427
 Neubert, L. A., 259
 Neuhaus, F. C., 425
 Neumann, H., 268
 Neumann, J., 276
 Neurath, H., 59, 88, 89, 90, 94, 96, 238
 Neuss, N., 3, 437
 Neuwirth, H., 142
 Nevaldine, B., 59
 Neville, D. M., jun., 51, 162, 300
 Newbold, P. C. H., 59
 Newman, D. J., 136
 Newmark, R. A., 18
 Newton, D. A., 31
 Ney, K. H., 314
 Ng, F., 378
 Niall, H. D., 80, 82, 83, 378, 379, 383
 Nicholls, C. H., 28
 Nicholson, B. H., 172
 Nicolaus, R. A., 5
 Nicoli, M. Z., 302
 Nicoud, J. F., 6
 Niederwieser, A., 29, 47
 Niedrich, H., 359, 386, 432
 Nielsen, E. B., 260
 Nielsen, L. D., 121
 Nierhaus, K., 69
 Nihei, N. N., 31
 Nikkel, H. J., 270
 Nilsson, S. F., 59, 133, 299, 300, 304
 Nimberg, R., 71
 Nimmi, M. E., 65
 Ninomiya, T., 24
 Nisanjan, P., 392
 Nisato, D., 25, 171
 Nishida, T., 242
 Nishikimi, M., 272
 Nishimura, H., 28
 Nishimura, O., 384
 Nishimura, Y., 237
 Nishinaga, A., 27
 Nissen, H. M., 17, 178
 Nitecki, D. E., 392
- Nóbrega, F. G., 136
 Nockolds, C. E., 214, 220
 Noda, H., 261
 Noda, K., 98, 363, 377, 385
 Noda, T., 179, 413
 Noelken, M. E., 265
 Nördstrom, B., 199
 Nogami, H., 20
 Noguchi, M., 4
 Nol, V., 34
 Nolan, C., 77
 Noland, B. J., 68
 Noller, H. F., 70
 Noltmann, E., 291
 Noma, M., 4
 Nordman, C. E., 180, 418
 Nordström, A., 81
 North, A. C. T., 182, 227, 234
 Norton, D. A., 17
 Norton, I. L., 175
 Norton, S. J., 11
 Nosikov, V. V., 118
 Notton, B. A., 135
 Novotný, J., 49, 153
 Nowak, T., 168
 Nowoswiat, E. F., 118
 Nozaki, M., 280
 Nozaki, Y., 160, 226
 Nuh, M. C., 30
 Nulty, W. L., 376
 Nulu, J. R., 2
 Nutting, G. C., 294
- Oakley, D. G., 70
 Obata, Y., 12, 28
 Obermeier, R., 21, 43, 100
 O'Carra, P., 49, 139
 Ochoa, S., 70, 132
 Odani, S., 101
 O'Donnell, I. J., 75
 Öberg, B., 222
 Oehme, P., 386
 Oesterheld, D., 163
 Oey, J. L., 132
 Offe, H. A., 328
 Offer, G., 61
 Offord, R. E., 132, 299, 326
 Ogawa, H., 396, 408
 Ogawa, S., 230, 248
 Ogihara, Y., 5
 Ogura, K., 7
 Oh, Y. H., 282
 Ohkawa, R., 408
 Ohki, S., 24
 Ohlsson, R., 59
 Ohmori, S., 5
 Ohnishi, M., 247, 372, 421
 Ohno, M., 396, 408, 432
 Ohta, M., 25
 Ohta, Y., 144
 Oikawa, K., 268
 Oka, T., 45
 Okabe, N., 166, 278
 Okada, K., 439
 Okada, Y., 276
 Okamura, K., 316

- Okamura, M. Y., 245
 Okawa, K., 397
 Okotore, R. O., 423
 Okude, M., 66
 Okunuki, K., 276
 Olafson, R. W., 102
 Olafsson, P. G., 22
 Olander, J., 132
 Oldham, S., 276
 O'Leary, M. H., 164
 Olesen, H., 57
 Olins, A. L., 282
 Olins, D. E., 282
 Olivecrona, T., 59
 Oliveira, B., 153
 Oliver, C. J., 294
 Oliver, D., 55
 Oliver, R. M., 122, 201
 Oliver, R. W. A., 31, 35
 Oliver, S. L., 108
 Olmsted, J. B., 62
 Olmsted, M. R., 303
 Olomucki, A., 172
 Olsen, B. R., 132
 Olson, A. C., 47
 Olson, J. S., 248, 296
 Olson, M. O. J., 67
 Olson, N. F., 47
 Omenn, G. S., 281
 Ondetti, M. A., 83, 285, 384
 Onodera, M., 238
 Onozawa, M., 264
 Ontjes, D. A., 381
 Oosterbaan, R. A., 234
 Oosterhoff, L. J., 258
 Oppenheimer, H. L., 91
 Orekhovich, V. N., 98
 Orgel, L. E., 354
 Oriel, P. J., 265
 O'Riordan, J. L. H., 82
 Orlandini, I., 385
 Orlov, V. A., 35
 Orłowska, A., 359
 Orman, R., 127, 293
 Orme-Johnson, W. H., 245, 249
 Oro, J., 2
 Orrell, K. G., 18
 Osborn, M., 299
 Osborne, R. M., 35
 Oshima, T., 114, 278
 Oshiro, Y., 286
 O'Sullivan, W. J., 168, 232
 Ota, H., 142
 Ota, Y., 281
 Otani, G., 24
 Otchin, N. S., 156, 169
 Otsuka, H., 278, 371, 384
 Otterburn, M. S., 74
 Oura, T., 5
 Ovadi, J., 111
 Ovchinnikov, Yu. A., 40, 118, 401, 403, 410, 411, 421, 424
 Ovchinnikova, V. G., 390
 Overberger, C. G., 263
 Overgaard-Hansen, K., 127
 Owen, M. C., 144
 Owens, C. E., 289
 Oya, M., 310, 353
 Oyer, P. E., 77
 Oza, N. B., 92
 Ozols, J., 136
 Pacaud, M., 45
 Pache, W., 409
 Packer, E. J., 28
 Packer, E. L., 18
 Paddle, B. M., 378
 Padlan, E. A., 214
 Paegle, R. A., 11, 431
 Page, D., 150
 Pahllich, E., 112
 Paik, W. K., 61
 Pailthorpe, M. T., 28
 Pain, R. H., 228
 Painter, R. H., 154
 Pais, M., 431
 Palacz, Z., 11
 Paladini, A. C., 80
 Paleveda, W. J., jun., 349
 Pallavicini, G., 428
 Palmer, G., 245, 276
 Palmour, R. M., 71
 Panetta, C. A., 314, 322
 Pankalainen, M., 65
 Pankova, S. S., 353
 Panyim, S., 52
 Paolillo, L., 247
 Papkoff, H., 79
 Pappenheimer, A. M., jun., 83
 Papsuevich, O. S., 388, 390
 Parameswaran, K. N., 317
 Parikh, I., 117, 281, 382
 Parker, J., 436
 Parkhouse, R. M. E., 156
 Parkhurst, L. J., 307
 Parmeganni, A., 303
 Parr, D. M., 149, 283
 Parr, W., 16, 29, 357, 358, 382
 Parris, D., 74
 Parrish, J. R., jun., 251, 261
 Parry, D. A. D., 220, 223
 Parsons, J. A., 365
 Parthasarathy, S., 182
 Paruszewski, R., 384
 Pastan, I., 299
 Pastuszak, J. J., 9
 Pataki, G., 29
 Patchornik, A., 170, 320
 Patel, C. C., 250
 Patel, D. J., 246, 411
 Patkar, S. A., 127
 Patrone, E., 251
 Patterson, E. K., 45
 Patterson, J. M., 22
 Paul, C., 151, 154, 427
 Paul, H., 28
 Paul, J., 69
 Paul, W. E., 392
 Paulus, H., 53, 132, 299
 Paus, P. N., 54
 Pavars, A., 384
 Paylyukonis, A. A. B., 440
 Paz, M. A., 66
 Peach, C. M., 64, 428
 Peacocke, A. R., 132, 294
 Pearson, A. M., 61
 Pearson, M. J., 435
 Peart, W. S., 364
 Pechère, J.-F., 62
 Pecile, A., 378
 Peck, H. D., jun., 136
 Pedersen, P. L., 161, 304
 Peggion, E., 262
 Pek, G. U., 438
 Pelef, M., 194
 Pellizzari, E. D., 29
 Peña, C., 80
 Penhoet, E. E., 114, 302
 Penner, P. E., 56
 Pennington, P. A., 435
 Pennington, R. J., 143
 Penny, I. F., 53, 195
 Pentchev, P. G., 122
 Penzer, G. R., 241
 Perahia, D., 227
 Percy, M. E., 149
 Perdue, J. F., 161
 Pereira, W. E., jun., 258
 Perera, D., 9
 Perham, R. N., 45, 115, 122, 166, 182
 Periti, P. F., 228
 Perkins, H. R., 426
 Perkins, J. P., 307
 Perlman, D., 400, 420, 424
 Perlman, R. L., 299
 Perlmann, G. E., 71, 105, 261, 270, 427
 Perlstein, M. T., 24, 167
 Peron, M., 264
 Perrin, J. H., 254, 286
 Persson, B. A., 31
 Perutz, M. F., 144, 145, 209, 212, 230, 306, 307
 Pesek, J. J., 248
 Pesina, G. A., 392
 Petef, G., 222
 Petering, D. H., 276
 Peters, J. H., 34
 Petersen, S., 37
 Petersen, U., 37
 Peterson, D. L., 273
 Peterson, E., 1, 2
 Peterson, J. A., 276
 Peterson, J. D., 77
 Peterson, P. A., 59, 133, 277, 299, 300, 304
 Peterson, P. J., 30
 Peticolas, W. L., 225
 Petitclerc, C., 16
 Pétra, P. H., 88
 Petrova, T. V., 431
 Petsko, G. A., 195
 Pettee, J. M., 317, 324, 356
 Pettersson, B. M., 83
 Pettersson, U., 222
 Pettigrew, G., 135
 Pettit, B. C., 29
 Pettit, G. R., 309
 Pfaff, W., 362
 Pfeiffer, S. E., 63
 Pfeleiderer, G., 112

- Pflumm, M. N., 268
 Philipson, L., 222, 223
 Phillips, D. A. S., 7
 Phillips, D. C., 195, 234
 Phillips, D. R., 159
 Phillips, J. L., 71
 Phillips, N. L., 108
 Phillips, W. D., 249
 Pho, D. B., 172
 Picco, C., 169
 Pichat, L., 14
 Pickering, B. T., 81
 Pierce, J. G., 78
 Pierce, J. V., 59
 Pietta, P. G., 368, 386
 Piette, L. H., 233
 Piez, K. A., 62, 63
 Pigiet, V., 299, 302
 Pike, E. R., 294
 Pikkarainen, J., 63
 Pilet, J., 257
 Pilot, J. F., 331
 Pinder, R. M., 10
 Pines, S. H., 10
 Pink, J. R. L., 148, 151
 Pinnell, S. R., 63
 Pintar, M. M., 19
 Piret, P., 180
 Pisano, J. J., 21, 29, 37
 Piszkiwicz, D., 111, 112
 Piva, F., 371
 Plata, M. G., 11
 Pless, J., 365
 Pleterski, J., 16
 Pletnev, V. Z., 403, 421, 424
 Plotnikoff, N. P., 370
 Plummer, T. H., jun., 89
 Plušćec, J., 83, 384
 Pocklington, R., 2
 Poddubnaya, N. A., 250, 392, 408
 Poduška, K., 7
 Poe, M., 249
 Pogell, B. M., 237
 Poggi, G., 235
 Pogson, C. I., 195
 Pohl, F. M., 183, 227
 Pohl, S. L., 60
 Poillon, W. N., 59, 289
 Poisel, H., 404
 Poland, D., 229
 Polevaya, L. K., 386
 Poljak, R. J., 220
 Pollard, H. B., 59
 Pollitt, R. J., 75
 Pollock, R. J., 132, 299
 Polyansky, O. L., 118
 Polzhofer, K. P., 314
 Ponds, S. L., 64
 Pongs, O., 248
 Ponnampereuma, C., 1, 2
 Ponnuswamy, P. K., 21, 227
 Ponstingl, H., 149
 Pont, M. J., 62, 270
 Ponticello, G., 180
 Pontremoli, S., 169, 269
 Poon, J., 168
 Poonian, M. S., 57
 Popel, Y. Y., 11
 Popernatskii, O. A., 388
 Popov, E. M., 403, 421, 424
 Porath, J., 46
 Porcelli, G., 389
 Poritere, S. E., 11, 431
 Poroshin, K. T., 390, 391, 392
 Portelli, M., 386
 Porter, J. C., 372
 Porter, R. R., 148, 151
 Porter, W. H., 106
 Portnova, S. L., 401
 Portnova, V. Z., 403
 Poskus, E., 80
 Potter, J., 262
 Potter, L. T., 162, 163
 Potts, J. T., jun., 82, 365, 379, 383
 Poulos, T. L., 118
 Poupko, R., 28
 Powers, J. C., 92, 184
 Pozdnev, V. E., 431
 Poznyak, M. G., 387
 Pradel, L. A., 125, 170
 Prager, E. M., 106, 108
 Prah, J. W., 151
 Preddie, E. C., 115
 Predescu, C., 144
 Pregosin, P. S., 19
 Prelli, F., 154
 Prelog, V., 471
 Preobrazhenskii, N. A., 353, 386, 392
 Preobrazhenskaya, M. N., 21
 Prescott, D. J., 376
 Prescott, J. M., 30, 35, 45
 Pressman, D., 150, 154, 170
 Previero, A., 36
 Pribadi, W., 144
 Price, N. C., 230, 233, 241
 Price, P. A., 118
 Pringle, J. R., 132
 Printz, M. P., 410, 440
 Prives, J., 163
 Prochazka, Z., 30
 Prockop, D. J., 33
 Prokofiev, M. A., 430
 Prokopyuk, T. N., 392
 Prosch, W., 50
 Protas, G., 5, 36
 Protas, J., 17
 Prothero, J. W., 228
 Prout, C. K., 178
 Prozorovskii, V. N., 119
 Prudchenko, A. T., 11
 Pruess, D. L., 3
 Prusik, Z., 78
 Przemeck, E., 30
 Ptak, M., 235
 Ptiitsyn, O. B., 228, 229
 Puchwein, G., 111
 Pudles, J., 264
 Puett, D., 229
 Puigserver, A., 95
 Pullmann, B., 227, 246, 404
 Purdie, J. W., 31, 49
 Purdy, W. C., 31
 Purygin, P. P., 429
 Pushkareva, Z. V., 12
 Putnam, F. W., 151, 154, 427
 Pysh, E. S., 255
 Quadrifoglio, F., 263
 Quagliatori, G., 228
 Quaroni, A., 428
 Quattrone, A. J., 389
 Querineau, P., 132
 Quick, A., 180
 Quiocho, F. A., 88, 214
 Rabinowitz, J. C., 296, 354
 Radda, G. K., 233, 236, 241, 297
 Radhakrishnan, T. M., 48, 89
 Raffalle, I., 34
 Raftery, M. A., 117, 162, 248
 Ragnarsson, U., 359
 Rahm, J., 30
 Raison, J. K., 235
 Rajagopalan, K. V., 3
 Raleigh, J. A., 5, 413
 Rall, S. C., 67, 68
 Ramachandran, G. N., 224, 246, 471
 Ramachandran, J., 262, 360
 Ramakrishnan, C., 471
 Ramaley, P. B., 65
 Ramasarma, T., 114
 Ramponi, G., 39, 68
 Ramsay, B. G., 433, 434
 Ramshaw, J. A. M., 134, 135
 Randall, E. W., 19
 Rando, R. R., 175
 Rao, K. K., 138, 244, 245
 Rapaka, S. R., 384
 Rask, L., 59, 133, 277, 299, 300, 304
 Rasmussen, K. T., 104
 Rathnam, P., 78, 304
 Ratner, S., 303
 Rattle, H. W. E., 249, 261
 Rautenberg, J., 63, 64
 Ravdel, G. A., 386
 Raven, D. J., 74
 Ray, A., 226
 Ray, T. K., 158
 Rechler, M. M., 127
 Records, R., 257
 Redding, T. W., 81, 82, 367, 372, 389
 Redford-Ellis, M., 30, 35
 Redkin, I. A., 12
 Reeck, G. R., 89, 90, 94
 Reed, L. J., 122, 123, 201
 Reeke, G. N., jun., 88, 214, 215

Rehmar, M. J., 296
 Rehnström, A., 238
 Reichard, P., 113
 Reichart, L. E., 78
 Reichert, R., 102
 Reid, B. R., 299
 Reid, T. W., 105
 Reidel, G., 100
 Reimann, E. M., 307
 Reimo, T., 78
 Reiner, M., 365
 Reiness, G., 132
 Reinhard, F., 142
 Reinhoudt, D. N., 316
 Reisler, E., 301
 Reissmann, S., 385
 Reistad, K. R., 12
 Reithel, F. J., 271, 287, 288, 296
 Rekowska, E., 393
 Renner, R., 386
 Renzi, G., 386
 Reporter, M., 62
 Requena, Y., 92
 Rerat, B., 218, 299
 Rerat, C., 218, 299
 Ressler, C., 3
 Rethy, V. B., 10
 Reynolds, C. A., 144
 Reynolds, J. A., 158, 160, 300
 Rhoads, R. E., 65
 Rhodes, W., 254
 Ribadeau-Dumas, B., 75, 105
 Ribereau-Gayon, G., 114, 173
 Richards, E. G., 287, 288
 Richards, F. M., 164, 177, 183, 191, 226
 Richards, R. E., 297
 Richardson, B. J., 141
 Richardson, D. C., 116, 192
 Richardson, J. S., 116, 192
 Richardson, M., 134, 135
 Richardson, T., 47
 Richaud, C., 7
 Riches, P. L., 249
 Rickli, E. E., 59
 Ridge, B., 332
 Rietzel, C., 411
 Righette, P., 55, 113, 132, 145
 Riggs, A., 147
 Riggs, A. D., 132
 Riggs, A. F., 143
 Rimpler, M., 388
 Rinaldi, A., 12
 Riordan, J. F., 90, 170
 Riordan, J. M., 8
 Rippe, M., 169
 Rippon, W. B., 263
 Rising, C., 29
 Rittel, W., 354
 Riva, A., 28
 Rivaille, P., 337
 Rivat, C., 150
 Rivat, L., 150
 Rivett, D. E., 28

Rizzo, R., 418
 Roach, D., 1
 Roark, D. E., 288
 Robbins, J., 268
 Robbins, K. C., 98
 Roberts, D. V., 90
 Roberts, G. C. K., 247, 248
 Roberts, R. C., 94
 Robertson, D. C., 116
 Robertson, J. W., 22
 Robertus, J. D., 184, 187
 Robins, M. J., 429
 Robins, R. K., 279, 429
 Robinson, A. B., 48, 337, 378
 Robinson, C. J., 82, 365
 Robinson, N. C., 59
 Robinson, P. J., 59
 Robison, G. A., 365
 Roboz Einstein E., 86
 Robson B., 228
 Robyt, J. F., 34, 132, 299
 Rocchi, R., 281, 387, 389
 Rocha e Silva, M., 364
 Rockey, J. H., 247, 284
 Rodbard, D., 51, 300
 Rodbell, M., 60
 Rodriguez, H., 355
 Rodwell, V. W., 175
 Romming, C., 17, 178
 Roepstorff, P., 39, 359
 Röschlau, P., 132
 Roets, E., 433
 Rogers, G. E., 74
 Rogers, H. J., 425
 Rogers, K. S., 33
 Rogers, P. L., 409
 Rogozhin, S. V., 16
 Rohde, W., 59
 Roholt, O. A., 150, 154, 170
 Rohrbach, M. S., 113
 Roig, A., 229
 Romanovskii, P. Ya., 384
 Romeo, A., 22, 413, 438
 Romero Herrera, A. E., 143, 145
 Ronchi, S., 110
 Ropartz, C., 150
 Rosa, J., 144
 Rosen, A., 280
 Rosen, C.-G., 237
 Rosenbaum, G., 182
 Rosenbaum, J. L., 62
 Rosenberg, A., 283
 Rosenberg, I. H., 392
 Rosenberry, T. L., 128
 Rosenbloom, J., 65
 Rosenblum, I. Y., 132, 299, 378
 Rosenbusch, J. P., 125, 132, 299, 300
 Rosenkranz, H., 256, 267
 Rosenthal, D., 3
 Roskoski, R., 408, 409
 Rosmus, J., 36
 Rossbach, V., 406
 Rossi, D., 407

Rossi-Bernardi, L., 147
 Rossi-Fanelli, A., 305
 Rossmann, M. G., 112, 199, 222
 Rostovtseva, L. I., 392
 Rotenberg, I. M., 428
 Roth, J. R., 124, 302
 Rothgery, E. F., 23
 Rotman, M., 155
 Rousseau, R. J., 429
 Roxburgh, C. M., 75
 Roxby, R., 50
 Royer, G. P., 47
 Rozacky, E. E., 122
 Rozynov, B. V., 40, 41
 Ruben, A. H., 77
 Rubin, B. H., 109
 Rudko, A. D., 178, 228
 Rudloff, V., 69
 Rudolph, F. B., 132
 Rühlmann, A., 98, 184
 Ruestow, B., 21
 Ruhfus, A., 37
 Rupley, J. A., 88, 249, 378
 Ruscica, J., 93
 Russell, D. W., 23, 423
 Russell, R., 334
 Russell, T. R., 148
 Russo, E., 407
 Ruterjans, H., 248
 Rutherford, D. B., 132
 Rutter, W. J., 114, 279, 302
 Ryabova, I. D., 421
 Ryan, C. A., 90
 Ryan, C. W., 435, 437
 Ryan, G., 408
 Ryan, R. J., 132
 Ryden, L., 62, 222
 Rydon, H. N., 18, 251, 332, 360
 Ryle, A. P., 105
 Saari, J. C., 121
 Sabesan, M. N., 180, 182
 Sabo, E. F., 83, 384
 Sachatello, C. R., 386
 Saffy, M. E., 334
 Safe, S., 405
 Saffran, M., 80, 87
 Safonova, E. N., 17
 Sagan, C., 7
 Sage, H. J., 299
 Sair, R. A., 47
 Sairam, M. R., 79
 Saito, T., 17
 Saito, Y., 178
 Sajgo, M., 82, 114
 Sakaguchi, K., 45
 Sakai, K., 311
 Sakai, R., 263
 Sakakibara, H., 179, 413
 Sakakibara, S., 320, 334, 338
 Sakamoto, Y., 410
 Sakazaki, R., 439
 Sakore, T. D., 180, 418
 Salach, J. I., 113
 Salaman, M. R., 56
 Salario, F., 251

- Salas, M. L., 307
 Salhany, J. M., 146
 Sallach, H. J., 132, 299
 Salmeen, I. T., 245
 Salmon, A. G., 233, 297
 Salokangas, A., 77
 Salomon, Y., 59
 Salser, J. R., 132
 Salton, M. J. R., 163
 Salvestrini, L., 407
 Samberg, G. A., 164
 Samejima, K., 30, 34
 Samejima, T., 280, 281
 Samejima, Y., 84
 Sammes, P. G., 435
 Sammons, D., 299
 Sams, W. M., 143
 Samson, L., 128, 201, 203
 Samuelsson, G., 83
 Sanasaryan, A. A., 421, 422
 Sanborn, B. M., 113
 Sandberg, B., 359
 Sandberg, L. B., 41, 66
 Sander, C., 278
 Sandermann, H., jun., 163
 Sanders, B., 149
 Sandrin, E., 365
 Sands, R. H., 245
 Sanger, D. G., 417
 Sans, S., 355
 Sanson, A., 235
 Santarius, K., 102
 Santema, J. S., 272
 Santer, V., 171
 Santi, D. V., 57
 Santomé, J., 80
 Saplin, B. J., 143
 Sarah, F. Y., 22
 Sarantakis, D., 343, 382
 Sarma, R. H., 248
 Sarma, V. R., 218, 219, 234
 Sarngadharan, M. G., 237
 Sasai, K., 28
 Sasaki, A., 95
 Sasaki, T., 84
 Sasisekharan, G. N., 471
 Sasisekharan, V., 21, 224, 227
 Sastchenko, L. P., 272
 Sathyanarayana, D. N., 250
 Sato, H., 72
 Sato, M., 21, 250
 Sato, N., 21, 30
 Sato, S., 84
 Sato, T., 47, 405
 Sauer, C., 414
 Sauer, R., 378, 379
 Saund, A. K., 23
 Savel'ev, E. P., 430
 Saveleva, T. F., 17
 Savige, W. E., 28
 Savranskaya, I. M., 391
 Sawyer, T. H., 122
 Sawyer, W. H., 372, 388
 Saxena, B. B., 78, 304
 Saxena, V. P., 256, 265
 Scandella, C. J., 124
 Scannell, J. P., 3
 Scanu, A. M., 55
 Scatturin, A., 269, 359
 Schachat, N., 319
 Schachman, H. K., 287, 288, 289, 292, 299, 301, 302, 305, 308
 Schäfer, K. P., 132
 Schafer, D. J., 385
 Schaffhausen, B., 282
 Schalch, D. S., 372
 Schally, A. V., 81, 82, 364, 366, 367, 368, 370, 371, 372, 389
 Schapira, G., 142
 Schattenkerk, C., 384
 Schechter, A. N., 242
 Schechter, B., 284, 360
 Schechter, I., 360
 Schejter, A., 133
 Schelechow, N., 434
 Schellman, C., 471
 Schellman, J. A., 260, 267, 471
 Shelton, J., 212
 Schenk, U., 36
 Scheraga, G. N., 471
 Scheraga, H. A., 44, 109, 133, 224, 228, 229, 247, 304, 373, 384, 391, 400, 471
 Schevitz, R. W., 199
 Schiechl, H., 149
 Schiffer, M., 214, 219, 228
 Schiller, P. W., 384
 Schiozawa, T., 142
 Schlaak, H.-E., 137
 Schlabach, A. J., 57
 Schleifer, K. H., 425
 Schlesinger, D. H., 80
 Schlueter, R. T., 365
 Schmatz, W., 212
 Schmid, K., 71, 427
 Schmidt, D. V., 108
 Schmidt, G., 313
 Schmidt, J., 162, 299
 Schmidt, U., 27, 404
 Schmidt, W., 164
 Schmir, L., 285
 Schmitz, E. S., 317
 Schmuely, U., 471
 Schnabel, E., 312, 313, 328
 Schneider, A., 73
 Schneider, A. B., 299
 Schneider, A. S., 255
 Schneider, F., 164, 406
 Schneider, H., 235
 Schneider, H. H., 36
 Schneider, M., 100
 Schneider, R., 212
 Schneider, R. G., 144
 Schnellbacher, E., 274
 Schoenborn, B. P., 182, 191
 Schöne, H.-H., 362
 Schoenewaldt, E. F., 349
 Schönsteiner-Altman, G., 391
 Scholes, P. B., 135
 Scholtan, W., 256, 267
 Schramm, H. J., 150, 184
 Schrank, B., 37
 Schroeder, D. D., 96
 Schröder, E., 309, 387
 Schrotenloher, R. E., 148
 Schueneman, C., 265
 Schüssler, H., 98
 Schütte, H. R., 5
 Schuijt, C., 10
 Schulenberg, E. P., 155
 Schullery, S. E., 286
 Schultz, J. E. R., 29
 Schulze, E., 418
 Schumaker, V., 289
 Schuster, I., 111
 Schwabe, C., 93
 Schwam, H., 349
 Schwartz, E. R., 123
 Schwartz, I. L., 80, 372, 373, 388, 390
 Schwartz, J., 437
 Schwartz, M., 133
 Schwartz, S., 102
 Schweizer, M. P., 429
 Schwyzler, R., 11, 260, 384, 397, 408
 Schyns, R., 54, 94
 Scoffone, E., 25, 171, 173, 266, 359, 389
 Scopes, P. M., 19, 20
 Scopes, R. K., 53, 132, 195, 198
 Scott, M., 59
 Scott, R. D., 63
 Scott, W. M., 1
 Scotty, S. J., 11
 Scozzie, J. A., 3
 Scrimgeour, K. G., 53
 Seavey, B. K., 80
 Secher, D., 45
 Sedwick, J., 386
 Seela, F., 418, 419
 Seelig, J., 235
 Seely, O., 178
 Seeman, P., 161
 Segal, D. M., 92, 184
 Seggery, P., 436
 Seghatchian, M. J., 237
 Segrest, J. P., 159
 Seidel, J. C., 235
 Seidl, D. S., 101
 Seifter, S., 66
 Seiler, N., 36
 Sela, M., 108, 148, 284, 360, 387
 Seligman, M., 154
 Selinger, Z., 59
 Seliskar, C. J., 236
 Sellers, M., 244
 Sémériva, M., 123
 Sem'onov, M. A., 253
 Seng, R. L., 133
 Sengupta, S., 400, 414
 Senior, A. E., 161, 304
 Senshu, T., 67, 68
 Senyavina, L. B., 401, 411, 421
 Seon, B. K., 150, 170
 Serafini-Fracassini, A., 47

- Sergeev, C. B., 250
 Settine, J. M., 284
 Severin, E. S., 119, 272
 Sevilla, C. L., 121
 Shabarova, Z. A., 20
 Shah, R., 3
 Shaikin, R., 71, 427
 Shakhmatova, E. I., 388
 Shakhnazaryan, G. M., 8
 Shalatin, N., 148
 Shall, S., 77, 362
 Shaltiel, S., 110, 156, 336, 337
 Shapanka, R., 100
 Shaper, J., 59
 Shapira, R., 87, 358
 Shapiro, A. L., 299
 Shapiro, H. M., 33
 Shapley, A., 116
 Sharifova, Z., 391
 Sharman, G. B., 141
 Sharon, M., 266
 Sharp, J. J., 378
 Shaw, D. C., 132
 Shaw, E., 93, 96, 97
 Shaw, K. P., 175
 Shaw, M. C., 94
 Shawky, N. A., 289
 Shchelchkov, B. V., 242
 Shcherbukhin, V. V., 35
 Shchukina, L. A., 386
 Shearer, D. A., 29
 Sheinker, Yu. N., 21
 Shelanski, M. L., 62
 Shelton, K. R., 33, 54, 300
 Shemin, D., 132, 299
 Shemyakin, M. M., 41, 400, 421
 Shepherd, G. J., 68
 Sheppard, R. C., 344, 356
 Sherman, G., 286
 Sherwood, L. M., 80
 Shiba, T., 179, 413
 Shibahara, S., 432
 Shibata, K., 237
 Shibata, S., 144
 Shibnev, V. A., 390, 391, 392
 Shichi, H., 277
 Shiga, K., 304
 Shiga, T., 304
 Shigezane, K., 384
 Shih, J. W.-K., 109
 Shih, T. B., 144
 Shih, T. Y., 282
 Shilin, V. V., 401
 Shimanouchi, T., 21, 225, 250
 Shimaoka, N., 439
 Shimizu, A., 151, 154, 427
 Shimoda, T., 378
 Shimokawa, Y., 263
 Shimomura, O., 299
 Shimonishi, Y., 361
 Shin, C., 25, 407
 Shinagawa, S., 384
 Shinitzky, M., 268
 Shinoda, T., 151
 Shintani, M., 17
 Shiozawa, C., 108
 Shipolini, R. A., 123, 132
 Shirai, N., 386
 Shkrob, A. A., 421
 Shlank, H., 373
 Shluke, Y. Y., 11, 431
 Shoji, J., 420, 439
 Shome, B., 87
 Shooter, E. M., 86
 Shotton, D. M., 103, 177, 184
 Shpitsberg, V. L., 195
 Shubata, S., 212
 Shulman, R. G., 248
 Shulman, S., 82
 Shuster, L., 51
 Shut, Yu. E., 31
 Shvachkin, Yu. P., 11, 387, 431
 Shvetsov, Yu. B., 392, 422
 Sia, C. L., 114, 132
 Sieber, P., 354
 Siegel, L., 113
 Sieker, L. C., 182, 245
 Siemion, I. Z., 353, 403
 Sievers, G., 141
 Sievers, R. E., 246, 358
 Sievertsson, H., 42, 81, 82, 368, 369, 371
 Sigel, H., 259
 Sigg, H. D., 405
 Sigler, P. B., 223
 Sigman, D. S., 93
 Signor, A., 25, 171
 Signorini, M., 169
 Silaev, A. B., 423
 Sillero, M. A. G., 70, 132
 Silman, I., 45
 Silver, B. L., 28
 Silverman, D. N., 247
 Silverman, S. J., 86
 Silverton, E. W., 218, 219
 Simic, M., 403
 Simms, E. S., 155
 Simon, A. M., 132, 136
 Simon, L. N., 429
 Simon, R. D., 76
 Simon, S. R., 146
 Simon, W., 421
 Simons, E. R., 279
 Simplicio, J., 111
 Simpson, R. J., 109
 Simpson, R. T., 170, 279, 280
 Sinahara, H., 427
 Sinclair, J., 18
 Singer, F. R., 365
 Singer, K., 225
 Singer, S. J., 155, 284, 286
 Singer, T. P., 113
 Singerman, A., 9
 Singh, J., 136
 Singh, R. N. P., 80
 Singhal, R. P., 45, 281
 Sioumis, A. A., 2
 Sipos, F., 393
 Sipos, T., 45
 Sireix, R., 257
 Sitroinak, F. M., 132
 Sivanandaiah, K. M., 384
 Sjöberg, L. B., 102
 Sjöstrand, J., 81
 Skalaban, T. D., 353
 Skorcz, J. A., 384
 Skrabka-Blotnicka, T., 31
 Skvaril, F., 148
 Slater, E. C., 232
 Slater, G. P., 406
 Sleight, R. W., 71
 Sletzinger, M., 10
 Slifkin, M. A., 251
 Slobin, L. I., 70
 Slusarek, L., 62
 Slusher, R., 366
 Small, E. W., 225
 Small, P. A., jun., 148
 Smart-Abbey, V., 388
 Smiley, I. E., 112, 199
 Smillie, L. B., 102, 103
 Smirnov, O. V., 386
 Smirnova, I. G., 423
 Smith, A., 30
 Smith, D. B., 165, 169
 Smith, E. L., 67, 111, 112
 Smith, G. D., 292
 Smith, G. P., 148
 Smith, H., 437
 Smith, I. C. P., 235
 Smith, J. D., 115
 Smith, J. L., 21
 Smith, J. N., 312
 Smith, L., 135, 238
 Smith, L. C., 40
 Smith, M. B., 71
 Smith, P. W. G., 8
 Smith, R. H., 31, 36
 Smith, S., 303
 Smith, T. E., 132, 299
 Smith, W. J., 22
 Smithers, M. J., 389
 Smithies, O., 37, 149, 150
 Smoliková, J., 21
 Smolka, G. E., 270
 Smyth, D. G., 77
 Snatzke, G., 400
 Snell, B. K., 423
 Snell, E. E., 119
 Snore, D., 431
 Snow, G. A., 400
 Snow, M. L., 3
 Sobel, J. H., 106, 108
 Sobell, H. M., 180, 418
 Sober, H. A., 261
 Sochilin, E. G., 12
 Šodek, J., 103, 105
 Söderberg, B.-O., 199
 Söderlund, G., 199
 Soffer, R. L., 70, 82, 149
 Sokhina, A. M., 119
 Sokolovsky, M., 59, 170
 Solie, T. N., 84
 Sollohu, S. J., 132
 Sologubovskaya, I. N., 385
 Solomon, I., 233
 Sondack, D. L., 95
 Sonnenberg, M., 268
 Sonnenberg, K.-D., 36
 Sonnenbichler, J., 67
 Sophianopoulos, A. J., 258
 Sorg, C., 262

- Šorm, F., 98, 388
 Southard, G. L., 317, 324, 356
 Southgate, R., 435
 Sova, O., 31
 Spach, G., 390
 Spangenberg, R., 314, 317, 329
 Spatz, L., 136
 Spear, R. K., 39
 Spector, A., 73
 Speedie, M. K., 439
 Speight, P. A., 19
 Spencer, R. B., 43
 Sperling, J., 391
 Sperling, R., 118, 267
 Spero, L., 31, 36, 86
 Spiewak, J. W., 317
 Spil, G., 427
 Spinola, M., 428
 Spivak, V. A., 35
 Sponar, J., 282
 Spragg, S. P., 301
 Spring, T. G., 132
 Springer, G. F., 283
 Sprössler, B., 45
 Spry, D. O., 260, 438
 Squire, P. G., 239
 Srere, P. A., 132
 Srinivasan, V. T., 27
 Stabel, H. H., 137
 Stace, B. C., 253
 Stahl, J., 69
 Stahl, P. D., 132
 Stallcup, W. B., 303
 Stalling, D. L., 1
 Stamatoyannopoulos, G., 144
 Stammer, C. H., 8, 406
 Stammers, D. K., 195
 Stanfield, S., 299
 Stanford, R. H., 182
 Stanford, R. L., jun., 121
 Staniforth, M. L., 18
 Stapleton, I. W., 44
 Stapley, E. O., 3
 Staprans, I., 269
 Starcher, B. C., 35
 Stark, G. R., 38, 125, 168, 300
 Stark, M., 64
 Stark, W. M., 437
 Starkweather, D. K., 280
 Starr, R., 61
 Staudinger, G. K., 23
 Stauffer, C. E., 44, 91
 Staunton, J., 14
 Stavnezer, J., 157
 Steck, T. L., 160
 Steers, E., jun., 59
 Steffen, H., 264
 Stegink, L. D., 113, 142
 Steglich, W., 9, 17, 315
 Steigemann, W., 142, 184, 213
 Stein, G., 240
 Stein, M. D., 299
 Stein, S., 55
 Stein, T. P., 105
 Stein, W. H., 33, 169
 Steinberg, I. Z., 118, 242, 267, 292
 Steiner, D. F., 77
 Steiner, H., 371
 Steiner, L. A., 154
 Steinhardt, J., 241, 264, 304
 Steinrauf, L. K., 178
 Steitz, T. A., 195
 Stellwagen, E., 132
 Stemmle, B., 8
 Stempel, A., 3
 Stenhagen, E., 21
 Stepanov, V. M., 37, 104, 105
 Stergemann, W., 219
 Sternlicht, H., 18
 Steven, F. S., 66
 Stevens, F. C., 101
 Stevens, L., 262
 Stevenson, D., 382
 Stevenson, G. T., 283
 Stevenson, K. J., 48, 59, 164
 Stewart, F. H. C., 18, 324, 325, 392, 393
 Stewart, J. M., 385
 Stewart, K. K., 59
 Steyn, P. S., 406
 Stibenz, D., 385
 Stiles, P. J., 255
 Stimson, W. H., 47
 Stirrup, J. A., 410
 Stirtz, T., 63
 Stock, W., 386
 Stoeckenius, W., 163
 Stöffler, G., 70
 Størmer, F. C., 132
 Stoev, S., 392
 Stoll, E., 409
 Stoltefuss, J., 328
 Stoltz, M. L., 82
 Stone, A. L., 258
 Stone, J., 30, 34
 Stonier, P. D., 75
 Stoodley, R. J., 433, 434
 Stoppani, A. O. M., 124
 Storey, H. T., 251, 360, 373
 Stouffer, J. E., 29
 Stout, M. G., 429
 Stove, E. R., 436
 Strachan, R. G., 349
 Strätling, W., 132
 Strandberg, B., 182, 194, 222
 Straukas, I., 11
 Straume, V., 431
 Strausbach, P. H., 153, 156
 Street, M. A., 53
 Strickland, E. H., 20, 257, 267
 Stringham, L. R., 31
 Strittmatter, P., 136
 Strominger, J. L., 163, 425
 Strosberg, A. D., 108
 Stroud, R. M., 184
 Struck, H., 31
 Strukova, S. M., 97
 Strydom, D. J., 84
 Stryer, L., 236
 Stuart, K. L., 431
 Studebaker, J. F., 248
 Studer, R. O., 371, 385
 Stulberg, M. P., 241
 Stupp, Y., 392
 Sturtevant, J. M., 241, 280
 Su, G., 240
 Suarato, A., 5
 Sudmeier, J. L., 248
 Suelter, S. H., 241
 Sümegi, J., 240
 Sugai, S., 262
 Sugeno, K., 135
 Sugihara, A., 128
 Sugita, Y., 274
 Sugura, K., 281
 Sugiyama, H., 261
 Sukhikh, A. P., 118
 Sullivan, C. B., 11
 Sullivan, P. T., 11
 Sullova, A., 31
 Sumida, I., 144
 Summaria, L., 98
 Summer, G. K., 31
 Summers, K. E., 62
 Sun, T., 21
 Sundaralingam, M., 178
 Sundby, F., 77
 Sundler, F., 49
 Susi, H., 252
 Suszkiw, J. B., 127
 Sutherland, E. W., 365
 Sutton, H. E., 71
 Suvorov, N. N., 21
 Suzuki, A., 423
 Suzuki, E., 223
 Suzuki, H., 72
 Suzuki, K., 109, 387
 Suzuki, M., 5
 Suzuki, T., 385
 Swaminathan, N., 78
 Swan, I. D. A., 104, 106, 109, 191, 193, 218, 299
 Swank, R. T., 52
 Swanljung, P., 158
 Swanson, R., 203
 Swart, L. S., 74
 Sweeney, C. M., 78
 Sykes, B. C., 63
 Sykes, B. D., 248
 Syrier, J. L. M., 371
 Szwarc, M., 359
 Taborsky, G., 270
 Tachikawa, I., 142
 Tahara, S., 12
 Tai, M. -S., 297
 Tajima, M., 28
 Takagi, T., 166, 259, 278
 Takahashi, K., 118, 172
 Takahashi, M., 57, 103
 Takahashi, N., 170, 423
 Takahashi, S., 432
 Takai, Y., 98
 Takamura, N., 259
 Takano, T., 128, 201, 203

- Take, T., 179, 413
 Takeda, Y., 170
 Takei, H., 142
 Takenaka, O., 237
 Taketa, F., 147
 Takeuchi, I., 397
 Takeuchi, Y., 344
 Takita, T., 5
 Talalay, P., 127
 Talbot, D. N., 54, 300
 Talcisnik, S., 370, 371
 Tam, J. W. O., 247
 Tamaki, E., 4
 Tamaki, T., 317
 Tambieva, O. A., 392
 Tamburro, A. M., 266, 269, 281
 Tamir, H., 303
 Tamiya, N., 84, 391
 Tamura, F., 21
 Tamura, S., 423
 Tan, C. G. L., 101
 Tanaka, M., 136, 138
 Tanaka, Y., 142
 Tancredi, T., 247
 Tanford, C., 50, 160, 224, 226, 229, 254, 283, 286, 300
 Tang, J., 175
 Taniguchi, M., 26
 Tanimura, Y., 31
 Taniuchi, H., 116, 117, 281, 382
 Tanizawa, K., 280
 Tanner, M. J. A., 110
 Tanzer, M. L., 63
 Tao, M., 307
 Tarasenko, A. G., 99
 Tarbell, D. S., 311
 Tarin, J., 133
 Tarrago-Litvak, L., 46
 Tarutani, O., 82
 Tata, S. J., 51
 Tatemoto, K., 240
 Tatsuno, T., 21, 250
 Tatsuta, K., 429
 Taub, W., 252
 Tauber-Finkelstein, M., 110
 Tax, L. J. W. M., 365
 Tayco, J., 35
 Taylor, A., 405
 Taylor, G. T., 247
 Taylor, J. S., 232
 Taylor, M. V., 435
 Taylor, P. W., 248
 Taylor, R. T., 280
 Teale, F. W. J., 241
 Tedro, S. M., 135
 Teichberg, V. I., 266
 Telegdi, M., 111
 Teller, D. C., 94, 287, 288
 Templeton, G. E., 414
 Temussi, P. A., 247
 Ten Eyck, L. F., 144, 209, 212, 307
 Teng, N., 272
 Terada, S., 98, 377, 385
 Terahara, A., 8
 Terashima, S., 259
 Terbojevich, M., 262
 Terlain, B., 3, 422
 Terris, S., 77
 Terry, W., 150
 Terry, W. D., 218, 219
 Tesser, G. I., 383
 Tetaert, D., 143
 Teutori, L., 143
 Thacker, B. P., 7
 Thamm, P., 314, 389
 Thanassi, J. W., 16
 Theilkäs, L., 148
 Theodoropoulos, D., 393
 Theorell, H., 240
 Thomas, A. M., 312
 Thomas, G., 70
 Thomas, J. E., 1
 Thomas, J. O., 122, 166, 182
 Thomas, J. P., 3, 422
 Thomas, R. N., 19, 20
 Thomas, W. A., 5, 422
 Thomé-Beau, F., 172
 Thompson, A. R., 59
 Thompson, C. J., 303
 Thompson, E. O. P., 71, 140, 141
 Thompson, E. W., 134, 135
 Thompson, R. C., 251, 360
 Thompson, T. E., 289
 Thomsen, J., 359
 Thorell, J. I., 171
 Thorn, N. A., 364
 Thorne, J. W., 53, 132, 299
 Thornley, J. H. M., 245
 Tiemeier, D. C., 273
 Tiepel, J. W., 304
 Tiezzi, E., 235
 Tiffany, M. L., 265
 Tilak, M. A., 334, 338, 355, 387
 Timasheff, S. N., 254, 262, 267, 268, 304
 Timokhina, E. A., 104
 Timpl, R., 52
 Ting, S.-M., 114, 115, 132
 Tinoco, I., jun., 254, 255
 Tipton, K. F., 296
 Tischendorf, F. W., 150
 Tischendorf, M. M., 150
 Tischio, J., 359, 391
 Titani, K., 133, 135
 Titlestad, K., 416
 Titov, M. I., 387
 To, C. M., 119
 Tobin, A. J., 269
 Tochilkin, A. I., 12
 Todd (Lord), 423
 Toeplitz, B., 433
 Tokunaga, R., 355
 Tolliday, P., 435
 Tollin, G., 271
 Tollin, J. A., 240
 Tomatis, R., 281, 387
 Tometsko, A., 338, 359, 381
 Tomimatsu, V., 47
 Tomita, S., 147
 Tomoda, K., 138
 Tonelli, A. E., 246, 411
 Tong, J. H., 16
 Tong, N.-T., 44
 Toni, K., 178
 Toniolo, C., 258, 259, 261, 392
 Torchia, D. A., 247, 400, 401
 Torii, K., 17
 Tosa, T., 47
 Toth, S., 240
 Tournon, J., 28
 Toustier, O., 132
 Towend, R., 262
 Trakatelis, A. C., 338
 Trask, E. G., 391
 Traub, W., 62, 224, 471
 Traut, R. R., 53
 Trautmann, P., 249
 Travers, F., 257
 Travis, J., 94, 102, 136
 Trayer, H. R., 158, 160
 Trayer, I. P., 59, 109, 299, 300
 Tregear, G. W., 379, 383
 Trentham, D. R., 111, 303
 Treves, C., 39
 Trifonova, Z. P., 423
 Tripatzis, I., 57
 Triplett, R. B., 160
 Tristram, E. W., 3
 Tritsch, G. L., 386
 Trittelvitz, E., 137
 Trivellone, E., 247
 Trop, M., 103
 Trott, G. F., 253
 Trotter, P. P., 53
 Troup, G. J., 246
 Trude, E., 78
 Trudelle, Y., 360
 Trzeciak, A., 98, 356, 390
 Tsangaris, J. M., 259
 Tschesche, H., 100
 Tschesche, R., 431
 Tsernoglou, D., 201
 Tsibris, J. C. M., 244, 245
 Ts'o, P. O., 262, 278
 Tsolas, O., 116
 Tsuboi, K. K., 132
 Tsuboi, M., 21
 Tsuchihashi, G., 7
 Tsuchiya, T., 429
 Tsugita, A., 109
 Tsukihara, T., 128
 Tsuru, D., 172
 Tsuzuki, H., 45
 Tsweiki, H., 45
 Tterlikkis, L., 254
 Tu, A. T., 84
 Tu, C. A., 275
 Tu, S. C., 240
 Tucker, W. P., 171
 Tulinsky, A., 184
 Tung, J. S., 51, 300
 Tun-kyi, A., 260
 Turano, C., 119
 Turchin, K. F., 21
 Turkeltaub, N., 360

- Turner, D. C., 236
 Turner, K. J., 151, 153
 Turner, L., 249
 Turoverov, K. K., 242
 Tyaglov, B. V., 20
 Tye, R. W., 59, 94
 Tyler, H. J., 34

 Uchida, T., 118
 Uda, J., 6
 Udenfriend, S., 30, 34, 65
 Ueki, M., 346, 347
 Ueki, T., 128, 178
 Uemura, I., 5
 Uesugi, S., 161
 Ughetto, G., 418
 Ugi, I., 354
 Uhlig, H., 45
 Uhmman, R., 358
 Ui, N., 56, 82
 Ulane, I. Y., 11
 Ullman, R., 246
 Ullrich, J., 49
 Umrikhima, N. V., 239
 Umeyama, H., 20
 Umezawa, H., 5, 432
 Umezawa, S., 429
 Umezawa, Y., 31
 Underwood, W. G. E., 435
 Undheim, K., 12
 Ungar, G., 42, 382
 Unkeless, J. C., 21
 Uno, A., 397
 Uno, K., 353
 Upham, R. A., 334
 Uren, J. R., 59
 Urey, H. C., 1
 Uriarte, A., 97
 Uriel, J., 45
 Urry, D. W., 257, 269, 284,
 285, 286, 372, 409, 421
 Usmanov, R. A., 279
 Uttenthal, L. O., 81
 Utter, M. F., 303
 Uvarova, N. N., 411
 Uyeda, K., 303

 Vafin, A. Z., 105
 Vagelos, P. R., 376
 Vahlquist, A., 59
 Vakhitova, E. A., 105
 Valdés, E., 133
 Vale, W., 42, 81, 369, 372
 Valenzuela, M. S., 282
 Valenzuela, P., 91, 92
 Vallee, B. L., 89, 170, 278,
 279, 280
 Vanaman, T. C., 168
 van Bruggen, E. F. J., 112
 van Cauwenberge, H., 364
 Vance, D. E., 37
 van de Graaf, B., 354
 Vandenheede, J., 76
 Van den Heuvel, W. J. A.,
 21
 Van der Broek, H. W. J.,
 272
 Van der Draft, C., 269
 Vanderhaeghe, H., 422,
 433

 Van der Hoeven, M. G.,
 436
 van der Westhuyzen, D. R.,
 67
 Van de Vorst, A., 27
 Vandlen, R. L., 184
 Vane, J. R., 365
 Vanecek, J., 113
 Van Etten, C. H., 4, 438
 Van Heyningen, E. M.,
 435, 437
 van Heyningen, S., 45,
 132
 Van Hoeck, B., 108
 van Kemp, G. J., 72
 Van Leemputten, E., 109
 Van Meerssche, M., 180
 van Os, G. A. J., 70, 71
 van Thoai, N., 125, 172
 Vanuela, E., 299
 van Wyk, P. J., 413
 Varfalvy, L., 407
 Varga, H. S., 383
 Vargha, E., 324
 Varshavsky, J. M., 35
 Vasenev, V. I., 105
 Vasileff, R. T., 437
 Vdovina, L. V., 119
 Vdovina, R. G., 387
 Veber, D. F., 349, 366
 Vecchini, P., 305
 Vedenkina, N. S., 242
 Veege, C., 272
 Vets, A., 63
 Veldstra, H., 75
 Velick, S. F., 241
 Venkatesan, K., 17, 180
 Venyaminov, S. Yu., 257
 Verdini, S., 251
 Vergnes, J. P., 61
 Vernon, C. A., 123, 132
 Vesa, V., 16
 Vesterberg, O., 55, 56
 Vestling, C. S., 39, 113
 Vetter, H., jun., 138
 Vidal, J. C., 124
 Vijayan, M., 177, 182,
 215, 216
 Vilka, V., 386
 Villanueva, G. B., 288
 Vincent, J.-P., 99, 264
 Vinograd, J., 305
 Vinogradov, I. P., 28
 Vinogradova, E. I., 41, 118,
 392, 421, 422
 Visser, L., 93, 264
 Viswanatha, T., 94
 Vitek, A., 21
 Vivaldi, G., 143
 Vlasov, G. P., 91, 349,
 392
 Vliengenthart, J. F. G., 40
 Vlietinck, A., 433
 Voelter, W., 18, 247, 257
 Vogel, O., 122, 132
 Vogels, G. D., 269
 Volkenstein, M. V., 239,
 254
 Volkova, T. A., 385
 Volpe, L. A., 3

 Volpin, D., 63
 Von Dreele, P. H., 247,
 373
 von Dungen, A., 392, 411
 von Frisch, K., 309
 von Holt, C., 67, 68
 von Sengbusch, P., 221
 Voskanyan, L. A., 8
 Voynick, I. M., 103
 Voytek, P., 95
 Vretblad, P., 46

 Waara, I., 194
 Wachter, E., 100
 Wada, H., 119
 Wade, R., 33, 339, 385, 439
 Wade, R. D., 132
 Waehnelde, T. V., 158
 Wälti, M., 2, 388
 Wagatsuma, M., 259
 Waggoner, A. S., 230
 Wagner, F. W., 45
 Wagner, K. G., 278
 Wagner, T. E., 282
 Wahl, Ph., 239, 242
 Wainberg, M. A., 97
 Wakamatsu, H., 6
 Wakamiya, T., 179, 413
 Waki, M., 98, 285, 310,
 377, 385, 386, 408
 Wakil, S. J., 132
 Wakselman, M., 310
 Waley, S. G., 73, 122
 Walker, J. E., 124
 Walker, W. H., 413
 Walkinshaw, C. H., 29
 Wallach, D. F. H., 160
 Waller, J.-P., 127
 Walsh, D. A., 307
 Walsh, K. A., 59, 88, 89,
 90, 94
 Walter, R., 80, 370, 371,
 372, 373, 388, 390
 Walters, J. A. L. I., 70
 Walters, S. L., 169
 Walton, A. G., 223, 263
 Walton, G. M., 364
 Wang, A. C., 148, 149, 151
 Wang, C. L., 144
 Wang, J., 171
 Wang, J. C., 132
 Wang, J. L., 237, 268
 Wang, K.-T., 334, 386
 Wang, R., 299
 Wang, S. S., 356
 Ward, D. N., 42, 78
 Ward, K. B., 214
 Ward, R., 1
 Ward, R. L., 249
 Ware, W. R., 237
 Warecka, K., 57
 Warner, P. E., 199
 Warner, R. C., 303
 Warner, R. M., 29
 Warnick, G. R., 132
 Warren, J. C., 175
 Warren, J. R., 50
 Warren, S. G., 201
 Warth, A. D., 425
 Wasielewski, C., 424

- Wassarman, P. M., 199, 238
 Wasserman, A. R., 136
 Wasserman, H. H., 438
 Wassermann, N. H., 163
 Wasyl, Z., 50
 Watanabe, K., 384
 Watanabe, S., 269
 Watanabe, T., 98, 119
 Watenpaugh, K. D., 182
 Waterfield, M. D., 154
 Waterman, M. R., 276
 Watson, F., 71
 Watson, H. C., 184, 195, 198
 Waxman, L., 132, 143
 Weatherall, D. J., 145
 Weaver, E. R., 83, 384
 Weaver, R. F., 3
 Webb, L. E., 306, 404
 Webb, T., 412
 Webber, J. A., 437
 Weber, B. H., 114, 201
 Weber, G., 242, 243
 Weber, H. P., 405
 Weber, K., 53, 76, 125, 132, 299, 300
 Weber, U., 77, 331, 386
 Wedler, F., 201
 Weeds, A. G., 61
 Weetall, H. H., 60
 Weete, J. D., 29
 Wehmiller, J., 2
 Weibel, M. K., 47, 60
 Weicker, H., 29
 Weihing, R. R., 61
 Weiner, A. M., 76
 Weiner, H., 233
 Weinert, M., 361
 Weinges, K., 8
 Weinheimer, P. F., 148
 Weinhold, P. A., 10
 Weinkam, R. J., 384
 Weinova, H., 30
 Weinstein, B., 334, 343, 382, 389
 Weinstein, I. B., 5
 Weinstein, Y., 156
 Weintraub, J., 376
 Weinzierl, J., 215
 Weisenborn, F. L., 437
 Weisleder, D., 4, 438
 Weiss, J. B., 426
 Weissbach, A., 57
 Weissenburger, H. W. O., 436
 Weissman, N., 41
 Weitzel, G., 77, 331, 386
 Weitzman, P. D. J., 34
 Welch, W. H., 132
 Welfle, H., 69
 Wells, M. A., 123, 269
 Welte, E., 30
 Wemer, P. E., 223
 Wenck, H., 406
 Wendel, A., 132
 Wendell, P. L., 195, 198
 Wendtberger, G., 389
 Wenger, L. Y., 35
 Wenkert, E., 248
 Wenzel, K. W., 132
 Werle, E., 98, 102
 Werner, T. C., 284
 Westall, F. C., 87
 Westhead, E. W., 294
 Westheimer, F. H., 93, 94, 173
 Westley, J. W., 3, 355
 Weston, P. D., 47
 Wetlaufer, D. B., 256, 265, 471
 Weygand, F., 17, 21, 43
 Wharton, C. W., 46
 Whatley, F. R., 245
 Wheeler, B., 31
 White, A. I., 19
 White, A. J., 184
 White, P. A., 41, 42, 382
 White, T. T., 90
 White, W. F., 81, 367
 Whitney, J. G., 437
 Widmer, U., 392
 Wieckowski, J., 163
 Wieland, A. A., 395
 Wieland, T., 246, 310, 359, 392, 411
 Wien, R., 248
 Wiesel, Y., 9
 Wightman, R. H., 14
 Wigle, D. T., 69
 Wilchek, M., 20, 26, 59, 60, 156, 170, 175
 Wilcox, G., 57
 Wilcox, P. E., 92, 184
 Wildes, R. A., 268
 Wiley, D. C., 201
 Wilgus, H., 132
 Wilkes, S. H., 45
 Wilkinson, J. M., 151
 Williams, A. W., 355
 Williams, D. H., 39
 Williams, E. B., jun., 312
 Williams, H. R., 88
 Williams, J., 71, 169
 Williams, J. G., 51
 Williams, J. W., 287
 Williams, N. J., 83, 384
 Williams, R. C., 410
 Williams, R. J. P., 245
 Williams, T., 3
 Williamson, A. R., 56, 148
 Wilson, A. C., 106, 108
 Wilson, J. B., 144
 Wilson, J. E., 240
 Wilson, K. A., 99
 Wilson, K. J., 45, 175
 Wilson, L., 62
 Wilson, M. T., 275
 Wilson, W. D., 257
 Wiman, B., 66
 Windridge, G. C., 384
 Windsor, C. R., 1
 Winitz, M., 309
 Winnik, M., 163
 Winter, A. J., 426
 Winter, D. P., 325
 Winzor, D. J., 304
 Wisnosky, D. E., 257
 Wiss, O., 133, 299
 Wissmann, H., 367, 390
 Witkop, B., 8
 Witman, G. B., 62
 Wittenberger, C. L., 110
 Wittmann, H. G., 69, 70
 Wittmann-Liebold, B., 70
 Witz, D. F., 439
 Witz, J., 182
 Woenckhaus, C., 112, 175
 Wolcott, M., 148
 Wolcott, R. G., 162
 Wold, F., 93, 126, 132
 Wolf, F. J., 3
 Wolf, H., 278
 Wolfe, R. G., 113
 Wolfenstein, C., 154
 Wolfenstein, C. E. M., 80
 Wolters, E. T., 312
 Wolthers, B. G., 106, 177
 Wong, L. T. L., 353
 Wong, K. P., 50
 Wong, M. C., 57
 Wong, P. T. S., 162, 235
 Wong, S. C. K., 401
 Wood, D. D., 86
 Wood, E., 276, 294
 Wood, G. C., 277
 Wood, M. K., 214, 219
 Wood, W. A., 115, 116, 132, 299, 302
 Woodhead, J. S., 82
 Woodhead, S. H., 414
 Woodhouse, N. J. Y., 365
 Woods, E. F., 62, 270
 Woodside, E. E., 253
 Woodward, R. B., 320
 Woody, R. W., 244, 255, 277
 Woolum, J. C., 235
 Woronick, C. L., 248
 Wray, J. S., 224
 Wright, C. S., 187
 Wright, I. G., 435, 437
 Wright, J. J., 406
 Wright, S., 11
 Wrigley, C. W., 55
 Wu, C. C., 22, 27
 Wu, C. W., 240
 Wu, F. Y. H., 28, 240
 Wu, K. C., 142
 Wu, M. T., 419
 Wu, T.-W., 53
 Wunsch, E., 41, 91, 310, 314, 317, 329, 389, 391
 Wulff, K., 278
 Wunner, W. H., 55
 Wu, T. C., 80, 388
 Wyckoff, H. W., 177, 191
 Wyman, J., 147, 302, 305
 Xuong, Ng. H., 205
 Yagi, K., 238, 272
 Yajima, H., 310, 311, 327, 359, 386
 Yamada, I. S., 20
 Yamada, K., 264
 Yamada, S., 22, 24, 26, 27, 259, 344
 Yamada, S. I., 259

- Yamaguchi, H., 427
 Yamakami, N., 6
 Yamamoto, M., 7, 30
 Yamaoka, K., 144, 258
 Yamashiro, D., 377
 Yamashita, S., 39
 Yanaihara, C., 373
 Yanaihara, N., 373
 Yanase, T., 144
 Yang, C., 16, 29, 357
 Yang, C. C., 86
 Yang, C. S., 136
 Yang, J. T., 256
 Yaniv, M., 241
 Yankeelov, J. A., jun., 167, 171
 Yariv, J., 175
 Yaron, A., 261, 360
 Yasunobu, K. T., 136, 138
 Yasushi, K., 250
 Yawson, G. I., 145
 Yielding, K. L., 112
 Yip, C. C., 77, 161
 Yonath, A., 116, 192, 471
 Yong, F. C., 275, 276
 Yonetani, T., 230
 Yoneyama, Y., 274
 York, J. L., 147
 Yoshida, C., 244
 Yoshida, H., 144
 Yoshida, N., 95, 278, 417
 Yoshimura, J., 407
 Yoshinaga, T., 270
 Yoshino, D., 7
 Yoshioka, H., 179, 413
 Yoshioka, T., 5
 Yost, F. J., jun., 113
 Young, G. T., 326, 340, 355, 385, 394
 Young, H., 11
 Young, M., 57
 Young, N. M., 155, 299
 Young-Cooper, G. O., 157
 Yourno, J., 127
 Yphantis, D. A., 54, 287, 288, 300, 410
 Yuasa, S., 7
 Yue, R., 291
 Yung, J., 248
 Yusupov, T. Yu., 391
 Zaborowsky, B. R., 317
 Zabrocki, J., 343
 Zaheer, F., 172
 Zahn, H., 361, 363
 Zakirov, A. V., 390
 Zalkin, H., 132, 299
 Zalut, C., 338
 Zapponi, M. C., 110
 Zegel'man, A. B., 391
 Zehnder, K., 365
 Zeikus, R. D., 66
 Zelikson, R., 94
 Zenda, H., 30
 Zenin, S. V., 250
 Zenker, N., 10
 Zeppezauer, E., 199
 Zeppezauer, M., 199
 Zeszotek, E., 113
 Zetter, G., 364
 Zeuner, G., 387
 Zevail, M. A., 414
 Zhukova, G. F., 386, 414
 Zhukova, I. G., 104
 Ziegler, S. M., 260, 401
 Ziegler Nicoli, M., 124
 Zikan, J., 154
 Zillig, W., 132
 Zima, V. I., 28
 Zimmer, T. L., 409
 Zimmerman, B., 148
 Zimmerman, G., 132
 Zimmerman, J. K., 293
 Zimmerman, S. B., 267
 Zisapel, N., 59
 Zito, R., 143
 Zubay, G., 132
 Zubkov, V. A., 254
 Zumwalt, R. W., 1, 29, 36
 Zundel, G., 252
 Zvonkova, E. N., 353
 Zwick, M., 182
 Zylber, N., 44



The Chemical Society

Specialist Periodical Reports

A series of reviews by leading specialists in their fields which gives systematic and comprehensive coverage of the progress in major areas of research.

Organophosphorus Chemistry Vol. 3

Senior Reporter, Professor S. TRIPPETT
University of Leicester

This volume, the third annual review of the literature on the subject, covers the significant work on all organophosphorus compounds and their derivatives over the period from June 1970 to July 1971. 316pp £7.00 (Still available, Vol. 2 £7.00)

Organic Compounds of Sulphur, Selenium, and Tellurium Vol. 1

Senior Reporter: Dr. D. H. REID
University of St. Andrews

This biennial report is designed to be used both for reference purposes and as a critical commentary. It covers the period from April 1969 to March 1970. 494pp £11.00. Vol. 2 available late 1972

Terpenoids and Steroids Vol. 2

Senior Reporter: Dr. K. H. OVERTON
University of Glasgow

Research in the area of terpenoids and steroids accounts for a substantial fraction of the literature of organic chemistry each year. This volume covers the literature published between September 1970 and August 1971. 450pp £9.00 (Still available, Vol. 1 557pp £11.00)

The Alkaloids Vol. 2

Senior Reporter: Dr. J. E. SAXTON
University of Leeds

This second volume, published in March 1972, covers the alkaloid literature of the period July 1970–June 1971. The whole field of alkaloid chemistry, with the exception of certain steroidal alkaloids, is critically reviewed. 293pp £7.50 (Still available, Vol. 1 505pp £11.00)

Amino-acids, Peptides, and Proteins Vol. 4

Senior Reporter: Dr. G. T. YOUNG
University of Oxford

"The reviewers have done a superlative job of assimilating the data. An indispensable key to the literature for the scientist working in any of these areas." *J. M. Stewart, Journal of Medicinal Chemistry, reviewing Vol. 3* 500pp. £9.00. Still available Vol. 1 £4.50 Vol. 2 £6.00 Vol. 3 £6.00.

Foreign Compound Metabolism in Mammals Vol. 2

Senior Reporter: Dr. D. E. HATHWAY
University of Essex

"The volume (and those promised to come) is clearly very timely and provides a most useful summary and guide to a complicated and highly important field of study." *H. Egan, Chemistry and Industry reviewing Vol. 1*. 500pp £11.00. Still available Vol. 1 £11.00.

Carbohydrate Chemistry Vol. 5

Senior Reporter: Professor J. S. BRIMACOMBE
University of Dundee

This volume is arranged into two parts: (i) the chemistry of mono-, di-, and tri-saccharides and their derivatives; (ii) structural studies of carbohydrate macromolecules. It covers the 1971 literature. 420pp £8.00 (Still available Vol. 1 £3.50 Vol. 2 £3.50 Vol. 3 £7.00 Vol. 4 £7.00)

Fluorocarbon and Related Chemistry Vol. 1

Senior Reporters: Dr. R. E. BANKS and Dr. M. G. BARLOW *University of Manchester Institute of Science and Technology*

This biennial review covers 1969 and 1970 literature on saturated fluorocarbons, fluorocarbon halides and hydrides, and poly-fluoro-organic compounds and their spectroscopic properties. 307pp £7.00

Further information about any of these publications can be obtained from: **The Marketing Officer, The Chemical Society, Burlington House, London W1V 0BN.** Orders (enclosing remittance) should be sent to: **The Publications Sales Officer, The Chemical Society, Blackhorse Road, Letchworth, Herts SG6 1HN, England.**